<SEC-DOCUMENT>0001370053-20-000065.txt : 20201104
<SEC-HEADER>0001370053-20-000065.hdr.sgml : 20201104
<ACCEPTANCE-DATETIME>20201104160341
ACCESSION NUMBER:		0001370053-20-000065
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201104
DATE AS OF CHANGE:		20201104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAPTYSBIO, INC
		CENTRAL INDEX KEY:			0001370053
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				203828755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37985
		FILM NUMBER:		201286607

	BUSINESS ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-362-6295

	MAIL ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANAPTYSBIO INC
		DATE OF NAME CHANGE:	20080828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANAPTYS BIOSCIENCES INC
		DATE OF NAME CHANGE:	20060724
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>anab-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:721272a1-28f6-479d-8921-55bf3792b729,g:e6e63eaa-4a73-42e1-87eb-dda12e114757,d:0833d33fa1bc4c56a5693b167f99fc20--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:anab="http://www.anaptysbio.com/20200930" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>anab-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80L2ZyYWc6NmE3YmRhYmE0Mjk3NGU4YWE5NTc5NDQ3YjQxZWU0ZmQvdGFibGU6MDdkOWE0Y2U0NWI4NDA0YTk5YjAyZjczYjI4ZWExZDgvdGFibGVyYW5nZTowN2Q5YTRjZTQ1Yjg0MDRhOTliMDJmNzNiMjhlYTFkOF80LTEtMS0xLTA_103dabaf-2704-42cc-9558-f744d3e5f084">0001370053</ix:nonNumeric><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80L2ZyYWc6NmE3YmRhYmE0Mjk3NGU4YWE5NTc5NDQ3YjQxZWU0ZmQvdGFibGU6MDdkOWE0Y2U0NWI4NDA0YTk5YjAyZjczYjI4ZWExZDgvdGFibGVyYW5nZTowN2Q5YTRjZTQ1Yjg0MDRhOTliMDJmNzNiMjhlYTFkOF81LTEtMS0xLTA_ec63b618-4995-4988-bada-1d08a097a3d8">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80L2ZyYWc6NmE3YmRhYmE0Mjk3NGU4YWE5NTc5NDQ3YjQxZWU0ZmQvdGFibGU6MDdkOWE0Y2U0NWI4NDA0YTk5YjAyZjczYjI4ZWExZDgvdGFibGVyYW5nZTowN2Q5YTRjZTQ1Yjg0MDRhOTliMDJmNzNiMjhlYTFkOF82LTEtMS0xLTA_3b5eb412-1aee-4056-a889-29581bf9d21a">2020</ix:nonNumeric><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80L2ZyYWc6NmE3YmRhYmE0Mjk3NGU4YWE5NTc5NDQ3YjQxZWU0ZmQvdGFibGU6MDdkOWE0Y2U0NWI4NDA0YTk5YjAyZjczYjI4ZWExZDgvdGFibGVyYW5nZTowN2Q5YTRjZTQ1Yjg0MDRhOTliMDJmNzNiMjhlYTFkOF83LTEtMS0xLTA_99542282-2571-41af-81ec-cde8d4891b23">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80L2ZyYWc6NmE3YmRhYmE0Mjk3NGU4YWE5NTc5NDQ3YjQxZWU0ZmQvdGFibGU6MDdkOWE0Y2U0NWI4NDA0YTk5YjAyZjczYjI4ZWExZDgvdGFibGVyYW5nZTowN2Q5YTRjZTQ1Yjg0MDRhOTliMDJmNzNiMjhlYTFkOF84LTEtMS0xLTA_408e04f8-1ce8-475a-940a-81655f0d28fd">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i7fc96d50997d416d9e45d9e489b28b0f_D20200101-20200930" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDMyMA_168e5752-1e53-49ab-989a-a68d50119366">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ib391ac02eeb746c0bba9221ead335968_D20200101-20200930" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMzEzNQ_106d4e12-4b32-4f29-8d26-2b1735c0fda4">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i0f2d1d9c88ae45deaceec9801cea355b_D20200101-20200930" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDY4MQ_e5da9ade-9ee6-43e3-9be3-70e98595210b">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MDgvZnJhZzo5MjIxOTk3YTFkMWI0MDE5YWI4ZTQxZjA5MGJhYzAwYS90YWJsZTo0YjA2MGVmNGVhNjE0NTg3ODc5MWI3YjhmOGY4NjdjMy90YWJsZXJhbmdlOjRiMDYwZWY0ZWE2MTQ1ODc4NzkxYjdiOGY4Zjg2N2MzXzEtMy0xLTEtOTE_6a2251c2-d5ad-4637-b9c7-5a53d21ab32d">us-gaap:OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MDgvZnJhZzo5MjIxOTk3YTFkMWI0MDE5YWI4ZTQxZjA5MGJhYzAwYS90YWJsZTo0YjA2MGVmNGVhNjE0NTg3ODc5MWI3YjhmOGY4NjdjMy90YWJsZXJhbmdlOjRiMDYwZWY0ZWE2MTQ1ODc4NzkxYjdiOGY4Zjg2N2MzXzItMy0xLTEtOTE_25b3641a-0c57-4b4c-a7a3-fcb7ec7bbf3c">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MDgvZnJhZzo5MjIxOTk3YTFkMWI0MDE5YWI4ZTQxZjA5MGJhYzAwYS90YWJsZTo0YjA2MGVmNGVhNjE0NTg3ODc5MWI3YjhmOGY4NjdjMy90YWJsZXJhbmdlOjRiMDYwZWY0ZWE2MTQ1ODc4NzkxYjdiOGY4Zjg2N2MzXzMtMy0xLTEtOTE_1ea122d2-3773-42dd-8ad1-1aee9247ccd0">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="anab-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="id3d8e7a79fe34836a6611798dfa6402d_I20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i197dcc146a064825a722c622e39823b6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f8388b833b04a14aa7b3b7d69daa5e3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b752f6a10ec473ab4469529bdecb756_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id504f195d28d4333af9e358584ff4c20_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79651fec1fe943d387f3c41aefb528e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17101efcf2d941cfa1317efa0e6a6d29_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i357b59d8716e4b85b7100017c7b775d2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fd425d2b1c34235b752166763d78ceb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9140c17c6ff541b4905365c4fa22b7ed_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0579a6e71aeb413daee069a798be563a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48fbda0280274166a0586adfa171945a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice4c5cb905674403beb71f5e810ab566_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6739116295d4dc896e69e608e97c76f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6198391c49854758a19ea7355d359c10_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50aea59aa1e849aab1bec2360f5663d0_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd3a6df5115a4148a71e445678d6304e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i213f296ddf4342eaae36eb522302fe38_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6f5d31ceca84e909c7ff8eba6ad5711_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if07ac049e6384b9eb3f756bd60ed16e0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83c45560d4d04c4d8d460117720b4d0c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic96af881aa1f4e0f9cbfba136350d1fe_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a03dc9bd9c345e9b3e5f735f284462f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e7a37ef3fbc48b8bfbd71ac11d46dfd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02ddd9390325464f87909298798898e6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f3eeec59a504f6aae08e693714a107f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fae86a718c54cb28203f4589f4ae14d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8405fd2c9af42b3ad40e73761f1b8b6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i944b329323c7414f9375a984348bacdd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd685fdf5e6746878ea46ac3dc5f5dcb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0683082d1ab40eab4b01d7c817b5d80_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6951884f2f9647878228f79ce16d0b71_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id80350b4ab804fab943fd2b3e0d00fe9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5d377b1ba9344a280a30d332ae1b931_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i667c1dbae6f546fab85e5fabd504fab3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b6fe4a6e5de4b5a82cabfeab9b65f59_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97a98cd885414727b67a6826b7552a42_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32de20025be940029a9af8399272f6f1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia19642c61e8545afa9130417d92767d4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4af12f6819b34f6a83947ba47498eefa_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a7d6bca25d24e2bb26123e8dcde48a9_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe9518b119be40879fc2dbaacdfd8964_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44dec769f5314a2990ce879992bf1d2f_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49e522e4b1724704a8bcc7e70955f164_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4507f2fa60434fe3a58a43f0bfb5ac25_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7846c140e24c41b1b46a068579c34d6c_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ed8446ec51444f3a853535c615dc1ca_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbc18062be6e433ea7729c90c6424e74_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c49610ebefc49989126a06a1c4800fd_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3b1c52d7eea4be9b490a69977fda245_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i898f639913e84acdaf09fc3451ae71fe_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ddeec5c1a824dd1b0a410b866cbc85f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i293e1639f7f448eb898ed9fbe929111d_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic831befbaf7b4ef59c2293c1c600c9ea_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c70240883514eddb497067bdc1a0d89_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53163832a44a4c72a73d784e3f2ff470_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadb088f6b63b44368f2345abfce054ce_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i980d58c527c04708ad659969362a43cf_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5f4eacb369c40a8a2cfe22a790e44f2_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6d60309ee7d481fa5ce4476a8abdc34_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66433ff9b85047cc817a25e24c74a772_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b565f7f97a4fb29b4ae5d124a4fde7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1eb595b079543ce95ba9cb5eadf6d99_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i607986a10b7947ca9d199fecd6596a2f_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d431333b5e442b4a517d3cbaa431601_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00dc647c0bac4896a34e44a91c3920f4_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ace0421c6554ea0aaf0d90e9aa8c8a3_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f0d75695e6c4e19919e8ee8cced3fdb_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>anab:segment</xbrli:measure></xbrli:unit><xbrli:context id="if39316fb1c754dec9de54a11b19471c9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cc476288eb442b5bf98c3be003a8dc9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22c2fc8f301f4097805ab635ea1c679b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9edb7d98f97f42518645609a12b3a888_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97829a1a0f0c4c658a231073c0b1761b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">anab:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97a95fbb42de4ae682693fc8fc7a2360_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">anab:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i176c0f8d5a494175860df633af0380ce_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia42c1948b5934a47909d55f51e1c2324_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9935f4f8c0d2424dad75609e066c7b8a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22374db23a0f4f9599b0ba0e269a3ee7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b714d1629c94dce9455c46ac8ae3df4_D20140301-20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-03-01</xbrli:startDate><xbrli:endDate>2014-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>anab:target</xbrli:measure></xbrli:unit><xbrli:context id="i970417eeaafd482f900c18e69347999b_I20140630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i841068aebaa745a89876b4497d36c406_I20141130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaed7d0c461e4199ad5b9a83b5ed6c0b_D20141101-20141130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-01</xbrli:startDate><xbrli:endDate>2014-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>anab:milestone</xbrli:measure></xbrli:unit><xbrli:context id="i043575917e6847649d70407ee576383b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8534bab099e842529d7164852e2d941c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3ClinicalTrialInitiationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6714296e1ede43c4b159fb8e384daff9_D20150401-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-04-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f48ce05ab804c08ac1a45c2c7193b29_D20151001-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a7d54c067c845509a3141ccbe591e65_D20160701-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7db5636cafbf422dbca6fb1af3c911b8_D20160101-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69196f35ad1e48409df3674b606bdaab_D20160401-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9048b7098214431bb4af6b977f80d956_D20170401-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49356d8d8f764282af58ba1fb686d94e_D20170401-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic85d714342d0443a9aae31c32b92429f_D20171001-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i817f5602cf4d49c1af5c2aa476a787d4_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied95da1a4f9848e981906b3694d41c40_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3ClinicalTrialInitiationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id37ccc32a0c64011b924874643fc2c43_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3clinicaltrialinitiationsecondindicationDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bccfffe562d49e3a383b78d7e3a473c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FilingofNDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4fb59f13064149aefe64f788700e08_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FilingofMMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8fda9259a0e4e1788f0cae962d442ec_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d6a141d3615439ea73e776ec0ec0704_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaebbe17d08a649598b21b99df30d512e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c1ff849295145de8d2e764ae6a508ec_D20110101-20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-01-01</xbrli:startDate><xbrli:endDate>2011-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12bdb60cf8e2409dbb82b9f0e626eca2_I20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6949b8d98a949efb75ebf6f3c2883f8_D20160401-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b954c77f99d46ecbdb66e0463daa4c8_D20161001-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase1ClinicalTrialInitiationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf7d0bcc12c74158bd008c8a54ad1ca3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3f3c54965f1409ab37615dab7b02091_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibda93a579438443ca855b712364fdb2c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id197285cdb5044f2ab240b49e82a1ecc_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47a1076cefcd4d0ab8d1b13c5a35388f_I20141224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>anab:installment</xbrli:measure></xbrli:unit><xbrli:context id="i2904dd9806a74afdb9680651604f96e4_D20141224-20141224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-24</xbrli:startDate><xbrli:endDate>2014-12-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77ef9b411b014186ae96e571e310a67c_I20141224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cbfbe6b71b1401990273e2858bb408d_D20141224-20141224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:TermALoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-24</xbrli:startDate><xbrli:endDate>2014-12-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4e2957bb03b74da888869ae5ceb98960_I20141224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:TermALoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e1900fbc5af4115b87781c0258509e7_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:TermBLoansAndTermCLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83f647fab752487aaffcadf4318bc4aa_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i486ee79f827548bc8e85e93940ce0440_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie988dd2210474da0a9388a1930bda1c6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e9365f8894d443d987a0236bea2df0c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id29df9c5b8854830bcd8981e7835fc35_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia56e6aad2b7c44aab9e288f7e9c76eef_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164e1f96760745ea976bbb632c4983c3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7af76d44387a46c89ac52e0449f254f5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadb2d6473570457a8faa9c1e6fb88863_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63a8061e93f9480896f76c4620112a7c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2f77996d88c440f99adbdd8f311cd20_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a809753553044369236456513af1721_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d91aeb2e9ae4d358e45e8c47c03c98b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fc2261a1be6464d85beeb08fdb8bd77_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4295dc2b4c0e4900bbb30c9191198893_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee0736e2d03d4071be6f21372a00b616_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06badbd8e437492aab95efec2695045d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id77ca4847bba4305b096e411a0f88a98_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4baf9e14edba45e69f2f019ccd63867e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86cf9503128d472eaa3c206335a0a2fe_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i507cac2c7cca438e8dbb277c0fe458d2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8b77072d590434e92a3cb60e8a64f76_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d965662c4e8442d9916e4cfd80ec8a7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i077e3faf20384ff0800aacc76bea84f4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba71325b1ced4476b954c2bc33ca1f44_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb57811cde1b45cdbd23bd6a14512d23_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia898b1250c31427581123c12f7daefee_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dd5a96a569344b783cdca534f4e6e9f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife860bdad5054daeaabbda9d6e52176d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12ee59f67b6f424b910cc0844c794eb7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i641d36b1119a4b48adad58e89443d069_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d6d9c78810d4e6ca294fa8649b67b58_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76c44023eb8043aeb3d411c59bc7cf4b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cabcd89e04549418fc44781cea4c283_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f51e0997cba47f6b82e8aa9efa6952b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3f40c73d02a434eaaf57929475ddfc6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3922432c0e84274970a003c02156320_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b87f9f76e3a4b858f05b03e5189102d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62c6c85777a546cc8922f55af953a635_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bf3fb2ff20a4a8f8e90a71d67af78ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad0530eb18bc4ab29d6f3710ab1c6e67_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8795b5aaad54f1a89041597a8c5f56f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i426b689f24654fc8a7cf7448cec90674_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75efafa8841f48729f56684090276568_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3f1b9a2b98b41029f0b45d0b59ff7f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc9672695c6d4ab2811e97fcee8bcfe5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d92717b6f68494ba0890fed7d159f14_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c61b5956d7e46c6a38b815d302d5850_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b730ef0ddc64ea19f1632b5ab752783_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ab47a7f50ba4fb2826b5e3dc7761fb5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7825d3ea7a9349ca843c88225054e573_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8635c548a31441e3992be83f1680e082_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0a28d83f2ea4dbea79c3907f37a6431_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a898126f7a043ec824730e437299a7b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ef17d9b49d24d5c984eab8bedf09095_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aa15223feec45779fc8eb2c483d51ec_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1b346b9aee2453e943c261bcb153fa8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i856a405b5e294005b0da97db3dbe7ce2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc96d50997d416d9e45d9e489b28b0f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i421e55d1b84c466089165cde97803903_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f35c8d2bb134707949ab2d642ffe73b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib391ac02eeb746c0bba9221ead335968_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i658c9943823c428392acd64ea6860e66_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a14f6c2f873440b8540983c27210b42_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f2d1d9c88ae45deaceec9801cea355b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1625cce2849647f3b4fdd28e3722f489_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04b8e21f36b048dfb63095af95035987_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eed3626fb0548498facb46e0bee7d8c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5dc4745f8114a8fbed72cc75adbb0dc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iede5636a43b44bc6be3c38a82fecb803_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1689cf0ddbf847f1a5d41386bf8e581a_D20170126-20170126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-26</xbrli:startDate><xbrli:endDate>2017-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib98c7394ae0241be92efa15ef59bb44f_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86d89ac9401d465a9ffa094c58d86268_D20180101-20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bdb7350e5c74ed089644cf190add40a_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd8286d24eb44b9dada0fe300127f5bc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aa924de6d814250973b8ca6c02725b7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef232fdc16443ab824f750c8ecbc67b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i746c849226304957812801a396d96d98_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa8e6f18cae84e3abeb28a87d7e99b95_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i619a360a42884bb8b5a3c0d6c4290323_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c89f0f0b0f4523aa6c1cc41b1ca2dd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2389b2e977c94f14aaafb743e9c2bf19_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13db0076e7d145118a79fd40a565430f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53442a555d5247dda9d21b2f725430ac_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>anab:lease</xbrli:measure></xbrli:unit><xbrli:unit id="renewal_option"><xbrli:measure>anab:renewal_option</xbrli:measure></xbrli:unit><xbrli:context id="i8eacadeab29a42608e859587a94fccfe_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="anab:LeaseArrangementAxis">anab:OneOfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i5d58efeb98774e8291e0a3b307d1a26b_I20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="anab:LeaseArrangementAxis">anab:A10770WateridgeCircleSanDiegoCalifornia92121Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie99b7535bd4a4aff813c79436f435dd6_D20200504-20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="anab:LeaseArrangementAxis">anab:A10770WateridgeCircleSanDiegoCalifornia92121Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-04</xbrli:startDate><xbrli:endDate>2020-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerSqft"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id3e3599ed3624134a82b70d95e79fc4c_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d1574d508d24c7a9d2272819c456ea4_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60cb8e6a37424af2bd4d11e7a7616ff7_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa95208aff9f4c2086046f2657751ac3_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79eecb7fb35c40ad8dec2e63fb261996_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa90cb92269c4595b23777618939cb79_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:36.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:36.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDky_57abc4d6-a396-4f30-a586-c761ff620ba4">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:36.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6NWQ0MWI5YjljODFkNDk3NWEzMzkzMzIzY2I5YWIxYTEvdGFibGVyYW5nZTo1ZDQxYjliOWM4MWQ0OTc1YTMzOTMzMjNjYjlhYjFhMV8wLTAtMS0xLTA_d9764359-0494-4afc-8d0b-b94cca6a521b">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Quarterly Report pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8xMzE_e175e801-398d-4e01-b9c7-bcdb2810f0cc">September&#160;30, 2020</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6ZDU3ZGRkNzRhY2ZmNDNmZjhhY2U3NThkNGEyMGFhOWIvdGFibGVyYW5nZTpkNTdkZGQ3NGFjZmY0M2ZmOGFjZTc1OGQ0YTIwYWE5Yl8wLTAtMS0xLTA_3f1b95d4-e97f-42d3-ac99-994bcfa1423a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Transition report pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDkz_b50b7c16-cdca-4987-9498-957105e00639">001-37985</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:36.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDg1_d60bd68c-df5b-4156-aa37-15f8ed7ed512">ANAPTYSBIO,&#160;INC</ix:nonNumeric>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:36.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.005%"><tr><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6ZGQ3ZDNiN2Q5MjBmNDg3MmJjMjIwMjQ2NjE0NmQ5ZDAvdGFibGVyYW5nZTpkZDdkM2I3ZDkyMGY0ODcyYmMyMjAyNDY2MTQ2ZDlkMF8wLTAtMS0xLTA_e5bdec56-d9bf-422f-95cd-dadc82726722">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6ZGQ3ZDNiN2Q5MjBmNDg3MmJjMjIwMjQ2NjE0NmQ5ZDAvdGFibGVyYW5nZTpkZDdkM2I3ZDkyMGY0ODcyYmMyMjAyNDY2MTQ2ZDlkMF8wLTItMS0xLTA_86c7091e-d763-4cd3-9e27-426dafd5530b">20-3828755</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDk0_77b4108f-5380-428f-b0d6-f1ef1e545820">10421 Pacific Center Court</ix:nonNumeric>, <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDg2_4c332cb2-5ce6-462f-a197-f0896150d68d">Suite 200</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDg3_34c95d8c-89b1-448f-a88c-4fbca281e932">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDg4_eeb95e20-513e-4a69-92ed-e860b8ea4c6f">CA</ix:nonNumeric> <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDg5_6af30775-34f0-4b13-8302-cdacdbe289db">92121</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code) </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDk1_007fc098-a368-4a49-9f5e-157a055220a4">858</ix:nonNumeric>) <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDkw_6541899a-cb78-4cbb-b455-35e26ee2d73f">362-6295</ix:nonNumeric>  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:36.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6OWRmNDRlZGQyODMzNDNiZDk5NzU3ODQwYTc1ZjUyZjIvdGFibGVyYW5nZTo5ZGY0NGVkZDI4MzM0M2JkOTk3NTc4NDBhNzVmNTJmMl8xLTAtMS0xLTA_f324c9f5-422b-4597-b12e-ddc3a23ffc3e">Common Stock, $0.001 par value</ix:nonNumeric> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6OWRmNDRlZGQyODMzNDNiZDk5NzU3ODQwYTc1ZjUyZjIvdGFibGVyYW5nZTo5ZGY0NGVkZDI4MzM0M2JkOTk3NTc4NDBhNzVmNTJmMl8xLTEtMS0xLTA_12df4b74-e21e-4939-af51-21d534843fa0">ANAB</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6OWRmNDRlZGQyODMzNDNiZDk5NzU3ODQwYTc1ZjUyZjIvdGFibGVyYW5nZTo5ZGY0NGVkZDI4MzM0M2JkOTk3NTc4NDBhNzVmNTJmMl8xLTItMS0xLTA_e5a20ee9-f2dd-4a24-a8df-07c954ed0c3a">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days:&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDk2_be627fae-d2fa-4f52-bdb5-a3b820810d5a">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDk3_437de8c9-7e34-486a-a05c-30d99ef35979">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:22.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large Accelerated Filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;Filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6MjFjNmRhZGJjZDI2NGI2M2JjNzg5OTY5M2Q4M2FhMGIvdGFibGVyYW5nZToyMWM2ZGFkYmNkMjY0YjYzYmM3ODk5NjkzZDgzYWEwYl8yLTAtMS0xLTA_448e9f8d-d296-4519-8495-da098c3bf976">Non-accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;Reporting&#160;Company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6MjFjNmRhZGJjZDI2NGI2M2JjNzg5OTY5M2Q4M2FhMGIvdGFibGVyYW5nZToyMWM2ZGFkYmNkMjY0YjYzYmM3ODk5NjkzZDgzYWEwYl8yLTYtMS0xLTA_fc0f4993-1134-43ee-8da1-acd93d7503e8">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Growth Company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6MjFjNmRhZGJjZDI2NGI2M2JjNzg5OTY5M2Q4M2FhMGIvdGFibGVyYW5nZToyMWM2ZGFkYmNkMjY0YjYzYmM3ODk5NjkzZDgzYWEwYl80LTYtMS0xLTA_c51b4d43-d523-4504-8419-76f61cc6ac20">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDkx_71651d59-d53c-422d-99ec-88cb5f73652c">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November&#160;2, 2020, there were <ix:nonFraction unitRef="shares" contextRef="id3d8e7a79fe34836a6611798dfa6402d_I20201102" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDI3_62de297f-6291-4874-994f-d4b2d5c53cf1">27,347,805</ix:nonFraction> shares of the Registrant&#8217;s Common Stock outstanding. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:36.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AnaptysBio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Table of Contents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:10.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.657%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page Number</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I. FINANCIAL INFORMATION</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_13">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_13">Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_13">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_16">Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_16">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_19">Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2020 and 2019</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_19"> </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_19">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_22">Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_22">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_25">Consolidated Statements of Stockholders&#8217; Equity for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_22">and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_25"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_25">Nine </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_25">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_25"> 30, 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_25">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_28">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_28">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_28"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_28">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_28"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_28">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_31">Notes to the Unaudited Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_31">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_64">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_64">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_64">20</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_67">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_67">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_67">29</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_70">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_70">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_70">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II. OTHER INFORMATION</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_76">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_76">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_76">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_79">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_79">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_79">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_82">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_82">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_82">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_85">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_85">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_85">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_88">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_88">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_88">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_91">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_91">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_91">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_94">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_94">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_94">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_97">Exhibit Index</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_97">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0833d33fa1bc4c56a5693b167f99fc20_100">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0833d33fa1bc4c56a5693b167f99fc20_100">68</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_13"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Consolidated Financial Statements (unaudited)</span></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AnaptysBio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value data) </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNC0xLTEtMS0w_9a2c9991-406d-407f-b6a4-866a01bd8cee">209,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNC0zLTEtMS0w_4d4b43be-f1bb-4af8-beeb-fb3dde434fe4">171,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNi0xLTEtMS0w_4e345707-958f-4726-ab1c-d2fc46ba3286">129,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNi0zLTEtMS0w_8e33058d-06ec-4b1f-83f7-d9396f176443">203,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNy0xLTEtMS0w_48633daa-4129-4456-85cd-250da8e29c27">7,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNy0zLTEtMS0w_acea03b8-b30a-4b4d-b26e-09f26de71b6d">3,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 40.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfOC0xLTEtMS0w_fe545087-f1c5-4947-a7b9-0dabc6440db0">345,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfOC0zLTEtMS0w_fc5d2985-a2de-4b8f-875b-37d07b84b751">377,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfOS0xLTEtMS0w_cdf7ba45-9684-4619-9ba7-fefc99058dc2">1,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfOS0zLTEtMS0w_e91fdea3-018b-4526-8a21-884964384af7">1,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTAtMS0xLTEtMA_0f3251a7-c4d2-4049-a690-648345938b24">36,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTAtMy0xLTEtMA_46f98ccb-2129-417c-928b-178b54d1c9a2">54,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTEtMS0xLTEtMA_b584e403-5045-4235-9e4d-9a556a228567">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTEtMy0xLTEtMA_3cdb26b5-983a-44b3-934f-4ffc2579e1c1">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTItMS0xLTEtMA_f1c89d36-60dc-48e7-a26e-3fab900255bf">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTItMy0xLTEtMA_789ae391-794f-4ab6-8be3-11054de33771">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 27pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTQtMS0xLTEtMA_82fde88d-1f4e-4295-8904-307a66d6bc41">384,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTQtMy0xLTEtMA_c03eedaa-61c4-488d-b008-d978e3697b1e">435,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTktMS0xLTEtMA_7a7a515b-9abc-4bd1-89f0-e2f60f1139cf">5,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTktMy0xLTEtMA_e542d37a-d440-4a89-b42e-f524d583de66">16,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjAtMS0xLTEtMA_46dc3a03-cdd7-4ca4-a878-57d794a5abb3">18,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjAtMy0xLTEtMA_bf57f90e-ffcc-4f08-9444-22884970c031">11,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjEtMS0xLTEtMA_9e9f57d6-c670-4b51-9119-8ea6f42fca12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjEtMy0xLTEtMA_5f3f8cce-f699-4aad-b718-f26104495fc4">1,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjItMS0xLTEtMA_6b176a77-fafb-4032-88a9-72fa7b893a1a">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjItMy0xLTEtMA_85a511e0-09d7-48a6-94e3-4ea2e7a91082">871</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 40.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjMtMS0xLTEtMA_9e33d1cf-8bbd-4a71-949d-61262681eb9a">24,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjMtMy0xLTEtMA_87458601-328f-462d-ae0e-d90a2066f618">29,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjYtMS0xLTEtMA_de4bb93a-0edd-4a63-9f5a-fadedabbd139">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjYtMy0xLTEtMA_7fa66c63-c243-4732-ad35-39abb42bc79a">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzIy_375cd9d5-1046-43e5-834c-9bb86dfc2864"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzIy_40feaa66-e15c-4057-be62-d27c8fa8ff37">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzM2_458d6550-5629-418b-ae1f-bfcc6a2a1765"><ix:nonFraction unitRef="shares" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzM2_dd869992-3429-4d67-a0a3-11694bd2cbe6">10,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzYx_0c6490fa-abc7-49d5-9690-dad4b3e03528"><ix:nonFraction unitRef="shares" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzYx_293b4a11-24cb-46b2-b212-6bbe4a4140a0"><ix:nonFraction unitRef="shares" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzYx_4f2de8e2-435d-4684-809c-393138daebc5"><ix:nonFraction unitRef="shares" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzYx_5e34ed45-6fea-47e8-8410-3475610b1ba5">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares, issued or outstanding at September 30, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMS0xLTEtMA_4126d66b-53f0-4f21-b9f4-275c3c4d1281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMy0xLTEtMA_07ad271b-c6da-42a5-be72-5f0d0bf962e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzE4_44bf18c4-c766-482a-bbc9-fac6f931242c"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzE4_d233acfe-713f-4368-a027-193f7bcdcd96">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzMy_0b8718a1-1180-492a-80d1-dcbe968a8ad2"><ix:nonFraction unitRef="shares" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzMy_bdd75af4-d3ec-4603-8b6a-dcc87ee13516">500,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzU0_28f80702-41c0-4f6e-95be-f313f08c7915"><ix:nonFraction unitRef="shares" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzU0_41b0c92a-b79b-423d-b037-55f877fed26d">27,346</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzY4_d6990f12-ebb3-48d0-9a1c-0b54499530f1"><ix:nonFraction unitRef="shares" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzY4_e431bf8c-7201-4e27-bf53-3e3e352949ea">27,255</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMS0xLTEtMA_ad2ada77-6a43-4a6d-8abf-b759bd6ab3c3">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMy0xLTEtMA_b82174c2-8edc-44d4-8390-0d7f67e1de6c">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzYtMS0xLTEtMA_0e9dffa5-297a-4076-b0b7-f970fbbdb612">657,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzYtMy0xLTEtMA_a680f8ee-118b-4c69-9ac0-71a067730508">648,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzctMS0xLTEtMA_b51f6088-72d1-4194-bfb6-b26c0afff0e0">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzctMy0xLTEtMA_380ff4c2-e3aa-48d3-9a5d-c287502e954a">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzgtMS0xLTEtMA_8e42937e-a63a-4a40-a733-d825e922dd21">297,603</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzgtMy0xLTEtMA_9112f799-9b6c-4a03-956f-8f5324265656">244,026</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzktMS0xLTEtMA_a7bba80b-d567-4fec-9ce2-fdf02e349001">360,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzktMy0xLTEtMA_85858bb6-3c81-4824-8939-362204058b9b">405,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 27pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNDAtMS0xLTEtMA_b220ddde-6b06-4a97-b2b6-20c464bb5673">384,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNDAtMy0xLTEtMA_08bfcf24-bdcf-4329-9cc3-0d2c40bbae1d">435,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;See accompanying notes to unaudited consolidated financial statements. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AnaptysBio, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMi0xLTEtMS0w_75a9a5ce-e8e1-4cbb-bc76-8198d584228c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMi0zLTEtMS0w_e9762185-3852-4666-8596-fb741afb3633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMi01LTEtMS0w_af7f9f8f-59f3-4333-b9ef-cc87b612e703">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMi03LTEtMS0w_5050c23e-c27a-47fd-810e-68be4c986d2b">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNC0xLTEtMS0w_5471e26c-6dcf-4558-b2df-9b91e31885c0">19,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNC0zLTEtMS0w_e025a234-eea1-41a2-8da6-753246117fd3">29,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNC01LTEtMS0w_cc1fbcd5-e2da-4ee0-b761-0781efa08f8b">58,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNC03LTEtMS0w_4b266030-3f51-4965-ad72-35380fde4ca3">77,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNS0xLTEtMS0w_0286902e-97f2-4032-beb9-34f105e8b703">4,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNS0zLTEtMS0w_2227d9f0-58f4-4d1f-a995-2d68e13e41cd">3,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNS01LTEtMS0w_cccc20ad-3e6a-4dd7-b4ab-0fd0ef379b4a">13,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNS03LTEtMS0w_f24b33b5-ed79-4508-9d33-17695836aaec">12,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 27pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNi0xLTEtMS0w_e20bf172-19a7-4787-ad9d-82cb522ce0b4">24,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNi0zLTEtMS0w_0a82ba9d-9bff-4d87-a409-afb859f523d7">33,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNi01LTEtMS0w_6d9becd8-1aa8-48d1-a42f-6a3eb9848c9e">72,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNi03LTEtMS0w_d1093217-69f9-4581-a9b9-1de974505f5a">90,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 40.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNy0xLTEtMS0w_382107bd-fbd7-42ad-bb15-ce5afb8eb899">24,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNy0zLTEtMS0w_dc612f90-fda4-4760-9781-94db7767993b">33,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNy01LTEtMS0w_73f96fb8-fe6b-4ea9-a077-9b11c64cb17c">57,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNy03LTEtMS0w_56ad77bd-9626-4963-a54c-5e7c64efb1bb">85,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfOS0xLTEtMS0w_321ddc94-1781-420c-9d15-71a9063294cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfOS0zLTEtMS0w_7ab959e6-5640-497c-a37a-5a46fc0a421d">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfOS01LTEtMS0w_7bd328c5-47f1-491e-93f0-0c3395d9342f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfOS03LTEtMS0w_caf7cbe2-8847-42c3-a675-e81445a0963d">841</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTEtMS0xLTEtMA_7b70ad1d-aec1-4199-bfd9-82685d0ec03d">625</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTEtMy0xLTEtMA_951646ff-bad2-4858-a467-2b3a50c7edd7">2,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTEtNS0xLTEtMA_f9594c62-e393-44c7-a7c4-617a31003945">3,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTEtNy0xLTEtMA_2a957677-3403-47c2-94cf-b24b35aa4fc0">8,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTItMS0xLTEtMA_55ae1ad6-9f79-45e7-a39c-4bf2d17dcf53">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTItMy0xLTEtMA_e80c2ce9-4074-4458-8acc-c48bb00b353f">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTItNS0xLTEtMA_a155efc5-6040-43ab-928f-838508856584">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTItNy0xLTEtMA_887a60d1-146e-4440-a54d-33a7b923e821">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 27pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTMtMS0xLTEtMA_c30795dd-190f-4f0b-a083-a998139fc1bc">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTMtMy0xLTEtMA_59dd5ea2-9808-4839-b3eb-b8db69af36ba">2,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTMtNS0xLTEtMA_6e80d85c-7026-405e-b569-c6ea10b52588">3,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTMtNy0xLTEtMA_924dbbb0-b278-48e0-b877-7c88ec8b5a54">7,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 40.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTQtMS0xLTEtMA_904b484c-8774-4b67-9e8c-39e8a267575d">23,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTQtMy0xLTEtMA_b3df17a4-1f24-4ccc-9df9-2e29293b9448">31,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTQtNS0xLTEtMA_009f5b49-9821-44e3-bba8-103123bf8f0e">53,577</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTQtNy0xLTEtMA_d84b2e6c-a09c-446d-b6a1-197362f32001">77,203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 27pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes </span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTUtMS0xLTEtMA_218ac409-dae9-4544-b6b5-ec80aa889b65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTUtMy0xLTEtMA_3fbffa47-150a-4e0f-a694-e87e7be3bf0f">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTUtNS0xLTEtMA_72cc5da4-7416-4cc3-8938-d773039d9938">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTUtNy0xLTEtMA_b1bc6516-88e7-46dd-ab80-de961ef27ada">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 38.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTctMS0xLTEtMA_c5aa5711-975d-4d2e-bf48-13faaa0633db">23,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTctMy0xLTEtMA_b4d9942a-f1ee-4589-a416-969e9c9b2331">31,033</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTctNS0xLTEtMA_50f62b2f-51eb-4182-93ca-943fb4ab11a2">53,577</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTctNy0xLTEtMA_03d723d7-43cb-491c-830d-f8da6ac9ce0c">77,073</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (loss) income on available for sale securities, net of tax of $<ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOjU1NWIxY2M3MGU3YjQ3OGVhNzk1MmU4ODExYWI3MWI3Xzc3_0331b039-1b5b-4e10-b65f-963c9926ffee">0</ix:nonFraction>, $(<ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOjU1NWIxY2M3MGU3YjQ3OGVhNzk1MmU4ODExYWI3MWI3Xzgx_c0f4178f-b22e-4d75-be81-c50073f4bba5">25</ix:nonFraction>), $<ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOjU1NWIxY2M3MGU3YjQ3OGVhNzk1MmU4ODExYWI3MWI3Xzg1_e1961165-88a1-4006-8cec-447012caa414">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOjU1NWIxY2M3MGU3YjQ3OGVhNzk1MmU4ODExYWI3MWI3Xzky_94c91f42-131f-4b50-8a99-d309ad916b17">189</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtMS0xLTEtMA_cb22dd70-3bde-470d-9d29-39e53e548a7a">494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtMy0xLTEtMA_80ac133d-37e9-4ed5-a2e4-88b8f08e2cd4">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtNS0xLTEtMA_0bdee5af-26b8-4604-a125-ee79ab1e5af7">79</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtNy0xLTEtMA_25cfd48c-9bf2-402d-ba2f-6c3fc1ea2d9e">703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 40.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjItMS0xLTEtMA_dc458dde-25df-4ed5-8bad-b0647a1a7798">24,261</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjItMy0xLTEtMA_683cfb29-92b1-4e7b-a09f-d69ef9516191">31,127</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjItNS0xLTEtMA_dd2753e3-8067-49e8-9a50-0df9d11d8498">53,656</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjItNy0xLTEtMA_3b882b6b-da1c-46ed-a931-9a8987d5e45c">76,370</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 27pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjQtMS0xLTEtMA_aea55aad-bf0a-488b-a59e-37b39c1c8c31">0.87</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjQtMy0xLTEtMA_1472547a-d6de-405c-a552-9ec03657824f">1.15</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjQtNS0xLTEtMA_649957ca-1827-464f-8165-73028f859d59">1.96</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjQtNy0xLTEtMA_2e500e1f-0967-4869-bd13-3e553e030d15">2.85</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 27pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjctMS0xLTEtMA_5b2d955e-4135-48ca-9f45-ceb2b18e44c9">27,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjctMy0xLTEtMA_1aea9a97-1815-49a3-b1b4-861e07cc731e">27,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjctNS0xLTEtMA_1f7a5288-a91b-47ce-8a5c-758b27dc8b13">27,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjctNy0xLTEtMA_6b6f432b-be57-4bcf-b1a0-4855ce21e0b5">27,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;See accompanying notes to unaudited consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AnaptysBio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.69pt;font-weight:700;line-height:120%">Consolidated Statement of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.885%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive (Loss) Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f8388b833b04a14aa7b3b7d69daa5e3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMi0xLTEtMS0w_301dab42-96ab-4129-b831-7306f1511f93">27,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f8388b833b04a14aa7b3b7d69daa5e3_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMi0zLTEtMS0w_d43ca327-baeb-4d87-a90e-56feb1b37ef9">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b752f6a10ec473ab4469529bdecb756_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMi01LTEtMS0w_d8c47785-814c-4602-9fe6-8f5ce7497a50">648,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id504f195d28d4333af9e358584ff4c20_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMi03LTEtMS0w_872b2486-a1b3-433a-ac12-f8391fd5eef9">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79651fec1fe943d387f3c41aefb528e9_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMi05LTEtMS0w_e1621736-f8c6-45c8-b67f-c23d2b76dae6">244,026</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMi0xMS0xLTEtMA_5beeaa52-cae3-4735-bfa1-a60d20adc478">405,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares issued under employee stock plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17101efcf2d941cfa1317efa0e6a6d29_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfNi0xLTEtMS0w_25ee50e9-50ee-460b-9322-27d299468ea2">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i357b59d8716e4b85b7100017c7b775d2_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfNi01LTEtMS0w_6a601e30-b1dc-4532-bd4d-5cb49c9791ed">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd425d2b1c34235b752166763d78ceb_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfNi0xMS0xLTEtMA_d6ec23bf-35ae-433b-93ed-fb0fee922356">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i357b59d8716e4b85b7100017c7b775d2_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTEtNS0xLTEtMA_0a42ef0d-5c01-4272-900c-7398ca8cd881">2,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd425d2b1c34235b752166763d78ceb_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTEtMTEtMS0xLTA_1432f615-99fe-41ab-bd62-65e11a248b98">2,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive income, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9140c17c6ff541b4905365c4fa22b7ed_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTItNy0xLTEtMA_92fc3c15-1962-4480-b071-9cac643c9200">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd425d2b1c34235b752166763d78ceb_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTItMTEtMS0xLTA_c8612a15-b68e-4068-97ee-ebcb1f3ceecd">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0579a6e71aeb413daee069a798be563a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTMtOS0xLTEtMA_fd004d8c-2a7b-4281-ab83-50adcf086f52">8,262</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fd425d2b1c34235b752166763d78ceb_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTMtMTEtMS0xLTA_d3c39f6a-490c-42af-b6c9-10c9d3cdd365">8,262</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48fbda0280274166a0586adfa171945a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTQtMS0xLTEtMA_a2dd8f1d-004a-4b2d-9b73-80511f3e86d8">27,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48fbda0280274166a0586adfa171945a_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTQtMy0xLTEtMA_d8f96938-5e52-475f-8f9b-b1edaf637923">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice4c5cb905674403beb71f5e810ab566_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTQtNS0xLTEtMA_6d056057-c816-4f36-9fdb-e2fcb7d16112">651,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6739116295d4dc896e69e608e97c76f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTQtNy0xLTEtMA_b9259831-93fa-4447-8396-7f1c145b2ce1">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6198391c49854758a19ea7355d359c10_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTQtOS0xLTEtMA_ff908a15-37ff-4eec-8c34-5b7703941950">252,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50aea59aa1e849aab1bec2360f5663d0_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTQtMTEtMS0xLTA_8c87cc5f-7177-4885-aa61-527ff4f5e850">400,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares issued under employee stock plans</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd3a6df5115a4148a71e445678d6304e_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTUtMS0xLTEtMA_3c3cec34-cb5b-42fb-939f-e5da13ea0a8a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213f296ddf4342eaae36eb522302fe38_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTUtNS0xLTEtMA_38d08dd9-fe6a-4f94-b5d3-8a2920eec364">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6f5d31ceca84e909c7ff8eba6ad5711_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTUtMTEtMS0xLTA_6151dd03-72b1-4025-ae60-334a520b1fb5">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213f296ddf4342eaae36eb522302fe38_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTYtNS0xLTEtMA_b7c2cee8-501f-4733-9c17-51ffe8a19bbf">2,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6f5d31ceca84e909c7ff8eba6ad5711_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTYtMTEtMS0xLTA_8f510b01-013e-40e1-afba-8c56bd84981d">2,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive loss, net</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if07ac049e6384b9eb3f756bd60ed16e0_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTctNy0xLTEtMA_8e3d7f4e-3bfd-4d89-8b5b-8b3333ab6018">392</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6f5d31ceca84e909c7ff8eba6ad5711_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTctMTEtMS0xLTA_e1d39667-9bf0-4ceb-8103-cb63e51ed747">392</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83c45560d4d04c4d8d460117720b4d0c_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTgtOS0xLTEtMA_f7f65693-719f-4fbc-b7d7-e085e6f2d202">21,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6f5d31ceca84e909c7ff8eba6ad5711_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTgtMTEtMS0xLTA_e2aea349-ecdc-4cd7-b970-54bcb210da46">21,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic96af881aa1f4e0f9cbfba136350d1fe_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTktMS0xLTEtMA_5aed5413-0276-4e1a-b353-15847ab81d41">27,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96af881aa1f4e0f9cbfba136350d1fe_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTktMy0xLTEtMA_dcbc5b20-6d3d-4a4d-bf61-d9f96971d3b2">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a03dc9bd9c345e9b3e5f735f284462f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTktNS0xLTEtMA_9806f336-3e74-4ce4-ab92-cd15d2eeb8ae">654,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e7a37ef3fbc48b8bfbd71ac11d46dfd_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTktNy0xLTEtMA_8b227be4-2b5e-4f63-a174-ed55f8bacfb8">753</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02ddd9390325464f87909298798898e6_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTktOS0xLTEtMA_e5b18d60-1825-4391-b60b-9350fe626414">273,836</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f3eeec59a504f6aae08e693714a107f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTktMTEtMS0xLTA_047e4d05-119c-4258-a3b4-45176af51490">381,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares issued under employee stock plans</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fae86a718c54cb28203f4589f4ae14d_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjAtMS0xLTEtMA_00a01707-23bb-437f-a167-3616fde182ef">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8405fd2c9af42b3ad40e73761f1b8b6_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjAtNS0xLTEtMA_128788ae-4a4a-4615-93a8-e7fc4014469a">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjAtMTEtMS0xLTA_ac806c05-2498-4691-bbf7-04328c8c673b">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8405fd2c9af42b3ad40e73761f1b8b6_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjItNS0xLTEtMA_063fdbf2-fcc4-4c6c-893c-f4ac53dd02fb">2,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjItMTEtMS0xLTA_7fb37c99-a041-4af1-a50f-a9026cf3dcba">2,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i944b329323c7414f9375a984348bacdd_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjMtNy0xLTEtMA_8d88f084-54b7-40f3-abb7-682da59d971d">494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjMtMTEtMS0xLTA_2b4c350b-3a5b-4f0b-be39-7a0572262b03">494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd685fdf5e6746878ea46ac3dc5f5dcb_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjQtOS0xLTEtMA_257d3d33-f731-4470-8a4a-553d960c4e97">23,767</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjQtMTEtMS0xLTA_32692b2b-1f41-4753-b212-62ef29d6745f">23,767</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0683082d1ab40eab4b01d7c817b5d80_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjUtMS0xLTEtMA_72bbc4bf-970a-4a35-b650-70eae9bf3410">27,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0683082d1ab40eab4b01d7c817b5d80_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjUtMy0xLTEtMA_294198b4-7607-472e-af68-c5033bc5244c">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6951884f2f9647878228f79ce16d0b71_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjUtNS0xLTEtMA_a75a9279-d50f-48e8-864f-cab49f40b62b">657,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id80350b4ab804fab943fd2b3e0d00fe9_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjUtNy0xLTEtMA_55307169-b0e0-4621-99d7-64ecc84ca252">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d377b1ba9344a280a30d332ae1b931_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjUtOS0xLTEtMA_615f96be-9500-4456-9a98-becd81442acd">297,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjUtMTEtMS0xLTA_6e850872-1de6-44f8-b2b6-20623cdcedef">360,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AnaptysBio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.69pt;font-weight:700;line-height:120%">Consolidated Statement of Stockholders&#8217; Equity  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:37.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.722%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive (Loss) Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i667c1dbae6f546fab85e5fabd504fab3_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMi0xLTEtMS0w_4e877201-025f-4a71-aad0-baedf9798ddd">26,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667c1dbae6f546fab85e5fabd504fab3_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMi0zLTEtMS0w_5799e066-4733-4c4e-a1e4-07779964db6b">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6fe4a6e5de4b5a82cabfeab9b65f59_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMi01LTEtMS0w_aac8d545-71a3-41f9-abb5-68c28f955a1b">633,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a98cd885414727b67a6826b7552a42_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMi03LTEtMS0w_5181c2c7-ddaa-4637-8369-7149eac3a0ba">223</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32de20025be940029a9af8399272f6f1_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMi05LTEtMS0w_0d749f01-f85d-4800-84ef-0af8794df457">146,690</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia19642c61e8545afa9130417d92767d4_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMi0xMS0xLTEtMA_dc564ddd-52e3-4740-b352-4bac576cef56">486,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares issued under employee stock plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4af12f6819b34f6a83947ba47498eefa_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfNi0xLTEtMS0w_4a112ccb-6eb2-4561-8af6-7ed53d8bd16a">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d6bca25d24e2bb26123e8dcde48a9_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfNi01LTEtMS0w_cc5fbb19-1a96-4c75-b05b-a25af2cc267f">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9518b119be40879fc2dbaacdfd8964_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfNi0xMS0xLTEtMA_770b62ea-5724-422f-b4d3-1dad6eb1a835">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7d6bca25d24e2bb26123e8dcde48a9_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTEtNS0xLTEtMA_cda31eb8-d06a-429d-866f-1362bd4d82eb">2,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9518b119be40879fc2dbaacdfd8964_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTEtMTEtMS0xLTA_cd4b1e92-7575-4f2e-b2e7-3aa1dbe81fc2">2,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive income, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dec769f5314a2990ce879992bf1d2f_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTItNy0xLTEtMA_519689dd-9d79-408b-b7c6-b28bc7cc1fbc">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9518b119be40879fc2dbaacdfd8964_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTItMTEtMS0xLTA_f5bd6b42-9bac-4690-9911-cab174daf592">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49e522e4b1724704a8bcc7e70955f164_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTMtOS0xLTEtMA_effa776c-b757-4297-8ae9-c7f6a977d93e">22,078</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe9518b119be40879fc2dbaacdfd8964_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTMtMTEtMS0xLTA_b0d735ca-763d-4e9c-8c6c-5d77c2f4c21e">22,078</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, March 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4507f2fa60434fe3a58a43f0bfb5ac25_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTQtMS0xLTEtMA_a359d6f3-df0e-432b-9318-cf0b1a873cb5">27,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4507f2fa60434fe3a58a43f0bfb5ac25_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTQtMy0xLTEtMA_fca497d7-d411-4f91-8096-d09881b72119">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7846c140e24c41b1b46a068579c34d6c_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTQtNS0xLTEtMA_3ef0212f-9d03-4439-ab06-2ee239f6aba7">636,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ed8446ec51444f3a853535c615dc1ca_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTQtNy0xLTEtMA_029ece3d-c973-4ca8-94db-e0fc3b2ee307">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc18062be6e433ea7729c90c6424e74_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTQtOS0xLTEtMA_380c95d0-1031-4f22-99cd-308497c7dcf4">168,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c49610ebefc49989126a06a1c4800fd_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTQtMTEtMS0xLTA_5c055f46-6d4e-4e23-b9c5-647136413bc9">468,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares issued under employee stock plans</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3b1c52d7eea4be9b490a69977fda245_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTUtMS0xLTEtMA_78e6d3cb-a6f0-43e6-aa70-63fab1d6dd4c">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898f639913e84acdaf09fc3451ae71fe_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTUtNS0xLTEtMA_8791826e-a1c3-484c-9798-eb874174a4c4">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ddeec5c1a824dd1b0a410b866cbc85f_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTUtMTEtMS0xLTA_d210d9e1-056e-4761-ad6b-4231ca4fe569">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898f639913e84acdaf09fc3451ae71fe_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTctNS0xLTEtMA_cdbf73a8-e05f-4635-b356-15d8faf0bdf8">3,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ddeec5c1a824dd1b0a410b866cbc85f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTctMTEtMS0xLTA_feca2e45-5cb6-489b-b9f1-9c04039fe507">3,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive income, net</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293e1639f7f448eb898ed9fbe929111d_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTgtNy0xLTEtMA_d252e2ea-07c6-465d-9d5d-63cb1261d2d2">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ddeec5c1a824dd1b0a410b866cbc85f_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTgtMTEtMS0xLTA_a4e764c2-cf56-40cc-bce7-075cf6a7d3f8">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic831befbaf7b4ef59c2293c1c600c9ea_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTktOS0xLTEtMA_3db74771-f138-4d6f-8fbb-9c59f2c4e392">23,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ddeec5c1a824dd1b0a410b866cbc85f_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTktMTEtMS0xLTA_2d2a2f7f-671e-4685-8f83-0bc2c8d94163">23,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, June 30, 2019</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c70240883514eddb497067bdc1a0d89_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjAtMS0xLTEtMA_64349a3a-6419-4d36-ba7e-910ef0a71626">27,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c70240883514eddb497067bdc1a0d89_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjAtMy0xLTEtMA_1df3436b-9731-4483-a021-6167a9782064">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53163832a44a4c72a73d784e3f2ff470_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjAtNS0xLTEtMA_807ddc6e-c3a6-4ff7-82e8-81fcbf2615b8">640,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadb088f6b63b44368f2345abfce054ce_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjAtNy0xLTEtMA_4ecfb885-5e78-4953-a356-1a691ade481a">574</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i980d58c527c04708ad659969362a43cf_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjAtOS0xLTEtMA_d8739e25-357f-4783-8bdd-5b29711b9ef6">192,730</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f4eacb369c40a8a2cfe22a790e44f2_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjAtMTEtMS0xLTA_3706475a-5d9f-4621-b1c3-f067c3c89641">448,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares issued under employee stock plans</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6d60309ee7d481fa5ce4476a8abdc34_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjMtMS0xLTEtMA_038bde5e-60b6-4a35-aaf3-edb14ea6a6af">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66433ff9b85047cc817a25e24c74a772_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjMtNS0xLTEtMA_f5819a6c-682a-4477-8a98-eac28f7f71ac">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjMtMTEtMS0xLTA_29c95ab9-3859-415c-84b7-83f82a2b0660">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66433ff9b85047cc817a25e24c74a772_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjUtNS0xLTEtMA_8aadaa9c-1399-4912-bb10-c000469dffda">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjUtMTEtMS0xLTA_aed1c749-fa17-4e0b-9c07-e9ae812969f6">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b565f7f97a4fb29b4ae5d124a4fde7_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjYtNy0xLTEtMA_17894445-a57c-4562-89ff-13f7d42845f0">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjYtMTEtMS0xLTA_c886f618-f81e-496b-8895-d56a42bfe2ad">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1eb595b079543ce95ba9cb5eadf6d99_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjctOS0xLTEtMA_763889b0-f359-4bb5-af59-880c624426db">31,033</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjctMTEtMS0xLTA_c87ccda8-104d-4700-8d14-e86058f8cd4b">31,033</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i607986a10b7947ca9d199fecd6596a2f_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjgtMS0xLTEtMA_84bfc719-b6a4-401e-82ec-2cb055f717bb">27,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607986a10b7947ca9d199fecd6596a2f_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjgtMy0xLTEtMA_fd58414b-2dd6-450a-8daf-5cf7a062902d">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d431333b5e442b4a517d3cbaa431601_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjgtNS0xLTEtMA_d4672fe4-bee8-46b3-91bd-d36328b45279">644,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00dc647c0bac4896a34e44a91c3920f4_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjgtNy0xLTEtMA_4c237d77-d549-4097-999f-4a0d40e29f8c">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ace0421c6554ea0aaf0d90e9aa8c8a3_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjgtOS0xLTEtMA_0d18651a-658f-402b-bfe7-402001f15bf9">223,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0d75695e6c4e19919e8ee8cced3fdb_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjgtMTEtMS0xLTA_fd06b2a4-62d0-4353-83fd-bf481094d35e">420,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AnaptysBio, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMy0xLTEtMS0w_39be3884-abde-4125-bd40-2a32f7204073">53,577</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMy0zLTEtMS0w_00ed85e4-4722-4010-887d-e95eb2723df2">77,073</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfNS0xLTEtMS0w_2981de01-2696-40e2-b6e1-e81218e11fbb">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfNS0zLTEtMS0w_b9629677-e131-48c8-b63d-2b328e6d50fe">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfNi0xLTEtMS0w_11f58070-7d83-4e4d-b1b3-8f84b900cf71">8,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfNi0zLTEtMS0w_fd9c0b99-e952-4e02-b187-b38f510f57bc">9,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion/amortization of investments, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfOC0xLTEtMS0w_98f3bc47-bbd0-49e3-8208-2345ad2764e6">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfOC0zLTEtMS0w_cd7baf8e-45fc-4913-b88e-713507fbd75e">2,449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfOS0xLTEtMS0w_bd420d36-7772-4df2-8d05-c3b2d83eae37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfOS0zLTEtMS0w_483c3a8e-6c68-4295-ab54-16d6497d6c59">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 27pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTMtMS0xLTEtMA_17a6516c-c8f4-405e-8756-a427ae813c7f">2,902</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTMtMy0xLTEtMA_d9cab3d6-b974-48e7-87e9-d1d4c42e140d">2,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 27pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTQtMS0xLTEtMA_722197d2-82ae-45a2-ae71-8e61359bf90a">4,431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTQtMy0xLTEtMA_fa5e00b5-b15d-4231-b433-dc22cee25961">13,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 40.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTctMS0xLTEtMA_45563b79-f9d7-4223-93a9-38e45a0d5017">51,735</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTctMy0xLTEtMA_d89c31ca-4905-45a7-ab02-1b5fa2ea96bf">53,712</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTktMS0xLTEtMA_f3ba78fe-f08b-4f4b-8a6e-d10956a5c83f">156,572</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTktMy0xLTEtMA_b0b668fd-c73f-4aff-b4aa-4d7a5452b3dd">175,049</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjAtMS0xLTEtMA_2e5685e6-98f3-458a-b142-d40d607bb581">247,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjAtMy0xLTEtMA_4c145469-302d-4ccb-bee2-a74ac2c42ede">303,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjEtMS0xLTEtMA_dd2ddde6-1cbc-49fb-8689-258279c5538e">258</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjEtMy0xLTEtMA_6dea892d-970f-41d3-9eb6-31b858469d15">701</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 40.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjItMS0xLTEtMA_81fc8ba6-dead-4e1e-9fc7-23523376a136">90,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjItMy0xLTEtMA_927891cc-896a-4e5c-b171-b87336355161">127,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, upon the exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjQtMS0xLTEtMA_8ca673e4-639e-413d-9594-44f1547f40cd">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjQtMy0xLTEtMA_f3608790-bc29-4d11-ad73-79a6a13763c8">1,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments on notes payable</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjctMS0xLTEtMA_e349f062-81d9-45b7-829b-a58c21cb24f3">1,375</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjctMy0xLTEtMA_71c00ddb-a8b1-4353-8c82-27679f343d54">5,625</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 40.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzAtMS0xLTEtMA_40c7dac5-f751-4b19-8e46-deb61331cbd1">1,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzAtMy0xLTEtMA_e432f3f1-ec76-4fc8-a653-69c3a3caa08c">4,382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 54pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzEtMS0xLTEtMA_10832ff9-ad81-4012-a39c-60eedf7b7b26">38,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzEtMy0xLTEtMA_e1102fef-aee8-4784-9284-5b23bea4a069">69,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzItMS0xLTEtMA_10b7df74-7b6e-4cc3-bac5-83bb82c36501">171,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia19642c61e8545afa9130417d92767d4_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzItMy0xLTEtMA_43e77bfa-9e5d-4a6a-abd0-cfbaa8d20be1">113,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzMtMS0xLTEtMA_b76a407b-7a3d-48e5-ba23-6cb8b2b6005c">209,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0d75695e6c4e19919e8ee8cced3fdb_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzMtMy0xLTEtMA_3770ad90-23af-43b0-a696-76721f33eaca">182,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzUtMS0xLTEtMA_bb15b256-ad81-42d8-ae43-fdd42984a879">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzUtMy0xLTEtMA_716b1700-86c2-4a62-acbb-e900d8bf0072">384</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts accrued for property and equipment</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzgtMS0xLTEtMA_9f71ad0a-4537-404d-aeb6-c6d95bd7f106">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzgtMy0xLTEtMA_6a814944-5d23-406f-a541-217e04379d5c">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AnaptysBio, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Consolidated Financial Statements </span></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNC9mcmFnOjlhZjI1OTIwNDUwMDQyMzc5MGQ2MmM2Y2Q3ODM2ZTY3L3RleHRyZWdpb246OWFmMjU5MjA0NTAwNDIzNzkwZDYyYzZjZDc4MzZlNjdfMTk1Ng_300e2880-6fe0-49e5-b353-596f177f39e1" continuedAt="iba74bc899ae14201a9973dce1df923b3" escape="true">Description of the Business </ix:nonNumeric></span></div><ix:continuation id="iba74bc899ae14201a9973dce1df923b3"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AnaptysBio, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in November 2005. We are a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We currently generate revenue from milestones achieved under our collaborative research and development arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Since our inception, we have devoted our primary effort to research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Our management believes our currently available resources will provide sufficient funds to enable us to meet our operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</span></div></ix:continuation><div id="i0833d33fa1bc4c56a5693b167f99fc20_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfODk0MQ_95976865-ff2e-4501-8c4e-fbedefd60ab5" continuedAt="ic635df0e4582444badf35a3fc7106933" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="ic635df0e4582444badf35a3fc7106933" continuedAt="ifdfb9655770c42c69e2e0acf57a568b5"><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfODkwOA_38afbe67-990a-42a9-9d19-cbcba2e71954" continuedAt="id9aea366d51c443682063e68e1823ee5" escape="true">Basis of Presentation </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id9aea366d51c443682063e68e1823ee5">The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2019 financial information to conform to the current year presentation of prepaid expenses and other assets on the Consolidated Statements of Cash Flows. Operating results for the nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus (&#8220;COVID-19&#8221;) pandemic, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions, including the issuance of stay-at-home orders and social distancing guidelines, which have resulted in some businesses suspending operations or experiencing a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business, and delay our development programs and regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;the COVID-19 pandemic on the costs and timing associated with the conduct of our clinical trials and other related business activities. The financial statements should be read in conjunction with our audited financial statements for the year ended December&#160;31, 2019 included in our Annual Form 10-K.</ix:continuation> </span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfODkzNA_2c31a46f-2db1-448b-8c6f-20ef20c46417" continuedAt="ie0e9b8e454ed49009a3dbd98074202b6" escape="true">Basis of Consolidation</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie0e9b8e454ed49009a3dbd98074202b6">The accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in <ix:nonFraction unitRef="segment" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfMjY5NQ_82a10bf2-cb30-44fd-894d-d19e2afa6eee">one</ix:nonFraction> reportable segment, and our functional and reporting currency is the U.S. dollar.</ix:continuation>  </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="ifdfb9655770c42c69e2e0acf57a568b5" continuedAt="ib38f9feab48240caa47e55cd8af42e94"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfODkwOQ_8e43f77f-e50a-48af-878c-6e6f714f942c" escape="true"><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfODkzNg_0a1c1c7e-2b4a-4964-8c1d-0df246f1e03a" escape="true"><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfODkzMg_f58a0af4-8151-4508-86b5-4dd11aa2a1fa" escape="true"><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the weighted-average o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">utstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if39316fb1c754dec9de54a11b19471c9_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RhYmxlOmE2ODlmYjEzYTY1YTQ5ZjdhMTVkZTY2YWFjZDYwNTFlL3RhYmxlcmFuZ2U6YTY4OWZiMTNhNjVhNDlmN2ExNWRlNjZhYWNkNjA1MWVfMy0xLTEtMS0w_568c379f-afed-4360-acf4-108fd5ca7de7">2,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7cc476288eb442b5bf98c3be003a8dc9_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RhYmxlOmE2ODlmYjEzYTY1YTQ5ZjdhMTVkZTY2YWFjZDYwNTFlL3RhYmxlcmFuZ2U6YTY4OWZiMTNhNjVhNDlmN2ExNWRlNjZhYWNkNjA1MWVfMy0zLTEtMS0w_3ed36cdd-70af-4aba-b868-849a5bf15e69">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22c2fc8f301f4097805ab635ea1c679b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RhYmxlOmE2ODlmYjEzYTY1YTQ5ZjdhMTVkZTY2YWFjZDYwNTFlL3RhYmxlcmFuZ2U6YTY4OWZiMTNhNjVhNDlmN2ExNWRlNjZhYWNkNjA1MWVfMy01LTEtMS0w_2baf099e-589f-49b4-9158-08a4cfa4dd1f">2,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9edb7d98f97f42518645609a12b3a888_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RhYmxlOmE2ODlmYjEzYTY1YTQ5ZjdhMTVkZTY2YWFjZDYwNTFlL3RhYmxlcmFuZ2U6YTY4OWZiMTNhNjVhNDlmN2ExNWRlNjZhYWNkNjA1MWVfMy03LTEtMS0w_e9cfcf0d-4de1-4505-a1e4-5a8cfb8a7f58">2,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfODkzOA_18b30c93-aed7-452a-a911-78f8c9e7ea78" continuedAt="i72097a8cac294236ae73683eb24a5951" escape="true"><div style="margin-top:18pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Recently Adopted</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intended to simplify the accounting for income taxes. The guidance removes the following exceptions: (1) exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, (2) exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, (3) exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary, and (4) exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. Additionally, the guidance simplifies the accounting for income taxes by: (1) requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, (2) requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, (3) specifying that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements (although the entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority), (4) requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, and (5) making minor improvements for income tax accounting related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method. The guidance will be effective for fiscal years and interim periods beginning after December 15, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption, and early adoption is permitted.&#160;We early adopted this standard on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:31.5pt"><ix:continuation id="ib38f9feab48240caa47e55cd8af42e94"><ix:continuation id="i72097a8cac294236ae73683eb24a5951"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses:&#160;Measurement of Credit Losses on Financial Instruments&#160;(Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;which changes the accounting treatment for recognizing the impairment of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also eliminates the other-than-temporary impairment model for available-for-sale (&#8220;AFS&#8221;) debt securities. Entities will begin to recognize credit losses on AFS debt securities as allowances rather than as reductions in the carrying value of the securities. Impairment that is not credit-related impairment will continue to be recognized in other comprehensive income and entities will no longer consider the length of time a security has been in an unrealized loss position when determining whether a credit loss exists. ASU 2016-13 becomes effective for annual and interim periods beginning after December 15, 2019.&#160;We adopted this standard prospectively on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements as credit losses are not expected to be significant based on historical trends, the financial condition of our investments and external market factors. We will continue to actively monitor the impact of the COVID-19 pandemic on expected credit losses.</span></ix:continuation></ix:continuation></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RleHRyZWdpb246MmE4MzI0YTc2ZTE4NGJlMmIzMzY4OThkNjliNjY3OGNfMjA5_9cc2539b-a107-4aab-aef2-e2417800ed19" continuedAt="ibcfcf6dddbba4db8a8fb842281406ace" escape="true">Balance Sheet Accounts and Supplemental Disclosures </ix:nonNumeric></span></div><ix:continuation id="ibcfcf6dddbba4db8a8fb842281406ace"><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment </span></div><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RleHRyZWdpb246MmE4MzI0YTc2ZTE4NGJlMmIzMzY4OThkNjliNjY3OGNfMjEz_c7499f0c-aaa2-4c25-bf03-d6d105563187" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following: </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97829a1a0f0c4c658a231073c0b1761b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfMS0xLTEtMS0w_c7df2db6-82c9-497d-9688-809288355cdb">5,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a95fbb42de4ae682693fc8fc7a2360_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfMS0zLTEtMS0w_bfffa661-f93a-45d6-8a06-5ce2a1a285a3">4,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176c0f8d5a494175860df633af0380ce_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfMi0xLTEtMS0w_dfb332eb-bbc2-4048-963b-b3b76ce26b92">827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42c1948b5934a47909d55f51e1c2324_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfMi0zLTEtMS0w_c44b2df1-96cd-4116-b32f-d59bece6b936">811</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9935f4f8c0d2424dad75609e066c7b8a_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfMy0xLTEtMS0w_46e8503d-4f14-46e4-89ff-6c16194e713c">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22374db23a0f4f9599b0ba0e269a3ee7_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfMy0zLTEtMS0w_42ed66cd-7b5a-4099-947f-a0eb29a71638">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfNC0xLTEtMS0w_e609b099-8279-418e-871b-9ce73d1df25a">6,662</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfNC0zLTEtMS0w_9bc3d0ac-afd9-4a7a-9f3e-f6112724c887">6,297</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfNS0xLTEtMS0w_5cabd3f8-f0c2-478f-a170-b97595a9989a">5,077</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfNS0zLTEtMS0w_697733ab-d75b-4bf9-964e-b976b040b5d9">4,679</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfNi0xLTEtMS0w_4356c98f-0026-4dd5-9ff3-2e78d5d5758e">1,585</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfNi0zLTEtMS0w_122b81dd-bd74-4e23-aa88-f4f8735811d7">1,618</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses </span></div><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RleHRyZWdpb246MmE4MzI0YTc2ZTE4NGJlMmIzMzY4OThkNjliNjY3OGNfMjA2_8c240622-6418-4663-81de-095c4707b9ed" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and related expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfMS0xLTEtMS0w_9e2c7fe1-5cf4-4585-87b8-32bec1cd33fc">2,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfMS0zLTEtMS0w_cb48a194-077d-415f-9878-143af50bf00e">2,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfMi0xLTEtMS0w_e528083a-8584-47c6-b96b-35d1f241e765">1,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfMi0zLTEtMS0w_151975eb-d7af-4da1-bbbc-f75881d38291">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research, development and manufacturing expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="anab:AccruedResearchAndDevelopmentExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfMy0xLTEtMS0w_9823f938-18a3-45b6-9d21-4399bf006abd">14,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="anab:AccruedResearchAndDevelopmentExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfMy0zLTEtMS0w_7e3b70e9-a771-4bad-84c5-3132466a50bc">8,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfNC0xLTEtMS0w_7fb753fe-b56e-431a-9fab-47cd6b2aaab0">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfNC0zLTEtMS0w_72cfe886-efe6-4465-8696-bd2e1fa9af97">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfNS0xLTEtMS0w_15a422bb-351f-448f-ace3-98d9be5b4146">18,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfNS0zLTEtMS0w_c6041de6-419c-416e-ba93-a21dfd33628c">11,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0833d33fa1bc4c56a5693b167f99fc20_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfODg5NA_20ea876e-d825-4edf-91ae-ae7ae13c3140" continuedAt="ic5a032f4f03849e6bb5f71a89b89082b" escape="true">Collaborative Research and Development Agreements</ix:nonNumeric></span></div><ix:continuation id="ic5a032f4f03849e6bb5f71a89b89082b" continuedAt="i16f741bc230d45bfb10e52d75d965ad2"><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GlaxoSmithKline Collaboration </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, we entered into a Collaboration and Exclusive License Agreement (the &#8220;GSK Agreement&#8221;) with TESARO, Inc., an oncology-focused biopharmaceutical company now a part of GlaxoSmithKline (&#8220;GSK&#8221;). Under the terms of the GSK Agreement, we agreed to perform certain discovery and early preclinical development of therapeutic antibodies with the goal of generating immunotherapy antibodies for subsequent preclinical, clinical, regulatory, and commercial development to be performed by GSK. Under the terms of the GSK Agreement, GSK paid an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i8b714d1629c94dce9455c46ac8ae3df4_D20140301-20140331" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNjQ4_3b9c6112-9be3-40f6-ba7f-29f95232e4d7">17.0</ix:nonFraction> million in March 2014 and agreed to provide funding to us for research and development services related to antibody discovery programs for <ix:nonFraction unitRef="target" contextRef="i970417eeaafd482f900c18e69347999b_I20140630" decimals="INF" format="ixt-sec:numwordsen" name="anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNzgy_11247730-01df-47be-b638-37cf0ea2f4c9">three</ix:nonFraction> specific targets. In November 2014, we and TESARO, Inc. entered into Amendment No.&#160;1 to the GSK Agreement to add an antibody discovery program against an undisclosed <ix:nonFraction unitRef="target" contextRef="i841068aebaa745a89876b4497d36c406_I20141130" decimals="INF" format="ixt-sec:numwordsen" name="anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfOTUx_b46a15fc-0254-41e2-8c3b-2c20baa57af7">four</ix:nonFraction>th target for an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ibaed7d0c461e4199ad5b9a83b5ed6c0b_D20141101-20141130" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfOTkz_ddc21b94-d5ae-413d-b2e5-0d072414e236">2.0</ix:nonFraction> million. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i16f741bc230d45bfb10e52d75d965ad2" continuedAt="iff5613859d904159bc9d75bf71bfd39b"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each development program, we are eligible to receive milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i841068aebaa745a89876b4497d36c406_I20141130" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfMTA4Mw_350df7a6-db89-4521-a5e0-0e85df249500">18.0</ix:nonFraction> million if certain preclinical and clinical trial events are achieved by GSK, up to an additional $<ix:nonFraction unitRef="usd" contextRef="i841068aebaa745a89876b4497d36c406_I20141130" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfMTE3Ng_f3add2ec-2428-42b2-a30e-87758497555b">90.0</ix:nonFraction> million if certain U.S. and European regulatory submissions and approvals in multiple indications are achieved, and up to an additional $<ix:nonFraction unitRef="usd" contextRef="i841068aebaa745a89876b4497d36c406_I20141130" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfMTMwNw_d5c256b8-7643-4072-9435-43095ac2a4d9">165.0</ix:nonFraction> million upon the achievement of specified levels of annual worldwide net sales. We will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products developed under the collaboration. Unless earlier terminated by either party upon specified circumstances, the GSK Agreement will terminate, with respect to each specific developed product, upon the later of the <ix:nonNumeric contextRef="ibaed7d0c461e4199ad5b9a83b5ed6c0b_D20141101-20141130" format="ixt-sec:duryear" name="anab:RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfMTcwMA_a319967d-d196-4909-b523-d97214dc5334">12</ix:nonNumeric>th anniversary of the first commercial sale of the product or the expiration of the last to expire of any patent. Prior to the adoption of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we determined that the upfront license fees and research funding under the GSK Agreement, as amended, should be accounted for as a single unit of accounting and that the upfront license fees should be deferred and recognized as revenue over the same period that the research and development services are performed. In December 2015, we determined that the research and development services would be extended through December 31, 2016. As a result, the period over which the unrecognized license fees and discovery milestones were recognized was extended through December 31, 2016 and have since been recognized in full. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, GSK, is a customer.&#160;We identified the following material promises under the GSK Agreement: (1) the licenses under certain patent rights relating to six discovery programs (four targets) and transfer of certain development and regulatory information, (2) research and development (&#8220;R&amp;D&#8221;) services, and (3) joint steering committee meetings. We considered the research and discovery capabilities of GSK for these specific programs, GSK&#8217;s inability to sub-license, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the joint steering committee participation would not have been provided without the R&amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated and therefore concluded that the promises should be combined into a single performance obligation at the inception of the arrangement. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the transaction price for the GSK Agreement includes the upfront payment, research reimbursement revenue, and milestones earned to date, which are allocated in their entirety to the single performance obligation. We earned and recognized <ix:nonFraction unitRef="milestone" contextRef="i043575917e6847649d70407ee576383b_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="anab:RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfMzg4Mw_f667099b-1887-40af-812e-75ed60b98180">two</ix:nonFraction> clinical milestones for $<ix:nonFraction unitRef="usd" contextRef="i8534bab099e842529d7164852e2d941c_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfMzkxMA_3c485581-96bb-4e4b-bea8-188a4f6a7c5a">15.0</ix:nonFraction> million during the nine months ended September&#160;30, 2020. No other future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials, an outcome that is difficult to predict, and GSK&#8217;s efforts. Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the intellectual property license granted to GSK and therefore have also been excluded from the transaction price. We will re-evaluate the variable transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfODkwMA_23afd6af-6653-46dd-bd8b-eaf155997251" continuedAt="i2b1f70b278ee40bdafe90bf2e3f4bca6" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones recognized through September&#160;30, 2020 under the GSK Agreement are as follows:</span></div><div style="margin-bottom:5pt;margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-PD-1 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK4057190A/Dostarlimab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-TIM-3 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK4069889A/Cobolimab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-LAG-3 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK40974386)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestone Event</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Initiated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> toxicology studies using good laboratory practices (GLPs) </span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i6714296e1ede43c4b159fb8e384daff9_D20150401-20150630" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfMi0xLTEtMS0w_f033abe3-3bd1-4a44-bfdc-b95f6a10aaf9">1.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'15</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i7f48ce05ab804c08ac1a45c2c7193b29_D20151001-20151231" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfMi00LTEtMS0w_f181d115-36d4-49a1-8279-f5347ec910fa">1.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'15</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i6a7d54c067c845509a3141ccbe591e65_D20160701-20160930" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfMi03LTEtMS0w_9025026f-692a-4853-8c68-cbee3bdbef5e">1.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q3'16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IND clearance from the FDA</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i7db5636cafbf422dbca6fb1af3c911b8_D20160101-20160331" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfMy0xLTEtMS0w_959ed7a1-c9fd-4140-9c2f-2a1f1143a931">4.0</ix:nonFraction>M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i69196f35ad1e48409df3674b606bdaab_D20160401-20160630" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfMy00LTEtMS0w_13029b6e-051b-4234-9309-9ce0ff8c6e85">4.0</ix:nonFraction>M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i9048b7098214431bb4af6b977f80d956_D20170401-20170630" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfMy03LTEtMS0w_a434403e-7e87-4d83-9aa3-f72bdabb7881">4.0</ix:nonFraction>M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'17</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2 clinical trial initiation</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i49356d8d8f764282af58ba1fb686d94e_D20170401-20170630" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfNC0xLTEtMS0w_5fe8ea29-1cd2-4834-b171-21165c7113e8">3.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'17</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ic85d714342d0443a9aae31c32b92429f_D20171001-20171231" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfNC00LTEtMS0w_135094b0-3d5c-4903-a001-5e06d4954980">3.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'17</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i817f5602cf4d49c1af5c2aa476a787d4_D20191001-20191231" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfNC03LTEtMS0w_925ed910-ce6c-4d6a-950e-6a0de86ce269">3.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'19</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3 clinical trial initiation - first indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ied95da1a4f9848e981906b3694d41c40_D20180701-20180930" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfNS0xLTEtMS0w_870b97c4-f960-4176-a07f-c21c1b1b7494">5.0</ix:nonFraction>M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q3'18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3 clinical trial initiation - second indication</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="id37ccc32a0c64011b924874643fc2c43_D20190401-20190630" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfNi0xLTEtMS0w_277c4585-ca16-449d-98d0-4506c7b8b888">5.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'19</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first NDA - first indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i5bccfffe562d49e3a383b78d7e3a473c_D20200101-20200331" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfNy0xLTEtMS0w_5e17082c-0cb8-43a3-9029-319c88f25a0d">10.0</ix:nonFraction>M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first MAA - first indication</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i6a4fb59f13064149aefe64f788700e08_D20200101-20200331" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfOC0xLTEtMS0w_225c6317-497b-43cc-b1cc-c16013288fc0">5.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'20</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:18pt;text-indent:31.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="iff5613859d904159bc9d75bf71bfd39b"><div style="margin-top:18pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones achieved during the discovery period were recognized as revenue pro-rata through December 31, 2016. Milestones achieved during fiscal 2017 were recognized as revenue in the period earned, while milestones after December 31, 2017 are recognized upon determination that a significant reversal of revenue would not be probable. Cash is generally received within 30 days of milestone achievement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $<ix:nonFraction unitRef="usd" contextRef="ic8fda9259a0e4e1788f0cae962d442ec_D20200701-20200930" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNTMwMw_57a5d3c3-3968-4f35-92f6-297e168e8592">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i043575917e6847649d70407ee576383b_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNTMxMA_b63c845f-5765-4069-a62b-44624d4d64ca">15.0</ix:nonFraction> million in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GSK Agreement </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three and nine months ended September 30, 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i3d6a141d3615439ea73e776ec0ec0704_D20190701-20190930" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNTM4OA_377ef945-7267-436e-a1c7-7932c7849f4d">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iaebbe17d08a649598b21b99df30d512e_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNTM5NQ_8dab0fb8-1bcb-4e15-9169-3b2ec901ee9a">5.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three and nine months ended September 30, 2019, respectively.</span></div><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antibody Generation Agreement with Bristol-Myers Squibb </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2011, we entered into a license and collaboration agreement (the &#8220;BMS Agreement&#8221;) with Celgene, now a part of Bristol-Myers Squibb (&#8220;BMS&#8221;), to develop therapeutic antibodies against multiple targets. We granted BMS the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters pertaining to each target under the agreement. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BMS Agreement provided for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i0c1ff849295145de8d2e764ae6a508ec_D20110101-20111231" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNjA1OQ_08900b23-2c18-4d54-a369-35ac88407346">6.0</ix:nonFraction> million from BMS, which we received in 2011 and recognized through 2014, milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i12bdb60cf8e2409dbb82b9f0e626eca2_I20111231" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNjE1NQ_a31c698e-8d5b-48f2-b026-3039e294766e">53.0</ix:nonFraction> million per target, low single-digit royalties on net sales of antibodies against each target, and reimbursement of specified research and development costs. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed this arrangement in accordance with ASC Topic 606 and concluded that the contract counterparty, BMS, is a customer.&#160;We identified the following material promises under the BMS Agreement: (1) the licenses under certain patent rights relating to four targets and transfer of certain development and regulatory information, (2) R&amp;D services, (3) a written report documenting findings, and (4) steering committee meetings. We considered the research and discovery capabilities of BMS, BMS&#8217;s inability to sub-license the four targets, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the report of findings and steering committee participation would not have been provided without the R&amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated, and therefore concluded that the promises should be combined into a single performance obligation at the inception the arrangement. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the transaction price of the BMS Agreement includes the upfront payment, success fees, expense reimbursement, and milestones earned to date, which are allocated in their entirety to the single performance obligation.&#160;None of the future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors, including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials and BMS&#8217;s efforts.&#160;Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the intellectual property license granted to BMS and therefore have also been excluded from the transaction price.&#160;We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></div><ix:continuation id="i2b1f70b278ee40bdafe90bf2e3f4bca6"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones achieved through September&#160;30, 2020 under the BMS Agreement are as follows:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-PD-1 <br/>(CC-90006)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestone Event</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completion of first </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> toxicology studies using GLPs</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ib6949b8d98a949efb75ebf6f3c2883f8_D20160401-20160630" decimals="-5" name="anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjViNmI4M2I0OWIzMDRjOTU4MWM2NzhhNzQzMDRmNjU5L3RhYmxlcmFuZ2U6NWI2YjgzYjQ5YjMwNGM5NTgxYzY3OGE3NDMwNGY2NTlfMi0xLTEtMS0w_0417d308-bb48-4202-9cca-2f0d32fbb04f">0.5</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1 clinical trial initiation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i2b954c77f99d46ecbdb66e0463daa4c8_D20161001-20161231" decimals="-5" name="anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjViNmI4M2I0OWIzMDRjOTU4MWM2NzhhNzQzMDRmNjU5L3RhYmxlcmFuZ2U6NWI2YjgzYjQ5YjMwNGM5NTgxYzY3OGE3NDMwNGY2NTlfMy0xLTEtMS0w_48521acf-995b-416a-9d25-e02e27f88a31">1.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'16</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from future contingent milestone payments will be recognized when it is more likely than not that the revenue will not be reversed in future periods. Cash is generally received within 30 days of milestone achievement. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  There was <ix:nonFraction unitRef="usd" contextRef="iaf7d0bcc12c74158bd008c8a54ad1ca3_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfODgxOA_01afc2de-2357-4ec3-897e-25bb04161b03"><ix:nonFraction unitRef="usd" contextRef="ia3f3c54965f1409ab37615dab7b02091_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfODgxOA_348311f1-adbb-46a6-9bc7-0a89d0a90fe6"><ix:nonFraction unitRef="usd" contextRef="ibda93a579438443ca855b712364fdb2c_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfODgxOA_5e7f125d-a0db-48df-98b9-02e552d38adf"><ix:nonFraction unitRef="usd" contextRef="id197285cdb5044f2ab240b49e82a1ecc_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfODgxOA_60867188-f7fe-49bf-a4fd-5d8dfd3ffea7">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue recognized under this agreement during the three and nine months ended September 30, 2020 and 2019.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_46"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfMTY4MQ_8de81d64-4082-45e7-9eab-8ff2ecd76260" continuedAt="i30b2c22975864ecfa1aa6888b09c2a13" escape="true">Notes Payable </ix:nonNumeric></span></div><ix:continuation id="i30b2c22975864ecfa1aa6888b09c2a13" continuedAt="i7e87c2ac5b7d49eca0c855e5a74ac34d"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;24, 2014, we entered into a Loan and Security Agreement, as amended from time to time (the &#8220;Loan Agreement&#8221;), with a bank and a financial institution whereby we may borrow up to $<ix:nonFraction unitRef="usd" contextRef="i47a1076cefcd4d0ab8d1b13c5a35388f_I20141224" decimals="INF" format="ixt:numdotdecimal" name="anab:DebtInstrumentMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfMjEw_bfe7c755-aa2c-42ff-96dc-cfaa73fc2fad">15.0</ix:nonFraction> million in <ix:nonFraction unitRef="installment" contextRef="i2904dd9806a74afdb9680651604f96e4_D20141224-20141224" decimals="INF" format="ixt-sec:numwordsen" name="anab:DebtInstrumentNumberOfLoanInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfMjE2_ecf3b28d-1f60-4634-bb27-ddd160fd36d2">three</ix:nonFraction> separate draws of $<ix:nonFraction unitRef="usd" contextRef="i77ef9b411b014186ae96e571e310a67c_I20141224" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfMjM3_4badb47c-2610-435d-962b-65d5bef88dbd">5.0</ix:nonFraction> million each. The Term A Loans, for an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i0cbfbe6b71b1401990273e2858bb408d_D20141224-20141224" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfMjg0_719dbe29-0beb-489b-8e6f-93b0f5d36ad1">5.0</ix:nonFraction> million, were drawn on December&#160;24, 2014 with a fixed interest rate of <ix:nonFraction unitRef="number" contextRef="i4e2957bb03b74da888869ae5ceb98960_I20141224" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfMzUw_0790fa34-58b6-4b66-ae86-f4ba376ffae1">6.97</ix:nonFraction>%. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, the Loan Agreement was amended to combine Term B Loans and Term C Loans for a total of $<ix:nonFraction unitRef="usd" contextRef="i4e1900fbc5af4115b87781c0258509e7_I20160131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfNDU5_68609463-a327-4f23-99f2-ca43622311ad">10.0</ix:nonFraction> million available for draw through December 31, 2016 and delay the beginning of our Term A Loans&#8217; principal repayments from February&#160;1, 2016 until February&#160;1, 2017. The Term B Loans and Term C Loans became available for draw on July&#160;1, 2016. In December 2016, we further amended the Loan Agreement to (i)&#160;allow for the Term B Loans and Term C Loans to be drawn on December&#160;30, 2016, (ii)&#160;delay principal repayments of all Term Loans until February&#160;1, 2018, and (iii)&#160;amend the interest rate for each Term Loan. The Term B Loans and the Term C Loans were drawn on December&#160;30, 2016, and Term A, B and C Loans are now collectively referred to as the Term Loans. Principal repayments began in February 2018, and the Term Loans were paid in full, without penalty or premium, on January 1, 2020.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7e87c2ac5b7d49eca0c855e5a74ac34d">The costs incurred to issue the Term Loans were deferred and were included in the discount to the carrying value of the Term Loans in the accompanying balance sheet. The Term Loans also included a final payment fee of $<ix:nonFraction unitRef="usd" contextRef="i83f647fab752487aaffcadf4318bc4aa_I20160131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfMTQ0Ng_3de5bfd4-9b3a-4ad3-86a7-9db1d2e2e9a9">0.8</ix:nonFraction> million due at the earlier of prepayment or the maturity date of the Term Loans. The deferred costs and the final payment fee were amortized to interest expense over the expected term of the Term A Loans using the effective interest method.</ix:continuation> </span></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDk5Mg_54b83546-e54f-4645-9f5f-0ce5f81d4630" continuedAt="i0fefbcfade7a42d8b16e44899fd7c4f7" escape="true">Fair Value Measurements and Available for Sale Investments</ix:nonNumeric></span></div><ix:continuation id="i0fefbcfade7a42d8b16e44899fd7c4f7" continuedAt="i47a204acc1ff4f9f93e777439c11b899"><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist principally of cash, cash equivalents, restricted cash, short-term and long-term investments, receivables, accounts payable, and notes payable. Certain of our financial assets and liabilities have been recorded at fair value in the consolidated balance sheet in accordance with the accounting standards for fair value measurements.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i47a204acc1ff4f9f93e777439c11b899" continuedAt="i244415dec3ed499abd1672af534967be"><div style="margin-top:12pt;padding-left:11.25pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDk4OQ_f0cf36e8-8b54-47f0-a292-5c0fba9642bb" continuedAt="i13b8e94b242940d6b8138c15ec256175" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at End of Period Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Market</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prices for</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identical&#160;Assets</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;Observable</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">At September 30, 2020</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486ee79f827548bc8e85e93940ce0440_I20200930" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMy0xLTEtMS0w_cabad914-02c0-4610-adab-c1426aad207a">204,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie988dd2210474da0a9388a1930bda1c6_I20200930" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMy0zLTEtMS0w_fbea5c23-a00d-45fe-9b64-e4232f7cdc65">204,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9365f8894d443d987a0236bea2df0c_I20200930" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMy01LTEtMS0w_e21d1e39-5fe2-4cbf-82e0-9d1a0b693ceb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id29df9c5b8854830bcd8981e7835fc35_I20200930" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMy03LTEtMS0w_97deda70-26fb-4699-bc9e-e5e46fdb60c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56e6aad2b7c44aab9e288f7e9c76eef_I20200930" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNC0xLTEtMS0w_a420e38f-fb3f-4a16-8b43-b14a7fd9c5e3">4,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164e1f96760745ea976bbb632c4983c3_I20200930" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNC0zLTEtMS0w_2d15af87-2811-48a5-ba8d-70b7e9db444e">4,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af76d44387a46c89ac52e0449f254f5_I20200930" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNC01LTEtMS0w_e1f31a5e-bf95-4e18-b664-11a990b93b22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadb2d6473570457a8faa9c1e6fb88863_I20200930" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNC03LTEtMS0w_89e95589-932d-4be3-854c-2e712e4deffa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a8061e93f9480896f76c4620112a7c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNS0xLTEtMS0w_d0aa13b0-bbf4-49f7-89e5-645781084b95">107,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f77996d88c440f99adbdd8f311cd20_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNS0zLTEtMS0w_f11b18a6-5109-491a-a9cb-9f8a867c5cdc">107,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a809753553044369236456513af1721_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNS01LTEtMS0w_b0eeba89-e522-4c58-ad7d-9e8fedc1856d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d91aeb2e9ae4d358e45e8c47c03c98b_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNS03LTEtMS0w_63592b03-800a-4ed8-af54-7e5f3acbfeda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc2261a1be6464d85beeb08fdb8bd77_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNi0xLTEtMS0w_1efa436a-2455-46db-a65a-d0e56a668835">3,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4295dc2b4c0e4900bbb30c9191198893_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNi0zLTEtMS0w_1f896596-4b4b-4e23-b4c4-a66ce9fe8d02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee0736e2d03d4071be6f21372a00b616_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNi01LTEtMS0w_0561c00a-7947-449a-90b0-2de3cbb790fc">3,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06badbd8e437492aab95efec2695045d_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNi03LTEtMS0w_ab9316c8-97da-49e8-b13c-31530cdec26c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id77ca4847bba4305b096e411a0f88a98_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNy0xLTEtMS0w_807db64b-ed63-4edc-b74c-8aea35703fae">15,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baf9e14edba45e69f2f019ccd63867e_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNy0zLTEtMS0w_50ba065d-a95d-4e53-9b1e-905874f2c21f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86cf9503128d472eaa3c206335a0a2fe_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNy01LTEtMS0w_1bb8136c-e9f5-47f0-a5f6-5705f6268fd1">15,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507cac2c7cca438e8dbb277c0fe458d2_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNy03LTEtMS0w_34c39243-4b0b-4796-8e2d-bb9144e84bb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b77072d590434e92a3cb60e8a64f76_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfOC0xLTEtMS0w_297bfcf2-c008-407d-b845-fcd49fa09816">38,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d965662c4e8442d9916e4cfd80ec8a7_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfOC0zLTEtMS0w_2b6d534e-df20-4c36-b67e-3031540bc085">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077e3faf20384ff0800aacc76bea84f4_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfOC01LTEtMS0w_7cf9445c-dce3-4353-a0bd-d237b482fff9">38,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba71325b1ced4476b954c2bc33ca1f44_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfOC03LTEtMS0w_d0476ceb-c0e5-42f8-b43e-3b2e041a5fc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">At December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb57811cde1b45cdbd23bd6a14512d23_I20191231" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTEtMS0xLTEtMA_4b40fd8b-819f-4927-aa24-137b8dfeca2a">162,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia898b1250c31427581123c12f7daefee_I20191231" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTEtMy0xLTEtMA_af110c63-11e6-4466-9a45-db8b590c3d0a">162,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd5a96a569344b783cdca534f4e6e9f_I20191231" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTEtNS0xLTEtMA_95a92d0a-3247-4760-a8aa-88062e4ea8a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife860bdad5054daeaabbda9d6e52176d_I20191231" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTEtNy0xLTEtMA_e3dbe611-c592-4abe-91a4-7412dfcfaa5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ee59f67b6f424b910cc0844c794eb7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTItMS0xLTEtMA_caae1c5c-f0c4-4334-80ca-7559d583a694">7,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641d36b1119a4b48adad58e89443d069_I20191231" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTItMy0xLTEtMA_8884b9f2-038d-4e4c-adeb-ac00205aea67">7,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6d9c78810d4e6ca294fa8649b67b58_I20191231" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTItNS0xLTEtMA_730f4800-3aab-4665-95b8-1cb716dd4166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c44023eb8043aeb3d411c59bc7cf4b_I20191231" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTItNy0xLTEtMA_61845aa8-ba3e-4c8b-8928-183d05a182f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cabcd89e04549418fc44781cea4c283_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTMtMS0xLTEtMA_c7f1961e-0f33-4aaa-b9ad-da8ee43eb10f">96,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f51e0997cba47f6b82e8aa9efa6952b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTMtMy0xLTEtMA_17d27789-cd56-4bf0-b04f-82739c1196d4">96,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f40c73d02a434eaaf57929475ddfc6_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTMtNS0xLTEtMA_b3c79049-8127-47c0-849e-c904e7ec9171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3922432c0e84274970a003c02156320_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTMtNy0xLTEtMA_dd0d9865-c488-4ba8-b8a9-0e9f694366b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b87f9f76e3a4b858f05b03e5189102d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTQtMS0xLTEtMA_4716205f-8556-4ea4-8d2c-b71d64b30072">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62c6c85777a546cc8922f55af953a635_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTQtMy0xLTEtMA_eeeba972-fdb4-471a-8af5-ebe57a898cbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bf3fb2ff20a4a8f8e90a71d67af78ea_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTQtNS0xLTEtMA_13a7f617-9b24-41fb-8850-2f00eef864e3">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad0530eb18bc4ab29d6f3710ab1c6e67_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTQtNy0xLTEtMA_c02404d8-4040-4c72-b1ee-91db75ce3d79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8795b5aaad54f1a89041597a8c5f56f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTUtMS0xLTEtMA_2c967910-e9ca-400a-a625-644dbc46517c">33,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i426b689f24654fc8a7cf7448cec90674_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTUtMy0xLTEtMA_aed85d61-9811-45ed-9b56-e1d82133a8bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75efafa8841f48729f56684090276568_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTUtNS0xLTEtMA_ef4dfbdc-f54a-4cf7-b214-67cef0f9157a">33,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3f1b9a2b98b41029f0b45d0b59ff7f9_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTUtNy0xLTEtMA_8a33191a-ccbe-4a6e-88da-582981c5fa9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9672695c6d4ab2811e97fcee8bcfe5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTYtMS0xLTEtMA_f7d58ce2-76c4-4a3f-a071-8bb78cc53df9">122,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d92717b6f68494ba0890fed7d159f14_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTYtMy0xLTEtMA_ba5bcad0-fce7-4e8d-862b-76fd1cfe0c94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c61b5956d7e46c6a38b815d302d5850_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTYtNS0xLTEtMA_7bd461c1-570d-40b4-93e8-18efc2c75396">122,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b730ef0ddc64ea19f1632b5ab752783_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTYtNy0xLTEtMA_4093fdfa-cf21-41c1-8906-54f2715081c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.</span></div></ix:nonNumeric><div style="margin-top:2pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i13b8e94b242940d6b8138c15ec256175" continuedAt="ic0e7f7ce3b5d44cfbab55a4c857452ac">(2)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic0e7f7ce3b5d44cfbab55a4c857452ac">Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date.</ix:continuation> </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods and assumptions were used to estimate the fair value of our financial instruments for which it is practicable to estimate that value: </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For fair values determined by Level 1 inputs, which utilize quoted prices in active markets for identical assets, the level of judgment required to estimate fair value is relatively low. For fair values determined by Level 2 inputs, which utilize quoted prices in less active markets for similar assets, the level of judgment required to estimate fair value is also considered relatively low. </span></div><div style="margin-top:18pt;padding-left:13.5pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Other Financial Instruments </span></div><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDk4NA_3242cd5a-54a9-45df-a035-62f664113639" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our other financial instruments estimated as of September&#160;30, 2020 and December&#160;31, 2019 are presented below: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.366%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ab47a7f50ba4fb2826b5e3dc7761fb5_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjcyZTUxNTcxYTRmYjRkMTc5YWViZTJkYmI3N2ZhMTVjL3RhYmxlcmFuZ2U6NzJlNTE1NzFhNGZiNGQxNzlhZWJlMmRiYjc3ZmExNWNfMi0xLTEtMS0w_0e590b50-be04-4d0c-bdbc-1f8d8b76c303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7825d3ea7a9349ca843c88225054e573_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjcyZTUxNTcxYTRmYjRkMTc5YWViZTJkYmI3N2ZhMTVjL3RhYmxlcmFuZ2U6NzJlNTE1NzFhNGZiNGQxNzlhZWJlMmRiYjc3ZmExNWNfMi0zLTEtMS0w_b7ec3c90-73e5-45b9-b4a0-1ec98565daf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8635c548a31441e3992be83f1680e082_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjcyZTUxNTcxYTRmYjRkMTc5YWViZTJkYmI3N2ZhMTVjL3RhYmxlcmFuZ2U6NzJlNTE1NzFhNGZiNGQxNzlhZWJlMmRiYjc3ZmExNWNfMi01LTEtMS0w_0501dabf-30c0-4f1c-a0e1-657c31a30678">1,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a28d83f2ea4dbea79c3907f37a6431_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjcyZTUxNTcxYTRmYjRkMTc5YWViZTJkYmI3N2ZhMTVjL3RhYmxlcmFuZ2U6NzJlNTE1NzFhNGZiNGQxNzlhZWJlMmRiYjc3ZmExNWNfMi03LTEtMS0w_6b557946-d090-432b-9b48-f684a163a572">1,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods and assumptions were used to estimate the fair value of our notes payable: </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes Payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We use the income approach to value the aforementioned debt instrument. We use a present value calculation to discount principal and interest payments and the final maturity payment on these liabilities using a discounted cash flow model based on observable inputs. We discount these debt instruments based on what the current market rates would offer us as of the reporting date. Based on the assumptions used to value these liabilities at fair value, these debt instruments are categorized as Level 2 in the fair value hierarchy. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i244415dec3ed499abd1672af534967be" continuedAt="i6afb9fcebade420a963a460f0af63232"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The carrying amounts of certain of our financial instruments, including cash and cash equivalents, accounts payable, and accrued expenses approximate fair value due to their short-term nature. </span></div><div style="margin-top:18pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available for Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our excess cash in agency securities, debt instruments of financial institutions and corporations, commercial obligations, and U.S. Treasury securities, which we classify as available-for-sale investments. These investments are carried at fair value and are included in the tables above. <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDk4NQ_23bc864e-23f6-45ea-9855-2d600d352825" continuedAt="i27d1e2f7a5174d23bd7f9084ba1014a3" escape="true">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of September&#160;30, 2020 are as follows:</ix:nonNumeric></span></div><ix:continuation id="i27d1e2f7a5174d23bd7f9084ba1014a3"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a898126f7a043ec824730e437299a7b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMS0xLTEtMS0w_adc6ea7d-0771-4a35-bd27-173c13f81cf5">15,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a898126f7a043ec824730e437299a7b_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMS0zLTEtMS0w_25f91f2e-3a93-4c82-bbe5-44b8c93760db">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a898126f7a043ec824730e437299a7b_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMS01LTEtMS0w_0541e0e7-2df5-4504-a88b-84c10d5ff63a">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a898126f7a043ec824730e437299a7b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMS03LTEtMS0w_0e952a03-0515-49e9-9498-1f605401691b">15,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef17d9b49d24d5c984eab8bedf09095_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMy0xLTEtMS0w_6b5cf696-9b29-405e-9858-9bc3e4f3ca72">3,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef17d9b49d24d5c984eab8bedf09095_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMy0zLTEtMS0w_e0691bfa-4b53-422b-ae8d-0cd556437391">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef17d9b49d24d5c984eab8bedf09095_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMy01LTEtMS0w_b3f395bd-b22b-456f-9da4-59fda627d20a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef17d9b49d24d5c984eab8bedf09095_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMy03LTEtMS0w_3da9b09a-4d07-4e75-b689-1fd378e08607">3,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNC0xLTEtMS0w_e9ce1ed2-79d9-4d7e-a1bd-3fdacad18b98">38,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNC0zLTEtMS0w_6e7d1313-16bd-4842-8cb0-87833a35c06c">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNC01LTEtMS0w_834b3a7d-40d9-4725-af13-bae7f92f320b">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNC03LTEtMS0w_3ad9b06e-2c8a-4833-837f-75540267349a">38,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNS0xLTEtMS0w_97c8c66a-7385-4e29-86a1-6ee187b2cefa">106,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNS0zLTEtMS0w_372902e7-3764-4eea-94d6-9ab145bfe6c7">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNS01LTEtMS0w_30be16c1-bc59-45dc-bfeb-00fc39eb9be2">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNS03LTEtMS0w_08611324-191a-4aa9-92a8-f10c568e8246">107,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNi0xLTEtMS0w_6d63432a-cd28-437c-b048-3675d43fcaa1">164,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNi0zLTEtMS0w_d35e6fc1-1710-43c2-92bb-e955ca897b52">481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNi01LTEtMS0w_b3e05dfc-b627-42f9-a8f4-78334d4b728a">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNi03LTEtMS0w_eb9c10e9-849e-470c-8d0a-34d38ba357fd">165,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding agency securities, $<ix:nonFraction unitRef="usd" contextRef="i8a898126f7a043ec824730e437299a7b_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDIzNg_315cffe5-f319-47c1-916b-5facfb1f3af7">0.8</ix:nonFraction> million have maturity dates of less than <ix:nonNumeric contextRef="i856a405b5e294005b0da97db3dbe7ce2_D20200101-20200930" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMzExOA_acc28fa8-ffa2-479a-a26d-58e2b3e7a9fd">one year</ix:nonNumeric> and $<ix:nonFraction unitRef="usd" contextRef="i8a898126f7a043ec824730e437299a7b_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDI4NQ_d28a2fe6-d809-4db4-babb-b473b7836e8f">15.0</ix:nonFraction> million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDMyMA_168e5752-1e53-49ab-989a-a68d50119366">one</span> to <ix:nonNumeric contextRef="i421e55d1b84c466089165cde97803903_D20200101-20200930" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDMyNg_55000c65-10c4-4b54-9b0e-b961141fc494">two years</ix:nonNumeric> as of September&#160;30, 2020.</span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding certificates of deposit, $<ix:nonFraction unitRef="usd" contextRef="i0ef17d9b49d24d5c984eab8bedf09095_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMjg0MQ_212b7f1b-4b4f-4bb2-85a2-3598a8eb5284">3.0</ix:nonFraction> million have maturity dates of less than <ix:nonNumeric contextRef="i8f35c8d2bb134707949ab2d642ffe73b_D20200101-20200930" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMzExOQ_ff6c2946-8b30-4fea-9f34-fd19b3e5b6cf">one year</ix:nonNumeric> and $<ix:nonFraction unitRef="usd" contextRef="i0ef17d9b49d24d5c984eab8bedf09095_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMjk0NQ_6919c3f3-aa52-430e-b4b0-fc440e627fb0">0.7</ix:nonFraction> million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMzEzNQ_106d4e12-4b32-4f29-8d26-2b1735c0fda4">one</span> to <ix:nonNumeric contextRef="i658c9943823c428392acd64ea6860e66_D20200101-20200930" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMzEzNA_a5a2f661-e239-486c-8725-87a545f19a85">two years</ix:nonNumeric> as of September&#160;30, 2020.</span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our outstanding commercial and corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations have maturity dates of less than <ix:nonNumeric contextRef="i3a14f6c2f873440b8540983c27210b42_D20200101-20200930" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDUzNA_1577f748-6b43-4305-a279-1fe7941a1479">one year</ix:nonNumeric> as of September&#160;30, 2020. </span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding U.S. Treasury securities, $<ix:nonFraction unitRef="usd" contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDU5Nw_9f24bc08-284f-4666-b925-4b31faaad7ba">86.7</ix:nonFraction> million have maturity dates of less than one year and $<ix:nonFraction unitRef="usd" contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDY0Ng_bc1a5f5c-98db-4b38-a846-bfa2531a3f8d">20.4</ix:nonFraction> million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDY4MQ_e5da9ade-9ee6-43e3-9be3-70e98595210b">one</span> to <ix:nonNumeric contextRef="i1625cce2849647f3b4fdd28e3722f489_D20200101-20200930" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDY4Nw_33fdc1d2-b91d-4f29-a122-55cbe78452f7">two years</ix:nonNumeric> as of September&#160;30, 2020.</span></div></ix:continuation><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDk5Nw_58855008-c898-4377-8f14-c42294c4dffa" continuedAt="i0c3be4ae126a49ecadf6335ca81ea944" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;September&#160;30, 2020&#160;and&#160;December&#160;31, 2019, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:26.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a898126f7a043ec824730e437299a7b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfMy0xLTEtMS0w_3fbbaba7-b9e8-40f6-b10f-6b1d035f12e0">9,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a898126f7a043ec824730e437299a7b_I20200930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfMy0zLTEtMS0w_68f2f5bd-340d-479c-8751-3c3e5e222182">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a898126f7a043ec824730e437299a7b_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfMy01LTEtMS0w_88a981d9-2733-401b-aac4-759584042d36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a898126f7a043ec824730e437299a7b_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfMy03LTEtMS0w_f3763275-f8ab-47ff-b091-84ffa1593bb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a898126f7a043ec824730e437299a7b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfMy05LTEtMS0w_10fc7c0d-5ffa-4477-bcd9-e05d757177bb">9,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a898126f7a043ec824730e437299a7b_I20200930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfMy0xMS0xLTEtMA_1f3acf6e-b690-4353-a574-7412b4ad94fc">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNC0xLTEtMS0w_778b57ee-63e8-4dd8-97f4-99d7b6b7f7dd">4,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNC0zLTEtMS0w_dc20618c-35be-4096-bae8-4e087a88a332">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNC01LTEtMS0w_9a02579a-8f55-4254-b81f-b3c1a4b51c08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNC03LTEtMS0w_87eb545a-afd0-487b-9304-0d2184d5c727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNC05LTEtMS0w_2affefe9-9c12-4372-967d-b6defe404733">4,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNC0xMS0xLTEtMA_8b14bf73-868b-41a7-8de3-fe5e7fc2fec9">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS0xLTEtMS0zODA_7f3c381a-8ae5-4f1e-a8c9-d4f41a58153f">25,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS0zLTEtMS0zODA_88759fb5-e213-4b46-a645-4c77fa154414">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS01LTEtMS0zODA_0a7aba0e-661e-4939-82cc-fb5400be0e7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS03LTEtMS0zODA_58a1f557-9f70-4146-b1d7-9716c08e95e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS05LTEtMS0zODQ_c4cd9be9-5672-43ca-8cae-474e4e3afbfd">25,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS0xMS0xLTEtMzg0_7468748b-e3a9-4b4f-ad49-cd14286e6174">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS0xLTEtMS0w_5227bef0-0c67-4d5c-ad9b-9144adebf7a6">39,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS0zLTEtMS0w_de7b31f2-7474-48c9-b325-476c8d9806ac">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS01LTEtMS0w_0eb73453-df1a-454d-b0ee-ef4d486b6ee2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS03LTEtMS0w_07a11df6-ffce-495a-92a2-1c0609fe3036">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS05LTEtMS0w_dc860b96-8374-4fca-aeae-19494936bcb2">39,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS0xMS0xLTEtMA_4fee012a-ce25-4648-9f9f-13646e185dc1">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><ix:continuation id="i6afb9fcebade420a963a460f0af63232"><ix:continuation id="i0c3be4ae126a49ecadf6335ca81ea944"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:26.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b8e21f36b048dfb63095af95035987_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfMy0xLTEtMS0w_da8ad655-7bee-43b4-9f86-02ae90b1f3f6">5,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04b8e21f36b048dfb63095af95035987_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfMy0zLTEtMS0w_730ce801-bfc1-437a-8acb-4b72b99bb5d1">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b8e21f36b048dfb63095af95035987_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfMy01LTEtMS0w_ede5da92-3ef8-4e8d-8df0-4658ea62c2e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b8e21f36b048dfb63095af95035987_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfMy03LTEtMS0w_34388d1e-acab-49ff-ade2-ca05c8a99313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b8e21f36b048dfb63095af95035987_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfMy05LTEtMS0w_ff5465e1-5d53-42c8-9019-19be6d2b9329">5,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04b8e21f36b048dfb63095af95035987_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfMy0xMS0xLTEtMA_591a5a25-6659-46b5-a484-506ea42698b4">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eed3626fb0548498facb46e0bee7d8c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNC0xLTEtMS0w_2fa40368-017e-4cd6-a193-ab7fbc5e46e8">17,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8eed3626fb0548498facb46e0bee7d8c_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNC0zLTEtMS0w_a84bf833-32b9-4b93-afca-c118e67766f0">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eed3626fb0548498facb46e0bee7d8c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNC01LTEtMS0w_09c113ce-8235-4bc8-a559-9010bfb6edd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eed3626fb0548498facb46e0bee7d8c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNC03LTEtMS0w_0f0389c6-2039-4aed-9c57-2d0fbbd0faf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eed3626fb0548498facb46e0bee7d8c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNC05LTEtMS0w_0640b778-a9ba-4c4f-8c57-0abb88c02217">17,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8eed3626fb0548498facb46e0bee7d8c_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNC0xMS0xLTEtMA_eb38e4f7-2b65-495a-a526-32652e725194">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNS0xLTEtMS0w_ded471a0-3c06-47f0-95b7-b2bd286d04da">23,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNS0zLTEtMS0w_f6a61b5d-78c9-48a8-ba63-b64ff38749af">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNS01LTEtMS0w_9e1ca62b-0f01-4d62-9317-7a55cf222915">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNS03LTEtMS0w_a7892151-c932-486f-b7aa-d8b77736049a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNS05LTEtMS0w_704332db-5463-49c5-949e-9a2cc6a1bc7c">23,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNS0xMS0xLTEtMA_62c91fdb-df25-42f1-b714-857788038e0d">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RleHRyZWdpb246MmZiMmRlMGQzNzdiNGE2Y2E0NWQwMjllZmUzYTMxYzFfMjg0_dcdffa3f-79f2-4ccc-a8c9-6b952e80dd1a" continuedAt="i90d66e2dc366441b850a366895d2d96a" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="i90d66e2dc366441b850a366895d2d96a"><div style="margin-top:12pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the <ix:nonFraction unitRef="shares" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RleHRyZWdpb246MmZiMmRlMGQzNzdiNGE2Y2E0NWQwMjllZmUzYTMxYzFfNTE_4b0e6a53-4d22-41bc-ae01-a8a9dbe042fe">500,000,000</ix:nonFraction>&#160;shares of common stock authorized, <ix:nonFraction unitRef="shares" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RleHRyZWdpb246MmZiMmRlMGQzNzdiNGE2Y2E0NWQwMjllZmUzYTMxYzFfODk_7974b356-0ec7-4ea2-8431-75296e3fd8b0"><ix:nonFraction unitRef="shares" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RleHRyZWdpb246MmZiMmRlMGQzNzdiNGE2Y2E0NWQwMjllZmUzYTMxYzFfODk_8dbc9e6d-51c8-498e-8f36-c13125f9bb71">27,346,228</ix:nonFraction></ix:nonFraction> shares were issued and outstanding as of September&#160;30, 2020. <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RleHRyZWdpb246MmZiMmRlMGQzNzdiNGE2Y2E0NWQwMjllZmUzYTMxYzFfMjg3_6bb7d230-bb9b-4fc0-a8ef-9b22612dea85" continuedAt="i45a21178be53448397466288ea842bd3" escape="true">Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at September&#160;30, 2020 are as follows: </ix:nonNumeric></span></div><ix:continuation id="i45a21178be53448397466288ea842bd3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued and Outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RhYmxlOmRjYWJjN2NjMDIyNzQ4NjNhZjVhMzk4NjRkMTI5Njg1L3RhYmxlcmFuZ2U6ZGNhYmM3Y2MwMjI3NDg2M2FmNWEzOTg2NGQxMjk2ODVfMS0xLTEtMS0w_fce7ad29-532f-4381-a683-3c23c7e1909e">2,876,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares Reserved For:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Equity Incentive Plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5dc4745f8114a8fbed72cc75adbb0dc_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RhYmxlOmRjYWJjN2NjMDIyNzQ4NjNhZjVhMzk4NjRkMTI5Njg1L3RhYmxlcmFuZ2U6ZGNhYmM3Y2MwMjI3NDg2M2FmNWEzOTg2NGQxMjk2ODVfNC0xLTEtMS0w_1b8fe2d9-d0e3-4578-a313-b715e42321ec">3,040,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iede5636a43b44bc6be3c38a82fecb803_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RhYmxlOmRjYWJjN2NjMDIyNzQ4NjNhZjVhMzk4NjRkMTI5Njg1L3RhYmxlcmFuZ2U6ZGNhYmM3Y2MwMjI3NDg2M2FmNWEzOTg2NGQxMjk2ODVfNS0xLTEtMS0w_769331f5-4932-405c-b5b3-13f1181ee683">997,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RhYmxlOmRjYWJjN2NjMDIyNzQ4NjNhZjVhMzk4NjRkMTI5Njg1L3RhYmxlcmFuZ2U6ZGNhYmM3Y2MwMjI3NDg2M2FmNWEzOTg2NGQxMjk2ODVfNi0xLTEtMS0w_b24de20e-a586-4248-bb4c-a3bb307a3958">6,913,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div id="i0833d33fa1bc4c56a5693b167f99fc20_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMzYyOA_1c1e874c-39be-4a19-a582-8d0751534190" continuedAt="i800bf58a39e947bc9144eed21764492d" escape="true">Equity Incentive Plans </ix:nonNumeric></span></div><ix:continuation id="i800bf58a39e947bc9144eed21764492d" continuedAt="i46013daeea304ce997f596ddeae67ec4"><div style="margin-top:12pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;). The 2017 Plan became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017 and replaced our existing 2006 Equity Incentive Plan. Under the 2017 Plan, we may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then our employees, officers, directors or consultants. In addition, the number of shares of stock available for issuance under the 2017 Plan will be automatically increased each January 1, beginning on January 1, 2018, by <ix:nonFraction unitRef="number" contextRef="i1689cf0ddbf847f1a5d41386bf8e581a_D20170126-20170126" decimals="INF" name="anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfNzcw_18c72e6a-3fa1-43b9-b09d-a3eb9b280a9c">4</ix:nonFraction>% of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The 2017 Plan automatically increased by <ix:nonFraction unitRef="shares" contextRef="ib98c7394ae0241be92efa15ef59bb44f_D20200101-20200101" decimals="INF" format="ixt:numdotdecimal" name="anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfOTg3_69816007-7d98-4101-adca-f389420481ef">1,090,203</ix:nonFraction> shares as of January 1, 2020.</span></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Employee Stock Purchase Plan or the ESPP. The ESPP became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017. In addition, the number shares of stock available for issuance under the ESPP will be automatically increased each January 1, beginning on January 1, 2018, by <ix:nonFraction unitRef="number" contextRef="i86d89ac9401d465a9ffa094c58d86268_D20180101-20180101" decimals="INF" name="anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMTQ4Mg_178166ce-af25-4496-839c-8a84d951457d">1</ix:nonFraction>% of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The ESPP automatically increased by <ix:nonFraction unitRef="shares" contextRef="i4bdb7350e5c74ed089644cf190add40a_D20200101-20200101" decimals="INF" format="ixt:numdotdecimal" name="anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMTY5NA_05db9ca5-ebd2-4b25-a7bb-5ef3f4e75249">272,550</ix:nonFraction> shares as of January 1, 2020.</span></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted to employees and non-employees generally vest over a <ix:nonNumeric contextRef="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMzYyMQ_951734cd-c6b3-4cfc-b53f-149d5607a8b1">four-year</ix:nonNumeric> period while stock options granted to directors vest over a <ix:nonNumeric contextRef="ifd8286d24eb44b9dada0fe300127f5bc_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMTg4NQ_08f56c22-170d-45ec-a462-c45d6e8879fc">one year</ix:nonNumeric> period. Each stock option award has a maximum term of <ix:nonNumeric contextRef="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMTkyNA_bbaa4911-7448-41bd-895a-adc95a49bb89"><ix:nonNumeric contextRef="ifd8286d24eb44b9dada0fe300127f5bc_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMTkyNA_e4ea9f4b-d198-4b55-9f15-bcd8de7dbdf0">10</ix:nonNumeric></ix:nonNumeric> years from the date of grant, subject to earlier cancellation prior to vesting upon cessation of service to us. <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMzYzMA_42498d85-1ce4-4906-b79a-36ef3ed1107b" continuedAt="idb86a47194644e528b09322401f125d2" escape="true">A summary of the activity related to stock option awards during the nine months ended September 30, 2020 is as follows: </ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i46013daeea304ce997f596ddeae67ec4" continuedAt="ic40b16eaf07843dba2ee0c53654a49d5"><ix:continuation id="idb86a47194644e528b09322401f125d2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subject to</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value&#160;(in</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfMS0xLTEtMS0w_fb6595aa-2709-4116-9b5f-aec5558a051c">3,039,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfMS0zLTEtMS0w_b5ba860e-3ed0-4466-b732-70421594b7d4">29.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfMi0xLTEtMS0w_ec27c9b5-f608-4c37-96ca-8bd49c1a093c">461,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfMi0zLTEtMS0w_38f56fe0-39ed-4259-b6b6-2c73ff0dfe65">18.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfMy0xLTEtMS0w_9021e4e9-6708-44ee-9bf4-56ed81b5b55b">91,146</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfMy0zLTEtMS0w_2ab64a5d-f159-4495-8479-8ff5b7b2cce6">4.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures and cancellations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNC0xLTEtMS0w_7a4f7e55-760d-4151-b764-b9af75ce0a5d">534,096</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNC0zLTEtMS0w_d493b715-41e8-4c5c-8455-6327502c3d32">37.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNS0xLTEtMS0w_86c791df-729d-498e-818b-042116a68430">2,876,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNS0zLTEtMS0w_5bbf1fcb-d981-4d31-a805-e3cd83a52165">26.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNS01LTEtMS0w_86c914b5-ac3f-416a-af44-8b0a966bfc39">7.47</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNS03LTEtMS0w_6d05fc20-0618-4444-bddd-aa8e176c3c4f">6,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNi0xLTEtMS0w_e119edb9-4d51-492e-87fd-b8e2dcb84a3f">1,355,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNi0zLTEtMS0w_9215b366-990f-45b8-9f96-2ea12252dd19">27.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNi01LTEtMS0w_f9a50d91-58b1-412d-895b-1b41fbf3fc27">5.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNi03LTEtMS0w_50633d97-4d8f-4a8f-81e1-0b629d7df68a">6,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMzYzMQ_936a0ca0-ba6f-41e2-8b2d-06b907abab48" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfMy0yLTEtMS0w_692f2549-6b74-4a12-901a-07c93f13fc84">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7aa924de6d814250973b8ca6c02725b7_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfMy02LTEtMS0w_4bfb1f6b-35bc-47bd-8e13-fd4bf04e9e74">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNC0yLTEtMS0w_c8ccc886-d792-48a8-8555-cbb6b20294f5">90.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7aa924de6d814250973b8ca6c02725b7_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNC02LTEtMS0w_a8830779-ab5a-447b-b02d-34e3491eea72">68.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNS0yLTEtMS0w_280d5443-4b5f-431f-bda1-0b01254b1b3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7aa924de6d814250973b8ca6c02725b7_D20190101-20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNS02LTEtMS0w_f6c75d97-9638-4d9d-90f7-aa2519baa676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNi0yLTEtMS0w_742be8cc-03fa-42f1-bb3c-784c237b447e">6.25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7aa924de6d814250973b8ca6c02725b7_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNi02LTEtMS0w_4abc23bb-aa7f-42a2-8df0-35c3f5638990">6.25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNy0yLTEtMS0w_75ea8fed-e683-45bf-a1b2-c3dbdd9ccaad">13.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7aa924de6d814250973b8ca6c02725b7_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNy02LTEtMS0w_e43f066c-f7af-4545-9d69-342fd73c8872">43.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the appropriate risk-free interest rate, expected term for employee stock-based awards, contractual term for non-employee stock-based awards, and volatility assumptions. The weighted-average expected option term for employee and non-employee stock-based awards reflects the application of the simplified method, which defines the life as the average of the contractual term of the options and the weighted-average vesting period for all option tranches. Estimated volatility incorporates historical volatility of our stock price as well as similar entities whose share prices are publicly available. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected or contractual term of the stock-based payment awards. The assumed dividend yield is based on our expectation of not paying dividends in the foreseeable future. </span></div><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMzYyNw_fae70a34-60d0-4bf9-a4cf-ff1462006b88" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef232fdc16443ab824f750c8ecbc67b_D20200701-20200930" decimals="-3" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMi0xLTEtMS0w_92a4e491-9a80-4925-a992-f4427246af4f">926</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746c849226304957812801a396d96d98_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMi0zLTEtMS0w_9f6f566b-4edb-4e1c-a3cc-c4f886bc43a6">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8e6f18cae84e3abeb28a87d7e99b95_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMi01LTEtMS0w_f7eb2a70-5f56-4adc-8abb-75a41c2ba119">3,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i619a360a42884bb8b5a3c0d6c4290323_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMi03LTEtMS0w_da1e4a2c-1ece-4d8e-b241-7b2625215ccc">4,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c89f0f0b0f4523aa6c1cc41b1ca2dd_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMy0xLTEtMS0w_4370d8ae-ae6a-4f8e-9961-89fac0e22951">1,879</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2389b2e977c94f14aaafb743e9c2bf19_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMy0zLTEtMS0w_8072633a-0580-4c03-8f6c-3f731772e9fb">1,564</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13db0076e7d145118a79fd40a565430f_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMy01LTEtMS0w_a1bac1a8-beea-4990-81c2-f12c6a52ebb9">5,491</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53442a555d5247dda9d21b2f725430ac_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMy03LTEtMS0w_b1c659cc-3051-4756-a56b-5046d5aa10fb">5,185</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfNC0xLTEtMS0w_ee09b55c-4aab-4184-bd7e-221485cc5c8a">2,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfNC0zLTEtMS0w_6f038b9b-122a-46f4-a102-e7229af01322">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfNC01LTEtMS0w_646ada31-d1c1-4105-acbe-c9ee26aa2f62">8,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfNC03LTEtMS0w_12e3300e-4005-4bc1-9914-21e374b72a29">9,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div><ix:continuation id="ic40b16eaf07843dba2ee0c53654a49d5" continuedAt="i860961f58df74d9eb894218f8c64cf3a"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, there was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMzQ0NA_f502bb49-096f-40f1-a5db-f69bf3d0df92">24.8</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of unrecognized compensation cost related to unvested stock option awards, which is expected to be recognized over a remaining weighted-average vesting period o</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i860961f58df74d9eb894218f8c64cf3a">f <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" format="ixt-sec:duryear" name="anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMzYwOQ_0d4d445d-45fc-46f5-a6f7-7f3687115ce3">3.03</ix:nonNumeric> years.</ix:continuation> </span></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMzU3NQ_33ed31cf-5877-4167-ac5b-9ab153fa03bd" continuedAt="ibeba099138784d05a8600c3514d456df" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ibeba099138784d05a8600c3514d456df" continuedAt="i139bbc624eaf4d95bdbdadfd3a35c9e3"><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="lease" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="anab:LesseeOperatingLeaseNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfNjM_4340ee87-442e-410c-8a15-38dbfaeb4151">two</ix:nonFraction> non-cancellable office leases (the &#8220;Office Leases&#8221;), with remaining lease terms of approximately <ix:nonNumeric contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMTYz_4e30cff7-d0ce-4e23-adc5-e8d6089acf6e">one year</ix:nonNumeric>, each of which are classified as operating leases. Both leases expire in 2021. Only one of our leases has remaining renewal </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i139bbc624eaf4d95bdbdadfd3a35c9e3" continuedAt="i0c00980e3de345c797358c7c06445a11"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options, which includes <ix:nonFraction unitRef="renewal_option" contextRef="i8eacadeab29a42608e859587a94fccfe_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="anab:LesseeOperatingLeaseOneYearRenewalOptionsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMzE0_61f7f8f5-d1b1-4cb1-90a2-2bd119b453e7">three</ix:nonFraction> options to renew for one additional year. The exercise of lease renewal options is at our sole discretion, which we currently do not anticipate exercising and as such were not recognized as part of our right-of-use (&#8220;ROU&#8221;)  asset and lease liabilities. Our lease payments are fixed, and we recognize lease expense for these leases on a straight-line basis over the lease term. Operating lease ROU assets and lease liabilities are recorded based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not provide an implicit rate, we used our incremental borrowing rate based on the information available at effective date of adoption in determining the present value of future payments. The weighted-average discount rate used was <ix:nonFraction unitRef="number" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMTExMA_c7967267-03d7-444b-b9f1-dff3224e22ed">8.59</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="anab:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMzU4OA_fb94d89d-7a36-45c7-81ed-b6b93501d98b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our balance sheet includes our ROU assets and lease liabilities as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:41.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating ROU assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjdhM2UyOTc1NjU3MDQyMjk5OTMyN2FiNmI1OTNmNDM0L3RhYmxlcmFuZ2U6N2EzZTI5NzU2NTcwNDIyOTk5MzI3YWI2YjU5M2Y0MzRfMS00LTEtMS0w_c0cb7c54-c4ed-4903-8420-c749fb583992">824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjdhM2UyOTc1NjU3MDQyMjk5OTMyN2FiNmI1OTNmNDM0L3RhYmxlcmFuZ2U6N2EzZTI5NzU2NTcwNDIyOTk5MzI3YWI2YjU5M2Y0MzRfMS02LTEtMS0w_79824138-af5a-425e-802b-f1f11216e8ce">1,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjdhM2UyOTc1NjU3MDQyMjk5OTMyN2FiNmI1OTNmNDM0L3RhYmxlcmFuZ2U6N2EzZTI5NzU2NTcwNDIyOTk5MzI3YWI2YjU5M2Y0MzRfMi00LTEtMS0w_dd164169-822f-4ade-a339-0c7a9ede660b">851</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjdhM2UyOTc1NjU3MDQyMjk5OTMyN2FiNmI1OTNmNDM0L3RhYmxlcmFuZ2U6N2EzZTI5NzU2NTcwNDIyOTk5MzI3YWI2YjU5M2Y0MzRfMi02LTEtMS0w_262c4add-bd44-4b62-bf83-db4c8b6ae39b">871</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjdhM2UyOTc1NjU3MDQyMjk5OTMyN2FiNmI1OTNmNDM0L3RhYmxlcmFuZ2U6N2EzZTI5NzU2NTcwNDIyOTk5MzI3YWI2YjU5M2Y0MzRfMy00LTEtMS0w_dd63708b-9ba1-479c-bb5b-c0590ecd472b">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjdhM2UyOTc1NjU3MDQyMjk5OTMyN2FiNmI1OTNmNDM0L3RhYmxlcmFuZ2U6N2EzZTI5NzU2NTcwNDIyOTk5MzI3YWI2YjU5M2Y0MzRfMy02LTEtMS0w_6f17d770-03ed-4c64-be5c-4aa7fc053c26">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMzU4MA_04624a83-b741-492e-a68d-1a07c5f74556" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following costs are included in our consolidated statements of cash flow (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Cash Flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgzMWY4YTFmZTRmMzRjZTZhMTkyYzEyYjJhYTlmYzFlL3RhYmxlcmFuZ2U6ODMxZjhhMWZlNGYzNGNlNmExOTJjMTJiMmFhOWZjMWVfMi00LTEtMS0w_b33ecb17-abd6-42f9-8b38-08b09c3a768d">660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgzMWY4YTFmZTRmMzRjZTZhMTkyYzEyYjJhYTlmYzFlL3RhYmxlcmFuZ2U6ODMxZjhhMWZlNGYzNGNlNmExOTJjMTJiMmFhOWZjMWVfMi02LTEtMS0w_a85055b9-866a-4223-af50-ac6506db8263">660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgzMWY4YTFmZTRmMzRjZTZhMTkyYzEyYjJhYTlmYzFlL3RhYmxlcmFuZ2U6ODMxZjhhMWZlNGYzNGNlNmExOTJjMTJiMmFhOWZjMWVfMy00LTEtMS0w_5490f72c-b5a7-40fd-8535-59f8880ec4d2">722</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgzMWY4YTFmZTRmMzRjZTZhMTkyYzEyYjJhYTlmYzFlL3RhYmxlcmFuZ2U6ODMxZjhhMWZlNGYzNGNlNmExOTJjMTJiMmFhOWZjMWVfMy02LTEtMS0w_9e4700b2-3bd6-4bd5-99a6-a38ea18e2ea8">698</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMzU3OA_1f0bc48c-4e5a-4304-80f5-07c746bc4ba8" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, the future minimum annual obligations for the Office Leases in excess of one year are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfMS0xLTEtMS0w_256e9680-4741-4587-975e-c7fe9913588e">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfMi0xLTEtMS0w_d2b30cd9-7d24-49d4-bd3a-d65ee3f32124">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfMy0xLTEtMS0w_01a48501-5ce0-43f0-a010-d58a6a9e0a0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfNC0xLTEtMS0w_6534bb43-52b6-4ea9-a676-5acd909e5f12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfNS0xLTEtMS0w_b6f5236b-a1f7-4dc9-b5a1-04b8a9997ca1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" format="ixt:zerodash" name="anab:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfNi0xLTEtMS0w_f3bdc473-a4f2-43e7-873f-6a77db2a06c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments required</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfNy0xLTEtMS0w_a32fb713-2a79-48b3-af96-e46e1f187afb">923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfOC0xLTEtMS0w_07f46127-4c84-4ec0-aae5-72aeb8ea7d6d">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfOS0xLTEtMS0w_c3dd98a8-ffe5-4f62-bc19-3ddbf3fa222a">884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2020, we entered into a lease agreement (the &#8220;Lease Agreement&#8221;) with Wateridge Property Owner, LP, with respect to facilities in the building at 10770 Wateridge Circle, San Diego, California 92121. Under the Lease Agreement, we agreed to lease approximately <ix:nonFraction unitRef="sqft" contextRef="i5d58efeb98774e8291e0a3b307d1a26b_I20200504" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMTY5Mw_b5ca71f7-b482-4b99-bd4f-571a4fa7ab9a">45,000</ix:nonFraction> square feet of space in the 10770 Wateridge Circle Building for a term of <ix:nonNumeric contextRef="i5d58efeb98774e8291e0a3b307d1a26b_I20200504" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMTc3MA_590ff0d1-e79a-4c5c-a331-11d740fa3e6e">124</ix:nonNumeric> months, beginning on March 1, 2021 (or on such later date as described in the Lease Agreement). The terms of the Lease Agreement provide us with an option to extend the term of the lease for an additional <ix:nonNumeric contextRef="i5d58efeb98774e8291e0a3b307d1a26b_I20200504" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMTk3MQ_e26a7b8d-4643-494f-b85f-f6afe4b5a84f">five years</ix:nonNumeric>, as well as a one-time option to terminate the lease after <ix:nonNumeric contextRef="ie99b7535bd4a4aff813c79436f435dd6_D20200504-20200504" format="ixt-sec:durwordsen" name="anab:LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMjA0MQ_3a2bb6bf-c733-4267-be11-614d948016dc">seven years</ix:nonNumeric> with the payment of a termination fee. The monthly base rent will be $<ix:nonFraction unitRef="usdPerSqft" contextRef="ie99b7535bd4a4aff813c79436f435dd6_D20200504-20200504" decimals="2" name="anab:RentPerSquareFoot" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMjExMw_42b20e69-a4d0-43c0-bcbe-cba5889379a6">4.20</ix:nonFraction> per rentable square foot and will be increased by <ix:nonFraction unitRef="number" contextRef="ie99b7535bd4a4aff813c79436f435dd6_D20200504-20200504" decimals="2" name="anab:AnnualRentIncreasePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMjE2Nw_6f23b3a0-3a4f-480f-b205-36577b687c53">3</ix:nonFraction>% annually. Under the Lease Agreement, we are also responsible for our pro rata share of real estate taxes, building insurance, maintenance, direct expenses, and utilities. As of September&#160;30, 2020, we have recorded $<ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidRent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMjM2Nw_d4624a82-d925-4b3d-8e44-a65140e2b021">0.2</ix:nonFraction>&#160;million in prepaid rent and $<ix:nonFraction unitRef="usd" contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMjM5MA_79301ab1-68df-42aa-99a5-9d2a087fe2ed">0.3</ix:nonFraction>&#160;million as a security deposit in accordance with the terms of the Lease Agreement.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i0c00980e3de345c797358c7c06445a11"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lawsuit</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 25, 2020, a putative securities class action was filed in the United States District Court for the Southern District of California naming the Company and certain of its current or former officers as defendants. The complaint purports to assert claims under Section 10(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), Exchange Act  Rule 10b-5, and Section 20(a) of the Exchange Act, on behalf of persons and entities who acquired our common stock between October 10, 2017 and November 7, 2019 (the &#8220;Class Period&#8221;). An amended complaint was filed on September 30, 2020 alleging that, during the Class Period, the defendants made material misrepresentations or omissions regarding our etokimab product candidate that artificially inflated our stock price. The plaintiff seeks, among other things, damages in an unspecified amount, as well as costs and expenses. We believe that the plaintiff&#8217;s allegations are without merit and intend to vigorously defend against the claims. On September 1, 2020, a related shareholder derivative complaint was filed based on allegations substantially similar to those in the class action, and asserting claims against current or former officers and directors for contribution under Sections 10(b) and 21D of the Exchange Act, breach of fiduciary duty, unjust enrichment and corporate waste. Because the Company is in the early stages of this litigation matter, we are unable to estimate a reasonably possible loss or range of loss, if any, that may result from these matters.</span></div></ix:continuation><div id="i0833d33fa1bc4c56a5693b167f99fc20_916"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MTYvZnJhZzo1NjZiZjE1YjA0ZWQ0YjcxODM5YTU0ZmVmMTAyZGY4ZS90ZXh0cmVnaW9uOjU2NmJmMTViMDRlZDRiNzE4MzlhNTRmZWYxMDJkZjhlXzI3NDg3NzkwNzY3ODg_db60d00d-28f5-4ef2-8ebd-fcd391596511" continuedAt="i67e47293ff7245f9bc45585a4a170444" escape="true">Subsequent Event </ix:nonNumeric></span></div><ix:continuation id="i67e47293ff7245f9bc45585a4a170444"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, we entered into a confidential settlement agreement (the &#8220;Settlement Agreement&#8221;) with GSK and TESARO, Inc., and TESARO Development, Ltd. (together, &#8220;Tesaro&#8221;) to resolve the claims previously raised in the notice of breach (the &#8220;Notice&#8221;) we delivered to GSK and Tesaro on August 20, 2020.  Pursuant to the Settlement Agreement, we, GSK and Tesaro agreed to the terms of the Amendment described below and a mutual release of claims relating to the Notice, the Delaware Chancery Court action related to the Notice, the Collaboration Agreement and the obligations of the parties under the Collaboration Agreement.  Pursuant to the terms of the Settlement Agreement, we and Tesaro agreed to enter into the Amendment that provided GSK with freedom to conduct development and commercialization of Zejula in combination with third-party molecules.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, we amended our GSK Agreement (the &#8220;Amendment&#8221;) with GSK and Tesaro.  Under the Amendment, we allowed for GSK to conduct development and commercialization of Zejula and we are entitled to increased royalties upon sales of dostarlimab, an anti-PD-1 antagonist antibody under development by GSK for multiple oncological disorders, including endometrial cancer, non-small cell lung cancer, ovarian cancer, colorectal cancer and mismatch repair deficient solid tumors, equal to <ix:nonFraction unitRef="number" contextRef="id3e3599ed3624134a82b70d95e79fc4c_D20201023-20201023" decimals="INF" name="anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MTYvZnJhZzo1NjZiZjE1YjA0ZWQ0YjcxODM5YTU0ZmVmMTAyZGY4ZS90ZXh0cmVnaW9uOjU2NmJmMTViMDRlZDRiNzE4MzlhNTRmZWYxMDJkZjhlXzI3NDg3NzkwNzY3OTA_2752f4a7-ef1f-4901-9a12-fdfdb0c95781">8</ix:nonFraction>% of Net Sales (as defined in the GSK Agreement) below $1.0&#160;billion and from <ix:nonFraction unitRef="number" contextRef="i0d1574d508d24c7a9d2272819c456ea4_D20201023-20201023" decimals="INF" name="anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MTYvZnJhZzo1NjZiZjE1YjA0ZWQ0YjcxODM5YTU0ZmVmMTAyZGY4ZS90ZXh0cmVnaW9uOjU2NmJmMTViMDRlZDRiNzE4MzlhNTRmZWYxMDJkZjhlXzI3NDg3NzkwNzY4MDY_e8aa9257-ea07-43cf-91a2-2d7121aea8eb">12</ix:nonFraction>% up to <ix:nonFraction unitRef="number" contextRef="i60cb8e6a37424af2bd4d11e7a7616ff7_D20201023-20201023" decimals="INF" name="anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MTYvZnJhZzo1NjZiZjE1YjA0ZWQ0YjcxODM5YTU0ZmVmMTAyZGY4ZS90ZXh0cmVnaW9uOjU2NmJmMTViMDRlZDRiNzE4MzlhNTRmZWYxMDJkZjhlXzI3NDg3NzkwNzY4MTE_daabdf38-0740-4c5a-81c8-d45669083b12">25</ix:nonFraction>% of Net Sales above $1.0&#160;billion.   The Amendment also entitles us a one-time non-refundable cash payment of $<ix:nonFraction unitRef="usd" contextRef="ifa95208aff9f4c2086046f2657751ac3_I20201023" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MTYvZnJhZzo1NjZiZjE1YjA0ZWQ0YjcxODM5YTU0ZmVmMTAyZGY4ZS90ZXh0cmVnaW9uOjU2NmJmMTViMDRlZDRiNzE4MzlhNTRmZWYxMDJkZjhlXzI3NDg3NzkwNzY4Mjg_5b7613ed-bdd3-48cc-b224-bcf41871e187">60.0</ix:nonFraction>&#160;million payable to us within 30 days of the date of the Amendment.  Tesaro also agreed, starting January 1, 2021, to pay us a <ix:nonFraction unitRef="number" contextRef="i79eecb7fb35c40ad8dec2e63fb261996_D20210101-20210101" decimals="INF" name="anab:NetSalesRoyaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MTYvZnJhZzo1NjZiZjE1YjA0ZWQ0YjcxODM5YTU0ZmVmMTAyZGY4ZS90ZXh0cmVnaW9uOjU2NmJmMTViMDRlZDRiNzE4MzlhNTRmZWYxMDJkZjhlXzI3NDg3NzkwNzY4NTU_2e08111a-a20d-4855-bad8-d36993144afa">1</ix:nonFraction>% royalty on all GSK and Tesaro Net Sales of Zejula </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which has received US approval for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, and is under development for additional cancer indications.  The $<ix:nonFraction unitRef="usd" contextRef="iaa90cb92269c4595b23777618939cb79_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MTYvZnJhZzo1NjZiZjE1YjA0ZWQ0YjcxODM5YTU0ZmVmMTAyZGY4ZS90ZXh0cmVnaW9uOjU2NmJmMTViMDRlZDRiNzE4MzlhNTRmZWYxMDJkZjhlXzU0OTc1NTgxNTA1NjU_c60bfa4a-a4a7-4353-808e-777673f47dc3">1.1</ix:nonFraction>&#160;billion in cash milestone payments due under the GSK Agreement remain unchanged.  Additionally, under the terms of the Amendment, Tesaro and GSK have agreed to certain diligence commitments with respect to the future development of dostarlimab, and the parties have agreed to review such commitments under regular joint review committee (JRC) meetings going forward.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q (&#8220;Quarterly Report&#8221;) contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; and &#8220;expect,&#8221; and similar expressions that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this report include, among other things, statements about:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success, cost, and timing of our product candidate development activities and ongoing and planned clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our plans to develop and commercialize antibodies, including our lead product candidate: imsidolimab for patients with generalized pustular psoriasis (&#8220;GPP&#8221;) and palmoplantar pustulosis (&#8220;PPP&#8221;);</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the coronavirus (&#8220;COVID-19&#8221;) pandemic on our business and the United States (&#8220;U.S.&#8221;) and global economies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood that the clinical data generated in any study we performed, are performing, or plan to perform in a non-U.S. jurisdiction will be subsequently accepted by the </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Food and Drug Administration (&#8220;FDA&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or by foreign regulatory authorities outside of the jurisdiction where the study was being performed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and ability of our collaborators to develop and commercialize our partnered product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits and advantages of our product candidates and approaches versus those of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to execute on our strategy, including advancing our lead product candidates, identifying emerging opportunities in key therapeutic areas, continuing to expand our wholly-owned pipeline, and retaining rights to strategic products in key commercial markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for imsidolimab and our other product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of any approved product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth potential of the markets for any approved product candidates, and our ability to serve those markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing, and manufacturing capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the U.S., the United Kingdom, Australia, and other foreign countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our use of the net proceeds from our public offerings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in Part II, Item 1A, &#8220;Risk Factors,&#8221; and elsewhere in this Quarterly Report. Moreover, we operate in a competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements to conform these statements to actual results or to changes in our expectations, except as required by law.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context indicates otherwise, as used in this Quarterly Report, the terms &#8220;AnaptysBio,&#8221; &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to AnaptysBio, Inc., a Delaware corporation, and its subsidiaries taken as a whole, unless otherwise noted. AnaptysBio is our common law trademark. This Quarterly Report contains additional trade names, trademarks, and service marks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited consolidated financial statements and related notes for the nine months ended September 30, 2020, included in Part I, Item&#160;1 of this report and with our audited consolidated financial statements and related notes thereto for the year ended December&#160;31, 2019 included in the Company&#8217;s Form 10-K. This discussion and other sections of this Quarterly Report contain forward-looking statements that involve risks and uncertainties, such as our plans, objectives, expectations, intentions, and beliefs. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section entitled &#8220;Risk Factors&#8221; included in Part II, Item&#160;1A of this Quarterly Report. You should also carefully read &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company developing first-in-class immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation (&#8220;SHM&#8221;), and replicates this natural process of antibody generation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our strategy is to advance the development of our proprietary product candidates, and where applicable, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights. Our most advanced wholly-owned antibody programs, imsidolimab, etokimab, ANB030 and ANB032, are designed to modulate therapeutic targets that are genetically associated with human inflammatory disorders.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Imsidolimab, our IL-36R antibody previously referred to as ANB019, inhibits the interleukin-36 receptor (&#8220;IL-36R&#8221;), and is being developed for the treatment of rare inflammatory diseases, including generalized pustular psoriasis (&#8220;GPP&#8221;) and palmoplantar pustulosis (&#8220;PPP&#8221;). We completed a Phase 1 clinical trial in healthy volunteers, which was presented at the European Academy of Allergy and Clinical Immunology in 2018, where imsidolimab was well-tolerated by all subjects, no dose-limiting toxicities were observed, and no serious adverse events were reported among any subjects in the trial. In July 2020, the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) granted Orphan Drug Designation for imsidolimab for the treatment of patients with GPP.  We are conducting an open-label, multi-dose, single-arm Phase 2 clinical trial of imsidolimab in 8 GPP patients, also referred to as the GALLOP trial, where we announced positive topline data in October 2020. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Six of 8 (75%) patients treated with imsidolimab monotherapy achieved the primary endpoint of improvement in the clinical global impression scale (&#8220;CGI&#8221;) on Day 29.  Two of 8 (25%) patients were considered to have not met the primary endpoint because they dropped out of the trial prior to Day 29. The modified Japanese Dermatology Association Severity Index (&#8220;mJDA-SI&#8221;) score, which incorporates both dermatological and systemic aspects of GPP, decreased on average by 29% on Day 8 and 54% on Day 29. Erythema with skin pustules, which clinically defines GPP, decreased by 60% on Day 8 and 94% on Day 29.  Serum c-reactive protein (&#8220;CRP&#8221;), which is an indicator of systemic inflammation, was normal (less than 5 mg/L) for 5 of the 6 patients achieving the primary endpoint on Day 29.  Genotypic testing indicated homozygous wild-type IL-36RN, CARD14 and AP1S3 alleles for all 8 patients.  We believe this suggests that imsidolimab may be broadly applicable to pustular diseases irrespective of genetic drivers.  Anti-drug antibodies were not detected as of Day 29 in any patient.  Imsidolimab was generally well-tolerated and most treatment-emergent adverse events were mild to moderate in severity and resolved without sequelae.  No infusion or injection site reactions were observed. One patient dropped out of the trial due to a diagnosis of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Staphylococcal aureus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> bacteremia in the first week, which was a serious adverse event deemed to be possibly drug-related.  Because the patient was symptomatic prior to dosing and had a prior medical history of bacteremia, a common comorbidity of GPP, we do not believe this event is likely attributable to imsidolimab. Another patient dropped out of the study on Day 22 due to investigator reported inadequate efficacy.  One patient contracted COVID-19 during the course of the trial, which was mild, unrelated to imsidolimab, and did not lead to study discontinuation. In September 2019, we announced from the first two patients to have completed the Day 113 treatment period under this trial, which indicated sustained efficacy in these two patients through Day 113.  We plan to report full data from the GALLOP trial at a medical conference in 2021. We anticipate an FDA end-of-Phase 2 meeting during the fourth quarter of 2020 to outline the registration path of imsidolimab for the treatment of GPP.  </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also conducting a randomized, double-blind, placebo-controlled approximately 50-patient multi-dose trial of imsidolimab in PPP, also referred to as the POPLAR trial, where enrollment has been completed and the trial was over-enrolled, and top-line data are anticipated in the first quarter of 2021.  We also plan to initiate a global registry of GPP and PPP </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">patients, also referred to as the RADIANCE study, starting in the first quarter of 2021, which we anticipate will assist in enrollment of future clinical trials.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to GPP and PPP, we anticipate initiation of Phase 2 clinical trials of imsidolimab in two additional indications: (1) skin toxicities associated with treatments with inhibitors of epidermal growth factor (&#8220;EGFRi&#8221;) and MAPK/ERK kinase (&#8220;MEKi&#8221;) and (2) ichthyosis Treatment of solid tumors with EGFRi and/or MEKI is frequently limited by the occurrence of skin toxicities, including acneiform or papulopustular rash. Recent translational data has suggested that these skin toxicities are mediated by excess IL-36 signaling, leading to IL-8-mediated cutaneous neutrophilia and acneiform rash. Based on existing claims data, approximately 60,000 patients are prescribed EGFRi and/or MEKi treatments annually, and the vast majority of these patients experience skin toxicity, which in some cases leads to dose reduction and/or discontinuation of treatment. Current standard-of-care treatments are generally ineffective in patients with the most severe grades of EGFRi and/or MEKi mediated skin toxicity. During the fourth quarter of 2020, we anticipate initiating a Phase 2 clinical trial of imsidolimab, in combination with EGFRi inhibitors, for the treatment of patients diagnosed with a certain baseline severity of skin toxicity, to assess the efficacy of imsidolimab in the treatment of this indication.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ichthyosis is a family of rare, inherited, dermatological disorders characterized by dry, scaling and thickened skin. Recent human translational studies have suggested that the underlying skin inflammation responsible for ichthyosis is mediated by dysregulated IL-36 signaling, and we believe that imsidolimab treatment may be efficacious in treatment of this condition. Approximately 6,000 patients in the United States are affected with moderate-to-severe levels of ichthyosis and no approved therapies are available for this disease. We anticipate initiating a Phase 2 clinical trial of imsidolimab in patients with certain baseline severity of ichthyosis, during the fourth quarter of 2020.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Etokimab, our anti-IL-33 antibody previously referred to as ANB020, inhibits the activity of the interleukin-33 cytokine (&#8220;IL-33&#8221;), which we believe may be applicable to the treatment of respiratory disorders. We are conducting a randomized, placebo-controlled Phase 2 clinical trial of etokimab in approximately 100 adult patients with CRSwNP (a debilitating atopic disorder associated with elevated IL-33 pathway signaling), also referred to as the ECLIPSE trial. We recently reported top-line data from a week 8 interim analysis of the ECLIPSE trial.  Patients dosed with etokimab every four (q4w) or eight weeks (q8w) failed to achieve statistically significant improvement in their bilateral nasal polyps score (&#8220;NPS&#8221;), an endoscopic measure of nasal occlusion, and in their sino-nasal outcome test (&#8220;SNOT-22&#8221;), a patient reported quality-of-life assessment, versus placebo at the week 8 time point. Both endpoints demonstrated statistically significant improvement over baseline levels of NPS and SNOT-22.  Blood eosinophil levels, which are a biomarker of etokimab&#8217;s mechanism, demonstrated statistically significant reduction relative to baseline in both etokimab treatment arms. We intend to determine next steps for the etokimab program after reviewing week 16 primary endpoint data by year-end 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third wholly-owned program, ANB030, is an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases. Genetic mutations in the PD-1 pathway are known to be associated with increased susceptibility to human inflammatory diseases, and hence we believe that ANB030 is applicable to diseases where PD-1 checkpoint receptor function may be under-represented. We presented preclinical data for ANB030 at the Festival of Biologics Annual Meeting in March 2020.  We initiated a Phase 1 healthy volunteer clinical trial in the first half of 2020 subsequent to clearance of our Investigational New Drug Application (&#8220;IND&#8221;) for ANB030 by the FDA, which is designed to assess the safety, pharmacokinetics and pharmacodynamics of ANB030 in single and multiple ascending dose cohorts. We anticipate top-line data from this Phase 1 clinical trial in mid-2021. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our fourth wholly-owned program is an anti-BTLA modulator antibody, known as ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. Mutations in the BTLA signaling pathway are associated with human inflammatory disease, and we believe ANB032 silences pro-inflammatory signaling by modulating BTLA binding to HVEM. We anticipate filing an IND for ANB032 during the fourth quarter of 2020. We presented preclinical data regarding ANB032 at the 2020 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting in October 2020.  </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to our wholly-owned antibody programs, multiple Company-developed antibody programs have been advanced to preclinical and clinical milestones under our collaborations. We have received to date approximately $105.0 million in cash receipts from collaborations. Our collaborations include an immuno-oncology-focused collaboration with GSK, Inc. (&#8220;GSK&#8221;) and an inflammation-focused collaboration with BMS Corporation. A Biologics License Application (&#8220;BLA&#8221;) for our most advanced partnered program, which is an anti-PD-1 antagonist antibody called dostarlimab, was submitted by GSK </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and accepted by the FDA for the treatment of advanced or recurrent deficient mismatch repair endometrial cancer (&#8220;dMMREC&#8221;). In addition, the European Medicines Agency (&#8220;EMA&#8221;) recently accepted GSK&#8217;s Marketing Authorization Application (&#8220;MAA&#8221;) for dostarlimab in the EU for dMMREC. We received a $10.0 million cash milestone payment upon the FDA acceptance of GSK&#8217;s NDA and anticipate an additional $20.0 million cash milestone payment upon first FDA approval of dostarlimab during the fourth quarter of 2020. This FDA approval is dependent on a pre-approval inspection of the dostarlimab manufacturing site by the FDA and is therefore contingent on easing of the coronavirus (&#8220;COVID-19&#8221;) pandemic travel restrictions. We also received a $5.0 million milestone payment for the EMA acceptance of GSK&#8217;s MAA and anticipate an additional $10.0 million cash milestone payment upon EMA approval. In addition, GSK anticipates submitting a regulatory filing for potential approval of dostarlimab in a second indication, the treatment of pan-deficient mismatch repair tumors, during the first half of 2021.We anticipate receiving additional milestones from GSK, of equal magnitude to the milestone payments outlined above, upon acceptance and approval of BLA and EMA filings of dostarlimab for this second indication. Depending upon the timing of the aforementioned dostarlimab regulatory acceptance and approval milestones, we anticipate a total of $75.0 million in such milestone payments over the upcoming 18 months. An additional $165.0 million in sales milestones is anticipated upon achievement of certain dostarlimab annual sales revenues. Dostarlimab is also under development at GSK for a number of oncological indications, including endometrial cancer, non-small cell lung cancer, ovarian cancer, colorectal cancer and mismatch repair deficient solid tumors.  In October 2020, we amended our GSK collaboration to increase royalties on global net sales of dostarlimab to 8-25%, add a royalty to GSK&#8217;s global net sales of Zejula</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and a one-time cash payment of $60.0 million.  For more information about these collaborations, see Part I-Note 4, Collaborative Research and Development Agreements, and Part I-Note 10, Subsequent Event above.</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain key information about our wholly-owned and partnered product candidates:</span></div><div style="margin-top:6pt;text-align:center"><img src="anab-20200930_g1.jpg" alt="anab-20200930_g1.jpg" style="height:431px;width:684px;"/></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in December 2019, a strain of coronavirus was reported in Wuhan, China and began to spread globally, including to the United States and Europe, in the following months. The World Health Organization has declared COVID-19 to be a pandemic and a public health emergency of international concern. The full impact of the COVID-19 pandemic is inherently uncertain at the time of this Quarterly Report. The COVID-19 pandemic has resulted in travel restrictions and, in some cases, prohibitions of non-essential activities, disruption and shutdown of businesses, and greater uncertainty in global </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial markets. As COVID-19 has spread, it has significantly impacted the health and economic environment around the world, and many governments have closed most public establishments, including restaurants, workplaces, and schools. Our ongoing clinical trials have been, and may continue to be, affected by the closure of offices, or country borders, among other measures being put in place around the world. The inability to travel and conduct face-to-face meetings can also make it more difficult to enroll new patients in ongoing or planned clinical trials. Any of these circumstances will potentially have a negative impact on our financial results and the timing of our clinical trials.  </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has caused us to modify our business practices (including but not limited to curtailing or modifying employee travel, moving to full remote work, and cancelling physical participation in meetings, events, and conferences), and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees, patients, and business partners.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent of the impact of the COVID-19 pandemic on our future liquidity and operational performance will depend on certain developments, including the duration and spread of the outbreak, the impact on our trials, patients, and collaboration partners, and the effect on our suppliers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Operating Results </span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated any revenue from product sales. Our revenue has been derived from amortization of upfront license payments, research and development funding and milestone payments under collaboration and license agreements with our collaborators. From inception through September&#160;30, 2020, we have received $104.6 million in cash in non-dilutive funding from our collaborators.</span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with our research and development activities, including drug discovery efforts, preclinical and clinical development of our programs, and manufacturing. Our research and development expenses include: </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">External research and development expenses incurred under arrangements with third parties, such as contract research organizations (&#8220;CROs&#8221;), consultants, members of our scientific and therapeutic advisory boards, and contract manufacturing organizations (&#8220;CMOs&#8221;); </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Employee-related expenses, including salaries, benefits, travel, and stock-based compensation; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory supplies; and </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">License and sub-license fees. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expense when the service has been performed or when the goods have been received.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting research and development activities primarily on inflammation programs. We have a research and development team that conducts antibody discovery, characterization, translational studies, IND-enabling preclinical studies, and clinical development. We conduct some of our early research and preclinical activities internally and plan to rely on third parties, such as CROs and CMOs, for the execution of certain of our research and development activities, such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> toxicology and pharmacology studies, drug product manufacturing, and clinical trials.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed Phase 1 and 2a clinical trials for etokimab and Phase 1 clinical trials for imsidolimab and have ongoing Phase 2 clinical trials as well</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation for our executive, finance, legal, business development, human resource, and support functions. Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses, travel expenses, and professional fees for auditing, tax, and legal services. </span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of floating interest payments and amortization of discounts on our outstanding notes payable relating to our Loan and Security Agreement with Oxford Finance LLC and Silicon Valley Bank, as amended (the &#8220;Loan Agreement&#8221;). On January 1, 2020, the Loan Agreement was paid in full, without penalty or premium.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of interest earned on our short-term and long-term investments and is recognized when earned.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form 10-K filed with the SEC on March 2, 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations - Comparison of the Three and Nine Months Ended September 30, 2020 and 2019 </span></div><div style="margin-top:12pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $0 million and $15.0 million in collaboration revenue for the three and nine months ended September&#160;30, 2020, respectively, related to two milestone payments associated with dostarlimab, the anti-PD-1 antagonist antibody partnered with GSK. The first milestone payment was for $10.0 million for successful filing of the first NDA in a first indication and the second milestone payment was for $5.0 million for successful filing of the first MAA in a first indication. We recognized $0 million and $5.0 million for the three and nine months ended September 30, 2019, respectively related to a milestone payment for the initiation of a Phase 3 clinical trial in a second indication for dostarlimab, the anti-PD-1 antagonist antibody. We expect that any collaboration revenue we generate will continue to fluctuate from period to period as a result of the timing and amount of milestones from our existing collaborations. </span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $19.5 million during the three months ended September 30, 2020 compared to $29.9 million during the three months ended September 30, 2019 for a decrease of $10.4 million, primarily due to a $7.8 million&#160;decrease in outside services for manufacturing expenses, $1.8 million decrease in clinical expenses, $0.7 million decrease in salaries and related expenses, including stock compensation expense, and a $0.1 million decrease in other research and development expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $58.5 million during the nine months ended September 30, 2020 compared to $77.9 million during the nine months ended September 30, 2019 for a decrease of $19.4 million, primarily due to a $15.2 million&#160;decrease in outside services for manufacturing expenses, $2.3 million decrease in clinical expenses, $1.7 million </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease in salaries and related expenses, including stock compensation expense, and a $0.2 million decrease in other research and development expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track fully burdened research and development costs separately for each of our product candidates. We review our research and development expenses by focusing on external development and internal development costs. External development expenses consist of costs associated with our external preclinical and clinical trials, including pharmaceutical development and manufacturing. Included in preclinical and other unallocated costs are external corporate overhead costs that are not specific to any one program. Internal costs consist of salaries and wages, share-based compensation and benefits, which are not tracked by product candidate as several of our departments support multiple product candidate research and development programs. The following table summarizes the external costs attributable to each program and internal costs (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External Costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imsidolimab</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Etokimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANB030</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,136)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical and other unallocated costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total External Costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,681)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,454&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,245&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,791)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal Costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,542&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,389)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,458&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,912&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,454)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $4.8 million during the three months ended September 30, 2020 compared to $3.8 million during the three months ended September 30, 2019 for an increase of $1.0 million, primarily due to a $0.5 million increase in personnel costs including stock compensation expense, $0.5 million increase in legal expenses and $0.2 million increase in insurance expense, offset by a $0.2 million decrease in professional fees.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $13.8 million during the nine months ended September 30, 2020 compared to $12.3 million during the nine months ended September 30, 2019 for an increase of $1.5 million, primarily due to a $1.0 million increase in legal expenses, $0.5 million increase in insurance expense and $0.4 million increase in personnel costs including stock compensation expense, offset by a $0.3 million decrease in professional fees and $0.1 million decrease in travel expenses.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase for the foreseeable future as we incur additional costs associated with being a publicly traded company, including legal, auditing and filing fees, additional insurance premiums, investor relations expenses and general compliance and consulting expenses. We also expect our intellectual property related legal expenses, including those related to preparing, filing, prosecuting and maintaining patent applications, to increase as our intellectual property portfolio expands. </span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $0 for both the three and nine months ended September 30, 2020, and $0.2 million and $0.8 million during the three and nine months ended September 30, 2019, respectively. The decrease in interest expense during the periods is due to the final payment made on the Loan Agreement on January 1, 2020.</span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $0.6 million and $3.6 million during the three and nine months ended September&#160;30, 2020, respectively, and was $2.8 million and $8.7 million during the three and nine months ended September&#160;30, 2019, respectively, which primarily related to our short-term and long-term investments, the balance of which decreased during the periods as a </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result of funding our clinical trial programs. The decrease in interest income is also attributable to lower interest rates during the three and nine months ended September&#160;30, 2020.</span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net was expense of less than $0.1 million and income of less than $0.1 million for the three and nine months ended September 30, 2020, respectively, and income of $0.1 million for both the three and nine months ended September 30, 2019, respectively, and primarily related to foreign exchange transactions through our Australian subsidiary and with our foreign CROs and CMOs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From our inception through September&#160;30, 2020, we have received an aggregate of $743.9 million to fund our operations, which included $620.2 million from the sale of equity securities, $104.6 million from our collaboration agreements and $19.1 million from venture debt. As of September&#160;30, 2020, we had $374.5 million in cash, cash equivalents and investments. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our existing cash, cash equivalents and investments, we are eligible to earn milestone and other contingent payments for the achievement of defined collaboration objectives and certain nonclinical, clinical, regulatory and sales-based events, and royalty payments under our collaboration agreements. Our ability to earn these milestone and contingent payments and the timing of achieving these milestones is primarily dependent upon the outcome of our collaborators&#8217; research and development activities and is uncertain at this time. Our rights to payments under our collaboration agreements are our only committed external source of funds. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, we amended our GSK Agreement, as disclosed in Note 10.  Under the Amendment, we allowed for GSK to conduct development and commercialization of Zejula and we are entitled to increased royalties upon sales of dostarlimab, an anti-PD-1 antagonist antibody under development by GSK for multiple oncological disorders, including endometrial cancer, non-small cell lung cancer, ovarian cancer, colorectal cancer and mismatch repair deficient solid tumors, equal to 8% of Net Sales (as defined in the GSK Agreement) below $1.0&#160;billion and from 12% up to 25% of Net Sales above $1.0&#160;billion.   The Amendment also entitles us to a one-time non-refundable cash payment of $60.0&#160;million payable to us within 30 days of the date of the Amendment.  Tesaro also agreed, starting January 1, 2021, to pay us a 1% royalty on all GSK and Tesaro Net Sales of Zejula </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which has received US approval for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, and is under development for additional cancer indications. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding Requirements </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek to obtain additional financing in the future through equity or debt financings or through collaborations or partnerships with other companies. If we are unable to obtain additional financing on commercially reasonable terms, our business, financial condition and results of operations will be materially adversely affected. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of capital are, and we expect will continue to be, third-party clinical and preclinical research and development services, including manufacturing, laboratory and related supplies, compensation and related expenses, legal, patent and other regulatory expenses, and general overhead costs. We have entered into agreements with certain vendors for the provision of services, including services related to commercial manufacturing, that we are unable to terminate for convenience.&#160;Under such agreements, we are contractually obligated to make certain minimum payments to the vendors with the amounts to be based on the timing of the termination and the specific terms of the agreement.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a publicly traded company, we incur significant legal, accounting, and other expenses that were not required as a private company.&#160;In addition, the Sarbanes-Oxley Act of 2002, as well as rules&#160;adopted by the Securities and Exchange Commission (the &#8220;SEC&#8221;) and The Nasdaq Global Stock Market, requires public companies to implement specified corporate governance practices that were inapplicable to us as a private company. These rules&#160;and regulations have increased our legal and financial compliance costs and have made and will continue to make certain activities more time-consuming and costly. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and investments totaled $374.5 million as of September&#160;30, 2020, compared to $428.5 million as of December&#160;31, 2019. We believe that our existing cash, cash equivalents and investments will fund our current operating plan </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at least into 2023. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.</span></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the nine months ended September 30, 2020 and 2019: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,735)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,712)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,877&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,396&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,137&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,302&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities during the nine months ended September 30, 2020 of $51.7 million was primarily due to our net loss of $53.6 million, adjusted for addbacks for non-cash expenses of $9.2 million, which includes stock-based compensation and net decreases in working capital of $7.3 million. Net cash used in operating activities during the nine months ended September 30, 2019 of $53.7 million was primarily due to our net loss of $77.1 million, adjusted for non-cash expenses of $8.1 million, which includes stock-based compensation and net increases in working capital of $15.3 million. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities during the nine months ended September 30, 2020 and 2019 of $90.9 million and $127.4 million, respectively, primarily relates to the timing of our investment maturity, which was used to fund our operating expenses.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net cash used in financing activities during the nine months ended September 30, 2020 of $1.0 million primarily related to principal and final payments of $1.4 million made on the Loan Agreement, offset by $0.4 million in proceeds from the issuance of common stock upon the exercise of stock options. The net cash used in financing activities during the nine months ended September 30, 2019 of $4.4 million primarily related to principal payments of $5.6 million made on the Loan Agreement, offset by $1.2 million in proceeds from the issuance of common stock upon the exercise of stock options. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations </span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two non-cancellable office leases (the &#8220;Office Leases&#8221;) with remaining lease terms of approximately one year, each of which are classified as operating leases. Both leases expire in 2021. Only one of our leases has remaining renewal options, which includes three options to renew for one additional year. The exercise of lease renewal options is at our sole discretion, which we currently do not anticipate exercising and as such were not recognized as part of our right-of-use (&#8220;ROU&#8221;) asset and lease liabilities. Our lease payments are fixed, and we recognize lease expense for these leases on a straight-line basis over the lease term. Operating lease ROU assets and lease liabilities are recorded based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not provide an implicit rate, we used our incremental borrowing rate based on the information available at effective date of adoption in determining the present value of future payments. The weighted-average discount rate used was 8.59%.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, the future minimum annual obligations under the Office Leases are $0.2 million and $0.7 million for the remainder of fiscal years ending 2020 and 2021, respectively.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 4, 2020, we entered into a lease agreement (the &#8220;Lease Agreement&#8221;) with Wateridge Property Owner, LP, with respect to facilities in the building at 10770 Wateridge Circle, San Diego, California 92121. Under the Lease Agreement, we agreed to lease approximately 45,000 square feet of space in the 10770 Wateridge Circle Building for a term of 124 months, beginning on March 1, 2021 (or on such later date as described in the Lease Agreement). The terms of the Lease Agreement provide us with an option to extend the term of the lease for an additional five years, as well as a one-time option we have to terminate the lease after seven years with the payment of a termination fee. The monthly base rent will be $4.20 per rentable square foot and will be increased by 3% annually. Under the Lease Agreement, we are also responsible for our pro rata share of real estate taxes, building insurance, maintenance, direct expenses, and utilities. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Contingencies</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with certain vendors for the provision of goods and services, which includes manufacturing services with CMOs and development services with CROs. These agreements may include certain provisions for purchase obligations and termination obligations that could require payments for the cancellation of committed purchase obligations or for early termination of the agreements. The amount of the cancellation or termination payments vary and are based on the timing of the cancellation or termination and the specific terms of the agreement.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into standard indemnification arrangements in the ordinary course of business. Pursuant to certain of these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party for third-party claims in connection with our breach of the agreement, our negligence or willful misconduct in connection with the agreement, or any trade secret, copyright, patent or other intellectual property infringement claim with respect to our technology. The term of these indemnification arrangements is generally perpetual. The maximum potential amount of future payments we could be required to make under these agreements is not determinable because it involves claims that may be made against us in the future but have not yet been made.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also entered into indemnification agreements with our officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving in such capacity, as permitted under Delaware law, in accordance with our certificate of incorporation and bylaws, and pursuant to agreements providing for indemnification entered into with our officers and directors. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum amount of potential future indemnification of directors and officers is unlimited; however, we currently hold director and officer liability insurance. This insurance allows the transfer of risk associated with our exposure and may enable us to recover a portion of any future amounts paid.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the fair value of these indemnification obligations is minimal. Accordingly, we have not recognized any liabilities relating to these obligations for any period presented.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.  Quantitative and Qualitative Disclosures About Market Risk </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2020, there have been no material changes surrounding our market risk, including interest rate risk, inflation risk, and foreign currency exchange risk from the discussion provided in Item 7A. Quantitative and Qualitative Disclosures About Market Risk of our Annual Report on Form 10-K filed with the SEC on March 2, 2020.</span></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Controls and Procedures </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. As of September&#160;30, 2020, our management, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on this evaluation, our Chief Executive Officer and Interim Chief Financial Officer concluded that the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(f) and 15d-15(f) of the Exchange Act that occurred during the quarter ended September&#160;30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings  </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 25, 2020, a putative securities class action was filed in the United States District Court for the Southern District of California naming the Company and certain of its current or former officers as defendants. The complaint purports to assert claims under Section 10(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), Exchange Act  Rule 10b-5, and Section 20(a) of the Exchange Act, on behalf of persons and entities who acquired our common stock between October 10, 2017 and November 7, 2019 (the &#8220;Class Period&#8221;). An amended complaint was filed on September 30, 2020 alleging that, during the Class Period, the defendants made material misrepresentations or omissions regarding our etokimab product candidate that artificially inflated our stock price. The plaintiff seeks, among other things, damages in an unspecified amount, as well as costs and expenses. We believe that the plaintiff&#8217;s allegations are without merit and intend to vigorously defend against the claims. On September 1, 2020, a related shareholder derivative complaint was filed based on allegations substantially similar to those in the class action, and asserting claims against current or former officers and directors for contribution under Sections 10(b) and 21D of the Exchange Act, breach of fiduciary duty, unjust enrichment and corporate waste. Because the Company is in the early stages of this litigation matter, we are unable to estimate a reasonably possible loss or range of loss, if any, that may result from these matters.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We investigate these claims as they arise and accrue estimates for resolution of legal and other contingencies when losses are probable and estimable. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors.</span></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this report, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Discovery and Development of Our Product Candidates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our product candidates are in early stages of development and may fail in development or suffer delays that adversely affect their commercial viability. Results from our initial clinical trials may not be representative of the results we will experience in later clinical trials. If we or our collaborators are unable to complete development of or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are using our proprietary technology platform to develop therapeutic antibodies, including our wholly-owned product candidates, as well as other programs that are being developed by our collaborators. However, all of our wholly-owned and partnered product candidates are in the early stages of development, and, for a wide variety of reasons discussed below, may fail in development or suffer delays that adversely affect their commercial viability.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care, and other variables. The results from preclinical testing or early clinical trials of a product candidate may not predict the results that will be obtained in later phase clinical trials of the product candidate. For example, results from our initial Phase 2a clinical trial of etokimab in moderate-to-severe atopic dermatitis patients was not representative of the results we experienced in our later etokimab moderate-to-severe atopic dermatitis Phase 2b clinical trial called &#8220;ATLAS&#8221;. Similarly, we reported interim results of our GALLOP Phase 2 clinical trial of imsidolimab, which included data for two patients who had completed the Day 113 trial period. While we believe these results are likely to be representative of subsequent patients in the clinical trial, the results we have observed to date may not be predictive of results once all 8 patients have completed the clinical trial. If our later clinical </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">trials are unsuccessful, our product candidates may be delayed in development or fail entirely, which would have a material adverse impact on our business.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to structure our initial Phase 2a clinical trials with etokimab as investigational studies that enroll a relatively limited number of patients and are intended to allow us to better assess patient responses and potential efficacy results before designing and commencing Phase 2b clinical trials. We believe the results we have observed in the initial Phase 2a clinical trials of etokimab in severe adult eosinophilic asthma may suggest a reasonable basis for continuing development of etokimab in this indication through a larger Phase 2b clinical trial. However, as a result of the recently announced topline data from our ATLAS etokimab Phase 2b trial in atopic dermatitis, we have decided to postpone the initiation of our planned Phase 2b etokimab clinical trial in eosinophilic asthma (a multi-dose, randomized, double-blinded, placebo-controlled trial in 300-400 patients) until we have the opportunity to analyze the complete results from our currently ongoing Phase 2 trial of etokimab in CRSwNP. Our Phase 2a clinical trials involved relatively small patient populations (for example, 25 patients in our Phase 2a clinical trial in severe adult eosinophilic asthma). The results we have observed in these smaller patient populations may not be predictive of results we will experience in later studies. Furthermore, the average results reported from our Phase 2a clinical trial in severe eosinophilic asthma (for example, the average change in FEV1 reported) were subject to significant variability due to the small number of patients enrolled and, as expected, were not statistically significant. In addition, we elected to structure our initial Phase 2a clinical trial in eosinophilic asthma as a single dose study, which may not be representative of the efficacy and/or safety observed in subsequent multi-dose Phase 2, Phase 2b, or Phase 3 clinical trials.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later studies may also include different design elements that could contribute to us experiencing different results than we have observed in our Phase 2a clinical trials. One such design element may be differences in efficacy endpoints between Phase 2a clinical trials and subsequent Phase 2, Phase 2b or Phase 3 clinical trials. For instance, while our single dose Phase 2a clinical trial of etokimab in eosinophilic asthma demonstrated efficacy in terms of FEV1 improvement versus placebo, we did not structure that clinical trial to assess efficacy in terms of exacerbation reduction, which is the endpoint historically used by the FDA for drug approval in asthma. Hence our future Phase 2, Phase 2b, or Phase 3 clinical trials in asthma may not demonstrate efficacy in exacerbation reduction leading to potential delays or failure to obtain approval of etokimab in asthma. In addition, the initial results we have reported from our Phase 2a clinical trials have included interim analyses and top-line results at early time points, which may not accurately predict the final results of these clinical trials or the results of future clinical trials. For instance, our single dose Phase 2a clinical trial of etokimab in atopic dermatitis demonstrated certain levels of EASI-50 response upon interim analysis at Day 29, but this EASI-50 response level was not maintained at the end of this clinical trial at Day 140.  In another example, interim analysis data from our Phase 2a clinical trial of severe adult eosinophilic asthma demonstrated FEV1 improvement over placebo at Day 64, but this FEV1 improvement was not maintained at the same levels through study completion at the Day 127 time point.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, our rationale for conducting clinical trials of etokimab in multiple indications is that we believe etokimab&#8217;s mechanism of action, the inhibition of IL-33, has the potential be effective for treatment of a range of atopic inflammatory disorders. However, in light of the recently announced topline data from our ATLAS Phase 2b clinical trial of etokimab in atopic dermatitis and our recently announced interim analysis from our ECLIPSE clinical trial of etokimab in CRSwNP, it is possible that our assumptions regarding the effectiveness of etokimab&#8217;s mechanism of action may be incorrect and that etokimab may be ineffective in certain inflammatory disorders or in treating inflammatory disorders generally. If this were the case, then the complete results from our ongoing Phase 2 clinical trial of etokimab in CRSwNP, and results from any other clinical trials of etokimab that we conduct, are less likely to be positive.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If our later clinical trials of imsidolimab or etokimab are unsuccessful, whether for one of the reasons mentioned above or otherwise, imsidolimab or etokimab may be delayed in development or fail entirely, which would have a material adverse impact on our business.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our current product candidates, and any other product candidates we may develop in the future, will depend on many factors, including the following:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">obtaining regulatory permission to initiate clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">successful enrollment of patients in, and the completion of, our planned clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">receiving marketing approvals from applicable regulatory authorities;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">establishing commercial manufacturing capabilities and/or making arrangements with third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and their components;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">enforcing and defending intellectual property rights and claims;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">achieving desirable therapeutic properties for our product candidates&#8217; intended indications;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with third parties;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">effectively competing with other therapies; and</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">maintaining an acceptable safety profile of our product candidates through clinical trials and following regulatory approval.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would harm our business.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development times, or termination of a clinical trial. Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites, and the availability of effective treatments for the relevant disease. We may not be able to initiate our planned clinical trials if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or foreign regulatory authorities. More specifically, some of our product candidates, including imsidolimab, initially target indications that are very rare, which can prolong the clinical trial timeline for the regulatory process if sufficient patients cannot be enrolled in a timely manner.</span></div><div style="margin-top:18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The COVID-19 pandemic has had a material impact on the U.S. and global economies and could have a material adverse impact on our employees, contractors, and patients, which could adversely and materially impact our business, financial condition, and results of operations. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic and mitigation measures have had, and may continue to have, an adverse impact on global economic conditions, which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the COVID-19 pandemic impacts our business and operations will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic has caused us to modify our business practices (including but not limited to curtailing or modifying employee travel, moving to full remote work, and cancelling physical participation in meetings, events and conferences), and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees and patients. In response to the COVID-19 pandemic, we limited our office to only those employees completing laboratory-based tasks essential to our development efforts, and are starting to allow other employees to work in our office with certain precautions in place that we believe will ensure our employees&#8217; safety and wellbeing. &#8220;Essential&#8221; employees that are unable to telework continue to work at our facilities, and we have implemented appropriate safety measures, including social distancing, face covering, and increased sanitation standards. We are following guidance from the Center for Disease Control and the Occupational Safety and Health Administration regarding suspension of nonessential travel, self-isolation recommendations for employees returning from certain geographic areas, confirmed reports of any COVID-19 diagnosis among our employees, and the return of such employees to our workplace. Pursuant to updated guidance from the Equal Employment Opportunity Commission, we are engaging in limited and appropriate inquiries of employees regarding potential COVID-19 exposure based on the direct threat that such exposure may present to our workforce. We continue to address other unique situations that arise among our workforce due to the COVID-19 pandemic on a case-by-case basis. While we believe that we </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">have taken appropriate measures to ensure the health and well-being of our &#8220;essential&#8221; employees, there can be no assurances that our measures will be sufficient to protect our employees in our workplace, and they may be exposed to COVID-19 outside of our workplace. If a number of our essential employees become ill, incapacitated or are otherwise unable to continue working during the current or any future epidemic, our operations may be adversely impacted.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A prolonged disruption or any further unforeseen delay in our operations or within any of our business activities could continue to result in reduced participation in ongoing clinical trials or delays in enrolling our planned clinical trials because we rely on contract research organizations (for non-clinical and clinical activities) (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;) to conduct our clinical trials and to manufacture our product candidates. If our CROs are unable to continue ongoing clinical trials or to enroll new patients for new clinical trials, or if our CMOs are unable to obtain sufficient quantities of reagents or manufacture adequate drug quantities, our clinical trials could be materially delayed or disrupted. We may also encounter delays from the FDA, EMA or other health authorities in our clinical development efforts. Any elongation or de-prioritization of our preclinical studies or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates. Further, in reaction to the spread of COVID-19 in the United States and internationally, many patients and medical facilities are delaying or canceling elective procedures, adding further strain to health care budgets globally.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic may result in the inability of our suppliers to deliver supplies to us on a timely basis. We currently utilize third parties to, among other things, manufacture components of our product candidates and, in the future, intend to utilize third parties to conduct our preclinical and clinical studies. If either we or any third-party parties in the supply chain for materials used in the production of our product candidates are adversely impacted by restrictions resulting from the COVID-19 pandemic, our supply chain may be disrupted, limiting our ability to manufacture our product candidates for our preclinical studies.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Both the health and economic aspects of the COVID-19 virus are highly fluid, and the future course of each is uncertain. For these reasons and other reasons that may come to light if the COVID-19 pandemic and associated protective or preventative measures expand, we may experience a material adverse effect, either directly or indirectly through our CROs, CMOs, collaboration partners or patients, on our business operations, revenues and financial condition; however, its ultimate impact is highly uncertain and subject to change.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">We have only limited data regarding the safety profile of our wholly-owned product candidates when dosed in humans. Our ongoing and planned clinical trials or those of our collaborators may reveal significant adverse events, toxicities or other side effects and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to obtain marketing approval for any of our product candidates, we must demonstrate the safety and efficacy of the product candidate for the relevant clinical indication or indications through preclinical studies and clinical trials as well as additional supporting data. If our product candidates are associated with undesirable side effects in preclinical studies or clinical trials or have characteristics that are unexpected, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have conducted various preclinical studies of our product candidates, but we do not know the predictive value of these studies for humans, and we cannot guarantee that any positive results in preclinical studies will successfully translate to human patients. We have only completed early clinical trials for etokimab, and subsequent patient trials with etokimab are currently ongoing. We also have only completed a Phase 1 clinical trial with imsidolimab, and subsequent patient trials with imsidolimab are currently ongoing. It is not uncommon to observe results in human clinical trials that are unexpected based on preclinical testing, or to observe results in later stage clinical trials that are unexpected based on early clinical trials. Many product candidates fail in clinical trials despite promising preclinical and early clinical results. In addition, top-line results of a clinical trial, which generally reflect preliminary reviews of primary efficacy and/or safety results, do not necessarily predict final results, and any top-line findings or assessments are subject to change pending the completion of final data review procedures. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some patients in our clinical trials have experienced adverse events, including serious adverse events. The most frequent treatment-emergent adverse events reported were mild dizziness or vomiting in patients subsequent to placebo dosing, and mild headache, strep throat, upper respiratory tract infection, or, in one case, severe neutropenia which was acute and not persistent in patients post-etokimab administration. In addition, we reported that one patient dropped out of the GALLOP Phase 2 clinical trial for imsidolimab due to diagnosis with&#160;Staphylococcal aureus&#160;bacteremia on Day 3 post-imsidolimab administration, which was a serious adverse event deemed to be possibly drug-related. Subjects in our ongoing and planned clinical trials may in the future suffer significant adverse events or other side effects not observed in our preclinical studies or in our Phase 1 or Phase 2 clinical trials. The observed potency and kinetics of our product candidates in preclinical studies may not be observed in human clinical trials. We have tested the dosing frequency and route of administration of our product candidates in preclinical studies, which will inform our dosing strategy for future clinical trials, however such dose and route of administration may not result in sufficient exposure or pharmacological effect in humans and may lead to unforeseen toxicity not previously observed in preclinical testing. If preclinical studies of our product candidates fail to provide preliminary evidence of safety to the satisfaction of regulatory authorities or do not otherwise produce satisfactory results, we may incur additional costs or experience delays in initiating and/or advancing the development and commercialization of our product candidates. Further, if clinical trials of our product candidates fail to demonstrate efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If further significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trial, patients may drop out of our trial, or we may be required to abandon the trial or our development efforts of that product candidate altogether. We, the FDA, or other applicable regulatory authorities, or an institutional review board or ethics committee, may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such clinical trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude a product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, if any of our product candidates obtain marketing approval, toxicities associated with our product candidates may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional warnings being added to the labeling, significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early stage clinical testing.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, required regulatory approvals in the United States or in foreign jurisdictions, which would materially impair our ability to commercialize and generate revenue from our product candidates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to continue to develop our product candidates, and to have the potential to achieve and sustain profitability, depends on the FDA and foreign regulatory authorities permitting us to conduct human clinical trials and, if our product candidates are safe and effective, obtaining approval from the FDA and foreign regulatory authorities to market them and subsequently successfully commercializing them, either alone or with our collaborators. The research, testing, manufacturing, labeling, approval, selling, marketing, and distribution of drug and biologic products are subject to extensive regulation by the FDA and foreign regulatory authorities. Though we have cleared an IND and clinical trial application (&#8220;CTA&#8221;) to conduct clinical trials for both etokimab and imsidolimab in the United States and certain foreign jurisdictions, before commencing clinical trials in the United States for any other product candidate, we must submit an IND to the FDA; foreign regulatory authorities enforce similar requirements for initiation of clinical trials in other countries. An IND or foreign equivalent requires extensive preclinical studies, and there is no guarantee that the FDA or foreign regulatory authorities will allow clinical trials to proceed based on the IND or equivalent submission. For example, although we have initiated toxicology studies for our product candidates, the FDA in the United States, or other foreign regulatory authorities, as applicable, may not allow our clinical trials to proceed in the regulatory authority&#8217;s jurisdiction if we are unable to show safety margins acceptable to the particular regulatory authority in appropriate animal species in our preclinical toxicology studies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if we or our collaborators initiate and complete clinical trials for our product candidates, these product candidates will not be permitted to be marketed in the United States until approval of a BLA from the FDA, is received, and will not be permitted to be marketed in other countries without marketing approval from foreign regulatory authorities. Obtaining approval of a BLA or other marketing approvals is often a lengthy, expensive and uncertain process over which the FDA and foreign regulatory authorities have substantial discretion. Other than submitting and receiving acceptance for initiation of our previous and current clinical trials in the United States and certain foreign jurisdictions, we have not yet discussed with the FDA or foreign regulatory authorities the development plans for any of our product candidates or the designs of any of our later-stage clinical studies. We thus may not have the full benefit of the FDA&#8217;s or foreign regulatory authorities&#8217; current thinking on clinical trial designs or product development for our target indications. For example, we believe a small pivotal clinical trial, potentially with less than 100 patients, may be sufficient to demonstrate substantial evidence of efficacy of imsidolimab in GPP patients. However, we have not yet discussed clinical trial design for this indication with the FDA, and the FDA may disagree with our proposed clinical trial design, including the number of patients necessary to demonstrate efficacy and/or may require us to conduct more than one pivotal clinical trial in order to obtain approval of a BLA. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies and clinical trials are expensive, difficult to design and implement, can take many years to complete, and are uncertain as to outcome. Product candidates, on average, take 10 to 15 years to be developed from the time they are discovered to the time they are approved and available for treating patients. The start or end of a clinical trial is often delayed or halted for many reasons, including:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">imposition of a clinical hold for safety reasons or following an inspection of clinical trial operations or site by the FDA or other regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">manufacturing challenges;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">insufficient supply or quality of product candidates or other materials necessary to conduct clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays in reaching or failure to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and CROs or failure by such CROs or trials sites to carry out the clinical trial in accordance with our agreed-upon terms;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">non-clinical or clinical sites becoming unavailable due to political, economic, or public health events, such as the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">clinical sites electing to terminate their participation in one of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">inability or unwillingness of patients or medical investigators to follow clinical trial protocols;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">required clinical trial administrative actions;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">slower than anticipated patient enrollment;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">changing standards of care;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">safety concerns;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">availability or prevalence of use of a comparative drug or required prior therapy; or</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">clinical outcomes or financial constraints.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. Regulatory authorities may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical or other studies or clinical trials. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Moreover, regulatory authorities may determine that the clinical and other benefits of a product candidate do not outweigh the safety or other risks. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application may also cause delays in or prevent the approval of an application.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience any of the issues described above, or other similar or related issues, we may:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">not obtain marketing approval at all;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">obtain marketing approval in some countries and not in others; obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">be subject to additional post-marketing testing requirements; or</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">have the product removed from the market after obtaining marketing approval.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:118%">We may not be successful in our efforts to use our technology platform to expand our pipeline of product candidates and develop marketable products.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. Our business depends on our successful development and commercialization of the limited number of internal product candidates we have in preclinical and early-stage clinical development. Even if we are successful in continuing to build our pipeline, development of the potential product candidates that we identify will require substantial investment in additional clinical development, management of clinical, preclinical and manufacturing activities, regulatory approval in multiple jurisdictions, building a commercial organization, and significant marketing efforts before we generate any revenue from product sales. Furthermore, such product candidates may not be suitable for clinical development, including as a result of their harmful side effects, limited efficacy or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we cannot validate our technology platform by successfully developing and commercializing product candidates based upon our technological approach, we may not be able to obtain product or partnership revenue in future periods, which would adversely affect our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of our current focus on our lead product candidates, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. Our understanding and evaluation of biological targets for the discovery and development of new product candidates may fail to identify challenges encountered in subsequent preclinical and clinical development. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:118%">We have recently commenced clinical development of etokimab, imsidolimab and ANB030 and have no other history of conducting clinical trials or commercializing biotechnology products, which may make it difficult to evaluate the prospects for our future viability.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations to date have been largely limited to financing and staffing our company, developing our technology, and developing our wholly-owned product candidates and other product candidates in partnerships with our collaborators. As a company, we have only very limited experience conducting clinical trials and have not had previous experience commercializing product candidates, including submitting a BLA to the FDA. In part because of this lack of experience, we cannot be certain that planned clinical trials will begin or be completed on time, if at all, that our planned development programs would be acceptable to the FDA or other regulatory authorities, or that, if approval is obtained, such product candidates can be successfully commercialized. Clinical trials and commercializing our wholly-owned product candidates will require significant additional financial and management resources, and reliance on third-party clinical investigators, CROs, consultants or collaborators. Relying on third-party clinical investigators, CROs or collaborators may result in delays that are outside of our control.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">Furthermore, we may not have the financial resources to continue development of, or to enter into collaborations for, a product candidate if we experience any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%;padding-left:19pt">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%;padding-left:19pt">delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">conditions imposed by the FDA or foreign regulatory authorities regarding the number, scope or design of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays in enrolling research subjects in clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">high drop-out rates of research subjects;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">inadequate supply or quality of clinical trial materials or other supplies necessary for the conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">greater than anticipated clinical trial costs;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">poor effectiveness or unacceptable side effects of our product candidates during clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">serious and unexpected drug-related side effects experienced by participants in our planned clinical trials or by individuals using drugs similar to our product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">varying interpretations of data by the FDA and foreign regulatory authorities.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, any predictions you make about our future success or viability based on our short operating history may not be as accurate as they could be if we had a longer operating history or an established track record in conducting clinical trials or commercializing products.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, as a clinical stage business, we may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown factors. We will need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face significant competition, and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology industry is highly competitive and subject to rapid and significant technological change. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical and biotechnology companies, established biotechnology companies, specialty biotechnology companies, emerging and start-up companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources and commercial expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development and collaborative arrangements in our target markets with leading companies and research </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or approval from the FDA or foreign regulatory authorities or discovering, developing and commercializing products in our field before we do.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For asthma, our competitors include omalizumab (Xolair; Roche), which has received FDA approval and functions by inhibiting the binding between free IgE and FceRI; antibodies that bind IL-5 and inhibit its interaction with the IL-5 receptor such as mepolizumab (Nucala; GSK) and reslizumab (Cinqair; Teva), both of which the FDA has approved for the add-on maintenance treatment in patients with severe eosinophilic asthma; antibodies such as benralizumab (FASENRA, AstraZeneca) that bind the IL-5 receptor; antibodies that bind the IL-4 receptor and inhibit its signaling through IL-4 and IL-13 cytokines such as dupilumab (Dupixent; Regeneron/Sanofi), which has been approved by the FDA for use with other asthma medicines for the&#160;maintenance treatment&#160;of moderate-to-severe asthma&#160;in patients aged 12 years and older whose asthma is not controlled&#160;with their current asthma medicines; antibodies that bind to IL-13 such as lebrikizumab (Dermira), tralokinumab (AstraZeneca, LEO Pharma) and anrukinzumab (Pfizer), which are in clinical testing; antibodies that bind the IL-4 receptor alpha chain, such as AMG 317 (Amgen) in clinical testing; ST2-binding antibodies including Roche&#8217;s RG6149 which is in clinical testing for asthma and the treatment of COVID-19, and GSK&#8217;s GSK3772847, and Regeneron&#8217;s IL-33 antibody (REGN3500) each in clinical development for asthma and chronic obstructive pulmonary disease; a recently announced IL-33 related program by AstraZeneca (MEDI3506) in a Phase 1 clinical trial indicated for chronic obstructive pulmonary disease and the treatment of COVID-19; DP-2 antagonists including fevipiprant (Novartis) under development for asthma and GB001 (Gossamer Bio) under development for asthma; and an anti-TSLP antibody called tezepelumab (AMG 157, MEDI9929, Amgen/AstraZeneca) being developed by Amgen and AstraZeneca for asthma.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors in CRSwNP include dupilumab (Regeneron/Sanofi), mepolizumab (GSK), benralizumab (AstraZeneca), omalizumab (Novartis), GB001 (Gossamer Bio) and PF-06817024 (Pfizer), each of which are in clinical testing.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For GPP and PPP, our competitors include marketed therapies such as secukinumab (Cosentyx; Novartis), which binds IL-17A; ustekinumab (Stelara; Janssen), which blocks IL-12 and 23 cytokine function; and acitretin (Soriatane; GSK), as well as therapies in development such as guselkumab (Janssen), which blocks IL-23 cytokine function, gevokizumab (Xoma 052) and canakinumab (Ilaris, Novartis), which binds IL-1 beta, anakinra (Kineret; Swedish Orphan Biovitrum AB), a recombinant form of the IL-1 receptor antagonist and an anti-IL-36 receptor antibody called BI-655130 (Boehringer Ingelheim).</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">For ichthyosis, systemically administered competitors include secukinumab (Cosentyx; Novartis), liarozole (GSK), dupilumab (Dupixent; Regeneron/Sanofi), and adalimumab (Humira; Abbvie). Various topical treatments may also be used off-label for treatment of ichthyosis related symptoms.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">  </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our anti-inflammatory checkpoint modulator antibody programs, our competitors include CC-90006 (BMS), which is an anti-PD-1 agonist antibody developed under our partnership with BMS, a BTLA modulator antibody called LY3361237 being developed by Eli Lilly and a PD-1 agonist antibody also being developed by Eli Lilly.  </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the enactment of the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), an abbreviated pathway for the approval of biosimilar and interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as interchangeable based on its similarity to an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product is approved under a BLA. To date, several biosimilar products have been approved under the BPCIA, but no interchangeable biological products have been approved. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that if any of our product candidates are approved as a biological product under a BLA it should qualify for the 12-year period of exclusivity. However, there is a risk that the FDA will not consider any of our product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Additionally, this period of regulatory exclusivity does not apply to companies pursuing regulatory approval via their own traditional BLA, rather than via the abbreviated pathway. Moreover, the extent to which a biosimilar, once approved, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, are less expensive or capture significant market share prior to or during our commercialization. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking to encourage the use of biosimilar products. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These companies compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for planned clinical trials and acquiring technologies complementary to, or necessary for, our programs. In addition, the biotechnology industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our product candidates may not achieve adequate market acceptance among physicians, patients, health care payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, health care payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the efficacy and safety profile as demonstrated in planned clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the timing of market introduction of the product candidate as well as competitive products;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the clinical indications for which the product candidate is approved;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">restrictions on the use of our products, if approved, such as boxed warnings or contraindications in labeling or a risk evaluation and mitigation strategy (&#8220;REMS&#8221;), if any, which may not be required of alternative treatments and competitor products;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">acceptance of the product candidate as a safe and effective treatment by physicians, clinics and patients;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the potential and perceived advantages of product candidates over alternative treatments, including any similar generic treatments;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the cost of treatment in relation to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the availability of coverage and adequate reimbursement and pricing by third parties and government authorities;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">relative convenience and ease of administration;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the frequency and severity of adverse events;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the effectiveness of sales and marketing efforts; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">unfavorable publicity relating to the product candidate.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, health care payors and patients, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If companion diagnostics for our product candidates, for which such diagnostics are required, are not successfully, and in a timely manner, validated, developed or approved, we may not achieve marketing approval or realize the full commercial potential of our product candidates.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If companion diagnostics are developed in conjunction with clinical programs, the FDA may require regulatory approval of a companion diagnostic as a condition to approval of the product candidate. For example, if we use a genetic test to determine which patients are most likely to benefit from imsidolimab for the treatment of GPP or PPP by designing our pivotal clinical trial or clinical trials of imsidolimab in that indication to require that subjects test positive for specific genetic mutations as a criterion for enrollment, then we will likely be required to obtain FDA approval or clearance of a companion diagnostic, concurrent with approval of imsidolimab, to test for those genetic mutations; we may also be required to demonstrate to the FDA the predictive utility of the companion diagnostic&#8212;namely, that the diagnostic selects for patients in whom the biologic therapy will be effective or more effective compared to patients not selected for by the diagnostic. We do not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on third parties to perform these functions. We do not currently have any agreement in place with any third party to develop or commercialize companion diagnostics for any of our product candidates. Companion diagnostics are subject to regulation by the FDA and foreign regulatory authorities as medical devices and require separate regulatory approval or clearance prior to commercialization.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our partners, or any third party, are unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the development of our product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our planned clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our product candidates may not receive marketing approval if their safe and effective use depends on a companion diagnostic; and</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we may not realize the full commercial potential of any product candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify patients with the specific genetic alterations targeted by our product candidates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we believe genetic testing is becoming more prevalent in the diagnosis and treatment of various diseases and conditions, our product candidates may be perceived negatively compared to alternative treatments that do not require the use of companion diagnostics, either due to the additional cost of the companion diagnostic or the need to complete additional procedures to identify genetic markers prior to administering our product candidates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events were to occur, our business would be harmed, possibly materially.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The manufacture of biologics is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our products for patients, if approved, could be delayed or stopped.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing biologics is complex, highly-regulated and subject to multiple risks. Manufacturing biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. Moreover, if the FDA determines that our manufacturer is not in compliance with FDA laws and regulations, including those governing current good manufacturing practices (&#8220;cGMPs&#8221;), the FDA may deny BLA approval until the deficiencies are corrected or we replace the manufacturer in our BLA with a manufacturer that is in compliance.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. Even if we or our collaborators obtain </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. Moreover, we source certain of the raw materials needed for our product candidates from outside the U.S.. Although we have not experienced any material supply interruptions to date, it is possible that the COVID-19 pandemic could cause such interruptions in the future. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scaling up a biologic manufacturing process is a difficult and uncertain task, and we may not be successful in transferring our production system or the manufacturer may not have the necessary capabilities to complete the implementation and development process. If we are unable to adequately validate or scale-up the manufacturing process with our current manufacturers, we will need to transfer to other manufacturers and complete the manufacturing validation process, which can be lengthy and costly. If we are able to adequately validate and scale-up the manufacturing process for our product candidates with contract manufacturers, we will still need to negotiate with such contract manufacturers agreements for commercial supply, and it is not certain we will be able to come to agreement on terms acceptable to us.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Capital Needs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have limited operating revenue and a history of operational losses and may not achieve or sustain profitability. We have no products approved for commercial sale, and to date we have not generated any revenue or profit from product sales.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an early-stage biotechnology company with a limited operating history. We have no approved products. To date, our revenue has been primarily derived from our GSK and BMS research collaboration and license agreements, and we are significantly dependent on such collaborators for the successful development of product candidates in these collaborations. Our ability to generate revenue and become profitable depends upon our ability, alone or with our collaborators, to successfully complete the development of our product candidates for our target indications and to obtain necessary regulatory approvals.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses in every year except fiscal year 2014. We had $15.0 million in collaboration revenue and our net loss was $53.6 million for the nine months ended September 30, 2020 and $77.1 million for the nine months ended September 30, 2019, with $5.0 million in collaboration revenue. As of September&#160;30, 2020, we had an accumulated deficit of $297.6 million.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations primarily through our initial public offering of common stock in January 2017, our follow-on public offerings of common stock in October 2017 and September 2018, private placements of our preferred stock and the issuance of debt. We have devoted substantially all of our efforts to research and development. We have only recently initiated clinical development for three of our product candidates and expect that it will be many years, if ever, before we have a product candidate ready for commercialization. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, and the net losses we incur may fluctuate significantly from quarter to quarter. Our revenue has been historically derived from amortization of upfront payments, research and development funding and milestone payments under collaboration and license agreements with our collaborators. Our ability to generate future product revenue from our current or future product candidates depends on a number of additional factors, including our ability (or as applicable our collaborators&#8217; ability) to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue research and preclinical development of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identify additional product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain existing and enter into new collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct additional preclinical studies and initiate clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approvals for the product candidates we develop or developed under our collaboration arrangements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional executive, clinical, quality control and scientific personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish and maintain supply and manufacturing relationships with third parties and ensure adequate and legally compliant manufacturing of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain coverage and adequate product reimbursement from third-party payors, including government payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other product candidates and technologies; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieve market acceptance for our or our collaborators&#8217; products, if any.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability because of the numerous risks and uncertainties associated with product development. In addition, our expenses could increase significantly beyond expectations if we are required by the FDA or other regulatory authorities to perform studies or clinical trials in addition to those that we currently anticipate. Even if imsidolimab and etokimab, or any of our other product candidates, are approved for commercial sale, we anticipate incurring significant costs associated with the commercial launch of any product candidate. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently only in the clinical development stages for our most advanced product candidates. In order to become and remain profitable we must, alone or with our collaborators, develop and eventually commercialize a product or products with significant market potential. This may require us to be successful in a range of challenging activities, including completing clinical trials of our product candidates, successfully developing companion diagnostics, obtaining marketing approval for these product candidates and manufacturing, marketing and selling those products for which we may obtain marketing approval. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain or expand our research and development efforts, expand our business or continue our operations. A decline in the value of our company would also cause you to lose part or even all of your investment.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of our product candidates or develop new product candidates.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a research and development company, our operations have consumed substantial amounts of cash since our inception. We expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we continue our discovery and preclinical development to identify new clinical candidates, and we and our collaborators conduct clinical trials of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we incur additional costs associated with operating as a public company. We believe that our existing cash, cash equivalents and investments will fund our current operating plan at least into 2023. However, circumstances may cause us to consume capital more rapidly than we currently anticipate. For example, as we continue to move our product candidates through preclinical studies, submit INDs or foreign equivalents and conduct clinical development, we may have adverse results requiring us to find new product candidates. Any of these events may increase our development costs more than we expect. We may need to raise additional funds or otherwise obtain funding through collaboration agreements to continue development of our product candidates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we need to secure additional financing, such additional fundraising efforts may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we do not raise additional capital when required or on acceptable terms, we may need to:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significantly delay, scale back or discontinue the development or commercialization of our product candidates or cease operations altogether;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek strategic alliances for research and development programs at an earlier stage than we would otherwise desire or on terms less favorable than might otherwise be available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relinquish, or license on unfavorable terms, our rights to technologies or future product candidates that we otherwise would seek to develop or commercialize ourselves; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eliminate staff to conserve resources.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we need to conduct additional fundraising activities and we do not raise additional capital in sufficient amounts or on terms acceptable to us, we may be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects. Our forecast of the period of time through which our financial resources will adequately support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &#8220;Risk Factors&#8221; section. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Our future funding requirements, both short and long-term, will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates and future product candidates we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and size of clinical trials needed to show safety, efficacy and an acceptable risk/benefit profile for any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and foreign regulatory authorities, including the potential for such authorities to require that we perform more studies or trials than those that we currently expect;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success or failure of products sold by our collaborators, such as dostarlimab by GSK, and the timing thereof;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain existing and enter into new collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost to establish, maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing of any patents or other intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of any approved product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of acquiring, licensing or investing in additional businesses, products, product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of recruiting and retaining key employees;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the costs and fees associated with any delays or cancellations of forecasted manufacturing batches;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of selecting, auditing and potentially validating manufacturing sites for commercial-scale manufacturing; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing sales, marketing and distribution capabilities for our product candidates for which we may receive regulatory approval and that we determine to commercialize ourselves or in collaboration with our collaborators.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our business, financial condition and results of operations could be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a variety of means, including through public or private equity, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations, or other restrictions that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Managing Growth, Operations and Macroeconomic Conditions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We must attract and retain highly skilled employees in order to succeed.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. This is especially critical as we ramp up our hiring needs entering into later-stage product development of our product candidates. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan, harm our operating results and adversely affect our ability to successfully commercialize our product candidates. In particular, we believe that our future success is highly dependent upon the contributions of our senior management, particularly our President and Chief Executive Officer, as well as our senior scientists. The loss of services of any of these individuals, who all have at-will employment arrangements with us, could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of our product candidates, if approved. The competition for qualified personnel in the biotechnology field is intense and, as a result, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. In addition, certain members of our senior management team have worked together for only a relatively short period of time, and it may be difficult to evaluate their effectiveness, on an individual or collective basis, and ability to address future challenges to our business.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover and develop product candidates and our business will be limited.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The manufacture of biotechnology products is complex, and manufacturers often encounter difficulties in production. If we or any of our third-party manufacturers encounter any loss of our master cell banks or if any of our third-party manufacturers encounter other difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide product candidates for clinical trials or our products to patients, once approved, could be delayed or stopped.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of biotechnology products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. We and our contract manufacturers must comply with cGMP regulations and guidelines for the manufacturing of biologics used in clinical trials and, if approved, marketed products. Manufacturers of biotechnology products often encounter difficulties in production, particularly in scaling up and validating initial production. Furthermore, if microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Delays in raw materials availability and supply may also extend the period of time required to develop our products.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our therapeutic antibodies are manufactured by starting with cells which are stored in a cell bank. We have one master cell bank for each antibody manufactured in accordance with cGMP and multiple working cell banks and believe we would have adequate backup should any cell bank be lost in a catastrophic event. However, it is possible that we could lose multiple cell banks and have our manufacturing severely impacted by the need to replace the cell banks.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that any stability or other issues relating to the manufacture of any of our product candidates or products will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide product candidates to patients in planned clinical trials and products to patients, once approved, would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the development and commercialization of our product candidates or products and could have an adverse effect on our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We currently have no marketing and sales force. If we are unable to establish effective sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to effectively sell or market our product candidates, if approved, or generate product revenue.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates that are able to obtain regulatory approval. In order to commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time-consuming and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval to market. With respect to the commercialization of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience growth in the number of our employees and the scope of our operations, particularly in the areas of product candidate development and growing our capability to conduct clinical trials. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:119%">We conduct certain operations through our Australian wholly-owned subsidiary. If we are unable to receive the research and development tax credit allowed by Australian regulations, our business and results of operations will suffer.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:119%">In March 2015, we formed a wholly-owned Australian subsidiary, AnaptysBio Pty Ltd, to develop and commercialize our imsidolimab and etokimab antibody program in Australia. We have no assurance that the results of any clinical trials that we conducted for our product candidates in Australia will be accepted by the FDA or foreign regulatory authorities for development and commercialization approvals.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:119%">In addition, current Australian tax regulations provide for a refundable research and development (&#8220;R&amp;D&#8221;), tax credit equal to 43.5% of qualified expenditures. We have received $9.3 million USD in R&amp;D tax credits since the inception of our operations in Australia and currently do not intend to submit for any additional tax credits. If we are ineligible or unable to retain the research and development tax credits received thus far and are required to repay all or a portion of the credit, our business and results of operation would be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be vulnerable to disruption, damage and financial obligation as a result of system failures.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, any of the internal computer systems belonging to us, our collaborators or our third-party service providers are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failure. Any system failure, accident or security breach that causes interruptions in our own, in collaborators&#8217; or in third-party service vendors&#8217; operations could result in a material disruption of our drug discovery and development programs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our or our collaborators&#8217; regulatory approval efforts and significantly increase our costs in order to recover or reproduce the lost data. To the extent that any disruption or security breach results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability as a result, our drug discovery programs and competitive position may be adversely affected, and the further development of our product candidates may be delayed. Furthermore, we may incur additional costs to remedy the damages caused by these disruptions or security breaches.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our operations, or the third parties upon whom we depend, are vulnerable to interruption by fire, earthquake, power loss, telecommunications failure, terrorist activity, health epidemics or pandemics and other events beyond our control, which could harm our business.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">Our facilities are located in San Diego, California, which is a seismically active region, and has also historically been subject to wildfires and electrical blackouts as a result of a shortage of available electrical power. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major earthquake, fire, power loss, terrorist activity, health epidemics or pandemics such as the COVID-19 pandemic or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. We maintain multiple copies of each of our antibody sequences and electronic data records, most of which we maintain at our headquarters. If our facility was impacted by a seismic or wildfire event, we could lose some of our antibody sequences, which would have an adverse effect on our ability to perform our obligations under our collaborations and discover new targets.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, integral parties in our supply chain are geographically concentrated and operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe and/or serious adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our existing collaborations, including those with GSK and BMS, are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaborations with GSK and BMS to develop several of our product candidates. We have also entered into antibody generation and/or development collaborations with various collaborators, including GSK and BMS, under </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which we have generated therapeutic quality antibodies using our technology platform and conducted certain preclinical studies in collaboration. We are currently aware that GSK and BMS have advanced multiple antibodies generated through our collaboration into clinical trials. If our collaborators terminate any of our collaborations, we may not receive all or any of this funding, which would adversely affect our business or financial condition. Our operational obligations under each of our collaborations has ended.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are unable to predict the success of our collaborations. Our collaborators have discretion in determining and directing the efforts and resources, including the ability to discontinue all efforts and resources, they apply to the development and, if approval is obtained, commercialization and marketing of the product candidates covered by such collaborations. As a result, our collaborators may elect to de-prioritize our programs, change their strategic focus or pursue alternative technologies in a manner that results in reduced, delayed or no revenue to us. Our collaborators may have other marketed products and product candidates under collaboration with other companies, including some of our competitors, and their corporate objectives may not be consistent with our best interests. Our collaborators may also be unsuccessful in developing or commercializing our products. If our collaborations are unsuccessful, our business, financial condition, results of operations and prospects could be adversely affected. In addition, any dispute or litigation proceedings we may have with our collaborators in the future could delay development programs, create uncertainty as to ownership of intellectual property rights, distract management from other business activities and generate substantial expense. For example, in October 2020, we settled a dispute with GSK related to an alleged breach of our collaboration agreement in connection with GSK&#8217;s use of certain antibodies originally developed by us for the development of a drug not covered by the agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There can be no assurance that we will not encounter such issues under our collaborations with GSK or other parties in the future.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not succeed in establishing and maintaining additional development and commercialization collaborations, which could adversely affect our ability to develop and commercialize product candidates.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our current licensing arrangements with GSK and BMS, a part of our strategy is to enter into additional strategic product development and commercialization collaborations in the future, including collaborations to broaden and accelerate clinical development and potential commercialization of our product candidates. We may face significant competition in seeking appropriate development partners, and the negotiation process is time-consuming and complex. Moreover, we may not succeed in our efforts to establish collaborations or other alternative arrangements for any of our other existing or future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of development for collaborative effort, and/or third parties may not view our product candidates and programs as having the requisite potential to demonstrate safety and efficacy or to be commercially viable. Even if we are successful in our efforts to establish new collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product candidate are disappointing. Any delay in entering into new collaboration agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, if we fail to establish and maintain additional collaborations related to our product candidates:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the development of certain of our current or future product candidates may be terminated or delayed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our cash expenditures related to development of certain of our current or future product candidates would increase significantly and we may need to seek additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to hire additional employees or otherwise develop expertise, such as sales and marketing expertise, for which we have not budgeted; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will bear all of the risk related to the development and commercialization of any such product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If third parties on which we depend to conduct our planned preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with adverse effects on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third party clinical investigators, CROs, CMOs, and consultants to design, conduct, supervise and monitor key activities relating to, discovery, manufacturing, non-clinical studies and clinical trials of our product candidates, and we </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intend to do the same for future activities relating to existing and future programs. Because we rely on third parties and do not have the ability to conduct all required discovery, manufacturing, preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of discovery, manufacturing, preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs, CMOs and consultants are not our employees, and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties we contract with might not be diligent, careful or timely in conducting our discovery, manufacturing, preclinical studies or clinical trials, resulting in discovery, manufacturing, preclinical studies or clinical trials being delayed or unsuccessful, in whole or in part.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Any such event could have an adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We rely completely on third parties to manufacture our nonclinical, clinical and future commercial drug supplies of any approved products.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We outsource the manufacture of our product candidates. We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. If we were to experience an unexpected loss of supply of our product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, our business would be harmed, and we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the clinical trial, we may be required to manufacture additional supplies of our product candidates to the extent our estimates of the amounts required prove inaccurate, we suffer unexpected losses of product candidate supplies, or we are required to have fresh product candidate supplies manufactured to satisfy regulatory requirements or specifications. Any significant delay or discontinuation in the supply of a product candidate, or the raw material components thereof, due to the need to replace a contract manufacturer or other third-party manufacturer, could considerably harm our business and ability to generate revenue and delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delays in our preclinical or clinical development could lead to delays or cancellations of forecasted manufacturing batches, which would typically result in significant fees owed by us to the manufacture and an uncertainty as to when the manufacturer will have the availability for a new time slot to manufacture the batch, which could lead to further delays in the development of the product candidate and have an adverse effect on our business.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails additional risks, including the possible breach of the manufacturing agreement by the third party and the possible termination or nonrenewal of the agreement by the manufacturer at a time that is costly or inconvenient for us. If our contract manufacturers were to breach or terminate their manufacturing arrangements with us, the development or commercialization of the affected product candidates could be significantly delayed, which could have an adverse effect on our business. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and processes could be significant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We depend on a small number of suppliers for the raw materials necessary to produce our product candidates. The loss of these suppliers, or their failure to supply us with these raw materials, would materially and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on the availability of key raw materials for our product candidates from a small number of third-party suppliers. Because there are a limited number of suppliers for the raw materials that we use to manufacture our product candidates, we may need to engage alternate suppliers to prevent a possible disruption of the manufacture of the materials </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">necessary to produce our product candidates for our clinical trials. We do not have any control over the availability of raw materials. If we or our manufacturers are unable to purchase these raw materials on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, the development of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to meet our development objectives for our product candidates or generate revenues from the sale of any approved products.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we may receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and good clinical practices for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and foreign regulatory requirements may, either before or after product approval, if any, subject our company to administrative or judicially imposed sanctions, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the products, manufacturers or manufacturing process;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning or untitled letters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">civil and criminal penalties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizures, detentions or import bans;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary or mandatory product recalls and publicity requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of production;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of restrictions on operations, including costly new manufacturing requirements; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending BLAs or supplements to approved BLAs.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by the FDA, the Department of Justice, the Department of Health and Human Services&#8217; Office of Inspector General, state attorneys general, members of Congress and the public. Violations, including promotion of our products for unapproved (or off-label) uses, are subject to enforcement letters, inquiries and investigations, and civil and criminal sanctions by the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government. Additionally, comparable foreign regulatory authorities will heavily scrutinize advertising and promotion of any product candidate that obtains approval outside of the United States.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, engaging in the impermissible promotion of our products for off-label uses can also subject us to false claims litigation under federal and state statutes, which can lead to civil and criminal penalties and fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. These false claims statutes include the federal False Claims Act, which allows any individual to bring a lawsuit against a biotechnology company on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government prevails in the lawsuit, the individual will share in any fines or settlement funds. Since 2004, these False Claims Act lawsuits against biotechnology companies have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements regarding certain sales practices promoting off-label drug uses involving fines in excess of $1.0 billion. This growth in litigation has increased the risk that a biotechnology company will have to defend a false claim action, pay settlement fines or restitution, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid and other federal and state health care programs. If we do not lawfully promote our approved products, we may become subject to such litigation and, if we do not successfully defend against such actions, those actions may have an adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the United States.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our products in other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, we must secure product reimbursement approvals before regulatory authorities will approve the product for sale in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with the regulatory requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed, and our business will be adversely affected. We may not obtain foreign regulatory approvals on a timely basis, if at all. Our failure to obtain approval of any of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and our business prospects could decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">We plan to seek Orphan Drug Designation for imsidolimab or certain of our other product candidates, and we may not be able to obtain or maintain Orphan Drug Designation or obtain the benefits associated with Orphan Drug status, including market exclusivity.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regulatory authorities in some jurisdictions, including the United States and the European Union (&#8220;EU&#8221;) may designate biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a biologic as an Orphan Drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States. We recently received Orphan Drug Designation from the FDA for imsidolimab for our GPP indication and plan to seek Orphan Drug Designation for imsidolimab in other indications and for certain of our other product candidates. Generally, if a biologic with an Orphan Drug Designation subsequently receives the first marketing approval for the indication for which it has such designation, the biologic is entitled to a period of marketing exclusivity, which precludes the FDA with respect to the United States or the EMA with respect to the EU from approving another marketing application for a drug containing the same active moiety for the same indication for that time period. The applicable period is seven years in the United States and ten years in the EU. The EU exclusivity period can be reduced to six years if a biologic no longer meets the criteria for Orphan Drug Designation or if the biologic is sufficiently profitable so that market exclusivity is no longer justified. Orphan Drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. In addition, the Orphan Drug Designation does not convey any advantage </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in, or shorten the duration of, the regulatory review or approval process. Also, regulatory approval for any product candidate may be withdrawn and other candidates may obtain approval before us.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have not been granted Orphan Drug Designation for imsidolimab for any indication other than GPP, and there can be no assurance that any of our other product candidates will be designated as an orphan drug. For example, we plan to seek FDA Orphan Drug Designation for imsidolimab for the treatment of PPP, which will likely require that we demonstrate to FDA that PPP is a distinct disease from psoriasis generally (a non-rare disease) or that use of imsidolimab may be appropriate for the treatment of PPP but not appropriate for use in the general psoriasis population.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if we obtain Orphan Drug Designation for imsidolimab in indications other than GPP, or for any of our other product candidates, we may not receive Orphan Drug exclusivity, and such exclusivity, if obtained, may not effectively protect the candidate from competition because different drugs or biologics can be approved for the same condition and only the first biologic with an Orphan Drug Designation to receive regulatory approval for a particular indication will receive marketing exclusivity. Even after a drug or biological with Orphan Drug Designation is approved, the FDA can subsequently approve another biologic containing the same active moiety (which in the case of an antibody is the principal molecular structure) for the same condition if the FDA concludes that the later biologic is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Any drugs we develop may become subject to unfavorable third-party reimbursement practices and pricing regulations.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and extent of coverage and adequate reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar health care management organizations or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only at limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), an agency within the U.S. Department of Health and Human Services, because CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare. Private payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly examining the medical necessity and reviewing the cost effectiveness of medical drug products. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific drug products on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We or our collaborators may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement and the timing of achieving a reimbursement determination will be.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics, including our product candidates. In many countries, particularly the countries of the EU, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidate to other available therapies. In general, the prices of products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors, in the United States and internationally, to cap or reduce health care costs may cause such organizations to limit both coverage and level of reimbursement for new products approved, and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on health care costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the health care market.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to CMS and private payors, professional organizations such as the American Medical Association can influence decisions about reimbursement for new products by determining standards for care. In addition, many private payors contract with commercial vendors who sell software that provide guidelines that attempt to limit utilization of, and therefore reimbursement for, certain products deemed to provide limited benefit to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of our product candidates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, some of our target indications, such as GPP, are rare diseases with small patient populations. In order for therapeutics that are designed to treat smaller patient populations to be commercially viable, the reimbursement for such therapeutics must be higher, on a relative basis, to account for the low volume of sales. Accordingly, we will need to implement a coverage and reimbursement strategy for any approved product candidate that accounts for the smaller potential market size.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently enacted legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of the provisions of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;) have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA. In addition, the current administration and Congress have previously sought, and will likely continue to seek, legislative and regulatory changes, including repeal and replacement of all or certain provisions of the ACA. While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act of 2017 included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, the current administration signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018, among other things, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amended the ACA, effective January 1, 2019, to increase from 50% to 70% the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; Congress may consider other legislation to repeal or replace elements of the ACA.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may face difficulties from changes to current regulations and future legislation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More recently, President Trump has signed an executive order and made statements that suggest he plans to seek repeal of all or portions of the ACA. There is uncertainty with respect to which legislation, if any, will be enacted and the impact President Trump&#8217;s administration may have, if any, and any changes likely will take time to unfold and could have an impact on coverage and reimbursement for health care items and services covered by plans that were authorized by the ACA. However, we cannot predict the ultimate content, timing or effect of any health care reform legislation or the impact of potential legislation on us. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, effective April 1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2027 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other health care funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Likewise, the annual Medicare Physician Fee Schedule update, which, until recently, was based on a target-setting formula system called the Sustainable Growth Rate (&#8220;SGR&#8221;) was adjusted to reflect the comparison of actual expenditures to target expenditures. Because one of the factors for calculating the SGR was linked to the growth in the U.S. gross domestic product (&#8220;GDP&#8221;), the SGR formula often resulted in a negative payment update when growth in Medicare beneficiaries&#8217; use of services exceeded GDP growth. Congress repeatedly intervened to delay the implementation of negative SGR payment updates. For example, on April 1, 2014, with the enactment of the Protecting Access to Medicare Act of 2014, Congress prevented the 24 percent cut that was to occur by continuing the previously implemented 0.5 percent payment increase through December 31, 2014 and maintaining a zero percent payment update from January 1, 2015 through March 31, 2015. However, on April 14, 2015, Congress passed the Medicare Access and CHIP Reauthorization Act of 2015, which was signed into law by President Obama on April 16, 2015. This law repeals the SGR methodology from the physician payment formula, institutes a zero percent update to the Medicare Physician Fee Schedule for the January 1 to July 1, 2015 period, a 0.5% payment update for July 2015 through the end of 2019, and a zero percent payment update for 2020 through 2025, along with a merit-based incentive payment system beginning January 1, 2019 that will replace current incentive programs. For 2026 and subsequent years, the payment update will be either 0.75% or 0.25%, depending on which Alternate Payment Model the physician participates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other health care reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other health care reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business entails a significant risk of product liability, and our ability to obtain sufficient insurance coverage could have an adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, transparency and other health care laws and regulations, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other health care laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state health care laws and regulations include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal health care program such as Medicare and Medicaid;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal false claims and civil monetary penalties laws, including the civil False Claims Act, impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal and civil liability for, among other things, executing or attempting to execute a scheme to defraud any health care benefit program or making false statements relating to health care matters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report to CMS annually information regarding payments and other transfers of value to physicians and teaching hospitals as well as information regarding ownership and investment interests held by physicians and their immediate family members. The information was initially made publicly available on a searchable website in September 2014 and is disclosed on an annual basis; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving health care items or services reimbursed by non-governmental third-party payors, including private insurers.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other health care providers or marketing expenditures. For example, several states now require prescription drug companies to report certain expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual health care practitioners in these states. Other states prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals. Still other states require the posting of information relating to clinical studies and their outcomes. Some states require the reporting of certain pricing information, including information pertaining to and justifying price increases, or prohibit prescription drug price gouging. And states such as California, Connecticut, Nevada, and Massachusetts require pharmaceutical companies to implement compliance programs and/or marketing codes. Other states are considering similar proposals. Compliance with these laws is difficult and time consuming, and companies that do not comply with these state laws face civil penalties.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For example, the collection and use of health data in the EU is governed by the General Data Protection Regulation (&#8220;GDPR&#8221;), which became fully applicable in May 2018. The GDPR extends the geographical scope of EU data protection law to non-EU entities under certain conditions, tightens existing EU data protection principles and creates new obligations for companies and new rights for individuals. The GDPR is new and guidance, interpretation and application under the GDPR are still developing. Failure to comply with the GDPR may result in substantial fines and other administrative penalties of up to the greater of &#8364;20 million or 4% of worldwide revenue. The GDPR may increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. The pending EU ePrivacy Regulation is also expected to establish new requirements applicable to the handling of personal data and imposes penalties for non-compliance. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the European Economic Area to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws. For example, following a decision of the Court of Justice of the EU in October 2015, the transfer of personal data to U.S. companies that had certified as members of the U.S. Safe Harbor Scheme was declared invalid. In July 2016, the European Commission adopted the EU-U.S. Privacy Shield Framework (the &#8220;Privacy Shield Framework&#8221;), which replaced the U.S. Safe Harbor Scheme. On July 16, 2020, the Court of Justice of the European Union issued a decision that declared the Privacy Shield Framework invalid, which will also result in additional compliance obligations for companies that implement standard contractual clauses to ensure a valid basis for the transfer of personal data outside of Europe. Additionally, in June 2018, California passed the California Consumer Privacy Act (&#8220;CCPA&#8221;), which provides new data privacy rights for consumers and new operational requirements for companies effective in 2020. The costs of compliance with, and other burdens imposed by, the GDPR, CCPA and other U.S., EU and worldwide laws may impose onerous requirements on our business and, if our efforts to comply with such laws are not successful, our business could be adversely affected.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable health care laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded health care programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other health care providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded health care programs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state health care fraud </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct. The precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to obtain or protect intellectual property rights, we may not be able to compete effectively in our market.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in significant part on our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; ability to establish, maintain and protect patents and other intellectual property rights and operate without infringing the intellectual property rights of others. We have filed numerous patent applications both in the United States and in foreign jurisdictions to obtain patent rights to inventions we have discovered. We have also licensed from third parties rights to patent portfolios. Some of these licenses give us the right to prepare, file and prosecute patent applications and maintain and enforce patents we have licensed, and other licenses may not give us such rights. The patent prosecution process is expensive and time-consuming, and we and our current or future licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors, licensees or collaborators will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors, licensees or collaborators. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. If our current or future licensors, licensees or collaborators fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors, licensees or collaborators are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; patent rights are highly uncertain. Our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our licensors, licensees or collaborators to narrow the scope of the claims of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. In the past, we have not always been able to obtain the full scope of patent protection we have initially sought in our patent applications, and as described above and as is typical for most biotechnology patent prosecution, we have been required to narrow or eliminate patent claims as part of the patent prosecution process. In addition, some patent applications that we or our licensors have filed have not resulted in issued patents because we or our licensors have abandoned those patent applications as changes in business and/or legal strategies dictated.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may initiate opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. Our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications cannot be enforced </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors, licensees, or collaborators were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications on or before March 15, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March 15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. In addition, patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar or generic medications.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms where these are available in any countries where we are prosecuting patents. This includes in the United States under the Drug Price Competition and Patent Term Restoration Act of 1984, which permits a patent term extension of up to five years beyond the expiration of the patent. However the applicable authorities, including the FDA and the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) in the United States, and any equivalent foreign regulatory authority, may not agree with our assessment of whether such extensions are available and may refuse to grant extensions to our patents or may grant more limited extensions than we request. If this occurs, our competitors may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, enforcing and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; intellectual property rights may not exist in some countries outside the United States or may be less extensive in some countries than in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we and our licensors, licensees or collaborators may not be able to prevent third parties from practicing our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; inventions in all countries outside the United States or from selling or importing products made using our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; inventions in and into the United States or other jurisdictions. Competitors may use our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors or collaborators have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us and our licensors or collaborators to stop the infringement of our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents or marketing of competing products in violation of our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; proprietary rights generally. Proceedings to enforce our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; efforts and attention from other aspects of our business, could put our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents at risk of being invalidated or interpreted narrowly and our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications at risk of not </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuing and could provoke third parties to assert claims against us or our licensors, licensees or collaborators. We or our licensors, licensees or collaborators may not prevail in any lawsuits that we or our licensors or collaborators initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve technological and legal complexity, and obtaining and enforcing biopharmaceutical patents is costly, time-consuming, and inherently uncertain.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications and the enforcement or defense of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; issued patents. On September 16, 2011, the Leahy-Smith America Invents Act (the &#8220;AIA&#8221;) was signed into law. The AIA includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, future and recent past changes in the patent laws in the U.S. and abroad could impact or could increase the uncertainties and costs surrounding the prosecution of our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications and the enforcement or defense of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; issued patents, which could have an impact on our business and financial conditions.  For example, over the past decade, the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have rendered decisions in several patent cases such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Association for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> BRCA1- &amp; BRCA2-Based Hereditary Cancer Test Patent Litig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., Mayo Collaborative Services v. Prometheus Laboratories, Inc., and Alice Corporation Pty. Ltd. v. CLS Bank International, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; ability to obtain patents in the future, these type of changes in the patent laws have created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; ability to obtain new patents or to enforce existing patents and patents that we and our licensors or collaborators may obtain in the future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors, licensees or collaborators fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which would have an adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we collaborate with various collaborators on the development and commercialization of one or more of our product candidates and because we rely on third parties to manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our wholly-owned technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with in the future may be granted rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of intellectual property rights arising from the collaboration, in addition to the opportunity to remove confidential or trade secret information from any such publication. Our existing collaborative research and development programs may require us to share trade secrets under the terms of our research and development collaborations or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have an adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third parties may infringe our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents or misappropriate or otherwise violate our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; intellectual property rights. In the future, we or our licensors, licensees or collaborators may initiate legal proceedings to enforce or defend our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; intellectual property rights, such as the litigation we initiated in August 2020 to enforce our rights under our collaboration with GSK, to protect our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; trade secrets or to determine the validity or scope of intellectual property rights we own or control. Also, third parties may initiate legal proceedings against us or our licensors, licensees or collaborators to challenge the validity or scope of intellectual property rights we own or control. These proceedings can be expensive and time-consuming, and many of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors, licensees or collaborators. In addition, in an infringement proceeding, a court may decide that a patent owned by or licensed to us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents do not cover the technology in question. Furthermore, an adverse result in any litigation or administrative proceeding could put one or more of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents at risk of being invalidated, held unenforceable or interpreted narrowly.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, despite our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; efforts, we or our licensors, licensees or collaborators may not prevent third parties from infringing upon or misappropriating intellectual property rights we own or control, particularly in countries where the laws may not protect those rights as fully as in the United States. In addition, litigation and administrative proceedings could result in substantial costs and diversion of management resources, which could harm our business and financial results.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within and outside of the United States, there has been a substantial amount of litigation and administrative proceedings regarding patent and other intellectual property rights in the pharmaceutical industry including opposition, derivation, reexamination, inter partes review or interference proceedings, or other preissuance or post-grant proceedings. Such proceedings may be provoked by third parties or by us or our licensors or collaborators to protect or enforce our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents or patent applications. Additionally, third-party preissuance submission of prior art to the USPTO or other foreign jurisdictions may jeopardize the issuance or scope of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications. An unfavorable outcome in any such proceedings could require us or our licensors, licensees or collaborators to cease using the related technology, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our licensors, licensees or collaborators a license on commercially reasonable terms or at all, and we could be forced to stop commercializing our product candidates. Even if we or our licensors, licensees or collaborators obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors, licensees or collaborators.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if the breadth or strength of protection provided by our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Even if we successfully defend such litigation or proceeding, we may incur substantial costs, and it may distract our management and other employees. We could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of shares of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we breach the license agreements related to our product candidates, we could lose the ability to continue the development and commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability, and the ability of our licensors, licensees and collaborators, to develop, manufacture, market and sell our product candidates and use our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; wholly-owned technologies without infringing the proprietary rights of third parties. A third party may hold intellectual property, including patent rights that are important or necessary to the development of our products. As a result, we are a party to a number of technology licenses that are important to our business and expect to enter into additional licenses in the future. For example, we have in-licensed the rights to certain intellectual property relating to SHM under our in-license agreement with the Medical Research Council, which is the subject of issued patents and pending patent applications in certain countries. If we fail to comply with the obligations under these agreements, including payment and diligence terms, our licensors may have the right to terminate these agreements, in which event we may not be able to develop, manufacture, market or sell any product that is covered by these agreements or may face other penalties under the agreements. Such an occurrence could adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements, which may not be available to us on equally favorable terms, or at all, or cause us to lose our rights under these agreements, including our rights to intellectual property or technology important to our development programs.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under any collaboration relationships we might enter into in the future;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third parties may initiate legal proceedings against us alleging that we infringe their intellectual property rights, or we may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be uncertain and could have an adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may initiate legal proceedings against us or our licensors, licensees or collaborators alleging that we or our licensors, licensees or collaborators infringe their intellectual property rights or that we or our licensors, licensees or collaborators may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, including in oppositions, interferences, reexaminations, post-grant reviews, inter partes reviews or derivation proceedings in the United States or other jurisdictions. These proceedings can be expensive and time-consuming, and many of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaborators.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. An unfavorable outcome could require us or our licensors, licensees or collaborators to cease using the related technology, to cease developing or commercializing our product candidates or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our licensors, licensees or collaborators a license on commercially reasonable terms or at all. Even if we or our licensors, licensees or collaborators obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors, licensees or collaborators. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could harm our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, including our senior management, were previously employed at universities or at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. Such a license may not be available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our inability to protect our confidential information and trade secrets would harm our business and competitive position.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts both within and outside the United States may be less willing or unwilling to protect trade secrets. Furthermore, if a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be harmed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (the &#8220;Hatch-Waxman Amendments&#8221;). The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened, and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The market price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock may be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this report, these factors include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory actions with respect to our products or our competitors&#8217; products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of preclinical studies and clinical trials of our product candidates or those of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our product candidates or clinical development programs;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments with respect to our existing collaboration agreements and announcements of new collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes, breaches and terminations of our manufacturing agreements, collaborations agreements or other important agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to in-license or acquire additional product candidates or products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us, our insiders or our other stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of health care payment systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the biotechnology sector; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the stock market in general, and the Nasdaq Global Select Market and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the overall market and the market price of a particular company&#8217;s securities, securities class action litigation has often been instituted against these companies. We are currently subject to securities litigation, which is described in Item 1, &#8220;Legal Proceedings.&#8221; This or any future securities litigation could result in substantial costs and a diversion of our management&#8217;s attention and resources. The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have broad discretion in the use of the net proceeds from our public offerings and may not use them effectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of the net proceeds from our public offerings, and you will be relying on the judgment of our management regarding the application of these proceeds. Our management might not apply the net proceeds from our public offerings in ways that ultimately increase the value of your investment. If we do not invest or apply the net proceeds from our public offerings in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The market price of our common stock is volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We have been, and may in the future be, the target of this type of litigation. We are currently subject to securities litigation, which is described in Item 1, &#8220;Legal Proceedings.&#8221; Regardless of the outcome, these matters or future litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We incur increased costs and devote substantial management time as a result of operating as a public company.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company, and these expenses have increased and will continue to increase. We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and the Nasdaq Global Select Market. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations substantially increase our legal and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial compliance costs and make some activities more time-consuming and costly. The increased costs increase our net loss. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these and future requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section&#160;404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on our internal controls on an annual basis. If we have material weaknesses in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We have only recently compiled the systems, processes and documentation necessary to comply with Section&#160;404 of the Sarbanes-Oxley Act. We will need to maintain and enhance these processes and controls as we grow, and we may require additional management and staff resources to do so. Additionally, even if we conclude our internal controls are effective for a given period, we may in the future identify one or more material weaknesses in our internal controls, in which case our management will be unable to conclude that our internal control over financial reporting is effective. Regardless of compliance with Section&#160;404, any failure of our internal control over financial reporting could have a material adverse effect on our reported operating results and harm our reputation. Internal control deficiencies could also result in a restatement of our financial results.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. We also have registered all shares of common stock that we may issue under our equity incentive plans or that are issuable upon exercise of outstanding options. These shares can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions in our restated certificate of incorporation and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation and restated bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors so that not all members of our board are elected at one time;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permit only the board of directors to establish the number of directors and fill vacancies on the board;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan (also known as a &#8220;poison pill&#8221;);</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eliminate the ability of our stockholders to call special meetings of stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit cumulative voting; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section 203 of the Delaware General Corporation Law (&#8220;DGCL&#8221;) may discourage, delay or prevent a change in control of our company. Section 203 of the DGCL imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trial results or operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We plan to use potential future operating losses and our federal and state net operating loss (&#8220;NOL&#8221;) carryforwards to offset taxable income from revenue generated from operations or corporate collaborations. However, our ability to use NOL carryforwards could be limited as a result of additional issuances of equity securities.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to use our current year operating losses to offset taxable income from any revenue generated from operations or corporate collaborations. To the extent we have taxable income, we plan to use our NOL carryforwards to offset income that would otherwise be taxable. However, under the Tax Reform Act of 1986, the benefits from the use of our NOL carryforwards may be impaired or limited under Section 382 of the Internal Revenue Code of 1984, as amended (the &#8220;Code&#8221;), if we incur a cumulative ownership change of more than 50%, as interpreted by the U.S. Internal Revenue Service, over a three-year period. In September 2015, we completed a Section 382 and 383 ownership change analysis through December 31, 2014 and determined that there was an ownership change in 2007 that may limit the utilization of approximately $5.3 million and $5.4 million in federal and state NOLs, respectively, and $0.2 million in both federal and state research tax credits. We extended the analysis period of the study through December 31, 2018, noting an additional ownership change during fiscal 2017 that may limit the utilization of federal and state NOLs. Our use of federal NOL carryforwards could be limited further by the provisions of Section 382 of the Code depending upon the timing and amount of additional equity securities that we have issued or will </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issue. State NOL carryforwards may be similarly limited. Any such disallowances may result in greater tax liabilities than we would incur in the absence of such a limitation, and any increased liabilities could adversely affect our business, results of operations, financial condition and cash flow.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2017, the President of the United States signed into law the Tax Reform Act. The legislation significantly changes U.S. tax law by, among other things, lowering the corporate income tax rates. The Tax Reform Act permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. Additionally, the Tax Reform Act will no longer allow deductions for compensation in excess of $1 million for certain employees, even if paid as commissions or performance-based compensation. We may be subject to these limitations as provided for under Section 162(m) of the Code in the future. The Tax Reform Act also limits the amount taxpayers are able to deduct for federal NOL carryforwards generated in taxable years beginning after December 31, 2017 to 80% of the taxpayer&#8217;s taxable income. The law also generally repeals all carrybacks. However, any NOLs generated in taxable years after December 31, 2017 can be carried forward indefinitely. Losses arising in taxable years beginning before December 31, 2017 may still be carried back two years and are subject to their current expiration period. As of December 31, 2019, we have federal NOLs of approximately $239.4 million, which expire beginning December 31, 2028 through December 31, 2037, if not used to reduce income taxes payable in the future. The federal net operating loss carry over includes $95.5 million of net operating losses generated in 2019. Federal net operating losses generated in 2019 carry over indefinitely and may generally be used to offset up to 80% of future taxable income in the year it is utilized. </span></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults upon Senior Securities </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Mine Safety Disclosures </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, below. </span></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_97"></div><div style="-sec-extract:summary;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.611%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.17*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="loumeauamendedandresta.htm">Amended and Restated Employment Agreement, effective July 15, 2020, by and between Registrant and Eric Loumeau</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.18*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="mulroyemploymentagreem.htm">Employment Agreement, effective July 15, 2020, by and between Registrant and Dennis Mulroy</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.19*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lizzulemploymentagreem.htm">Employment Agreement, effective July 31, 2020, by and between Registrant and Paul Lizzul</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="anab-93020x10qxexx311.htm">Certification of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="anab-93020x10qxexx312.htm">Certification of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="anab-93020x10qxexx321.htm">Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="anab-93020x10qxexx322.htm">Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Report Instance Document - The Instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Calculation Linkbase Document</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Label Linkbase Document</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Presentation Linkbase Document</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File -  (formatted in Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Executive compensation plan or agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i0833d33fa1bc4c56a5693b167f99fc20_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AnaptysBio, Inc.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Hamza Suria</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hamza Suria</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Dennis Mulroy</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dennis Mulroy</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>2
<FILENAME>loumeauamendedandresta.htm
<DESCRIPTION>EX-10.17
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i7b1e58893e414ad2bd948de0052b4a89_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ANAPTYSBIO, INC.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDED AND RESTATED EMPLOYMENT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Amended and Restated Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is made effective from July 15, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) by and among AnaptysBio, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and Eric Loumeau (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The Company and Executive are hereinafter collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,&#8221; and individually referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;  This Agreement amends and restates in its entirety that certain Employment Agreement between Executive and the Company dated August 6, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">RECITAL</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company desires to employ Executive, and Executive is willing to accept such employment by Company, on the terms and subject to the conditions set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In consideration of the foregoing Recitals and the mutual promises and covenants herein contained, and for other good and valuable consideration, the Parties, intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">EMPLOYMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.1&#160;&#160;&#160;&#160;Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Effective as of the Effective Date, Executive&#8217;s position shall be Chief Operating Officer and General Counsel of the Company, subject to the terms and conditions set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.2&#160;&#160;&#160;&#160;Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The term of this Agreement shall begin on the Effective Date and shall continue until it is terminated pursuant to Section 4 herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.3&#160;&#160;&#160;&#160;Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Executive shall do and perform all services, acts or things necessary or advisable to manage and conduct the business of the Company and that are normally associated with the positions of Chief Operating Officer and General Counsel of the Company.  Executive shall also do and perform all services, acts or things necessary or advisable to manage and conduct the business of the Company and that are normally associated with the positions of Secretary and Chief Compliance Officer of the Company.  Executive shall report to the Chief Executive Officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.4&#160;&#160;&#160;&#160;Policies and Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The employment relationship between the Parties shall be governed by this Agreement and by the policies and practices established by the Company and&#47;or the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or any designated committee thereof.  In the event that the terms of this Agreement differ from or are in conflict with the Company&#8217;s policies or practices or the Company&#8217;s Employee Handbook, this Agreement shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.5&#160;&#160;&#160;&#160;Location</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Unless the Parties otherwise agree in writing, and except as provided in this Section 1.5, during the Term Executive shall perform the services Executive is required to perform pursuant to this Agreement at the Company&#8217;s offices in San Diego, California&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the Company may from time to time require Executive to travel temporarily to other locations in connection with the Company&#8217;s business&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, upon the Effective Date, and until applicable government COVID-19 quarantine restrictions applicable to the San Diego office are lifted and the San </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Diego office reopens, the Company will allow Executive to perform the services remotely from Executive&#8217;s home.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">LOYALTY&#59; NONCOMPETITION&#59; NONSOLICITATION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;Loyalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  During Executive&#8217;s employment with the Company, Executive shall devote Executive&#8217;s full business energies, interest, abilities and productive time to the proper and efficient performance of Executive&#8217;s duties under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.2&#160;&#160;&#160;&#160;Agreement not to Participate in Company&#8217;s Competitors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  During Executive&#8217;s employment with the Company, Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by Executive to be adverse or antagonistic to the Company, its business, or prospects, financial or otherwise, or in any company, person, or entity that is, directly or indirectly, in competition with the business of the Company or any of its Affiliates (as defined below).  Ownership by Executive, in professionally managed funds over which Executive does not have control or discretion in investment decisions, or as a passive investment, of less than two percent (2%) of the outstanding shares of capital stock of any corporation with one or more classes of its capital stock listed on a national securities exchange or publicly traded on a national securities exchange or in the over-the-counter market shall not constitute a breach of this Section.  For purposes of this Agreement, &#8220;Affiliate,&#8221; means, with respect to any specific entity, any other entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such specified entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.3&#160;&#160;&#160;&#160;Covenant not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  During Executive&#8217;s employment with the Company, Executive shall not engage in competition with the Company and&#47;or any of its Affiliates in any manner or capacity, as adviser, principal, agent, affiliate, promoter, partner, officer, director, employee, owner, co-owner, consultant, in any phase of the business of developing, manufacturing and marketing of products or services that directly compete with the products or services of the Company, except with the prior written consent of the CEO.  Executive shall be entitled to request written consent of the CEO with respect to potential advisory and&#47;or director opportunities presented to Executive by a third party, which Executive believes in good faith will not interfere or compete with the on-going business of the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">COMPENSATION OF EXECUTIVE.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company shall pay Executive a base salary at the annualized rate of $420,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), less payroll deductions and all required withholdings, payable in regular periodic installments in accordance with the Company&#8217;s normal payroll practices.  The Base Salary shall be prorated for any partial year of employment on the basis of a 365-day fiscal year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;Discretionary Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  At the sole discretion of the Board and Chief Executive Officer, promptly following each calendar year of employment Executive shall be eligible to receive a discretionary cash bonus of up to 40% of Executive&#8217;s then-current base salary (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), based on Executive&#8217;s achievement relative to certain performance goals (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to be established by the Chief Executive Officer and&#47;or the Board or the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in writing in a manner reasonably consistent with the Company&#8217;s priorities.  The determination of whether Executive has met the Performance Goals for any given year, and if so, the amount of any Bonus that will be paid for such year (if any), shall be determined by the Board or the Committee and Chief Executive Officer in their sole and absolute discretion.  In order to be eligible to earn or receive any Bonus, Executive must remain employed by the Company through and including the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">date of payment of such Bonus.  For the first calendar year of Executive&#8217;s employment with the Company, the Bonus payable shall be pro-rated in accordance with the percentage of the calendar year that the Executive is an employee of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.3&#160;&#160;&#160;&#160;Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  As soon as practicable following the Effective Date, subject to the approval of the Board or the Committee, Executive will be granted an option to purchase up to 10,000 shares of the Company&#8217;s Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Promotion Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) pursuant to the terms of the Company&#8217;s 2017 Equity Incentive Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The Promotion Option shall be subject to vesting such that, subject to Executive&#8217;s continued employment with the Company, 1&#47;4 of the shares subject to the Promotion Option shall vest as of the first anniversary of the Effective Date and l&#47;48th of the shares subject to the Promotion Option shall vest in equal monthly installments on the monthly anniversary of the Effective Date of each month for the 36 months thereafter.  The exercise price per share of the Promotion Option will be equal to the closing selling price as reported on the Nasdaq Stock Market on the date the Promotion Option is granted.  The Promotion Option will be governed by the Plan and shall be granted pursuant to a separate stock option grant notice and stock option agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.4&#160;&#160;&#160;&#160;Expense Reimbursements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company will reimburse Executive for all reasonable business expenses Executive incurs in conducting his duties hereunder, pursuant to the Company&#8217;s usual expense reimbursement policies&#59; provided that Executive supplies the appropriate substantiation for such expenses no later than the end of the calendar month following the month in which such expenses were incurred by Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.5&#160;&#160;&#160;&#160;Changes to Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Executive&#8217;s compensation will be reviewed annually and may be changed from time to time in the Company&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.6&#160;&#160;&#160;&#160;Employment Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  All of Executive&#8217;s compensation shall be subject to customary withholding taxes and any other employment taxes as are commonly required to be collected or withheld by the Company, as determined by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.7&#160;&#160;&#160;&#160;Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Executive shall, in accordance with Company policy and the terms of the applicable plan documents, be eligible to participate in benefits under any benefit plan or arrangement that may be in effect from time to time and made available to the Company&#8217;s senior management employees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.8&#160;&#160;&#160;&#160;Holidays and Vacation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Executive shall be eligible for paid holiday and vacation time in accordance with Company policy as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">TERMINATION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;Termination by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Executive&#8217;s employment with the Company is at will and may be terminated by the Company at any time and for any reason, or for no reason, including, but not limited to, under the following conditions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.1.1&#160;&#160;&#160;&#160;Termination by the Company for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company may terminate Executive&#8217;s employment under this Agreement for Cause (as defined below) by delivery of written notice to Executive.  Any notice of termination given pursuant to this section shall effect termination as of the date of the notice, or as of such other date specified in the notice.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.1.2&#160;&#160;&#160;&#160;Termination by the Company without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company may terminate Executive&#8217;s employment under this Agreement without Cause at any time and for any reason, or for no reason.  Such termination shall be effective on the date Executive is so informed, or as otherwise specified by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.2&#160;&#160;&#160;&#160;Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Executive may terminate his employment with the Company at any time and for any reason, or for no reason, upon thirty (30) days written notice to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.3&#160;&#160;&#160;&#160;Termination for Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Executive&#8217;s employment with the Company shall automatically terminate effective upon the date of Executive&#8217;s death or Disability (as defined in the Plan).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.4&#160;&#160;&#160;&#160;Termination by Mutual Agreement of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Executive&#8217;s employment with the Company may be terminated at any time upon a mutual agreement in writing of the Parties.  Any such termination of employment shall have the consequences specified in such agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5&#160;&#160;&#160;&#160;Compensation upon Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5.1&#160;&#160;&#160;&#160;Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If Executive&#8217;s employment is terminated by death or Disability, the Company shall pay to Executive, or to Executive&#8217;s heirs, Executive&#8217;s accrued and unpaid base salary and accrued and unused vacation benefits earned through the date of termination at the rate in effect at the time of termination, less standard deductions and withholdings.  The Company shall thereafter have no further obligations to Executive and&#47;or Executive&#8217;s heirs under this Agreement, except as otherwise provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5.2&#160;&#160;&#160;&#160;Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If the Company terminates Executive&#8217;s employment for Cause, then the Company shall pay Executive&#8217;s accrued and unpaid base salary and accrued and unused vacation benefits earned through the date of termination, at the rate in effect at the time of termination, less standard deductions and withholdings.  The Company shall thereafter have no further obligations to Executive under this Agreement, except as otherwise provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5.3&#160;&#160;&#160;&#160;Termination by Company without Cause or by Executive for Good Reason Not In Connection with a Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If the Company terminates Executive&#8217;s employment without Cause or if Executive resigns his employment for Good Reason (as defined below), in either case at any time other than upon the occurrence of, or within the 13 months immediately following, the effective date of a Change in Control, the Company shall pay Executive&#8217;s accrued and unpaid base salary and accrued and unused vacation benefits earned through the date of termination, at the rate in effect at the time of termination, less standard deductions and withholdings.  In addition to the above, if Executive furnishes to the Company an executed waiver and release of claims in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (or in such other form as may be specified by the Company) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) within the time period specified therein, but in no event later than 45 days following Executive&#8217;s termination, and if Executive allows such Release to become effective in accordance with its terms, then (i) Executive shall be entitled to severance in the form of continuation of his base salary, at the base salary rate equal to the greater of the rate in effect at the time of termination or the rate immediately prior to the event giving rise to Good Reason (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Severance Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), for a period of nine (9) months following the termination date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and (ii) if Executive timely elects COBRA coverage, the Company will pay directly to the insurance provider the premium for COBRA continuation coverage for Executive and Executive&#8217;s family during the Severance Period or until he obtains new employment, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">whichever comes first (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">COBRA Coverage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that, if the Company determines that it cannot provide the COBRA Coverage without potentially violating applicable law or incurring additional expense under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company will provide Executive, in lieu thereof, taxable, continued installment payments equal to the COBRA premium, payable on the last day of a given month, for 9 months (measured from the termination date), which payments will be made regardless of whether Executive elects COBRA continuation coverage (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">COBRA Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Notwithstanding the foregoing, the number of months of COBRA Bonus to be paid, in any case, shall be reduced by the number of months of COBRA Coverage previously paid by the Company.  The Severance Payments will be subject to standard payroll deductions and withholdings and will be made on the Company&#8217;s regular payroll cycle, provided, however, that any Severance Payments otherwise scheduled to be made prior to the effective date of the Release shall accrue and be paid in the first payroll period that follows such effective date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if the 45 day period to execute the Release spans two calendar years, no Severance Payments will be made until the later calendar year.  The Company shall thereafter have no further obligations to Executive under this Agreement, except as otherwise provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5.4&#160;&#160;&#160;&#160;Termination by Company without Cause or by Executive for Good Reason In Connection with a Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If the Company terminates Executive&#8217;s employment without Cause or if Executive resigns his employment for Good Reason, in either case upon the occurrence of, or within the 13 months immediately following, the effective date of a Change in Control, the Company shall pay Executive&#8217;s accrued and unpaid base salary and accrued and unused vacation benefits earned through the date of termination, at the rate in effect at the time of termination, less standard deductions and withholdings.  In addition, if Executive furnishes to the Company an executed Release within the time period specified therein, but in no event later than 45 days following Executive&#8217;s termination, and if Executive allows such Release to become effective in accordance with its terms, then Executive shall be entitled to&#58; (1) the Severance Payments and COBRA payments described in Section 4.5.3 above&#59; provided, however, that the Severance Payments and COBRA payments shall be increased from 9 months to 12 months and (2) accelerated vesting of all of Executive&#8217;s unvested Company equity awards, such that Executive shall become vested in 100% of the shares subject to all such equity awards on the effective date of the Release&#59; provided, however, that the vesting of any performance-based awards shall be as if all applicable performance criteria were achieved at target levels.  The Company shall thereafter have no further obligations to Executive under this Agreement, except as otherwise provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.6&#160;&#160;&#160;&#160;Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  For purposes of this Agreement, the following terms shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the occurrence of any one or more of the following&#58; (i) Executive&#8217;s commission of any crime involving fraud, dishonesty or moral turpitude&#59; (ii) Executive&#8217;s attempted commission of or participation in a fraud or act of dishonesty against the Company that results in (or might have reasonably resulted in) material harm to the business of the Company&#59; (iii) Executive&#8217;s intentional, material violation of any contract or agreement between Executive and the Company or any statutory duty Executive owes to the Company&#59; or (iv) Executive&#8217;s conduct that constitutes gross insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the action or conduct described in clauses (iii) and (iv) above will constitute &#8220;Cause&#8221; only if such action or conduct continues after the Company has provided Executive with written notice thereof and thirty (30) days to cure, or otherwise remedy to the extent possible under direct control of the Executive, the same.  An occurrence of &#8220;Cause&#8221; as set forth in the preceding sentence shall be based upon a good faith determination by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Board.  Executive&#8217;s Disability shall not constitute Cause as set forth herein.  The determination that a termination is for Cause shall be by the Board in its sole and exclusive judgment and discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Amended and Restated 2006 Equity Incentive Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any of the following actions&#58; (i) the assignment to Executive of any duties or responsibilities that results in a material diminution in Executive&#8217;s function as in effect immediately prior to the effective date of the Change in Control&#59; provided, however, that it will be considered a material diminution in Executive&#8217;s function if, following a Change in Control, the Executive is not reporting directly to the Chief Executive Officer who is in turn reporting to the Company&#8217;s (or if applicable ultimate parent entity&#8217;s) corporate board of directors&#59; (ii) a reduction by the Company in Executive&#8217;s annual base salary as in effect on the effective date of the Change in Control&#59; provided, however, that Good Reason shall not be deemed to have occurred in the event of a reduction in Executive&#8217;s annual base salary that is pursuant to a salary reduction program affecting substantially all of the employees of the Company and that does not adversely affect Executive to a greater extent than other similarly situated employees&#59; or (iii) a relocation of Executive&#8217;s primary business office to a location more than 50 miles from the location of Executive&#8217;s primary business office as of the effective date of the Change in Control, except for required travel by Executive on the Company&#8217;s business to an extent substantially consistent with Executive&#8217;s business travel obligations prior to the effective date of the Change in Control.  For the purposes of application of this definition of Good Reason to Section 4.5.3, the words &#8220;as in effect immediately prior to the effective date of the Change in Control&#8221; shall be read to mean as of, or immediately prior to, the date of the event giving rise to Good Reason.  In all events, in order for a termination for Good Reason to occur, the Executive must provide the Company with written notice of the condition constituting Good Reason within 90 days of the initial occurrence of such condition, and allow the Company a 30-day cure period in which to cure such condition, and the Executive must resign employment within 10 days of the end of such 30-day cure period if the Company does not cure the condition in such cure period.  For clarity, &#8220;corporate board of directors&#8221; as used in the definition of Good Reason means the Company&#8217;s (or if applicable ultimate parent entity&#8217;s) board of directors as such term is used in Section 141 of the Delaware General Corporation Law, or if the Company (or if applicable ultimate parent entity) is not a corporation organized under Delaware law, the most senior governing body of the Company (or if applicable ultimate parent entity) the majority of which is comprised of non-employee and independent members and has responsibility and authority for managing the business and affairs of the Company (or if applicable ultimate parent entity).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.7&#160;&#160;&#160;&#160;Survival of Certain Sections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Sections 3.4, 3.6 and 4 through 18 of this Agreement will survive the termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.8&#160;&#160;&#160;&#160;Parachute Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If any payment or benefit Executive would receive pursuant to this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) would (i) constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Parachute Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then such Payment shall be equal to the Reduced Amount.  The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Reduced Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&#8217;s receipt, on an after-tax basis, of the greatest economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in payments or benefits constituting Parachute Payments is necessary so </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit for Executive.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event it is subsequently determined by the Internal Revenue Service that some portion of the Reduced Amount (as determined pursuant to clause (x) in the preceding paragraph) is subject to the Excise Tax, Executive agrees to promptly return to the Company a sufficient amount of the Payment so that no portion of the Reduced Amount is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount is determined in accordance with clause (y) in the preceding paragraph, Executive will have no obligation to return any portion of the Payment pursuant to the preceding sentence. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unless Executive and the Company agree on an alternative accounting or law firm, the accounting firm then engaged by the Company for general tax compliance purposes shall perform the foregoing calculations.  If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting, law or consulting firm to make the determinations required hereunder.  The Company shall bear all expenses with respect to the determinations by such accounting, law or consulting firm required to be made hereunder. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company shall use commercially reasonable efforts such that the accounting, law or consulting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to Executive and the Company within 15 calendar days after the date on which Executive&#8217;s right to a Payment is triggered (if requested at that time by Executive or the Company) or such other time as requested by Executive or the Company.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.9&#160;&#160;&#160;&#160;Application of Internal Revenue Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that constitute &#8220;deferred compensation&#8221; within the meaning of Section 409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall not commence in connection with Executive&#8217;s termination of employment unless and until Executive has also incurred a &#8220;separation from service&#8221; (as such term is defined in Treasury Regulation Section 1.409A-1(h)) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Separation From Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), unless the Company reasonably determines that such amounts may be provided to Executive without causing Executive to incur the additional 20% tax under Section 409A. </font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is intended that each installment of the Severance Benefits payments provided for in this Agreement is a separate &#8220;payment&#8221; for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i). For the avoidance of doubt, it is intended that payments of the Severance Benefits set forth in this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if the Company (or, if applicable, the successor entity thereto) determines that the Severance Benefits constitute &#8220;deferred compensation&#8221; under Section 409A and Executive is, on the termination of service, a &#8220;specified employee&#8221; of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Severance Benefit payments shall be delayed until the earlier to occur of&#58; (i) the date that is six months and one day after Executive&#8217;s Separation From Service, or (ii) the date of Executive&#8217;s death (such applicable date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Specified Employee Initial Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the Company (or the successor entity thereto, as applicable) shall (A) pay to Executive a lump sum amount equal to the sum of the Severance Benefit payments that Executive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">would otherwise have received through the Specified Employee Initial Payment Date if the commencement of the payment of the Severance Benefits had not been so delayed pursuant to this Section and (B) commence paying the balance of the Severance Benefits in accordance with the applicable payment schedules set forth in this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary set forth herein, Executive shall receive the Severance Benefits described above, if and only if Executive duly executes and returns to the Company within the applicable time period set forth therein, but in no event more than forty-five days following Separation From Service, the Release and permits the Release to become effective in accordance with its terms.  Notwithstanding any other payment schedule set forth in this Agreement, none of the Severance Benefits will be paid or otherwise delivered prior to the effective date of the Release.  Except to the extent that payments may be delayed until the Specified Employee Initial Payment Date pursuant to the preceding paragraph, on the first regular payroll pay day following the effective date of the Release, the Company will pay Executive the Severance Benefits Executive would otherwise have received under the Agreement on or prior to such date but for the delay in payment related to the effectiveness of the Release, with the balance of the Severance Benefits being paid as originally scheduled.  All amounts payable under the Agreement will be subject to standard payroll taxes and deductions. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">CONFIDENTIAL AND PROPRIETARY INFORMATION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Executive has already executed, as a condition of Executive&#8217;s employment with the Company, the Company&#8217;s standard form of Proprietary Information and Inventions Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">PIIA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The PIIA remains in full force and effect.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">ASSIGNMENT AND BINDING EFFECT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement shall be binding upon and inure to the benefit of Executive and Executive&#8217;s heirs, executors, personal representatives, assigns, administrators and legal representatives.  Because of the unique and personal nature of Executive&#8217;s duties under this Agreement, neither this Agreement nor any rights or obligations under this Agreement shall be assignable by Executive.  This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives.  Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes.  For this purpose, &#8220;successor&#8221; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">NOTICES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All notices or demands of any kind required or permitted to be given by the Company or Executive under this Agreement shall be given in writing and shall be personally delivered (and receipted for) or faxed during normal business hours or mailed by certified mail, return receipt requested, postage prepaid, addressed as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">If to the Company&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10421 Pacific Center Court, Suite 200</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">San Diego, CA 92121</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Chief Executive Officer</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">If to Executive&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Eric Loumeau</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15024 Huntington Gate Drive</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Poway, CA 92064</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any such written notice shall be deemed given on the earlier of the date on which such notice is personally delivered or three days after its deposit in the United States mail as specified above.  Either Party may change its address for notices by giving notice to the other Party in the manner specified in this Section. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">CHOICE OF LAW.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement shall be construed and interpreted in accordance with the internal laws of the State of California without regard to its conflict of laws principles. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">INTEGRATION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the PIIA, contains the complete, final and exclusive agreement of the Parties relating to the terms and conditions of Executive&#8217;s employment and the termination of Executive&#8217;s employment, and supersedes any and all prior and&#47;or contemporaneous oral and written employment agreements or arrangements between the Parties, including the Prior Agreement, which is hereby terminated.  By signing below, Executive acknowledges that he has been paid all compensation and benefits owed to him by the Company and that the Company has fully performed all of its obligations under the Prior Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">AMENDMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement cannot be amended or modified except by a written agreement signed by Executive and the Company. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">WAIVER.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with the written consent of the Party against whom the wavier is claimed, and any waiver or any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">SEVERABILITY.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The finding by a court of competent jurisdiction of the unenforceability, invalidity or illegality of any provision of this Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal.  Such court shall have the authority to modify or replace the invalid or unenforceable term or provision with a valid and enforceable term or provision, which most accurately represents the Parties&#8217; intention with respect to the invalid or unenforceable term, or provision. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">INTERPRETATION&#59; CONSTRUCTION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The headings set forth in this Agreement are for convenience of reference only and shall not be used in interpreting this Agreement.  This Agreement has been drafted by legal counsel representing the Company, but Executive has been encouraged to consult with, and has consulted with, Executive&#8217;s own </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">independent counsel and tax advisors with respect to the terms of this Agreement.  The Parties acknowledge that each Party and its counsel has reviewed and revised, or had an opportunity to review and revise, this Agreement, and any rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">REPRESENTATIONS AND WARRANTIES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Executive represents and warrants that Executive is not restricted or prohibited, contractually or otherwise, from entering into and performing each of the terms and covenants contained in this Agreement, and that Executive&#8217;s execution and performance of this Agreement will not violate or breach any other agreements between Executive and any other person or entity. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">COUNTERPARTS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement may be executed in two counterparts, each of which shall be deemed an original, all of which together shall contribute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">ARBITRATION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To ensure the rapid and economical resolution of disputes that may arise in connection with Executive&#8217;s employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action, in law or equity, arising from or relating to Executive&#8217;s employment, or the termination of that employment, will be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration pursuant to both the substantive and procedural provisions of the Federal Arbitration Act in San Diego, California conducted by the Judicial Arbitration and Mediation Services&#47;Endispute, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or its successors, under the then current rules of JAMS for employment disputes&#59; provided that the arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; and (b) issue a written arbitration decision including the arbitrator&#8217;s essential findings and conclusions and a statement of the award.  Accordingly, Executive and the Company hereby waive any right to a jury trial.  Both Executive and the Company shall be entitled to all rights and remedies that either Executive or the Company would be entitled to pursue in a court of law.  The Company shall pay any JAMS filing fee and shall pay the arbitrator&#8217;s fee.  Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  Notwithstanding the foregoing, Executive and the Company each have the right to resolve any issue or dispute involving confidential, proprietary or trade secret information, or intellectual property rights, by Court action instead of arbitration. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">TRADE SECRETS OF OTHERS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is the understanding of both the Company and Executive that Executive shall not divulge to the Company and&#47;or its subsidiaries any confidential information or trade secrets belonging to others, including Executive&#8217;s former employers, nor shall the Company and&#47;or its Affiliates seek to elicit from Executive any such information.  Consistent with the foregoing, Executive shall not provide to the Company and&#47;or its Affiliates, and the Company and&#47;or its Affiliates shall not request, any documents or copies of documents containing such information. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">ADVERTISING WAIVER.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Executive agrees to permit the Company, and persons or other organizations authorized by the Company, to use, publish and distribute advertising or sales promotional literature concerning the products and&#47;or services of the Company, or the machinery and equipment used in the provision thereof, in which Executive&#8217;s name and&#47;or pictures of Executive taken in the course of Executive&#8217;s provision of services to the Company appear.  Executive hereby waives and releases any claim or right Executive may otherwise have arising out of such use, publication or distribution. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div></div></div><div id="i7b1e58893e414ad2bd948de0052b4a89_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Parties have executed the Agreement as of the date below.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ANAPTYSBIO, INC.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Hamza Suria</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; &#160;&#160;&#160;&#160;Hamza Suria</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;President &#38; CEO</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;&#160;&#160;July 14, 2020</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Executive&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Eric Loumeau</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ERIC LOUMEAU</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;&#160;&#160;July 14, 2020</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;SIGNATURE PAGE TO EMPLOYMENT AGREEMENT&#93;</font></div></div></div><div id="i7b1e58893e414ad2bd948de0052b4a89_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT A </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RELEASE AND WAIVER OF CLAIMS </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TO BE SIGNED ON OR FOLLOWING THE SEPARATION DATE ONLY </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In consideration of the payments and other benefits set forth in the Amended and Restated Employment Agreement effective July 15, 2020, to which this form is attached, I, Eric Loumeau, hereby furnish </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ANAPTYSBIO, INC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), with the following release and waiver (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Release and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In exchange for the consideration provided to me by the Amended and Restated Employment Agreement that I am not otherwise entitled to receive, I hereby generally and completely release the Company and its current and former directors, officers, employees, stockholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Released Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date that I sign this Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Released Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The Released Claims include, but are not limited to&#58; (a) all claims arising out of or in any way related to my employment with the Company, or the termination of that employment&#59; (b) all claims related to my compensation or benefits from the Company including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company&#59; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing&#59; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy&#59; and (e) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, misclassification, attorneys&#8217; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ADEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the California Labor Code, and the California Fair Employment and Housing Act (as amended).  Notwithstanding the foregoing, the following are not included in the Released Claims (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Excluded Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58; (a) any rights or claims for indemnification I may have pursuant to the charter or bylaws of the Company or under applicable law&#59; (b) any rights or claims to unemployment compensation, funds accrued in my 401k account, or any vested equity incentives&#59; (c) any rights that are not waivable as a matter of law&#59; or (d) any claims arising from the breach of this Agreement.  I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or might have against any of the Released Parties that are not included in the Released Claims. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I also acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows&#58; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221; I hereby expressly waive and relinquish all rights and benefits under that Section and any law of any jurisdiction, including New York, of similar effect with respect to any claims I may have against the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I acknowledge that, among other rights, I am waiving and releasing any rights I may have under ADEA, that this Release and Waiver is knowing and voluntary, and that the consideration given for this Release and Waiver is in addition to anything of value to which I was already entitled as an executive of the Company.  I further acknowledge that I have been advised, as required by the Older Workers Benefit Protection Act, that&#58; (a) the release and waiver granted herein does not relate to claims under the ADEA </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">which may arise after this Release and Waiver is executed&#59; (b) I should consult with an attorney prior to executing this Release and Waiver&#59; and (c) if I am age 40 or older at the time of execution of this release, I have 21 days from the date of termination of my employment with the Company in which to consider this Release and Waiver (although I may choose voluntarily to execute this Release and Waiver earlier)&#59; and (d) if I am age 40 or older at the time of execution of this release, I have seven days following the execution of this Release and Waiver to revoke my consent to this Release and Waiver and this Release and Waiver shall not be effective until the seven day revocation period has expired without my having previously revoked this Release and Waiver.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I agree not to disparage the Company and its officers, directors, employees, shareholders and&#47;or agents, in any manner likely to be harmful to them or their business, business reputations or personal reputations&#59; provided that I may respond accurately and fully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I acknowledge my continuing obligations under my Proprietary Information and Inventions Agreement.  Pursuant to the Proprietary Information and Inventions Agreement I understand that among other things, I must not use or disclose any confidential or proprietary information of the Company and I must immediately return all Company property and documents (including all embodiments of proprietary information) and all copies thereof in my possession or control.  I understand and agree that my right to the severance pay I am receiving in exchange for my agreement to the terms of this Release and Waiver is contingent upon my continued compliance with my Proprietary Information and Inventions Agreement.</font></div><div style="margin-bottom:30pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Release and Waiver constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof.  I am not relying on any promise or representation by the Company that is not expressly stated herein.  This Release and Waiver may only be modified by a writing signed by both me and a duly authorized officer of the Company.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58;________________________&#160;&#160;&#160;&#160;By&#58;__________________________________</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;ERIC LOUMEAU</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>3
<FILENAME>mulroyemploymentagreem.htm
<DESCRIPTION>EX-10.18
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ib9fd5a6785884fab8d7610aed4fce4a9_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ANAPTYSBIO, INC.</font></div><div style="margin-bottom:0.12pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EMPLOYMENT AGREEMENT</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EMPLOYMENT AGREEMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is made effective from July 15, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) by and among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ANAPTYSBIO, INC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and Dennis Mulroy (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">CFO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The Company and CFO are hereinafter collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,&#8221; and individually referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">RECITAL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company desires to employ CFO, and CFO is willing to accept such employment by Company, on the terms and subject to the conditions set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In consideration of the foregoing Recitals and the mutual promises and covenants herein contained, and for other good and valuable consideration, the Parties, intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">EMPLOYMENT.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.1&#160;&#160;&#160;&#160;Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Effective as of the Effective Date, CFO&#8217;s position shall be Chief Financial Officer of the Company, subject to the terms and conditions set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.2&#160;&#160;&#160;&#160;Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The term of this Agreement shall begin on the Effective Date and shall continue until it is terminated pursuant to Section 4 herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.3&#160;&#160;&#160;&#160;Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CFO shall do and perform all services, acts or things necessary or advisable to manage and conduct the business of the Company and that are normally associated with the position of Chief Financial Officer of the Company.  CFO shall report to the Chief Executive Officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.4&#160;&#160;&#160;&#160;Policies and Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The employment relationship between the Parties shall be governed by this Agreement and by the policies and practices established by the Company and&#47;or the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or any designated committee thereof.  In the event that the terms of this Agreement differ from or are in conflict with the Company&#8217;s policies or practices or the Company&#8217;s Employee Handbook, this Agreement shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.5&#160;&#160;&#160;&#160;Location</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Unless the Parties otherwise agree in writing, and except as provided in this Section 1.5, during the Term CFO shall perform the services CFO is required to perform pursuant to this Agreement at the Company&#8217;s offices in San Diego, California&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the Company may from time to time require CFO to travel temporarily to other locations in connection with the Company&#8217;s business&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, upon the Effective Date, and until applicable government COVID-19 quarantine restrictions applicable to the San Diego office are lifted and the San Diego office reopens, the Company will allow CFO to perform the services remotely from CFO&#8217;s home.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;LOYALTY&#59; NONCOMPETITION&#59; NONSOLICITATION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;Loyalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  During CFO&#8217;s employment with the Company, CFO shall devote CFO&#8217;s full business energies, interest, abilities and productive time to the proper and efficient performance of CFO&#8217;s duties under this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.2&#160;&#160;&#160;&#160;Agreement not to Participate in Company&#8217;s Competitors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  During CFO&#8217;s employment with the Company, CFO agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by CFO to be adverse or antagonistic to the Company, its business, or prospects, financial or otherwise, or in any company, person, or entity that is, directly or indirectly, in competition with the business of the Company or any of its Affiliates (as defined below).  Ownership by CFO, in professionally managed funds over which CFO does not have control or discretion in investment decisions, or as a passive investment, of less than two percent (2%) of the outstanding shares of capital stock of any corporation with one or more classes of its capital stock listed on a national securities exchange or publicly traded on a national securities exchange or in the over-the-counter market shall not constitute a breach of this Section.  For purposes of this Agreement, &#8220;Affiliate,&#8221; means, with respect to any specific entity, any other entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such specified entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.3&#160;&#160;&#160;&#160;Covenant not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  During CFO&#8217;s employment with the Company, CFO shall not engage in competition with the Company and&#47;or any of its Affiliates in any manner or capacity, as adviser, principal, agent, Affiliate, promoter, partner, officer, director, employee, owner, co-owner, consultant, in any phase of the business of developing, manufacturing and marketing of products or services that directly compete with the products or services of the Company, except with the prior written consent of the CEO.  CFO shall be entitled to request written consent of the CEO with respect to potential advisory and&#47;or director opportunities presented to CFO by a third party, which CFO believes in good faith will not interfere or compete with the on-going business of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;COMPENSATION OF CFO.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company shall pay CFO a base salary at the annualized rate of $400,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), less payroll deductions and all required withholdings, payable in regular periodic installments in accordance with the Company&#8217;s normal payroll practices.  The Base Salary shall be prorated for any partial year of employment on the basis of a 365-day fiscal year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;Discretionary Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  At the sole discretion of the Board and the Chief Executive Officer, promptly following each calendar year of employment CFO shall be eligible to receive a discretionary cash bonus of up to 40% of CFO&#8217;s then-current base salary (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), based on CFO&#8217;s achievement relative to certain performance goals (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to be established by the Chief Executive Officer and&#47;or the Board or the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in writing in a manner reasonably consistent with the Company&#8217;s priorities.  The determination of whether CFO has met the Performance Goals for any given year, and if so, the amount of any Bonus that will be paid for such year (if any), shall be determined by the Board or the Committee and Chief Executive Officer in their sole and absolute discretion.  In order to be eligible to earn or receive any Bonus, CFO must remain employed by the Company through and including the date of payment of such Bonus.  For the first calendar year of CFO&#8217;s employment with the Company, the Bonus payable shall be pro-rated in accordance with the percentage of the calendar year that the CFO is an employee of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.3&#160;&#160;&#160;&#160;Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  As soon as practicable following the Effective Date, subject to the approval of the Board or the Committee, CFO will be granted an option to purchase up to 90,600 shares of the Company&#8217;s Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Base Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) pursuant to the terms of the Company&#8217;s 2017 Equity Incentive Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The Base Option shall be subject to vesting such that, subject to CFO&#8217;s continued employment with the Company, 1&#47;4 of the shares subject to the Base Option shall vest as of the first anniversary of the Effective Date and l&#47;48th of the shares </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">subject to the Base Option shall vest in equal monthly installments on the monthly anniversary of the Effective Date of each month for the 36 months thereafter.  The exercise price per share of the Base Option will be equal to the closing selling price as reported on the Nasdaq Stock Market on the date the Base Option is granted.  The Base Option will be governed by the Plan and shall be granted pursuant to a separate stock option grant notice and stock option agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.4&#160;&#160;&#160;&#160;Expense Reimbursements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company will reimburse CFO for all reasonable business expenses CFO incurs in conducting his duties hereunder, pursuant to the Company&#8217;s usual expense reimbursement policies&#59; provided that CFO supplies the appropriate substantiation for such expenses no later than the end of the calendar month following the month in which such expenses were incurred by CFO.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.5&#160;&#160;&#160;&#160;Changes to Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CFO&#8217;s compensation will be reviewed annually and may be changed from time to time in the Company&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.6&#160;&#160;&#160;&#160;Employment Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  All of CFO&#8217;s compensation shall be subject to customary withholding taxes and any other employment taxes as are commonly required to be collected or withheld by the Company, as determined by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.7&#160;&#160;&#160;&#160;Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CFO shall, in accordance with Company policy and the terms of the applicable plan documents, be eligible to participate in benefits under any benefit plan or arrangement that may be in effect from time to time and made available to the Company&#8217;s senior management employees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.8&#160;&#160;&#160;&#160;Holidays and Vacation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CFO shall be eligible for paid holiday and vacation time in accordance with Company policy as in effect from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;TERMINATION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;Termination by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CFO&#8217;s employment with the Company is at will and may be terminated by the Company at any time and for any reason, or for no reason, including, but not limited to, under the following conditions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.1.1&#160;&#160;&#160;&#160;Termination by the Company for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company may terminate CFO&#8217;s employment under this Agreement for Cause (as defined below) by delivery of written notice to CFO.  Any notice of termination given pursuant to this section shall effect termination as of the date of the notice, or as of such other date specified in the notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.1.2&#160;&#160;&#160;&#160;Termination by the Company without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company may terminate CFO&#8217;s employment under this Agreement without Cause at any time and for any reason, or for no reason.  Such termination shall be effective on the date CFO is so informed, or as otherwise specified by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.2&#160;&#160;&#160;&#160;Termination by CFO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CFO may terminate his employment with the Company at any time and for any reason, or for no reason, upon thirty (30) days written notice to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.3&#160;&#160;&#160;&#160;Termination for Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CFO&#8217;s employment with the Company shall automatically terminate effective upon the date of CFO&#8217;s death or Disability (as defined in the Plan).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.4&#160;&#160;&#160;&#160;Termination by Mutual Agreement of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CFO&#8217;s employment with the Company may be terminated at any time upon a mutual agreement in writing of the Parties.  Any such termination of employment shall have the consequences specified in such agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5&#160;&#160;&#160;&#160;Compensation upon Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5.1&#160;&#160;&#160;&#160;Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If CFO&#8217;s employment is terminated by death or Disability, the Company shall pay to CFO, or to CFO&#8217;s heirs, CFO&#8217;s accrued and unpaid base salary and accrued and unused vacation benefits earned through the date of termination at the rate in effect at the time of termination, less standard deductions and withholdings.  The Company shall thereafter have no further obligations to CFO and&#47;or CFO&#8217;s heirs under this Agreement, except as otherwise provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5.2&#160;&#160;&#160;&#160;Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If the Company terminates CFO&#8217;s employment for Cause, then the Company shall pay CFO&#8217;s accrued and unpaid base salary and accrued and unused vacation benefits earned through the date of termination, at the rate in effect at the time of termination, less standard deductions and withholdings.  The Company shall thereafter have no further obligations to CFO under this Agreement, except as otherwise provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5.3&#160;&#160;&#160;&#160;Termination by Company without Cause or by CFO for Good Reason Not In Connection with a Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If the Company terminates CFO&#8217;s employment without Cause or if CFO resigns his employment for Good Reason (as defined below), in either case at any time other than upon the occurrence of, or within the 13 months immediately following, the effective date of a Change in Control, the Company shall pay CFO&#8217;s accrued and unpaid base salary and accrued and unused vacation benefits earned through the date of termination, at the rate in effect at the time of termination, less standard deductions and withholdings.  In addition to the above, if CFO furnishes to the Company an executed waiver and release of claims in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (or in such other form as may be specified by the Company) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) within the time period specified therein, but in no event later than 45 days following CFO&#8217;s termination, and if CFO allows such Release to become effective in accordance with its terms, then (i) CFO shall be entitled to severance in the form of continuation of his base salary, at the base salary rate equal to the greater of the rate in effect at the time of termination or the rate immediately prior to the event giving rise to Good Reason (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Severance Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), for a period of nine (9) months following the termination date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and (ii) if CFO timely elects COBRA coverage, the Company will pay directly to the insurance provider the premium for COBRA continuation coverage for CFO and CFO&#8217;s family during the Severance Period or until he obtains new employment, whichever comes first (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">COBRA Coverage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that, if the Company determines that it cannot provide the COBRA Coverage without potentially violating applicable law or incurring additional expense under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company will provide CFO, in lieu thereof, taxable, continued installment payments equal to the COBRA premium, payable on the last day of a given month, for 9 months (measured from the termination date), which payments will be made regardless of whether CFO elects COBRA continuation coverage (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">COBRA Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Notwithstanding the foregoing, the number of months of COBRA Bonus to be paid, in any case, shall be reduced by the number of months of COBRA Coverage previously paid by the Company.  The Severance Payments will be subject to standard payroll deductions and withholdings and will be made on the Company&#8217;s regular payroll cycle, provided, however, that any Severance Payments otherwise scheduled to be made prior to the effective date of the Release shall accrue and be paid in the first payroll period that follows such effective date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if the 45 day period to execute the Release spans two calendar years, no Severance Payments </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will be made until the later calendar year.  The Company shall thereafter have no further obligations to CFO under this Agreement, except as otherwise provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5.4&#160;&#160;&#160;&#160;Termination by Company without Cause or by CFO for Good Reason in Connection with a Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If the Company terminates CFO&#8217;s employment without Cause or if CFO resigns his employment for Good Reason, in either case upon the occurrence of, or within the 13 months immediately following, the effective date of a Change in Control, the Company shall pay CFO&#8217;s accrued and unpaid base salary and accrued and unused vacation benefits earned through the date of termination, at the rate in effect at the time of termination, less standard deductions and withholdings.  In addition, if CFO furnishes to the Company an executed Release within the time period specified therein, but in no event later than 45 days following CFO&#8217;s termination, and if CFO allows such Release to become effective in accordance with its terms, then CFO shall be entitled to&#58; (1) the Severance Payments and COBRA payments described in Section 4.5.3 above&#59; provided, however, that the Severance Payments and COBRA payments shall be increased from 9 months to 12 months and (2) accelerated vesting of all of CFO&#8217;s unvested Company equity awards, such that CFO shall become vested in 100% of the shares subject to all such equity awards on the effective date of the Release&#59; provided, however, that the vesting of any performance-based awards shall be as if all applicable performance criteria were achieved at target levels.  The Company shall thereafter have no further obligations to CFO under this Agreement, except as otherwise provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.6&#160;&#160;&#160;&#160;Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  For purposes of this Agreement, the following terms shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the occurrence of any one or more of the following&#58; (i) CFO&#8217;s commission of any crime involving fraud, dishonesty or moral turpitude&#59; (ii) CFO&#8217;s attempted commission of or participation in a fraud or act of dishonesty against the Company that results in (or might have reasonably resulted in) material harm to the business of the Company&#59; (iii) CFO&#8217;s intentional, material violation of any contract or agreement between CFO and the Company or any statutory duty CFO owes to the Company&#59; or (iv) CFO&#8217;s conduct that constitutes gross insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the action or conduct described in clauses (iii) and (iv) above will constitute &#8220;Cause&#8221; only if such action or conduct continues after the Company has provided CFO with written notice thereof and thirty (30) days to cure, or otherwise remedy to the extent possible under direct control of the CFO, the same.  An occurrence of &#8220;Cause&#8221; as set forth in the preceding sentence shall be based upon a good faith determination by the Board.  CFO&#8217;s Disability shall not constitute Cause as set forth herein.  The determination that a termination is for Cause shall be by the Board in its sole and exclusive judgment and discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Amended and Restated 2006 Equity Incentive Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any of the following actions&#58; (i) the assignment to CFO of any duties or responsibilities that results in a material diminution in CFO&#8217;s function as in effect immediately prior to the effective date of the Change in Control&#59; provided, however, that it will be considered a material diminution in CFO&#8217;s function if, following a Change in Control, the CFO is not reporting directly to the Chief Executive Officer who is in turn reporting to the Company&#8217;s (or if applicable ultimate parent entity&#8217;s) corporate board of directors&#59; (ii) a reduction by the Company in CFO&#8217;s annual base salary as in effect on the effective date of the Change in Control&#59; provided, however, that Good Reason shall not be deemed to have occurred in the event of a reduction in CFO&#8217;s annual base </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">salary that is pursuant to a salary reduction program affecting substantially all of the employees of the Company and that does not adversely affect CFO to a greater extent than other similarly situated employees&#59; or (iii) a relocation of CFO&#8217;s primary business office to a location more than 50 miles from the location of CFO&#8217;s primary business office as of the effective date of the Change in Control, except for required travel by CFO on the Company&#8217;s business to an extent substantially consistent with CFO&#8217;s business travel obligations prior to the effective date of the Change in Control.  For the purposes of application of this definition of Good Reason to Section 4.5.3, the words &#8220;as in effect immediately prior to the effective date of the Change in Control&#8221; shall be read to mean as of, or immediately prior to, the date of the event giving rise to Good Reason.  In all events, in order for a termination for Good Reason to occur, the CFO must provide the Company with written notice of the condition constituting Good Reason within 90 days of the initial occurrence of such condition, and allow the Company a 30-day cure period in which to cure such condition, and the CFO must resign employment within 10 days of the end of such 30-day cure period if the Company does not cure the condition in such cure period.  For clarity, &#8220;corporate board of directors&#8221; as used in the definition of Good Reason means the Company&#8217;s (or if applicable ultimate parent entity&#8217;s) board of directors as such term is used in Section 141 of the Delaware General Corporation Law, or if the Company (or if applicable ultimate parent entity) is not a corporation organized under Delaware law, the most senior governing body of the Company (or if applicable ultimate parent entity) the majority of which is comprised of non-employee and independent members and has responsibility and authority for managing the business and affairs of the Company (or if applicable ultimate parent entity).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.7&#160;&#160;&#160;&#160;Survival of Certain Sections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Sections 3.4, 3.6 and 4 through 18 of this Agreement will survive the termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.8&#160;&#160;&#160;&#160;Parachute Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If any payment or benefit CFO would receive pursuant to this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) would (i) constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Parachute Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then such Payment shall be equal to the Reduced Amount.  The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Reduced Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in CFO&#8217;s receipt, on an after-tax basis, of the greatest economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in payments or benefits constituting Parachute Payments is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit for CFO.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event it is subsequently determined by the Internal Revenue Service that some portion of the Reduced Amount (as determined pursuant to clause (x) in the preceding paragraph) is subject to the Excise Tax, CFO agrees to promptly return to the Company a sufficient amount of the Payment so that no portion of the Reduced Amount is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount is determined in accordance with clause (y) in the preceding paragraph, CFO will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unless CFO and the Company agree on an alternative accounting or law firm, the accounting firm then engaged by the Company for general tax compliance purposes shall perform the foregoing calculations.  If the accounting firm so engaged by the Company is serving as accountant or auditor for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting, law or consulting firm to make the determinations required hereunder.  The Company shall bear all expenses with respect to the determinations by such accounting, law or consulting firm required to be made hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company shall use commercially reasonable efforts such that the accounting, law or consulting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to CFO and the Company within 15 calendar days after the date on which CFO&#8217;s right to a Payment is triggered (if requested at that time by CFO or the Company) or such other time as requested by CFO or the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.9&#160;&#160;&#160;&#160;Application of Internal Revenue Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that constitute &#8220;deferred compensation&#8221; within the meaning of Section 409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall not commence in connection with CFO&#8217;s termination of employment unless and until CFO has also incurred a &#8220;separation from service&#8221; (as such term is defined in Treasury Regulation Section 1.409A-1(h)) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Separation From Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), unless the Company reasonably determines that such amounts may be provided to CFO without causing CFO to incur the additional 20% tax under Section 409A. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is intended that each installment of the Severance Benefits payments provided for in this Agreement is a separate &#8220;payment&#8221; for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i).  For the avoidance of doubt, it is intended that payments of the Severance Benefits set forth in this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9).  However, if the Company (or, if applicable, the successor entity thereto) determines that the Severance Benefits constitute &#8220;deferred compensation&#8221; under Section 409A and CFO is, on the termination of service, a &#8220;specified employee&#8221; of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Severance Benefit payments shall be delayed until the earlier to occur of&#58; (i) the date that is six months and one day after CFO&#8217;s Separation From Service, or (ii) the date of CFO&#8217;s death (such applicable date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Specified Employee Initial Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the Company (or the successor entity thereto, as applicable) shall (A) pay to CFO a lump sum amount equal to the sum of the Severance Benefit payments that CFO would otherwise have received through the Specified Employee Initial Payment Date if the commencement of the payment of the Severance Benefits had not been so delayed pursuant to this Section and (B) commence paying the balance of the Severance Benefits in accordance with the applicable payment schedules set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary set forth herein, CFO shall receive the Severance Benefits described above, if and only if CFO duly executes and returns to the Company within the applicable time period set forth therein, but in no event more than forty-five days following Separation From Service, the Release and permits the Release to become effective in accordance with its terms.  Notwithstanding any other payment schedule set forth in this Agreement, none of the Severance Benefits will be paid or otherwise delivered prior to the effective date of the Release.  Except to the extent that payments may be delayed until the Specified Employee Initial Payment Date pursuant to the preceding paragraph, on the first regular payroll pay day following the effective date of the Release, the Company will pay CFO the Severance Benefits that CFO would otherwise have received under the Agreement on or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">prior to such date but for the delay in payment related to the effectiveness of the Release, with the balance of the Severance Benefits being paid as originally scheduled.  All amounts payable under the Agreement will be subject to standard payroll taxes and deductions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;CONFIDENTIAL AND PROPRIETARY INFORMATION.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  CFO has already executed, as a condition of CFO&#8217;s employment with the Company, the Company&#8217;s standard form of Proprietary Information and Inventions Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">PIIA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The PIIA remains in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;ASSIGNMENT AND BINDING EFFECT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement shall be binding upon and inure to the benefit of CFO and CFO&#8217;s heirs, executors, personal representatives, assigns, administrators and legal representatives.  Because of the unique and personal nature of CFO&#8217;s duties under this Agreement, neither this Agreement nor any rights or obligations under this Agreement shall be assignable by CFO.  This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives.  Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes.  For this purpose, &#8220;successor&#8221; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;NOTICES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All notices or demands of any kind required or permitted to be given by the Company or CFO under this Agreement shall be given in writing and shall be personally delivered (and receipted for) or faxed during normal business hours or mailed by certified mail, return receipt requested, postage prepaid, addressed as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">If to the Company&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10421 Pacific Center Court, Suite 200</font></div><div style="margin-bottom:0.12pt;padding-left:36pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">San Diego, CA 92121</font></div><div style="margin-bottom:0.12pt;padding-left:36pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Chief Executive Officer</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">If to CFO&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dennis Mulroy</font></div><div style="margin-bottom:0.12pt;padding-left:36pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4370 Mensha Place</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">San Diego, CA 92130</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any such written notice shall be deemed given on the earlier of the date on which such notice is personally delivered or three days after its deposit in the United States mail as specified above.  Either Party may change its address for notices by giving notice to the other Party in the manner specified in this Section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;CHOICE OF LAW.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement shall be construed and interpreted in accordance with the internal laws of the State of California without regard to its conflict of laws principles.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;INTEGRATION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the PIIA, contains the complete, final and exclusive agreement of the Parties relating to the terms and conditions of CFO&#8217;s employment and the termination of CFO&#8217;s employment, and supersedes any and all prior and&#47;or contemporaneous oral and written employment agreements or arrangements between the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;AMENDMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement cannot be amended or modified except by a written agreement signed by CFO and the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;WAIVER.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with the written consent of the Party against whom the wavier is claimed, and any waiver or any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;SEVERABILITY.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The finding by a court of competent jurisdiction of the unenforceability, invalidity or illegality of any provision of this Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal.  Such court shall have the authority to modify or replace the invalid or unenforceable term or provision with a valid and enforceable term or provision, which most accurately represents the Parties&#8217; intention with respect to the invalid or unenforceable term, or provision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;INTERPRETATION&#59; CONSTRUCTION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The headings set forth in this Agreement are for convenience of reference only and shall not be used in interpreting this Agreement.  This Agreement has been drafted by legal counsel representing the Company, but CFO has been encouraged to consult with, and has consulted with, CFO&#8217;s own independent counsel and tax advisors with respect to the terms of this Agreement.  The Parties acknowledge that each Party and its counsel has reviewed and revised, or had an opportunity to review and revise, this Agreement, and any rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;REPRESENTATIONS AND WARRANTIES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CFO represents and warrants that CFO is not restricted or prohibited, contractually or otherwise, from entering into and performing each of the terms and covenants contained in this Agreement, and that CFO&#8217;s execution and performance of this Agreement will not violate or breach any other agreements between CFO and any other person or entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;COUNTERPARTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement may be executed in two counterparts, each of which shall be deemed an original, all of which together shall contribute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;ARBITRATION.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To ensure the rapid and economical resolution of disputes that may arise in connection with CFO&#8217;s employment with the Company, CFO and the Company agree that any and all disputes, claims, or causes of action, in law or equity, arising from or relating to CFO&#8217;s employment, or the termination of that employment, will be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration pursuant to both the substantive and procedural provisions of the Federal Arbitration Act in San Diego, California conducted by the Judicial Arbitration and Mediation Services&#47;Endispute, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or its successors, under the then current rules of JAMS for employment disputes&#59; provided that the arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; and (b) issue a written arbitration decision including the arbitrator&#8217;s essential findings and conclusions and a statement of the award.  Accordingly, CFO and the Company hereby waive any right to a jury trial.  Both CFO and the Company shall be entitled to all rights and remedies that either CFO or the Company would be entitled to pursue in a court of law.  The Company shall pay any JAMS filing fee and shall pay the arbitrator&#8217;s fee.  Nothing in this Agreement is intended to prevent either CFO or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  Notwithstanding the foregoing, CFO and the Company each have the right to resolve any issue or dispute involving confidential, proprietary or trade secret information, or intellectual property rights, by Court action instead of arbitration. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;TRADE SECRETS OF OTHERS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is the understanding of both the Company and CFO that CFO shall not divulge to the Company and&#47;or its subsidiaries any confidential information or trade secrets belonging to others, including CFO&#8217;s former employers, nor shall the Company and&#47;or its Affiliates seek to elicit from CFO any such information.  Consistent with the foregoing, CFO shall not provide to the Company and&#47;or its Affiliates, and the Company and&#47;or its Affiliates shall not request, any documents or copies of documents containing such information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;ADVERTISING WAIVER.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CFO agrees to permit the Company, and persons or other organizations authorized by the Company, to use, publish and distribute advertising or sales promotional literature concerning the products and&#47;or services of the Company, or the machinery and equipment used in the provision thereof, in which CFO&#8217;s name and&#47;or pictures of CFO taken in the course of CFO&#8217;s provision of services to the Company appear.  CFO hereby waives and releases any claim or right CFO may otherwise have arising out of such use, publication or distribution.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="ib9fd5a6785884fab8d7610aed4fce4a9_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Parties have executed the Agreement as of the date below.</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ANAPTYSBIO, INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Hamza Suria</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; &#160;&#160;&#160;&#160;Hamza Suria</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;President &#38; CEO</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;&#160;&#160;July 15, 2020</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CFO&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Dennis Mulroy</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DENNIS MULROY</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;&#160;&#160;July 15, 2020</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;SIGNATURE PAGE TO EMPLOYMENT AGREEMENT&#93;</font></div></div></div><div id="ib9fd5a6785884fab8d7610aed4fce4a9_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RELEASE AND WAIVER OF CLAIMS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TO BE SIGNED ON OR FOLLOWING THE SEPARATION DATE ONLY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In consideration of the payments and other benefits set forth in the Employment Agreement effective July 15, 2020, to which this form is attached, I, Dennis Mulroy, hereby furnish AnaptysBio, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), with the following release and waiver (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Release and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In exchange for the consideration provided to me by the Employment Agreement that I am not otherwise entitled to receive, I hereby generally and completely release the Company and its current and former directors, officers, employees, stockholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Released Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date that I sign this Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Released Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The Released Claims include, but are not limited to&#58; (a) all claims arising out of or in any way related to my employment with the Company, or the termination of that employment&#59; (b) all claims related to my compensation or benefits from the Company including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company&#59; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing&#59; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy&#59; and (e) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, misclassification, attorneys&#8217; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ADEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the California Labor Code, and the California Fair Employment and Housing Act (as amended).  Notwithstanding the foregoing, the following are not included in the Released Claims (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Excluded Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58; (a) any rights or claims for indemnification I may have pursuant to the charter or bylaws of the Company or under applicable law&#59; (b) any rights or claims to unemployment compensation, funds accrued in my 401k account, or any vested equity incentives&#59; (c) any rights that are not waivable as a matter of law&#59; or (d) any claims arising from the breach of this Agreement.  I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or might have against any of the Released Parties that are not included in the Released Claims.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I also acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows&#58; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221; I hereby expressly waive and relinquish all rights and benefits under that Section and any law of any jurisdiction, including New York, of similar effect with respect to any claims I may have against the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I acknowledge that, among other rights, I am waiving and releasing any rights I may have under ADEA, that this Release and Waiver is knowing and voluntary, and that the consideration given for this Release and Waiver is in addition to anything of value to which I was already entitled as an executive of the Company.  I further acknowledge that I have been advised, as required by the Older Workers Benefit Protection Act, that&#58; (a) the release and waiver granted herein does not relate to claims under the ADEA which may arise after this Release and Waiver is executed&#59; (b) I should consult with an attorney prior to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">executing this Release and Waiver&#59; and (c) if I am age 40 or older at the time of execution of this release, I have 21 days from the date of termination of my employment with the Company in which to consider this Release and Waiver (although I may choose voluntarily to execute this Release and Waiver earlier)&#59; and (d) if I am age 40 or older at the time of execution of this release, I have seven days following the execution of this Release and Waiver to revoke my consent to this Release and Waiver and this Release and Waiver shall not be effective until the seven day revocation period has expired without my having previously revoked this Release and Waiver. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I agree not to disparage the Company and its officers, directors, employees, shareholders and&#47;or agents, in any manner likely to be harmful to them or their business, business reputations or personal reputations&#59; provided that I may respond accurately and fully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I acknowledge my continuing obligations under my Proprietary Information and Inventions Agreement.  Pursuant to the Proprietary Information and Inventions Agreement I understand that among other things, I must not use or disclose any confidential or proprietary information of the Company and I must immediately return all Company property and documents (including all embodiments of proprietary information) and all copies thereof in my possession or control.  I understand and agree that my right to the severance pay I am receiving in exchange for my agreement to the terms of this Release and Waiver is contingent upon my continued compliance with my Proprietary Information and Inventions Agreement. </font></div><div style="margin-bottom:30pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Release and Waiver constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof.  I am not relying on any promise or representation by the Company that is not expressly stated herein.  This Release and Waiver may only be modified by a writing signed by both me and a duly authorized officer of the Company.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;DENNIS MULROY</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>4
<FILENAME>lizzulemploymentagreem.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i6941f64b216042be82dad2867eefe095_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ANAPTYSBIO, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EMPLOYMENT AGREEMENT</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EMPLOYMENT AGREEMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is made effective from July 31, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) by and among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ANAPTYSBIO, INC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and Paul Lizzul, MD (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The Company and CMO are hereinafter collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,&#8221; and individually referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">RECITAL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company desires to employ CMO, and CMO is willing to accept such employment by Company, on the terms and subject to the conditions set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In consideration of the foregoing Recitals and the mutual promises and covenants herein contained, and for other good and valuable consideration, the Parties, intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;EMPLOYMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.1&#160;&#160;&#160;&#160;Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Effective as of the Effective Date, CMO&#8217;s position shall be Chief Medical Officer of the Company, subject to the terms and conditions set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.2&#160;&#160;&#160;&#160;Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The term of this Agreement shall begin on the Effective Date and shall continue until it is terminated pursuant to Section 4 herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.3&#160;&#160;&#160;&#160;Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CMO shall do and perform all services, acts or things necessary or advisable to manage and conduct the business of the Company and that are normally associated with the position of Chief Medical Officer of the Company.  CMO shall report to the Chief Executive Officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.4&#160;&#160;&#160;&#160;Policies and Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The employment relationship between the Parties shall be governed by this Agreement and by the policies and practices established by the Company and&#47;or the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or any designated committee thereof.  In the event that the terms of this Agreement differ from or are in conflict with the Company&#8217;s policies or practices or the Company&#8217;s Employee Handbook, this Agreement shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.5&#160;&#160;&#160;&#160;Location</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Unless the Parties otherwise agree in writing or as permitted from time to time by the Chief Executive Officer, and except as provided in this Section 1.5, during the Term CMO shall perform the services CMO is required to perform pursuant to this Agreement at least two (2) days per calendar week from the Company&#8217;s offices in San Diego, California&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the Company may from time to time require CMO to travel temporarily to other locations in connection with the Company&#8217;s business&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, upon the Effective Date, and until applicable government COVID-19 quarantine restrictions applicable to the San Diego office are lifted and the San Diego office reopens, the Company will allow CMO to perform the services remotely from CMO&#8217;s home.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;LOYALTY&#59; NONCOMPETITION&#59; NONSOLICITATION.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;Loyalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  During CMO&#8217;s employment with the Company, CMO shall devote CMO&#8217;s full business energies, interest, abilities and productive time to the proper and efficient performance of CMO&#8217;s duties under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.2&#160;&#160;&#160;&#160;Agreement not to Participate in Company&#8217;s Competitors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  During CMO&#8217;s employment with the Company, CMO agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by CMO to be adverse or antagonistic to the Company, its business, or prospects, financial or otherwise, or in any company, person, or entity that is, directly or indirectly, in competition with the business of the Company or any of its Affiliates (as defined below).  Ownership by CMO, in professionally managed funds over which CMO does not have control or discretion in investment decisions, or as a passive investment, of less than two percent (2%) of the outstanding shares of capital stock of any corporation with one or more classes of its capital stock listed on a national securities exchange or publicly traded on a national securities exchange or in the over-the-counter market shall not constitute a breach of this Section.  For purposes of this Agreement, &#8220;Affiliate,&#8221; means, with respect to any specific entity, any other entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such specified entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.3&#160;&#160;&#160;&#160;Covenant not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  During CMO&#8217;s employment with the Company, CMO shall not engage in competition with the Company and&#47;or any of its Affiliates in any manner or capacity, as adviser, principal, agent, Affiliate, promoter, partner, officer, director, employee, owner, co-owner, consultant, in any phase of the business of developing, manufacturing and marketing of products or services that directly compete with the products or services of the Company, except with the prior written consent of the CEO.  CMO shall be entitled to request written consent of the CEO with respect to potential advisory and&#47;or director opportunities presented to CMO by a third party, which CMO believes in good faith will not interfere or compete with the on-going business of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;COMPENSATION OF CMO.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company shall pay CMO a base salary at the annualized rate of $400,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), less payroll deductions and all required withholdings, payable in regular periodic installments in accordance with the Company&#8217;s normal payroll practices.  The Base Salary shall be prorated for any partial year of employment on the basis of a 365-day fiscal year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;Discretionary Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  At the sole discretion of the Board and the Chief Executive Officer, promptly following each calendar year of employment CMO shall be eligible to receive a discretionary cash bonus of up to 40% of CMO&#8217;s then-current base salary (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), based on CMO&#8217;s achievement relative to certain performance goals (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to be established by the Chief Executive Officer and&#47;or the Board or the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in writing in a manner reasonably consistent with the Company&#8217;s priorities.  The determination of whether CMO has met the Performance Goals for any given year, and if so, the amount of any Bonus that will be paid for such year (if any), shall be determined by the Board or the Committee and Chief Executive Officer in their sole and absolute discretion.  In order to be eligible to earn or receive any Bonus, CMO must remain employed by the Company through and including the date of payment of such Bonus.  For the first calendar year of CMO&#8217;s employment with the Company, the Bonus payable shall be pro-rated in accordance with the percentage of the calendar year that the CMO is an employee of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.3&#160;&#160;&#160;&#160;Sign-On Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company agrees to pay CMO an aggregate&#160;sign-on&#160;bonus of $100,000 (the &#8220;Sign-On Bonus&#8221;).  The Sign-On Bonus will be paid in one lump sum in a separate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">check on the next regularly scheduled pay date after the Effective Date. The Sign-On Bonus is taxable, and all regular payroll taxes will be withheld.  The Sign-On Bonus is subject to the following vesting schedule&#58;  1&#47;24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of the Sign-On Bonus shall vest on each monthly anniversary of the Effective Date.  In the event that CMO&#8217;s employment is terminated by the Company for Cause or by CMO without Good Reason (both as hereinafter defined) prior to the second anniversary of the Effective Date, CMO shall be required to pay back the Company, within 30 days after such termination, any unvested portion of the Sign-On Bonus as of the dated of such termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.4&#160;&#160;&#160;&#160;Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  As soon as practicable following the Effective Date, subject to the approval of the Board or the Committee, CMO will be granted an option to purchase up to 90,000 shares of the Company&#8217;s Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Base Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) pursuant to the terms of the Company&#8217;s 2017 Equity Incentive Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The Base Option shall be subject to vesting such that, subject to CMO&#8217;s continued employment with the Company, 1&#47;4 of the shares subject to the Base Option shall vest as of the first anniversary of the Effective Date and l&#47;48th of the shares subject to the Base Option shall vest in equal monthly installments on the monthly anniversary of the Effective Date of each month for the 36 months thereafter.  The exercise price per share of the Base Option will be equal to the closing selling price as reported on the Nasdaq Stock Market on the date the Base Option is granted.  The Base Option will be governed by the Plan and shall be granted pursuant to a separate stock option grant notice and stock option agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.5&#160;&#160;&#160;&#160;Expense Reimbursements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company will reimburse CMO for all  reasonable business expenses CMO incurs in conducting his duties hereunder, including all reasonable Commuting Expenses (as defined below), pursuant to the Company&#8217;s usual expense reimbursement policies&#59; provided that CMO supplies the appropriate substantiation for such expenses no later than the end of the calendar month following the month in which such expenses were incurred by CMO.  &#8220;Commuting Expenses&#8221; shall mean all reasonable travel and lodging expenses incurred by CMO in connection with CMO&#8217;s travel from his home in Oak Park, California to the Company&#8217;s offices in San Diego, California.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.6&#160;&#160;&#160;&#160;Changes to Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CMO&#8217;s compensation will be reviewed annually and may be changed from time to time in the Company&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.7&#160;&#160;&#160;&#160;Employment Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  All of CMO&#8217;s compensation shall be subject to customary withholding taxes and any other employment taxes as are commonly required to be collected or withheld by the Company, as determined by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.8&#160;&#160;&#160;&#160;Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CMO shall, in accordance with Company policy and the terms of the applicable plan documents, be eligible to participate in benefits under any benefit plan or arrangement that may be in effect from time to time and made available to the Company&#8217;s senior management employees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.9&#160;&#160;&#160;&#160;Holidays and Vacation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CMO shall be eligible for paid holiday and vacation time in accordance with Company policy as in effect from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;TERMINATION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;Termination by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CMO&#8217;s employment with the Company is at will and may be terminated by the Company at any time and for any reason, or for no reason, including, but not limited to, under the following conditions&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.1.1&#160;&#160;&#160;&#160;Termination by the Company for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company may terminate CMO&#8217;s employment under this Agreement for Cause (as defined below) by delivery of written notice to CMO.  Any notice of termination given pursuant to this section shall effect termination as of the date of the notice, or as of such other date specified in the notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.1.2&#160;&#160;&#160;&#160;Termination by the Company without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company may terminate CMO&#8217;s employment under this Agreement without Cause at any time and for any reason, or for no reason.  Such termination shall be effective on the date CMO is so informed, or as otherwise specified by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.2&#160;&#160;&#160;&#160;Termination by CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CMO may terminate his employment with the Company at any time and for any reason, or for no reason, upon thirty (30) days written notice to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.3&#160;&#160;&#160;&#160;Termination for Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CMO&#8217;s employment with the Company shall automatically terminate effective upon the date of CMO&#8217;s death or Disability (as defined in the Plan).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.4&#160;&#160;&#160;&#160;Termination by Mutual Agreement of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  CMO&#8217;s employment with the Company may be terminated at any time upon a mutual agreement in writing of the Parties.  Any such termination of employment shall have the consequences specified in such agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5&#160;&#160;&#160;&#160;Compensation upon Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5.1&#160;&#160;&#160;&#160;Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If CMO&#8217;s employment is terminated by death or Disability, the Company shall pay to CMO, or to CMO&#8217;s heirs, CMO&#8217;s accrued and unpaid base salary and accrued and unused vacation benefits earned through the date of termination at the rate in effect at the time of termination, less standard deductions and withholdings.  The Company shall thereafter have no further obligations to CMO and&#47;or CMO&#8217;s heirs under this Agreement, except as otherwise provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5.2&#160;&#160;&#160;&#160;Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If the Company terminates CMO&#8217;s employment for Cause, then the Company shall pay CMO&#8217;s accrued and unpaid base salary and accrued and unused vacation benefits earned through the date of termination, at the rate in effect at the time of termination, less standard deductions and withholdings.  The Company shall thereafter have no further obligations to CMO under this Agreement, except as otherwise provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5.3&#160;&#160;&#160;&#160;Termination by Company without Cause or by CMO for Good Reason Not In Connection with a Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If the Company terminates CMO&#8217;s employment without Cause or if CMO resigns his employment for Good Reason (as defined below), in either case at any time other than upon the occurrence of, or within the 13 months immediately following, the effective date of a Change in Control, the Company shall pay CMO&#8217;s accrued and unpaid base salary and accrued and unused vacation benefits earned through the date of termination, at the rate in effect at the time of termination, less standard deductions and withholdings.  In addition to the above, if CMO furnishes to the Company an executed waiver and release of claims in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (or in such other form as may be specified by the Company) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) within the time period specified therein, but in no event later than 45 days following CMO&#8217;s termination, and if CMO allows such Release to become effective in accordance with its terms, then (i) CMO shall be entitled to severance in the form of continuation of his base salary, at the base salary rate equal to the greater of the rate in effect at the time of termination or the rate immediately prior to the event giving rise to Good Reason (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Severance Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), for a period of nine (9) months following the termination date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii) if CMO timely elects COBRA coverage, the Company will pay directly to the insurance provider the premium for COBRA continuation coverage for CMO and CMO&#8217;s family during the Severance Period or until he obtains new employment, whichever comes first (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">COBRA Coverage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that, if the Company determines that it cannot provide the COBRA Coverage without potentially violating applicable law or incurring additional expense under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company will provide CMO, in lieu thereof, taxable, continued installment payments equal to the COBRA premium, payable on the last day of a given month, for 9 months (measured from the termination date), which payments will be made regardless of whether CMO elects COBRA continuation coverage (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">COBRA Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Notwithstanding the foregoing, the number of months of COBRA Bonus to be paid, in any case, shall be reduced by the number of months of COBRA Coverage previously paid by the Company.  The Severance Payments will be subject to standard payroll deductions and withholdings and will be made on the Company&#8217;s regular payroll cycle, provided, however, that any Severance Payments otherwise scheduled to be made prior to the effective date of the Release shall accrue and be paid in the first payroll period that follows such effective date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if the 45 day period to execute the Release spans two calendar years, no Severance Payments will be made until the later calendar year.  The Company shall thereafter have no further obligations to CMO under this Agreement, except as otherwise provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.5.4&#160;&#160;&#160;&#160;Termination by Company without Cause or by CMO for Good Reason in Connection with a Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If the Company terminates CMO&#8217;s employment without Cause or if CMO resigns his employment for Good Reason, in either case upon the occurrence of, or within the 13 months immediately following, the effective date of a Change in Control, the Company shall pay CMO&#8217;s accrued and unpaid base salary and accrued and unused vacation benefits earned through the date of termination, at the rate in effect at the time of termination, less standard deductions and withholdings.  In addition, if CMO furnishes to the Company an executed Release within the time period specified therein, but in no event later than 45 days following CMO&#8217;s termination, and if CMO allows such Release to become effective in accordance with its terms, then CMO shall be entitled to&#58; (1) the Severance Payments and COBRA payments described in Section 4.5.3 above&#59; provided, however, that the Severance Payments and COBRA payments shall be increased from 9 months to 12 months and (2) accelerated vesting of all of CMO&#8217;s unvested Company equity awards, such that CMO shall become vested in 100% of the shares subject to all such equity awards on the effective date of the Release&#59; provided, however, that the vesting of any performance-based awards shall be as if all applicable performance criteria were achieved at target levels.  The Company shall thereafter have no further obligations to CMO under this Agreement, except as otherwise provided by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.6&#160;&#160;&#160;&#160;Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  For purposes of this Agreement, the following terms shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the occurrence of any one or more of the following&#58; (i) CMO&#8217;s commission of any crime involving fraud, dishonesty or moral turpitude&#59; (ii) CMO&#8217;s attempted commission of or participation in a fraud or act of dishonesty against the Company that results in (or might have reasonably resulted in) material harm to the business of the Company&#59; (iii) CMO&#8217;s intentional, material violation of any contract or agreement between CMO and the Company or any statutory duty CMO owes to the Company&#59; or (iv) CMO&#8217;s conduct that constitutes gross insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the action or conduct described in clauses (iii) and (iv) above will constitute &#8220;Cause&#8221; only if such action or conduct continues after the Company has provided CMO with written notice thereof and thirty (30) days to cure, or otherwise remedy to the extent possible under direct control of the CMO, the same.  An occurrence of &#8220;Cause&#8221; as set forth in the preceding </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sentence shall be based upon a good faith determination by the Board.  CMO&#8217;s Disability shall not constitute Cause as set forth herein.  The determination that a termination is for Cause shall be by the Board in its sole and exclusive judgment and discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Amended and Restated 2006 Equity Incentive Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any of the following actions&#58; (i) the assignment to CMO of any duties or responsibilities that results in a material diminution in CMO&#8217;s function as in effect immediately prior to the effective date of the Change in Control&#59; provided, however, that it will be considered a material diminution in CMO&#8217;s function if, following a Change in Control, the CMO is not reporting directly to the Chief Executive Officer who is in turn reporting to the Company&#8217;s (or if applicable ultimate parent entity&#8217;s) corporate board of directors&#59; (ii) a reduction by the Company in CMO&#8217;s annual base salary as in effect on the effective date of the Change in Control&#59; provided, however, that Good Reason shall not be deemed to have occurred in the event of a reduction in CMO&#8217;s annual base salary that is pursuant to a salary reduction program affecting substantially all of the employees of the Company and that does not adversely affect CMO to a greater extent than other similarly situated employees&#59; or (iii) a relocation of CMO&#8217;s primary business office to a location more than 50 miles from the location of CMO&#8217;s primary business office as of the effective date of the Change in Control, except for required travel by CMO on the Company&#8217;s business to an extent substantially consistent with CMO&#8217;s business travel obligations prior to the effective date of the Change in Control.  For the purposes of application of this definition of Good Reason to Section 4.5.3, the words &#8220;as in effect immediately prior to the effective date of the Change in Control&#8221; shall be read to mean as of, or immediately prior to, the date of the event giving rise to Good Reason.  In all events, in order for a termination for Good Reason to occur, the CMO must provide the Company with written notice of the condition constituting Good Reason within 90 days of the initial occurrence of such condition, and allow the Company a 30-day cure period in which to cure such condition, and the CMO must resign employment within 10 days of the end of such 30-day cure period if the Company does not cure the condition in such cure period.  For clarity, &#8220;corporate board of directors&#8221; as used in the definition of Good Reason means the Company&#8217;s (or if applicable ultimate parent entity&#8217;s) board of directors as such term is used in Section 141 of the Delaware General Corporation Law, or if the Company (or if applicable ultimate parent entity) is not a corporation organized under Delaware law, the most senior governing body of the Company (or if applicable ultimate parent entity) the majority of which is comprised of non-employee and independent members and has responsibility and authority for managing the business and affairs of the Company (or if applicable ultimate parent entity).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.7&#160;&#160;&#160;&#160;Survival of Certain Sections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Sections 3.5, 3.7 and 4 through 18 of this Agreement will survive the termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.8&#160;&#160;&#160;&#160;Parachute Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If any payment or benefit CMO would receive pursuant to this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) would (i) constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Parachute Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then such Payment shall be equal to the Reduced Amount.  The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Reduced Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in CMO&#8217;s receipt, on an after-tax basis, of the greatest economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tax.  If a reduction in payments or benefits constituting Parachute Payments is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit for CMO.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event it is subsequently determined by the Internal Revenue Service that some portion of the Reduced Amount (as determined pursuant to clause (x) in the preceding paragraph) is subject to the Excise Tax, CMO agrees to promptly return to the Company a sufficient amount of the Payment so that no portion of the Reduced Amount is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount is determined in accordance with clause (y) in the preceding paragraph, CMO will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unless CMO and the Company agree on an alternative accounting or law firm, the accounting firm then engaged by the Company for general tax compliance purposes shall perform the foregoing calculations.  If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting, law or consulting firm to make the determinations required hereunder.  The Company shall bear all expenses with respect to the determinations by such accounting, law or consulting firm required to be made hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company shall use commercially reasonable efforts such that the accounting, law or consulting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to CMO and the Company within 15 calendar days after the date on which CMO&#8217;s right to a Payment is triggered (if requested at that time by CMO or the Company) or such other time as requested by CMO or the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.9&#160;&#160;&#160;&#160;Application of Internal Revenue Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that constitute &#8220;deferred compensation&#8221; within the meaning of Section 409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall not commence in connection with CMO&#8217;s termination of employment unless and until CMO has also incurred a &#8220;separation from service&#8221; (as such term is defined in Treasury Regulation Section 1.409A-1(h)) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Separation From Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), unless the Company reasonably determines that such amounts may be provided to CMO without causing CMO to incur the additional 20% tax under Section 409A. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is intended that each installment of the Severance Benefits payments provided for in this Agreement is a separate &#8220;payment&#8221; for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i).  For the avoidance of doubt, it is intended that payments of the Severance Benefits set forth in this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9).  However, if the Company (or, if applicable, the successor entity thereto) determines that the Severance Benefits constitute &#8220;deferred compensation&#8221; under Section 409A and CMO is, on the termination of service, a &#8220;specified employee&#8221; of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Severance Benefit payments shall be delayed until the earlier to occur of&#58; (i) the date that is six months and one day after CMO&#8217;s Separation From Service, or (ii) the date of CMO&#8217;s death (such applicable date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Specified Employee Initial Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the Company (or the successor entity thereto, as applicable) shall (A) pay to CMO a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">lump sum amount equal to the sum of the Severance Benefit payments that CMO would otherwise have received through the Specified Employee Initial Payment Date if the commencement of the payment of the Severance Benefits had not been so delayed pursuant to this Section and (B) commence paying the balance of the Severance Benefits in accordance with the applicable payment schedules set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary set forth herein, CMO shall receive the Severance Benefits described above, if and only if CMO duly executes and returns to the Company within the applicable time period set forth therein, but in no event more than forty-five days following Separation From Service, the Release and permits the Release to become effective in accordance with its terms.  Notwithstanding any other payment schedule set forth in this Agreement, none of the Severance Benefits will be paid or otherwise delivered prior to the effective date of the Release.  Except to the extent that payments may be delayed until the Specified Employee Initial Payment Date pursuant to the preceding paragraph, on the first regular payroll pay day following the effective date of the Release, the Company will pay CMO the Severance Benefits that CMO would otherwise have received under the Agreement on or prior to such date but for the delay in payment related to the effectiveness of the Release, with the balance of the Severance Benefits being paid as originally scheduled.  All amounts payable under the Agreement will be subject to standard payroll taxes and deductions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;CONFIDENTIAL AND PROPRIETARY INFORMATION.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  CMO has already executed, as a condition of CMO&#8217;s employment with the Company, the Company&#8217;s standard form of Proprietary Information and Inventions Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">PIIA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The PIIA remains in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;ASSIGNMENT AND BINDING EFFECT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement shall be binding upon and inure to the benefit of CMO and CMO&#8217;s heirs, executors, personal representatives, assigns, administrators and legal representatives.  Because of the unique and personal nature of CMO&#8217;s duties under this Agreement, neither this Agreement nor any rights or obligations under this Agreement shall be assignable by CMO.  This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives.  Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes.  For this purpose, &#8220;successor&#8221; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;NOTICES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All notices or demands of any kind required or permitted to be given by the Company or CMO under this Agreement shall be given in writing and shall be personally delivered (and receipted for) or faxed during normal business hours or mailed by certified mail, return receipt requested, postage prepaid, addressed as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">If to the Company&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10421 Pacific Center Court, Suite 200</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">San Diego, CA 92121</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Chief Executive Officer</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">If to CMO&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Paul Lizzul, MD</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">788 Sassafrass Way</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Oak Park, CA 91377</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any such written notice shall be deemed given on the earlier of the date on which such notice is personally delivered or three days after its deposit in the United States mail as specified above.  Either Party may change its address for notices by giving notice to the other Party in the manner specified in this Section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;CHOICE OF LAW.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement shall be construed and interpreted in accordance with the internal laws of the State of California without regard to its conflict of laws principles.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;INTEGRATION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the PIIA, contains the complete, final and exclusive agreement of the Parties relating to the terms and conditions of CMO&#8217;s employment and the termination of CMO&#8217;s employment, and supersedes any and all prior and&#47;or contemporaneous oral and written employment agreements or arrangements between the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;AMENDMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement cannot be amended or modified except by a written agreement signed by CMO and the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;WAIVER.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with the written consent of the Party against whom the wavier is claimed, and any waiver or any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;SEVERABILITY.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The finding by a court of competent jurisdiction of the unenforceability, invalidity or illegality of any provision of this Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal.  Such court shall have the authority to modify or replace the invalid or unenforceable term or provision with a valid and enforceable term or provision, which most accurately represents the Parties&#8217; intention with respect to the invalid or unenforceable term, or provision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;INTERPRETATION&#59; CONSTRUCTION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The headings set forth in this Agreement are for convenience of reference only and shall not be used in interpreting this Agreement.  This Agreement has been drafted by legal counsel representing the Company, but CMO has been encouraged to consult with, and has consulted with, CMO&#8217;s own independent counsel and tax advisors with respect to the terms of this Agreement.  The Parties acknowledge that each Party and its counsel has reviewed and revised, or had an opportunity to review </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and revise, this Agreement, and any rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;REPRESENTATIONS AND WARRANTIES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CMO represents and warrants that CMO is not restricted or prohibited, contractually or otherwise, from entering into and performing each of the terms and covenants contained in this Agreement, and that CMO&#8217;s execution and performance of this Agreement will not violate or breach any other agreements between CMO and any other person or entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;COUNTERPARTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement may be executed in two counterparts, each of which shall be deemed an original, all of which together shall contribute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;ARBITRATION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To ensure the rapid and economical resolution of disputes that may arise in connection with CMO&#8217;s employment with the Company, CMO and the Company agree that any and all disputes, claims, or causes of action, in law or equity, arising from or relating to CMO&#8217;s employment, or the termination of that employment, will be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration pursuant to both the substantive and procedural provisions of the Federal Arbitration Act in San Diego, California conducted by the Judicial Arbitration and Mediation Services&#47;Endispute, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or its successors, under the then current rules of JAMS for employment disputes&#59; provided that the arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; and (b) issue a written arbitration decision including the arbitrator&#8217;s essential findings and conclusions and a statement of the award.  Accordingly, CMO and the Company hereby waive any right to a jury trial.  Both CMO and the Company shall be entitled to all rights and remedies that either CMO or the Company would be entitled to pursue in a court of law.  The Company shall pay any JAMS filing fee and shall pay the arbitrator&#8217;s fee.  Nothing in this Agreement is intended to prevent either CMO or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  Notwithstanding the foregoing, CMO and the Company each have the right to resolve any issue or dispute involving confidential, proprietary or trade secret information, or intellectual property rights, by Court action instead of arbitration. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;TRADE SECRETS OF OTHERS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is the understanding of both the Company and CMO that CMO shall not divulge to the Company and&#47;or its subsidiaries any confidential information or trade secrets belonging to others, including CMO&#8217;s former employers, nor shall the Company and&#47;or its Affiliates seek to elicit from CMO any such information.  Consistent with the foregoing, CMO shall not provide to the Company and&#47;or its Affiliates, and the Company and&#47;or its Affiliates shall not request, any documents or copies of documents containing such information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;ADVERTISING WAIVER.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CMO agrees to permit the Company, and persons or other organizations authorized by the Company, to use, publish and distribute advertising or sales promotional literature concerning the products and&#47;or services of the Company, or the machinery and equipment used in the provision thereof, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in which CMO&#8217;s name and&#47;or pictures of CMO taken in the course of CMO&#8217;s provision of services to the Company appear.  CMO hereby waives and releases any claim or right CMO may otherwise have arising out of such use, publication or distribution.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div></div></div><div id="i6941f64b216042be82dad2867eefe095_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Parties have executed the Agreement as of the date below.</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ANAPTYSBIO, INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Hamza Suria</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; &#160;&#160;&#160;&#160;Hamza Suria</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;President &#38; CEO</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;&#160;&#160;July 20, 2020</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CMO&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Paul Lizzul</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PAUL LIZZUL, MD</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;&#160;&#160;July 19, 2020</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;SIGNATURE PAGE TO EMPLOYMENT AGREEMENT&#93;</font></div></div></div><div id="i6941f64b216042be82dad2867eefe095_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RELEASE AND WAIVER OF CLAIMS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TO BE SIGNED ON OR FOLLOWING THE SEPARATION DATE ONLY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In consideration of the payments and other benefits set forth in the Employment Agreement effective July 31, 2020, to which this form is attached, I, Paul Lizzul, MD, hereby furnish AnaptysBio, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), with the following release and waiver (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Release and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In exchange for the consideration provided to me by the Employment Agreement that I am not otherwise entitled to receive, I hereby generally and completely release the Company and its current and former directors, officers, employees, stockholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Released Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date that I sign this Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Released Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The Released Claims include, but are not limited to&#58; (a) all claims arising out of or in any way related to my employment with the Company, or the termination of that employment&#59; (b) all claims related to my compensation or benefits from the Company including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company&#59; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing&#59; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy&#59; and (e) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, misclassification, attorneys&#8217; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ADEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the California Labor Code, and the California Fair Employment and Housing Act (as amended).  Notwithstanding the foregoing, the following are not included in the Released Claims (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Excluded Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58; (a) any rights or claims for indemnification I may have pursuant to the charter or bylaws of the Company or under applicable law&#59; (b) any rights or claims to unemployment compensation, funds accrued in my 401k account, or any vested equity incentives&#59; (c) any rights that are not waivable as a matter of law&#59; or (d) any claims arising from the breach of this Agreement.  I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or might have against any of the Released Parties that are not included in the Released Claims.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I also acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows&#58; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221; I hereby expressly waive and relinquish all rights and benefits under that Section and any law of any jurisdiction, including New York, of similar effect with respect to any claims I may have against the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I acknowledge that, among other rights, I am waiving and releasing any rights I may have under ADEA, that this Release and Waiver is knowing and voluntary, and that the consideration given for this Release and Waiver is in addition to anything of value to which I was already entitled as an executive of the Company.  I further acknowledge that I have been advised, as required by the Older Workers Benefit Protection Act, that&#58; (a) the release and waiver granted herein does not relate to claims under the ADEA which may arise after this Release and Waiver is executed&#59; (b) I should consult with an attorney prior to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">executing this Release and Waiver&#59; and (c) if I am age 40 or older at the time of execution of this release, I have 21 days from the date of termination of my employment with the Company in which to consider this Release and Waiver (although I may choose voluntarily to execute this Release and Waiver earlier)&#59; and (d) if I am age 40 or older at the time of execution of this release, I have seven days following the execution of this Release and Waiver to revoke my consent to this Release and Waiver and this Release and Waiver shall not be effective until the seven day revocation period has expired without my having previously revoked this Release and Waiver. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I agree not to disparage the Company and its officers, directors, employees, shareholders and&#47;or agents, in any manner likely to be harmful to them or their business, business reputations or personal reputations&#59; provided that I may respond accurately and fully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I acknowledge my continuing obligations under my Proprietary Information and Inventions Agreement.  Pursuant to the Proprietary Information and Inventions Agreement I understand that among other things, I must not use or disclose any confidential or proprietary information of the Company and I must immediately return all Company property and documents (including all embodiments of proprietary information) and all copies thereof in my possession or control.  I understand and agree that my right to the severance pay I am receiving in exchange for my agreement to the terms of this Release and Waiver is contingent upon my continued compliance with my Proprietary Information and Inventions Agreement. </font></div><div style="margin-bottom:30pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Release and Waiver constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof.  I am not relying on any promise or representation by the Company that is not expressly stated herein.  This Release and Waiver may only be modified by a writing signed by both me and a duly authorized officer of the Company.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;PAUL LIZZUL, MD</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>anab-93020x10qxexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ida95c54ed31f41a89b5033648211c8ce_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">I, Hamza Suria, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this quarterly report on Form 10-Q of AnaptysBio, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control&#160;over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially&#160;affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;4, 2020 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.903%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Hamza Suria</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hamza Suria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>anab-93020x10qxexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i023d762ee44d443bb26121a9ef0ccd18_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">I, Dennis Mulroy, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">1. I have reviewed this quarterly report on Form 10-Q of AnaptysBio, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control&#160;over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially&#160;affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;4, 2020</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.897%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Dennis Mulroy</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dennis Mulroy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>anab-93020x10qxexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i3324cd12d8c14c3f856ffab81c5f3b83_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, I, Hamza Suria, Chief Executive Officer of AnaptysBio, Inc. (the &#34;Company&#34;), do hereby certify that to my knowledge&#58; </font></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended September&#160;30, 2020 (the &#8220;Report&#8221;), as filed with the Securities and Exchange Commission, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;4, 2020 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.903%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Hamza Suria</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hamza Suria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">)</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>anab-93020x10qxexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="icded31d05066497abdc6004a89b3b999_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, I, Dennis Mulroy, Chief Financial Officer of AnaptysBio, Inc. (the &#34;Company&#34;), do hereby certify, that to my knowledge&#58; </font></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended September&#160;30, 2020 (the &#8220;Report&#8221;), as filed with the Securities and Exchange Commission, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;4, 2020</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:59.455%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Dennis Mulroy</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dennis Mulroy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>anab-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:721272a1-28f6-479d-8921-55bf3792b729,g:e6e63eaa-4a73-42e1-87eb-dda12e114757-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:anab="http://www.anaptysbio.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.anaptysbio.com/20200930">
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.anaptysbio.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical">
        <link:definition>1004005 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofStockholdersEquity" roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity">
        <link:definition>1005006 - Statement - Consolidated Statement of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusiness" roleURI="http://www.anaptysbio.com/role/DescriptionoftheBusiness">
        <link:definition>2101101 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2405401 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails" roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsandSupplementalDisclosures" roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures">
        <link:definition>2107103 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsandSupplementalDisclosuresTables" roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables">
        <link:definition>2308302 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails" roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails">
        <link:definition>2409403 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails" roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails">
        <link:definition>2410404 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchandDevelopmentAgreements" roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements">
        <link:definition>2111104 - Disclosure - Collaborative Research and Development Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchandDevelopmentAgreementsTables" roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables">
        <link:definition>2312303 - Disclosure - Collaborative Research and Development Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchandDevelopmentAgreementsDetails" roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails">
        <link:definition>2413405 - Disclosure - Collaborative Research and Development Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayable" roleURI="http://www.anaptysbio.com/role/NotesPayable">
        <link:definition>2114105 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableDetails" roleURI="http://www.anaptysbio.com/role/NotesPayableDetails">
        <link:definition>2415406 - Disclosure - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestments" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments">
        <link:definition>2116106 - Disclosure - Fair Value Measurements and Available for Sale Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestmentsTables" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables">
        <link:definition>2317304 - Disclosure - Fair Value Measurements and Available for Sale Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2418407 - Disclosure - Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails">
        <link:definition>2419408 - Disclosure - Fair Value Measurements and Available for Sale Investments - Fair Value of Other Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails">
        <link:definition>2420409 - Disclosure - Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails">
        <link:definition>2421410 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.anaptysbio.com/role/StockholdersEquity">
        <link:definition>2122107 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.anaptysbio.com/role/StockholdersEquityTables">
        <link:definition>2323305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>2424411 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails" roleURI="http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails">
        <link:definition>2425412 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlans" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlans">
        <link:definition>2126108 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansTables" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansTables">
        <link:definition>2327306 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansNarrativeDetails" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails">
        <link:definition>2428413 - Disclosure - Equity Incentive Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansOptionActivityDetails" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails">
        <link:definition>2429414 - Disclosure - Equity Incentive Plans - Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansOptionFairValueAssumptionsDetails" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails">
        <link:definition>2430415 - Disclosure - Equity Incentive Plans - Option Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails">
        <link:definition>2431416 - Disclosure - Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.anaptysbio.com/role/CommitmentsandContingencies">
        <link:definition>2132109 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesTables">
        <link:definition>2333307 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2434417 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesClassificationontheBalanceSheetDetails" roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails">
        <link:definition>2435418 - Disclosure - Commitments and Contingencies - Classification on the Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails" roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails">
        <link:definition>2436419 - Disclosure - Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails" roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails">
        <link:definition>2437420 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1" roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1">
        <link:definition>2437420 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.anaptysbio.com/role/SubsequentEvents">
        <link:definition>2138110 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://www.anaptysbio.com/role/SubsequentEventDetails">
        <link:definition>2439421 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" abstract="true" name="AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_TermBLoansAndTermCLoansMember" abstract="true" name="TermBLoansAndTermCLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_LeaseArrangementAxis" abstract="true" name="LeaseArrangementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="anab_TermALoansMember" abstract="true" name="TermALoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="anab_LeaseArrangementDomain" abstract="true" name="LeaseArrangementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_LesseeOperatingLeaseNumber" abstract="false" name="LesseeOperatingLeaseNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anab_RentPerSquareFoot" abstract="false" name="RentPerSquareFoot" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="srt-types:perUnitItemType"/>
  <xs:element id="anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member" abstract="true" name="AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_Phase2ClinicalTrialInitiationMember" abstract="true" name="Phase2ClinicalTrialInitiationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_DebtInstrumentMaximumBorrowingCapacity" abstract="false" name="DebtInstrumentMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" abstract="false" name="RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_OneOfficeLeaseMember" abstract="true" name="OneOfficeLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_InVivoToxicologyStudiesMember" abstract="true" name="InVivoToxicologyStudiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" abstract="false" name="RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_CelgeneCorporationMember" abstract="true" name="CelgeneCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_TESAROInc.AndTESARODevelopmentInc.Member" abstract="true" name="TESAROInc.AndTESARODevelopmentInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_EmployeeStockPurchasePlan2017Member" abstract="true" name="EmployeeStockPurchasePlan2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" abstract="false" name="EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="anab_AnnualRentIncreasePercent" abstract="false" name="AnnualRentIncreasePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="anab_Phase3ClinicalTrialInitiationMember" abstract="true" name="Phase3ClinicalTrialInitiationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_AvailableforsaleDebtSecuritiesRemainingMaturity" abstract="false" name="AvailableforsaleDebtSecuritiesRemainingMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member" abstract="true" name="AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_CommercialAndCorporateObligationsMember" abstract="true" name="CommercialAndCorporateObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" abstract="false" name="EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent" abstract="false" name="RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="anab_DebtInstrumentNumberOfLoanInstallments" abstract="false" name="DebtInstrumentNumberOfLoanInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" abstract="false" name="RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_ClearanceOfInvestigationalNewDrugFromFDAMember" abstract="true" name="ClearanceOfInvestigationalNewDrugFromFDAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" abstract="false" name="RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" abstract="false" name="CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="anab_NetSalesRoyaltyPercent" abstract="false" name="NetSalesRoyaltyPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="anab_CollaborationAndExclusiveLicenseAgreementMember" abstract="true" name="CollaborationAndExclusiveLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" abstract="false" name="RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" abstract="false" name="RevenueRecognizedMilestoneMethodMilestonePaymentEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent" abstract="false" name="RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" abstract="false" name="LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="anab_LoanAndSecurityAgreementMember" abstract="true" name="LoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" abstract="false" name="RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="anab_EquityIncentivePlan2017Member" abstract="true" name="EquityIncentivePlan2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" abstract="false" name="SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_FilingofMMAMember" abstract="true" name="FilingofMMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" abstract="false" name="RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_Phase3clinicaltrialinitiationsecondindicationDomain" abstract="true" name="Phase3clinicaltrialinitiationsecondindicationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_FilingofNDAMember" abstract="true" name="FilingofNDAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_A10770WateridgeCircleSanDiegoCalifornia92121Member" abstract="true" name="A10770WateridgeCircleSanDiegoCalifornia92121Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_AccruedResearchAndDevelopmentExpensesCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber" abstract="false" name="LesseeOperatingLeaseOneYearRenewalOptionsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member" abstract="true" name="AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" abstract="false" name="RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="anab_Phase1ClinicalTrialInitiationMember" abstract="true" name="Phase1ClinicalTrialInitiationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>anab-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:721272a1-28f6-479d-8921-55bf3792b729,g:e6e63eaa-4a73-42e1-87eb-dda12e114757-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CoverPage" xlink:type="simple" xlink:href="anab-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6956e7fe-3270-4b1b-aa06-4beea8f8a56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cae4d810-c543-41a5-bd57-5801ecc09de4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6956e7fe-3270-4b1b-aa06-4beea8f8a56f" xlink:to="loc_us-gaap_AssetsCurrent_cae4d810-c543-41a5-bd57-5801ecc09de4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8b9e0d03-cc36-4035-ae01-e1a8eeda3d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6956e7fe-3270-4b1b-aa06-4beea8f8a56f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8b9e0d03-cc36-4035-ae01-e1a8eeda3d7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0820cbd8-b02e-49b8-bc29-7eee5b5c8505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6956e7fe-3270-4b1b-aa06-4beea8f8a56f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0820cbd8-b02e-49b8-bc29-7eee5b5c8505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0fe4988a-7e18-40a9-95f3-9773aca6a020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6956e7fe-3270-4b1b-aa06-4beea8f8a56f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0fe4988a-7e18-40a9-95f3-9773aca6a020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1ffeb006-7d20-4fdd-88d7-c04e95ce6315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6956e7fe-3270-4b1b-aa06-4beea8f8a56f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1ffeb006-7d20-4fdd-88d7-c04e95ce6315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4845b992-45ce-4e2e-89cf-721bdd7977ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_65eea326-1b85-4f50-b1ad-f1befcaf98c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4845b992-45ce-4e2e-89cf-721bdd7977ae" xlink:to="loc_us-gaap_LiabilitiesCurrent_65eea326-1b85-4f50-b1ad-f1befcaf98c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4542b53-7873-4f55-8a79-7be42264d87d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4845b992-45ce-4e2e-89cf-721bdd7977ae" xlink:to="loc_us-gaap_StockholdersEquity_d4542b53-7873-4f55-8a79-7be42264d87d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7c677204-1a21-41b4-b712-083065190b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4845b992-45ce-4e2e-89cf-721bdd7977ae" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7c677204-1a21-41b4-b712-083065190b93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_294a3ed2-94e5-47e6-b48b-05609069a33e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_494f35c7-8485-4e7f-b7fd-aed7b91cd0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_294a3ed2-94e5-47e6-b48b-05609069a33e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_494f35c7-8485-4e7f-b7fd-aed7b91cd0e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2bbd50e6-31b3-4711-afa6-4df66d840fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_294a3ed2-94e5-47e6-b48b-05609069a33e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2bbd50e6-31b3-4711-afa6-4df66d840fd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0c5fd101-2dd1-4b7e-8a68-c8bbd72de6ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_294a3ed2-94e5-47e6-b48b-05609069a33e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0c5fd101-2dd1-4b7e-8a68-c8bbd72de6ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ca86beac-bc85-4215-9359-79920ab4f4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8b21fc8a-f7eb-4948-b004-4ffe3040903f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ca86beac-bc85-4215-9359-79920ab4f4c8" xlink:to="loc_us-gaap_CommonStockValue_8b21fc8a-f7eb-4948-b004-4ffe3040903f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_02c165ba-1358-4483-aa47-e5dc1d0d3424" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ca86beac-bc85-4215-9359-79920ab4f4c8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_02c165ba-1358-4483-aa47-e5dc1d0d3424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e176a5cf-a5a3-4e70-a0bf-a7fd9f283ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ca86beac-bc85-4215-9359-79920ab4f4c8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e176a5cf-a5a3-4e70-a0bf-a7fd9f283ea7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0731329-ee08-4f8f-8d26-a1c807157cd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ca86beac-bc85-4215-9359-79920ab4f4c8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0731329-ee08-4f8f-8d26-a1c807157cd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_842abd74-adb0-4240-9329-6457ca05cd0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ca86beac-bc85-4215-9359-79920ab4f4c8" xlink:to="loc_us-gaap_PreferredStockValue_842abd74-adb0-4240-9329-6457ca05cd0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9f1e08dc-9fa7-450a-ad66-45f865ba4dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4b2c6ced-17ca-439f-a50d-0ccbf484a0f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9f1e08dc-9fa7-450a-ad66-45f865ba4dfd" xlink:to="loc_us-gaap_AccountsPayableCurrent_4b2c6ced-17ca-439f-a50d-0ccbf484a0f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1e4d8d42-95cc-4f61-b3a4-47796440f9d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9f1e08dc-9fa7-450a-ad66-45f865ba4dfd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1e4d8d42-95cc-4f61-b3a4-47796440f9d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_f1fd7118-c2af-4258-bdad-c3502749dcff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9f1e08dc-9fa7-450a-ad66-45f865ba4dfd" xlink:to="loc_us-gaap_NotesPayableCurrent_f1fd7118-c2af-4258-bdad-c3502749dcff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_de840ad3-c76f-4872-9673-65ea8f50313a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9f1e08dc-9fa7-450a-ad66-45f865ba4dfd" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_de840ad3-c76f-4872-9673-65ea8f50313a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_086398db-92de-4e3a-9e2a-710a8377e8ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4dce63dd-0076-48e9-8b2c-fc19a8b64919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_086398db-92de-4e3a-9e2a-710a8377e8ca" xlink:to="loc_us-gaap_OperatingExpenses_4dce63dd-0076-48e9-8b2c-fc19a8b64919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b63f9dd6-8f2d-4bbd-b06f-252eced214d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_086398db-92de-4e3a-9e2a-710a8377e8ca" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b63f9dd6-8f2d-4bbd-b06f-252eced214d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_eb8e62d6-10e2-4d11-b1e1-d02b0e340585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d8b292be-0a89-4ddc-a007-e9668d2f8b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_eb8e62d6-10e2-4d11-b1e1-d02b0e340585" xlink:to="loc_us-gaap_InterestExpense_d8b292be-0a89-4ddc-a007-e9668d2f8b3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_a0b73bce-8847-4b2d-b205-164dcc6bb04f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_eb8e62d6-10e2-4d11-b1e1-d02b0e340585" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_a0b73bce-8847-4b2d-b205-164dcc6bb04f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6eb6133d-e9ff-4343-9b23-9b5139306ac6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_eb8e62d6-10e2-4d11-b1e1-d02b0e340585" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6eb6133d-e9ff-4343-9b23-9b5139306ac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_34d274b3-07d2-4e61-9c36-124aa1eee491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d3b0fc84-3fb7-46a2-94cf-9c3a000d9543" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_34d274b3-07d2-4e61-9c36-124aa1eee491" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d3b0fc84-3fb7-46a2-94cf-9c3a000d9543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ef02eb7a-c34a-49b2-97fb-cad23f48e2fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_34d274b3-07d2-4e61-9c36-124aa1eee491" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ef02eb7a-c34a-49b2-97fb-cad23f48e2fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5921583b-7d39-466b-a25a-70dfa28ae6e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cc083492-8479-48dc-87b7-10dca506bfaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5921583b-7d39-466b-a25a-70dfa28ae6e2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cc083492-8479-48dc-87b7-10dca506bfaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_44229cef-2d0d-4bf8-a585-90e33164f0ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5921583b-7d39-466b-a25a-70dfa28ae6e2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_44229cef-2d0d-4bf8-a585-90e33164f0ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6dc4b66c-b2e7-445e-9cfb-54398e981d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2b9a1d27-02e2-42e3-b7b0-bde6fb6d7812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6dc4b66c-b2e7-445e-9cfb-54398e981d0a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2b9a1d27-02e2-42e3-b7b0-bde6fb6d7812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bb747f35-d7b9-462c-a80d-a09858f7a34f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6dc4b66c-b2e7-445e-9cfb-54398e981d0a" xlink:to="loc_us-gaap_OperatingIncomeLoss_bb747f35-d7b9-462c-a80d-a09858f7a34f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_843be62b-05c4-47d5-ba71-af3e42820d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3b7092ee-ea3e-4266-8d5f-599d7653541e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_843be62b-05c4-47d5-ba71-af3e42820d5c" xlink:to="loc_us-gaap_NetIncomeLoss_3b7092ee-ea3e-4266-8d5f-599d7653541e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b55315f4-a8e8-4b7e-b0c8-a07b7d33a59a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_843be62b-05c4-47d5-ba71-af3e42820d5c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b55315f4-a8e8-4b7e-b0c8-a07b7d33a59a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedStatementofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3f1073ab-5a07-419f-842c-c973e271a14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55d24aaf-4e0b-4425-bb10-e19d8b4a167e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3f1073ab-5a07-419f-842c-c973e271a14f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55d24aaf-4e0b-4425-bb10-e19d8b4a167e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8aba2362-9a1a-42dd-872d-c517b51bc647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3f1073ab-5a07-419f-842c-c973e271a14f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8aba2362-9a1a-42dd-872d-c517b51bc647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cc07f5e-7b4b-46a7-bd04-2438a8b5231e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3f1073ab-5a07-419f-842c-c973e271a14f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cc07f5e-7b4b-46a7-bd04-2438a8b5231e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2fb617b-7049-4c29-bc18-2e7deed721ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4199cbff-0500-45ae-941d-878c1a91e681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2fb617b-7049-4c29-bc18-2e7deed721ee" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4199cbff-0500-45ae-941d-878c1a91e681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_b7e03451-b8d5-462f-a41b-1782a9e3b49c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2fb617b-7049-4c29-bc18-2e7deed721ee" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_b7e03451-b8d5-462f-a41b-1782a9e3b49c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0b8073c6-dba8-4b87-b9ba-dd79e37eb3a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_46e73a27-55f9-4f37-8be0-9b26c0c452f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0b8073c6-dba8-4b87-b9ba-dd79e37eb3a8" xlink:to="loc_us-gaap_NetIncomeLoss_46e73a27-55f9-4f37-8be0-9b26c0c452f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c6ca0c68-0dc1-4ccd-aba0-76331f23d571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0b8073c6-dba8-4b87-b9ba-dd79e37eb3a8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c6ca0c68-0dc1-4ccd-aba0-76331f23d571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_203454eb-2348-4466-b27d-27f5cb0bdb8c" xlink:href="anab-20200930.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0b8073c6-dba8-4b87-b9ba-dd79e37eb3a8" xlink:to="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_203454eb-2348-4466-b27d-27f5cb0bdb8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_faa8b603-78c1-46d3-8c27-06318621fe95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0b8073c6-dba8-4b87-b9ba-dd79e37eb3a8" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_faa8b603-78c1-46d3-8c27-06318621fe95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_64eda904-000a-492a-9420-7403df56c7fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0b8073c6-dba8-4b87-b9ba-dd79e37eb3a8" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_64eda904-000a-492a-9420-7403df56c7fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6be71696-fa28-46cc-804d-bdef1a9fdb74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0b8073c6-dba8-4b87-b9ba-dd79e37eb3a8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6be71696-fa28-46cc-804d-bdef1a9fdb74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bac164a6-0520-428e-86cc-8dae677ea268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0b8073c6-dba8-4b87-b9ba-dd79e37eb3a8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bac164a6-0520-428e-86cc-8dae677ea268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c88267c5-3a52-4720-a251-51c39b04d168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c27d51d5-032c-4cee-9e6f-41b6c87971ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c88267c5-3a52-4720-a251-51c39b04d168" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c27d51d5-032c-4cee-9e6f-41b6c87971ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9c0a190b-26d5-437b-b9ba-429b8c4af980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c88267c5-3a52-4720-a251-51c39b04d168" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9c0a190b-26d5-437b-b9ba-429b8c4af980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_98d23865-49a6-4d6e-af5e-551197fce7e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c88267c5-3a52-4720-a251-51c39b04d168" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_98d23865-49a6-4d6e-af5e-551197fce7e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="anab-20200930.xsd#DescriptionoftheBusiness"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/DescriptionoftheBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures" xlink:type="simple" xlink:href="anab-20200930.xsd#BalanceSheetAccountsandSupplementalDisclosures"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables" xlink:type="simple" xlink:href="anab-20200930.xsd#BalanceSheetAccountsandSupplementalDisclosuresTables"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cab8997b-e1bd-4495-9af4-4272fd7cabd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3482b413-50f6-49f1-937c-90642d8f8d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cab8997b-e1bd-4495-9af4-4272fd7cabd5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3482b413-50f6-49f1-937c-90642d8f8d8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0c315188-d2cc-4be8-95ba-c82096b7be17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cab8997b-e1bd-4495-9af4-4272fd7cabd5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0c315188-d2cc-4be8-95ba-c82096b7be17" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b806680d-9b9f-4d45-a2aa-3c764783bf0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_44a56a99-d9e5-45ad-955f-a11a5387fbb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b806680d-9b9f-4d45-a2aa-3c764783bf0a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_44a56a99-d9e5-45ad-955f-a11a5387fbb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_c9770470-aa87-4092-aab5-343b0c416bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b806680d-9b9f-4d45-a2aa-3c764783bf0a" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_c9770470-aa87-4092-aab5-343b0c416bd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent_abc3a946-c675-4d4d-8472-355f3e422a8b" xlink:href="anab-20200930.xsd#anab_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b806680d-9b9f-4d45-a2aa-3c764783bf0a" xlink:to="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent_abc3a946-c675-4d4d-8472-355f3e422a8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3bfeedd2-3905-4d72-8ff7-41aa69a7f21c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b806680d-9b9f-4d45-a2aa-3c764783bf0a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3bfeedd2-3905-4d72-8ff7-41aa69a7f21c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements" xlink:type="simple" xlink:href="anab-20200930.xsd#CollaborativeResearchandDevelopmentAgreements"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables" xlink:type="simple" xlink:href="anab-20200930.xsd#CollaborativeResearchandDevelopmentAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CollaborativeResearchandDevelopmentAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/NotesPayable" xlink:type="simple" xlink:href="anab-20200930.xsd#NotesPayable"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/NotesPayable" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/NotesPayableDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#NotesPayableDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/NotesPayableDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestments"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8db51d1d-9eb6-4e46-907a-8844dc76d397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0c3e64b8-97a8-4432-80ae-2005206762a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8db51d1d-9eb6-4e46-907a-8844dc76d397" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0c3e64b8-97a8-4432-80ae-2005206762a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_71fa6406-c96d-4311-9633-f75f241590fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8db51d1d-9eb6-4e46-907a-8844dc76d397" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_71fa6406-c96d-4311-9633-f75f241590fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_58f483ed-1d63-4e17-a9f8-7ff392cbcc12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8db51d1d-9eb6-4e46-907a-8844dc76d397" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_58f483ed-1d63-4e17-a9f8-7ff392cbcc12" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="anab-20200930.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="anab-20200930.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6268fab1-9195-4e59-ba2c-42a46a5cc203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30fc57a0-271e-4dd3-94a6-384f2d0fd121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6268fab1-9195-4e59-ba2c-42a46a5cc203" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30fc57a0-271e-4dd3-94a6-384f2d0fd121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b3d260cb-8d5e-4ec4-89cf-70d90732c1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6268fab1-9195-4e59-ba2c-42a46a5cc203" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b3d260cb-8d5e-4ec4-89cf-70d90732c1f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlans" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlans"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansTables" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansTables"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansOptionFairValueAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesClassificationontheBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fff105ea-1d04-4492-9ae5-69f37be0556a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_33a4baaf-b064-4ac0-87e4-d9729b302c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fff105ea-1d04-4492-9ae5-69f37be0556a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_33a4baaf-b064-4ac0-87e4-d9729b302c7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9f60c5d7-8e1f-4bef-8d25-9337f7fa492f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fff105ea-1d04-4492-9ae5-69f37be0556a" xlink:to="loc_us-gaap_OperatingLeaseLiability_9f60c5d7-8e1f-4bef-8d25-9337f7fa492f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_825060eb-96dd-40b3-b6af-6e84db1cef9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2930fa80-831a-4d49-b07a-467079fd426f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_825060eb-96dd-40b3-b6af-6e84db1cef9b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2930fa80-831a-4d49-b07a-467079fd426f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cddcf878-5ff1-4645-bec6-fc30811720ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_825060eb-96dd-40b3-b6af-6e84db1cef9b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cddcf878-5ff1-4645-bec6-fc30811720ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2faefc61-3f99-45df-a49e-1aa460cf3684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_825060eb-96dd-40b3-b6af-6e84db1cef9b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2faefc61-3f99-45df-a49e-1aa460cf3684" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_53f8afd4-46f4-4c02-8981-4e91e9eed510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_825060eb-96dd-40b3-b6af-6e84db1cef9b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_53f8afd4-46f4-4c02-8981-4e91e9eed510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0f038ccc-146a-47e2-991d-fb4713f20867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_825060eb-96dd-40b3-b6af-6e84db1cef9b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0f038ccc-146a-47e2-991d-fb4713f20867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_4a5c5c2f-3064-4b3d-bef7-03457bc94349" xlink:href="anab-20200930.xsd#anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_825060eb-96dd-40b3-b6af-6e84db1cef9b" xlink:to="loc_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_4a5c5c2f-3064-4b3d-bef7-03457bc94349" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="anab-20200930.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#SubsequentEventDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/SubsequentEventDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>anab-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:721272a1-28f6-479d-8921-55bf3792b729,g:e6e63eaa-4a73-42e1-87eb-dda12e114757-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CoverPage" xlink:type="simple" xlink:href="anab-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CoverPage" xlink:type="extended" id="i3e94e4452ec0462a83339d46cbf84c80_CoverPage"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="ia50d738fd0214547af8ee4b3cc9b2779_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i6aa5904b424548d0b301519549192f7c_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="iab17f0e89920438393c7a952a7978b28_ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended" id="i092151af0cab4151a1e7c40ca51a7c71_ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedStatementofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity" xlink:type="extended" id="i214bb7481ee4468eb453f51995501ea6_ConsolidatedStatementofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_682e1965-1bba-4621-84fe-661d83cf3967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_682e1965-1bba-4621-84fe-661d83cf3967" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bd00c8ce-46a6-4db8-9e72-dafd12d1550e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_StockholdersEquity_bd00c8ce-46a6-4db8-9e72-dafd12d1550e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3b46ae96-69c8-4ff9-b842-79b3decca59f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_SharesOutstanding_3b46ae96-69c8-4ff9-b842-79b3decca59f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a8bd847a-ecd4-4a4a-8a86-1e4ad1b8f50e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a8bd847a-ecd4-4a4a-8a86-1e4ad1b8f50e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_08f22d76-ab83-4812-8217-2da224049da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_08f22d76-ab83-4812-8217-2da224049da7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_e79d210d-d40e-43f4-bbd8-cc6d600ea09b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_e79d210d-d40e-43f4-bbd8-cc6d600ea09b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d58bdf00-bfb5-47b3-992d-830ddf53740e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d58bdf00-bfb5-47b3-992d-830ddf53740e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1017e701-fcfb-48e5-9ed4-ae43a2e17d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_NetIncomeLoss_1017e701-fcfb-48e5-9ed4-ae43a2e17d45" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f29b9fed-925b-4f4e-80e3-475726b6f7ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_14775057-1216-4b4b-81ad-2ab980bbf65d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c83219a5-353d-4a9c-9d53-a398a4a1576d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_682e1965-1bba-4621-84fe-661d83cf3967" xlink:to="loc_us-gaap_StatementTable_c83219a5-353d-4a9c-9d53-a398a4a1576d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e1318e31-916f-4c2d-a91b-24f582201e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c83219a5-353d-4a9c-9d53-a398a4a1576d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e1318e31-916f-4c2d-a91b-24f582201e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e1318e31-916f-4c2d-a91b-24f582201e91_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e1318e31-916f-4c2d-a91b-24f582201e91" xlink:to="loc_us-gaap_EquityComponentDomain_e1318e31-916f-4c2d-a91b-24f582201e91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b51f03a-758f-4406-91ec-b1732cd6673f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e1318e31-916f-4c2d-a91b-24f582201e91" xlink:to="loc_us-gaap_EquityComponentDomain_6b51f03a-758f-4406-91ec-b1732cd6673f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_08d928e2-8cad-414d-81a9-afb694b6fc59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6b51f03a-758f-4406-91ec-b1732cd6673f" xlink:to="loc_us-gaap_CommonStockMember_08d928e2-8cad-414d-81a9-afb694b6fc59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9c740bd5-cc06-43c6-8811-b2a44828e8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6b51f03a-758f-4406-91ec-b1732cd6673f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9c740bd5-cc06-43c6-8811-b2a44828e8fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e0177f07-626e-4456-afc8-f26492ad6519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6b51f03a-758f-4406-91ec-b1732cd6673f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e0177f07-626e-4456-afc8-f26492ad6519" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bff468b8-3af2-48e0-b74c-904c35c14dd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6b51f03a-758f-4406-91ec-b1732cd6673f" xlink:to="loc_us-gaap_RetainedEarningsMember_bff468b8-3af2-48e0-b74c-904c35c14dd5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i46eab42b22224f04a18271d4c6772223_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="anab-20200930.xsd#DescriptionoftheBusiness"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/DescriptionoftheBusiness" xlink:type="extended" id="id8a56b8715b64a6c991c33c9e1beeb36_DescriptionoftheBusiness"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i7c22c23a14cb466686eeed1de9c4d6aa_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ib08b29484f0d48959bd534ca1dfe0a13_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="ib60d2e6cf40346aaa77fbee7bea42d6b_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i8a7bdc34016948c7ace63981b3adb6f0_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails" xlink:type="extended" id="ie0c8214a5a0044baa3770a754ca3887e_SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_13a33b6c-4280-482c-82da-cd7f23cde3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_64334047-4a99-4c2c-9018-dcb967d63b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_13a33b6c-4280-482c-82da-cd7f23cde3b3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_64334047-4a99-4c2c-9018-dcb967d63b06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_000a3946-ab49-461e-9b2f-8fd51dc172dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_13a33b6c-4280-482c-82da-cd7f23cde3b3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_000a3946-ab49-461e-9b2f-8fd51dc172dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c18334c2-5ae6-4d72-b774-a8fecd33a7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_000a3946-ab49-461e-9b2f-8fd51dc172dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c18334c2-5ae6-4d72-b774-a8fecd33a7b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c18334c2-5ae6-4d72-b774-a8fecd33a7b7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c18334c2-5ae6-4d72-b774-a8fecd33a7b7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c18334c2-5ae6-4d72-b774-a8fecd33a7b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_704c61b2-0fc1-4dd5-badd-5d5fa7c40c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c18334c2-5ae6-4d72-b774-a8fecd33a7b7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_704c61b2-0fc1-4dd5-badd-5d5fa7c40c93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4f0fec92-f6e6-4014-8281-7a8dda11f2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_704c61b2-0fc1-4dd5-badd-5d5fa7c40c93" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4f0fec92-f6e6-4014-8281-7a8dda11f2ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures" xlink:type="simple" xlink:href="anab-20200930.xsd#BalanceSheetAccountsandSupplementalDisclosures"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures" xlink:type="extended" id="i3f0ddd3e04fb4c209e2e345fb7fc41d2_BalanceSheetAccountsandSupplementalDisclosures"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables" xlink:type="simple" xlink:href="anab-20200930.xsd#BalanceSheetAccountsandSupplementalDisclosuresTables"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables" xlink:type="extended" id="icac83e9adf4548e1b94cfc47ed6f2a26_BalanceSheetAccountsandSupplementalDisclosuresTables"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails" xlink:type="extended" id="ie3a88915652b46b9a648c171c4efc57f_BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f486e67d-108c-4764-8ca6-7a7e2abe33cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e103bec9-e716-47a8-b70d-6904e2683f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f486e67d-108c-4764-8ca6-7a7e2abe33cb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e103bec9-e716-47a8-b70d-6904e2683f42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4c4bb277-7d76-4ff9-b338-617282881a3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f486e67d-108c-4764-8ca6-7a7e2abe33cb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4c4bb277-7d76-4ff9-b338-617282881a3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_20d6c621-8797-4697-adfa-ad43e4b1d38f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f486e67d-108c-4764-8ca6-7a7e2abe33cb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_20d6c621-8797-4697-adfa-ad43e4b1d38f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3d67f792-5985-4110-acb6-a847a8e71cd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f486e67d-108c-4764-8ca6-7a7e2abe33cb" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3d67f792-5985-4110-acb6-a847a8e71cd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0dc9b81c-5139-4b6a-81f9-e6c628f2f84b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3d67f792-5985-4110-acb6-a847a8e71cd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0dc9b81c-5139-4b6a-81f9-e6c628f2f84b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0dc9b81c-5139-4b6a-81f9-e6c628f2f84b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0dc9b81c-5139-4b6a-81f9-e6c628f2f84b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0dc9b81c-5139-4b6a-81f9-e6c628f2f84b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76f69063-0cfc-45cf-b7a9-6be17dadd534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0dc9b81c-5139-4b6a-81f9-e6c628f2f84b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76f69063-0cfc-45cf-b7a9-6be17dadd534" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LaboratoryEquipmentMember_74632548-cc96-455d-8a29-3f8963e87e61" xlink:href="anab-20200930.xsd#anab_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76f69063-0cfc-45cf-b7a9-6be17dadd534" xlink:to="loc_anab_LaboratoryEquipmentMember_74632548-cc96-455d-8a29-3f8963e87e61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_1b9e842e-9aaa-4480-b8fc-6c2d878f137a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76f69063-0cfc-45cf-b7a9-6be17dadd534" xlink:to="loc_us-gaap_OfficeEquipmentMember_1b9e842e-9aaa-4480-b8fc-6c2d878f137a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8d8691d1-4374-417e-8a36-6a1c97962b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76f69063-0cfc-45cf-b7a9-6be17dadd534" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8d8691d1-4374-417e-8a36-6a1c97962b08" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails" xlink:type="extended" id="ifee8715a049a4a3f84a4750349d6800e_BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements" xlink:type="simple" xlink:href="anab-20200930.xsd#CollaborativeResearchandDevelopmentAgreements"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements" xlink:type="extended" id="ib023d9001dda4c86a05d3f59476aa5ee_CollaborativeResearchandDevelopmentAgreements"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables" xlink:type="simple" xlink:href="anab-20200930.xsd#CollaborativeResearchandDevelopmentAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables" xlink:type="extended" id="i418f4e91d45c44169daab0af91e76c85_CollaborativeResearchandDevelopmentAgreementsTables"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CollaborativeResearchandDevelopmentAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails" xlink:type="extended" id="ib943a9cd6d5545f3966f96931294e5d6_CollaborativeResearchandDevelopmentAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_d87204d7-790a-4857-b23d-e38290db4860" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_d87204d7-790a-4857-b23d-e38290db4860" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_e71ac2c6-00fb-42d9-883f-f25da77af048" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_e71ac2c6-00fb-42d9-883f-f25da77af048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_bcaa2971-62b2-414e-a088-96cd58d13d42" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_bcaa2971-62b2-414e-a088-96cd58d13d42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_01077a85-e480-4027-9fc0-6f93643b31c1" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_01077a85-e480-4027-9fc0-6f93643b31c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_bf26524e-3bd4-4a76-884f-1cfa7c6e654e" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_bf26524e-3bd4-4a76-884f-1cfa7c6e654e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_03fdd7ff-0b80-4c04-8e28-c27fe25b65bb" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_03fdd7ff-0b80-4c04-8e28-c27fe25b65bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_21ea5729-afe0-409b-8e7f-fd427e6f35d6" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_21ea5729-afe0-409b-8e7f-fd427e6f35d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_a41e3961-0409-43de-bf5a-d05b6ce5e0e2" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_a41e3961-0409-43de-bf5a-d05b6ce5e0e2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_300e87c4-22a6-4d79-a924-e1b22758b3b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_300e87c4-22a6-4d79-a924-e1b22758b3b6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_c5131d4a-728f-4cde-ba0a-55a1f769cf4d" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_c5131d4a-728f-4cde-ba0a-55a1f769cf4d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_be7c256f-53a5-40c0-ac6f-df090fdc0667" xlink:href="anab-20200930.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_be7c256f-53a5-40c0-ac6f-df090fdc0667" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_bdec1950-d0be-4bbd-ade9-da020c22f65e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_bdec1950-d0be-4bbd-ade9-da020c22f65e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e847d76e-ed62-4c34-a3a8-686441dc4b5d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_bdec1950-d0be-4bbd-ade9-da020c22f65e" xlink:to="loc_srt_CounterpartyNameAxis_e847d76e-ed62-4c34-a3a8-686441dc4b5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e847d76e-ed62-4c34-a3a8-686441dc4b5d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e847d76e-ed62-4c34-a3a8-686441dc4b5d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e847d76e-ed62-4c34-a3a8-686441dc4b5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cd888592-154d-4cde-aeaa-c22a889f9481" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e847d76e-ed62-4c34-a3a8-686441dc4b5d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cd888592-154d-4cde-aeaa-c22a889f9481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member_b582e306-17f8-4799-8e90-71652111ef88" xlink:href="anab-20200930.xsd#anab_TESAROInc.AndTESARODevelopmentInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cd888592-154d-4cde-aeaa-c22a889f9481" xlink:to="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member_b582e306-17f8-4799-8e90-71652111ef88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CelgeneCorporationMember_5ec8464f-7e07-40f9-8007-9364eb7c4d21" xlink:href="anab-20200930.xsd#anab_CelgeneCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cd888592-154d-4cde-aeaa-c22a889f9481" xlink:to="loc_anab_CelgeneCorporationMember_5ec8464f-7e07-40f9-8007-9364eb7c4d21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_dc786cdd-4b90-4d3d-8120-ed4b65a862be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_bdec1950-d0be-4bbd-ade9-da020c22f65e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_dc786cdd-4b90-4d3d-8120-ed4b65a862be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dc786cdd-4b90-4d3d-8120-ed4b65a862be_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dc786cdd-4b90-4d3d-8120-ed4b65a862be" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dc786cdd-4b90-4d3d-8120-ed4b65a862be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4a64c13-e3e6-41ca-b1e5-ad5a87e1b786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dc786cdd-4b90-4d3d-8120-ed4b65a862be" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4a64c13-e3e6-41ca-b1e5-ad5a87e1b786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4a64c13-e3e6-41ca-b1e5-ad5a87e1b786" xlink:to="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_InVivoToxicologyStudiesMember_a08a3574-17dc-4a08-9daf-187fc65862f3" xlink:href="anab-20200930.xsd#anab_InVivoToxicologyStudiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_InVivoToxicologyStudiesMember_a08a3574-17dc-4a08-9daf-187fc65862f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_a58f57dd-a045-4759-bbb4-036e98e4c0dc" xlink:href="anab-20200930.xsd#anab_ClearanceOfInvestigationalNewDrugFromFDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_a58f57dd-a045-4759-bbb4-036e98e4c0dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase2ClinicalTrialInitiationMember_b91b50b9-bfec-474c-a91b-b5eafb90c8fd" xlink:href="anab-20200930.xsd#anab_Phase2ClinicalTrialInitiationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_Phase2ClinicalTrialInitiationMember_b91b50b9-bfec-474c-a91b-b5eafb90c8fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase3ClinicalTrialInitiationMember_4d306f95-8033-4196-999e-43f3616476e6" xlink:href="anab-20200930.xsd#anab_Phase3ClinicalTrialInitiationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_Phase3ClinicalTrialInitiationMember_4d306f95-8033-4196-999e-43f3616476e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase3clinicaltrialinitiationsecondindicationDomain_bbdb8308-9a09-4576-8dd9-49115c0b9779" xlink:href="anab-20200930.xsd#anab_Phase3clinicaltrialinitiationsecondindicationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_Phase3clinicaltrialinitiationsecondindicationDomain_bbdb8308-9a09-4576-8dd9-49115c0b9779" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingofNDAMember_3f377473-9f19-4103-af71-ed22a6bebde8" xlink:href="anab-20200930.xsd#anab_FilingofNDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_FilingofNDAMember_3f377473-9f19-4103-af71-ed22a6bebde8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingofMMAMember_07eafe99-ea4a-4c29-a1a3-3f26ec344236" xlink:href="anab-20200930.xsd#anab_FilingofMMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_FilingofMMAMember_07eafe99-ea4a-4c29-a1a3-3f26ec344236" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase1ClinicalTrialInitiationMember_776f8d7b-7d22-48ca-9a8e-998f1e6b05ae" xlink:href="anab-20200930.xsd#anab_Phase1ClinicalTrialInitiationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_Phase1ClinicalTrialInitiationMember_776f8d7b-7d22-48ca-9a8e-998f1e6b05ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2f7b37a0-82bf-4a51-a189-11dc3a408b56" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_bdec1950-d0be-4bbd-ade9-da020c22f65e" xlink:to="loc_srt_ProductOrServiceAxis_2f7b37a0-82bf-4a51-a189-11dc3a408b56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2f7b37a0-82bf-4a51-a189-11dc3a408b56_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2f7b37a0-82bf-4a51-a189-11dc3a408b56" xlink:to="loc_srt_ProductsAndServicesDomain_2f7b37a0-82bf-4a51-a189-11dc3a408b56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6288632d-97cd-4d5c-8a53-af1ca286f441" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2f7b37a0-82bf-4a51-a189-11dc3a408b56" xlink:to="loc_srt_ProductsAndServicesDomain_6288632d-97cd-4d5c-8a53-af1ca286f441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_ddabd32f-95b8-40fb-a04d-4d90478c475f" xlink:href="anab-20200930.xsd#anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6288632d-97cd-4d5c-8a53-af1ca286f441" xlink:to="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_ddabd32f-95b8-40fb-a04d-4d90478c475f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_ad54682d-5b76-4598-acb2-0e73029ea4f6" xlink:href="anab-20200930.xsd#anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6288632d-97cd-4d5c-8a53-af1ca286f441" xlink:to="loc_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_ad54682d-5b76-4598-acb2-0e73029ea4f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_9cc1d194-8bda-425b-baa2-ef9833155827" xlink:href="anab-20200930.xsd#anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6288632d-97cd-4d5c-8a53-af1ca286f441" xlink:to="loc_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_9cc1d194-8bda-425b-baa2-ef9833155827" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_f485404c-8bdf-4cde-a44b-87a878899800" xlink:href="anab-20200930.xsd#anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6288632d-97cd-4d5c-8a53-af1ca286f441" xlink:to="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_f485404c-8bdf-4cde-a44b-87a878899800" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/NotesPayable" xlink:type="simple" xlink:href="anab-20200930.xsd#NotesPayable"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/NotesPayable" xlink:type="extended" id="ic470e99e52e04734a898c1cb343379ce_NotesPayable"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/NotesPayableDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#NotesPayableDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/NotesPayableDetails" xlink:type="extended" id="i47b643264f734e7f9081c7bda11c7f64_NotesPayableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_DebtInstrumentMaximumBorrowingCapacity_89054ade-3ced-4aee-a098-49fc482bf490" xlink:href="anab-20200930.xsd#anab_DebtInstrumentMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:to="loc_anab_DebtInstrumentMaximumBorrowingCapacity_89054ade-3ced-4aee-a098-49fc482bf490" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_DebtInstrumentNumberOfLoanInstallments_0743ed1e-932b-4b77-8890-c6bff8ef5fe2" xlink:href="anab-20200930.xsd#anab_DebtInstrumentNumberOfLoanInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:to="loc_anab_DebtInstrumentNumberOfLoanInstallments_0743ed1e-932b-4b77-8890-c6bff8ef5fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_929ec3c4-947e-43a8-af3a-83c587b38984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_929ec3c4-947e-43a8-af3a-83c587b38984" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_c01501c2-1228-4fd4-9978-686fa77e25c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_c01501c2-1228-4fd4-9978-686fa77e25c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5bb06120-d1f9-426e-83df-0d55b5e51ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5bb06120-d1f9-426e-83df-0d55b5e51ff9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_865fac9c-894f-4a4d-a44a-307e44116750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_865fac9c-894f-4a4d-a44a-307e44116750" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_568f4f50-2c39-45df-bae6-80adf7442163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:to="loc_us-gaap_DebtInstrumentTable_568f4f50-2c39-45df-bae6-80adf7442163" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a50b323d-e137-4f34-ba5a-a9899e9ddd36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_568f4f50-2c39-45df-bae6-80adf7442163" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a50b323d-e137-4f34-ba5a-a9899e9ddd36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a50b323d-e137-4f34-ba5a-a9899e9ddd36_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a50b323d-e137-4f34-ba5a-a9899e9ddd36" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a50b323d-e137-4f34-ba5a-a9899e9ddd36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f8e242c1-2461-4dd2-aae5-51008aceaf48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a50b323d-e137-4f34-ba5a-a9899e9ddd36" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f8e242c1-2461-4dd2-aae5-51008aceaf48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_0810bf23-0a34-4816-8b37-fbc94a1553b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f8e242c1-2461-4dd2-aae5-51008aceaf48" xlink:to="loc_us-gaap_NotesPayableToBanksMember_0810bf23-0a34-4816-8b37-fbc94a1553b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fd0cef48-4ac7-4c2a-ac0f-54b3860fc6b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_568f4f50-2c39-45df-bae6-80adf7442163" xlink:to="loc_us-gaap_DebtInstrumentAxis_fd0cef48-4ac7-4c2a-ac0f-54b3860fc6b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fd0cef48-4ac7-4c2a-ac0f-54b3860fc6b7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fd0cef48-4ac7-4c2a-ac0f-54b3860fc6b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fd0cef48-4ac7-4c2a-ac0f-54b3860fc6b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f22298a7-fe20-4721-8ac8-41f08ad3eaf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fd0cef48-4ac7-4c2a-ac0f-54b3860fc6b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f22298a7-fe20-4721-8ac8-41f08ad3eaf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LoanAndSecurityAgreementMember_145eba5d-0a7b-4c1c-aaaf-3f89b33d529c" xlink:href="anab-20200930.xsd#anab_LoanAndSecurityAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f22298a7-fe20-4721-8ac8-41f08ad3eaf0" xlink:to="loc_anab_LoanAndSecurityAgreementMember_145eba5d-0a7b-4c1c-aaaf-3f89b33d529c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_TermALoansMember_a3708eac-4386-4b43-83a8-131eda691d40" xlink:href="anab-20200930.xsd#anab_TermALoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f22298a7-fe20-4721-8ac8-41f08ad3eaf0" xlink:to="loc_anab_TermALoansMember_a3708eac-4386-4b43-83a8-131eda691d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_TermBLoansAndTermCLoansMember_41a9e646-d533-437f-9046-d4100c4359a8" xlink:href="anab-20200930.xsd#anab_TermBLoansAndTermCLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f22298a7-fe20-4721-8ac8-41f08ad3eaf0" xlink:to="loc_anab_TermBLoansAndTermCLoansMember_41a9e646-d533-437f-9046-d4100c4359a8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestments"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments" xlink:type="extended" id="iaa1284ad5582420b9eb3a7e229e3fd1a_FairValueMeasurementsandAvailableforSaleInvestments"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables" xlink:type="extended" id="i9340659286784724a3a737f4e3081740_FairValueMeasurementsandAvailableforSaleInvestmentsTables"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i1fe8be7647b04a5a939770f1faa2f21a_FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_865a5de8-e0fc-48f4-88ab-537331a81580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_885bf5d1-87ab-458b-90c3-f87ec860fa7e" xlink:href="anab-20200930.xsd#anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_865a5de8-e0fc-48f4-88ab-537331a81580" xlink:to="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_885bf5d1-87ab-458b-90c3-f87ec860fa7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c102e38-c1d9-4c38-8522-bbdc56d8e182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_865a5de8-e0fc-48f4-88ab-537331a81580" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c102e38-c1d9-4c38-8522-bbdc56d8e182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7b3bdc4-1245-45dd-b78a-309ebbb4fbb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_865a5de8-e0fc-48f4-88ab-537331a81580" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7b3bdc4-1245-45dd-b78a-309ebbb4fbb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e9e846b6-0842-49a1-a1be-b026fce0c14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7b3bdc4-1245-45dd-b78a-309ebbb4fbb2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e9e846b6-0842-49a1-a1be-b026fce0c14d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e9e846b6-0842-49a1-a1be-b026fce0c14d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e9e846b6-0842-49a1-a1be-b026fce0c14d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e9e846b6-0842-49a1-a1be-b026fce0c14d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4d8fdc49-53e9-428c-aabe-ec84d6d54e29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e9e846b6-0842-49a1-a1be-b026fce0c14d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4d8fdc49-53e9-428c-aabe-ec84d6d54e29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7fbe6147-ba83-4c23-bca4-8a6bb47d7e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4d8fdc49-53e9-428c-aabe-ec84d6d54e29" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7fbe6147-ba83-4c23-bca4-8a6bb47d7e6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_27edfc0c-4a87-4122-b0e5-d5e8bd4eaab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7b3bdc4-1245-45dd-b78a-309ebbb4fbb2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_27edfc0c-4a87-4122-b0e5-d5e8bd4eaab0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_27edfc0c-4a87-4122-b0e5-d5e8bd4eaab0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_27edfc0c-4a87-4122-b0e5-d5e8bd4eaab0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_27edfc0c-4a87-4122-b0e5-d5e8bd4eaab0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f674b6cd-26ae-4921-b731-1dba3bdd1fb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_27edfc0c-4a87-4122-b0e5-d5e8bd4eaab0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f674b6cd-26ae-4921-b731-1dba3bdd1fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fa63a14d-52a3-4822-bab5-88d8a8f74826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f674b6cd-26ae-4921-b731-1dba3bdd1fb2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fa63a14d-52a3-4822-bab5-88d8a8f74826" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c11b7150-e602-404d-b5f0-3db128b0cb87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f674b6cd-26ae-4921-b731-1dba3bdd1fb2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c11b7150-e602-404d-b5f0-3db128b0cb87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1bdf5c73-9f38-46f9-8f1f-8903f7833234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f674b6cd-26ae-4921-b731-1dba3bdd1fb2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1bdf5c73-9f38-46f9-8f1f-8903f7833234" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_54b17703-0751-4468-810a-f271a3974018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7b3bdc4-1245-45dd-b78a-309ebbb4fbb2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_54b17703-0751-4468-810a-f271a3974018" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_54b17703-0751-4468-810a-f271a3974018_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_54b17703-0751-4468-810a-f271a3974018" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_54b17703-0751-4468-810a-f271a3974018_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1da1f4b3-c537-45c0-947d-3ae004e91395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_54b17703-0751-4468-810a-f271a3974018" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1da1f4b3-c537-45c0-947d-3ae004e91395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_94590256-ce06-477e-a7f7-043ad35f34d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1da1f4b3-c537-45c0-947d-3ae004e91395" xlink:to="loc_us-gaap_MoneyMarketFundsMember_94590256-ce06-477e-a7f7-043ad35f34d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_5f40270e-fcbd-467d-9a26-80b27c1dc189" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1da1f4b3-c537-45c0-947d-3ae004e91395" xlink:to="loc_us-gaap_MutualFundMember_5f40270e-fcbd-467d-9a26-80b27c1dc189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_80ececaf-b9ee-4c39-823d-b50b3b905c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7b3bdc4-1245-45dd-b78a-309ebbb4fbb2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_80ececaf-b9ee-4c39-823d-b50b3b905c7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80ececaf-b9ee-4c39-823d-b50b3b905c7f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_80ececaf-b9ee-4c39-823d-b50b3b905c7f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80ececaf-b9ee-4c39-823d-b50b3b905c7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2872cab-1933-41f3-ad9f-7bf283399eab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_80ececaf-b9ee-4c39-823d-b50b3b905c7f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2872cab-1933-41f3-ad9f-7bf283399eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_155bfb8e-aa8a-4be8-a410-ffa90e5e97d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2872cab-1933-41f3-ad9f-7bf283399eab" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_155bfb8e-aa8a-4be8-a410-ffa90e5e97d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_419b923d-bd68-4630-9a6e-8cbbd7fb7d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2872cab-1933-41f3-ad9f-7bf283399eab" xlink:to="loc_us-gaap_CertificatesOfDepositMember_419b923d-bd68-4630-9a6e-8cbbd7fb7d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_63469ad1-c368-472f-bd6b-74835d9bbea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2872cab-1933-41f3-ad9f-7bf283399eab" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_63469ad1-c368-472f-bd6b-74835d9bbea8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_8011caf2-ef66-408e-87d9-63caa91f32ae" xlink:href="anab-20200930.xsd#anab_CommercialAndCorporateObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2872cab-1933-41f3-ad9f-7bf283399eab" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_8011caf2-ef66-408e-87d9-63caa91f32ae" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails" xlink:type="extended" id="iaf1b18eed03044a6adcb97d6176c145f_FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3ac907a6-858a-446e-8771-cf8df4d47bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_2b8a988f-2b2b-42c5-9a55-0422bccca0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3ac907a6-858a-446e-8771-cf8df4d47bc0" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_2b8a988f-2b2b-42c5-9a55-0422bccca0d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f385c960-d23c-4e91-adb9-a4fc56cbf85f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3ac907a6-858a-446e-8771-cf8df4d47bc0" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f385c960-d23c-4e91-adb9-a4fc56cbf85f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_6eb0bdfc-5aec-4811-87fd-88fe3b0b6537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f385c960-d23c-4e91-adb9-a4fc56cbf85f" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_6eb0bdfc-5aec-4811-87fd-88fe3b0b6537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6eb0bdfc-5aec-4811-87fd-88fe3b0b6537_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_6eb0bdfc-5aec-4811-87fd-88fe3b0b6537" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6eb0bdfc-5aec-4811-87fd-88fe3b0b6537_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9ee5f1de-0adf-452f-886d-dc2fd80453cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_6eb0bdfc-5aec-4811-87fd-88fe3b0b6537" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9ee5f1de-0adf-452f-886d-dc2fd80453cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d234efb9-0aa1-45f1-bc6b-7e84028e13d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9ee5f1de-0adf-452f-886d-dc2fd80453cf" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d234efb9-0aa1-45f1-bc6b-7e84028e13d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_356cb7c2-df02-47dc-847a-50e705911ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9ee5f1de-0adf-452f-886d-dc2fd80453cf" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_356cb7c2-df02-47dc-847a-50e705911ba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5b496402-4711-4558-a7be-c50626cbee5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9ee5f1de-0adf-452f-886d-dc2fd80453cf" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5b496402-4711-4558-a7be-c50626cbee5a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails" xlink:type="extended" id="iba40fea35f664a558368e1a117750a72_FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6528a632-a8d8-4606-9029-c183d291d1a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6528a632-a8d8-4606-9029-c183d291d1a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1489a30d-da26-4e8c-8c1f-773792dfd16c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1489a30d-da26-4e8c-8c1f-773792dfd16c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fc6dfa59-8830-4f95-8c2e-fd75f2e7ee71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fc6dfa59-8830-4f95-8c2e-fd75f2e7ee71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a1933f9a-d635-4f15-b75d-44fe79b93fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a1933f9a-d635-4f15-b75d-44fe79b93fd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3e313d93-5ddc-42e0-8394-b07c7e269e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3e313d93-5ddc-42e0-8394-b07c7e269e54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_4436ce46-d337-4078-b1fb-0daca8857ec2" xlink:href="anab-20200930.xsd#anab_AvailableforsaleDebtSecuritiesRemainingMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_4436ce46-d337-4078-b1fb-0daca8857ec2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e9bf07de-0665-4d99-9bbf-a52c1327d451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e9bf07de-0665-4d99-9bbf-a52c1327d451" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c50ee7fe-4562-408b-9f56-0dd54b8f27ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c50ee7fe-4562-408b-9f56-0dd54b8f27ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6e6818a1-9a52-4c03-ab96-8bd98ead60e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c50ee7fe-4562-408b-9f56-0dd54b8f27ca" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6e6818a1-9a52-4c03-ab96-8bd98ead60e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6e6818a1-9a52-4c03-ab96-8bd98ead60e2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6e6818a1-9a52-4c03-ab96-8bd98ead60e2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6e6818a1-9a52-4c03-ab96-8bd98ead60e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36c195d1-6d79-45bd-92a7-e34c4f73fd80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6e6818a1-9a52-4c03-ab96-8bd98ead60e2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36c195d1-6d79-45bd-92a7-e34c4f73fd80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_17a447d2-0503-494b-a1a0-421dc7ac6373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36c195d1-6d79-45bd-92a7-e34c4f73fd80" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_17a447d2-0503-494b-a1a0-421dc7ac6373" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f58fda0f-baff-449b-bd42-369c239748d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36c195d1-6d79-45bd-92a7-e34c4f73fd80" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f58fda0f-baff-449b-bd42-369c239748d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_03ae1db9-29f1-4e36-a4c8-a731d2cac8c4" xlink:href="anab-20200930.xsd#anab_CommercialAndCorporateObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36c195d1-6d79-45bd-92a7-e34c4f73fd80" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_03ae1db9-29f1-4e36-a4c8-a731d2cac8c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_341a36b7-cc40-4fbd-b281-c3a5abe80a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36c195d1-6d79-45bd-92a7-e34c4f73fd80" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_341a36b7-cc40-4fbd-b281-c3a5abe80a5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e43f1f35-bf98-48ee-aede-2a78d1473f56" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c50ee7fe-4562-408b-9f56-0dd54b8f27ca" xlink:to="loc_srt_RangeAxis_e43f1f35-bf98-48ee-aede-2a78d1473f56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e43f1f35-bf98-48ee-aede-2a78d1473f56_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e43f1f35-bf98-48ee-aede-2a78d1473f56" xlink:to="loc_srt_RangeMember_e43f1f35-bf98-48ee-aede-2a78d1473f56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1fa12c6-3e12-46f5-b3e1-fd42580b4ff6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e43f1f35-bf98-48ee-aede-2a78d1473f56" xlink:to="loc_srt_RangeMember_e1fa12c6-3e12-46f5-b3e1-fd42580b4ff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a693bf25-fc51-4daf-9bb3-973309dde3ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e1fa12c6-3e12-46f5-b3e1-fd42580b4ff6" xlink:to="loc_srt_MinimumMember_a693bf25-fc51-4daf-9bb3-973309dde3ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6eff9d70-80f1-4485-bf70-e99d9cc490c7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e1fa12c6-3e12-46f5-b3e1-fd42580b4ff6" xlink:to="loc_srt_MaximumMember_6eff9d70-80f1-4485-bf70-e99d9cc490c7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails" xlink:type="extended" id="i6916c6a7d6e84e3bb73cf4182c2898f2_FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_fb3b1379-ce8b-4504-8b8e-979f6b21c8f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_fb3b1379-ce8b-4504-8b8e-979f6b21c8f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_cce7b43d-bb21-4cf5-ab85-cb5a7c4e5482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_cce7b43d-bb21-4cf5-ab85-cb5a7c4e5482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_ce49d1bc-088e-400d-b2b4-00ec781c65ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_ce49d1bc-088e-400d-b2b4-00ec781c65ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_7dcbb75f-2195-410d-8e48-014bb8e7899e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_7dcbb75f-2195-410d-8e48-014bb8e7899e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c0c45fed-3d00-4f2b-bbfd-a5c576b83914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c0c45fed-3d00-4f2b-bbfd-a5c576b83914" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_50bad50b-6075-4684-aab9-d623a09a770c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_50bad50b-6075-4684-aab9-d623a09a770c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67a03285-e62f-452d-9c61-6b8c8b7106ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67a03285-e62f-452d-9c61-6b8c8b7106ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_789b4e8b-ab78-4f05-ada6-549bb3294a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67a03285-e62f-452d-9c61-6b8c8b7106ae" xlink:to="loc_us-gaap_FinancialInstrumentAxis_789b4e8b-ab78-4f05-ada6-549bb3294a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_789b4e8b-ab78-4f05-ada6-549bb3294a24_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_789b4e8b-ab78-4f05-ada6-549bb3294a24" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_789b4e8b-ab78-4f05-ada6-549bb3294a24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_799d3c17-47a8-4bf5-81a5-604cfdedfddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_789b4e8b-ab78-4f05-ada6-549bb3294a24" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_799d3c17-47a8-4bf5-81a5-604cfdedfddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ed4a61ed-89f7-4b2d-be0d-9e9791f9dbce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_799d3c17-47a8-4bf5-81a5-604cfdedfddb" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ed4a61ed-89f7-4b2d-be0d-9e9791f9dbce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_1b13662a-1717-4575-b3df-cd6f02c7b344" xlink:href="anab-20200930.xsd#anab_CommercialAndCorporateObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_799d3c17-47a8-4bf5-81a5-604cfdedfddb" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_1b13662a-1717-4575-b3df-cd6f02c7b344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_dae19b7c-eb87-4bf1-94e1-565e5f1bf9ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_799d3c17-47a8-4bf5-81a5-604cfdedfddb" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_dae19b7c-eb87-4bf1-94e1-565e5f1bf9ce" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="anab-20200930.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquity" xlink:type="extended" id="i3b69e4dbc45d4bd9a4b343223bfa4596_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="anab-20200930.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquityTables" xlink:type="extended" id="i0812f2a4653c41d9933029544e36a756_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="i3a5a12ce1ed94bf7be844e5b2643ffc7_StockholdersEquityAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended" id="i5bd7679a3f7942e4bd8e2dc1ed3a9d35_StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_284e7a76-589c-4b42-83aa-381adf25b442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e9778f4f-67a2-47ed-b7b8-603fac2fb14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_284e7a76-589c-4b42-83aa-381adf25b442" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e9778f4f-67a2-47ed-b7b8-603fac2fb14f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fcafb2b1-01c3-4955-85db-f3d1a097b162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e9778f4f-67a2-47ed-b7b8-603fac2fb14f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fcafb2b1-01c3-4955-85db-f3d1a097b162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2ca3478a-2f54-41ed-b499-0294c4c0c350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_284e7a76-589c-4b42-83aa-381adf25b442" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2ca3478a-2f54-41ed-b499-0294c4c0c350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_365ebae5-8d62-4e02-a72f-f1bb4e8cae2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_284e7a76-589c-4b42-83aa-381adf25b442" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_365ebae5-8d62-4e02-a72f-f1bb4e8cae2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e6fcae41-fe4d-423e-962a-91cf46315bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_284e7a76-589c-4b42-83aa-381adf25b442" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e6fcae41-fe4d-423e-962a-91cf46315bd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_86c863ec-b89b-4ac3-ac86-40bbff98e308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e6fcae41-fe4d-423e-962a-91cf46315bd3" xlink:to="loc_us-gaap_PlanNameAxis_86c863ec-b89b-4ac3-ac86-40bbff98e308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_86c863ec-b89b-4ac3-ac86-40bbff98e308_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_86c863ec-b89b-4ac3-ac86-40bbff98e308" xlink:to="loc_us-gaap_PlanNameDomain_86c863ec-b89b-4ac3-ac86-40bbff98e308_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5e735b19-6e59-47ed-9499-ada342818da1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_86c863ec-b89b-4ac3-ac86-40bbff98e308" xlink:to="loc_us-gaap_PlanNameDomain_5e735b19-6e59-47ed-9499-ada342818da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EquityIncentivePlan2017Member_fb104ec5-e552-4caa-b5fc-27816b4a033b" xlink:href="anab-20200930.xsd#anab_EquityIncentivePlan2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5e735b19-6e59-47ed-9499-ada342818da1" xlink:to="loc_anab_EquityIncentivePlan2017Member_fb104ec5-e552-4caa-b5fc-27816b4a033b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member_74640f64-6244-4eb9-8f99-c050ca380a09" xlink:href="anab-20200930.xsd#anab_EmployeeStockPurchasePlan2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5e735b19-6e59-47ed-9499-ada342818da1" xlink:to="loc_anab_EmployeeStockPurchasePlan2017Member_74640f64-6244-4eb9-8f99-c050ca380a09" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlans" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlans"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlans" xlink:type="extended" id="i2879b18aece5409493348ce834d96a5f_EquityIncentivePlans"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansTables" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansTables"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansTables" xlink:type="extended" id="iae9bc938ba4840b2ba0d1756dc427dee_EquityIncentivePlansTables"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended" id="i3e894f5f1d8f4211a4184c78fe5bc61e_EquityIncentivePlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_b6e7ced0-d539-4138-97d0-847210396855" xlink:href="anab-20200930.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:to="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_b6e7ced0-d539-4138-97d0-847210396855" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_f3d8ad3f-9404-4668-8752-32cf94040df0" xlink:href="anab-20200930.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:to="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_f3d8ad3f-9404-4668-8752-32cf94040df0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_54795cf6-2fb7-482a-b86f-a9d5b697c986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_54795cf6-2fb7-482a-b86f-a9d5b697c986" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_95946c11-e0f5-40d2-8121-43241cf75fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_95946c11-e0f5-40d2-8121-43241cf75fe2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_1f1c86fb-fd73-4fcf-bf53-460813568900" xlink:href="anab-20200930.xsd#anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:to="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_1f1c86fb-fd73-4fcf-bf53-460813568900" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_8547e657-1514-4f2a-acf6-c781ea719fc0" xlink:href="anab-20200930.xsd#anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:to="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_8547e657-1514-4f2a-acf6-c781ea719fc0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33050d09-a899-4fa1-aa42-8d80dbe522d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33050d09-a899-4fa1-aa42-8d80dbe522d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_40713782-5ac8-494c-b8c9-f318b411dd7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33050d09-a899-4fa1-aa42-8d80dbe522d9" xlink:to="loc_us-gaap_PlanNameAxis_40713782-5ac8-494c-b8c9-f318b411dd7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_40713782-5ac8-494c-b8c9-f318b411dd7a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_40713782-5ac8-494c-b8c9-f318b411dd7a" xlink:to="loc_us-gaap_PlanNameDomain_40713782-5ac8-494c-b8c9-f318b411dd7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e04988f0-44c3-496f-855a-88243e596c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_40713782-5ac8-494c-b8c9-f318b411dd7a" xlink:to="loc_us-gaap_PlanNameDomain_e04988f0-44c3-496f-855a-88243e596c9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EquityIncentivePlan2017Member_bbabc723-630e-43d9-b347-bc650b874ed0" xlink:href="anab-20200930.xsd#anab_EquityIncentivePlan2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e04988f0-44c3-496f-855a-88243e596c9d" xlink:to="loc_anab_EquityIncentivePlan2017Member_bbabc723-630e-43d9-b347-bc650b874ed0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member_39e347c8-8bad-41c5-aff0-0b334c2585e6" xlink:href="anab-20200930.xsd#anab_EmployeeStockPurchasePlan2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e04988f0-44c3-496f-855a-88243e596c9d" xlink:to="loc_anab_EmployeeStockPurchasePlan2017Member_39e347c8-8bad-41c5-aff0-0b334c2585e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b563a241-a7d0-4139-95b3-e31786e1d0cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33050d09-a899-4fa1-aa42-8d80dbe522d9" xlink:to="loc_us-gaap_AwardTypeAxis_b563a241-a7d0-4139-95b3-e31786e1d0cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b563a241-a7d0-4139-95b3-e31786e1d0cd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b563a241-a7d0-4139-95b3-e31786e1d0cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b563a241-a7d0-4139-95b3-e31786e1d0cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97166377-9fe2-482c-ad3e-35af6d34e794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b563a241-a7d0-4139-95b3-e31786e1d0cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97166377-9fe2-482c-ad3e-35af6d34e794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_32f66517-5a26-4300-84b9-bf264eeff35f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97166377-9fe2-482c-ad3e-35af6d34e794" xlink:to="loc_us-gaap_EmployeeStockMember_32f66517-5a26-4300-84b9-bf264eeff35f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a5d1afba-00f7-437b-b8ed-f130f53eeef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97166377-9fe2-482c-ad3e-35af6d34e794" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a5d1afba-00f7-437b-b8ed-f130f53eeef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_309f52cc-62db-4bf5-929f-396899046cd1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33050d09-a899-4fa1-aa42-8d80dbe522d9" xlink:to="loc_srt_TitleOfIndividualAxis_309f52cc-62db-4bf5-929f-396899046cd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_309f52cc-62db-4bf5-929f-396899046cd1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_309f52cc-62db-4bf5-929f-396899046cd1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_309f52cc-62db-4bf5-929f-396899046cd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b144b2ee-8657-4196-9d31-96ae6dffb66d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_309f52cc-62db-4bf5-929f-396899046cd1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b144b2ee-8657-4196-9d31-96ae6dffb66d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_a86f07a4-6881-4a97-90f8-fdbb6a181283" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b144b2ee-8657-4196-9d31-96ae6dffb66d" xlink:to="loc_srt_DirectorMember_a86f07a4-6881-4a97-90f8-fdbb6a181283" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails" xlink:type="extended" id="iba741b1ee5c0434cbdadcf8642a87489_EquityIncentivePlansOptionActivityDetails"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansOptionFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:type="extended" id="i14445cfae8dd46b4863db4527f93d7cf_EquityIncentivePlansOptionFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_829fa3ee-fc79-4d31-acbc-ecb142ca07e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dcfc988e-4324-4e09-80a6-c28ae13498be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_829fa3ee-fc79-4d31-acbc-ecb142ca07e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dcfc988e-4324-4e09-80a6-c28ae13498be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_97de8361-9199-4cd5-8de8-050dc4d721e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_829fa3ee-fc79-4d31-acbc-ecb142ca07e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_97de8361-9199-4cd5-8de8-050dc4d721e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_54d02cd4-a1a7-4e1b-81eb-4978be359c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_829fa3ee-fc79-4d31-acbc-ecb142ca07e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_54d02cd4-a1a7-4e1b-81eb-4978be359c15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44f5c61d-e582-41b7-9745-f7eecf6068c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_829fa3ee-fc79-4d31-acbc-ecb142ca07e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44f5c61d-e582-41b7-9745-f7eecf6068c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_be866d0b-1b8e-416b-b18a-15f2a13109f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_829fa3ee-fc79-4d31-acbc-ecb142ca07e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_be866d0b-1b8e-416b-b18a-15f2a13109f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a235c515-5582-4f74-a119-955dfaec77fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_829fa3ee-fc79-4d31-acbc-ecb142ca07e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a235c515-5582-4f74-a119-955dfaec77fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dfcba747-1669-4310-aff9-59f11b14606a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a235c515-5582-4f74-a119-955dfaec77fb" xlink:to="loc_us-gaap_AwardTypeAxis_dfcba747-1669-4310-aff9-59f11b14606a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dfcba747-1669-4310-aff9-59f11b14606a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dfcba747-1669-4310-aff9-59f11b14606a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dfcba747-1669-4310-aff9-59f11b14606a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53a7c55d-f0a0-48c9-8a81-a69e67745d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dfcba747-1669-4310-aff9-59f11b14606a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53a7c55d-f0a0-48c9-8a81-a69e67745d18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2b56fec0-e2d3-49bc-8420-f3751c9a9f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53a7c55d-f0a0-48c9-8a81-a69e67745d18" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2b56fec0-e2d3-49bc-8420-f3751c9a9f0f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails" xlink:type="extended" id="i29ffea6d09b24666a0be647bd78eeba1_EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_960c6dbe-a1de-4c14-8566-201140d99640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_3a20d973-fe1f-4b67-bf11-4ad532023498" xlink:href="anab-20200930.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_960c6dbe-a1de-4c14-8566-201140d99640" xlink:to="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_3a20d973-fe1f-4b67-bf11-4ad532023498" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e92fda97-ffa9-4275-9517-96d05b6d7f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_960c6dbe-a1de-4c14-8566-201140d99640" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e92fda97-ffa9-4275-9517-96d05b6d7f40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3eded385-f592-4493-87b6-f9cba3a4f27f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e92fda97-ffa9-4275-9517-96d05b6d7f40" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3eded385-f592-4493-87b6-f9cba3a4f27f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3eded385-f592-4493-87b6-f9cba3a4f27f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3eded385-f592-4493-87b6-f9cba3a4f27f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3eded385-f592-4493-87b6-f9cba3a4f27f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_479b8ec2-f1e3-4e43-b3f4-b6b92e347493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3eded385-f592-4493-87b6-f9cba3a4f27f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_479b8ec2-f1e3-4e43-b3f4-b6b92e347493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f9411078-f4d9-4a19-9fcc-90094e646e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_479b8ec2-f1e3-4e43-b3f4-b6b92e347493" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f9411078-f4d9-4a19-9fcc-90094e646e07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_661c63bf-062b-4240-8e6e-162b61b5bb19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_479b8ec2-f1e3-4e43-b3f4-b6b92e347493" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_661c63bf-062b-4240-8e6e-162b61b5bb19" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingencies" xlink:type="extended" id="icd69df4b21af4eb990e46e56a892c2ba_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="ia9ce4f9b22ef4edb82b1a747131c170f_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i7c3f1def931e42da90997d35722b146d_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseNumber_00f1a249-a3dc-46b2-b2e1-1d63ea6d3158" xlink:href="anab-20200930.xsd#anab_LesseeOperatingLeaseNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_anab_LesseeOperatingLeaseNumber_00f1a249-a3dc-46b2-b2e1-1d63ea6d3158" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_42e33d33-a17d-4271-9917-60fe06a2d2e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_42e33d33-a17d-4271-9917-60fe06a2d2e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_fce18844-a4af-4aa1-aabd-288613add4d0" xlink:href="anab-20200930.xsd#anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_fce18844-a4af-4aa1-aabd-288613add4d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f7aa34e4-ef53-40b9-b006-7c72dc17536a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f7aa34e4-ef53-40b9-b006-7c72dc17536a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_5e29668b-1f29-4125-85b4-91d8444e265b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_5e29668b-1f29-4125-85b4-91d8444e265b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0d705bb0-b471-42ef-823a-bd65a4ae0f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0d705bb0-b471-42ef-823a-bd65a4ae0f9f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_f00ff885-7b53-4548-874e-fb1a3a8cd3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_f00ff885-7b53-4548-874e-fb1a3a8cd3b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_24b947fe-b830-46f3-acdd-28ec08d6e5ad" xlink:href="anab-20200930.xsd#anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_24b947fe-b830-46f3-acdd-28ec08d6e5ad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RentPerSquareFoot_8e07cc17-8837-4dd8-9dd8-3a22a61ab280" xlink:href="anab-20200930.xsd#anab_RentPerSquareFoot"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_anab_RentPerSquareFoot_8e07cc17-8837-4dd8-9dd8-3a22a61ab280" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnnualRentIncreasePercent_4a96356a-6a98-45bc-ac62-a31fd987e1da" xlink:href="anab-20200930.xsd#anab_AnnualRentIncreasePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_anab_AnnualRentIncreasePercent_4a96356a-6a98-45bc-ac62-a31fd987e1da" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent_b252d8ae-e1c8-43b9-a8f9-00dc80b31ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_PrepaidRent_b252d8ae-e1c8-43b9-a8f9-00dc80b31ef5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_ca548509-c9c2-458e-b03d-2f9a4293eb08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_SecurityDeposit_ca548509-c9c2-458e-b03d-2f9a4293eb08" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24c8bed6-8f70-4eb5-b6b5-e66272fdb609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24c8bed6-8f70-4eb5-b6b5-e66272fdb609" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LeaseArrangementAxis_1dbc0d0d-5c43-460a-b15c-ca1bb5f351c9" xlink:href="anab-20200930.xsd#anab_LeaseArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24c8bed6-8f70-4eb5-b6b5-e66272fdb609" xlink:to="loc_anab_LeaseArrangementAxis_1dbc0d0d-5c43-460a-b15c-ca1bb5f351c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LeaseArrangementDomain_1dbc0d0d-5c43-460a-b15c-ca1bb5f351c9_default" xlink:href="anab-20200930.xsd#anab_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_anab_LeaseArrangementAxis_1dbc0d0d-5c43-460a-b15c-ca1bb5f351c9" xlink:to="loc_anab_LeaseArrangementDomain_1dbc0d0d-5c43-460a-b15c-ca1bb5f351c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LeaseArrangementDomain_5e65844b-b1f5-45e0-8f13-cd482e461615" xlink:href="anab-20200930.xsd#anab_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_anab_LeaseArrangementAxis_1dbc0d0d-5c43-460a-b15c-ca1bb5f351c9" xlink:to="loc_anab_LeaseArrangementDomain_5e65844b-b1f5-45e0-8f13-cd482e461615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_OneOfficeLeaseMember_c21a8a35-3caa-4044-9328-e95360ccba9b" xlink:href="anab-20200930.xsd#anab_OneOfficeLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anab_LeaseArrangementDomain_5e65844b-b1f5-45e0-8f13-cd482e461615" xlink:to="loc_anab_OneOfficeLeaseMember_c21a8a35-3caa-4044-9328-e95360ccba9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member_335b0eda-a68f-416a-be00-1a199eab2436" xlink:href="anab-20200930.xsd#anab_A10770WateridgeCircleSanDiegoCalifornia92121Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anab_LeaseArrangementDomain_5e65844b-b1f5-45e0-8f13-cd482e461615" xlink:to="loc_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member_335b0eda-a68f-416a-be00-1a199eab2436" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesClassificationontheBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails" xlink:type="extended" id="i96601ddf23ac4e84a34a76af98c3ae63_CommitmentsandContingenciesClassificationontheBalanceSheetDetails"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails" xlink:type="extended" id="ia22521e8801f4cf39a2bfa82b827b3d7_CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails" xlink:type="extended" id="iab1da22b78a045b1b9920e495f995670_CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="anab-20200930.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SubsequentEvents" xlink:type="extended" id="ied7c758f26a74abb935604b942263964_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SubsequentEventDetails" xlink:type="extended" id="iaa52c3b9f638432e80d9e73a5776d879_SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent_47e421c4-47c6-4814-ab90-73ae02abf2d3" xlink:href="anab-20200930.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:to="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent_47e421c4-47c6-4814-ab90-73ae02abf2d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent_393086b1-5878-47c3-ae0d-1356b5b0cba5" xlink:href="anab-20200930.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:to="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent_393086b1-5878-47c3-ae0d-1356b5b0cba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_cdb796ff-be7b-4fd4-9f2c-904d26212f64" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:to="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_cdb796ff-be7b-4fd4-9f2c-904d26212f64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_b534a2bf-f8cc-4df7-b0d1-415c5c3181d3" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_b534a2bf-f8cc-4df7-b0d1-415c5c3181d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_NetSalesRoyaltyPercent_af797034-2739-4662-99c6-7473e03a36ad" xlink:href="anab-20200930.xsd#anab_NetSalesRoyaltyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:to="loc_anab_NetSalesRoyaltyPercent_af797034-2739-4662-99c6-7473e03a36ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable_95329a03-5a56-43b4-94f6-3d083e7c5301" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:to="loc_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable_95329a03-5a56-43b4-94f6-3d083e7c5301" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:to="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a4518508-42fc-4c8f-9073-9e169024461b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a4518508-42fc-4c8f-9073-9e169024461b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a4518508-42fc-4c8f-9073-9e169024461b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a4518508-42fc-4c8f-9073-9e169024461b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a4518508-42fc-4c8f-9073-9e169024461b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2b103617-32c4-4f7b-bf3f-1daf6fe5de80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a4518508-42fc-4c8f-9073-9e169024461b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2b103617-32c4-4f7b-bf3f-1daf6fe5de80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dfd137bb-9a20-4681-89fa-7384a2823f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2b103617-32c4-4f7b-bf3f-1daf6fe5de80" xlink:to="loc_us-gaap_SubsequentEventMember_dfd137bb-9a20-4681-89fa-7384a2823f45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3a5c6fac-a66d-4b1b-8b8b-facd0f0bc207" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:to="loc_srt_ProductOrServiceAxis_3a5c6fac-a66d-4b1b-8b8b-facd0f0bc207" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3a5c6fac-a66d-4b1b-8b8b-facd0f0bc207_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3a5c6fac-a66d-4b1b-8b8b-facd0f0bc207" xlink:to="loc_srt_ProductsAndServicesDomain_3a5c6fac-a66d-4b1b-8b8b-facd0f0bc207_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_14bf05d1-2924-49d1-8042-527174235909" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3a5c6fac-a66d-4b1b-8b8b-facd0f0bc207" xlink:to="loc_srt_ProductsAndServicesDomain_14bf05d1-2924-49d1-8042-527174235909" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_9b666a61-38b2-4c0d-b847-0fd69a055e14" xlink:href="anab-20200930.xsd#anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_14bf05d1-2924-49d1-8042-527174235909" xlink:to="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_9b666a61-38b2-4c0d-b847-0fd69a055e14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f08b41ae-8a21-41e7-9811-709c99db8630" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:to="loc_srt_CounterpartyNameAxis_f08b41ae-8a21-41e7-9811-709c99db8630" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f08b41ae-8a21-41e7-9811-709c99db8630_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f08b41ae-8a21-41e7-9811-709c99db8630" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f08b41ae-8a21-41e7-9811-709c99db8630_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f293b4b2-5c54-4f4a-ba08-b3ad6fae2e85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f08b41ae-8a21-41e7-9811-709c99db8630" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f293b4b2-5c54-4f4a-ba08-b3ad6fae2e85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member_bcbb59a0-787d-485a-9589-0c00a6a7595c" xlink:href="anab-20200930.xsd#anab_TESAROInc.AndTESARODevelopmentInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f293b4b2-5c54-4f4a-ba08-b3ad6fae2e85" xlink:to="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member_bcbb59a0-787d-485a-9589-0c00a6a7595c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8e54ecb1-1027-4ba8-994b-46128be40962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8e54ecb1-1027-4ba8-994b-46128be40962" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e54ecb1-1027-4ba8-994b-46128be40962_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8e54ecb1-1027-4ba8-994b-46128be40962" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e54ecb1-1027-4ba8-994b-46128be40962_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de021c6c-2397-43f5-841e-7eb96fd50b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8e54ecb1-1027-4ba8-994b-46128be40962" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de021c6c-2397-43f5-841e-7eb96fd50b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CollaborationAndExclusiveLicenseAgreementMember_731071b6-7d90-4609-90e8-f906bdb8677c" xlink:href="anab-20200930.xsd#anab_CollaborationAndExclusiveLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de021c6c-2397-43f5-841e-7eb96fd50b0c" xlink:to="loc_anab_CollaborationAndExclusiveLicenseAgreementMember_731071b6-7d90-4609-90e8-f906bdb8677c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4a9da63e-f979-46fd-b718-38e2c4726efb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:to="loc_srt_RangeAxis_4a9da63e-f979-46fd-b718-38e2c4726efb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4a9da63e-f979-46fd-b718-38e2c4726efb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4a9da63e-f979-46fd-b718-38e2c4726efb" xlink:to="loc_srt_RangeMember_4a9da63e-f979-46fd-b718-38e2c4726efb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ee8a5cc2-a7a2-43f2-bb6a-9bd1927418e6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4a9da63e-f979-46fd-b718-38e2c4726efb" xlink:to="loc_srt_RangeMember_ee8a5cc2-a7a2-43f2-bb6a-9bd1927418e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b21dee62-8abd-4df7-a002-10919d8e945f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ee8a5cc2-a7a2-43f2-bb6a-9bd1927418e6" xlink:to="loc_srt_MinimumMember_b21dee62-8abd-4df7-a002-10919d8e945f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d11ff4ad-dc2b-43e9-82e8-fecb55f1819f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ee8a5cc2-a7a2-43f2-bb6a-9bd1927418e6" xlink:to="loc_srt_MaximumMember_d11ff4ad-dc2b-43e9-82e8-fecb55f1819f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_df3eb441-7810-4800-91df-fa743553866d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:to="loc_srt_StatementScenarioAxis_df3eb441-7810-4800-91df-fa743553866d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_df3eb441-7810-4800-91df-fa743553866d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_df3eb441-7810-4800-91df-fa743553866d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_df3eb441-7810-4800-91df-fa743553866d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a1c5ccd5-242c-4aab-8841-98ce59f526e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_df3eb441-7810-4800-91df-fa743553866d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a1c5ccd5-242c-4aab-8841-98ce59f526e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_75d72e61-27e3-4fcd-b437-848bce2f1a61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a1c5ccd5-242c-4aab-8841-98ce59f526e9" xlink:to="loc_srt_ScenarioForecastMember_75d72e61-27e3-4fcd-b437-848bce2f1a61" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>anab-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:721272a1-28f6-479d-8921-55bf3792b729,g:e6e63eaa-4a73-42e1-87eb-dda12e114757-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_f9391170-bd9e-483f-880b-e816796993f5_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of leased property (sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_CommercialAndCorporateObligationsMember_1fffc189-c20a-4766-9395-5b5e5ea386a1_verboseLabel_en-US" xlink:label="lab_anab_CommercialAndCorporateObligationsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and corporate obligations</link:label>
    <link:label id="lab_anab_CommercialAndCorporateObligationsMember_label_en-US" xlink:label="lab_anab_CommercialAndCorporateObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Corporate Obligations [Member]</link:label>
    <link:label id="lab_anab_CommercialAndCorporateObligationsMember_documentation_en-US" xlink:label="lab_anab_CommercialAndCorporateObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Corporate Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommercialAndCorporateObligationsMember" xlink:href="anab-20200930.xsd#anab_CommercialAndCorporateObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CommercialAndCorporateObligationsMember" xlink:to="lab_anab_CommercialAndCorporateObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2e39798d-9f62-4e51-ba44-57b9d9b2790e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_d95245be-5b32-488c-9b95-86bbf4c55e69_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e60013f5-84fc-46a0-8967-d76b10c33292_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_17665deb-9540-43be-8995-fc7050178c11_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued and Outstanding:</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_79a3c4e1-cd3e-402e-becf-143496b629a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b941282b-4422-472d-a341-ebc2a90dbcee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_06940a7a-e802-4da2-83c2-d431a74a627a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f3ea0958-4c8d-47d8-8459-da329d9dc589_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_4fc524f4-0c3b-4cce-9182-604ea766def8_terseLabel_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in number of shares available for issuance</link:label>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_label_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding</link:label>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_documentation_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:href="anab-20200930.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:to="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3d662fad-2d1a-43f4-9e94-afa1cd1e573e_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e4778464-27e1-4fb8-9611-320beb57f006_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7e710b89-6d70-4d1d-a698-f97856ae60da_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a7bc4af1-0bea-4f53-b035-ef2a2249064b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e3cf91de-3918-4c4a-b450-e183abf04df6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_9341d751-c677-4e1f-8ca9-8d10ca282ff4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_22e4a9d7-d82c-48c4-bfb8-4d394fbc0137_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8fd29ca6-90ae-4697-b676-34405bf1d81f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_b5b1d124-1472-4db6-842c-58086c114422_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final payment fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_dc143e44-f5c6-47e9-943b-c3089b6169a9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_3b6f74d3-3247-4c78-bbb8-6065414e60be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent_7a437ee3-32aa-4e23-b2d8-756112699039_terseLabel_en-US" xlink:label="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research, development and manufacturing expenses</link:label>
    <link:label id="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent_label_en-US" xlink:label="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expenses, Current</link:label>
    <link:label id="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent_documentation_en-US" xlink:label="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:href="anab-20200930.xsd#anab_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_fe51a7d9-7e39-470a-9244-eb23a8dc9f0b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_59731022-5e13-4777-8303-c63fd2e21284_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_671b8ece-bb58-46d9-bff9-934a3f98147b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11ca0fea-86d4-4313-aca2-76efebdb3573_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Weighted Average Assumptions in Stock Option Valuations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_DebtInstrumentNumberOfLoanInstallments_27210fe1-7d07-441a-ac9e-df45072aec40_terseLabel_en-US" xlink:label="lab_anab_DebtInstrumentNumberOfLoanInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of loan installments (in installments)</link:label>
    <link:label id="lab_anab_DebtInstrumentNumberOfLoanInstallments_label_en-US" xlink:label="lab_anab_DebtInstrumentNumberOfLoanInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Loan Installments</link:label>
    <link:label id="lab_anab_DebtInstrumentNumberOfLoanInstallments_documentation_en-US" xlink:label="lab_anab_DebtInstrumentNumberOfLoanInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Loan Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_DebtInstrumentNumberOfLoanInstallments" xlink:href="anab-20200930.xsd#anab_DebtInstrumentNumberOfLoanInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_DebtInstrumentNumberOfLoanInstallments" xlink:to="lab_anab_DebtInstrumentNumberOfLoanInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f246b3af-9d8d-497d-9397-caabc1daf626_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d21a687d-656f-47ba-8597-5f44f6d92fcb_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0a8b84c4-0985-4204-be2f-ede5a7a71bbf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements and Available for Sale Investments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_908bf604-3f1d-4906-915c-ad0b07197b28_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_95250ddd-a830-4e71-b931-1daab4c01d1a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9c2f5a65-67b2-427b-96e9-142c48ea222e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d5cf6298-6717-4951-9e21-65320d7ee867_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_ca2a4e1f-b010-4835-899c-ab82c0f76b9c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6b875716-f73f-45d2-9315-3bfa950260ea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1fcb3ef6-53a4-4ea9-a0f6-190009ea6268_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8e9303a4-72c9-4475-b028-520f1c49ea85_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ef08b15a-7fab-48d6-83a3-86023a49ac9a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_bb97b930-2d0d-4c44-b38d-bebcb84a8bb2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f18b47f2-949e-4c49-a55d-07851be2e4d1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_8ad6a551-0f18-49ff-9866-e087e9e84bee_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_TESAROInc.AndTESARODevelopmentInc.Member_2b942389-2c27-4e85-8824-e99b67684995_terseLabel_en-US" xlink:label="lab_anab_TESAROInc.AndTESARODevelopmentInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TESARO</link:label>
    <link:label id="lab_anab_TESAROInc.AndTESARODevelopmentInc.Member_label_en-US" xlink:label="lab_anab_TESAROInc.AndTESARODevelopmentInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TESARO, Inc. And TESARO Development, Inc. [Member]</link:label>
    <link:label id="lab_anab_TESAROInc.AndTESARODevelopmentInc.Member_documentation_en-US" xlink:label="lab_anab_TESAROInc.AndTESARODevelopmentInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TESARO, Inc. And TESARO Development, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member" xlink:href="anab-20200930.xsd#anab_TESAROInc.AndTESARODevelopmentInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member" xlink:to="lab_anab_TESAROInc.AndTESARODevelopmentInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6fad26bd-1432-46d8-ba00-78a7af615764_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_4823a5d4-cc72-4a1c-9b6d-ec5e9467e1ae_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_720c47c6-a64a-4283-a69a-11ff706e0c58_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dd2f7a77-4221-437a-93cb-69925fffa1c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ec10fdfa-f156-4ccf-b506-ba61ca9183d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aed242a0-b0b3-4650-a697-06947b63d156_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_ff2ce53d-c8de-41c9-a0e0-693fcd2b4697_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6fa38334-b08d-41c0-ad96-224aac2124d4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_46cf7711-9d98-40f9-bb62-43bbaebe7f45_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_516d9436-e2d0-4d13-913d-f460108bf224_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_21469f62-0022-4f13-b896-d22cc54b8dfc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_32b10ab0-7792-464e-ab67-d5c49c0571c7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_627c99f8-6888-4a7a-ba1b-e1b6e2a48a5c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_e9feb668-f916-4819-be39-fe0541464f29_terseLabel_en-US" xlink:label="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="anab-20200930.xsd#anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47e6d267-d41b-48bc-ae33-3121f2d04409_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_daa00666-d3f9-4199-9f0e-5867cd84a941_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7c144478-ebf3-49fc-bf7d-d3fb5a66175a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating ROU assets, Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e5ecd903-a76f-4523-b88f-5f3ee60a7916_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum payments required</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_f943712b-7650-45b5-ba22-f1fc044d2130_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_NetSalesRoyaltyPercent_5b434c47-f2b8-46e3-a844-86d8f11bb455_terseLabel_en-US" xlink:label="lab_anab_NetSalesRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percent on net sales</link:label>
    <link:label id="lab_anab_NetSalesRoyaltyPercent_label_en-US" xlink:label="lab_anab_NetSalesRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Royalty, Percent</link:label>
    <link:label id="lab_anab_NetSalesRoyaltyPercent_documentation_en-US" xlink:label="lab_anab_NetSalesRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Royalty, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_NetSalesRoyaltyPercent" xlink:href="anab-20200930.xsd#anab_NetSalesRoyaltyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_NetSalesRoyaltyPercent" xlink:to="lab_anab_NetSalesRoyaltyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e0073c9b-9f1c-4d8a-8841-86e3d2b97232_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_CelgeneCorporationMember_c6edf375-0baa-4ed9-a729-03dfd32fc597_terseLabel_en-US" xlink:label="lab_anab_CelgeneCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene Corporation</link:label>
    <link:label id="lab_anab_CelgeneCorporationMember_label_en-US" xlink:label="lab_anab_CelgeneCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene Corporation [Member]</link:label>
    <link:label id="lab_anab_CelgeneCorporationMember_documentation_en-US" xlink:label="lab_anab_CelgeneCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CelgeneCorporationMember" xlink:href="anab-20200930.xsd#anab_CelgeneCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CelgeneCorporationMember" xlink:to="lab_anab_CelgeneCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eb4fb485-b65e-4a12-876a-ac2f2c561de3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options issued and outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d40bea3c-ae01-46a2-ba0d-906d1ed212a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_527a7986-434b-4073-b863-5a5c1027b9d1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_119cd3b9-ed3d-41a2-9068-31d8639e6b0d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b37ba78c-68c5-4a1f-861e-316167e2b76f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a3dc572e-3875-4407-981c-1ed60e434af2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_TermBLoansAndTermCLoansMember_d5a42644-674e-4037-8769-e38f7c9534a2_terseLabel_en-US" xlink:label="lab_anab_TermBLoansAndTermCLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B and Term C Loans</link:label>
    <link:label id="lab_anab_TermBLoansAndTermCLoansMember_label_en-US" xlink:label="lab_anab_TermBLoansAndTermCLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loans And Term C Loans [Member]</link:label>
    <link:label id="lab_anab_TermBLoansAndTermCLoansMember_documentation_en-US" xlink:label="lab_anab_TermBLoansAndTermCLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loans And Term C Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_TermBLoansAndTermCLoansMember" xlink:href="anab-20200930.xsd#anab_TermBLoansAndTermCLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_TermBLoansAndTermCLoansMember" xlink:to="lab_anab_TermBLoansAndTermCLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_361c26fc-9c57-4854-8db4-8752884f031c_terseLabel_en-US" xlink:label="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IND clearance from the FDA</link:label>
    <link:label id="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_label_en-US" xlink:label="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearance Of Investigational New Drug From FDA [Member]</link:label>
    <link:label id="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_documentation_en-US" xlink:label="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearance Of Investigational New Drug From FDA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:href="anab-20200930.xsd#anab_ClearanceOfInvestigationalNewDrugFromFDAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:to="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RentPerSquareFoot_1b9abf6c-ecc8-438f-89ed-0ef898d875ae_terseLabel_en-US" xlink:label="lab_anab_RentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base rate (usd per sqft)</link:label>
    <link:label id="lab_anab_RentPerSquareFoot_label_en-US" xlink:label="lab_anab_RentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Per Square Foot</link:label>
    <link:label id="lab_anab_RentPerSquareFoot_documentation_en-US" xlink:label="lab_anab_RentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Per Square Foot</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RentPerSquareFoot" xlink:href="anab-20200930.xsd#anab_RentPerSquareFoot"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RentPerSquareFoot" xlink:to="lab_anab_RentPerSquareFoot" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AssetsAndLiabilitiesLesseeTableTextBlock_b69e1eaa-3d75-45ee-bf57-5c2f7f86032c_terseLabel_en-US" xlink:label="lab_anab_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification on the Balance Sheet</link:label>
    <link:label id="lab_anab_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_anab_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_anab_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_anab_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="anab-20200930.xsd#anab_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_anab_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_fdf8c1f4-e02a-4e24-bf68-08f42e3925ba_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_7a9eb0fa-5631-4040-b822-ac4bc1854877_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_aff16f51-bca6-48e2-8fa4-06d0990c88d9_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_c2980289-f42b-4272-b2f7-3b35ff945a79_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at September 30, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent_efede9a2-1aa8-4111-876a-e23c1b0de03a_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of net sales above $1 billion</link:label>
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent_label_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognized, Milestone Method, Milestone Payment Earned, Net Sales above $1 Billion, Percent</link:label>
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent_documentation_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognized, Milestone Method, Milestone Payment Earned, Net Sales above $1 Billion, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent" xlink:href="anab-20200930.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent" xlink:to="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_dd2cf801-fc4a-49a3-9edc-94ef25dba0a6_terseLabel_en-US" xlink:label="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments outstanding, maturity date range (in years)</link:label>
    <link:label id="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_label_en-US" xlink:label="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Debt Securities, Remaining Maturity</link:label>
    <link:label id="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_documentation_en-US" xlink:label="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Debt Securities, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:href="anab-20200930.xsd#anab_AvailableforsaleDebtSecuritiesRemainingMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:to="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4418547-b777-427f-ab2b-3b1a7e03aafb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_53ef09f3-8779-480f-ae40-c9a669d34e1f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_5e11ea5d-a627-423a-a13c-6b87f2998df2_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5fc3b51e-92e3-4363-85a1-7dfbb239b4d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercisable, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_e7558340-8c71-4275-8e5e-ee7351062442_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payments per target</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_19814690-9d49-4c30-a188-71c42d8b9f38_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_08cc0c37-53f0-4cfb-9f06-58baadecf311_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_29344dfd-cf1b-4c9c-a39a-e534975602f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Greater, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2ab7670d-4ab3-4236-98dc-9e16d8d87ac7_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3303035f-4783-4aa3-ab8e-da5861ff2227_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_71083fb6-09a5-4fbb-a4eb-2102de1c751d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeitures and cancellations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_LoanAndSecurityAgreementMember_585c5d36-0b67-40fe-87aa-b94269c7c586_terseLabel_en-US" xlink:label="lab_anab_LoanAndSecurityAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan and Security Agreement (LSA)</link:label>
    <link:label id="lab_anab_LoanAndSecurityAgreementMember_label_en-US" xlink:label="lab_anab_LoanAndSecurityAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan And Security Agreement [Member]</link:label>
    <link:label id="lab_anab_LoanAndSecurityAgreementMember_documentation_en-US" xlink:label="lab_anab_LoanAndSecurityAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan And Security Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LoanAndSecurityAgreementMember" xlink:href="anab-20200930.xsd#anab_LoanAndSecurityAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LoanAndSecurityAgreementMember" xlink:to="lab_anab_LoanAndSecurityAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0128e14e-2f13-4942-96d3-723613c01d26_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_f056a4e0-fe30-475e-84f6-efebe6eecf61_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate borrowing capacity</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5c7dff41-4e51-408f-b941-2dbf9cf1b6a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other&#160;Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_555b9926-329c-43ea-8cce-8f3ae361d157_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeitures and cancellations (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_324ee306-c358-4a6d-aecb-98ed5a558dfc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9363d1fa-e569-4075-8a22-07c71069162a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_ebfffadd-fbc4-4209-8156-97f04241c524_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_78d960c0-a86c-467a-a57e-ab7d993bb776_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_27759ee3-d4d6-40fd-81fb-229269054796_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_2fe9211c-76ee-4998-8fb2-945c9a6a56a3_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to)</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c1b3872f-0879-49c5-9e0b-54ccb3626542_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_40ac2098-615c-4352-b4c9-05409a691cb6_terseLabel_en-US" xlink:label="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments at fair value</link:label>
    <link:label id="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_label_en-US" xlink:label="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure</link:label>
    <link:label id="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_documentation_en-US" xlink:label="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:href="anab-20200930.xsd#anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:to="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86e667aa-05f2-4e34-b4c1-e8d9020b742b_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3c3a771a-d3f3-4dc4-bbf9-8a4a66b62d89_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b4d8a026-3e27-495d-98a6-8b3039bcbe7d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_895ecc3b-3dc6-4b98-9245-df3620e14d5b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_97bc70e4-ac7d-4e30-b421-69fdebe74389_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6cd7ef31-cce0-4b32-9409-0c5eb8a73cf6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_adac68ee-b9c4-44f2-bdee-84454c612411_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a91d4f8e-b660-417e-ad02-d491d2cc3359_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_08bd7684-8af8-4a6d-bf5f-dc4502502e6f_terseLabel_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-TIM-3 (GSK4069889A/Cobolimab)</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_label_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio Generated Anti-TIM3 Antagonist Antibody (TSR-022) [Member]</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_documentation_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio Generated Anti-TIM3 Antagonist Antibody (TSR-022) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member" xlink:href="anab-20200930.xsd#anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member" xlink:to="lab_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MutualFundMember_06f7630f-4efe-4609-9de8-5230c47c947f_terseLabel_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_us-gaap_MutualFundMember_label_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Fund [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MutualFundMember" xlink:to="lab_us-gaap_MutualFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fff8046a-1037-41f5-a12f-6e596778e743_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_ef1c22be-7ca3-4319-b9ff-864c168e6243_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_b4d09cb5-4a18-4afa-b578-e65a342f2aa9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_e77cbdab-b965-4fca-b374-416a3e72c92d_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion/amortization of investments, net</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b13666d4-ed40-4d9b-aa83-d062a8138851_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4a0a3d63-5106-4f0a-bf06-cd26178ad0b1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_d761ddd2-77f5-4879-9b3e-6c87682b8391_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_131ccb71-5167-431a-9bd5-1f7cefbfcf30_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_21a82d3f-89ea-43c5-a971-344532b86106_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_74e019ef-5090-413d-ac62-6ca4eecb8489_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_174c2829-f25e-4a74-b9b5-b37578593e94_terseLabel_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="anab-20200930.xsd#anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_baf945ba-81d5-4742-a24c-31b27a10dd18_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d2123bc4-08d4-48e8-9315-39343e53aa74_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5ccff46c-fe51-4497-a4d9-c26b0167166c_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_4d22742f-0dfa-4643-94ba-11438e2bf75f_terseLabel_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease termination term</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_label_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_documentation_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:href="anab-20200930.xsd#anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:to="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f5a1500d-d86d-4e03-bb62-89b1c7ca4f6e_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_7244d2e7-3149-4de0-aca6-78ceec10298e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares outstanding:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0bab999c-5b8e-4670-9dbe-bf99438de2e4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 500,000 shares authorized, 27,346 shares and 27,255 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_372646aa-05bb-464d-9c07-540f6f6f4c48_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable_e54b9954-6fc3-4cb1-93ce-32fb7765a920_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Receivable</link:label>
    <link:label id="lab_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable_label_en-US" xlink:label="lab_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Receivable</link:label>
    <link:label id="lab_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable" xlink:to="lab_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_6fa0ec65-a24b-46b4-8508-28266ad20f61_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_FilingofMMAMember_dff27e5d-081a-4869-b103-02359038d909_terseLabel_en-US" xlink:label="lab_anab_FilingofMMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of the first MAA - first indication</link:label>
    <link:label id="lab_anab_FilingofMMAMember_label_en-US" xlink:label="lab_anab_FilingofMMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of MMA [Member]</link:label>
    <link:label id="lab_anab_FilingofMMAMember_documentation_en-US" xlink:label="lab_anab_FilingofMMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of MMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingofMMAMember" xlink:href="anab-20200930.xsd#anab_FilingofMMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_FilingofMMAMember" xlink:to="lab_anab_FilingofMMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_FilingofNDAMember_645720cf-3bcd-4d37-8675-5cf69ddf3dc2_terseLabel_en-US" xlink:label="lab_anab_FilingofNDAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of the first NDA - first indication</link:label>
    <link:label id="lab_anab_FilingofNDAMember_label_en-US" xlink:label="lab_anab_FilingofNDAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of NDA [Member]</link:label>
    <link:label id="lab_anab_FilingofNDAMember_documentation_en-US" xlink:label="lab_anab_FilingofNDAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of NDA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingofNDAMember" xlink:href="anab-20200930.xsd#anab_FilingofNDAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_FilingofNDAMember" xlink:to="lab_anab_FilingofNDAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_c6494d5b-79cf-4710-8100-16002fe25328_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_182a440a-6c4b-411d-a88e-1474d5d4b841_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_720edb22-824f-47de-9d80-8b7d228c9b48_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_c4227726-1ba2-453e-b8e2-2eddd886438f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7693d96a-8610-4df6-a243-0b1f423e98fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4071c4f2-9af0-4fdb-b355-c70fd7ff3673_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_a7462ef2-2760-4b23-81ff-a3c3ce7ec2c4_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments, contingent upon preclinical and clinical trial events (up to)</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_05f189eb-232b-434f-8b0f-fab8b464c273_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, options exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_28a715d6-d8dc-499a-a84a-6906f20944d7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Research And Development Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_46bb9481-7316-4ef1-b1ae-a5517414894b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_157b269a-7389-4ac8-9bfc-8ad17c4767b2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_69e8fba1-570b-43b3-a526-1f65cc7f44ce_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_758d9f64-b39c-4f70-9a1c-f0206989897a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidRent_a4b7466b-48e6-41c4-a116-0f02ca9dc952_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid rent</link:label>
    <link:label id="lab_us-gaap_PrepaidRent_label_en-US" xlink:label="lab_us-gaap_PrepaidRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRent" xlink:to="lab_us-gaap_PrepaidRent" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AnnualRentIncreasePercent_99b890eb-1356-460c-b8b0-8ee67add1cd4_terseLabel_en-US" xlink:label="lab_anab_AnnualRentIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in annual rent</link:label>
    <link:label id="lab_anab_AnnualRentIncreasePercent_label_en-US" xlink:label="lab_anab_AnnualRentIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Rent Increase, Percent</link:label>
    <link:label id="lab_anab_AnnualRentIncreasePercent_documentation_en-US" xlink:label="lab_anab_AnnualRentIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Rent Increase, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnnualRentIncreasePercent" xlink:href="anab-20200930.xsd#anab_AnnualRentIncreasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnnualRentIncreasePercent" xlink:to="lab_anab_AnnualRentIncreasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_4a470957-6931-4666-9df3-45ad84869685_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_c78a8859-fd5e-417f-84d2-6dd38f2bb3f8_terseLabel_en-US" xlink:label="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims</link:label>
    <link:label id="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_documentation_en-US" xlink:label="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="anab-20200930.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c3b5d273-46c7-4975-928e-69ee94214bfd_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_02efdfa6-c182-4c2a-bdc3-ed127fc26c02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_8249f0d3-0aa8-4fd3-98e9-15c7012c4982_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Research and Development Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6081184e-ec46-4ac8-99fb-7f7ccaa0a26b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_45e19ea5-290e-4104-9265-e5f0ec1bef1b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8280297b-601e-4379-8caa-7ae0cf0abbfb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4ba7fdb6-27a7-46a7-bbce-092b8d859c70_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f9f22f23-0d32-4563-9bcc-2f9945fc47db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future award grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_916eb82f-b5c5-41f0-8494-4cb81910a3cd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1ee7b51d-81d2-4b35-83c5-d49df517b031_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Accounts and Supplemental Disclosures</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_EquityIncentivePlan2017Member_ab95a53c-c89d-4a8b-8e80-8cbc70f9cf30_terseLabel_en-US" xlink:label="lab_anab_EquityIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:label id="lab_anab_EquityIncentivePlan2017Member_label_en-US" xlink:label="lab_anab_EquityIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan, 2017 [Member]</link:label>
    <link:label id="lab_anab_EquityIncentivePlan2017Member_documentation_en-US" xlink:label="lab_anab_EquityIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan, 2017 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EquityIncentivePlan2017Member" xlink:href="anab-20200930.xsd#anab_EquityIncentivePlan2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_EquityIncentivePlan2017Member" xlink:to="lab_anab_EquityIncentivePlan2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0df63489-473b-4ed1-baa0-78d0f0f046a0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_146d4d44-70f5-42d3-9b00-64efba3456a7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_52f4ce1a-2580-4a96-b28a-b2abad133e72_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_da46b531-0bfc-46a8-9104-1b8d29163bbb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_99db627c-ac7a-4c47-8006-e73518beec68_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_25c1c863-dbe8-43a6-8a2b-e889ead6e644_terseLabel_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital shares reserved for future issuance, increase (in shares)</link:label>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_label_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Increase</link:label>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_documentation_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:href="anab-20200930.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:to="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1cc45d3-e102-4933-8c66-632a8e10334d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ac728020-6e7d-4917-9cf5-a626271a90c8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b18d06cd-d7b5-4fa9-8266-c18acbf01ab5_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_bde20564-9837-4c13-b84d-9f6e58c5a082_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_CollaborationAndExclusiveLicenseAgreementMember_56e95945-7bb6-44d2-a338-a2d3b200db79_terseLabel_en-US" xlink:label="lab_anab_CollaborationAndExclusiveLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment</link:label>
    <link:label id="lab_anab_CollaborationAndExclusiveLicenseAgreementMember_label_en-US" xlink:label="lab_anab_CollaborationAndExclusiveLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Exclusive License Agreement [Member]</link:label>
    <link:label id="lab_anab_CollaborationAndExclusiveLicenseAgreementMember_documentation_en-US" xlink:label="lab_anab_CollaborationAndExclusiveLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Exclusive License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CollaborationAndExclusiveLicenseAgreementMember" xlink:href="anab-20200930.xsd#anab_CollaborationAndExclusiveLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CollaborationAndExclusiveLicenseAgreementMember" xlink:to="lab_anab_CollaborationAndExclusiveLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_828b1a72-9880-4081-98c3-ce99671d5d4e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Other Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_5162b936-27f1-4fca-8164-dea0901956fb_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_LeaseArrangementDomain_8472494b-1ac5-4f9b-9d71-e0477d8ddfa7_terseLabel_en-US" xlink:label="lab_anab_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_anab_LeaseArrangementDomain_label_en-US" xlink:label="lab_anab_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_anab_LeaseArrangementDomain_documentation_en-US" xlink:label="lab_anab_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Lease Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LeaseArrangementDomain" xlink:href="anab-20200930.xsd#anab_LeaseArrangementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LeaseArrangementDomain" xlink:to="lab_anab_LeaseArrangementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_1b1a9e26-7a3a-4ee6-98df-1f7aa3fe9fe3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_7de815d9-af80-43d3-a46d-914e89850a34_terseLabel_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-LAG-3 (GSK40974386)</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_label_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio Generated Anti-LAG3 Antagonist Antibody (TSR-033) [Member]</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_documentation_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio Generated Anti-LAG3 Antagonist Antibody (TSR-033) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member" xlink:href="anab-20200930.xsd#anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member" xlink:to="lab_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_d913facb-a926-448a-820e-3f2b61edbe6e_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of outstanding research and development targets</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_a3fea844-1a89-4c75-967d-8d9d0bc4ba71_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Greater, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f9074882-b9fa-48ae-a22d-8d4d6857d68c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ec756a3a-c1bd-4086-ac5f-3aff18d4435b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_9d7d48d5-0fa3-43cd-b10c-335e591e0e67_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts accrued for property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_8586730b-57ad-4770-980f-3a8646367b87_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_6a430279-916d-4e0d-84d5-739eac3fe6c4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_615e2181-601f-4e60-90a4-82dcb89c0239_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_fbbbabea-0944-4224-9bd1-4436c1343314_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_98f35462-7636-4e64-8285-28844eb070df_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_aed5afc2-52e9-421a-ba36-02b0a4c3074b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_431d47e3-4fcb-4feb-93df-088c1af9745d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b4a5ff54-347d-42b3-9b90-776344af3147_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6dea4bc3-e6be-4d46-bb32-1053e80437ec_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_a160a6f1-61fd-43c3-a2a2-ab7c729e13cd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:to="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1527bc74-5900-45c0-84a4-fcd062caa90e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities excluded from computation of net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_76fbee65-2446-4d17-90c4-ab16c0f6486d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_120db8dc-a05a-4889-8aab-f133b15fad47_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_8ce7182a-a02d-4731-910b-5d66b04c36c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0d738c57-d659-4815-b331-06e8c9deabf9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_2341f66b-aa50-45a1-a3f7-fef324b1c857_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_23a53e55-a93e-482a-832f-7a314ae210be_terseLabel_en-US" xlink:label="lab_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of one year renewal options</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_label_en-US" xlink:label="lab_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, One Year Renewal Options, Number</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_documentation_en-US" xlink:label="lab_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, One Year Renewal Options, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber" xlink:href="anab-20200930.xsd#anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber" xlink:to="lab_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_63d94989-94d0-47ad-be38-8438b578b2e6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_EmployeeStockPurchasePlan2017Member_00c5f360-c4b1-4a8a-997d-178ecbef61bf_terseLabel_en-US" xlink:label="lab_anab_EmployeeStockPurchasePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_anab_EmployeeStockPurchasePlan2017Member_label_en-US" xlink:label="lab_anab_EmployeeStockPurchasePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, 2017 [Member]</link:label>
    <link:label id="lab_anab_EmployeeStockPurchasePlan2017Member_documentation_en-US" xlink:label="lab_anab_EmployeeStockPurchasePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, 2017 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member" xlink:href="anab-20200930.xsd#anab_EmployeeStockPurchasePlan2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_EmployeeStockPurchasePlan2017Member" xlink:to="lab_anab_EmployeeStockPurchasePlan2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_cb3d3743-f558-4623-b34c-7b428f9594c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_02bf0d97-8f8e-4fae-8fe6-ee88949ad46f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_aed27dda-a849-4165-9cb1-af7a5c8aa6ad_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f04577d8-da2e-4b12-a16f-32f60c2bc018_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_06b0ba59-a886-47e4-87b7-bdc939273cdb_terseLabel_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-PD-1 (CC-90006)</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_label_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member]</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_documentation_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:href="anab-20200930.xsd#anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:to="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_1955d958-4feb-4f77-9208-f5df737a646f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_56aca9ec-c89e-4d02-9e05-7851ca19c8d4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eae6bbf4-318a-44d1-84be-247c052e5153_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5c7c7407-d4c6-484f-9a9f-a2f14a7e6546_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_380a337f-fb9b-47d3-9a19-759b4cda4c4a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_dcb022f9-3623-4a29-b9d8-17b5af8600f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_f685fd4d-cbf5-43e6-8d7b-697e25ee20ea_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_577d8999-1de7-4abd-9fb7-34f09bb12f24_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f3172b46-2757-4f8a-b5c9-ae22d71f9d92_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bac72a48-67c2-4cbc-bad7-68a7c4b10fd4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_de3b7d4e-f198-42b1-b14c-c4825f36a66c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_f36afe2b-7798-4547-b0f3-3121770206d6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Included in Cash Flow Statement</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e76dac25-d4fe-4af0-81ce-181e4f71163e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_514447df-1638-477f-8333-e7430dcbd0fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cd4b9ba5-b68c-4556-8604-8269fdac43d9_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_784f72dc-5d73-42cd-b330-f2c9c124cec7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0852d314-ddb9-47e7-b327-99f67165a27b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f64285cc-d205-4c59-a43c-18bb8b2da862_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9fa9af86-f2bb-4e50-aca3-1fd5a29c0b01_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c608e6aa-f5a3-4b52-b2e5-4e529312fea5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_OneOfficeLeaseMember_a34f95cc-119c-4715-8fd0-9279665f5ef1_terseLabel_en-US" xlink:label="lab_anab_OneOfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One office lease</link:label>
    <link:label id="lab_anab_OneOfficeLeaseMember_label_en-US" xlink:label="lab_anab_OneOfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Office Lease [Member]</link:label>
    <link:label id="lab_anab_OneOfficeLeaseMember_documentation_en-US" xlink:label="lab_anab_OneOfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Office Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_OneOfficeLeaseMember" xlink:href="anab-20200930.xsd#anab_OneOfficeLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_OneOfficeLeaseMember" xlink:to="lab_anab_OneOfficeLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_LesseeOperatingLeaseNumber_6d81bcb8-8f89-4b3e-ae0c-979dc1135e7a_terseLabel_en-US" xlink:label="lab_anab_LesseeOperatingLeaseNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancellable office leases</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseNumber_label_en-US" xlink:label="lab_anab_LesseeOperatingLeaseNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseNumber_documentation_en-US" xlink:label="lab_anab_LesseeOperatingLeaseNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseNumber" xlink:href="anab-20200930.xsd#anab_LesseeOperatingLeaseNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LesseeOperatingLeaseNumber" xlink:to="lab_anab_LesseeOperatingLeaseNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_4162ec36-9830-433f-b96f-7b7edcf3aee0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_LaboratoryEquipmentMember_ed56f875-cda6-4fcf-89a0-ba08ac67e7f5_terseLabel_en-US" xlink:label="lab_anab_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_anab_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_anab_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_anab_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_anab_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LaboratoryEquipmentMember" xlink:href="anab-20200930.xsd#anab_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LaboratoryEquipmentMember" xlink:to="lab_anab_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_f4a2034b-2dbb-450e-aef1-cb972edea8f8_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_db3fb948-daf8-4df3-a2b8-9d22e79ff4b2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3449b114-4cc3-40aa-887e-cb717f6de953_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_74c00498-50de-40d8-ae59-d5320a094990_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_538f6b84-84ac-4921-a077-8d43fb9cbcb0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eb7cface-6242-4a8e-b568-5fbc048baf29_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43ea594b-195f-4cfb-b92e-32a8dc30de12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_cb865a96-0e6a-4db1-8162-ad5e716a724f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8787caf6-bd6f-417e-a8c4-b0ca0c93661e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) income on available for sale securities, net of tax of $0, $(25), $0 and $189, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c043c556-8920-4471-8c01-6b4222ab8d89_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2928ddcf-e74a-4aca-aca0-8b64ee28383a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_3c33e0b6-7cc8-4e55-92b1-e550752e7f11_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized income (loss) on available for sale securities, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_fe96e3ac-2140-450e-afdc-8ccad659447d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_77e4374e-e940-4082-b98d-82cdcbda63e4_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a884bf06-a5ef-48eb-be57-e37269a1efe9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Subject to Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_265ffb2b-543f-4da1-a9c1-b37c74af230e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2f24bb3a-2dda-41ef-94b4-2421da38a989_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_c5350ebe-f813-4d73-aa0b-b6318d3707e1_terseLabel_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options</link:label>
    <link:label id="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_documentation_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" xlink:href="anab-20200930.xsd#anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" xlink:to="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_47569614-fed8-42ea-a9a1-fff0abaa9a7e_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d1d92a84-0d68-4321-8d1a-e526270cd444_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_11140940-760c-4ed6-9b44-24c1f4ddc13d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_53beb6f6-82c7-4680-9056-585f43493d24_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_93ecab0d-b2e0-4264-a5e1-ada0abdb0fa7_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1602f801-7b0e-449d-a517-49b7cc5663d7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d53280e5-c560-43a8-9c3f-26bd28cd0787_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_3051d2ba-fdbb-4d23-b92e-257b0ffd638e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_2cc45c14-bae4-4dd8-b396-b9c9a970b030_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate draw on term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_df1bc09c-3fd2-4566-8120-de82be0006ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_eb2da02d-fd6f-4689-9a63-dd223aeb25ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_915f9c0b-b7e9-4736-97d7-b20e9bbec03b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_922484b2-09e8-4da0-9fe8-3f001ac72db7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_cebd7eef-6c42-4fbc-a0bb-149ba994b5c8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ca07e6a4-d516-4f4b-81b0-821071cd2312_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_de7f4d73-9881-4b08-9b37-df370f0f4f5f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_2d66ae6f-cbee-4371-b966-83cb5402cfdd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_Phase1ClinicalTrialInitiationMember_6d18b2b3-5a1d-408a-9580-a5a471ba2040_verboseLabel_en-US" xlink:label="lab_anab_Phase1ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 clinical trial initiation</link:label>
    <link:label id="lab_anab_Phase1ClinicalTrialInitiationMember_label_en-US" xlink:label="lab_anab_Phase1ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 Clinical Trial Initiation [Member]</link:label>
    <link:label id="lab_anab_Phase1ClinicalTrialInitiationMember_documentation_en-US" xlink:label="lab_anab_Phase1ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 Clinical Trial Initiation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase1ClinicalTrialInitiationMember" xlink:href="anab-20200930.xsd#anab_Phase1ClinicalTrialInitiationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_Phase1ClinicalTrialInitiationMember" xlink:to="lab_anab_Phase1ClinicalTrialInitiationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_14eacabb-96f1-43db-a8bc-866af4e06217_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_471bf16c-9e33-41e5-9866-e3f35b42db59_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Market Prices for Identical&#160;Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_b5a1b41f-06f8-49b5-bc83-c438f0c35267_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license fee received</link:label>
    <link:label id="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_label_en-US" xlink:label="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received</link:label>
    <link:label id="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:to="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ae5beb63-7645-4998-afcd-c6d8d19d013b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_ce268b8b-29e6-42e3-aece-a9bf7b704541_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to)</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ce03694-88f6-46d9-b344-99b9a3110456_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a7e5724c-3d24-4795-ba4e-5bea81ba6fb3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1a103ddf-e7c3-4fa2-8cf0-b072b6373fa9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a8f253b7-19f7-43b5-9cfa-35b60f8a6a47_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_1d274337-d337-4244-a1d5-faa2b428e39a_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_9d2301f1-7824-4255-acf3-018cfc19f57e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f0d715a1-8e02-4d02-8625-18ee8879d591_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_69a9a80e-56b0-4ebb-b8f6-89ae38ab1b2c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_8824f533-d768-4fec-83c2-58ad61617e2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 Months, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_c3a7abf3-68ff-49ed-8ab8-0ab5ea8a793a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_24faee0b-3951-4aee-8420-cecaf004a34e_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_e3476d9d-66c4-4632-ae12-858308e3bee8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9b674b7c-da14-4d0c-8180-8013a5f91306_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_1d899b0e-9662-42ff-b8a7-8dde7a4f786a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_836a2ec6-b346-46ed-81ee-187e75753bd5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2a6efba7-716b-436c-8370-453d4d240d70_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under employee stock plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5e46427a-db29-4330-bf53-bee05dd9d2dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d401dc6e-1475-40cc-8d6d-547095bea534_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_c31d8df1-57ad-450a-8d46-ced0924d2ee0_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0b188f61-3342-4163-acfc-854642af0e32_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c1e96ee2-837d-49f8-a8c0-703b37cad021_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Annual Obligations</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3709d58f-d0ce-4138-931e-86f2ada5a5a4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4e033f3d-7d6a-4d93-a9d7-50ca4bd3e565_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ad6525d7-bb28-43db-8f6b-a6fc3382c2cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_55fc2f78-9db5-4d82-afd5-eed29a0ad8b5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_f8346e02-3955-4eff-be99-2db7dfe6bcac_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_8504275a-7de5-444c-9b42-f96787ba488a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_150e9f66-b26e-486c-9f7a-32ee0e385138_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Event</link:label>
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_label_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognized, Milestone Method, Milestone Payment Earned</link:label>
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_documentation_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognized, Milestone Method, Milestone Payment Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:href="anab-20200930.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:to="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_95b3b1b9-a744-4b7e-9d2a-a65e19ed7357_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7e4869ca-d2c3-4903-97fd-12e736bb86e6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_0e984a37-c01e-4865-bd5c-a9e8f49b1398_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable to Banks</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember" xlink:to="lab_us-gaap_NotesPayableToBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4fc11107-cc4a-45f9-8545-7815d2950666_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_f379133f-79f9-48ef-9f6d-f7760fac7872_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_49bf00c9-30dd-4ea0-804c-d4b6476987b0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_74efd13a-f4bd-46ef-aecc-3dfd415af40d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_88e40e5f-1792-442f-b34e-15ecf79a82b0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, upon the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_74b2d55a-f413-40e9-8246-d962c2160f7c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_05c9a2d9-04ac-4add-9552-82a7b881a67d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_77f9c3b4-10d5-4d52-b774-183a3e4fc2b5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_04b828d1-0d83-4b4f-af92-b81313de8803_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a502ba99-419b-4cac-9422-125b33291275_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_dc87f18a-9147-495f-83fc-6f667b440f13_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones achieved, amount</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_cb3e74ac-3b8a-431c-9304-12da336b30cd_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_f818cdcf-456d-4de9-8fdd-faa8302aabc2_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b3cc112e-7019-4a67-8925-1cfc731a651b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1bc531fa-2239-400e-b203-0b751f589874_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_455962a2-870e-4dd6-8640-03eea702c461_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_157f1120-64f4-4dc5-92e5-801660f1f285_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_c1390ab9-e1cf-4375-bd00-0e6ee7cb2ad6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a258d2bc-fdee-4a7e-b5f9-c09aaa4ffe8c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_a452fe65-c3cb-4d07-a786-862de1725648_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_2e99b636-b338-4ddc-b6ee-20fe46a1bfdb_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_10f82157-f87d-405f-bc6f-439bfe9d5057_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_41f08598-ab45-41ca-9739-4d9676b15492_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_da9442ac-b43c-4aba-9010-42518c417001_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_521b3061-f0b3-474a-bf9a-a7b549781d58_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_68e6c7bd-c426-46de-9499-b8c979c97c99_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_380b3daf-aa2a-415e-a537-97cd8d1f45d0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_42638b61-27ac-4985-951e-6ce77d812cbb_terseLabel_en-US" xlink:label="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-PD-1 (GSK4057190A/Dostarlimab)</link:label>
    <link:label id="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_44fac3c8-0cc6-400f-9b97-acf390dc2342_verboseLabel_en-US" xlink:label="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-PD-1</link:label>
    <link:label id="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_label_en-US" xlink:label="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) [Member]</link:label>
    <link:label id="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_documentation_en-US" xlink:label="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member" xlink:href="anab-20200930.xsd#anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member" xlink:to="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member_980e5cc9-0979-45bc-a1d5-b640908406de_terseLabel_en-US" xlink:label="lab_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10770 Wateridge Circle, San Diego, California 92121</link:label>
    <link:label id="lab_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member_label_en-US" xlink:label="lab_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10770 Wateridge Circle, San Diego, California 92121 [Member]</link:label>
    <link:label id="lab_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member_documentation_en-US" xlink:label="lab_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10770 Wateridge Circle, San Diego, California 92121</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member" xlink:href="anab-20200930.xsd#anab_A10770WateridgeCircleSanDiegoCalifornia92121Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member" xlink:to="lab_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_Phase3ClinicalTrialInitiationMember_51880fab-b3c3-493a-b3c9-60bc34c919ff_terseLabel_en-US" xlink:label="lab_anab_Phase3ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 clinical trial initiation</link:label>
    <link:label id="lab_anab_Phase3ClinicalTrialInitiationMember_label_en-US" xlink:label="lab_anab_Phase3ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial Initiation [Member]</link:label>
    <link:label id="lab_anab_Phase3ClinicalTrialInitiationMember_documentation_en-US" xlink:label="lab_anab_Phase3ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial Initiation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase3ClinicalTrialInitiationMember" xlink:href="anab-20200930.xsd#anab_Phase3ClinicalTrialInitiationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_Phase3ClinicalTrialInitiationMember" xlink:to="lab_anab_Phase3ClinicalTrialInitiationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0b013334-f174-426c-9b7a-5dea4817a4e7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under employee stock plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_33fd998a-c09e-4fe6-bf59-b7effd4f8937_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0166f023-e907-4bf3-a1a2-df2804ff37ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_0cea1ac8-6896-4c35-92fe-8c1240dab8b5_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement term following first commercial sale or expiration of the last to expire patent (in years)</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_04c30493-e823-4632-b941-6516450ba649_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_e0f2720b-1010-474a-9f7d-97c2168974c3_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones achieved during period</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_LeaseArrangementAxis_eeea3c87-0ef2-4617-874a-81c33b471b0f_terseLabel_en-US" xlink:label="lab_anab_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_anab_LeaseArrangementAxis_label_en-US" xlink:label="lab_anab_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_anab_LeaseArrangementAxis_documentation_en-US" xlink:label="lab_anab_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LeaseArrangementAxis" xlink:href="anab-20200930.xsd#anab_LeaseArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LeaseArrangementAxis" xlink:to="lab_anab_LeaseArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_36105fc1-7854-4769-aa75-9333fae54007_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_03bfd609-a762-41a0-b918-64ef86ed2215_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_DebtInstrumentMaximumBorrowingCapacity_2498bd29-a149-466f-aa98-fbc6fc0218aa_terseLabel_en-US" xlink:label="lab_anab_DebtInstrumentMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, maximum borrowing capacity</link:label>
    <link:label id="lab_anab_DebtInstrumentMaximumBorrowingCapacity_label_en-US" xlink:label="lab_anab_DebtInstrumentMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_anab_DebtInstrumentMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_anab_DebtInstrumentMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_DebtInstrumentMaximumBorrowingCapacity" xlink:href="anab-20200930.xsd#anab_DebtInstrumentMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_DebtInstrumentMaximumBorrowingCapacity" xlink:to="lab_anab_DebtInstrumentMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_5f4e8f53-802c-454d-b876-cc590aa2154f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5f02e6f9-9963-4a7e-9719-957829e42f13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_bcff7286-ae68-4454-b1f4-6c8224f98995_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_25dc64d9-0be1-49c2-91d8-6c44119f3d08_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_Phase2ClinicalTrialInitiationMember_2f29a02f-e351-49cd-bb61-de9e9e49c4d3_terseLabel_en-US" xlink:label="lab_anab_Phase2ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 2 clinical trial initiation</link:label>
    <link:label id="lab_anab_Phase2ClinicalTrialInitiationMember_label_en-US" xlink:label="lab_anab_Phase2ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 2 Clinical Trial Initiation [Member]</link:label>
    <link:label id="lab_anab_Phase2ClinicalTrialInitiationMember_documentation_en-US" xlink:label="lab_anab_Phase2ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 2 Clinical Trial Initiation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase2ClinicalTrialInitiationMember" xlink:href="anab-20200930.xsd#anab_Phase2ClinicalTrialInitiationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_Phase2ClinicalTrialInitiationMember" xlink:to="lab_anab_Phase2ClinicalTrialInitiationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_04c0b423-fff0-4d3c-bb53-3f663b991d67_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9636ae0a-7f0a-483d-a9db-025c07121734_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_TermALoansMember_b1626b66-7c4c-4d77-8964-6a6e3a6e1272_terseLabel_en-US" xlink:label="lab_anab_TermALoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Loans</link:label>
    <link:label id="lab_anab_TermALoansMember_label_en-US" xlink:label="lab_anab_TermALoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Loans [Member]</link:label>
    <link:label id="lab_anab_TermALoansMember_documentation_en-US" xlink:label="lab_anab_TermALoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_TermALoansMember" xlink:href="anab-20200930.xsd#anab_TermALoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_TermALoansMember" xlink:to="lab_anab_TermALoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6aa976fe-969f-416d-89de-ded20ae92780_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_194ab8bc-78c3-4fbd-9833-2196218e6e72_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_4e7c9ece-de8c-4748-9dd9-bfd61bd3b705_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_add52eab-a5ba-4744-969f-f588a6987757_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_71e60007-5f34-49a2-a85d-d16a2c3f8aae_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_097286fe-90b6-4fa0-9a4a-5a29c209722e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0ebfe78c-701c-4765-a038-ffeed2ba6d3e_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d36572ff-9d59-4f16-90e2-30c263bf8f86_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_811da730-e9b3-4015-9806-da7f144a7df8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_f36a0efc-e1e0-4eba-be92-190f60e9d548_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director Stock options</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30e79ae4-f969-4f85-a5e7-6dfe4eee3c70_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, options outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee51acf6-a496-4a72-8af0-f3f85618b2f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a26054af-d955-453d-8f5d-fe517d7bed09_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_92488aa1-c758-48de-abfc-1665f831af58_terseLabel_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period remaining for amortization of unrecognized compensation cost (in years)</link:label>
    <link:label id="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_label_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition</link:label>
    <link:label id="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_documentation_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" xlink:href="anab-20200930.xsd#anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" xlink:to="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_8d08fc96-5f00-4398-a6cb-dbc48b597d5c_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6053b42-a325-4e16-9603-d3f1e5e25f96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c24d5d79-8e63-4d69-87a4-1153d2890056_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ff709dbe-4562-438c-bbf7-602b8a8e1fcd_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_6803820f-6907-445e-b801-b736477f5884_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c3d0a437-9c51-44d3-8dec-21b335a027c2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fa5ec625-6c3f-45c9-80b7-b6f80c87e648_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercisable, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_2ddfb057-1ab2-4236-859f-e228f0a00136_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, current portion</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b892709a-cf2a-4419-898b-5941ccfb0e00_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Non-cash Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_30978326-d78d-46c3-ac46-83c2f8cb15c0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_120a498d-c239-4ecb-a2f6-93edd9da3d3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_f8390f7c-5bfa-4288-8706-641c24d7bc7d_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_a9d460a8-f564-4032-b8c0-dadc6c308514_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office furniture and equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb13b9cf-ab03-475a-9e79-c5be16e3cbc5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ce08050d-1ef4-45aa-9eb7-e1a4addf1b45_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4714c2f3-8299-4e66-81a2-df431ef36b06_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_Phase3clinicaltrialinitiationsecondindicationDomain_33f63779-f0e5-4482-9704-41d2d1319420_terseLabel_en-US" xlink:label="lab_anab_Phase3clinicaltrialinitiationsecondindicationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 clinical trial initiation - second indication [Domain]</link:label>
    <link:label id="lab_anab_Phase3clinicaltrialinitiationsecondindicationDomain_label_en-US" xlink:label="lab_anab_Phase3clinicaltrialinitiationsecondindicationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 clinical trial initiation - second indication [Domain]</link:label>
    <link:label id="lab_anab_Phase3clinicaltrialinitiationsecondindicationDomain_documentation_en-US" xlink:label="lab_anab_Phase3clinicaltrialinitiationsecondindicationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 clinical trial initiation - second indication [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase3clinicaltrialinitiationsecondindicationDomain" xlink:href="anab-20200930.xsd#anab_Phase3clinicaltrialinitiationsecondindicationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_Phase3clinicaltrialinitiationsecondindicationDomain" xlink:to="lab_anab_Phase3clinicaltrialinitiationsecondindicationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent_b578ca95-5aee-4084-8adf-9b11dff66aa2_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of net sales below $1 billion</link:label>
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent_label_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognized, Milestone Method, Milestone Payment Earned, Net Sales below $1 Billion, Percent</link:label>
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent_documentation_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognized, Milestone Method, Milestone Payment Earned, Net Sales below $1 Billion, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent" xlink:href="anab-20200930.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent" xlink:to="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_957c8aae-72d6-4c70-9552-99a9a5682973_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_41b2d13b-7775-4f03-b743-9ef965eea936_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrealized Loss and Fair Values in a Loss Position</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_78b80378-e063-4609-8e74-2b5539bc7aed_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Pronouncements Recently Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_599eec02-edaf-41d6-bf8a-6fe6265fea28_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_6aa84dfe-6c9b-4904-bf88-33454756c81b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_InVivoToxicologyStudiesMember_8ae460cd-882d-492f-9af2-359b119ddc04_terseLabel_en-US" xlink:label="lab_anab_InVivoToxicologyStudiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initiated in vivo toxicology studies using good laboratory practices (GLPs)</link:label>
    <link:label id="lab_anab_InVivoToxicologyStudiesMember_label_en-US" xlink:label="lab_anab_InVivoToxicologyStudiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Vivo Toxicology Studies [Member]</link:label>
    <link:label id="lab_anab_InVivoToxicologyStudiesMember_documentation_en-US" xlink:label="lab_anab_InVivoToxicologyStudiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Vivo Toxicology Studies [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_InVivoToxicologyStudiesMember" xlink:href="anab-20200930.xsd#anab_InVivoToxicologyStudiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_InVivoToxicologyStudiesMember" xlink:to="lab_anab_InVivoToxicologyStudiesMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>anab-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:721272a1-28f6-479d-8921-55bf3792b729,g:e6e63eaa-4a73-42e1-87eb-dda12e114757-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CoverPage" xlink:type="simple" xlink:href="anab-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5a8b156e-d687-4c5c-b72d-6ea885a612da" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_DocumentType_5a8b156e-d687-4c5c-b72d-6ea885a612da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_1a3e0b4a-dd72-400c-99b4-432f639fe34b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_DocumentQuarterlyReport_1a3e0b4a-dd72-400c-99b4-432f639fe34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_efda4967-5f9e-46f0-9af4-3ed3e26bc29a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_DocumentPeriodEndDate_efda4967-5f9e-46f0-9af4-3ed3e26bc29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e972aace-0a90-452c-8a21-722416baba34" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_DocumentTransitionReport_e972aace-0a90-452c-8a21-722416baba34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ca50d511-fdad-4a36-a3d6-210ca7410e07" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityFileNumber_ca50d511-fdad-4a36-a3d6-210ca7410e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c7e46266-5cac-4792-99e1-ce7ded2e208f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityRegistrantName_c7e46266-5cac-4792-99e1-ce7ded2e208f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_28a35167-91a1-4f87-9e17-83c71457e862" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityIncorporationStateCountryCode_28a35167-91a1-4f87-9e17-83c71457e862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ba6a723c-8fa1-4834-bef1-21a05b5cdb98" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityTaxIdentificationNumber_ba6a723c-8fa1-4834-bef1-21a05b5cdb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c32989dd-7ca8-4699-a036-b3e914c464cb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityAddressAddressLine1_c32989dd-7ca8-4699-a036-b3e914c464cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_00aceee6-8791-44ec-9dfa-02f36426090b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityAddressAddressLine2_00aceee6-8791-44ec-9dfa-02f36426090b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ccb7dae3-a4d0-4eee-8d4b-1ddeef524a69" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityAddressCityOrTown_ccb7dae3-a4d0-4eee-8d4b-1ddeef524a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ef2ea369-6ba3-49b3-bcd2-21442ac794d5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityAddressStateOrProvince_ef2ea369-6ba3-49b3-bcd2-21442ac794d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_89ab85d7-215c-44c1-84f6-6ec255353cb5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityAddressPostalZipCode_89ab85d7-215c-44c1-84f6-6ec255353cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2688cea4-f0a4-41ce-b7ae-69ac3a525dc8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_CityAreaCode_2688cea4-f0a4-41ce-b7ae-69ac3a525dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_04325419-04bc-470d-b16a-304126c92ce1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_LocalPhoneNumber_04325419-04bc-470d-b16a-304126c92ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_fc8d8d5f-8ddc-4438-9fa3-0d3412622b36" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_Security12bTitle_fc8d8d5f-8ddc-4438-9fa3-0d3412622b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1928a3cf-20e4-49f7-8979-001e9c3c95c8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_TradingSymbol_1928a3cf-20e4-49f7-8979-001e9c3c95c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2c4096af-2d79-45ed-bbf0-3250500e2644" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_SecurityExchangeName_2c4096af-2d79-45ed-bbf0-3250500e2644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_47c5d70f-6829-4189-9a8c-25580dc98a93" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityCurrentReportingStatus_47c5d70f-6829-4189-9a8c-25580dc98a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4a502ee7-cf70-416c-bb87-273310623e19" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityInteractiveDataCurrent_4a502ee7-cf70-416c-bb87-273310623e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e51ba77f-6fd6-474a-9440-e728893a3988" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityFilerCategory_e51ba77f-6fd6-474a-9440-e728893a3988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_cd2fa260-4fc8-4192-aa40-bbb22b9139eb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntitySmallBusiness_cd2fa260-4fc8-4192-aa40-bbb22b9139eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_48c5cb35-1f99-4296-b71d-c66df6f92138" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityEmergingGrowthCompany_48c5cb35-1f99-4296-b71d-c66df6f92138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_88fddaa6-e1a0-4484-bc93-a65657da3eaa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityShellCompany_88fddaa6-e1a0-4484-bc93-a65657da3eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c483d0b3-4a82-4b34-9ecc-f319df8703c1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c483d0b3-4a82-4b34-9ecc-f319df8703c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3353c0b8-aacb-4f6b-863a-02ec62130a09" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_EntityCentralIndexKey_3353c0b8-aacb-4f6b-863a-02ec62130a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f056d04c-aab5-46c0-a416-fd2afbbcb082" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_CurrentFiscalYearEndDate_f056d04c-aab5-46c0-a416-fd2afbbcb082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0e4c4f2b-cc0f-4310-b83e-825b4c11803c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_DocumentFiscalYearFocus_0e4c4f2b-cc0f-4310-b83e-825b4c11803c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_69c95b28-4463-4063-a578-c7b1e019aaa1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_DocumentFiscalPeriodFocus_69c95b28-4463-4063-a578-c7b1e019aaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ba2297e2-af8e-41bd-b22f-695eb35928d2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c96a3b49-a7d5-45ee-8f7e-83b1bcc77907" xlink:to="loc_dei_AmendmentFlag_ba2297e2-af8e-41bd-b22f-695eb35928d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8a4d1b78-239f-4c22-954d-7cf5fbc9ca26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_2a605ee9-1cc9-46db-a73f-77e0216aadf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8a4d1b78-239f-4c22-954d-7cf5fbc9ca26" xlink:to="loc_us-gaap_AssetsAbstract_2a605ee9-1cc9-46db-a73f-77e0216aadf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_53f58a67-7dbf-4984-9a72-ad9c5c9459f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2a605ee9-1cc9-46db-a73f-77e0216aadf1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_53f58a67-7dbf-4984-9a72-ad9c5c9459f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ab442cf5-7d62-41d6-a8a6-21fcab3c951d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_53f58a67-7dbf-4984-9a72-ad9c5c9459f7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ab442cf5-7d62-41d6-a8a6-21fcab3c951d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e45116cf-e059-4572-bdc6-251e6a3369eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_53f58a67-7dbf-4984-9a72-ad9c5c9459f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e45116cf-e059-4572-bdc6-251e6a3369eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f002ee0a-df23-4238-82a1-46367d180669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_53f58a67-7dbf-4984-9a72-ad9c5c9459f7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f002ee0a-df23-4238-82a1-46367d180669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_57c4dfad-9992-4d4c-b595-3e7bc4bb1130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_53f58a67-7dbf-4984-9a72-ad9c5c9459f7" xlink:to="loc_us-gaap_AssetsCurrent_57c4dfad-9992-4d4c-b595-3e7bc4bb1130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4a5aa640-6e7d-4559-96ac-d12c9b6b1a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2a605ee9-1cc9-46db-a73f-77e0216aadf1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4a5aa640-6e7d-4559-96ac-d12c9b6b1a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e8a75b2b-fc0f-4bda-87a1-5fec530ed269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2a605ee9-1cc9-46db-a73f-77e0216aadf1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e8a75b2b-fc0f-4bda-87a1-5fec530ed269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b5959471-5eb9-4637-baf4-5b4da54ba479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2a605ee9-1cc9-46db-a73f-77e0216aadf1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b5959471-5eb9-4637-baf4-5b4da54ba479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ba5010ef-0dbb-4d01-bbf9-5256a664e558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2a605ee9-1cc9-46db-a73f-77e0216aadf1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ba5010ef-0dbb-4d01-bbf9-5256a664e558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ccb82b48-6e31-4d9f-b6c9-96ea001c6b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2a605ee9-1cc9-46db-a73f-77e0216aadf1" xlink:to="loc_us-gaap_Assets_ccb82b48-6e31-4d9f-b6c9-96ea001c6b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_072d3627-fdc2-41f4-aa1a-3e20b715d64a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8a4d1b78-239f-4c22-954d-7cf5fbc9ca26" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_072d3627-fdc2-41f4-aa1a-3e20b715d64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_45dbb9f4-cc5b-4db1-8af9-e99d8266247a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_072d3627-fdc2-41f4-aa1a-3e20b715d64a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_45dbb9f4-cc5b-4db1-8af9-e99d8266247a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_47e995c1-5da8-46d6-9556-ed61d4b55c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45dbb9f4-cc5b-4db1-8af9-e99d8266247a" xlink:to="loc_us-gaap_AccountsPayableCurrent_47e995c1-5da8-46d6-9556-ed61d4b55c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_beb9b532-372d-43e8-acb6-b2b37890d6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45dbb9f4-cc5b-4db1-8af9-e99d8266247a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_beb9b532-372d-43e8-acb6-b2b37890d6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_20c983f2-3e6f-4b92-b789-b6d3f1bb3f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45dbb9f4-cc5b-4db1-8af9-e99d8266247a" xlink:to="loc_us-gaap_NotesPayableCurrent_20c983f2-3e6f-4b92-b789-b6d3f1bb3f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_40465a8a-c625-4e61-9759-05834d6bc3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45dbb9f4-cc5b-4db1-8af9-e99d8266247a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_40465a8a-c625-4e61-9759-05834d6bc3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d7d8e650-1fa3-45b3-b2a9-3198a0821687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_45dbb9f4-cc5b-4db1-8af9-e99d8266247a" xlink:to="loc_us-gaap_LiabilitiesCurrent_d7d8e650-1fa3-45b3-b2a9-3198a0821687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bf6a19ea-64c5-4cc7-a7f8-4130c9bebd14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_072d3627-fdc2-41f4-aa1a-3e20b715d64a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bf6a19ea-64c5-4cc7-a7f8-4130c9bebd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c33d9661-e3dd-49f1-82e4-c09343d4dd75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_072d3627-fdc2-41f4-aa1a-3e20b715d64a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_c33d9661-e3dd-49f1-82e4-c09343d4dd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7f83afc6-bb29-4b92-bd23-aa30517654b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c33d9661-e3dd-49f1-82e4-c09343d4dd75" xlink:to="loc_us-gaap_PreferredStockValue_7f83afc6-bb29-4b92-bd23-aa30517654b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ecb20859-4886-446c-a45f-c51c7954b744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c33d9661-e3dd-49f1-82e4-c09343d4dd75" xlink:to="loc_us-gaap_CommonStockValue_ecb20859-4886-446c-a45f-c51c7954b744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_437bb8ef-e213-4bc7-8004-920f83b1b893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c33d9661-e3dd-49f1-82e4-c09343d4dd75" xlink:to="loc_us-gaap_AdditionalPaidInCapital_437bb8ef-e213-4bc7-8004-920f83b1b893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_de295516-2225-40ea-911d-0d84aa1e046d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c33d9661-e3dd-49f1-82e4-c09343d4dd75" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_de295516-2225-40ea-911d-0d84aa1e046d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a8d15e12-c370-4e4f-bd03-1b2d5707d059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c33d9661-e3dd-49f1-82e4-c09343d4dd75" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a8d15e12-c370-4e4f-bd03-1b2d5707d059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4dad9085-24fc-4f61-8182-2b7a60d8d994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c33d9661-e3dd-49f1-82e4-c09343d4dd75" xlink:to="loc_us-gaap_StockholdersEquity_4dad9085-24fc-4f61-8182-2b7a60d8d994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cfacea2d-d066-4c0c-9438-6fc274cbd2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_072d3627-fdc2-41f4-aa1a-3e20b715d64a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_cfacea2d-d066-4c0c-9438-6fc274cbd2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b6426457-a0e8-4021-9ef3-3f0e8cf38fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_08b1807b-87fb-4e95-acc7-2aef03dbc901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6426457-a0e8-4021-9ef3-3f0e8cf38fcd" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_08b1807b-87fb-4e95-acc7-2aef03dbc901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0c5299b6-4500-490a-821a-66d5de3ae614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6426457-a0e8-4021-9ef3-3f0e8cf38fcd" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0c5299b6-4500-490a-821a-66d5de3ae614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4431c448-3716-4bc0-8f76-a6f0c05ddfaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6426457-a0e8-4021-9ef3-3f0e8cf38fcd" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4431c448-3716-4bc0-8f76-a6f0c05ddfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_72b41663-dfd2-429e-92a8-972ae62e66eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6426457-a0e8-4021-9ef3-3f0e8cf38fcd" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_72b41663-dfd2-429e-92a8-972ae62e66eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e79e1440-541d-41fd-ae83-35f4f6e7b41b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6426457-a0e8-4021-9ef3-3f0e8cf38fcd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e79e1440-541d-41fd-ae83-35f4f6e7b41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_38d7bf03-40e6-4908-82e3-0afcf35c2810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6426457-a0e8-4021-9ef3-3f0e8cf38fcd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_38d7bf03-40e6-4908-82e3-0afcf35c2810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_dcd834de-ddba-4e2b-992a-31b92a83b5aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6426457-a0e8-4021-9ef3-3f0e8cf38fcd" xlink:to="loc_us-gaap_CommonStockSharesIssued_dcd834de-ddba-4e2b-992a-31b92a83b5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d98d0bd5-d11e-48be-a7c1-5c7d62e6a63c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6426457-a0e8-4021-9ef3-3f0e8cf38fcd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d98d0bd5-d11e-48be-a7c1-5c7d62e6a63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b5c79c30-a87b-450b-90dd-2050dc9ef4ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2144f68-c0f8-4f2a-b307-144b18f45741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c79c30-a87b-450b-90dd-2050dc9ef4ac" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2144f68-c0f8-4f2a-b307-144b18f45741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7fe361c7-fdc9-4209-a5bd-58597acaf478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c79c30-a87b-450b-90dd-2050dc9ef4ac" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7fe361c7-fdc9-4209-a5bd-58597acaf478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4ea69f6d-8632-4d49-85e1-8b37722571d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe361c7-fdc9-4209-a5bd-58597acaf478" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4ea69f6d-8632-4d49-85e1-8b37722571d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_01710f60-825e-4170-a6e1-9a110f9bf0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe361c7-fdc9-4209-a5bd-58597acaf478" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_01710f60-825e-4170-a6e1-9a110f9bf0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d54ee6d7-6179-4781-995c-3e96106063e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7fe361c7-fdc9-4209-a5bd-58597acaf478" xlink:to="loc_us-gaap_OperatingExpenses_d54ee6d7-6179-4781-995c-3e96106063e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c0fd825f-1cb5-4c15-a245-27893f9dc615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c79c30-a87b-450b-90dd-2050dc9ef4ac" xlink:to="loc_us-gaap_OperatingIncomeLoss_c0fd825f-1cb5-4c15-a245-27893f9dc615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_756c7372-1711-46bb-9fee-8cae281c4625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c79c30-a87b-450b-90dd-2050dc9ef4ac" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_756c7372-1711-46bb-9fee-8cae281c4625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a5321c3d-66d2-4eb1-9c96-e0e602e38f76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_756c7372-1711-46bb-9fee-8cae281c4625" xlink:to="loc_us-gaap_InterestExpense_a5321c3d-66d2-4eb1-9c96-e0e602e38f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c9538134-2443-463b-a3ca-61f7494cb586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_756c7372-1711-46bb-9fee-8cae281c4625" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c9538134-2443-463b-a3ca-61f7494cb586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b0e9d663-b974-4f69-8a87-37334ba0d39b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_756c7372-1711-46bb-9fee-8cae281c4625" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b0e9d663-b974-4f69-8a87-37334ba0d39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5d53d722-57fb-474b-98c2-beca34497b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_756c7372-1711-46bb-9fee-8cae281c4625" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5d53d722-57fb-474b-98c2-beca34497b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2d11e056-e8db-47ae-a23c-15ce507634ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c79c30-a87b-450b-90dd-2050dc9ef4ac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2d11e056-e8db-47ae-a23c-15ce507634ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_52b74bdc-3389-4b77-94d0-9a66365bc6f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c79c30-a87b-450b-90dd-2050dc9ef4ac" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_52b74bdc-3389-4b77-94d0-9a66365bc6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_59c9e576-1d89-400a-81df-b749b036609e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c79c30-a87b-450b-90dd-2050dc9ef4ac" xlink:to="loc_us-gaap_NetIncomeLoss_59c9e576-1d89-400a-81df-b749b036609e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ee72dd17-5813-4b69-b09b-d6062e742e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c79c30-a87b-450b-90dd-2050dc9ef4ac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ee72dd17-5813-4b69-b09b-d6062e742e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_af7b8434-e67d-428c-80a6-044d0dbd61f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c79c30-a87b-450b-90dd-2050dc9ef4ac" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_af7b8434-e67d-428c-80a6-044d0dbd61f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f51ffc9c-3155-4ae3-bc92-772b876cafc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c79c30-a87b-450b-90dd-2050dc9ef4ac" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f51ffc9c-3155-4ae3-bc92-772b876cafc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_81dda936-1c6e-4d2b-b4cb-d01ec65bb17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f51ffc9c-3155-4ae3-bc92-772b876cafc4" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_81dda936-1c6e-4d2b-b4cb-d01ec65bb17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2c4c163e-fbf4-4629-a8a8-eeaff6c311f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5c79c30-a87b-450b-90dd-2050dc9ef4ac" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2c4c163e-fbf4-4629-a8a8-eeaff6c311f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_687f83cb-c609-423e-988b-384a768e4d20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2c4c163e-fbf4-4629-a8a8-eeaff6c311f2" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_687f83cb-c609-423e-988b-384a768e4d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_429a801d-38f9-4113-8781-636f0cd9f919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_dd0c0bb9-874f-4161-b6d8-b123948e401e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_429a801d-38f9-4113-8781-636f0cd9f919" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_dd0c0bb9-874f-4161-b6d8-b123948e401e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedStatementofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_492807e5-b81b-48ed-8334-2151f44b96a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c83219a5-353d-4a9c-9d53-a398a4a1576d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_492807e5-b81b-48ed-8334-2151f44b96a9" xlink:to="loc_us-gaap_StatementTable_c83219a5-353d-4a9c-9d53-a398a4a1576d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e1318e31-916f-4c2d-a91b-24f582201e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c83219a5-353d-4a9c-9d53-a398a4a1576d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e1318e31-916f-4c2d-a91b-24f582201e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b51f03a-758f-4406-91ec-b1732cd6673f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e1318e31-916f-4c2d-a91b-24f582201e91" xlink:to="loc_us-gaap_EquityComponentDomain_6b51f03a-758f-4406-91ec-b1732cd6673f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_08d928e2-8cad-414d-81a9-afb694b6fc59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6b51f03a-758f-4406-91ec-b1732cd6673f" xlink:to="loc_us-gaap_CommonStockMember_08d928e2-8cad-414d-81a9-afb694b6fc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9c740bd5-cc06-43c6-8811-b2a44828e8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6b51f03a-758f-4406-91ec-b1732cd6673f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9c740bd5-cc06-43c6-8811-b2a44828e8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e0177f07-626e-4456-afc8-f26492ad6519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6b51f03a-758f-4406-91ec-b1732cd6673f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e0177f07-626e-4456-afc8-f26492ad6519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bff468b8-3af2-48e0-b74c-904c35c14dd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6b51f03a-758f-4406-91ec-b1732cd6673f" xlink:to="loc_us-gaap_RetainedEarningsMember_bff468b8-3af2-48e0-b74c-904c35c14dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_682e1965-1bba-4621-84fe-661d83cf3967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c83219a5-353d-4a9c-9d53-a398a4a1576d" xlink:to="loc_us-gaap_StatementLineItems_682e1965-1bba-4621-84fe-661d83cf3967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_682e1965-1bba-4621-84fe-661d83cf3967" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bd00c8ce-46a6-4db8-9e72-dafd12d1550e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_StockholdersEquity_bd00c8ce-46a6-4db8-9e72-dafd12d1550e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3b46ae96-69c8-4ff9-b842-79b3decca59f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_SharesOutstanding_3b46ae96-69c8-4ff9-b842-79b3decca59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a8bd847a-ecd4-4a4a-8a86-1e4ad1b8f50e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a8bd847a-ecd4-4a4a-8a86-1e4ad1b8f50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_08f22d76-ab83-4812-8217-2da224049da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_08f22d76-ab83-4812-8217-2da224049da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_e79d210d-d40e-43f4-bbd8-cc6d600ea09b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_e79d210d-d40e-43f4-bbd8-cc6d600ea09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d58bdf00-bfb5-47b3-992d-830ddf53740e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d58bdf00-bfb5-47b3-992d-830ddf53740e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1017e701-fcfb-48e5-9ed4-ae43a2e17d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_NetIncomeLoss_1017e701-fcfb-48e5-9ed4-ae43a2e17d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f29b9fed-925b-4f4e-80e3-475726b6f7ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_StockholdersEquity_f29b9fed-925b-4f4e-80e3-475726b6f7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_14775057-1216-4b4b-81ad-2ab980bbf65d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_39cd5735-cc60-47ff-bc49-3e28fad4e97b" xlink:to="loc_us-gaap_SharesOutstanding_14775057-1216-4b4b-81ad-2ab980bbf65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="anab-20200930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_87206e0f-6609-4f6a-a226-d0bbd15f8237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_15fedebe-0dfb-4fe3-ab19-f62fbb1df887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87206e0f-6609-4f6a-a226-d0bbd15f8237" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_15fedebe-0dfb-4fe3-ab19-f62fbb1df887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_06f22814-6eb2-4be7-a60d-044e281145e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_15fedebe-0dfb-4fe3-ab19-f62fbb1df887" xlink:to="loc_us-gaap_NetIncomeLoss_06f22814-6eb2-4be7-a60d-044e281145e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e377a92c-5c40-41b5-baa9-d75e1dec8ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_15fedebe-0dfb-4fe3-ab19-f62fbb1df887" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e377a92c-5c40-41b5-baa9-d75e1dec8ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8584ed07-835c-4ed1-bdf4-4ccb072c4afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e377a92c-5c40-41b5-baa9-d75e1dec8ce9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8584ed07-835c-4ed1-bdf4-4ccb072c4afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_5b1bba96-10a9-4525-a06e-5f9d5ef24d65" xlink:href="anab-20200930.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e377a92c-5c40-41b5-baa9-d75e1dec8ce9" xlink:to="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_5b1bba96-10a9-4525-a06e-5f9d5ef24d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_ed137ba4-9286-43de-b3ec-4d55f8242897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e377a92c-5c40-41b5-baa9-d75e1dec8ce9" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_ed137ba4-9286-43de-b3ec-4d55f8242897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3b0e5661-48f2-4693-98e3-b229b13b38e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e377a92c-5c40-41b5-baa9-d75e1dec8ce9" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_3b0e5661-48f2-4693-98e3-b229b13b38e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3f34ab18-9313-4a55-9fc6-7fe7993c0877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e377a92c-5c40-41b5-baa9-d75e1dec8ce9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3f34ab18-9313-4a55-9fc6-7fe7993c0877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_208bcc3e-678f-4ad2-a230-a56a02cb2a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3f34ab18-9313-4a55-9fc6-7fe7993c0877" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_208bcc3e-678f-4ad2-a230-a56a02cb2a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4ae4e6d8-7267-43e4-9403-07f8245bf2e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3f34ab18-9313-4a55-9fc6-7fe7993c0877" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4ae4e6d8-7267-43e4-9403-07f8245bf2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_452f0e12-bf7d-4226-8b81-c1e5a0be30a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_15fedebe-0dfb-4fe3-ab19-f62fbb1df887" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_452f0e12-bf7d-4226-8b81-c1e5a0be30a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_696ee0a5-44df-4893-988e-ee6c1f58dc5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87206e0f-6609-4f6a-a226-d0bbd15f8237" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_696ee0a5-44df-4893-988e-ee6c1f58dc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2b52bf09-39ce-4304-96f6-56bcc627dc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_696ee0a5-44df-4893-988e-ee6c1f58dc5d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2b52bf09-39ce-4304-96f6-56bcc627dc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_fefea183-8d1a-422c-99a7-d0ac596a0dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_696ee0a5-44df-4893-988e-ee6c1f58dc5d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_fefea183-8d1a-422c-99a7-d0ac596a0dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f847e575-1275-4a26-9006-84e650315413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_696ee0a5-44df-4893-988e-ee6c1f58dc5d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f847e575-1275-4a26-9006-84e650315413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6068cc7c-3519-4f14-848c-387fbaaa8fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_696ee0a5-44df-4893-988e-ee6c1f58dc5d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6068cc7c-3519-4f14-848c-387fbaaa8fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_12fbe95a-3011-4bb1-bc0b-c8d1bcee12b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87206e0f-6609-4f6a-a226-d0bbd15f8237" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_12fbe95a-3011-4bb1-bc0b-c8d1bcee12b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_69175716-cfad-4330-abff-1609077b7336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_12fbe95a-3011-4bb1-bc0b-c8d1bcee12b0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_69175716-cfad-4330-abff-1609077b7336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_b32b0bdd-e801-4b24-b0bd-fe6e4024b087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_12fbe95a-3011-4bb1-bc0b-c8d1bcee12b0" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_b32b0bdd-e801-4b24-b0bd-fe6e4024b087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95db200a-3c02-44af-9a66-e5d7ec78dffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_12fbe95a-3011-4bb1-bc0b-c8d1bcee12b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95db200a-3c02-44af-9a66-e5d7ec78dffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_11614a37-7d53-4a05-9480-3f74bb0928e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87206e0f-6609-4f6a-a226-d0bbd15f8237" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_11614a37-7d53-4a05-9480-3f74bb0928e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a266869d-b135-4e26-9b3e-dc51e9be635c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87206e0f-6609-4f6a-a226-d0bbd15f8237" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a266869d-b135-4e26-9b3e-dc51e9be635c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af58fe81-40a8-4574-9a68-bb8e01ecc267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87206e0f-6609-4f6a-a226-d0bbd15f8237" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af58fe81-40a8-4574-9a68-bb8e01ecc267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3ad88ad7-0c2a-4dba-9090-041ab5859a47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87206e0f-6609-4f6a-a226-d0bbd15f8237" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3ad88ad7-0c2a-4dba-9090-041ab5859a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_532f91ef-0a9d-45af-821e-46e0f89594ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3ad88ad7-0c2a-4dba-9090-041ab5859a47" xlink:to="loc_us-gaap_InterestPaidNet_532f91ef-0a9d-45af-821e-46e0f89594ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_20a4de64-9b52-4f33-822e-982147bac199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3ad88ad7-0c2a-4dba-9090-041ab5859a47" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_20a4de64-9b52-4f33-822e-982147bac199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c8030ed3-e179-418e-b7f4-f3f9d498d1ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_20a4de64-9b52-4f33-822e-982147bac199" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c8030ed3-e179-418e-b7f4-f3f9d498d1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="anab-20200930.xsd#DescriptionoftheBusiness"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/DescriptionoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b445e77d-4e05-408f-8758-b3d19b251157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_3f3da44a-79ce-4861-be78-a59f9e54a1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b445e77d-4e05-408f-8758-b3d19b251157" xlink:to="loc_us-gaap_NatureOfOperations_3f3da44a-79ce-4861-be78-a59f9e54a1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a03bbc32-1966-4ab3-995f-bb5e6ae416ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3ad3c104-e903-488b-aca3-89d91631102f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a03bbc32-1966-4ab3-995f-bb5e6ae416ca" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3ad3c104-e903-488b-aca3-89d91631102f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_820f7ec4-dceb-408d-9de0-827dc1b0c5d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_31f88bb1-1c9b-41b3-8a79-b70cc3919098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_820f7ec4-dceb-408d-9de0-827dc1b0c5d3" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_31f88bb1-1c9b-41b3-8a79-b70cc3919098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_30924e7b-8916-4b00-86af-97fc4da192d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_820f7ec4-dceb-408d-9de0-827dc1b0c5d3" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_30924e7b-8916-4b00-86af-97fc4da192d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_2f3ac5da-50e3-4cf3-ac39-457832fe10c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_820f7ec4-dceb-408d-9de0-827dc1b0c5d3" xlink:to="loc_us-gaap_UseOfEstimates_2f3ac5da-50e3-4cf3-ac39-457832fe10c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7e9d6627-fa72-4ce0-bde9-c087a9288a7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_820f7ec4-dceb-408d-9de0-827dc1b0c5d3" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7e9d6627-fa72-4ce0-bde9-c087a9288a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e3bd0c83-59f8-4dee-a78a-5b855247d895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_820f7ec4-dceb-408d-9de0-827dc1b0c5d3" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e3bd0c83-59f8-4dee-a78a-5b855247d895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a8237b26-51db-44a9-97f0-cebb52aed1d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3cae5a7b-763f-4674-9034-d973983d99e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8237b26-51db-44a9-97f0-cebb52aed1d2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3cae5a7b-763f-4674-9034-d973983d99e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_93c55d6a-d434-460a-9c5f-dfbf44b4c223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_16c64b55-63aa-46fa-9bd9-246ac5f62f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_93c55d6a-d434-460a-9c5f-dfbf44b4c223" xlink:to="loc_us-gaap_NumberOfReportableSegments_16c64b55-63aa-46fa-9bd9-246ac5f62f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_15490cc7-6831-4898-9f9a-1456bb28ab37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_000a3946-ab49-461e-9b2f-8fd51dc172dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15490cc7-6831-4898-9f9a-1456bb28ab37" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_000a3946-ab49-461e-9b2f-8fd51dc172dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c18334c2-5ae6-4d72-b774-a8fecd33a7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_000a3946-ab49-461e-9b2f-8fd51dc172dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c18334c2-5ae6-4d72-b774-a8fecd33a7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_704c61b2-0fc1-4dd5-badd-5d5fa7c40c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c18334c2-5ae6-4d72-b774-a8fecd33a7b7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_704c61b2-0fc1-4dd5-badd-5d5fa7c40c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4f0fec92-f6e6-4014-8281-7a8dda11f2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_704c61b2-0fc1-4dd5-badd-5d5fa7c40c93" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4f0fec92-f6e6-4014-8281-7a8dda11f2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_13a33b6c-4280-482c-82da-cd7f23cde3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_000a3946-ab49-461e-9b2f-8fd51dc172dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_13a33b6c-4280-482c-82da-cd7f23cde3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_64334047-4a99-4c2c-9018-dcb967d63b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_13a33b6c-4280-482c-82da-cd7f23cde3b3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_64334047-4a99-4c2c-9018-dcb967d63b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures" xlink:type="simple" xlink:href="anab-20200930.xsd#BalanceSheetAccountsandSupplementalDisclosures"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c697d74d-1cf8-4a50-b881-e8b976dd77d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5a4d0dd2-5358-4717-a286-6f94e76fe3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c697d74d-1cf8-4a50-b881-e8b976dd77d9" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5a4d0dd2-5358-4717-a286-6f94e76fe3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables" xlink:type="simple" xlink:href="anab-20200930.xsd#BalanceSheetAccountsandSupplementalDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bbe28477-98da-4ba4-b062-9e1170d65d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_00b93acf-3209-4c1f-81b9-d9d3694394b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bbe28477-98da-4ba4-b062-9e1170d65d41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_00b93acf-3209-4c1f-81b9-d9d3694394b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_cde8f147-a558-4b13-b2de-ef42f9645030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bbe28477-98da-4ba4-b062-9e1170d65d41" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_cde8f147-a558-4b13-b2de-ef42f9645030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aed74c03-cfcd-428e-9ac8-4bfe14780bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3d67f792-5985-4110-acb6-a847a8e71cd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aed74c03-cfcd-428e-9ac8-4bfe14780bf1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3d67f792-5985-4110-acb6-a847a8e71cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0dc9b81c-5139-4b6a-81f9-e6c628f2f84b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3d67f792-5985-4110-acb6-a847a8e71cd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0dc9b81c-5139-4b6a-81f9-e6c628f2f84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76f69063-0cfc-45cf-b7a9-6be17dadd534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0dc9b81c-5139-4b6a-81f9-e6c628f2f84b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76f69063-0cfc-45cf-b7a9-6be17dadd534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LaboratoryEquipmentMember_74632548-cc96-455d-8a29-3f8963e87e61" xlink:href="anab-20200930.xsd#anab_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76f69063-0cfc-45cf-b7a9-6be17dadd534" xlink:to="loc_anab_LaboratoryEquipmentMember_74632548-cc96-455d-8a29-3f8963e87e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_1b9e842e-9aaa-4480-b8fc-6c2d878f137a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76f69063-0cfc-45cf-b7a9-6be17dadd534" xlink:to="loc_us-gaap_OfficeEquipmentMember_1b9e842e-9aaa-4480-b8fc-6c2d878f137a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8d8691d1-4374-417e-8a36-6a1c97962b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76f69063-0cfc-45cf-b7a9-6be17dadd534" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8d8691d1-4374-417e-8a36-6a1c97962b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f486e67d-108c-4764-8ca6-7a7e2abe33cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3d67f792-5985-4110-acb6-a847a8e71cd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f486e67d-108c-4764-8ca6-7a7e2abe33cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e103bec9-e716-47a8-b70d-6904e2683f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f486e67d-108c-4764-8ca6-7a7e2abe33cb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e103bec9-e716-47a8-b70d-6904e2683f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4c4bb277-7d76-4ff9-b338-617282881a3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f486e67d-108c-4764-8ca6-7a7e2abe33cb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4c4bb277-7d76-4ff9-b338-617282881a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_20d6c621-8797-4697-adfa-ad43e4b1d38f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f486e67d-108c-4764-8ca6-7a7e2abe33cb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_20d6c621-8797-4697-adfa-ad43e4b1d38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_5cd54e5c-ecae-450d-8558-ee3278818403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8b52f8a2-0952-4813-afb8-da62b884e6c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_5cd54e5c-ecae-450d-8558-ee3278818403" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8b52f8a2-0952-4813-afb8-da62b884e6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2b5f7aaf-24c1-454f-b68d-fb2652f3954d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_5cd54e5c-ecae-450d-8558-ee3278818403" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2b5f7aaf-24c1-454f-b68d-fb2652f3954d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent_a8ecfb2e-211d-41ea-83b5-9ceba731bba3" xlink:href="anab-20200930.xsd#anab_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_5cd54e5c-ecae-450d-8558-ee3278818403" xlink:to="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent_a8ecfb2e-211d-41ea-83b5-9ceba731bba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a4e8af1e-1c57-46fd-85b6-a9d2c4c94177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_5cd54e5c-ecae-450d-8558-ee3278818403" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a4e8af1e-1c57-46fd-85b6-a9d2c4c94177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0c0c8a16-4d42-4de9-bc87-7e2e5b91b69c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_5cd54e5c-ecae-450d-8558-ee3278818403" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0c0c8a16-4d42-4de9-bc87-7e2e5b91b69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements" xlink:type="simple" xlink:href="anab-20200930.xsd#CollaborativeResearchandDevelopmentAgreements"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_f2c892b1-1db5-4125-88fe-4aaa7c577684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_99f18f25-13a7-4ec2-9cc4-b7851a518c8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_f2c892b1-1db5-4125-88fe-4aaa7c577684" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_99f18f25-13a7-4ec2-9cc4-b7851a518c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables" xlink:type="simple" xlink:href="anab-20200930.xsd#CollaborativeResearchandDevelopmentAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_0ae6b2e4-b280-45a6-af91-af3499ec8f96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_6ed092b7-3ce1-4c87-9f34-95707adde242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_0ae6b2e4-b280-45a6-af91-af3499ec8f96" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_6ed092b7-3ce1-4c87-9f34-95707adde242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CollaborativeResearchandDevelopmentAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_28b596bf-aa0c-48e4-a610-b4e92b7db110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_bdec1950-d0be-4bbd-ade9-da020c22f65e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_28b596bf-aa0c-48e4-a610-b4e92b7db110" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_bdec1950-d0be-4bbd-ade9-da020c22f65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e847d76e-ed62-4c34-a3a8-686441dc4b5d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_bdec1950-d0be-4bbd-ade9-da020c22f65e" xlink:to="loc_srt_CounterpartyNameAxis_e847d76e-ed62-4c34-a3a8-686441dc4b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cd888592-154d-4cde-aeaa-c22a889f9481" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e847d76e-ed62-4c34-a3a8-686441dc4b5d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cd888592-154d-4cde-aeaa-c22a889f9481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member_b582e306-17f8-4799-8e90-71652111ef88" xlink:href="anab-20200930.xsd#anab_TESAROInc.AndTESARODevelopmentInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cd888592-154d-4cde-aeaa-c22a889f9481" xlink:to="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member_b582e306-17f8-4799-8e90-71652111ef88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CelgeneCorporationMember_5ec8464f-7e07-40f9-8007-9364eb7c4d21" xlink:href="anab-20200930.xsd#anab_CelgeneCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cd888592-154d-4cde-aeaa-c22a889f9481" xlink:to="loc_anab_CelgeneCorporationMember_5ec8464f-7e07-40f9-8007-9364eb7c4d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_dc786cdd-4b90-4d3d-8120-ed4b65a862be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_bdec1950-d0be-4bbd-ade9-da020c22f65e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_dc786cdd-4b90-4d3d-8120-ed4b65a862be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4a64c13-e3e6-41ca-b1e5-ad5a87e1b786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dc786cdd-4b90-4d3d-8120-ed4b65a862be" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4a64c13-e3e6-41ca-b1e5-ad5a87e1b786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4a64c13-e3e6-41ca-b1e5-ad5a87e1b786" xlink:to="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_InVivoToxicologyStudiesMember_a08a3574-17dc-4a08-9daf-187fc65862f3" xlink:href="anab-20200930.xsd#anab_InVivoToxicologyStudiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_InVivoToxicologyStudiesMember_a08a3574-17dc-4a08-9daf-187fc65862f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_a58f57dd-a045-4759-bbb4-036e98e4c0dc" xlink:href="anab-20200930.xsd#anab_ClearanceOfInvestigationalNewDrugFromFDAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_a58f57dd-a045-4759-bbb4-036e98e4c0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase2ClinicalTrialInitiationMember_b91b50b9-bfec-474c-a91b-b5eafb90c8fd" xlink:href="anab-20200930.xsd#anab_Phase2ClinicalTrialInitiationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_Phase2ClinicalTrialInitiationMember_b91b50b9-bfec-474c-a91b-b5eafb90c8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase3ClinicalTrialInitiationMember_4d306f95-8033-4196-999e-43f3616476e6" xlink:href="anab-20200930.xsd#anab_Phase3ClinicalTrialInitiationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_Phase3ClinicalTrialInitiationMember_4d306f95-8033-4196-999e-43f3616476e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase3clinicaltrialinitiationsecondindicationDomain_bbdb8308-9a09-4576-8dd9-49115c0b9779" xlink:href="anab-20200930.xsd#anab_Phase3clinicaltrialinitiationsecondindicationDomain"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_Phase3clinicaltrialinitiationsecondindicationDomain_bbdb8308-9a09-4576-8dd9-49115c0b9779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingofNDAMember_3f377473-9f19-4103-af71-ed22a6bebde8" xlink:href="anab-20200930.xsd#anab_FilingofNDAMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_FilingofNDAMember_3f377473-9f19-4103-af71-ed22a6bebde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingofMMAMember_07eafe99-ea4a-4c29-a1a3-3f26ec344236" xlink:href="anab-20200930.xsd#anab_FilingofMMAMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_FilingofMMAMember_07eafe99-ea4a-4c29-a1a3-3f26ec344236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase1ClinicalTrialInitiationMember_776f8d7b-7d22-48ca-9a8e-998f1e6b05ae" xlink:href="anab-20200930.xsd#anab_Phase1ClinicalTrialInitiationMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_e73d0fed-73a2-436b-81a8-5eb330891532" xlink:to="loc_anab_Phase1ClinicalTrialInitiationMember_776f8d7b-7d22-48ca-9a8e-998f1e6b05ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2f7b37a0-82bf-4a51-a189-11dc3a408b56" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_bdec1950-d0be-4bbd-ade9-da020c22f65e" xlink:to="loc_srt_ProductOrServiceAxis_2f7b37a0-82bf-4a51-a189-11dc3a408b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6288632d-97cd-4d5c-8a53-af1ca286f441" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2f7b37a0-82bf-4a51-a189-11dc3a408b56" xlink:to="loc_srt_ProductsAndServicesDomain_6288632d-97cd-4d5c-8a53-af1ca286f441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_ddabd32f-95b8-40fb-a04d-4d90478c475f" xlink:href="anab-20200930.xsd#anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6288632d-97cd-4d5c-8a53-af1ca286f441" xlink:to="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_ddabd32f-95b8-40fb-a04d-4d90478c475f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_ad54682d-5b76-4598-acb2-0e73029ea4f6" xlink:href="anab-20200930.xsd#anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6288632d-97cd-4d5c-8a53-af1ca286f441" xlink:to="loc_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_ad54682d-5b76-4598-acb2-0e73029ea4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_9cc1d194-8bda-425b-baa2-ef9833155827" xlink:href="anab-20200930.xsd#anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6288632d-97cd-4d5c-8a53-af1ca286f441" xlink:to="loc_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_9cc1d194-8bda-425b-baa2-ef9833155827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_f485404c-8bdf-4cde-a44b-87a878899800" xlink:href="anab-20200930.xsd#anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6288632d-97cd-4d5c-8a53-af1ca286f441" xlink:to="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_f485404c-8bdf-4cde-a44b-87a878899800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_bdec1950-d0be-4bbd-ade9-da020c22f65e" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_d87204d7-790a-4857-b23d-e38290db4860" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_d87204d7-790a-4857-b23d-e38290db4860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_e71ac2c6-00fb-42d9-883f-f25da77af048" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_e71ac2c6-00fb-42d9-883f-f25da77af048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_bcaa2971-62b2-414e-a088-96cd58d13d42" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_bcaa2971-62b2-414e-a088-96cd58d13d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_01077a85-e480-4027-9fc0-6f93643b31c1" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_01077a85-e480-4027-9fc0-6f93643b31c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_bf26524e-3bd4-4a76-884f-1cfa7c6e654e" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_bf26524e-3bd4-4a76-884f-1cfa7c6e654e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_03fdd7ff-0b80-4c04-8e28-c27fe25b65bb" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_03fdd7ff-0b80-4c04-8e28-c27fe25b65bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_21ea5729-afe0-409b-8e7f-fd427e6f35d6" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_21ea5729-afe0-409b-8e7f-fd427e6f35d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_a41e3961-0409-43de-bf5a-d05b6ce5e0e2" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_a41e3961-0409-43de-bf5a-d05b6ce5e0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_300e87c4-22a6-4d79-a924-e1b22758b3b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_300e87c4-22a6-4d79-a924-e1b22758b3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_c5131d4a-728f-4cde-ba0a-55a1f769cf4d" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_c5131d4a-728f-4cde-ba0a-55a1f769cf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_be7c256f-53a5-40c0-ac6f-df090fdc0667" xlink:href="anab-20200930.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_c98ef609-fac1-4235-b23c-6ce7cfb6539d" xlink:to="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_be7c256f-53a5-40c0-ac6f-df090fdc0667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/NotesPayable" xlink:type="simple" xlink:href="anab-20200930.xsd#NotesPayable"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/NotesPayable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_21e94346-a573-43e0-bfa4-ce00a5f1d573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_a2a2372f-8731-4231-a002-2d8bac0fd236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_21e94346-a573-43e0-bfa4-ce00a5f1d573" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_a2a2372f-8731-4231-a002-2d8bac0fd236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/NotesPayableDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#NotesPayableDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/NotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8f3664d1-4a18-474e-a31b-982c3ea75f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_568f4f50-2c39-45df-bae6-80adf7442163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8f3664d1-4a18-474e-a31b-982c3ea75f91" xlink:to="loc_us-gaap_DebtInstrumentTable_568f4f50-2c39-45df-bae6-80adf7442163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a50b323d-e137-4f34-ba5a-a9899e9ddd36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_568f4f50-2c39-45df-bae6-80adf7442163" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a50b323d-e137-4f34-ba5a-a9899e9ddd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f8e242c1-2461-4dd2-aae5-51008aceaf48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a50b323d-e137-4f34-ba5a-a9899e9ddd36" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f8e242c1-2461-4dd2-aae5-51008aceaf48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_0810bf23-0a34-4816-8b37-fbc94a1553b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f8e242c1-2461-4dd2-aae5-51008aceaf48" xlink:to="loc_us-gaap_NotesPayableToBanksMember_0810bf23-0a34-4816-8b37-fbc94a1553b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fd0cef48-4ac7-4c2a-ac0f-54b3860fc6b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_568f4f50-2c39-45df-bae6-80adf7442163" xlink:to="loc_us-gaap_DebtInstrumentAxis_fd0cef48-4ac7-4c2a-ac0f-54b3860fc6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f22298a7-fe20-4721-8ac8-41f08ad3eaf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fd0cef48-4ac7-4c2a-ac0f-54b3860fc6b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f22298a7-fe20-4721-8ac8-41f08ad3eaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LoanAndSecurityAgreementMember_145eba5d-0a7b-4c1c-aaaf-3f89b33d529c" xlink:href="anab-20200930.xsd#anab_LoanAndSecurityAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f22298a7-fe20-4721-8ac8-41f08ad3eaf0" xlink:to="loc_anab_LoanAndSecurityAgreementMember_145eba5d-0a7b-4c1c-aaaf-3f89b33d529c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_TermALoansMember_a3708eac-4386-4b43-83a8-131eda691d40" xlink:href="anab-20200930.xsd#anab_TermALoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f22298a7-fe20-4721-8ac8-41f08ad3eaf0" xlink:to="loc_anab_TermALoansMember_a3708eac-4386-4b43-83a8-131eda691d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_TermBLoansAndTermCLoansMember_41a9e646-d533-437f-9046-d4100c4359a8" xlink:href="anab-20200930.xsd#anab_TermBLoansAndTermCLoansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f22298a7-fe20-4721-8ac8-41f08ad3eaf0" xlink:to="loc_anab_TermBLoansAndTermCLoansMember_41a9e646-d533-437f-9046-d4100c4359a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_568f4f50-2c39-45df-bae6-80adf7442163" xlink:to="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_DebtInstrumentMaximumBorrowingCapacity_89054ade-3ced-4aee-a098-49fc482bf490" xlink:href="anab-20200930.xsd#anab_DebtInstrumentMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:to="loc_anab_DebtInstrumentMaximumBorrowingCapacity_89054ade-3ced-4aee-a098-49fc482bf490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_DebtInstrumentNumberOfLoanInstallments_0743ed1e-932b-4b77-8890-c6bff8ef5fe2" xlink:href="anab-20200930.xsd#anab_DebtInstrumentNumberOfLoanInstallments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:to="loc_anab_DebtInstrumentNumberOfLoanInstallments_0743ed1e-932b-4b77-8890-c6bff8ef5fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_929ec3c4-947e-43a8-af3a-83c587b38984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_929ec3c4-947e-43a8-af3a-83c587b38984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_c01501c2-1228-4fd4-9978-686fa77e25c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_c01501c2-1228-4fd4-9978-686fa77e25c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5bb06120-d1f9-426e-83df-0d55b5e51ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5bb06120-d1f9-426e-83df-0d55b5e51ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_865fac9c-894f-4a4d-a44a-307e44116750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fe5433e1-6b91-4320-b868-e29e7f889084" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_865fac9c-894f-4a4d-a44a-307e44116750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestments"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2f3ebfda-575e-4d0b-90d2-7066021e1309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5e1ae2ae-6976-4655-9fee-9b1e0df15145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2f3ebfda-575e-4d0b-90d2-7066021e1309" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5e1ae2ae-6976-4655-9fee-9b1e0df15145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_506067ee-24c0-4569-8ed6-c1550bfb6c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f29fd065-7bd0-434a-a51c-b8a9f5fd4c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_506067ee-24c0-4569-8ed6-c1550bfb6c43" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f29fd065-7bd0-434a-a51c-b8a9f5fd4c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_e7636579-ea4a-4360-82e5-7f9357116d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_506067ee-24c0-4569-8ed6-c1550bfb6c43" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_e7636579-ea4a-4360-82e5-7f9357116d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_e5c57b2d-c489-4eca-9bef-36b927373e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_506067ee-24c0-4569-8ed6-c1550bfb6c43" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_e5c57b2d-c489-4eca-9bef-36b927373e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_d8006ac9-f8cf-44c0-a672-6e96c48845cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_506067ee-24c0-4569-8ed6-c1550bfb6c43" xlink:to="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_d8006ac9-f8cf-44c0-a672-6e96c48845cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_30b4bb05-7a46-49c1-aba3-32208aca52c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7b3bdc4-1245-45dd-b78a-309ebbb4fbb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_30b4bb05-7a46-49c1-aba3-32208aca52c0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7b3bdc4-1245-45dd-b78a-309ebbb4fbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e9e846b6-0842-49a1-a1be-b026fce0c14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7b3bdc4-1245-45dd-b78a-309ebbb4fbb2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e9e846b6-0842-49a1-a1be-b026fce0c14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4d8fdc49-53e9-428c-aabe-ec84d6d54e29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e9e846b6-0842-49a1-a1be-b026fce0c14d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4d8fdc49-53e9-428c-aabe-ec84d6d54e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7fbe6147-ba83-4c23-bca4-8a6bb47d7e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4d8fdc49-53e9-428c-aabe-ec84d6d54e29" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7fbe6147-ba83-4c23-bca4-8a6bb47d7e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_27edfc0c-4a87-4122-b0e5-d5e8bd4eaab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7b3bdc4-1245-45dd-b78a-309ebbb4fbb2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_27edfc0c-4a87-4122-b0e5-d5e8bd4eaab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f674b6cd-26ae-4921-b731-1dba3bdd1fb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_27edfc0c-4a87-4122-b0e5-d5e8bd4eaab0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f674b6cd-26ae-4921-b731-1dba3bdd1fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fa63a14d-52a3-4822-bab5-88d8a8f74826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f674b6cd-26ae-4921-b731-1dba3bdd1fb2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fa63a14d-52a3-4822-bab5-88d8a8f74826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c11b7150-e602-404d-b5f0-3db128b0cb87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f674b6cd-26ae-4921-b731-1dba3bdd1fb2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c11b7150-e602-404d-b5f0-3db128b0cb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1bdf5c73-9f38-46f9-8f1f-8903f7833234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f674b6cd-26ae-4921-b731-1dba3bdd1fb2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1bdf5c73-9f38-46f9-8f1f-8903f7833234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_54b17703-0751-4468-810a-f271a3974018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7b3bdc4-1245-45dd-b78a-309ebbb4fbb2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_54b17703-0751-4468-810a-f271a3974018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1da1f4b3-c537-45c0-947d-3ae004e91395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_54b17703-0751-4468-810a-f271a3974018" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1da1f4b3-c537-45c0-947d-3ae004e91395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_94590256-ce06-477e-a7f7-043ad35f34d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1da1f4b3-c537-45c0-947d-3ae004e91395" xlink:to="loc_us-gaap_MoneyMarketFundsMember_94590256-ce06-477e-a7f7-043ad35f34d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_5f40270e-fcbd-467d-9a26-80b27c1dc189" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1da1f4b3-c537-45c0-947d-3ae004e91395" xlink:to="loc_us-gaap_MutualFundMember_5f40270e-fcbd-467d-9a26-80b27c1dc189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_80ececaf-b9ee-4c39-823d-b50b3b905c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7b3bdc4-1245-45dd-b78a-309ebbb4fbb2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_80ececaf-b9ee-4c39-823d-b50b3b905c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2872cab-1933-41f3-ad9f-7bf283399eab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_80ececaf-b9ee-4c39-823d-b50b3b905c7f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2872cab-1933-41f3-ad9f-7bf283399eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_155bfb8e-aa8a-4be8-a410-ffa90e5e97d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2872cab-1933-41f3-ad9f-7bf283399eab" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_155bfb8e-aa8a-4be8-a410-ffa90e5e97d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_419b923d-bd68-4630-9a6e-8cbbd7fb7d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2872cab-1933-41f3-ad9f-7bf283399eab" xlink:to="loc_us-gaap_CertificatesOfDepositMember_419b923d-bd68-4630-9a6e-8cbbd7fb7d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_63469ad1-c368-472f-bd6b-74835d9bbea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2872cab-1933-41f3-ad9f-7bf283399eab" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_63469ad1-c368-472f-bd6b-74835d9bbea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_8011caf2-ef66-408e-87d9-63caa91f32ae" xlink:href="anab-20200930.xsd#anab_CommercialAndCorporateObligationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2872cab-1933-41f3-ad9f-7bf283399eab" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_8011caf2-ef66-408e-87d9-63caa91f32ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_865a5de8-e0fc-48f4-88ab-537331a81580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f7b3bdc4-1245-45dd-b78a-309ebbb4fbb2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_865a5de8-e0fc-48f4-88ab-537331a81580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_885bf5d1-87ab-458b-90c3-f87ec860fa7e" xlink:href="anab-20200930.xsd#anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_865a5de8-e0fc-48f4-88ab-537331a81580" xlink:to="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_885bf5d1-87ab-458b-90c3-f87ec860fa7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c102e38-c1d9-4c38-8522-bbdc56d8e182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_865a5de8-e0fc-48f4-88ab-537331a81580" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c102e38-c1d9-4c38-8522-bbdc56d8e182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_31c61257-a35f-4fce-9b24-f8e9da833f79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f385c960-d23c-4e91-adb9-a4fc56cbf85f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_31c61257-a35f-4fce-9b24-f8e9da833f79" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f385c960-d23c-4e91-adb9-a4fc56cbf85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_6eb0bdfc-5aec-4811-87fd-88fe3b0b6537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f385c960-d23c-4e91-adb9-a4fc56cbf85f" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_6eb0bdfc-5aec-4811-87fd-88fe3b0b6537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9ee5f1de-0adf-452f-886d-dc2fd80453cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_6eb0bdfc-5aec-4811-87fd-88fe3b0b6537" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9ee5f1de-0adf-452f-886d-dc2fd80453cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d234efb9-0aa1-45f1-bc6b-7e84028e13d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9ee5f1de-0adf-452f-886d-dc2fd80453cf" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d234efb9-0aa1-45f1-bc6b-7e84028e13d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_356cb7c2-df02-47dc-847a-50e705911ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9ee5f1de-0adf-452f-886d-dc2fd80453cf" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_356cb7c2-df02-47dc-847a-50e705911ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5b496402-4711-4558-a7be-c50626cbee5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9ee5f1de-0adf-452f-886d-dc2fd80453cf" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5b496402-4711-4558-a7be-c50626cbee5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3ac907a6-858a-446e-8771-cf8df4d47bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f385c960-d23c-4e91-adb9-a4fc56cbf85f" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3ac907a6-858a-446e-8771-cf8df4d47bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_2b8a988f-2b2b-42c5-9a55-0422bccca0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3ac907a6-858a-446e-8771-cf8df4d47bc0" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_2b8a988f-2b2b-42c5-9a55-0422bccca0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_52c41ac8-234d-4101-9dbf-2e6955d9246b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c50ee7fe-4562-408b-9f56-0dd54b8f27ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_52c41ac8-234d-4101-9dbf-2e6955d9246b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c50ee7fe-4562-408b-9f56-0dd54b8f27ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6e6818a1-9a52-4c03-ab96-8bd98ead60e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c50ee7fe-4562-408b-9f56-0dd54b8f27ca" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6e6818a1-9a52-4c03-ab96-8bd98ead60e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36c195d1-6d79-45bd-92a7-e34c4f73fd80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6e6818a1-9a52-4c03-ab96-8bd98ead60e2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36c195d1-6d79-45bd-92a7-e34c4f73fd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_17a447d2-0503-494b-a1a0-421dc7ac6373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36c195d1-6d79-45bd-92a7-e34c4f73fd80" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_17a447d2-0503-494b-a1a0-421dc7ac6373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f58fda0f-baff-449b-bd42-369c239748d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36c195d1-6d79-45bd-92a7-e34c4f73fd80" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f58fda0f-baff-449b-bd42-369c239748d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_03ae1db9-29f1-4e36-a4c8-a731d2cac8c4" xlink:href="anab-20200930.xsd#anab_CommercialAndCorporateObligationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36c195d1-6d79-45bd-92a7-e34c4f73fd80" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_03ae1db9-29f1-4e36-a4c8-a731d2cac8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_341a36b7-cc40-4fbd-b281-c3a5abe80a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36c195d1-6d79-45bd-92a7-e34c4f73fd80" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_341a36b7-cc40-4fbd-b281-c3a5abe80a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e43f1f35-bf98-48ee-aede-2a78d1473f56" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c50ee7fe-4562-408b-9f56-0dd54b8f27ca" xlink:to="loc_srt_RangeAxis_e43f1f35-bf98-48ee-aede-2a78d1473f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1fa12c6-3e12-46f5-b3e1-fd42580b4ff6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e43f1f35-bf98-48ee-aede-2a78d1473f56" xlink:to="loc_srt_RangeMember_e1fa12c6-3e12-46f5-b3e1-fd42580b4ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a693bf25-fc51-4daf-9bb3-973309dde3ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e1fa12c6-3e12-46f5-b3e1-fd42580b4ff6" xlink:to="loc_srt_MinimumMember_a693bf25-fc51-4daf-9bb3-973309dde3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6eff9d70-80f1-4485-bf70-e99d9cc490c7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e1fa12c6-3e12-46f5-b3e1-fd42580b4ff6" xlink:to="loc_srt_MaximumMember_6eff9d70-80f1-4485-bf70-e99d9cc490c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c50ee7fe-4562-408b-9f56-0dd54b8f27ca" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6528a632-a8d8-4606-9029-c183d291d1a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6528a632-a8d8-4606-9029-c183d291d1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1489a30d-da26-4e8c-8c1f-773792dfd16c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1489a30d-da26-4e8c-8c1f-773792dfd16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fc6dfa59-8830-4f95-8c2e-fd75f2e7ee71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fc6dfa59-8830-4f95-8c2e-fd75f2e7ee71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a1933f9a-d635-4f15-b75d-44fe79b93fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a1933f9a-d635-4f15-b75d-44fe79b93fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3e313d93-5ddc-42e0-8394-b07c7e269e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3e313d93-5ddc-42e0-8394-b07c7e269e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_4436ce46-d337-4078-b1fb-0daca8857ec2" xlink:href="anab-20200930.xsd#anab_AvailableforsaleDebtSecuritiesRemainingMaturity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_4436ce46-d337-4078-b1fb-0daca8857ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e9bf07de-0665-4d99-9bbf-a52c1327d451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3debf9c2-4106-4068-a9f4-7677348b8fb1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e9bf07de-0665-4d99-9bbf-a52c1327d451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ef5842ff-d24f-4ac6-af2a-fe914e5e29f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67a03285-e62f-452d-9c61-6b8c8b7106ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ef5842ff-d24f-4ac6-af2a-fe914e5e29f3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67a03285-e62f-452d-9c61-6b8c8b7106ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_789b4e8b-ab78-4f05-ada6-549bb3294a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67a03285-e62f-452d-9c61-6b8c8b7106ae" xlink:to="loc_us-gaap_FinancialInstrumentAxis_789b4e8b-ab78-4f05-ada6-549bb3294a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_799d3c17-47a8-4bf5-81a5-604cfdedfddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_789b4e8b-ab78-4f05-ada6-549bb3294a24" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_799d3c17-47a8-4bf5-81a5-604cfdedfddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ed4a61ed-89f7-4b2d-be0d-9e9791f9dbce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_799d3c17-47a8-4bf5-81a5-604cfdedfddb" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ed4a61ed-89f7-4b2d-be0d-9e9791f9dbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_1b13662a-1717-4575-b3df-cd6f02c7b344" xlink:href="anab-20200930.xsd#anab_CommercialAndCorporateObligationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_799d3c17-47a8-4bf5-81a5-604cfdedfddb" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_1b13662a-1717-4575-b3df-cd6f02c7b344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_dae19b7c-eb87-4bf1-94e1-565e5f1bf9ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_799d3c17-47a8-4bf5-81a5-604cfdedfddb" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_dae19b7c-eb87-4bf1-94e1-565e5f1bf9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_67a03285-e62f-452d-9c61-6b8c8b7106ae" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_fb3b1379-ce8b-4504-8b8e-979f6b21c8f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_fb3b1379-ce8b-4504-8b8e-979f6b21c8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_cce7b43d-bb21-4cf5-ab85-cb5a7c4e5482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_cce7b43d-bb21-4cf5-ab85-cb5a7c4e5482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_ce49d1bc-088e-400d-b2b4-00ec781c65ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_ce49d1bc-088e-400d-b2b4-00ec781c65ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_7dcbb75f-2195-410d-8e48-014bb8e7899e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_7dcbb75f-2195-410d-8e48-014bb8e7899e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c0c45fed-3d00-4f2b-bbfd-a5c576b83914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c0c45fed-3d00-4f2b-bbfd-a5c576b83914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_50bad50b-6075-4684-aab9-d623a09a770c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a3426f5-c88f-46ef-af71-efd4286b30cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_50bad50b-6075-4684-aab9-d623a09a770c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="anab-20200930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5a526232-d508-4124-9e7e-c61ab609dfdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_10913f77-1d3b-4e3f-8c4b-985988d4edc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5a526232-d508-4124-9e7e-c61ab609dfdc" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_10913f77-1d3b-4e3f-8c4b-985988d4edc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="anab-20200930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fe9dfb4a-319e-4596-a91f-0455c7ba36e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_4378269a-ec60-406f-922e-349c1e6741c8" xlink:href="anab-20200930.xsd#anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fe9dfb4a-319e-4596-a91f-0455c7ba36e0" xlink:to="loc_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_4378269a-ec60-406f-922e-349c1e6741c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_90d9de3b-c560-4353-a4bd-48f368a60b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a5936315-3546-4457-bce6-69ec1a6ef4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_90d9de3b-c560-4353-a4bd-48f368a60b1a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a5936315-3546-4457-bce6-69ec1a6ef4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_17289d79-8edc-4504-a1ee-c09d1f072808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_90d9de3b-c560-4353-a4bd-48f368a60b1a" xlink:to="loc_us-gaap_CommonStockSharesIssued_17289d79-8edc-4504-a1ee-c09d1f072808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2bf9d29c-8fdf-4351-9521-f14092ddf894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_90d9de3b-c560-4353-a4bd-48f368a60b1a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2bf9d29c-8fdf-4351-9521-f14092ddf894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_71be5705-c738-48fa-abc2-e49dddae4162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e6fcae41-fe4d-423e-962a-91cf46315bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_71be5705-c738-48fa-abc2-e49dddae4162" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e6fcae41-fe4d-423e-962a-91cf46315bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_86c863ec-b89b-4ac3-ac86-40bbff98e308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e6fcae41-fe4d-423e-962a-91cf46315bd3" xlink:to="loc_us-gaap_PlanNameAxis_86c863ec-b89b-4ac3-ac86-40bbff98e308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5e735b19-6e59-47ed-9499-ada342818da1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_86c863ec-b89b-4ac3-ac86-40bbff98e308" xlink:to="loc_us-gaap_PlanNameDomain_5e735b19-6e59-47ed-9499-ada342818da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EquityIncentivePlan2017Member_fb104ec5-e552-4caa-b5fc-27816b4a033b" xlink:href="anab-20200930.xsd#anab_EquityIncentivePlan2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5e735b19-6e59-47ed-9499-ada342818da1" xlink:to="loc_anab_EquityIncentivePlan2017Member_fb104ec5-e552-4caa-b5fc-27816b4a033b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member_74640f64-6244-4eb9-8f99-c050ca380a09" xlink:href="anab-20200930.xsd#anab_EmployeeStockPurchasePlan2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5e735b19-6e59-47ed-9499-ada342818da1" xlink:to="loc_anab_EmployeeStockPurchasePlan2017Member_74640f64-6244-4eb9-8f99-c050ca380a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_284e7a76-589c-4b42-83aa-381adf25b442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e6fcae41-fe4d-423e-962a-91cf46315bd3" xlink:to="loc_us-gaap_ClassOfStockLineItems_284e7a76-589c-4b42-83aa-381adf25b442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e9778f4f-67a2-47ed-b7b8-603fac2fb14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_284e7a76-589c-4b42-83aa-381adf25b442" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e9778f4f-67a2-47ed-b7b8-603fac2fb14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fcafb2b1-01c3-4955-85db-f3d1a097b162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e9778f4f-67a2-47ed-b7b8-603fac2fb14f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fcafb2b1-01c3-4955-85db-f3d1a097b162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2ca3478a-2f54-41ed-b499-0294c4c0c350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_284e7a76-589c-4b42-83aa-381adf25b442" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2ca3478a-2f54-41ed-b499-0294c4c0c350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_365ebae5-8d62-4e02-a72f-f1bb4e8cae2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_284e7a76-589c-4b42-83aa-381adf25b442" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_365ebae5-8d62-4e02-a72f-f1bb4e8cae2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlans" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f554498e-a072-4402-bec0-1fb3fd67fee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_75c1f790-9028-4788-881f-ed7e6c89f94b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f554498e-a072-4402-bec0-1fb3fd67fee9" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_75c1f790-9028-4788-881f-ed7e6c89f94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansTables" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7445cd3a-7341-40d9-ba6c-7eb31785c818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6166036e-80af-4a51-8b33-bde3ec00842b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7445cd3a-7341-40d9-ba6c-7eb31785c818" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6166036e-80af-4a51-8b33-bde3ec00842b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a0025424-68f8-4dfc-9732-4dba05edd05b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7445cd3a-7341-40d9-ba6c-7eb31785c818" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a0025424-68f8-4dfc-9732-4dba05edd05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_125f73ba-b235-4593-a397-77607ac77c42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7445cd3a-7341-40d9-ba6c-7eb31785c818" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_125f73ba-b235-4593-a397-77607ac77c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4852923b-8e33-40c3-8e47-b3179d4cb34e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33050d09-a899-4fa1-aa42-8d80dbe522d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4852923b-8e33-40c3-8e47-b3179d4cb34e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33050d09-a899-4fa1-aa42-8d80dbe522d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_40713782-5ac8-494c-b8c9-f318b411dd7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33050d09-a899-4fa1-aa42-8d80dbe522d9" xlink:to="loc_us-gaap_PlanNameAxis_40713782-5ac8-494c-b8c9-f318b411dd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e04988f0-44c3-496f-855a-88243e596c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_40713782-5ac8-494c-b8c9-f318b411dd7a" xlink:to="loc_us-gaap_PlanNameDomain_e04988f0-44c3-496f-855a-88243e596c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EquityIncentivePlan2017Member_bbabc723-630e-43d9-b347-bc650b874ed0" xlink:href="anab-20200930.xsd#anab_EquityIncentivePlan2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e04988f0-44c3-496f-855a-88243e596c9d" xlink:to="loc_anab_EquityIncentivePlan2017Member_bbabc723-630e-43d9-b347-bc650b874ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member_39e347c8-8bad-41c5-aff0-0b334c2585e6" xlink:href="anab-20200930.xsd#anab_EmployeeStockPurchasePlan2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e04988f0-44c3-496f-855a-88243e596c9d" xlink:to="loc_anab_EmployeeStockPurchasePlan2017Member_39e347c8-8bad-41c5-aff0-0b334c2585e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b563a241-a7d0-4139-95b3-e31786e1d0cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33050d09-a899-4fa1-aa42-8d80dbe522d9" xlink:to="loc_us-gaap_AwardTypeAxis_b563a241-a7d0-4139-95b3-e31786e1d0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97166377-9fe2-482c-ad3e-35af6d34e794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b563a241-a7d0-4139-95b3-e31786e1d0cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97166377-9fe2-482c-ad3e-35af6d34e794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_32f66517-5a26-4300-84b9-bf264eeff35f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97166377-9fe2-482c-ad3e-35af6d34e794" xlink:to="loc_us-gaap_EmployeeStockMember_32f66517-5a26-4300-84b9-bf264eeff35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a5d1afba-00f7-437b-b8ed-f130f53eeef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97166377-9fe2-482c-ad3e-35af6d34e794" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a5d1afba-00f7-437b-b8ed-f130f53eeef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_309f52cc-62db-4bf5-929f-396899046cd1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33050d09-a899-4fa1-aa42-8d80dbe522d9" xlink:to="loc_srt_TitleOfIndividualAxis_309f52cc-62db-4bf5-929f-396899046cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b144b2ee-8657-4196-9d31-96ae6dffb66d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_309f52cc-62db-4bf5-929f-396899046cd1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b144b2ee-8657-4196-9d31-96ae6dffb66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_a86f07a4-6881-4a97-90f8-fdbb6a181283" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b144b2ee-8657-4196-9d31-96ae6dffb66d" xlink:to="loc_srt_DirectorMember_a86f07a4-6881-4a97-90f8-fdbb6a181283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_33050d09-a899-4fa1-aa42-8d80dbe522d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_b6e7ced0-d539-4138-97d0-847210396855" xlink:href="anab-20200930.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:to="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_b6e7ced0-d539-4138-97d0-847210396855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_f3d8ad3f-9404-4668-8752-32cf94040df0" xlink:href="anab-20200930.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:to="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_f3d8ad3f-9404-4668-8752-32cf94040df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_54795cf6-2fb7-482a-b86f-a9d5b697c986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_54795cf6-2fb7-482a-b86f-a9d5b697c986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_95946c11-e0f5-40d2-8121-43241cf75fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_95946c11-e0f5-40d2-8121-43241cf75fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_1f1c86fb-fd73-4fcf-bf53-460813568900" xlink:href="anab-20200930.xsd#anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:to="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_1f1c86fb-fd73-4fcf-bf53-460813568900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_8547e657-1514-4f2a-acf6-c781ea719fc0" xlink:href="anab-20200930.xsd#anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65020e0f-1982-467b-af70-bb36e8274019" xlink:to="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_8547e657-1514-4f2a-acf6-c781ea719fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04babbd5-b614-4eed-8d2b-087c0aa7ad99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8b8c8090-e9c9-4a9c-9852-a9a5ec11525b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04babbd5-b614-4eed-8d2b-087c0aa7ad99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8b8c8090-e9c9-4a9c-9852-a9a5ec11525b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_64490ec3-51ea-48f9-8369-de0fadcf522d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8b8c8090-e9c9-4a9c-9852-a9a5ec11525b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_64490ec3-51ea-48f9-8369-de0fadcf522d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9f74dc1d-e03a-47e1-9ae8-951de52c730e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8b8c8090-e9c9-4a9c-9852-a9a5ec11525b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9f74dc1d-e03a-47e1-9ae8-951de52c730e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d95c9b6c-6d8d-41fb-9160-4e277df82fba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8b8c8090-e9c9-4a9c-9852-a9a5ec11525b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d95c9b6c-6d8d-41fb-9160-4e277df82fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_fe3a7209-5c36-4909-9511-90917c5533e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8b8c8090-e9c9-4a9c-9852-a9a5ec11525b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_fe3a7209-5c36-4909-9511-90917c5533e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_72449e17-3527-4749-bdac-c8fd4a53d612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8b8c8090-e9c9-4a9c-9852-a9a5ec11525b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_72449e17-3527-4749-bdac-c8fd4a53d612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b82a2d62-bfc2-4794-9b5e-ff001c7fec30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04babbd5-b614-4eed-8d2b-087c0aa7ad99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b82a2d62-bfc2-4794-9b5e-ff001c7fec30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5cdfef99-2044-416f-ae1c-1c36a7786b3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04babbd5-b614-4eed-8d2b-087c0aa7ad99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5cdfef99-2044-416f-ae1c-1c36a7786b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3b679557-0f2f-4bb8-97a2-7158e8594931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5cdfef99-2044-416f-ae1c-1c36a7786b3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3b679557-0f2f-4bb8-97a2-7158e8594931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8db8fe8b-85a3-44c8-a16b-65e735480406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5cdfef99-2044-416f-ae1c-1c36a7786b3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8db8fe8b-85a3-44c8-a16b-65e735480406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_acb95072-2ba2-48c0-8632-5bb0b9a091d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5cdfef99-2044-416f-ae1c-1c36a7786b3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_acb95072-2ba2-48c0-8632-5bb0b9a091d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_4a7e065a-f7a1-4588-9e2d-c098adb91611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5cdfef99-2044-416f-ae1c-1c36a7786b3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_4a7e065a-f7a1-4588-9e2d-c098adb91611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f91f39ce-1e6d-4963-9ebc-16ef44f47545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5cdfef99-2044-416f-ae1c-1c36a7786b3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f91f39ce-1e6d-4963-9ebc-16ef44f47545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5b3cc76f-59e0-4e32-aa01-73547cf15a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04babbd5-b614-4eed-8d2b-087c0aa7ad99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5b3cc76f-59e0-4e32-aa01-73547cf15a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ac1777c0-f68b-4cd5-9c17-ff692b852595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04babbd5-b614-4eed-8d2b-087c0aa7ad99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ac1777c0-f68b-4cd5-9c17-ff692b852595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f8d809e5-7ea0-4252-a80d-28839c63fc19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ac1777c0-f68b-4cd5-9c17-ff692b852595" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f8d809e5-7ea0-4252-a80d-28839c63fc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b5b5eb87-290a-412c-8ca8-66678340ffb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ac1777c0-f68b-4cd5-9c17-ff692b852595" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b5b5eb87-290a-412c-8ca8-66678340ffb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d8b0a8f9-8e7d-4573-b032-cf7ce18eed76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ac1777c0-f68b-4cd5-9c17-ff692b852595" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d8b0a8f9-8e7d-4573-b032-cf7ce18eed76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2f2d94df-82e5-498e-9db2-4976fa130fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ac1777c0-f68b-4cd5-9c17-ff692b852595" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2f2d94df-82e5-498e-9db2-4976fa130fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansOptionFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e9158cb-df6d-4690-8188-ddad5992dc29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a235c515-5582-4f74-a119-955dfaec77fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e9158cb-df6d-4690-8188-ddad5992dc29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a235c515-5582-4f74-a119-955dfaec77fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dfcba747-1669-4310-aff9-59f11b14606a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a235c515-5582-4f74-a119-955dfaec77fb" xlink:to="loc_us-gaap_AwardTypeAxis_dfcba747-1669-4310-aff9-59f11b14606a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53a7c55d-f0a0-48c9-8a81-a69e67745d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dfcba747-1669-4310-aff9-59f11b14606a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53a7c55d-f0a0-48c9-8a81-a69e67745d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2b56fec0-e2d3-49bc-8420-f3751c9a9f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53a7c55d-f0a0-48c9-8a81-a69e67745d18" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2b56fec0-e2d3-49bc-8420-f3751c9a9f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_829fa3ee-fc79-4d31-acbc-ecb142ca07e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a235c515-5582-4f74-a119-955dfaec77fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_829fa3ee-fc79-4d31-acbc-ecb142ca07e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dcfc988e-4324-4e09-80a6-c28ae13498be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_829fa3ee-fc79-4d31-acbc-ecb142ca07e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dcfc988e-4324-4e09-80a6-c28ae13498be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_97de8361-9199-4cd5-8de8-050dc4d721e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_829fa3ee-fc79-4d31-acbc-ecb142ca07e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_97de8361-9199-4cd5-8de8-050dc4d721e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_54d02cd4-a1a7-4e1b-81eb-4978be359c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_829fa3ee-fc79-4d31-acbc-ecb142ca07e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_54d02cd4-a1a7-4e1b-81eb-4978be359c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44f5c61d-e582-41b7-9745-f7eecf6068c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_829fa3ee-fc79-4d31-acbc-ecb142ca07e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_44f5c61d-e582-41b7-9745-f7eecf6068c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_be866d0b-1b8e-416b-b18a-15f2a13109f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_829fa3ee-fc79-4d31-acbc-ecb142ca07e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_be866d0b-1b8e-416b-b18a-15f2a13109f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d39499a-384c-4414-85d4-40738cace67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e92fda97-ffa9-4275-9517-96d05b6d7f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d39499a-384c-4414-85d4-40738cace67e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e92fda97-ffa9-4275-9517-96d05b6d7f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3eded385-f592-4493-87b6-f9cba3a4f27f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e92fda97-ffa9-4275-9517-96d05b6d7f40" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3eded385-f592-4493-87b6-f9cba3a4f27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_479b8ec2-f1e3-4e43-b3f4-b6b92e347493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3eded385-f592-4493-87b6-f9cba3a4f27f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_479b8ec2-f1e3-4e43-b3f4-b6b92e347493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f9411078-f4d9-4a19-9fcc-90094e646e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_479b8ec2-f1e3-4e43-b3f4-b6b92e347493" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f9411078-f4d9-4a19-9fcc-90094e646e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_661c63bf-062b-4240-8e6e-162b61b5bb19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_479b8ec2-f1e3-4e43-b3f4-b6b92e347493" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_661c63bf-062b-4240-8e6e-162b61b5bb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_960c6dbe-a1de-4c14-8566-201140d99640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e92fda97-ffa9-4275-9517-96d05b6d7f40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_960c6dbe-a1de-4c14-8566-201140d99640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_3a20d973-fe1f-4b67-bf11-4ad532023498" xlink:href="anab-20200930.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_960c6dbe-a1de-4c14-8566-201140d99640" xlink:to="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_3a20d973-fe1f-4b67-bf11-4ad532023498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_36c07f6a-38c9-4a04-99c0-7361ab45449b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_eec5dd04-5d2a-4e7e-b39a-110767de991e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_36c07f6a-38c9-4a04-99c0-7361ab45449b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_eec5dd04-5d2a-4e7e-b39a-110767de991e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65dfbcef-081d-46ae-948f-9d1ac5ecae8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AssetsAndLiabilitiesLesseeTableTextBlock_9689da90-c326-495b-a0b4-5f7379612ab0" xlink:href="anab-20200930.xsd#anab_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65dfbcef-081d-46ae-948f-9d1ac5ecae8b" xlink:to="loc_anab_AssetsAndLiabilitiesLesseeTableTextBlock_9689da90-c326-495b-a0b4-5f7379612ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_f8fc524e-50bd-4117-b377-6717adfd6abf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65dfbcef-081d-46ae-948f-9d1ac5ecae8b" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_f8fc524e-50bd-4117-b377-6717adfd6abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4a8b2570-8eb9-42cb-8dcd-858d97fb209a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65dfbcef-081d-46ae-948f-9d1ac5ecae8b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4a8b2570-8eb9-42cb-8dcd-858d97fb209a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_85c15b72-f232-421f-89ed-70b25cc91935" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24c8bed6-8f70-4eb5-b6b5-e66272fdb609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_85c15b72-f232-421f-89ed-70b25cc91935" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24c8bed6-8f70-4eb5-b6b5-e66272fdb609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LeaseArrangementAxis_1dbc0d0d-5c43-460a-b15c-ca1bb5f351c9" xlink:href="anab-20200930.xsd#anab_LeaseArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24c8bed6-8f70-4eb5-b6b5-e66272fdb609" xlink:to="loc_anab_LeaseArrangementAxis_1dbc0d0d-5c43-460a-b15c-ca1bb5f351c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LeaseArrangementDomain_5e65844b-b1f5-45e0-8f13-cd482e461615" xlink:href="anab-20200930.xsd#anab_LeaseArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anab_LeaseArrangementAxis_1dbc0d0d-5c43-460a-b15c-ca1bb5f351c9" xlink:to="loc_anab_LeaseArrangementDomain_5e65844b-b1f5-45e0-8f13-cd482e461615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_OneOfficeLeaseMember_c21a8a35-3caa-4044-9328-e95360ccba9b" xlink:href="anab-20200930.xsd#anab_OneOfficeLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anab_LeaseArrangementDomain_5e65844b-b1f5-45e0-8f13-cd482e461615" xlink:to="loc_anab_OneOfficeLeaseMember_c21a8a35-3caa-4044-9328-e95360ccba9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member_335b0eda-a68f-416a-be00-1a199eab2436" xlink:href="anab-20200930.xsd#anab_A10770WateridgeCircleSanDiegoCalifornia92121Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anab_LeaseArrangementDomain_5e65844b-b1f5-45e0-8f13-cd482e461615" xlink:to="loc_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member_335b0eda-a68f-416a-be00-1a199eab2436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_24c8bed6-8f70-4eb5-b6b5-e66272fdb609" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseNumber_00f1a249-a3dc-46b2-b2e1-1d63ea6d3158" xlink:href="anab-20200930.xsd#anab_LesseeOperatingLeaseNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_anab_LesseeOperatingLeaseNumber_00f1a249-a3dc-46b2-b2e1-1d63ea6d3158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_42e33d33-a17d-4271-9917-60fe06a2d2e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_42e33d33-a17d-4271-9917-60fe06a2d2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_fce18844-a4af-4aa1-aabd-288613add4d0" xlink:href="anab-20200930.xsd#anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_fce18844-a4af-4aa1-aabd-288613add4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f7aa34e4-ef53-40b9-b006-7c72dc17536a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f7aa34e4-ef53-40b9-b006-7c72dc17536a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_5e29668b-1f29-4125-85b4-91d8444e265b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_5e29668b-1f29-4125-85b4-91d8444e265b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0d705bb0-b471-42ef-823a-bd65a4ae0f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0d705bb0-b471-42ef-823a-bd65a4ae0f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_f00ff885-7b53-4548-874e-fb1a3a8cd3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_f00ff885-7b53-4548-874e-fb1a3a8cd3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_24b947fe-b830-46f3-acdd-28ec08d6e5ad" xlink:href="anab-20200930.xsd#anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_24b947fe-b830-46f3-acdd-28ec08d6e5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RentPerSquareFoot_8e07cc17-8837-4dd8-9dd8-3a22a61ab280" xlink:href="anab-20200930.xsd#anab_RentPerSquareFoot"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_anab_RentPerSquareFoot_8e07cc17-8837-4dd8-9dd8-3a22a61ab280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnnualRentIncreasePercent_4a96356a-6a98-45bc-ac62-a31fd987e1da" xlink:href="anab-20200930.xsd#anab_AnnualRentIncreasePercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_anab_AnnualRentIncreasePercent_4a96356a-6a98-45bc-ac62-a31fd987e1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent_b252d8ae-e1c8-43b9-a8f9-00dc80b31ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_PrepaidRent_b252d8ae-e1c8-43b9-a8f9-00dc80b31ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_ca548509-c9c2-458e-b03d-2f9a4293eb08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ba678681-286f-46a3-9f1d-ff96b741f96f" xlink:to="loc_us-gaap_SecurityDeposit_ca548509-c9c2-458e-b03d-2f9a4293eb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesClassificationontheBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ed37c54b-3b51-4c8a-b9cb-921d3498eabe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c6deccf-a13b-4684-858f-35d0ee4fc441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ed37c54b-3b51-4c8a-b9cb-921d3498eabe" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c6deccf-a13b-4684-858f-35d0ee4fc441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2c9889ec-1aae-4a9d-bffa-0070ff09a3f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ed37c54b-3b51-4c8a-b9cb-921d3498eabe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2c9889ec-1aae-4a9d-bffa-0070ff09a3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fb8fd45c-cb09-4498-9237-edc2510265f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ed37c54b-3b51-4c8a-b9cb-921d3498eabe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fb8fd45c-cb09-4498-9237-edc2510265f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_973b5f4c-8435-48e2-946b-394df6623fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ed37c54b-3b51-4c8a-b9cb-921d3498eabe" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_973b5f4c-8435-48e2-946b-394df6623fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_14862bb9-c6a6-4cd4-bd80-f83a1ba8ce1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ed37c54b-3b51-4c8a-b9cb-921d3498eabe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_14862bb9-c6a6-4cd4-bd80-f83a1ba8ce1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6cbfdea1-476d-40c7-a181-92bdb8dabc03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ed37c54b-3b51-4c8a-b9cb-921d3498eabe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6cbfdea1-476d-40c7-a181-92bdb8dabc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f6f040f9-2bd5-4ee4-9c1b-68ce127857bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_225fc2ba-34a2-4ed9-937d-f4455637bcad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f6f040f9-2bd5-4ee4-9c1b-68ce127857bf" xlink:to="loc_us-gaap_OperatingLeaseCost_225fc2ba-34a2-4ed9-937d-f4455637bcad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_da9143f5-e19f-4635-bde2-17704e8b5b1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f6f040f9-2bd5-4ee4-9c1b-68ce127857bf" xlink:to="loc_us-gaap_OperatingLeasePayments_da9143f5-e19f-4635-bde2-17704e8b5b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22ee9fdf-f008-4a1c-afc3-16c79d946aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_03da5620-f499-46b5-9692-57a9e6d4771c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22ee9fdf-f008-4a1c-afc3-16c79d946aa5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_03da5620-f499-46b5-9692-57a9e6d4771c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_987b6cf9-969a-4fd0-86c5-76b53d9076aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22ee9fdf-f008-4a1c-afc3-16c79d946aa5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_987b6cf9-969a-4fd0-86c5-76b53d9076aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4b9ff4bd-066c-4134-a736-bdd725d5f4be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22ee9fdf-f008-4a1c-afc3-16c79d946aa5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4b9ff4bd-066c-4134-a736-bdd725d5f4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c4ea2710-6c35-4a96-9040-cbbd520da2c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22ee9fdf-f008-4a1c-afc3-16c79d946aa5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c4ea2710-6c35-4a96-9040-cbbd520da2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c81f6bf3-7544-457b-af56-d9de03f75b49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22ee9fdf-f008-4a1c-afc3-16c79d946aa5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c81f6bf3-7544-457b-af56-d9de03f75b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_19b0c8e2-a684-4fed-96ac-9376ecab5edb" xlink:href="anab-20200930.xsd#anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22ee9fdf-f008-4a1c-afc3-16c79d946aa5" xlink:to="loc_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_19b0c8e2-a684-4fed-96ac-9376ecab5edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_14b293d7-ce83-456e-bbdd-29903f03e4b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22ee9fdf-f008-4a1c-afc3-16c79d946aa5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_14b293d7-ce83-456e-bbdd-29903f03e4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_508d53e6-631d-4626-9cc2-28be0a76af53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22ee9fdf-f008-4a1c-afc3-16c79d946aa5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_508d53e6-631d-4626-9cc2-28be0a76af53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1ba24820-2bd2-4df9-a2c7-0e6504dfc8f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22ee9fdf-f008-4a1c-afc3-16c79d946aa5" xlink:to="loc_us-gaap_OperatingLeaseLiability_1ba24820-2bd2-4df9-a2c7-0e6504dfc8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1" xlink:type="simple" xlink:href="anab-20200930.xsd#CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="anab-20200930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_71e53a70-47c0-4a13-a713-304b58c01f4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_72f05281-2e4c-42fd-ae56-0c722b8dce93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_71e53a70-47c0-4a13-a713-304b58c01f4b" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_72f05281-2e4c-42fd-ae56-0c722b8dce93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="anab-20200930.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_a521c372-2ae6-4aec-82da-efecf10d67fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_a521c372-2ae6-4aec-82da-efecf10d67fc" xlink:to="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a4518508-42fc-4c8f-9073-9e169024461b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a4518508-42fc-4c8f-9073-9e169024461b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2b103617-32c4-4f7b-bf3f-1daf6fe5de80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a4518508-42fc-4c8f-9073-9e169024461b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2b103617-32c4-4f7b-bf3f-1daf6fe5de80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dfd137bb-9a20-4681-89fa-7384a2823f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2b103617-32c4-4f7b-bf3f-1daf6fe5de80" xlink:to="loc_us-gaap_SubsequentEventMember_dfd137bb-9a20-4681-89fa-7384a2823f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3a5c6fac-a66d-4b1b-8b8b-facd0f0bc207" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:to="loc_srt_ProductOrServiceAxis_3a5c6fac-a66d-4b1b-8b8b-facd0f0bc207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_14bf05d1-2924-49d1-8042-527174235909" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3a5c6fac-a66d-4b1b-8b8b-facd0f0bc207" xlink:to="loc_srt_ProductsAndServicesDomain_14bf05d1-2924-49d1-8042-527174235909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_9b666a61-38b2-4c0d-b847-0fd69a055e14" xlink:href="anab-20200930.xsd#anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_14bf05d1-2924-49d1-8042-527174235909" xlink:to="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_9b666a61-38b2-4c0d-b847-0fd69a055e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f08b41ae-8a21-41e7-9811-709c99db8630" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:to="loc_srt_CounterpartyNameAxis_f08b41ae-8a21-41e7-9811-709c99db8630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f293b4b2-5c54-4f4a-ba08-b3ad6fae2e85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f08b41ae-8a21-41e7-9811-709c99db8630" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f293b4b2-5c54-4f4a-ba08-b3ad6fae2e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member_bcbb59a0-787d-485a-9589-0c00a6a7595c" xlink:href="anab-20200930.xsd#anab_TESAROInc.AndTESARODevelopmentInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f293b4b2-5c54-4f4a-ba08-b3ad6fae2e85" xlink:to="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member_bcbb59a0-787d-485a-9589-0c00a6a7595c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8e54ecb1-1027-4ba8-994b-46128be40962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8e54ecb1-1027-4ba8-994b-46128be40962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de021c6c-2397-43f5-841e-7eb96fd50b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8e54ecb1-1027-4ba8-994b-46128be40962" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de021c6c-2397-43f5-841e-7eb96fd50b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CollaborationAndExclusiveLicenseAgreementMember_731071b6-7d90-4609-90e8-f906bdb8677c" xlink:href="anab-20200930.xsd#anab_CollaborationAndExclusiveLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de021c6c-2397-43f5-841e-7eb96fd50b0c" xlink:to="loc_anab_CollaborationAndExclusiveLicenseAgreementMember_731071b6-7d90-4609-90e8-f906bdb8677c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4a9da63e-f979-46fd-b718-38e2c4726efb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:to="loc_srt_RangeAxis_4a9da63e-f979-46fd-b718-38e2c4726efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ee8a5cc2-a7a2-43f2-bb6a-9bd1927418e6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4a9da63e-f979-46fd-b718-38e2c4726efb" xlink:to="loc_srt_RangeMember_ee8a5cc2-a7a2-43f2-bb6a-9bd1927418e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b21dee62-8abd-4df7-a002-10919d8e945f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ee8a5cc2-a7a2-43f2-bb6a-9bd1927418e6" xlink:to="loc_srt_MinimumMember_b21dee62-8abd-4df7-a002-10919d8e945f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d11ff4ad-dc2b-43e9-82e8-fecb55f1819f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ee8a5cc2-a7a2-43f2-bb6a-9bd1927418e6" xlink:to="loc_srt_MaximumMember_d11ff4ad-dc2b-43e9-82e8-fecb55f1819f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_df3eb441-7810-4800-91df-fa743553866d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:to="loc_srt_StatementScenarioAxis_df3eb441-7810-4800-91df-fa743553866d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a1c5ccd5-242c-4aab-8841-98ce59f526e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_df3eb441-7810-4800-91df-fa743553866d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a1c5ccd5-242c-4aab-8841-98ce59f526e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_75d72e61-27e3-4fcd-b437-848bce2f1a61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a1c5ccd5-242c-4aab-8841-98ce59f526e9" xlink:to="loc_srt_ScenarioForecastMember_75d72e61-27e3-4fcd-b437-848bce2f1a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_004738ea-154e-4b83-81c3-f5f7b6016b1c" xlink:to="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent_47e421c4-47c6-4814-ab90-73ae02abf2d3" xlink:href="anab-20200930.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:to="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent_47e421c4-47c6-4814-ab90-73ae02abf2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent_393086b1-5878-47c3-ae0d-1356b5b0cba5" xlink:href="anab-20200930.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:to="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent_393086b1-5878-47c3-ae0d-1356b5b0cba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_cdb796ff-be7b-4fd4-9f2c-904d26212f64" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:to="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_cdb796ff-be7b-4fd4-9f2c-904d26212f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_b534a2bf-f8cc-4df7-b0d1-415c5c3181d3" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_b534a2bf-f8cc-4df7-b0d1-415c5c3181d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_NetSalesRoyaltyPercent_af797034-2739-4662-99c6-7473e03a36ad" xlink:href="anab-20200930.xsd#anab_NetSalesRoyaltyPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:to="loc_anab_NetSalesRoyaltyPercent_af797034-2739-4662-99c6-7473e03a36ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable_95329a03-5a56-43b4-94f6-3d083e7c5301" xlink:href="anab-20200930.xsd#anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fd79f86f-11ef-4650-8ed6-3ea696db124f" xlink:to="loc_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable_95329a03-5a56-43b4-94f6-3d083e7c5301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>anab-20200930_g1.jpg
<DESCRIPTION>PIPELINE CHART
<TEXT>
begin 644 anab-20200930_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IU9'D@4&%D
M:6QL80    60 P "    %   $*:0!  "    %   $+J2D0 "     S X  "2
MD@ "     S X  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MT+FA_P#@]F_^1*/^$@\9?]"YH?\ X/9O_D2M&BCD0<S,[_A(/&7_ $+FA_\
M@]F_^1*/^$@\9?\ 0N:'_P"#V;_Y$K1HHY$',S._X2#QE_T+FA_^#V;_ .1*
M/^$@\9?]"YH?_@]F_P#D2M&BCD0<S,[_ (2#QE_T+FA_^#V;_P"1*/\ A(/&
M7_0N:'_X/9O_ )$K1HHY$',S._X2#QE_T+FA_P#@]F_^1*/^$@\9?]"YH?\
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M .1*/^$@\9?]"YH?_@]F_P#D2M&BCD0<S,[_ (2#QE_T+FA_^#V;_P"1*/\
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MW:&52HR04SGC'/%'*A<S'?\ "0>,O^A<T/\ \'LW_P B4?\ "0>,O^A<T/\
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ME7/^$GT$Z0=5&MZ=_9P?8;S[7'Y.[IC?G;GVS1RQM<.9[#_^$@\9?]"YH?\
MX/9O_D2C_A(/&7_0N:'_ .#V;_Y$K+L/&MM=>"]0\23VS);6+W09(7$A=(79
M=RDX'S!<@>_7O6==_%;0K/P7!XE>WOV@FG>W^RI$GGHZ!BX92V!@(2?FZ8]:
M.6/]>87E^?X'2_\ "0>,O^A<T/\ \'LW_P B4?\ "0>,O^A<T/\ \'LW_P B
M5@R>.WC\06VG'3HBEUJ2V,<J7R.P!MS-O9%!*'C;L;![YQ6]!XBT2ZFNX;;6
M+":6R!-TD=TC-;@=2X!^7&#G.*.5?U]_ZBYF'_"0>,O^A<T/_P 'LW_R)1_P
MD'C+_H7-#_\ ![-_\B5EW'Q"\+P:CI=HNLV4YU1W2":&ZB:,%?4[NY&T8SEN
M*UDU_1Y-6DTN/5K%M1C!+V:W*&9!C.2F<C@@]*.6(^9C?^$@\9?]"YH?_@]F
M_P#D2C_A(/&7_0N:'_X/9O\ Y$HL?$.BZI<20:;J]A>31QB5X[>Y21E0@$,0
M"2 <CGW%1P>*?#]SI]Q?VVNZ;-9VI GN([R-HXB>FY@<+^-'*@YF2?\ "0>,
MO^A<T/\ \'LW_P B4?\ "0>,O^A<T/\ \'LW_P B5<M;NWOK2.ZLIXKFWE4-
M'-"X=''J"."*EI\B%S,SO^$@\9?]"YH?_@]F_P#D2C_A(/&7_0N:'_X/9O\
MY$K1HHY$',S._P"$@\9?]"YH?_@]F_\ D2C_ (2#QE_T+FA_^#V;_P"1*T:*
M.1!S,SO^$@\9?]"YH?\ X/9O_D2C_A(/&7_0N:'_ .#V;_Y$K1HHY$',S._X
M2#QE_P!"YH?_ (/9O_D2C_A(/&7_ $+FA_\ @]F_^1*T:*.1!S,SO^$@\9?]
M"YH?_@]F_P#D2C_A(/&7_0N:'_X/9O\ Y$K1HHY$',S._P"$@\9?]"YH?_@]
MF_\ D2C_ (2#QE_T+FA_^#V;_P"1*T:*.1!S,SO^$@\9?]"YH?\ X/9O_D2C
M_A(/&7_0N:'_ .#V;_Y$K1HHY$',S._X2#QE_P!"YH?_ (/9O_D2C_A(/&7_
M $+FA_\ @]F_^1*T:*.1!S,SO^$@\9?]"YH?_@]F_P#D2C_A(/&7_0N:'_X/
M9O\ Y$K1HHY$',S._P"$@\9?]"YH?_@]F_\ D2C_ (2#QE_T+FA_^#V;_P"1
M*T:*.1!S,SO^$@\9?]"YH?\ X/9O_D2C_A(/&7_0N:'_ .#V;_Y$K1HHY$',
MS._X2#QE_P!"YH?_ (/9O_D2C_A(/&7_ $+FA_\ @]F_^1*T:*.1!S,SO^$@
M\9?]"YH?_@]F_P#D2C_A(/&7_0N:'_X/9O\ Y$K1HHY$',S._P"$@\9?]"YH
M?_@]F_\ D2C_ (2#QE_T+FA_^#V;_P"1*T:*.1!S,SO^$@\9?]"YH?\ X/9O
M_D2C_A(/&7_0N:'_ .#V;_Y$K1HHY$',S._X2#QE_P!"YH?_ (/9O_D2C_A(
M/&7_ $+FA_\ @]F_^1*T:*.1!S,SO^$@\9?]"YH?_@]F_P#D2C_A(/&7_0N:
M'_X/9O\ Y$K1HHY$',S._P"$@\9?]"YH?_@]F_\ D2C_ (2#QE_T+FA_^#V;
M_P"1*T:*.1!S,SO^$@\9?]"YH?\ X/9O_D2C_A(/&7_0N:'_ .#V;_Y$K1HH
MY$',S._X2#QE_P!"YH?_ (/9O_D2C_A(/&7_ $+FA_\ @]F_^1*T:*.1!S,S
MO^$@\9?]"YH?_@]F_P#D2C_A(/&7_0N:'_X/9O\ Y$K1HHY$',S._P"$@\9?
M]"YH?_@]F_\ D2C_ (2#QE_T+FA_^#V;_P"1*T:*.1!S,SO^$@\9?]"YH?\
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M Y;D8 *4E;^O/_(?*_Z^7^9W5%>>#XIRPZ?'?ZAH7E6MYID^IV!AN_,>6.(
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MJ'C*?0O%UVEY:3RZA)9V,45FFH%K4S32NBA<Q@KR/FDP<@#Y>.6])<O]=?\
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MS2HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEV^9C_2-N/,QGY.F?X:=_P"OZ_#NPM_7]?CV._HKSVWB\4JVF6=Z^H-_:]O
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV922?FX/?MTK3JGN)!1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IDTT=O"\T\BQ11J6=W8!5 Y))/04^LOQ1#)<>$
M=7A@C>662QF5$1268E"  !U-3-N,6T5%7DDQL'BK0;NS:[L=8L[VW2:.!I+2
M99@LDC!$4[,XR6 _'TK6KSN^\*:I+H2W>H79N-0G_LZV4:?9F V\*7*.3@LY
M+#+$L3@ =!SEFK6NIV.GWVG1-K#62:LH@NV>^N9((3;*Q(\F19IE\PLOWR 3
MS]T"J>E_Z[?YBCJK_P!;'H]%>53OK*^%='EOVURZNX%N ;".'4+=KH>;B,M-
M 6:)@H&/-+Y!Y.<O6I;Q:[)\2'EOM0OK2(7 \BU6PNY89+?RA\IE63[.IW;L
MEDWY'!P5HW=OZ_K]!=+G9WVN:3IEW;VNI:I96EQ<G$$-Q<)&\ISC"J3EN2!Q
M5ZN'\=AIVGMK2'5GNY+=1';V^G>;:W[!B4BEF5"T:ANN9(P Y.2,UVZ%BBEP
M V.0#G!H6J&]&+1110(**** "BBB@ HHHH *9-#'<0/#/&LL4BE'1URK*>""
M#U%/HHW YV/P%X=CT^2Q^QS26S(L:I->SR>2JD%1$6<F+!"D;-OW5]!B:W\&
M:#;+;^79NSV]Y]N266XEDD:?:5WL[,6<[3CYB1C'H*W** ,2+P?H4!MC%8[3
M:W4UY#^^<[99=WF-][G.YN#P,\ 46O@W0;)+);:PV+8VLEI;CSI#LBDQO7EN
M<X')R1V-;=%*RM;^NWY#N_Z^\YT^!/#X6S\BVN;1K*V%I#)9W\]NXA'(1GC<
M,X!'&XGOZU>?PUI$JZFLUDLJZLJK>K(S,)@J!!D$\?* .,>O6M2BF]=P6FQS
M3_#WPS+#Y5QI\ER/(DMRUQ=S2L8Y-H8%F<D_<3!SE=HQBI+/P+X>L+B.XM[*
M4SQW0O%EFNYI7,WEF/>6=R6.TXYR*Z&BCK?^N_YB\C*OO#&CZE<WMQ?68FDO
M[/[#<DR,/,AR3MP#@<L>1@^]<]K7PVM;N2WGT&[;2IX[CSY79YW\X^3Y0.Y)
MHY%(4 <. ><@UVU%*R_K[QW?]?<<Q8^!-.72&MM<DFU>[N+ :?>7D\KJ]Q%D
MG:?FXY8\Y+8ZL>M77\(Z,]]/>?9I4GN+9;65H[J5 \:_<RH8#<N>'QN'8BMJ
MBG_7]?>_O%_7]?<ON*.CZ+8:#8FTTN%HHFE>9R\K2/(['+,SN2S$GN235ZBB
M@ JEX)_Y"WB__L-)_P"D%I5VJ7@G_D+>+_\ L-)_Z06E1/8N.YUE%%%9&@5Y
M/X'\465O\/?#L+V.N,T>EVR%HM!O9$)$2C*LL15AZ$$@]J]8KF_AQ_R2SPI_
MV!;/_P!$)33L)JYD?\)=8?\ 0/\ $'_A.W__ ,9H_P"$NL/^@?X@_P#"=O\
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M_P"$NL/^@?X@_P#"=O\ _P",T?\ "76'_0/\0?\ A.W_ /\ &:7_ (3;4O\
MGA:_]\-_\51_PFVI?\\+7_OAO_BJ/J];R#VU,3_A+K#_ *!_B#_PG;__ .,T
M?\)=8?\ 0/\ $'_A.W__ ,9I?^$VU+_GA:_]\-_\51_PFVI?\\+7_OAO_BJ/
MJ];R#VU,3_A+K#_H'^(/_"=O_P#XS1_PEUA_T#_$'_A.W_\ \9I?^$VU+_GA
M:_\ ?#?_ !5'_";:E_SPM?\ OAO_ (JCZO6\@]M3$_X2ZP_Z!_B#_P )V_\
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M4?\ ";:E_P \+7_OAO\ XJCZO6\@]M3$_P"$NL/^@?X@_P#"=O\ _P",T?\
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MPFVI?\\+7_OAO_BJ/J];R#VU,3_A+K#_ *!_B#_PG;__ .,T?\)=8?\ 0/\
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MW]U/R/\ C1[P>Z<O_P )=8?] _Q!_P"$[?\ _P 9H_X2ZP_Z!_B#_P )V_\
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M-_=3\C_C1[P>Z<O_ ,)=8?\ 0/\ $'_A.W__ ,9H_P"$NL/^@?X@_P#"=O\
M_P",UU']I3?W4_(_XT?VE-_=3\C_ (T>\'NG+_\ "76'_0/\0?\ A.W_ /\
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MNG*_\)=8?] _Q!_X3M__ /&:/^$NL/\ H'^(/_"=O_\ XS7=T5/.RN5'"?\
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MRF0*4GE 3=W5< =N!VJ1Y-7\.ZKHS7^O3:K!J,S6]Q%/;PHL9\EY-\?EHK
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?!KVUU]HU'4;F98[^YO(;))%\A&DDD97^X'W!7QMW%<Y.,\TG>UAZ6T_K?\
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MJG\7E_7Z?C^ [6T_K1?K?Y%73?%E]>VY>[TZ73R-6-BK2QQR"5?,9<#9,2K
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M5M.)B$47F$LQ1@@D'))&7(&>G PK^%))K2W2X\0:K+=VLQEMK]EMQ-#E"A4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^NIY=?\ B,****Z#$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ/\ ]-]G725S?A?_ )&+QG_V&H__ $WV= '24444 %<W\./^26>%/^P+9_\
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MB@ HHHH Y'QW_P N'_;3_P!EKD:Z[QW_ ,N'_;3_ -EKD:]K"_P5_74\NO\
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MJ%U-=-HTEH-.#Q-"9#&5'[QD#D\@9+@<=*T(QJ.JZII%W+HUWIR6;3+*MU)
M6PT6 P\N1Q@GCKGVIR=D["Z+^NQTM%>8V_@+4+#P[:0Z-:+IVH3>'YK6^FCE
M4,]R?)V!VR=Q&)0&Y"@X'&!72> ]"&AZ7=1I9ZC8K+,&^SWJV:!3M RBVOR
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MZY+9:1-8Q+#:I,1<V[N9&9G&-RNNT?+UPW6J,WCVQLK*PN-1MI+<7D0D.;B
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MET=:FG]:%VBM#^R_^FW_ ([_ /7H_LO_ *;?^.__ %Z\WF1W<K,^BM#^R_\
MIM_X[_\ 7H_LO_IM_P"._P#UZ.9!RLSZ*T/[+_Z;?^.__7H_LO\ Z;?^._\
MUZ.9!RLSZ*T/[+_Z;?\ CO\ ]>C^R_\ IM_X[_\ 7HYD'*S/HK0_LO\ Z;?^
M._\ UZ/[+_Z;?^.__7HYD'*S/HK0_LO_ *;?^.__ %Z/[+_Z;?\ CO\ ]>CF
M0<K,^BM#^R_^FW_CO_UZ/[+_ .FW_CO_ ->CF0<K,^BM#^R_^FW_ ([_ /7H
M_LO_ *;?^.__ %Z.9!RLSZ*T/[+_ .FW_CO_ ->C^R_^FW_CO_UZ.9!RLSZ*
MT/[+_P"FW_CO_P!>C^R_^FW_ ([_ /7HYD'*S/HK0_LO_IM_X[_]>C^R_P#I
MM_X[_P#7HYD'*S/HK0_LO_IM_P"._P#UZ/[+_P"FW_CO_P!>CF0<K,^BM#^R
M_P#IM_X[_P#7H_LO_IM_X[_]>CF0<K,^BM#^R_\ IM_X[_\ 7H_LO_IM_P".
M_P#UZ.9!RLSZ*T/[+_Z;?^.__7H_LO\ Z;?^._\ UZ.9!RLSZ*T/[+_Z;?\
MCO\ ]>C^R_\ IM_X[_\ 7HYD'*S/HK0_LO\ Z;?^._\ UZ/[+_Z;?^.__7HY
MD'*S/HK0_LO_ *;?^.__ %Z/[+_Z;?\ CO\ ]>CF0<K,^BM#^R_^FW_CO_UZ
M/[+_ .FW_CO_ ->CF0<K,^BM#^R_^FW_ ([_ /7H_LO_ *;?^.__ %Z.9!RL
MSZ*T/[+_ .FW_CO_ ->C^R_^FW_CO_UZ.9!RLSZD@_X^8O\ ?'\ZN?V7_P!-
MO_'?_KTZ/3MDBOYN=I!QM_\ KT<R#E9=HHHK$U"BBB@ HHHH **** "BBB@
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MI'//>W.I6TU^\*P0NMFRQ1J#DDIYA+$D\G<.@X'.97/I?]//_@%/EZ?KY?\
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M/*;B,&5R"PR"Q]:KU)!_Q\Q?[X_G2L!MT445@;!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%5M0O
MHM-TZ>\N-QC@0NP49)Q0!9HKAK#QA)!XF(U*8-INI*KV<O18^V#Z<Y!]QZ5W
M/7I6M2G*G:_4PHUXUKI;IV:_KN%%%(SJ@!=@H) &3CD]!61N+1110 5S?A?_
M )&+QG_V&H__ $WV==)7-^%_^1B\9_\ 8:C_ /3?9T =)1110 5S?PX_Y)9X
M4_[ MG_Z(2NDKF_AQ_R2SPI_V!;/_P!$)0!TE%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 5M0TZRU:QDLM4L[>]M)<>9!<Q+)&^#D95@0>
M0#^%4!X1\-C1SI(\/:4--,GFFR^Q1^27_O;-NW/OBMBB@"G9:/IFFPV\6G:=
M:6D=LK) D$"H(E8Y8* /E!(!..M/ETZRG6=9K.WD6X8-,'B4B4C !;CDC QG
MT%6:* (XK>&#S/(BCB\QS(^Q0-['JQQU/'6H?[,L-T;?8K?=%,T\9\I<I*V=
MSCCACN;)ZG)]:M$94@''N.U<"MSJ>A:IKUYJ7B;6-2LM%@CG%H\-FOG[D8E2
M5@4]0,89?>@#JK[PQH&IVB6NI:'IMW;I*TR0W%I'(BR,26< C 8DDD]3DT^3
MP[HDVIKJ,VCV$E\BJBW36J&554Y4!\9P" 0,\8KGY_&NIZ3#J'_"0:';VTUA
M:I?R"UOS/&;;<1(P9HT.] K'9C#<8;KBQ:^*?[1&@7Z"6"RU-9YHU5U(DA$9
M='<%-P)7#;5(P3@D]*+V5_Z_K_)AN[?UW_KY&S?:#H^IV<EIJ6E6-Y;2R^=)
M#<6R2(\G]\J1@M[]:3_A']&,-I$=(L/+L9/.M4^S)BW?.=R#'RMDGD8-<]_P
MD^K7G@FXUZ>PCTZUE@CN+)[:]$D[(Y!&]7AV(=I' \P<D9XS47_"5ZYI^O:X
M=1L+672+/4+>W62*[)D@218QO*>4 0-^YLMQR.0,T[-/E_KL+1JYT,/A/P[;
MQWJ0:!I<2:@,7BI9Q@7/)/[P ?/R3USU-7-/TO3])MOL^E6-M90<?NK:%8UX
M  X4 = !]!4&B:J=9LYKH0"*$7,L4+;]WFHC%=_08R0V!SQ@YYP-&ET'U,NQ
M\+Z!I<,L.F:'IMG%-(DLB6]I'&KNAW(Q  R01D'L:MIIUC',)8[.W202-*'6
M)0=[##-G'4CJ>]6:* *\.G65M]G^SV=O%]EB,,&R)5\J,XRBX'RK\J\#CY1Z
M58HHH Y'QW_RX?\ ;3_V6N1KKO'?_+A_VT_]EKD:]K"_P5_74\NO_$84445T
M&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\-\L)&.,\$@O?&&LZ*VL/K44,;VUO<7%E8K9,#/&C +(+GS61A@@E2J.,Y(
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MP2OU'44 7Z*Q;CQCX>M)I8[C6+5&A;;)^\R$/H2. :GN_$>C6"P->:E;PQW
M!BD9P$<'H0W3]: -.BLB?Q9H%M="WGU>T20N$ ,HQN],],^U8?COQRGAHV5M
M936YNYKF-9EDY\J$GEL?08H [.BL)?&WAIPI&M6@5FV!F?"[O3)XK<5E=0R$
M,K#((.010 M%9<_B;1;:QBO)]3MDMYV*Q2&08D(."%]>1VJ(ZAIGB*TN(--U
M4^;$"6-M,4DC.."1UQ]>*:5WJ*3:5T;-%<%X&M+O7O#$=_?:WJGVAI77*7.
M,' X((_.KFA:]?6OBK5- UBZ6\CLH1.EWL 8+P<.%XS\WZ5TRP[3E%.[CN<-
M/&*482E&RGM^>IV-1SP1W-O)!.H>.12CJ>X(P:Q?#E_=7]]J;RZI9W]HLP%L
MMN,/".?E<>O3\C5JZ\2Z+97#P76IVT<L>-ZE_N?7T_&L72DI<J5V=$:\'!3;
MLO.QYGK5HOA2273=>#OH\SEK>Y RT3?WE]_5>]:OA3Q7=Z1J-KI.LS)<Z;>
M?V=?H<JPZ 9].V#RIXKO-2TW3O$6CO:7T<=U:7"]0<CV92._H17C#:#<^&O$
M4O@[493+IVI$R:;<-QY<W\##T)/RL/<&MZ-56]E4^%_AYHY\3AVW[>CI-?\
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MTQ_\>_\ K47EV"T>Y3\B;_GD_P#WR:D@@E%Q&3$X 89)4^M6/[4_Z8_^/?\
MUJ='J.^14\K&X@9W?_6I7EV'9%VBBBLC0**** "BBB@ HHHH **** "BBB@
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M[+7(UUWCO_EP_P"VG_LM<C7M87^"OZZGEU_XC"BBBN@Q"BBB@ HHHH ****
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M'6-)7L9A S-]T>=L\O)R /FZ\=>*9#XJTF>2["27 CLUD::X>SF2 !#AL2E
MC8.>%8]#Z&F!L450TK6K+689)+$S9B;9)'<6TD$B'&1E)%5AD'(.,&J6E:Y?
MW.N3:9JNF164@MUN8C%=^<2A8KB0;5V/QT!9>N&.*.MA=+FY16+=^*++3;C4
M_P"U&%K;:>8 UP<MN,IPO &1S@=^O:DB\4V-Y:Q3Z>^\->K9RI<QRV\D3GG!
M1DW!L$$!@H((.0#FE>X=+FW17-:=XS@U2%GAM98"FHFQ87<,\(;YV4,I:+YF
M.W.WH.A(JZ?%.F#4I+%_ML=PF_:)=.N$64H"6$;% LAP"0$)) )&:+JU_P"N
M_P"H[.]C8HKG-#\7PZY9:5<Q6[6RWX?<ERDL3*53<=FZ,!Q_M94>A/2I(?''
MA^>*XE2\D6*WMWNC)):RQK)"GWI(V90)5''*;AR/44_(+-F_169I'B+3-=>9
M-,G=W@"LZR021':V=K@.HW(V#AAE3@X-8MSXQU".SO=6M=%BGT.QDD6:X:\V
MSNL3%972+RR" 0V,NI.T\=,@+78ZVBL'4?$ZVFNZ?IUK:_:A<R*D\PDVK;AP
MQ3L=Q.T\<8 R3T!G\1:IJ.DV#W6FZ;!>K#&\TYN+O[.J(HS@':Q+'L" .#EA
MQE75K@E=V1KT5RU_XMO@9FT31TOH[2RCO;L3W?D.BN&*HBA&#/A2<$J.G/)Q
M8G\27<6H:<RZ9&VE7\L<,5T;K$Q9T+ B+;@KV)+AN"=N!DOK872YT-%<M;^+
M;R:]MI6TJ(:/=WKV4%XEV6EWJ64,T6S 0LA (<GE20,G'4T+57#9V"BBB@ H
MHHH **** "BBB@ HHHH *D@_X^8O]\?SJ.I(/^/F+_?'\Z!FW1117.;!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5;4=.L]6L7L]2MTN
M;:3&^*09!P<C]15FB@"."".VMXX+=!'%$@1$7HJ@8 J2BB@".XMX[JW>"<%H
MY!A@&*Y'U'-1:?IMGI5J+;3K>.WAR6VH.I/4GU/N:LT4 %%%% !1110 4444
M %%%% #8XTB4B,8!8L?J3D_K3J** "BBB@ KF_"__(Q>,_\ L-1_^F^SKI*Y
MOPO_ ,C%XS_[#4?_ *;[.@#I**** "N;^''_ "2SPI_V!;/_ -$)725S?PX_
MY)9X4_[ MG_Z(2@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:_\ @6?_ (JN&HH^KR_G8>VC_*CN?[,\*?\ /2U_\"S_ /%4?V9X4_YZ6O\
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M.B_\_EK_ .! _P :/M.B_P#/Y:_^! _QKS:BCZFOYF+ZR^QZ3]IT7_G\M?\
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M,H+FSN86C^49 \]F=@>O7'7%9EM>&]&IWMKI=]!.E@8+2R:SFMCY:YQ^\VJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7-^%_\ D8O&?_8:C_\ 3?9UTE<WX7_Y&+QG_P!AJ/\
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M1F\_YZP?]]'_  KS.5GL>VI]S'HK8_X1F\_YZP?]]'_"C_A&;S_GK!_WT?\
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MT5PB^?J/B+1)[._U%M5VPW&HQ+=.MK:P&+E'ASLW.QRN07SDYVKQG:?<2O\
MV/KW]JW_ /:-_KDUI-:O>R/ T8DE0Q" ML78B!LA0WR9).3FFFG;SM^GW?\
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M6.+3YI9WO[PSQW4F,H43S&* 8.?N<'&#VU-0UKQ':R65G9VMO>WT\#W+^3
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M+#@R9P0<<@4<M*]G%?<'-4M=,[O_ (2K6?\ G\_\A)_A1_PE6L_\_G_D)/\
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ML6?RXF(Z< *W49QSB%[%QYN5?=Z?YC?M4[7_ !/0O^$JUG_G\_\ (2?X4?\
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MX'GB:5C&SXP&_=>6#EAP9,X(..0*KDI:7BM?(7-4[_B=W_PE6L_\_G_D)/\
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M2^"M!EACA-G(D*636'E174L:O 004=58!_O-@MD@DD$'FJW>O]:?YZA%I/\
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M4LJVYN9/MDRHVT.(6B *,>CH[KD@<G.-7PMX@NM?M;A[[2IM.EAD"@/'.J2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *YOPO_P C%XS_ .PU'_Z;[.NDKF_"_P#R
M,7C/_L-1_P#IOLZ .DHHHH *YOX<?\DL\*?]@6S_ /1"5TE<W\./^26>%/\
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MVL+_  5_74\NO_$84445T&(4444 %%%% !1110 4444 %%%% !1110 4444
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MJM:P<S[E(:39"RM;,0 6]F4,$88X0I]WOSCW]*1]'L9-835'@S>(@19-[8
M8#Y<XSAF&<9YJ]13LA791@T>QMM5GU*&#;=W Q(^]B#PH.%)P,[5S@#.!26.
MBZ?ISW+6=OL-TQ:;+LV[))Q@DX&68X&!R:OT4N56M8=V4[#2[/3$V641C&Q(
M^79OE084<D]!5:U\.Z=97\EY;"Z2261I9%-[,8W9NI,9?8?R]/2M6BBRO<+L
MRK/PWIFGR-):PRHQC,2YN9&$2'JL8+'RQP.$QT'H*+7PWIUG:W=M"+HQ7@(F
M66]FDW9SD@LY*DY.2,$UJT4N6/8.:7<:B+%&J1J%10 J@8  [4ZBNR\(7<=O
MI$JN&),Y/ _V5J:M1TX\UKE4X<\K;'&T5ZC_ &E#_=?\A_C1_:4/]U_R'^-<
MGUQ_R_B=/U9?S'EU%>H_VE#_ '7_ "'^-']I0_W7_(?XT?7'_+^(?5E_,>74
M5ZC_ &E#_=?\A_C1_:4/]U_R'^-'UQ_R_B'U9?S'EU%>H_VE#_=?\A_C1_:4
M/]U_R'^-'UQ_R_B'U9?S'EU9NMZ.NMV2VLEY<6J"0.WD;#YF/X6#JP9?8CG%
M>Q_VE#_=?\A_C1_:4/\ =?\ (?XTGBVU9Q_$%ATOM?@>*S>'VF^SR#5[^.\A
M1H_MB"$22(QR58>7LQD#!"@C'7DY9<>&(Y+:QM[/4KVQAL<&)(/*;+#(W,9$
M8D\GOWKVW^TH?[K_ )#_ !H_M*'^Z_Y#_&I^L_W/Q'[#^]^!XW/HIN[Y)KO4
M;N:".19%LSY8B#K@J>$#G!&[!8C/:M.O4?[2A_NO^0_QH_M*'^Z_Y#_&J6+:
M^S^(OJZ_F/+J*]1_M*'^Z_Y#_&C^TH?[K_D/\:?UQ_R_B'U9?S'EU%>H_P!I
M0_W7_(?XT?VE#_=?\A_C1]<?\OXA]67\QY=17J/]I0_W7_(?XT?VE#_=?\A_
MC1]<?\OXA]67\QY=17J/]I0_W7_(?XT?VE#_ '7_ "'^-'UQ_P OXA]67\QY
M=7;6'_(-MO\ KDO\A6W_ &E#_=?\A_C1_:4/]U_R'^-8U:[J*W*:4Z*@]S+H
MK4_M*'^Z_P"0_P :/[2A_NO^0_QK#F?8ULNYET5J?VE#_=?\A_C1_:4/]U_R
M'^-',^P67<RZ*U/[2A_NO^0_QH_M*'^Z_P"0_P :.9]@LNYET5J?VE#_ '7_
M "'^-']I0_W7_(?XT<S[!9=S+HK4_M*'^Z_Y#_&C^TH?[K_D/\:.9]@LNYET
M5J?VE#_=?\A_C1_:4/\ =?\ (?XT<S[!9=S+HK4_M*'^Z_Y#_&C^TH?[K_D/
M\:.9]@LNYET5J?VE#_=?\A_C1_:4/]U_R'^-',^P67<RZ*U/[2A_NO\ D/\
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MY)9X4_[ MG_Z(2@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=?\ ?:__ !-<-11[&K_/^ >UI_R'<_\ "$Z;_P ][K_OM?\ XFC_ (0G3?\
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M HHHH **** "BBB@ HHHH *YOPO_ ,C%XS_[#4?_ *;[.NDKF_"__(Q>,_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>9%*IAF . ?\:HU)!_Q\Q?[X_G2Y4.[-NBBBL34**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEGD,LD>8U9XC(<E]I;J23S@GBM2Z\.Z)>V\T%[H]A<0SS?:)8Y;5'627&-[
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M_.@9MT445SFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$#)K5HH Y'QW_P N'_;3_P!EKD:Z[QW_ ,N'_;3_ -EKD:]K"_P5_74\NO\
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MORU_,/Z_,Z6BBBL#8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#H8?#_ /X(9_\ Y,H^P^-_^AA\/_\ @AG_ /DR@#I**YO[#XW_ .AA\/\
M_@AG_P#DRC[#XW_Z&'P__P""&?\ ^3* .DHKF_L/C?\ Z&'P_P#^"&?_ .3*
M/L/C?_H8?#__ ((9_P#Y,H Z2BN;^P^-_P#H8?#_ /X(9_\ Y,H^P^-_^AA\
M/_\ @AG_ /DR@#I**YO[#XW_ .AA\/\ _@AG_P#DRC[#XW_Z&'P__P""&?\
M^3* .DHKF_L/C?\ Z&'P_P#^"&?_ .3*/L/C?_H8?#__ ((9_P#Y,H Z2BN;
M^P^-_P#H8?#_ /X(9_\ Y,H^P^-_^AA\/_\ @AG_ /DR@#I**YO[#XW_ .AA
M\/\ _@AG_P#DRC[#XW_Z&'P__P""&?\ ^3* .DHKF_L/C?\ Z&'P_P#^"&?_
M .3*/L/C?_H8?#__ ((9_P#Y,H Z2BN;^P^-_P#H8?#_ /X(9_\ Y,H^P^-_
M^AA\/_\ @AG_ /DR@#I**YO[#XW_ .AA\/\ _@AG_P#DRC[#XW_Z&'P__P""
M&?\ ^3* .DHKF_L/C?\ Z&'P_P#^"&?_ .3*/L/C?_H8?#__ ((9_P#Y,H Z
M2BN;^P^-_P#H8?#_ /X(9_\ Y,H^P^-_^AA\/_\ @AG_ /DR@#I**YO[#XW_
M .AA\/\ _@AG_P#DRC[#XW_Z&'P__P""&?\ ^3* .DHKF_L/C?\ Z&'P_P#^
M"&?_ .3*/L/C?_H8?#__ ((9_P#Y,H Z2BN;^P^-_P#H8?#_ /X(9_\ Y,H^
MP^-_^AA\/_\ @AG_ /DR@#I**YO[#XW_ .AA\/\ _@AG_P#DRC[#XW_Z&'P_
M_P""&?\ ^3* %\6:5>:G]D^PP^;Y>_=\P&,[<=3[&N=_X176?^?/_P BI_C7
M0_8?&_\ T,/A_P#\$,__ ,F4?8?&_P#T,/A__P $,_\ \F5U4\3.G'E21A.A
M&<N9G/?\(KK/_/G_ .14_P :/^$5UG_GS_\ (J?XUT/V'QO_ -##X?\ _!#/
M_P#)E'V'QO\ ]##X?_\ !#/_ /)E7]<J=D1]5AW9SW_"*ZS_ ,^?_D5/\:/^
M$5UG_GS_ /(J?XUT/V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F
M4?7*G9!]5AW9SW_"*ZS_ ,^?_D5/\:/^$5UG_GS_ /(J?XUT/V'QO_T,/A__
M ,$,_P#\F4?8?&__ $,/A_\ \$,__P F4?7*G9!]5AW9SW_"*ZS_ ,^?_D5/
M\:/^$5UG_GS_ /(J?XUT/V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,_
M_P F4?7*G9!]5AW9SW_"*ZS_ ,^?_D5/\:/^$5UG_GS_ /(J?XUT/V'QO_T,
M/A__ ,$,_P#\F4?8?&__ $,/A_\ \$,__P F4?7*G9!]5AW9SW_"*ZS_ ,^?
M_D5/\:/^$5UG_GS_ /(J?XUT/V'QO_T,/A__ ,$,_P#\F4?8?&__ $,/A_\
M\$,__P F4?7*G9!]5AW9B6GAG5XKV"1[3"K(K,?-3@ _6NH^PW'_ #S_ /'A
M5+[#XW_Z&'P__P""&?\ ^3*/L/C?_H8?#_\ X(9__DRL:E>51W9I"C&&Q=^P
MW'_//_QX4?8;C_GG_P"/"J7V'QO_ -##X?\ _!#/_P#)E'V'QO\ ]##X?_\
M!#/_ /)E9\[+Y47?L-Q_SS_\>%'V&X_YY_\ CPJE]A\;_P#0P^'_ /P0S_\
MR91]A\;_ /0P^'__  0S_P#R91SL.5%W[#<?\\__ !X4?8;C_GG_ ./"J7V'
MQO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F4<[#E1=^PW'_//_ ,>%
M'V&X_P">?_CPJE]A\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E'.
MPY47?L-Q_P \_P#QX4?8;C_GG_X\*I?8?&__ $,/A_\ \$,__P F4?8?&_\
MT,/A_P#\$,__ ,F4<[#E1=^PW'_//_QX4?8;C_GG_P"/"J7V'QO_ -##X?\
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MFJW%O<W8UI/,EMK=H8V_T"TQA&=R.,#[QR>>.@ .MHHHH *YOX<?\DL\*?\
M8%L__1"5TE<W\./^26>%/^P+9_\ HA* .DHHHH **** "BBB@ HHHH ****
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M1117*=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]:?U\A79W<7^N3_>%:59L7^N3_>%:5:TMC.KN%%%%:F(4444 %%%% !1110
M4444 %%%% !1110 4444 %<WX7_Y&+QG_P!AJ/\ ]-]G725S?A?_ )&+QG_V
M&H__ $WV= '24444 %<W\./^26>%/^P+9_\ HA*Z2N;^''_)+/"G_8%L_P#T
M0E '24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y=XBMK
M^^\3W4=U!K\EU'K%A)8K;B<V7V-9(&=FQ^Y)#"4G=^\X&/E KU&BA:23_KO_
M %Y7#H>6?V5KEAJ5X-,L;Q4\17MU974JJ5%J/M#LEQ[ Q/* W=A$.]58/">H
M#2-.MM/TZ>UFTZ;5I[(&,QK'(MXLD"DXX5PH ]5)QQ7KM%"T22_KM]PV[N[[
MW_/^OD>23Z9JVJWUUX@N-(O8;K5O#^I#R'A8O;J?)6"!L#ARJLVW^\SXKJO"
M5AJEGXEU"37XTENYK&U6.\M;5H8'B3S/D*EF(D5G;.7.05( P178T4[VT7];
M_P"8GJOZ\O\ (\GLSJ5GH_B^TMKKQ+'J$KZK):62Z4Z6ZLSR-')%.( 2QX*_
MO3DMP.F+^J:?K6C+JMKI]QKUW820:?+-(9YIYOFGD%T86Y96\M5.R/&W.44$
MBO2:*71?+\/ZU&W>_P _QM_7S/)[:TN+:&]D6+Q0F@W&N+),RBZ^VR6_V.-4
M.1_I)7S5 ./GP,-QNJ>/3=<U2UM()KCQ%#8+:ZE);GSYX)R!)%]E$K A]^"Y
M <[B!A@3NKU&BAZ_=;\+7]03LT_Z_P"&_P" >3W5GXKM?#THM+O6&DO+#3[F
M^EG$\[Q2-(WVGRD1E=3MQF.(J0!\H!ZV-+TB1-5\+ZAJ5[KNI+&;J%)UMM1M
MO++.AC26)W9]O#Y>4D$ ;B0%KU"BFWJW_7]+H3;2W]?T^IPFCZ=JECX2T*5I
MM8FU"YO;:2_^TW$TCJN3N!5C\B@<$  <9.3S63I#:]_PM"&7&K06TMY=)=VD
MD%\\$<05_+;SI96@.XJC 1(-N=N1R&]1HI+1_P!=DOT&]?Z]?\S#\&V\UKX4
MM8;F*2&57ERDBE6&96(X/L<UN444 8/B;_EV_P"!_P!*PJW?$W_+M_P/^E85
M>%B_XTOZZ'N83^"OZZA1117*=04444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5L:1_QZ-_OG^0K'K8TC_CT;_?/\A71A_XASXC^&7Z*
M**](\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** $9@BEF(50,DD\ 5G6WB+1;W2YM3L]8L+BP@SYMW%=(T4>!D[G!P, Y.35
MC4Y(8M)NY+JV>[A6%S);QP^:TJX.5"?Q$],=Z\]$DNKZ9>ZN--U!;B34K*[O
M+%M,GB9+>)UPBB2-?.<!=S;,\\#.%RTKO[OS$W9?>=P/$^@MH[:LNMZ:=-5M
MC7HNX_)#9QC?G;G) QFG7OB+1=-T^"^U'6+"TL[C'DW$]TB1RY&1M8G!R.>.
MU<?)JYL)M8U^T\/ZA.MY=PI9*^FS[_-$)1IWB"&1$ ^4MMW$#@$$9;I_D:!<
M:'>FTU2[TN'39[4.FD3^:D[2HS$P!/,C5MK8.W& !GD9=OZ^5_Z]17_KYV_K
MT/08Y$FB26%UDC=0RNIR&!Z$'N*HZKX@T;0A$=<U>QTT39\K[9<I#OQC.-Q&
M<9'YU4\&V4^G^#M.MKJW-K(D9_T=CDPJ6)5../E! P.F*PO&RSQ^+=!NTN=9
MLH(K:[22ZTG3S=NI8P[59?)E !VGG:/N]:+>]8:U5SKK75=.OKAX+*_M;F:.
M-)'CAF5V5'&48@'@,.0>_:DCU?39;>[GBU"U>&Q=TNI%G4K;LHRP<YPI Y(.
M,5P6H1:OIWB"_P#$NAZ;>7D\DT=LL31,AFBEMX@KLI .$E5-W'RCS..,55@T
M#5=-M=1T'2],:[6\UJ)Y);MGABFB2VA>1WD"-]]T*G@Y+-Z&G:_]>:_1BO\
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M%/\ L"V?_HA*Z2N;^''_ "2SPI_V!;/_ -$)0!TE%%% !1110 4444 %%%%
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M%%%>D><%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110 5S?A?_D8O&?_ &&H_P#TWV==)7-^%_\ D8O&?_8:C_\ 3?9T =)1110
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MG-HMOYJIC:3&+F9BK;@?F\LC&,$YV]VOAS1$MK*W71]/6#3W\RSB%JFVV?\
MO1C&$//48IEIX6\/Z>UPUAH6F6QNE99S#9QIYP;[P; ^8''.>M+_ (/]??\
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M_;>H?\_'_CB_X4?VWJ'_ #\?^.+_ (4<^$_E?]?,.3%?S+^OD7O^$9_Z>_\
MR'_]>C_A&?\ I[_\A_\ UZH_VWJ'_/Q_XXO^%']MZA_S\?\ CB_X4<^$_E?]
M?,.3%?S+^OD7O^$9_P"GO_R'_P#7H_X1G_I[_P#(?_UZH_VWJ'_/Q_XXO^%'
M]MZA_P _'_CB_P"%'/A/Y7_7S#DQ7\R_KY%[_A&?^GO_ ,A__7H_X1G_ *>_
M_(?_ ->J/]MZA_S\?^.+_A1_;>H?\_'_ (XO^%'/A/Y7_7S#DQ7\R_KY%[_A
M&?\ I[_\A_\ UZ/^$9_Z>_\ R'_]>J/]MZA_S\?^.+_A1_;>H?\ /Q_XXO\
MA1SX3^5_U\PY,5_,OZ^1>_X1G_I[_P#(?_UZ/^$9_P"GO_R'_P#7JC_;>H?\
M_'_CB_X4?VWJ'_/Q_P".+_A1SX3^5_U\PY,5_,OZ^1>_X1G_ *>__(?_ ->C
M_A&?^GO_ ,A__7JC_;>H?\_'_CB_X4?VWJ'_ #\?^.+_ (4<^$_E?]?,.3%?
MS+^OD7O^$9_Z>_\ R'_]>C_A&?\ I[_\A_\ UZH_VWJ'_/Q_XXO^%']MZA_S
M\?\ CB_X4<^$_E?]?,.3%?S+^OD7O^$9_P"GO_R'_P#7H_X1G_I[_P#(?_UZ
MH_VWJ'_/Q_XXO^%']MZA_P _'_CB_P"%'/A/Y7_7S#DQ7\R_KY%[_A&?^GO_
M ,A__7H_X1G_ *>__(?_ ->J/]MZA_S\?^.+_A1_;>H?\_'_ (XO^%'/A/Y7
M_7S#DQ7\R_KY%[_A&?\ I[_\A_\ UZ/^$9_Z>_\ R'_]>J/]MZA_S\?^.+_A
M1_;>H?\ /Q_XXO\ A1SX3^5_U\PY,5_,OZ^1>_X1G_I[_P#(?_UZ/^$9_P"G
MO_R'_P#7JC_;>H?\_'_CB_X4?VWJ'_/Q_P".+_A1SX3^5_U\PY,5_,OZ^1>_
MX1G_ *>__(?_ ->C_A&?^GO_ ,A__7JC_;>H?\_'_CB_X4?VWJ'_ #\?^.+_
M (4<^$_E?]?,.3%?S+^OD7O^$9_Z>_\ R'_]>C_A&?\ I[_\A_\ UZH_VWJ'
M_/Q_XXO^%']MZA_S\?\ CB_X4<^$_E?]?,.3%?S+^OD7O^$9_P"GO_R'_P#7
MH_X1G_I[_P#(?_UZH_VWJ'_/Q_XXO^%']MZA_P _'_CB_P"%'/A/Y7_7S#DQ
M7\R_KY%[_A&?^GO_ ,A__7H_X1G_ *>__(?_ ->J/]MZA_S\?^.+_A1_;>H?
M\_'_ (XO^%'/A/Y7_7S#DQ7\R_KY%[_A&?\ I[_\A_\ UZ/^$9_Z>_\ R'_]
M>J/]MZA_S\?^.+_A1_;>H?\ /Q_XXO\ A1SX3^5_U\PY,5_,OZ^1>_X1G_I[
M_P#(?_UZ/^$9_P"GO_R'_P#7JC_;>H?\_'_CB_X4?VWJ'_/Q_P".+_A1SX3^
M5_U\PY,5_,OZ^1>_X1G_ *>__(?_ ->C_A&?^GO_ ,A__7JC_;>H?\_'_CB_
MX4?VWJ'_ #\?^.+_ (4<^$_E?]?,.3%?S+^OD7O^$9_Z>_\ R'_]>C_A&?\
MI[_\A_\ UZH_VWJ'_/Q_XXO^%']MZA_S\?\ CB_X4<^$_E?]?,.3%?S+^OD7
MO^$9_P"GO_R'_P#7J[::3]EA*>=ORV<[,?UK$_MO4/\ GX_\<7_"M+3M0N9[
M=FEEW$/C.T#L/:M:4\.Y>[%W_KS,JL,0H^])6_KR-#[%_P!-/_':/L7_ $T_
M\=J+[3+_ '_T%'VF7^_^@KKO3['):IW)?L7_ $T_\=H^Q?\ 33_QVHOM,O\
M?_04?:9?[_Z"B]/L%JG<E^Q?]-/_ !VC[%_TT_\ ':B^TR_W_P!!1]IE_O\
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MG<E^Q?\ 33_QVC[%_P!-/_':B^TR_P!_]!1]IE_O_H*+T^P6J=R7[%_TT_\
M':/L7_33_P =J+[3+_?_ $%'VF7^_P#H*+T^P6J=R7[%_P!-/_':/L7_ $T_
M\=J+[3+_ '_T%'VF7^_^@HO3[!:IW)?L7_33_P =H^Q?]-/_ !VHOM,O]_\
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MZ#%B/0[&#05T:V2:WLDC$:B"YDCD4>TBL'SZMNR><GFCI\OU![_,X]];UQ_
M_AZY-WJ.+IRNHZCI]BMS<QJ%<JRQ+&P^9U521&0 3P.HJZ!KVM^*Y+/2TUN]
MT\QI>R/?QV4<<]RL-P(8]T<T9"'!)<;%.X<;1Q756_@C1[31ETNU?58;19/-
M58]9O%=3C& XEW!?]G.W/.,TZY\%:%=6-G:_9);=+%62W>SNYK:1%;[R^9&R
ML0Q )!)W$ G)YI>O]:?YATT_K_AS!T#7]7N[[2'=X[JXU#1[DO&9&CA>>WE1
M0XP&V!_-.2 >B\' KNT+&-3( KX&X*<@'V/&:Q(_"MG%J"2Q?N+2#3?[.M;>
MWS$;=&;+E74@@D+&!C!&S.>>-M$$<:HN2%  W,2?Q)Y-5T_KN_TL']?@A:**
M*0!1110 445C>(=;N-)-A;:=9QWM_J-P8+>*:<PQ\(SLS.%<@!4/122<#U(
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ML_'6I7EK#$/#S0ZG<W?V:WAN6N+>"0>6TA?S);=7P%1AQ&><#H<C<?PCHCK
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MYP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&L6\\':W<V=UJL5Q90>)9;Y+V *[FWM\1>3Y>_;N<>66RVT98C@ 4NG]=_\
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MC2/^/1O]\_R%=&'_ (ASXC^&7Z***](\X**** "BBB@ HHHH **** "BBB@
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M%-1D<U172_\ ".6G_/2;_OH?X4?\(Y:?\])O^^A_A6'U*J;_ %RD<U172_\
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M@NKB7PTLNJW-Y;SVFO)<1$:?$HCWQ!F(E&"LGRHA5]_.-S8%K_7]?Y ]#O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;_-A1117I'B!1110 4444 %<WX7_ .1B\9_]AJ/_ --]G725S?A?_D8O&?\
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MQ?+#)B%0+<HB?9AF5LDL^XD;2O.*]5B_UR?[PK+_ .$=T7^VO[8_L>P_M/\
MY_OLJ>=]W;_K,;NG'7IQ6I%_KD_WA0GHD3:US2HHHKJ.4**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *YOPO\ \C%XS_[#4?\ Z;[.NDKF_"__ ",7C/\
M[#4?_IOLZ .DHHHH *YOX<?\DL\*?]@6S_\ 1"5TE<W\./\ DEGA3_L"V?\
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M#7+:))+V26??!);N3<MF0^9&74[,'!#+V/%"U_#\4#T/5J*** ,'Q-_R[?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOPO\
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MR[_YZ0_]]'_"CZO5_E#ZQ2_F,FBM;_A'+O\ YZ0_]]'_  H_X1R[_P">D/\
MWT?\*/J]7^4/K%+^8R:*UO\ A'+O_GI#_P!]'_"C_A'+O_GI#_WT?\*/J]7^
M4/K%+^8R:*UO^$<N_P#GI#_WT?\ "C_A'+O_ )Z0_P#?1_PH^KU?Y0^L4OYC
M)HK6_P"$<N_^>D/_ 'T?\*/^$<N_^>D/_?1_PH^KU?Y0^L4OYC)HK6_X1R[_
M .>D/_?1_P */^$<N_\ GI#_ -]'_"CZO5_E#ZQ2_F,FBM;_ (1R[_YZ0_\
M?1_PH_X1R[_YZ0_]]'_"CZO5_E#ZQ2_F,FBM;_A'+O\ YZ0_]]'_  H_X1R[
M_P">D/\ WT?\*/J]7^4/K%+^8R:*UO\ A'+O_GI#_P!]'_"C_A'+O_GI#_WT
M?\*/J]7^4/K%+^8R:*UO^$<N_P#GI#_WT?\ "C_A'+O_ )Z0_P#?1_PH^KU?
MY0^L4OYC)HK6_P"$<N_^>D/_ 'T?\*/^$<N_^>D/_?1_PH^KU?Y0^L4OYC)H
MK6_X1R[_ .>D/_?1_P */^$<N_\ GI#_ -]'_"CZO5_E#ZQ2_F,FBM;_ (1R
M[_YZ0_\ ?1_PH_X1R[_YZ0_]]'_"CZO5_E#ZQ2_F,FBM;_A'+O\ YZ0_]]'_
M  H_X1R[_P">D/\ WT?\*/J]7^4/K%+^8R:*UO\ A'+O_GI#_P!]'_"C_A'+
MO_GI#_WT?\*/J]7^4/K%+^8R:*UO^$<N_P#GI#_WT?\ "C_A'+O_ )Z0_P#?
M1_PH^KU?Y0^L4OYC)HK6_P"$<N_^>D/_ 'T?\*/^$<N_^>D/_?1_PH^KU?Y0
M^L4OYC)HK6_X1R[_ .>D/_?1_P */^$<N_\ GI#_ -]'_"CZO5_E#ZQ2_F,F
MMC2/^/1O]\_R%-_X1R[_ .>D/_?1_P *OV.E3VL!21HR2V?E)]![5O0H5(SN
MT85ZU.4+)CJ*G^QR>J_G1]CD]5_.N_DEV.'GCW/,M$F\.+JUP^M?9&\9+J%P
M$67_ (_2OF-Y00#Y_*\K9T^3;N)_BK/@\8ZF-(N+FQ\2#5;S^QKJ[OK4P1#^
MRKA$#*N$0,F'++LE+,=O7@Y]=^QR>J_G1]CD]5_.FHOL'-'FO<\QDO\ Q'I^
MJWRR>(YKJ+3IK!_+DM(%\\7$@1T8J@(4 $KC# M\S/P*K^'M9DMO$$5E9Z_Y
ML\VNWT<VB>5&=L/G3L9ON^8,$#Y]VS^'&:]6^QR>J_G1]CD]5_.G:78FZY;7
M_K7_ #/-=/FU6^30M-TW5#H\-Q;7\TS6=I!DF.>,)M#(57[YS\O.3W((P==\
M>ZU#I&E7MOJ\5E>-H]O>R6\T\,,=Y(^21%$8)))3Q\P61, KR,DCVC[')ZK^
M='V.3U7\Z(IKI_6O^?X#<HVM<\LU!Q:ZCXT6;5_M$[^3.FFW,=NZ^64B'F!"
MFXJ#\@))''.6YJQK'B:]MO$M["FOBVOX+V"&RT$Q1?Z;"P3=)@J96SND^=&"
MKY?(X;/I?V.3U7\Z/L<GJOYTE%IK05U;<\\TW4]<.L6%W<ZP\]M>:W>Z>;(V
M\2QI%']H*$,%W[QY(&2V"#]W/S&QXD\*^'M0\:Z+/?Z#IEU-<O-Y\DUG&[2[
M8OEW$CYL8&,],5W?V.3U7\Z/L<GJOYT<LNB&Y1;>O]7/.KF6_E\*>(;V]OOM
M4,=U-;V]E):PF&%(Y]J\%,L<#N2.G&1DT=<\7:E9_$1+.RU9(X5O[:UDTVYN
M(0\BR; SQPBW,A3#_?,P&X'@@ 'U/[')ZK^='V.3U7\Z%&2:;6PFXM.SW.6\
M.[]NO^3CS/[3FV9]=B8K@[+_ (1V;0M(;3?LK^///MC<E<'45F$BBX\[^,)M
M\P-N^7;@#C;7LOV.3U7\Z/L<GJOYT1C)6TVM^'^8W*+OKW_$\YLM6UU-2L[Z
MXUEY[:ZUF^L#9-;1B-(H_M!0AE7>7!A SG!!^[GYCSFB>,]8U#2KS4?^$H)A
M2&U2X#O83M9&27$\X6 $K&B8V^:>,,64XKV:73O/A>&81R1R*5=&Y# C!!K+
MT?P7I^A2F33Q.7\L1*UU?3W)C0?PIYK-L' X7 .!GH*:B[ZH)23V?]7_ *^X
MXRSUB6_B14U.+7["#6[6.UU.2&%_-! + ,B",E6) = ".G4$F2RU;74U*SOK
MC67GMKK6;ZP-DUM&(TBC^T%"&5=Y<&$#.<$'[N?F/HWV.3U7\Z9+IWGPO#,(
MY(Y%*NC<A@1@@TG&7*TE_5DOT#FCU?\ 6O\ G^!YK\-/$6H>)+ZXN+K7S>PI
M9Q%K)Y[&1HYV)+L!;Y98\!0HD.[[V17HU9^C^"]/T*4R:>)R_EB)6NKZ>Y,:
M#^%/-9M@X'"X!P,]!6O]CD]5_.G*+;T0E)=605I1?ZE/]T54^QR>J_G5Q!MC
M53U  JJ<6GJ34DFM!:***V,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOPO\
M\C%XS_[#4?\ Z;[.NDKF_"__ ",7C/\ [#4?_IOLZ .DHHHH *YOX<?\DL\*
M?]@6S_\ 1"5TE<)X?@NY?@?X<DT_5KO2YK?0K:82VJ0L6VVRG:1+&XQGT /'
M6E*7*KL:5W8[NBO.+J;Q+INAZ5J4_B'6;C3I+4W-[>06=I++ Y5"NZ-8@6@'
MSD[%,GN!R&7GBG4&\</!I^MWA#7]G#:V1LD^Q30R1H\A,YCR)-ID95\T$D+A
M3G!JWO<OG8E.ZYO*YZ517(:OXAEU34=-T?1;K4=+>[O)(9[M].:*15CB9R(_
MM$>ULE0-P5AC..2",F\U'5X_"=_<3^)]0CO-+O9;"%K.*T#:A(7585<20L Y
M+*IV!1G)QZ3?^ON_S'_7]?<>BT5YYXANO%&ARVMSJ%_K;Z19:9&]_>Z5#8',
MRD^;)(DR[]NT XB7UP,UWEO+/+)*TD<*V^5,$B2EC(I4$E@5 7G(P"V1@Y&<
M"O/^OZ["_K^O3J3T5Y9IOQ4B;4M>N1J^GZK;BQN;VPT^VGC\R 6Q8,CE<D>8
MNQP6SCYL<#%:>L>,O$D>GWL$&CVECJ=N]C,@:_WHT$\Q0 MY1P^496 ! !R&
M;%+HGW*:L_Z\O\T>@45S<?B)[/4-4_M:.[(M4MMT%G"]X$9U.0BQ1>81D<D@
M^N%Z5S&H>(M=G\:ZC:Z/?ZL\D%S:+:Z>NE@VC1NB-(9IC#F,X+G!D4C PIZ$
MZV%TN>ET5YY-J6OV=E>>(8]=FN([?6'M3I4\, @>'[3Y(5&6,2!\$$$N02,$
M'/&]K6LW%]X7U>;P_<W.G7-C'(6FN],E0_*I/[L2JJMTX;#K[&I<DH\S]1I-
MRY?.QTM%<QK-]=W'AS2;*VN'BOM9>&#SHR59%*^9*X(Q@^6CX(Z$K5V[O[F+
MQQI6GQRXM9["[FDCV@[G1X ISUX$C=^_TK1Q:ER^OX*Y,7=)_,VJ*\WD^(\$
M/Q(FM#K=C+8J\NGKI<<L9N/M"1B3S<??P2)(L'C(7UJUH>O7+W&A7VK^([YY
M=:MQ<II\.E[[(JT32"..98MP=0N?FE);:?E^88E:J_\ 7]=?S&]'8[ZBJFF:
MG!JUF+JUCNHXRQ7;=6DML^1_L2JK8]\5;H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#)UR]N+/R/LTFS?NW?*#G&/7ZUD_P!MZA_S\?\ CB_X
M5>\3?\NW_ _Z5A5XV*J3C6:3?](]G#4X2I)M+^F7_P"V]0_Y^/\ QQ?\*/[;
MU#_GX_\ '%_PJA17-[:K_,_O.CV-/^5?<7_[;U#_ )^/_'%_PH_MO4/^?C_Q
MQ?\ "J%%'MJO\S^\/8T_Y5]Q?_MO4/\ GX_\<7_"C^V]0_Y^/_'%_P *H44>
MVJ_S/[P]C3_E7W%_^V]0_P"?C_QQ?\*/[;U#_GX_\<7_  JA11[:K_,_O#V-
M/^5?<7_[;U#_ )^/_'%_PH_MO4/^?C_QQ?\ "J%%'MJO\S^\/8T_Y5]Q?_MO
M4/\ GX_\<7_"C^V]0_Y^/_'%_P *H44>VJ_S/[P]C3_E7W&E!K%^]Q&K3Y#.
M 1L7U^E;7VF7^_\ H*YBV_X^X?\ ?7^==%7;AJDY)W9QXBG!-61+]IE_O_H*
M/M,O]_\ 05%175S2[G+RKL2_:9?[_P"@H^TR_P!_]!7F%WXLU^V_X1^[AF\^
M#RKZYU& 1+F>&*5$^7"Y#*KE@!C<5P>M7+/5-5\0W.G06^O7-E%<7&IDSV<4
M#-(D-QLB'[R-Q@*>H&3W-/WK7N*T>QZ']IE_O_H*/M,O]_\ 05R/A[Q+-);+
M9:QYUQ?)=SV@NK6QE:&;RG*[V9%*1$XY#$#(..*YWPSXFU^#P9%X@U6/6=2E
MN$MDC@NVL8H)GFE5-T1A7>,;NDF./?D-<SV?;\=@LNQZA]IE_O\ Z"C[3+_?
M_05P]UXWO[/3;DW&DVJ:G:WXLGM%NYI5E)B$H,1BMWD<[6!(\L8PQS@9-2'Q
M5J^LZCH%YHVG9EN;*^$MA=7;V\:O%-"A+$QEN"&"YC#?-R%R<'O?UZ7"T;VL
M>A_:9?[_ .@H^TR_W_T%<1;>(9=2O8[^(W%M%+H4ES]G\P'RY XSZJ6'(S@_
ME45YXVU"PM2]MHXOX;/1X-4O)YKU8WV-OW!5$>&?$9('RJ>>5XRDY/K_ %=K
M] M&^W]:?YH[S[3+_?\ T%'VF7^_^@KAIO'DQ\<1^'[&QL9V-TD$H?42MS&I
MA\TS>0(V_=@$+N+#+$#CK7:47E:X6BR7[3+_ '_T%203R/,JLV0?:JU2VW_'
MPOX_RHC)W6H2BK/0OT445U'*%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMM_Q]P_[Z_SKHJR%UN]1@R_#O6E8'((DT[C_ ,FJG_X2C5_^A$\0?]_]/_\
MDJNFCAG3339SUL2JC32+-[;?;+&:W$\UN9%*B:!MKQGLRGD9'N"/4$<5@#P7
M%Y;O)K.I2:@UTET=180><&1"BC:(O+V[2PQL[D]>:UO^$HU?_H1/$'_?_3__
M )*H_P"$HU?_ *$3Q!_W_P!/_P#DJMU3MU,/:WZ&5'X)M(]6CNSJ.H/!%=RW
ML5BTB>0DLJNLA^YO(/F.<%C@GC XINF^!K33FCSJ>I74<%G)8VT<\D96W@?9
ME%VH"<;%PS;FXY)K7_X2C5_^A$\0?]_]/_\ DJC_ (2C5_\ H1/$'_?_ $__
M .2J/9Z6N'M=;V*">%([:^M[K3=5O[!HX(;>9(?)9;I(L[ ^^-L'!(RFTX/L
M,+9^%8[?Q.=>NM2O+^\$+V\1GC@011LP;8#'&C, 1P'+8Z]3FKW_  E&K_\
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M_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\
M_)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE
M&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>
M(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z
M?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50
M!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_
M\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\
M]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^
M_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\
M_)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE
M&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>
M(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z
M?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50
M!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_
M\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\
M]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^
M_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\
M_)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE
M&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>
M(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z
M?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50
M!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_
M\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\
M]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^
M_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\
M_)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE
M&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>
M(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z
M?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50
M!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_
M\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\
M]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^
M_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\
M_)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE
M&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>
M(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z
M?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50
M!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_
M\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\
M]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^
M_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\
M_)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE
M&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>
M(/\ O_I__P E4 =)7-^%_P#D8O&?_8:C_P#3?9T?\)1J_P#T(GB#_O\ Z?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_"__(Q>,_\
ML-1_^F^SKI*YOPO_ ,C%XS_[#4?_ *;[.@#I**** "N;^''_ "2SPI_V!;/_
M -$)725S?PX_Y)9X4_[ MG_Z(2@#I*Q%\(:*FLMJ:6\R3O-]H>)+N9;=Y?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ;'; XK2HHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.G?\A"/\?Y&NJ^V1^C?E3DN$E;8 >?454<'%23YOP)EBY.+7+^)1HK2\J/\
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M6YH%MFT41N)Y-BEO-W 9..W-<S&L$]K:6DTQ?0X_$J0Z<\LA7=;X;> >,IG
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV= '24444 %<W\./^26>%/\ L"V?_HA*Z2N;_P"%<>"/^A-\/_\ @K@_^)H
MZ2BN;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)H Z2BN;_X5
MQX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)H Z2BN;_X5QX(_Z$WP
M_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)H Z2BN;_X5QX(_Z$WP_P#^"N#_
M .)H_P"%<>"/^A-\/_\ @K@_^)H Z2BN;_X5QX(_Z$WP_P#^"N#_ .)H_P"%
M<>"/^A-\/_\ @K@_^)H Z2BN;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\
M/_\ @K@_^)H Z2BN;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_
M^)H Z2BN;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)H Z2BN
M;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)H Z2BN;_X5QX(_
MZ$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)H Z2BN;_X5QX(_Z$WP_P#^
M"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)H Z2BN;_X5QX(_Z$WP_P#^"N#_ .)H
M_P"%<>"/^A-\/_\ @K@_^)H Z2BN;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/
M^A-\/_\ @K@_^)H Z2BN;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\
M@K@_^)H Z2BN;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)H
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M_H3?#_\ X*X/_B:.2/8.>7<W/L<?JWYTY+9(W#*6R/6L'_A7'@C_ *$WP_\
M^"N#_P")H_X5QX(_Z$WP_P#^"N#_ .)HY8AS2.DHKF_^%<>"/^A-\/\ _@K@
M_P#B:/\ A7'@C_H3?#__ (*X/_B:HDZ2BN;_ .%<>"/^A-\/_P#@K@_^)H_X
M5QX(_P"A-\/_ /@K@_\ B: .DHKF_P#A7'@C_H3?#_\ X*X/_B:/^%<>"/\
MH3?#_P#X*X/_ (F@#I**YO\ X5QX(_Z$WP__ ."N#_XFC_A7'@C_ *$WP_\
M^"N#_P")H Z2BN;_ .%<>"/^A-\/_P#@K@_^)H_X5QX(_P"A-\/_ /@K@_\
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M5QX(_P"A-\/_ /@K@_\ B: .DHKF_P#A7'@C_H3?#_\ X*X/_B:/^%<>"/\
MH3?#_P#X*X/_ (F@#I**YO\ X5QX(_Z$WP__ ."N#_XFC_A7'@C_ *$WP_\
M^"N#_P")H Z2BN;_ .%<>"/^A-\/_P#@K@_^)H_X5QX(_P"A-\/_ /@K@_\
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M5QX(_P"A-\/_ /@K@_\ B: .DHKF_P#A7'@C_H3?#_\ X*X/_B:/^%<>"/\
MH3?#_P#X*X/_ (F@#I**YO\ X5QX(_Z$WP__ ."N#_XFC_A7'@C_ *$WP_\
M^"N#_P")H Z2BN;_ .%<>"/^A-\/_P#@K@_^)H_X5QX(_P"A-\/_ /@K@_\
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M5QX(_P"A-\/_ /@K@_\ B: .DHKF_P#A7'@C_H3?#_\ X*X/_B:/^%<>"/\
MH3?#_P#X*X/_ (F@#I**YO\ X5QX(_Z$WP__ ."N#_XFC_A7'@C_ *$WP_\
M^"N#_P")H Z2BN;_ .%<>"/^A-\/_P#@K@_^)H_X5QX(_P"A-\/_ /@K@_\
MB: .DHKF_P#A7'@C_H3?#_\ X*X/_B:/^%<>"/\ H3?#_P#X*X/_ (F@#I**
MYO\ X5QX(_Z$WP__ ."N#_XFC_A7'@C_ *$WP_\ ^"N#_P")H Z2BN;_ .%<
M>"/^A-\/_P#@K@_^)H_X5QX(_P"A-\/_ /@K@_\ B: .DHKF_P#A7'@C_H3?
M#_\ X*X/_B:/^%<>"/\ H3?#_P#X*X/_ (F@#I**YO\ X5QX(_Z$WP__ ."N
M#_XFC_A7'@C_ *$WP_\ ^"N#_P")H Z2BN;_ .%<>"/^A-\/_P#@K@_^)H_X
M5QX(_P"A-\/_ /@K@_\ B: .DHKF_P#A7'@C_H3?#_\ X*X/_B:/^%<>"/\
MH3?#_P#X*X/_ (F@#I**YO\ X5QX(_Z$WP__ ."N#_XFC_A7'@C_ *$WP_\
M^"N#_P")H Z2BN;_ .%<>"/^A-\/_P#@K@_^)H_X5QX(_P"A-\/_ /@K@_\
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M5QX(_P"A-\/_ /@K@_\ B: .DHKF_P#A7'@C_H3?#_\ X*X/_B:/^%<>"/\
MH3?#_P#X*X/_ (F@#I**YO\ X5QX(_Z$WP__ ."N#_XFC_A7'@C_ *$WP_\
M^"N#_P")H Z2BN;_ .%<>"/^A-\/_P#@K@_^)H_X5QX(_P"A-\/_ /@K@_\
MB: .DKF_"_\ R,7C/_L-1_\ IOLZ/^%<>"/^A-\/_P#@K@_^)K6TK1=*T&U:
MUT/3+/3;=W,C16=NL*,Q !8A0!G  S["@"]1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>anab-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:anab="http://www.anaptysbio.com/20200930"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="anab-20200930.xsd" xlink:type="simple"/>
    <context id="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id3d8e7a79fe34836a6611798dfa6402d_I20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iaa7414d9fb2645cab8e4048e6169b41d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i197dcc146a064825a722c622e39823b6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3f8388b833b04a14aa7b3b7d69daa5e3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0b752f6a10ec473ab4469529bdecb756_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id504f195d28d4333af9e358584ff4c20_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i79651fec1fe943d387f3c41aefb528e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i17101efcf2d941cfa1317efa0e6a6d29_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i357b59d8716e4b85b7100017c7b775d2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9fd425d2b1c34235b752166763d78ceb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9140c17c6ff541b4905365c4fa22b7ed_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0579a6e71aeb413daee069a798be563a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i48fbda0280274166a0586adfa171945a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ice4c5cb905674403beb71f5e810ab566_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia6739116295d4dc896e69e608e97c76f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6198391c49854758a19ea7355d359c10_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i50aea59aa1e849aab1bec2360f5663d0_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibd3a6df5115a4148a71e445678d6304e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i213f296ddf4342eaae36eb522302fe38_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic6f5d31ceca84e909c7ff8eba6ad5711_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if07ac049e6384b9eb3f756bd60ed16e0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i83c45560d4d04c4d8d460117720b4d0c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic96af881aa1f4e0f9cbfba136350d1fe_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4a03dc9bd9c345e9b3e5f735f284462f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5e7a37ef3fbc48b8bfbd71ac11d46dfd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i02ddd9390325464f87909298798898e6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9f3eeec59a504f6aae08e693714a107f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8fae86a718c54cb28203f4589f4ae14d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic8405fd2c9af42b3ad40e73761f1b8b6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i944b329323c7414f9375a984348bacdd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd685fdf5e6746878ea46ac3dc5f5dcb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia0683082d1ab40eab4b01d7c817b5d80_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6951884f2f9647878228f79ce16d0b71_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id80350b4ab804fab943fd2b3e0d00fe9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if5d377b1ba9344a280a30d332ae1b931_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i667c1dbae6f546fab85e5fabd504fab3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1b6fe4a6e5de4b5a82cabfeab9b65f59_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i97a98cd885414727b67a6826b7552a42_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i32de20025be940029a9af8399272f6f1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia19642c61e8545afa9130417d92767d4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4af12f6819b34f6a83947ba47498eefa_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i8a7d6bca25d24e2bb26123e8dcde48a9_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ibe9518b119be40879fc2dbaacdfd8964_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i44dec769f5314a2990ce879992bf1d2f_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i49e522e4b1724704a8bcc7e70955f164_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i4507f2fa60434fe3a58a43f0bfb5ac25_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i7846c140e24c41b1b46a068579c34d6c_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i5ed8446ec51444f3a853535c615dc1ca_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ifbc18062be6e433ea7729c90c6424e74_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i4c49610ebefc49989126a06a1c4800fd_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ie3b1c52d7eea4be9b490a69977fda245_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i898f639913e84acdaf09fc3451ae71fe_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9ddeec5c1a824dd1b0a410b866cbc85f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i293e1639f7f448eb898ed9fbe929111d_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic831befbaf7b4ef59c2293c1c600c9ea_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5c70240883514eddb497067bdc1a0d89_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i53163832a44a4c72a73d784e3f2ff470_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iadb088f6b63b44368f2345abfce054ce_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i980d58c527c04708ad659969362a43cf_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ie5f4eacb369c40a8a2cfe22a790e44f2_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ie6d60309ee7d481fa5ce4476a8abdc34_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i66433ff9b85047cc817a25e24c74a772_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i89b565f7f97a4fb29b4ae5d124a4fde7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib1eb595b079543ce95ba9cb5eadf6d99_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i607986a10b7947ca9d199fecd6596a2f_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i8d431333b5e442b4a517d3cbaa431601_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i00dc647c0bac4896a34e44a91c3920f4_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7ace0421c6554ea0aaf0d90e9aa8c8a3_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2f0d75695e6c4e19919e8ee8cced3fdb_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if39316fb1c754dec9de54a11b19471c9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7cc476288eb442b5bf98c3be003a8dc9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i22c2fc8f301f4097805ab635ea1c679b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9edb7d98f97f42518645609a12b3a888_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i97829a1a0f0c4c658a231073c0b1761b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">anab:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i97a95fbb42de4ae682693fc8fc7a2360_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">anab:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i176c0f8d5a494175860df633af0380ce_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia42c1948b5934a47909d55f51e1c2324_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9935f4f8c0d2424dad75609e066c7b8a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i22374db23a0f4f9599b0ba0e269a3ee7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b714d1629c94dce9455c46ac8ae3df4_D20140301-20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-03-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="i970417eeaafd482f900c18e69347999b_I20140630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-06-30</instant>
        </period>
    </context>
    <context id="i841068aebaa745a89876b4497d36c406_I20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-30</instant>
        </period>
    </context>
    <context id="ibaed7d0c461e4199ad5b9a83b5ed6c0b_D20141101-20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="i043575917e6847649d70407ee576383b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8534bab099e842529d7164852e2d941c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6714296e1ede43c4b159fb8e384daff9_D20150401-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-04-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="i7f48ce05ab804c08ac1a45c2c7193b29_D20151001-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i6a7d54c067c845509a3141ccbe591e65_D20160701-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i7db5636cafbf422dbca6fb1af3c911b8_D20160101-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i69196f35ad1e48409df3674b606bdaab_D20160401-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="i9048b7098214431bb4af6b977f80d956_D20170401-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i49356d8d8f764282af58ba1fb686d94e_D20170401-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="ic85d714342d0443a9aae31c32b92429f_D20171001-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i817f5602cf4d49c1af5c2aa476a787d4_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ied95da1a4f9848e981906b3694d41c40_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="id37ccc32a0c64011b924874643fc2c43_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3clinicaltrialinitiationsecondindicationDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5bccfffe562d49e3a383b78d7e3a473c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FilingofNDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6a4fb59f13064149aefe64f788700e08_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FilingofMMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic8fda9259a0e4e1788f0cae962d442ec_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3d6a141d3615439ea73e776ec0ec0704_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iaebbe17d08a649598b21b99df30d512e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0c1ff849295145de8d2e764ae6a508ec_D20110101-20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-01-01</startDate>
            <endDate>2011-12-31</endDate>
        </period>
    </context>
    <context id="i12bdb60cf8e2409dbb82b9f0e626eca2_I20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-12-31</instant>
        </period>
    </context>
    <context id="ib6949b8d98a949efb75ebf6f3c2883f8_D20160401-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="i2b954c77f99d46ecbdb66e0463daa4c8_D20161001-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase1ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="iaf7d0bcc12c74158bd008c8a54ad1ca3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia3f3c54965f1409ab37615dab7b02091_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibda93a579438443ca855b712364fdb2c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id197285cdb5044f2ab240b49e82a1ecc_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i47a1076cefcd4d0ab8d1b13c5a35388f_I20141224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-24</instant>
        </period>
    </context>
    <context id="i2904dd9806a74afdb9680651604f96e4_D20141224-20141224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-24</startDate>
            <endDate>2014-12-24</endDate>
        </period>
    </context>
    <context id="i77ef9b411b014186ae96e571e310a67c_I20141224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-24</instant>
        </period>
    </context>
    <context id="i0cbfbe6b71b1401990273e2858bb408d_D20141224-20141224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:TermALoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-24</startDate>
            <endDate>2014-12-24</endDate>
        </period>
    </context>
    <context id="i4e2957bb03b74da888869ae5ceb98960_I20141224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:TermALoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-24</instant>
        </period>
    </context>
    <context id="i4e1900fbc5af4115b87781c0258509e7_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:TermBLoansAndTermCLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="i83f647fab752487aaffcadf4318bc4aa_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="i486ee79f827548bc8e85e93940ce0440_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie988dd2210474da0a9388a1930bda1c6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2e9365f8894d443d987a0236bea2df0c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id29df9c5b8854830bcd8981e7835fc35_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia56e6aad2b7c44aab9e288f7e9c76eef_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i164e1f96760745ea976bbb632c4983c3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7af76d44387a46c89ac52e0449f254f5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iadb2d6473570457a8faa9c1e6fb88863_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i63a8061e93f9480896f76c4620112a7c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie2f77996d88c440f99adbdd8f311cd20_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3a809753553044369236456513af1721_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1d91aeb2e9ae4d358e45e8c47c03c98b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5fc2261a1be6464d85beeb08fdb8bd77_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4295dc2b4c0e4900bbb30c9191198893_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iee0736e2d03d4071be6f21372a00b616_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i06badbd8e437492aab95efec2695045d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id77ca4847bba4305b096e411a0f88a98_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4baf9e14edba45e69f2f019ccd63867e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i86cf9503128d472eaa3c206335a0a2fe_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i507cac2c7cca438e8dbb277c0fe458d2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib8b77072d590434e92a3cb60e8a64f76_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1d965662c4e8442d9916e4cfd80ec8a7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i077e3faf20384ff0800aacc76bea84f4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iba71325b1ced4476b954c2bc33ca1f44_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ieb57811cde1b45cdbd23bd6a14512d23_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia898b1250c31427581123c12f7daefee_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8dd5a96a569344b783cdca534f4e6e9f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ife860bdad5054daeaabbda9d6e52176d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i12ee59f67b6f424b910cc0844c794eb7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i641d36b1119a4b48adad58e89443d069_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8d6d9c78810d4e6ca294fa8649b67b58_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i76c44023eb8043aeb3d411c59bc7cf4b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3cabcd89e04549418fc44781cea4c283_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3f51e0997cba47f6b82e8aa9efa6952b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id3f40c73d02a434eaaf57929475ddfc6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3922432c0e84274970a003c02156320_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0b87f9f76e3a4b858f05b03e5189102d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i62c6c85777a546cc8922f55af953a635_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1bf3fb2ff20a4a8f8e90a71d67af78ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iad0530eb18bc4ab29d6f3710ab1c6e67_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie8795b5aaad54f1a89041597a8c5f56f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i426b689f24654fc8a7cf7448cec90674_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i75efafa8841f48729f56684090276568_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if3f1b9a2b98b41029f0b45d0b59ff7f9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc9672695c6d4ab2811e97fcee8bcfe5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1d92717b6f68494ba0890fed7d159f14_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c61b5956d7e46c6a38b815d302d5850_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b730ef0ddc64ea19f1632b5ab752783_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2ab47a7f50ba4fb2826b5e3dc7761fb5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7825d3ea7a9349ca843c88225054e573_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8635c548a31441e3992be83f1680e082_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia0a28d83f2ea4dbea79c3907f37a6431_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a898126f7a043ec824730e437299a7b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0ef17d9b49d24d5c984eab8bedf09095_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0aa15223feec45779fc8eb2c483d51ec_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib1b346b9aee2453e943c261bcb153fa8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i856a405b5e294005b0da97db3dbe7ce2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7fc96d50997d416d9e45d9e489b28b0f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i421e55d1b84c466089165cde97803903_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8f35c8d2bb134707949ab2d642ffe73b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib391ac02eeb746c0bba9221ead335968_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i658c9943823c428392acd64ea6860e66_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3a14f6c2f873440b8540983c27210b42_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0f2d1d9c88ae45deaceec9801cea355b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1625cce2849647f3b4fdd28e3722f489_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i04b8e21f36b048dfb63095af95035987_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8eed3626fb0548498facb46e0bee7d8c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie5dc4745f8114a8fbed72cc75adbb0dc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iede5636a43b44bc6be3c38a82fecb803_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1689cf0ddbf847f1a5d41386bf8e581a_D20170126-20170126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-26</startDate>
            <endDate>2017-01-26</endDate>
        </period>
    </context>
    <context id="ib98c7394ae0241be92efa15ef59bb44f_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="i86d89ac9401d465a9ffa094c58d86268_D20180101-20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-01</endDate>
        </period>
    </context>
    <context id="i4bdb7350e5c74ed089644cf190add40a_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifd8286d24eb44b9dada0fe300127f5bc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7aa924de6d814250973b8ca6c02725b7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5ef232fdc16443ab824f750c8ecbc67b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i746c849226304957812801a396d96d98_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifa8e6f18cae84e3abeb28a87d7e99b95_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i619a360a42884bb8b5a3c0d6c4290323_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i99c89f0f0b0f4523aa6c1cc41b1ca2dd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2389b2e977c94f14aaafb743e9c2bf19_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i13db0076e7d145118a79fd40a565430f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i53442a555d5247dda9d21b2f725430ac_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8eacadeab29a42608e859587a94fccfe_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="anab:LeaseArrangementAxis">anab:OneOfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5d58efeb98774e8291e0a3b307d1a26b_I20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="anab:LeaseArrangementAxis">anab:A10770WateridgeCircleSanDiegoCalifornia92121Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-04</instant>
        </period>
    </context>
    <context id="ie99b7535bd4a4aff813c79436f435dd6_D20200504-20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="anab:LeaseArrangementAxis">anab:A10770WateridgeCircleSanDiegoCalifornia92121Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-04</startDate>
            <endDate>2020-05-04</endDate>
        </period>
    </context>
    <context id="id3e3599ed3624134a82b70d95e79fc4c_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="i0d1574d508d24c7a9d2272819c456ea4_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="i60cb8e6a37424af2bd4d11e7a7616ff7_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="ifa95208aff9f4c2086046f2657751ac3_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i79eecb7fb35c40ad8dec2e63fb261996_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="iaa90cb92269c4595b23777618939cb79_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>anab:segment</measure>
    </unit>
    <unit id="target">
        <measure>anab:target</measure>
    </unit>
    <unit id="milestone">
        <measure>anab:milestone</measure>
    </unit>
    <unit id="installment">
        <measure>anab:installment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="lease">
        <measure>anab:lease</measure>
    </unit>
    <unit id="renewal_option">
        <measure>anab:renewal_option</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="usdPerSqft">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utr:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80L2ZyYWc6NmE3YmRhYmE0Mjk3NGU4YWE5NTc5NDQ3YjQxZWU0ZmQvdGFibGU6MDdkOWE0Y2U0NWI4NDA0YTk5YjAyZjczYjI4ZWExZDgvdGFibGVyYW5nZTowN2Q5YTRjZTQ1Yjg0MDRhOTliMDJmNzNiMjhlYTFkOF80LTEtMS0xLTA_103dabaf-2704-42cc-9558-f744d3e5f084">0001370053</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80L2ZyYWc6NmE3YmRhYmE0Mjk3NGU4YWE5NTc5NDQ3YjQxZWU0ZmQvdGFibGU6MDdkOWE0Y2U0NWI4NDA0YTk5YjAyZjczYjI4ZWExZDgvdGFibGVyYW5nZTowN2Q5YTRjZTQ1Yjg0MDRhOTliMDJmNzNiMjhlYTFkOF81LTEtMS0xLTA_ec63b618-4995-4988-bada-1d08a097a3d8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80L2ZyYWc6NmE3YmRhYmE0Mjk3NGU4YWE5NTc5NDQ3YjQxZWU0ZmQvdGFibGU6MDdkOWE0Y2U0NWI4NDA0YTk5YjAyZjczYjI4ZWExZDgvdGFibGVyYW5nZTowN2Q5YTRjZTQ1Yjg0MDRhOTliMDJmNzNiMjhlYTFkOF82LTEtMS0xLTA_3b5eb412-1aee-4056-a889-29581bf9d21a">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80L2ZyYWc6NmE3YmRhYmE0Mjk3NGU4YWE5NTc5NDQ3YjQxZWU0ZmQvdGFibGU6MDdkOWE0Y2U0NWI4NDA0YTk5YjAyZjczYjI4ZWExZDgvdGFibGVyYW5nZTowN2Q5YTRjZTQ1Yjg0MDRhOTliMDJmNzNiMjhlYTFkOF83LTEtMS0xLTA_99542282-2571-41af-81ec-cde8d4891b23">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80L2ZyYWc6NmE3YmRhYmE0Mjk3NGU4YWE5NTc5NDQ3YjQxZWU0ZmQvdGFibGU6MDdkOWE0Y2U0NWI4NDA0YTk5YjAyZjczYjI4ZWExZDgvdGFibGVyYW5nZTowN2Q5YTRjZTQ1Yjg0MDRhOTliMDJmNzNiMjhlYTFkOF84LTEtMS0xLTA_408e04f8-1ce8-475a-940a-81655f0d28fd">false</dei:AmendmentFlag>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i7fc96d50997d416d9e45d9e489b28b0f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDMyMA_168e5752-1e53-49ab-989a-a68d50119366">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="ib391ac02eeb746c0bba9221ead335968_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMzEzNQ_106d4e12-4b32-4f29-8d26-2b1735c0fda4">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i0f2d1d9c88ae45deaceec9801cea355b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDY4MQ_e5da9ade-9ee6-43e3-9be3-70e98595210b">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MDgvZnJhZzo5MjIxOTk3YTFkMWI0MDE5YWI4ZTQxZjA5MGJhYzAwYS90YWJsZTo0YjA2MGVmNGVhNjE0NTg3ODc5MWI3YjhmOGY4NjdjMy90YWJsZXJhbmdlOjRiMDYwZWY0ZWE2MTQ1ODc4NzkxYjdiOGY4Zjg2N2MzXzEtMy0xLTEtOTE_6a2251c2-d5ad-4637-b9c7-5a53d21ab32d">us-gaap:OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MDgvZnJhZzo5MjIxOTk3YTFkMWI0MDE5YWI4ZTQxZjA5MGJhYzAwYS90YWJsZTo0YjA2MGVmNGVhNjE0NTg3ODc5MWI3YjhmOGY4NjdjMy90YWJsZXJhbmdlOjRiMDYwZWY0ZWE2MTQ1ODc4NzkxYjdiOGY4Zjg2N2MzXzItMy0xLTEtOTE_25b3641a-0c57-4b4c-a7a3-fcb7ec7bbf3c">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MDgvZnJhZzo5MjIxOTk3YTFkMWI0MDE5YWI4ZTQxZjA5MGJhYzAwYS90YWJsZTo0YjA2MGVmNGVhNjE0NTg3ODc5MWI3YjhmOGY4NjdjMy90YWJsZXJhbmdlOjRiMDYwZWY0ZWE2MTQ1ODc4NzkxYjdiOGY4Zjg2N2MzXzMtMy0xLTEtOTE_1ea122d2-3773-42dd-8ad1-1aee9247ccd0">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDky_57abc4d6-a396-4f30-a586-c761ff620ba4">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6NWQ0MWI5YjljODFkNDk3NWEzMzkzMzIzY2I5YWIxYTEvdGFibGVyYW5nZTo1ZDQxYjliOWM4MWQ0OTc1YTMzOTMzMjNjYjlhYjFhMV8wLTAtMS0xLTA_d9764359-0494-4afc-8d0b-b94cca6a521b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8xMzE_e175e801-398d-4e01-b9c7-bcdb2810f0cc">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6ZDU3ZGRkNzRhY2ZmNDNmZjhhY2U3NThkNGEyMGFhOWIvdGFibGVyYW5nZTpkNTdkZGQ3NGFjZmY0M2ZmOGFjZTc1OGQ0YTIwYWE5Yl8wLTAtMS0xLTA_3f1b95d4-e97f-42d3-ac99-994bcfa1423a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDkz_b50b7c16-cdca-4987-9498-957105e00639">001-37985</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDg1_d60bd68c-df5b-4156-aa37-15f8ed7ed512">ANAPTYSBIO,&#160;INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6ZGQ3ZDNiN2Q5MjBmNDg3MmJjMjIwMjQ2NjE0NmQ5ZDAvdGFibGVyYW5nZTpkZDdkM2I3ZDkyMGY0ODcyYmMyMjAyNDY2MTQ2ZDlkMF8wLTAtMS0xLTA_e5bdec56-d9bf-422f-95cd-dadc82726722">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6ZGQ3ZDNiN2Q5MjBmNDg3MmJjMjIwMjQ2NjE0NmQ5ZDAvdGFibGVyYW5nZTpkZDdkM2I3ZDkyMGY0ODcyYmMyMjAyNDY2MTQ2ZDlkMF8wLTItMS0xLTA_86c7091e-d763-4cd3-9e27-426dafd5530b">20-3828755</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDk0_77b4108f-5380-428f-b0d6-f1ef1e545820">10421 Pacific Center Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDg2_4c332cb2-5ce6-462f-a197-f0896150d68d">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDg3_34c95d8c-89b1-448f-a88c-4fbca281e932">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDg4_eeb95e20-513e-4a69-92ed-e860b8ea4c6f">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDg5_6af30775-34f0-4b13-8302-cdacdbe289db">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDk1_007fc098-a368-4a49-9f5e-157a055220a4">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDkw_6541899a-cb78-4cbb-b455-35e26ee2d73f">362-6295</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6OWRmNDRlZGQyODMzNDNiZDk5NzU3ODQwYTc1ZjUyZjIvdGFibGVyYW5nZTo5ZGY0NGVkZDI4MzM0M2JkOTk3NTc4NDBhNzVmNTJmMl8xLTAtMS0xLTA_f324c9f5-422b-4597-b12e-ddc3a23ffc3e">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6OWRmNDRlZGQyODMzNDNiZDk5NzU3ODQwYTc1ZjUyZjIvdGFibGVyYW5nZTo5ZGY0NGVkZDI4MzM0M2JkOTk3NTc4NDBhNzVmNTJmMl8xLTEtMS0xLTA_12df4b74-e21e-4939-af51-21d534843fa0">ANAB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6OWRmNDRlZGQyODMzNDNiZDk5NzU3ODQwYTc1ZjUyZjIvdGFibGVyYW5nZTo5ZGY0NGVkZDI4MzM0M2JkOTk3NTc4NDBhNzVmNTJmMl8xLTItMS0xLTA_e5a20ee9-f2dd-4a24-a8df-07c954ed0c3a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDk2_be627fae-d2fa-4f52-bdb5-a3b820810d5a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDk3_437de8c9-7e34-486a-a05c-30d99ef35979">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6MjFjNmRhZGJjZDI2NGI2M2JjNzg5OTY5M2Q4M2FhMGIvdGFibGVyYW5nZToyMWM2ZGFkYmNkMjY0YjYzYmM3ODk5NjkzZDgzYWEwYl8yLTAtMS0xLTA_448e9f8d-d296-4519-8495-da098c3bf976">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6MjFjNmRhZGJjZDI2NGI2M2JjNzg5OTY5M2Q4M2FhMGIvdGFibGVyYW5nZToyMWM2ZGFkYmNkMjY0YjYzYmM3ODk5NjkzZDgzYWEwYl8yLTYtMS0xLTA_fc0f4993-1134-43ee-8da1-acd93d7503e8">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGFibGU6MjFjNmRhZGJjZDI2NGI2M2JjNzg5OTY5M2Q4M2FhMGIvdGFibGVyYW5nZToyMWM2ZGFkYmNkMjY0YjYzYmM3ODk5NjkzZDgzYWEwYl80LTYtMS0xLTA_c51b4d43-d523-4504-8419-76f61cc6ac20">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDkx_71651d59-d53c-422d-99ec-88cb5f73652c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id3d8e7a79fe34836a6611798dfa6402d_I20201102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xL2ZyYWc6ZGRjNzkyMjlhNmMyNDU5Yzk4ZThjNWE0ZmRmMDYzNjEvdGV4dHJlZ2lvbjpkZGM3OTIyOWE2YzI0NTljOThlOGM1YTRmZGYwNjM2MV8yMDI3_62de297f-6291-4874-994f-d4b2d5c53cf1"
      unitRef="shares">27347805</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNC0xLTEtMS0w_9a2c9991-406d-407f-b6a4-866a01bd8cee"
      unitRef="usd">209154000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNC0zLTEtMS0w_4d4b43be-f1bb-4af8-beeb-fb3dde434fe4"
      unitRef="usd">171017000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNi0xLTEtMS0w_4e345707-958f-4726-ab1c-d2fc46ba3286"
      unitRef="usd">129192000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNi0zLTEtMS0w_8e33058d-06ec-4b1f-83f7-d9396f176443"
      unitRef="usd">203210000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNy0xLTEtMS0w_48633daa-4129-4456-85cd-250da8e29c27"
      unitRef="usd">7468000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNy0zLTEtMS0w_acea03b8-b30a-4b4d-b26e-09f26de71b6d"
      unitRef="usd">3506000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfOC0xLTEtMS0w_fe545087-f1c5-4947-a7b9-0dabc6440db0"
      unitRef="usd">345814000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfOC0zLTEtMS0w_fc5d2985-a2de-4b8f-875b-37d07b84b751"
      unitRef="usd">377733000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfOS0xLTEtMS0w_cdf7ba45-9684-4619-9ba7-fefc99058dc2"
      unitRef="usd">1585000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfOS0zLTEtMS0w_e91fdea3-018b-4526-8a21-884964384af7"
      unitRef="usd">1618000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTAtMS0xLTEtMA_0f3251a7-c4d2-4049-a690-648345938b24"
      unitRef="usd">36177000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTAtMy0xLTEtMA_46f98ccb-2129-417c-928b-178b54d1c9a2"
      unitRef="usd">54305000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTEtMS0xLTEtMA_b584e403-5045-4235-9e4d-9a556a228567"
      unitRef="usd">1114000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTEtMy0xLTEtMA_3cdb26b5-983a-44b3-934f-4ffc2579e1c1"
      unitRef="usd">1481000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTItMS0xLTEtMA_f1c89d36-60dc-48e7-a26e-3fab900255bf"
      unitRef="usd">60000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTItMy0xLTEtMA_789ae391-794f-4ab6-8be3-11054de33771"
      unitRef="usd">60000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:Assets
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTQtMS0xLTEtMA_82fde88d-1f4e-4295-8904-307a66d6bc41"
      unitRef="usd">384750000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTQtMy0xLTEtMA_c03eedaa-61c4-488d-b008-d978e3697b1e"
      unitRef="usd">435197000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTktMS0xLTEtMA_7a7a515b-9abc-4bd1-89f0-e2f60f1139cf"
      unitRef="usd">5484000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMTktMy0xLTEtMA_e542d37a-d440-4a89-b42e-f524d583de66"
      unitRef="usd">16237000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjAtMS0xLTEtMA_46dc3a03-cdd7-4ca4-a878-57d794a5abb3"
      unitRef="usd">18139000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjAtMy0xLTEtMA_bf57f90e-ffcc-4f08-9444-22884970c031"
      unitRef="usd">11052000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjEtMS0xLTEtMA_9e9f57d6-c670-4b51-9119-8ea6f42fca12"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjEtMy0xLTEtMA_5f3f8cce-f699-4aad-b718-f26104495fc4"
      unitRef="usd">1375000</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjItMS0xLTEtMA_6b176a77-fafb-4032-88a9-72fa7b893a1a"
      unitRef="usd">851000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjItMy0xLTEtMA_85a511e0-09d7-48a6-94e3-4ea2e7a91082"
      unitRef="usd">871000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjMtMS0xLTEtMA_9e33d1cf-8bbd-4a71-949d-61262681eb9a"
      unitRef="usd">24474000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjMtMy0xLTEtMA_87458601-328f-462d-ae0e-d90a2066f618"
      unitRef="usd">29535000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjYtMS0xLTEtMA_de4bb93a-0edd-4a63-9f5a-fadedabbd139"
      unitRef="usd">33000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMjYtMy0xLTEtMA_7fa66c63-c243-4732-ad35-39abb42bc79a"
      unitRef="usd">654000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzIy_375cd9d5-1046-43e5-834c-9bb86dfc2864"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzIy_40feaa66-e15c-4057-be62-d27c8fa8ff37"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzM2_458d6550-5629-418b-ae1f-bfcc6a2a1765"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzM2_dd869992-3429-4d67-a0a3-11694bd2cbe6"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzYx_0c6490fa-abc7-49d5-9690-dad4b3e03528"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzYx_293b4a11-24cb-46b2-b212-6bbe4a4140a0"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzYx_4f2de8e2-435d-4684-809c-393138daebc5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjI1YWI4OWI3NGE5MzRmMDliNzUwN2UzOTE5YTcwMTI2XzYx_5e34ed45-6fea-47e8-8410-3475610b1ba5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMS0xLTEtMA_4126d66b-53f0-4f21-b9f4-275c3c4d1281"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzQtMy0xLTEtMA_07ad271b-c6da-42a5-be72-5f0d0bf962e6"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzE4_44bf18c4-c766-482a-bbc9-fac6f931242c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzE4_d233acfe-713f-4368-a027-193f7bcdcd96"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzMy_0b8718a1-1180-492a-80d1-dcbe968a8ad2"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzMy_bdd75af4-d3ec-4603-8b6a-dcc87ee13516"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzU0_28f80702-41c0-4f6e-95be-f313f08c7915"
      unitRef="shares">27346000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzU0_41b0c92a-b79b-423d-b037-55f877fed26d"
      unitRef="shares">27346000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzY4_d6990f12-ebb3-48d0-9a1c-0b54499530f1"
      unitRef="shares">27255000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjEyMzI0OGVkYjI1NDQ2NmI5MjZkNjgwNDFmYmQ0ODk0XzY4_e431bf8c-7201-4e27-bf53-3e3e352949ea"
      unitRef="shares">27255000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMS0xLTEtMA_ad2ada77-6a43-4a6d-8abf-b759bd6ab3c3"
      unitRef="usd">27000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzUtMy0xLTEtMA_b82174c2-8edc-44d4-8390-0d7f67e1de6c"
      unitRef="usd">27000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzYtMS0xLTEtMA_0e9dffa5-297a-4076-b0b7-f970fbbdb612"
      unitRef="usd">657560000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzYtMy0xLTEtMA_a680f8ee-118b-4c69-9ac0-71a067730508"
      unitRef="usd">648669000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzctMS0xLTEtMA_b51f6088-72d1-4194-bfb6-b26c0afff0e0"
      unitRef="usd">259000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzctMy0xLTEtMA_380ff4c2-e3aa-48d3-9a5d-c287502e954a"
      unitRef="usd">338000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzgtMS0xLTEtMA_8e42937e-a63a-4a40-a733-d825e922dd21"
      unitRef="usd">-297603000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzgtMy0xLTEtMA_9112f799-9b6c-4a03-956f-8f5324265656"
      unitRef="usd">-244026000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzktMS0xLTEtMA_a7bba80b-d567-4fec-9ce2-fdf02e349001"
      unitRef="usd">360243000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfMzktMy0xLTEtMA_85858bb6-3c81-4824-8939-362204058b9b"
      unitRef="usd">405008000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNDAtMS0xLTEtMA_b220ddde-6b06-4a97-b2b6-20c464bb5673"
      unitRef="usd">384750000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xNi9mcmFnOmEwYjU0OWViMmE5ODQ0Mjk5YzU5NmE4MWEyZjcyNTliL3RhYmxlOjU4OTcxMDhhN2I5NjRhZWJhZTc1Yjc0ZDU3NTYzMDIxL3RhYmxlcmFuZ2U6NTg5NzEwOGE3Yjk2NGFlYmFlNzViNzRkNTc1NjMwMjFfNDAtMy0xLTEtMA_08bfcf24-bdcf-4329-9cc3-0d2c40bbae1d"
      unitRef="usd">435197000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMi0xLTEtMS0w_75a9a5ce-e8e1-4cbb-bc76-8198d584228c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMi0zLTEtMS0w_e9762185-3852-4666-8596-fb741afb3633"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMi01LTEtMS0w_af7f9f8f-59f3-4333-b9ef-cc87b612e703"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMi03LTEtMS0w_5050c23e-c27a-47fd-810e-68be4c986d2b"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNC0xLTEtMS0w_5471e26c-6dcf-4558-b2df-9b91e31885c0"
      unitRef="usd">19542000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNC0zLTEtMS0w_e025a234-eea1-41a2-8da6-753246117fd3"
      unitRef="usd">29931000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNC01LTEtMS0w_cc1fbcd5-e2da-4ee0-b761-0781efa08f8b"
      unitRef="usd">58458000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNC03LTEtMS0w_4b266030-3f51-4965-ad72-35380fde4ca3"
      unitRef="usd">77912000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNS0xLTEtMS0w_0286902e-97f2-4032-beb9-34f105e8b703"
      unitRef="usd">4794000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNS0zLTEtMS0w_2227d9f0-58f4-4d1f-a995-2d68e13e41cd"
      unitRef="usd">3814000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNS01LTEtMS0w_cccc20ad-3e6a-4dd7-b4ab-0fd0ef379b4a"
      unitRef="usd">13766000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNS03LTEtMS0w_f24b33b5-ed79-4508-9d33-17695836aaec"
      unitRef="usd">12262000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNi0xLTEtMS0w_e20bf172-19a7-4787-ad9d-82cb522ce0b4"
      unitRef="usd">24336000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNi0zLTEtMS0w_0a82ba9d-9bff-4d87-a409-afb859f523d7"
      unitRef="usd">33745000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNi01LTEtMS0w_6d9becd8-1aa8-48d1-a42f-6a3eb9848c9e"
      unitRef="usd">72224000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNi03LTEtMS0w_d1093217-69f9-4581-a9b9-1de974505f5a"
      unitRef="usd">90174000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNy0xLTEtMS0w_382107bd-fbd7-42ad-bb15-ce5afb8eb899"
      unitRef="usd">-24336000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNy0zLTEtMS0w_dc612f90-fda4-4760-9781-94db7767993b"
      unitRef="usd">-33745000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNy01LTEtMS0w_73f96fb8-fe6b-4ea9-a077-9b11c64cb17c"
      unitRef="usd">-57224000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfNy03LTEtMS0w_56ad77bd-9626-4963-a54c-5e7c64efb1bb"
      unitRef="usd">-85174000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfOS0xLTEtMS0w_321ddc94-1781-420c-9d15-71a9063294cb"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfOS0zLTEtMS0w_7ab959e6-5640-497c-a37a-5a46fc0a421d"
      unitRef="usd">240000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfOS01LTEtMS0w_7bd328c5-47f1-491e-93f0-0c3395d9342f"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfOS03LTEtMS0w_caf7cbe2-8847-42c3-a675-e81445a0963d"
      unitRef="usd">841000</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTEtMS0xLTEtMA_7b70ad1d-aec1-4199-bfd9-82685d0ec03d"
      unitRef="usd">625000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTEtMy0xLTEtMA_951646ff-bad2-4858-a467-2b3a50c7edd7"
      unitRef="usd">2757000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTEtNS0xLTEtMA_f9594c62-e393-44c7-a7c4-617a31003945"
      unitRef="usd">3583000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTEtNy0xLTEtMA_2a957677-3403-47c2-94cf-b24b35aa4fc0"
      unitRef="usd">8702000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTItMS0xLTEtMA_55ae1ad6-9f79-45e7-a39c-4bf2d17dcf53"
      unitRef="usd">-56000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTItMy0xLTEtMA_e80c2ce9-4074-4458-8acc-c48bb00b353f"
      unitRef="usd">144000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTItNS0xLTEtMA_a155efc5-6040-43ab-928f-838508856584"
      unitRef="usd">64000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTItNy0xLTEtMA_887a60d1-146e-4440-a54d-33a7b923e821"
      unitRef="usd">110000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTMtMS0xLTEtMA_c30795dd-190f-4f0b-a083-a998139fc1bc"
      unitRef="usd">569000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTMtMy0xLTEtMA_59dd5ea2-9808-4839-b3eb-b8db69af36ba"
      unitRef="usd">2661000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTMtNS0xLTEtMA_6e80d85c-7026-405e-b569-c6ea10b52588"
      unitRef="usd">3647000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTMtNy0xLTEtMA_924dbbb0-b278-48e0-b877-7c88ec8b5a54"
      unitRef="usd">7971000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTQtMS0xLTEtMA_904b484c-8774-4b67-9e8c-39e8a267575d"
      unitRef="usd">-23767000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTQtMy0xLTEtMA_b3df17a4-1f24-4ccc-9df9-2e29293b9448"
      unitRef="usd">-31084000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTQtNS0xLTEtMA_009f5b49-9821-44e3-bba8-103123bf8f0e"
      unitRef="usd">-53577000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTQtNy0xLTEtMA_d84b2e6c-a09c-446d-b6a1-197362f32001"
      unitRef="usd">-77203000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTUtMS0xLTEtMA_218ac409-dae9-4544-b6b5-ec80aa889b65"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTUtMy0xLTEtMA_3fbffa47-150a-4e0f-a694-e87e7be3bf0f"
      unitRef="usd">-51000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTUtNS0xLTEtMA_72cc5da4-7416-4cc3-8938-d773039d9938"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTUtNy0xLTEtMA_b1bc6516-88e7-46dd-ab80-de961ef27ada"
      unitRef="usd">-130000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTctMS0xLTEtMA_c5aa5711-975d-4d2e-bf48-13faaa0633db"
      unitRef="usd">-23767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTctMy0xLTEtMA_b4d9942a-f1ee-4589-a416-969e9c9b2331"
      unitRef="usd">-31033000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTctNS0xLTEtMA_50f62b2f-51eb-4182-93ca-943fb4ab11a2"
      unitRef="usd">-53577000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMTctNy0xLTEtMA_03d723d7-43cb-491c-830d-f8da6ac9ce0c"
      unitRef="usd">-77073000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOjU1NWIxY2M3MGU3YjQ3OGVhNzk1MmU4ODExYWI3MWI3Xzc3_0331b039-1b5b-4e10-b65f-963c9926ffee"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOjU1NWIxY2M3MGU3YjQ3OGVhNzk1MmU4ODExYWI3MWI3Xzgx_c0f4178f-b22e-4d75-be81-c50073f4bba5"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOjU1NWIxY2M3MGU3YjQ3OGVhNzk1MmU4ODExYWI3MWI3Xzg1_e1961165-88a1-4006-8cec-447012caa414"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOjU1NWIxY2M3MGU3YjQ3OGVhNzk1MmU4ODExYWI3MWI3Xzky_94c91f42-131f-4b50-8a99-d309ad916b17"
      unitRef="usd">189000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtMS0xLTEtMA_cb22dd70-3bde-470d-9d29-39e53e548a7a"
      unitRef="usd">-494000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtMy0xLTEtMA_80ac133d-37e9-4ed5-a2e4-88b8f08e2cd4"
      unitRef="usd">-94000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtNS0xLTEtMA_0bdee5af-26b8-4604-a125-ee79ab1e5af7"
      unitRef="usd">-79000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjAtNy0xLTEtMA_25cfd48c-9bf2-402d-ba2f-6c3fc1ea2d9e"
      unitRef="usd">703000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjItMS0xLTEtMA_dc458dde-25df-4ed5-8bad-b0647a1a7798"
      unitRef="usd">-24261000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjItMy0xLTEtMA_683cfb29-92b1-4e7b-a09f-d69ef9516191"
      unitRef="usd">-31127000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjItNS0xLTEtMA_dd2753e3-8067-49e8-9a50-0df9d11d8498"
      unitRef="usd">-53656000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjItNy0xLTEtMA_3b882b6b-da1c-46ed-a931-9a8987d5e45c"
      unitRef="usd">-76370000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjQtMS0xLTEtMA_aea55aad-bf0a-488b-a59e-37b39c1c8c31"
      unitRef="usdPerShare">-0.87</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjQtMy0xLTEtMA_1472547a-d6de-405c-a552-9ec03657824f"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjQtNS0xLTEtMA_649957ca-1827-464f-8165-73028f859d59"
      unitRef="usdPerShare">-1.96</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjQtNy0xLTEtMA_2e500e1f-0967-4869-bd13-3e553e030d15"
      unitRef="usdPerShare">-2.85</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjctMS0xLTEtMA_5b2d955e-4135-48ca-9f45-ceb2b18e44c9"
      unitRef="shares">27316000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjctMy0xLTEtMA_1aea9a97-1815-49a3-b1b4-861e07cc731e"
      unitRef="shares">27058000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjctNS0xLTEtMA_1f7a5288-a91b-47ce-8a5c-758b27dc8b13"
      unitRef="shares">27286000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8xOS9mcmFnOmM3Y2IzMjlkNWNlOTQxMDM4ZmRhM2E1OGU0ZDc3NWMxL3RhYmxlOmMzZjUyZWZkZDhhYTQ4YTI4MWE0ZWFlNTM1MTc5NDQ4L3RhYmxlcmFuZ2U6YzNmNTJlZmRkOGFhNDhhMjgxYTRlYWU1MzUxNzk0NDhfMjctNy0xLTEtMA_6b6f432b-be57-4bcf-b1a0-4855ce21e0b5"
      unitRef="shares">27022000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i3f8388b833b04a14aa7b3b7d69daa5e3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMi0xLTEtMS0w_301dab42-96ab-4129-b831-7306f1511f93"
      unitRef="shares">27255000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3f8388b833b04a14aa7b3b7d69daa5e3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMi0zLTEtMS0w_d43ca327-baeb-4d87-a90e-56feb1b37ef9"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0b752f6a10ec473ab4469529bdecb756_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMi01LTEtMS0w_d8c47785-814c-4602-9fe6-8f5ce7497a50"
      unitRef="usd">648669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id504f195d28d4333af9e358584ff4c20_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMi03LTEtMS0w_872b2486-a1b3-433a-ac12-f8391fd5eef9"
      unitRef="usd">338000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i79651fec1fe943d387f3c41aefb528e9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMi05LTEtMS0w_e1621736-f8c6-45c8-b67f-c23d2b76dae6"
      unitRef="usd">-244026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMi0xMS0xLTEtMA_5beeaa52-cae3-4735-bfa1-a60d20adc478"
      unitRef="usd">405008000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i17101efcf2d941cfa1317efa0e6a6d29_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfNi0xLTEtMS0w_25ee50e9-50ee-460b-9322-27d299468ea2"
      unitRef="shares">22000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i357b59d8716e4b85b7100017c7b775d2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfNi01LTEtMS0w_6a601e30-b1dc-4532-bd4d-5cb49c9791ed"
      unitRef="usd">36000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9fd425d2b1c34235b752166763d78ceb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfNi0xMS0xLTEtMA_d6ec23bf-35ae-433b-93ed-fb0fee922356"
      unitRef="usd">36000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i357b59d8716e4b85b7100017c7b775d2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTEtNS0xLTEtMA_0a42ef0d-5c01-4272-900c-7398ca8cd881"
      unitRef="usd">2975000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i9fd425d2b1c34235b752166763d78ceb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTEtMTEtMS0xLTA_1432f615-99fe-41ab-bd62-65e11a248b98"
      unitRef="usd">2975000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9140c17c6ff541b4905365c4fa22b7ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTItNy0xLTEtMA_92fc3c15-1962-4480-b071-9cac643c9200"
      unitRef="usd">807000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9fd425d2b1c34235b752166763d78ceb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTItMTEtMS0xLTA_c8612a15-b68e-4068-97ee-ebcb1f3ceecd"
      unitRef="usd">807000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i0579a6e71aeb413daee069a798be563a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTMtOS0xLTEtMA_fd004d8c-2a7b-4281-ab83-50adcf086f52"
      unitRef="usd">-8262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9fd425d2b1c34235b752166763d78ceb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTMtMTEtMS0xLTA_d3c39f6a-490c-42af-b6c9-10c9d3cdd365"
      unitRef="usd">-8262000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i48fbda0280274166a0586adfa171945a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTQtMS0xLTEtMA_a2dd8f1d-004a-4b2d-9b73-80511f3e86d8"
      unitRef="shares">27277000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i48fbda0280274166a0586adfa171945a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTQtMy0xLTEtMA_d8f96938-5e52-475f-8f9b-b1edaf637923"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice4c5cb905674403beb71f5e810ab566_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTQtNS0xLTEtMA_6d056057-c816-4f36-9fdb-e2fcb7d16112"
      unitRef="usd">651680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia6739116295d4dc896e69e608e97c76f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTQtNy0xLTEtMA_b9259831-93fa-4447-8396-7f1c145b2ce1"
      unitRef="usd">1145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6198391c49854758a19ea7355d359c10_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTQtOS0xLTEtMA_ff908a15-37ff-4eec-8c34-5b7703941950"
      unitRef="usd">-252288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50aea59aa1e849aab1bec2360f5663d0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTQtMTEtMS0xLTA_8c87cc5f-7177-4885-aa61-527ff4f5e850"
      unitRef="usd">400564000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibd3a6df5115a4148a71e445678d6304e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTUtMS0xLTEtMA_3c3cec34-cb5b-42fb-939f-e5da13ea0a8a"
      unitRef="shares">10000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i213f296ddf4342eaae36eb522302fe38_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTUtNS0xLTEtMA_38d08dd9-fe6a-4f94-b5d3-8a2920eec364"
      unitRef="usd">71000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic6f5d31ceca84e909c7ff8eba6ad5711_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTUtMTEtMS0xLTA_6151dd03-72b1-4025-ae60-334a520b1fb5"
      unitRef="usd">71000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i213f296ddf4342eaae36eb522302fe38_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTYtNS0xLTEtMA_b7c2cee8-501f-4733-9c17-51ffe8a19bbf"
      unitRef="usd">2741000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ic6f5d31ceca84e909c7ff8eba6ad5711_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTYtMTEtMS0xLTA_8f510b01-013e-40e1-afba-8c56bd84981d"
      unitRef="usd">2741000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if07ac049e6384b9eb3f756bd60ed16e0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTctNy0xLTEtMA_8e3d7f4e-3bfd-4d89-8b5b-8b3333ab6018"
      unitRef="usd">-392000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic6f5d31ceca84e909c7ff8eba6ad5711_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTctMTEtMS0xLTA_e1d39667-9bf0-4ceb-8103-cb63e51ed747"
      unitRef="usd">-392000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i83c45560d4d04c4d8d460117720b4d0c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTgtOS0xLTEtMA_f7f65693-719f-4fbc-b7d7-e085e6f2d202"
      unitRef="usd">-21548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic6f5d31ceca84e909c7ff8eba6ad5711_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTgtMTEtMS0xLTA_e2aea349-ecdc-4cd7-b970-54bcb210da46"
      unitRef="usd">-21548000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ic96af881aa1f4e0f9cbfba136350d1fe_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTktMS0xLTEtMA_5aed5413-0276-4e1a-b353-15847ab81d41"
      unitRef="shares">27287000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic96af881aa1f4e0f9cbfba136350d1fe_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTktMy0xLTEtMA_dcbc5b20-6d3d-4a4d-bf61-d9f96971d3b2"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a03dc9bd9c345e9b3e5f735f284462f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTktNS0xLTEtMA_9806f336-3e74-4ce4-ab92-cd15d2eeb8ae"
      unitRef="usd">654492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e7a37ef3fbc48b8bfbd71ac11d46dfd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTktNy0xLTEtMA_8b227be4-2b5e-4f63-a174-ed55f8bacfb8"
      unitRef="usd">753000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i02ddd9390325464f87909298798898e6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTktOS0xLTEtMA_e5b18d60-1825-4391-b60b-9350fe626414"
      unitRef="usd">-273836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f3eeec59a504f6aae08e693714a107f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMTktMTEtMS0xLTA_047e4d05-119c-4258-a3b4-45176af51490"
      unitRef="usd">381436000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8fae86a718c54cb28203f4589f4ae14d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjAtMS0xLTEtMA_00a01707-23bb-437f-a167-3616fde182ef"
      unitRef="shares">59000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic8405fd2c9af42b3ad40e73761f1b8b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjAtNS0xLTEtMA_128788ae-4a4a-4615-93a8-e7fc4014469a"
      unitRef="usd">263000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjAtMTEtMS0xLTA_ac806c05-2498-4691-bbf7-04328c8c673b"
      unitRef="usd">263000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ic8405fd2c9af42b3ad40e73761f1b8b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjItNS0xLTEtMA_063fdbf2-fcc4-4c6c-893c-f4ac53dd02fb"
      unitRef="usd">2805000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjItMTEtMS0xLTA_7fb37c99-a041-4af1-a50f-a9026cf3dcba"
      unitRef="usd">2805000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i944b329323c7414f9375a984348bacdd_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjMtNy0xLTEtMA_8d88f084-54b7-40f3-abb7-682da59d971d"
      unitRef="usd">-494000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjMtMTEtMS0xLTA_2b4c350b-3a5b-4f0b-be39-7a0572262b03"
      unitRef="usd">-494000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="icd685fdf5e6746878ea46ac3dc5f5dcb_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjQtOS0xLTEtMA_257d3d33-f731-4470-8a4a-553d960c4e97"
      unitRef="usd">-23767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjQtMTEtMS0xLTA_32692b2b-1f41-4753-b212-62ef29d6745f"
      unitRef="usd">-23767000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ia0683082d1ab40eab4b01d7c817b5d80_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjUtMS0xLTEtMA_72bbc4bf-970a-4a35-b650-70eae9bf3410"
      unitRef="shares">27346000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia0683082d1ab40eab4b01d7c817b5d80_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjUtMy0xLTEtMA_294198b4-7607-472e-af68-c5033bc5244c"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6951884f2f9647878228f79ce16d0b71_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjUtNS0xLTEtMA_a75a9279-d50f-48e8-864f-cab49f40b62b"
      unitRef="usd">657560000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id80350b4ab804fab943fd2b3e0d00fe9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjUtNy0xLTEtMA_55307169-b0e0-4621-99d7-64ecc84ca252"
      unitRef="usd">259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if5d377b1ba9344a280a30d332ae1b931_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjUtOS0xLTEtMA_615f96be-9500-4456-9a98-becd81442acd"
      unitRef="usd">-297603000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yMi9mcmFnOmZkMGUxYTMwYzBlNzQ5OTY4OGQ1MmQ5ZWNmN2ZlZWIwL3RhYmxlOmY3N2Y5ZjBjMGUyMzQ2OGM5MDdjNGNhODA3Yzg0NzdjL3RhYmxlcmFuZ2U6Zjc3ZjlmMGMwZTIzNDY4YzkwN2M0Y2E4MDdjODQ3N2NfMjUtMTEtMS0xLTA_6e850872-1de6-44f8-b2b6-20623cdcedef"
      unitRef="usd">360243000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i667c1dbae6f546fab85e5fabd504fab3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMi0xLTEtMS0w_4e877201-025f-4a71-aad0-baedf9798ddd"
      unitRef="shares">26922000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i667c1dbae6f546fab85e5fabd504fab3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMi0zLTEtMS0w_5799e066-4733-4c4e-a1e4-07779964db6b"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1b6fe4a6e5de4b5a82cabfeab9b65f59_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMi01LTEtMS0w_aac8d545-71a3-41f9-abb5-68c28f955a1b"
      unitRef="usd">633251000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i97a98cd885414727b67a6826b7552a42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMi03LTEtMS0w_5181c2c7-ddaa-4637-8369-7149eac3a0ba"
      unitRef="usd">-223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i32de20025be940029a9af8399272f6f1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMi05LTEtMS0w_0d749f01-f85d-4800-84ef-0af8794df457"
      unitRef="usd">-146690000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia19642c61e8545afa9130417d92767d4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMi0xMS0xLTEtMA_dc564ddd-52e3-4740-b352-4bac576cef56"
      unitRef="usd">486365000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4af12f6819b34f6a83947ba47498eefa_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfNi0xLTEtMS0w_4a112ccb-6eb2-4561-8af6-7ed53d8bd16a"
      unitRef="shares">84000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8a7d6bca25d24e2bb26123e8dcde48a9_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfNi01LTEtMS0w_cc5fbb19-1a96-4c75-b05b-a25af2cc267f"
      unitRef="usd">574000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibe9518b119be40879fc2dbaacdfd8964_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfNi0xMS0xLTEtMA_770b62ea-5724-422f-b4d3-1dad6eb1a835"
      unitRef="usd">574000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i8a7d6bca25d24e2bb26123e8dcde48a9_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTEtNS0xLTEtMA_cda31eb8-d06a-429d-866f-1362bd4d82eb"
      unitRef="usd">2867000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ibe9518b119be40879fc2dbaacdfd8964_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTEtMTEtMS0xLTA_cd4b1e92-7575-4f2e-b2e7-3aa1dbe81fc2"
      unitRef="usd">2867000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i44dec769f5314a2990ce879992bf1d2f_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTItNy0xLTEtMA_519689dd-9d79-408b-b7c6-b28bc7cc1fbc"
      unitRef="usd">427000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibe9518b119be40879fc2dbaacdfd8964_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTItMTEtMS0xLTA_f5bd6b42-9bac-4690-9911-cab174daf592"
      unitRef="usd">427000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i49e522e4b1724704a8bcc7e70955f164_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTMtOS0xLTEtMA_effa776c-b757-4297-8ae9-c7f6a977d93e"
      unitRef="usd">-22078000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibe9518b119be40879fc2dbaacdfd8964_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTMtMTEtMS0xLTA_b0d735ca-763d-4e9c-8c6c-5d77c2f4c21e"
      unitRef="usd">-22078000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i4507f2fa60434fe3a58a43f0bfb5ac25_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTQtMS0xLTEtMA_a359d6f3-df0e-432b-9318-cf0b1a873cb5"
      unitRef="shares">27006000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4507f2fa60434fe3a58a43f0bfb5ac25_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTQtMy0xLTEtMA_fca497d7-d411-4f91-8096-d09881b72119"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7846c140e24c41b1b46a068579c34d6c_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTQtNS0xLTEtMA_3ef0212f-9d03-4439-ab06-2ee239f6aba7"
      unitRef="usd">636692000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5ed8446ec51444f3a853535c615dc1ca_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTQtNy0xLTEtMA_029ece3d-c973-4ca8-94db-e0fc3b2ee307"
      unitRef="usd">204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifbc18062be6e433ea7729c90c6424e74_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTQtOS0xLTEtMA_380c95d0-1031-4f22-99cd-308497c7dcf4"
      unitRef="usd">-168768000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c49610ebefc49989126a06a1c4800fd_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTQtMTEtMS0xLTA_5c055f46-6d4e-4e23-b9c5-647136413bc9"
      unitRef="usd">468155000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie3b1c52d7eea4be9b490a69977fda245_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTUtMS0xLTEtMA_78e6d3cb-a6f0-43e6-aa70-63fab1d6dd4c"
      unitRef="shares">39000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i898f639913e84acdaf09fc3451ae71fe_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTUtNS0xLTEtMA_8791826e-a1c3-484c-9798-eb874174a4c4"
      unitRef="usd">215000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9ddeec5c1a824dd1b0a410b866cbc85f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTUtMTEtMS0xLTA_d210d9e1-056e-4761-ad6b-4231ca4fe569"
      unitRef="usd">215000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i898f639913e84acdaf09fc3451ae71fe_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTctNS0xLTEtMA_cdbf73a8-e05f-4635-b356-15d8faf0bdf8"
      unitRef="usd">3643000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i9ddeec5c1a824dd1b0a410b866cbc85f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTctMTEtMS0xLTA_feca2e45-5cb6-489b-b9f1-9c04039fe507"
      unitRef="usd">3643000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i293e1639f7f448eb898ed9fbe929111d_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTgtNy0xLTEtMA_d252e2ea-07c6-465d-9d5d-63cb1261d2d2"
      unitRef="usd">370000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9ddeec5c1a824dd1b0a410b866cbc85f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTgtMTEtMS0xLTA_a4e764c2-cf56-40cc-bce7-075cf6a7d3f8"
      unitRef="usd">370000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ic831befbaf7b4ef59c2293c1c600c9ea_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTktOS0xLTEtMA_3db74771-f138-4d6f-8fbb-9c59f2c4e392"
      unitRef="usd">-23962000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ddeec5c1a824dd1b0a410b866cbc85f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMTktMTEtMS0xLTA_2d2a2f7f-671e-4685-8f83-0bc2c8d94163"
      unitRef="usd">-23962000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i5c70240883514eddb497067bdc1a0d89_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjAtMS0xLTEtMA_64349a3a-6419-4d36-ba7e-910ef0a71626"
      unitRef="shares">27045000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5c70240883514eddb497067bdc1a0d89_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjAtMy0xLTEtMA_1df3436b-9731-4483-a021-6167a9782064"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i53163832a44a4c72a73d784e3f2ff470_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjAtNS0xLTEtMA_807ddc6e-c3a6-4ff7-82e8-81fcbf2615b8"
      unitRef="usd">640550000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iadb088f6b63b44368f2345abfce054ce_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjAtNy0xLTEtMA_4ecfb885-5e78-4953-a356-1a691ade481a"
      unitRef="usd">574000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i980d58c527c04708ad659969362a43cf_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjAtOS0xLTEtMA_d8739e25-357f-4783-8bdd-5b29711b9ef6"
      unitRef="usd">-192730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5f4eacb369c40a8a2cfe22a790e44f2_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjAtMTEtMS0xLTA_3706475a-5d9f-4621-b1c3-f067c3c89641"
      unitRef="usd">448421000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie6d60309ee7d481fa5ce4476a8abdc34_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjMtMS0xLTEtMA_038bde5e-60b6-4a35-aaf3-edb14ea6a6af"
      unitRef="shares">53000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i66433ff9b85047cc817a25e24c74a772_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjMtNS0xLTEtMA_f5819a6c-682a-4477-8a98-eac28f7f71ac"
      unitRef="usd">454000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjMtMTEtMS0xLTA_29c95ab9-3859-415c-84b7-83f82a2b0660"
      unitRef="usd">454000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i66433ff9b85047cc817a25e24c74a772_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjUtNS0xLTEtMA_8aadaa9c-1399-4912-bb10-c000469dffda"
      unitRef="usd">3144000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjUtMTEtMS0xLTA_aed1c749-fa17-4e0b-9c07-e9ae812969f6"
      unitRef="usd">3144000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i89b565f7f97a4fb29b4ae5d124a4fde7_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjYtNy0xLTEtMA_17894445-a57c-4562-89ff-13f7d42845f0"
      unitRef="usd">-94000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjYtMTEtMS0xLTA_c886f618-f81e-496b-8895-d56a42bfe2ad"
      unitRef="usd">-94000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ib1eb595b079543ce95ba9cb5eadf6d99_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjctOS0xLTEtMA_763889b0-f359-4bb5-af59-880c624426db"
      unitRef="usd">-31033000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjctMTEtMS0xLTA_c87ccda8-104d-4700-8d14-e86058f8cd4b"
      unitRef="usd">-31033000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i607986a10b7947ca9d199fecd6596a2f_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjgtMS0xLTEtMA_84bfc719-b6a4-401e-82ec-2cb055f717bb"
      unitRef="shares">27098000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i607986a10b7947ca9d199fecd6596a2f_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjgtMy0xLTEtMA_fd58414b-2dd6-450a-8daf-5cf7a062902d"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d431333b5e442b4a517d3cbaa431601_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjgtNS0xLTEtMA_d4672fe4-bee8-46b3-91bd-d36328b45279"
      unitRef="usd">644148000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i00dc647c0bac4896a34e44a91c3920f4_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjgtNy0xLTEtMA_4c237d77-d549-4097-999f-4a0d40e29f8c"
      unitRef="usd">480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7ace0421c6554ea0aaf0d90e9aa8c8a3_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjgtOS0xLTEtMA_0d18651a-658f-402b-bfe7-402001f15bf9"
      unitRef="usd">-223763000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f0d75695e6c4e19919e8ee8cced3fdb_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yNS9mcmFnOmU1MDU0ZTA1YzYyZDQyY2Y5MzQ3N2Y2MjIwN2FhNTZhL3RhYmxlOjNmY2UyZTU4MGEyZTQ4OWRiMzliODA4NzgyOGQ3ZjkzL3RhYmxlcmFuZ2U6M2ZjZTJlNTgwYTJlNDg5ZGIzOWI4MDg3ODI4ZDdmOTNfMjgtMTEtMS0xLTA_fd06b2a4-62d0-4353-83fd-bf481094d35e"
      unitRef="usd">420892000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMy0xLTEtMS0w_39be3884-abde-4125-bd40-2a32f7204073"
      unitRef="usd">-53577000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMy0zLTEtMS0w_00ed85e4-4722-4010-887d-e95eb2723df2"
      unitRef="usd">-77073000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfNS0xLTEtMS0w_2981de01-2696-40e2-b6e1-e81218e11fbb"
      unitRef="usd">415000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfNS0zLTEtMS0w_b9629677-e131-48c8-b63d-2b328e6d50fe"
      unitRef="usd">374000</us-gaap:DepreciationDepletionAndAmortization>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfNi0xLTEtMS0w_11f58070-7d83-4e4d-b1b3-8f84b900cf71"
      unitRef="usd">8521000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfNi0zLTEtMS0w_fd9c0b99-e952-4e02-b187-b38f510f57bc"
      unitRef="usd">9654000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfOC0xLTEtMS0w_98f3bc47-bbd0-49e3-8208-2345ad2764e6"
      unitRef="usd">-239000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfOC0zLTEtMS0w_cd7baf8e-45fc-4913-b88e-713507fbd75e"
      unitRef="usd">2449000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfOS0xLTEtMS0w_bd420d36-7772-4df2-8d05-c3b2d83eae37"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfOS0zLTEtMS0w_483c3a8e-6c68-4295-ab54-16d6497d6c59"
      unitRef="usd">-503000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTMtMS0xLTEtMA_17a6516c-c8f4-405e-8756-a427ae813c7f"
      unitRef="usd">2902000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTMtMy0xLTEtMA_d9cab3d6-b974-48e7-87e9-d1d4c42e140d"
      unitRef="usd">-2099000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTQtMS0xLTEtMA_722197d2-82ae-45a2-ae71-8e61359bf90a"
      unitRef="usd">-4431000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTQtMy0xLTEtMA_fa5e00b5-b15d-4231-b433-dc22cee25961"
      unitRef="usd">13180000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTctMS0xLTEtMA_45563b79-f9d7-4223-93a9-38e45a0d5017"
      unitRef="usd">-51735000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTctMy0xLTEtMA_d89c31ca-4905-45a7-ab02-1b5fa2ea96bf"
      unitRef="usd">-53712000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTktMS0xLTEtMA_f3ba78fe-f08b-4f4b-8a6e-d10956a5c83f"
      unitRef="usd">156572000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMTktMy0xLTEtMA_b0b668fd-c73f-4aff-b4aa-4d7a5452b3dd"
      unitRef="usd">175049000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjAtMS0xLTEtMA_2e5685e6-98f3-458a-b142-d40d607bb581"
      unitRef="usd">247707000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjAtMy0xLTEtMA_4c145469-302d-4ccb-bee2-a74ac2c42ede"
      unitRef="usd">303146000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjEtMS0xLTEtMA_dd2ddde6-1cbc-49fb-8689-258279c5538e"
      unitRef="usd">258000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjEtMy0xLTEtMA_6dea892d-970f-41d3-9eb6-31b858469d15"
      unitRef="usd">701000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjItMS0xLTEtMA_81fc8ba6-dead-4e1e-9fc7-23523376a136"
      unitRef="usd">90877000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjItMy0xLTEtMA_927891cc-896a-4e5c-b171-b87336355161"
      unitRef="usd">127396000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjQtMS0xLTEtMA_8ca673e4-639e-413d-9594-44f1547f40cd"
      unitRef="usd">370000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjQtMy0xLTEtMA_f3608790-bc29-4d11-ad73-79a6a13763c8"
      unitRef="usd">1243000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjctMS0xLTEtMA_e349f062-81d9-45b7-829b-a58c21cb24f3"
      unitRef="usd">1375000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMjctMy0xLTEtMA_71c00ddb-a8b1-4353-8c82-27679f343d54"
      unitRef="usd">5625000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzAtMS0xLTEtMA_40c7dac5-f751-4b19-8e46-deb61331cbd1"
      unitRef="usd">-1005000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzAtMy0xLTEtMA_e432f3f1-ec76-4fc8-a653-69c3a3caa08c"
      unitRef="usd">-4382000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzEtMS0xLTEtMA_10832ff9-ad81-4012-a39c-60eedf7b7b26"
      unitRef="usd">38137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzEtMy0xLTEtMA_e1102fef-aee8-4784-9284-5b23bea4a069"
      unitRef="usd">69302000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzItMS0xLTEtMA_10b7df74-7b6e-4cc3-bac5-83bb82c36501"
      unitRef="usd">171077000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia19642c61e8545afa9130417d92767d4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzItMy0xLTEtMA_43e77bfa-9e5d-4a6a-abd0-cfbaa8d20be1"
      unitRef="usd">113656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzMtMS0xLTEtMA_b76a407b-7a3d-48e5-ba23-6cb8b2b6005c"
      unitRef="usd">209214000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2f0d75695e6c4e19919e8ee8cced3fdb_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzMtMy0xLTEtMA_3770ad90-23af-43b0-a696-76721f33eaca"
      unitRef="usd">182958000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzUtMS0xLTEtMA_bb15b256-ad81-42d8-ae43-fdd42984a879"
      unitRef="usd">4000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzUtMy0xLTEtMA_716b1700-86c2-4a62-acbb-e900d8bf0072"
      unitRef="usd">384000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzgtMS0xLTEtMA_9f71ad0a-4537-404d-aeb6-c6d95bd7f106"
      unitRef="usd">165000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8yOC9mcmFnOjVkMjYxZDMyYTg1MDRlODQ5ZTNkNTY1M2IyZDZmZGI4L3RhYmxlOjNjNzQ0NTJmNzdkOTRhMjI4MDJjMzZkMzlhZTlkOTQwL3RhYmxlcmFuZ2U6M2M3NDQ1MmY3N2Q5NGEyMjgwMmMzNmQzOWFlOWQ5NDBfMzgtMy0xLTEtMA_6a814944-5d23-406f-a541-217e04379d5c"
      unitRef="usd">82000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNC9mcmFnOjlhZjI1OTIwNDUwMDQyMzc5MGQ2MmM2Y2Q3ODM2ZTY3L3RleHRyZWdpb246OWFmMjU5MjA0NTAwNDIzNzkwZDYyYzZjZDc4MzZlNjdfMTk1Ng_300e2880-6fe0-49e5-b353-596f177f39e1">Description of the Business &lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AnaptysBio, Inc. (&#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; or the &#x201c;Company&#x201d;) was incorporated in the state of Delaware in November 2005. We are a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vitro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We currently generate revenue from milestones achieved under our collaborative research and development arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Since our inception, we have devoted our primary effort to research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Our management believes our currently available resources will provide sufficient funds to enable us to meet our operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfODk0MQ_95976865-ff2e-4501-8c4e-fbedefd60ab5">Summary of Significant Accounting Policies &lt;div style="margin-top:6pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2019 financial information to conform to the current year presentation of prepaid expenses and other assets on the Consolidated Statements of Cash Flows. Operating results for the nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus (&#x201c;COVID-19&#x201d;) pandemic, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions, including the issuance of stay-at-home orders and social distancing guidelines, which have resulted in some businesses suspending operations or experiencing a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business, and delay our development programs and regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;the COVID-19 pandemic on the costs and timing associated with the conduct of our clinical trials and other related business activities. The financial statements should be read in conjunction with our audited financial statements for the year ended December&#160;31, 2019 included in our Annual Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in one reportable segment, and our functional and reporting currency is the U.S. dollar.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the weighted-average o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;utstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued ASU 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intended to simplify the accounting for income taxes. The guidance removes the following exceptions: (1) exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, (2) exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, (3) exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary, and (4) exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. Additionally, the guidance simplifies the accounting for income taxes by: (1) requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, (2) requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, (3) specifying that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements (although the entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority), (4) requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, and (5) making minor improvements for income tax accounting related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method. The guidance will be effective for fiscal years and interim periods beginning after December 15, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption, and early adoption is permitted.&#160;We early adopted this standard on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses:&#160;Measurement of Credit Losses on Financial Instruments&#160;(Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#160;which changes the accounting treatment for recognizing the impairment of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also eliminates the other-than-temporary impairment model for available-for-sale (&#x201c;AFS&#x201d;) debt securities. Entities will begin to recognize credit losses on AFS debt securities as allowances rather than as reductions in the carrying value of the securities. Impairment that is not credit-related impairment will continue to be recognized in other comprehensive income and entities will no longer consider the length of time a security has been in an unrealized loss position when determining whether a credit loss exists. ASU 2016-13 becomes effective for annual and interim periods beginning after December 15, 2019.&#160;We adopted this standard prospectively on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements as credit losses are not expected to be significant based on historical trends, the financial condition of our investments and external market factors. We will continue to actively monitor the impact of the COVID-19 pandemic on expected credit losses.&lt;/span&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfODkwOA_38afbe67-990a-42a9-9d19-cbcba2e71954">Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2019 financial information to conform to the current year presentation of prepaid expenses and other assets on the Consolidated Statements of Cash Flows. Operating results for the nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus (&#x201c;COVID-19&#x201d;) pandemic, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions, including the issuance of stay-at-home orders and social distancing guidelines, which have resulted in some businesses suspending operations or experiencing a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business, and delay our development programs and regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;the COVID-19 pandemic on the costs and timing associated with the conduct of our clinical trials and other related business activities. The financial statements should be read in conjunction with our audited financial statements for the year ended December&#160;31, 2019 included in our Annual Form 10-K.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfODkzNA_2c31a46f-2db1-448b-8c6f-20ef20c46417">Basis of ConsolidationThe accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in one reportable segment, and our functional and reporting currency is the U.S. dollar.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfMjY5NQ_82a10bf2-cb30-44fd-894d-d19e2afa6eee"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:UseOfEstimates
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfODkwOQ_8e43f77f-e50a-48af-878c-6e6f714f942c">&lt;div style="margin-top:18pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfODkzNg_0a1c1c7e-2b4a-4964-8c1d-0df246f1e03a">&lt;div style="margin-top:18pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfODkzMg_f58a0af4-8151-4508-86b5-4dd11aa2a1fa">&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the weighted-average o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;utstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if39316fb1c754dec9de54a11b19471c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RhYmxlOmE2ODlmYjEzYTY1YTQ5ZjdhMTVkZTY2YWFjZDYwNTFlL3RhYmxlcmFuZ2U6YTY4OWZiMTNhNjVhNDlmN2ExNWRlNjZhYWNkNjA1MWVfMy0xLTEtMS0w_568c379f-afed-4360-acf4-108fd5ca7de7"
      unitRef="shares">2838000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7cc476288eb442b5bf98c3be003a8dc9_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RhYmxlOmE2ODlmYjEzYTY1YTQ5ZjdhMTVkZTY2YWFjZDYwNTFlL3RhYmxlcmFuZ2U6YTY4OWZiMTNhNjVhNDlmN2ExNWRlNjZhYWNkNjA1MWVfMy0zLTEtMS0w_3ed36cdd-70af-4aba-b868-849a5bf15e69"
      unitRef="shares">2467000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i22c2fc8f301f4097805ab635ea1c679b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RhYmxlOmE2ODlmYjEzYTY1YTQ5ZjdhMTVkZTY2YWFjZDYwNTFlL3RhYmxlcmFuZ2U6YTY4OWZiMTNhNjVhNDlmN2ExNWRlNjZhYWNkNjA1MWVfMy01LTEtMS0w_2baf099e-589f-49b4-9158-08a4cfa4dd1f"
      unitRef="shares">2899000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9edb7d98f97f42518645609a12b3a888_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RhYmxlOmE2ODlmYjEzYTY1YTQ5ZjdhMTVkZTY2YWFjZDYwNTFlL3RhYmxlcmFuZ2U6YTY4OWZiMTNhNjVhNDlmN2ExNWRlNjZhYWNkNjA1MWVfMy03LTEtMS0w_e9cfcf0d-4de1-4505-a1e4-5a8cfb8a7f58"
      unitRef="shares">2451000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF8zNy9mcmFnOmZjMDE3MDkzMjcxOTQxODBiZWM4Y2IxNmM4NDIzY2MxL3RleHRyZWdpb246ZmMwMTcwOTMyNzE5NDE4MGJlYzhjYjE2Yzg0MjNjYzFfODkzOA_18b30c93-aed7-452a-a911-78f8c9e7ea78">&lt;div style="margin-top:18pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued ASU 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intended to simplify the accounting for income taxes. The guidance removes the following exceptions: (1) exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, (2) exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, (3) exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary, and (4) exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. Additionally, the guidance simplifies the accounting for income taxes by: (1) requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, (2) requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, (3) specifying that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements (although the entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority), (4) requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, and (5) making minor improvements for income tax accounting related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method. The guidance will be effective for fiscal years and interim periods beginning after December 15, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption, and early adoption is permitted.&#160;We early adopted this standard on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses:&#160;Measurement of Credit Losses on Financial Instruments&#160;(Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#160;which changes the accounting treatment for recognizing the impairment of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also eliminates the other-than-temporary impairment model for available-for-sale (&#x201c;AFS&#x201d;) debt securities. Entities will begin to recognize credit losses on AFS debt securities as allowances rather than as reductions in the carrying value of the securities. Impairment that is not credit-related impairment will continue to be recognized in other comprehensive income and entities will no longer consider the length of time a security has been in an unrealized loss position when determining whether a credit loss exists. ASU 2016-13 becomes effective for annual and interim periods beginning after December 15, 2019.&#160;We adopted this standard prospectively on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements as credit losses are not expected to be significant based on historical trends, the financial condition of our investments and external market factors. We will continue to actively monitor the impact of the COVID-19 pandemic on expected credit losses.&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RleHRyZWdpb246MmE4MzI0YTc2ZTE4NGJlMmIzMzY4OThkNjliNjY3OGNfMjA5_9cc2539b-a107-4aab-aef2-e2417800ed19">Balance Sheet Accounts and Supplemental Disclosures &lt;div style="margin-top:6pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research, development and manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RleHRyZWdpb246MmE4MzI0YTc2ZTE4NGJlMmIzMzY4OThkNjliNjY3OGNfMjEz_c7499f0c-aaa2-4c25-bf03-d6d105563187">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i97829a1a0f0c4c658a231073c0b1761b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfMS0xLTEtMS0w_c7df2db6-82c9-497d-9688-809288355cdb"
      unitRef="usd">5218000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i97a95fbb42de4ae682693fc8fc7a2360_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfMS0zLTEtMS0w_bfffa661-f93a-45d6-8a06-5ce2a1a285a3"
      unitRef="usd">4911000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i176c0f8d5a494175860df633af0380ce_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfMi0xLTEtMS0w_dfb332eb-bbc2-4048-963b-b3b76ce26b92"
      unitRef="usd">827000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia42c1948b5934a47909d55f51e1c2324_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfMi0zLTEtMS0w_c44b2df1-96cd-4116-b32f-d59bece6b936"
      unitRef="usd">811000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9935f4f8c0d2424dad75609e066c7b8a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfMy0xLTEtMS0w_46e8503d-4f14-46e4-89ff-6c16194e713c"
      unitRef="usd">617000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i22374db23a0f4f9599b0ba0e269a3ee7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfMy0zLTEtMS0w_42ed66cd-7b5a-4099-947f-a0eb29a71638"
      unitRef="usd">575000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfNC0xLTEtMS0w_e609b099-8279-418e-871b-9ce73d1df25a"
      unitRef="usd">6662000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfNC0zLTEtMS0w_9bc3d0ac-afd9-4a7a-9f3e-f6112724c887"
      unitRef="usd">6297000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfNS0xLTEtMS0w_5cabd3f8-f0c2-478f-a170-b97595a9989a"
      unitRef="usd">5077000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfNS0zLTEtMS0w_697733ab-d75b-4bf9-964e-b976b040b5d9"
      unitRef="usd">4679000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfNi0xLTEtMS0w_4356c98f-0026-4dd5-9ff3-2e78d5d5758e"
      unitRef="usd">1585000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmU0ZDVkZmNiNGZlNjRiMmRhM2JlODY0ZmRhNDM0YTY0L3RhYmxlcmFuZ2U6ZTRkNWRmY2I0ZmU2NGIyZGEzYmU4NjRmZGE0MzRhNjRfNi0zLTEtMS0w_122b81dd-bd74-4e23-aa88-f4f8735811d7"
      unitRef="usd">1618000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RleHRyZWdpb246MmE4MzI0YTc2ZTE4NGJlMmIzMzY4OThkNjliNjY3OGNfMjA2_8c240622-6418-4663-81de-095c4707b9ed">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research, development and manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfMS0xLTEtMS0w_9e2c7fe1-5cf4-4585-87b8-32bec1cd33fc"
      unitRef="usd">2782000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfMS0zLTEtMS0w_cb48a194-077d-415f-9878-143af50bf00e"
      unitRef="usd">2152000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfMi0xLTEtMS0w_e528083a-8584-47c6-b96b-35d1f241e765"
      unitRef="usd">1039000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfMi0zLTEtMS0w_151975eb-d7af-4da1-bbbc-f75881d38291"
      unitRef="usd">435000</us-gaap:AccruedProfessionalFeesCurrent>
    <anab:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfMy0xLTEtMS0w_9823f938-18a3-45b6-9d21-4399bf006abd"
      unitRef="usd">14094000</anab:AccruedResearchAndDevelopmentExpensesCurrent>
    <anab:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfMy0zLTEtMS0w_7e3b70e9-a771-4bad-84c5-3132466a50bc"
      unitRef="usd">8196000</anab:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfNC0xLTEtMS0w_7fb753fe-b56e-431a-9fab-47cd6b2aaab0"
      unitRef="usd">224000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfNC0zLTEtMS0w_72cfe886-efe6-4465-8696-bd2e1fa9af97"
      unitRef="usd">269000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfNS0xLTEtMS0w_15a422bb-351f-448f-ace3-98d9be5b4146"
      unitRef="usd">18139000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80MC9mcmFnOjJhODMyNGE3NmUxODRiZTJiMzM2ODk4ZDY5YjY2NzhjL3RhYmxlOmMzYTVkN2YyZjUwNDQ3M2M4ZDJkZjVjYzBhYzJmY2I5L3RhYmxlcmFuZ2U6YzNhNWQ3ZjJmNTA0NDczYzhkMmRmNWNjMGFjMmZjYjlfNS0zLTEtMS0w_c6041de6-419c-416e-ba93-a21dfd33628c"
      unitRef="usd">11052000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfODg5NA_20ea876e-d825-4edf-91ae-ae7ae13c3140">Collaborative Research and Development Agreements&lt;div style="margin-top:6pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GlaxoSmithKline Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2014, we entered into a Collaboration and Exclusive License Agreement (the &#x201c;GSK Agreement&#x201d;) with TESARO, Inc., an oncology-focused biopharmaceutical company now a part of GlaxoSmithKline (&#x201c;GSK&#x201d;). Under the terms of the GSK Agreement, we agreed to perform certain discovery and early preclinical development of therapeutic antibodies with the goal of generating immunotherapy antibodies for subsequent preclinical, clinical, regulatory, and commercial development to be performed by GSK. Under the terms of the GSK Agreement, GSK paid an upfront license fee of $17.0 million in March 2014 and agreed to provide funding to us for research and development services related to antibody discovery programs for three specific targets. In November 2014, we and TESARO, Inc. entered into Amendment No.&#160;1 to the GSK Agreement to add an antibody discovery program against an undisclosed fourth target for an upfront license fee of $2.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each development program, we are eligible to receive milestone payments of up to $18.0 million if certain preclinical and clinical trial events are achieved by GSK, up to an additional $90.0 million if certain U.S. and European regulatory submissions and approvals in multiple indications are achieved, and up to an additional $165.0 million upon the achievement of specified levels of annual worldwide net sales. We will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products developed under the collaboration. Unless earlier terminated by either party upon specified circumstances, the GSK Agreement will terminate, with respect to each specific developed product, upon the later of the 12th anniversary of the first commercial sale of the product or the expiration of the last to expire of any patent. Prior to the adoption of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we determined that the upfront license fees and research funding under the GSK Agreement, as amended, should be accounted for as a single unit of accounting and that the upfront license fees should be deferred and recognized as revenue over the same period that the research and development services are performed. In December 2015, we determined that the research and development services would be extended through December 31, 2016. As a result, the period over which the unrecognized license fees and discovery milestones were recognized was extended through December 31, 2016 and have since been recognized in full. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, GSK, is a customer.&#160;We identified the following material promises under the GSK Agreement: (1) the licenses under certain patent rights relating to six discovery programs (four targets) and transfer of certain development and regulatory information, (2) research and development (&#x201c;R&amp;amp;D&#x201d;) services, and (3) joint steering committee meetings. We considered the research and discovery capabilities of GSK for these specific programs, GSK&#x2019;s inability to sub-license, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the joint steering committee participation would not have been provided without the R&amp;amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated and therefore concluded that the promises should be combined into a single performance obligation at the inception of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the transaction price for the GSK Agreement includes the upfront payment, research reimbursement revenue, and milestones earned to date, which are allocated in their entirety to the single performance obligation. We earned and recognized two clinical milestones for $15.0 million during the nine months ended September&#160;30, 2020. No other future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials, an outcome that is difficult to predict, and GSK&#x2019;s efforts. Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the intellectual property license granted to GSK and therefore have also been excluded from the transaction price. We will re-evaluate the variable transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestones recognized through September&#160;30, 2020 under the GSK Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:18pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-PD-1 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(GSK4057190A/Dostarlimab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-TIM-3 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(GSK4069889A/Cobolimab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-LAG-3 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(GSK40974386)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Milestone Event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Initiated &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; toxicology studies using good laboratory practices (GLPs) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q3'16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IND clearance from the FDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$4.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q1'16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$4.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$4.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 2 clinical trial initiation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 3 clinical trial initiation - first indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$5.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q3'18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 3 clinical trial initiation - second indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$5.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Filing of the first NDA - first indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$10.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q1'20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Filing of the first MAA - first indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$5.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q1'20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestones achieved during the discovery period were recognized as revenue pro-rata through December 31, 2016. Milestones achieved during fiscal 2017 were recognized as revenue in the period earned, while milestones after December 31, 2017 are recognized upon determination that a significant reversal of revenue would not be probable. Cash is generally received within 30 days of milestone achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized $0 and $15.0 million in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenue under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GSK Agreement &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the three and nine months ended September 30, 2020, respectively, and $0 and $5.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the three and nine months ended September 30, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Antibody Generation Agreement with Bristol-Myers Squibb &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2011, we entered into a license and collaboration agreement (the &#x201c;BMS Agreement&#x201d;) with Celgene, now a part of Bristol-Myers Squibb (&#x201c;BMS&#x201d;), to develop therapeutic antibodies against multiple targets. We granted BMS the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters pertaining to each target under the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BMS Agreement provided for an upfront payment of $6.0 million from BMS, which we received in 2011 and recognized through 2014, milestone payments of up to $53.0 million per target, low single-digit royalties on net sales of antibodies against each target, and reimbursement of specified research and development costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed this arrangement in accordance with ASC Topic 606 and concluded that the contract counterparty, BMS, is a customer.&#160;We identified the following material promises under the BMS Agreement: (1) the licenses under certain patent rights relating to four targets and transfer of certain development and regulatory information, (2) R&amp;amp;D services, (3) a written report documenting findings, and (4) steering committee meetings. We considered the research and discovery capabilities of BMS, BMS&#x2019;s inability to sub-license the four targets, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the report of findings and steering committee participation would not have been provided without the R&amp;amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated, and therefore concluded that the promises should be combined into a single performance obligation at the inception the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the transaction price of the BMS Agreement includes the upfront payment, success fees, expense reimbursement, and milestones earned to date, which are allocated in their entirety to the single performance obligation.&#160;None of the future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors, including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials and BMS&#x2019;s efforts.&#160;Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the intellectual property license granted to BMS and therefore have also been excluded from the transaction price.&#160;We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestones achieved through September&#160;30, 2020 under the BMS Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-PD-1 &lt;br/&gt;(CC-90006)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Milestone Event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completion of first &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; toxicology studies using GLPs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$0.5M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 1 clinical trial initiation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from future contingent milestone payments will be recognized when it is more likely than not that the revenue will not be reversed in future periods. Cash is generally received within 30 days of milestone achievement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  There was no revenue recognized under this agreement during the three and nine months ended September 30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived
      contextRef="i8b714d1629c94dce9455c46ac8ae3df4_D20140301-20140331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNjQ4_3b9c6112-9be3-40f6-ba7f-29f95232e4d7"
      unitRef="usd">17000000.0</anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived>
    <anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets
      contextRef="i970417eeaafd482f900c18e69347999b_I20140630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNzgy_11247730-01df-47be-b638-37cf0ea2f4c9"
      unitRef="target">3</anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets>
    <anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets
      contextRef="i841068aebaa745a89876b4497d36c406_I20141130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfOTUx_b46a15fc-0254-41e2-8c3b-2c20baa57af7"
      unitRef="target">4</anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets>
    <anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived
      contextRef="ibaed7d0c461e4199ad5b9a83b5ed6c0b_D20141101-20141130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfOTkz_ddc21b94-d5ae-413d-b2e5-0d072414e236"
      unitRef="usd">2000000.0</anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived>
    <anab:RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents
      contextRef="i841068aebaa745a89876b4497d36c406_I20141130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfMTA4Mw_350df7a6-db89-4521-a5e0-0e85df249500"
      unitRef="usd">18000000.0</anab:RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents>
    <anab:RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals
      contextRef="i841068aebaa745a89876b4497d36c406_I20141130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfMTE3Ng_f3add2ec-2428-42b2-a30e-87758497555b"
      unitRef="usd">90000000.0</anab:RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals>
    <anab:RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales
      contextRef="i841068aebaa745a89876b4497d36c406_I20141130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfMTMwNw_d5c256b8-7643-4072-9435-43095ac2a4d9"
      unitRef="usd">165000000.0</anab:RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales>
    <anab:RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent
      contextRef="ibaed7d0c461e4199ad5b9a83b5ed6c0b_D20141101-20141130"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfMTcwMA_a319967d-d196-4909-b523-d97214dc5334">P12Y</anab:RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent>
    <anab:RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod
      contextRef="i043575917e6847649d70407ee576383b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfMzg4Mw_f667099b-1887-40af-812e-75ed60b98180"
      unitRef="milestone">2</anab:RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i8534bab099e842529d7164852e2d941c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfMzkxMA_3c485581-96bb-4e4b-bea8-188a4f6a7c5a"
      unitRef="usd">15000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfODkwMA_23afd6af-6653-46dd-bd8b-eaf155997251">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestones recognized through September&#160;30, 2020 under the GSK Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:18pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-PD-1 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(GSK4057190A/Dostarlimab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-TIM-3 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(GSK4069889A/Cobolimab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-LAG-3 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(GSK40974386)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Milestone Event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Initiated &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; toxicology studies using good laboratory practices (GLPs) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q3'16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IND clearance from the FDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$4.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q1'16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$4.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$4.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 2 clinical trial initiation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 3 clinical trial initiation - first indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$5.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q3'18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 3 clinical trial initiation - second indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$5.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Filing of the first NDA - first indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$10.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q1'20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Filing of the first MAA - first indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$5.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q1'20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestones achieved through September&#160;30, 2020 under the BMS Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-PD-1 &lt;br/&gt;(CC-90006)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Milestone Event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completion of first &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; toxicology studies using GLPs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$0.5M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 1 clinical trial initiation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i6714296e1ede43c4b159fb8e384daff9_D20150401-20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfMi0xLTEtMS0w_f033abe3-3bd1-4a44-bfdc-b95f6a10aaf9"
      unitRef="usd">1000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i7f48ce05ab804c08ac1a45c2c7193b29_D20151001-20151231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfMi00LTEtMS0w_f181d115-36d4-49a1-8279-f5347ec910fa"
      unitRef="usd">1000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i6a7d54c067c845509a3141ccbe591e65_D20160701-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfMi03LTEtMS0w_9025026f-692a-4853-8c68-cbee3bdbef5e"
      unitRef="usd">1000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i7db5636cafbf422dbca6fb1af3c911b8_D20160101-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfMy0xLTEtMS0w_959ed7a1-c9fd-4140-9c2f-2a1f1143a931"
      unitRef="usd">4000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i69196f35ad1e48409df3674b606bdaab_D20160401-20160630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfMy00LTEtMS0w_13029b6e-051b-4234-9309-9ce0ff8c6e85"
      unitRef="usd">4000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i9048b7098214431bb4af6b977f80d956_D20170401-20170630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfMy03LTEtMS0w_a434403e-7e87-4d83-9aa3-f72bdabb7881"
      unitRef="usd">4000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i49356d8d8f764282af58ba1fb686d94e_D20170401-20170630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfNC0xLTEtMS0w_5fe8ea29-1cd2-4834-b171-21165c7113e8"
      unitRef="usd">3000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="ic85d714342d0443a9aae31c32b92429f_D20171001-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfNC00LTEtMS0w_135094b0-3d5c-4903-a001-5e06d4954980"
      unitRef="usd">3000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i817f5602cf4d49c1af5c2aa476a787d4_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfNC03LTEtMS0w_925ed910-ce6c-4d6a-950e-6a0de86ce269"
      unitRef="usd">3000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="ied95da1a4f9848e981906b3694d41c40_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfNS0xLTEtMS0w_870b97c4-f960-4176-a07f-c21c1b1b7494"
      unitRef="usd">5000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="id37ccc32a0c64011b924874643fc2c43_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfNi0xLTEtMS0w_277c4585-ca16-449d-98d0-4506c7b8b888"
      unitRef="usd">5000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i5bccfffe562d49e3a383b78d7e3a473c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfNy0xLTEtMS0w_5e17082c-0cb8-43a3-9029-319c88f25a0d"
      unitRef="usd">10000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i6a4fb59f13064149aefe64f788700e08_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjM5ZTdkZGJhMTBhZTQ3ZThiNDc2Y2IxYTM4YmQ4NWZmL3RhYmxlcmFuZ2U6MzllN2RkYmExMGFlNDdlOGI0NzZjYjFhMzhiZDg1ZmZfOC0xLTEtMS0w_225c6317-497b-43cc-b1cc-c16013288fc0"
      unitRef="usd">5000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8fda9259a0e4e1788f0cae962d442ec_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNTMwMw_57a5d3c3-3968-4f35-92f6-297e168e8592"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i043575917e6847649d70407ee576383b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNTMxMA_b63c845f-5765-4069-a62b-44624d4d64ca"
      unitRef="usd">15000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d6a141d3615439ea73e776ec0ec0704_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNTM4OA_377ef945-7267-436e-a1c7-7932c7849f4d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaebbe17d08a649598b21b99df30d512e_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNTM5NQ_8dab0fb8-1bcb-4e15-9169-3b2ec901ee9a"
      unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived
      contextRef="i0c1ff849295145de8d2e764ae6a508ec_D20110101-20111231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNjA1OQ_08900b23-2c18-4d54-a369-35ac88407346"
      unitRef="usd">6000000.0</anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived>
    <anab:RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone
      contextRef="i12bdb60cf8e2409dbb82b9f0e626eca2_I20111231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfNjE1NQ_a31c698e-8d5b-48f2-b026-3039e294766e"
      unitRef="usd">53000000.0</anab:RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone>
    <anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned
      contextRef="ib6949b8d98a949efb75ebf6f3c2883f8_D20160401-20160630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjViNmI4M2I0OWIzMDRjOTU4MWM2NzhhNzQzMDRmNjU5L3RhYmxlcmFuZ2U6NWI2YjgzYjQ5YjMwNGM5NTgxYzY3OGE3NDMwNGY2NTlfMi0xLTEtMS0w_0417d308-bb48-4202-9cca-2f0d32fbb04f"
      unitRef="usd">500000</anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned>
    <anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned
      contextRef="i2b954c77f99d46ecbdb66e0463daa4c8_D20161001-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RhYmxlOjViNmI4M2I0OWIzMDRjOTU4MWM2NzhhNzQzMDRmNjU5L3RhYmxlcmFuZ2U6NWI2YjgzYjQ5YjMwNGM5NTgxYzY3OGE3NDMwNGY2NTlfMy0xLTEtMS0w_48521acf-995b-416a-9d25-e02e27f88a31"
      unitRef="usd">1000000.0</anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf7d0bcc12c74158bd008c8a54ad1ca3_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfODgxOA_01afc2de-2357-4ec3-897e-25bb04161b03"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3f3c54965f1409ab37615dab7b02091_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfODgxOA_348311f1-adbb-46a6-9bc7-0a89d0a90fe6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibda93a579438443ca855b712364fdb2c_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfODgxOA_5e7f125d-a0db-48df-98b9-02e552d38adf"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id197285cdb5044f2ab240b49e82a1ecc_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80My9mcmFnOjRkZGQ5MzFiZGM1NzQ4YWZhY2M1Y2Y0ODJhNzBlY2UxL3RleHRyZWdpb246NGRkZDkzMWJkYzU3NDhhZmFjYzVjZjQ4MmE3MGVjZTFfODgxOA_60867188-f7fe-49bf-a4fd-5d8dfd3ffea7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfMTY4MQ_8de81d64-4082-45e7-9eab-8ff2ecd76260">Notes Payable &lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;24, 2014, we entered into a Loan and Security Agreement, as amended from time to time (the &#x201c;Loan Agreement&#x201d;), with a bank and a financial institution whereby we may borrow up to $15.0 million in three separate draws of $5.0 million each. The Term A Loans, for an aggregate of $5.0 million, were drawn on December&#160;24, 2014 with a fixed interest rate of 6.97%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2016, the Loan Agreement was amended to combine Term B Loans and Term C Loans for a total of $10.0 million available for draw through December 31, 2016 and delay the beginning of our Term A Loans&#x2019; principal repayments from February&#160;1, 2016 until February&#160;1, 2017. The Term B Loans and Term C Loans became available for draw on July&#160;1, 2016. In December 2016, we further amended the Loan Agreement to (i)&#160;allow for the Term B Loans and Term C Loans to be drawn on December&#160;30, 2016, (ii)&#160;delay principal repayments of all Term Loans until February&#160;1, 2018, and (iii)&#160;amend the interest rate for each Term Loan. The Term B Loans and the Term C Loans were drawn on December&#160;30, 2016, and Term A, B and C Loans are now collectively referred to as the Term Loans. Principal repayments began in February 2018, and the Term Loans were paid in full, without penalty or premium, on January 1, 2020.&lt;/span&gt;&lt;/div&gt;The costs incurred to issue the Term Loans were deferred and were included in the discount to the carrying value of the Term Loans in the accompanying balance sheet. The Term Loans also included a final payment fee of $0.8 million due at the earlier of prepayment or the maturity date of the Term Loans. The deferred costs and the final payment fee were amortized to interest expense over the expected term of the Term A Loans using the effective interest method.</us-gaap:DebtDisclosureTextBlock>
    <anab:DebtInstrumentMaximumBorrowingCapacity
      contextRef="i47a1076cefcd4d0ab8d1b13c5a35388f_I20141224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfMjEw_bfe7c755-aa2c-42ff-96dc-cfaa73fc2fad"
      unitRef="usd">15000000.0</anab:DebtInstrumentMaximumBorrowingCapacity>
    <anab:DebtInstrumentNumberOfLoanInstallments
      contextRef="i2904dd9806a74afdb9680651604f96e4_D20141224-20141224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfMjE2_ecf3b28d-1f60-4634-bb27-ddd160fd36d2"
      unitRef="installment">3</anab:DebtInstrumentNumberOfLoanInstallments>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i77ef9b411b014186ae96e571e310a67c_I20141224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfMjM3_4badb47c-2610-435d-962b-65d5bef88dbd"
      unitRef="usd">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i0cbfbe6b71b1401990273e2858bb408d_D20141224-20141224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfMjg0_719dbe29-0beb-489b-8e6f-93b0f5d36ad1"
      unitRef="usd">5000000.0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4e2957bb03b74da888869ae5ceb98960_I20141224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfMzUw_0790fa34-58b6-4b66-ae86-f4ba376ffae1"
      unitRef="number">0.0697</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4e1900fbc5af4115b87781c0258509e7_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfNDU5_68609463-a327-4f23-99f2-ca43622311ad"
      unitRef="usd">10000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="i83f647fab752487aaffcadf4318bc4aa_I20160131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80Ni9mcmFnOmYyYTQ1NTIyMDAxNDRkZTNiYWY4YTNkYWM1YTgwNzkwL3RleHRyZWdpb246ZjJhNDU1MjIwMDE0NGRlM2JhZjhhM2RhYzVhODA3OTBfMTQ0Ng_3de5bfd4-9b3a-4ad3-86a7-9db1d2e2e9a9"
      unitRef="usd">800000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDk5Mg_54b83546-e54f-4645-9f5f-0ce5f81d4630">Fair Value Measurements and Available for Sale Investments&lt;div style="margin-top:12pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist principally of cash, cash equivalents, restricted cash, short-term and long-term investments, receivables, accounts payable, and notes payable. Certain of our financial assets and liabilities have been recorded at fair value in the consolidated balance sheet in accordance with the accounting standards for fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:11.25pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at End of Period Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Market&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Prices for&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Identical&#160;Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&#160;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;At September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;At December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following methods and assumptions were used to estimate the fair value of our financial instruments for which it is practicable to estimate that value: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Securities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For fair values determined by Level 1 inputs, which utilize quoted prices in active markets for identical assets, the level of judgment required to estimate fair value is relatively low. For fair values determined by Level 2 inputs, which utilize quoted prices in less active markets for similar assets, the level of judgment required to estimate fair value is also considered relatively low. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:13.5pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Other Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our other financial instruments estimated as of September&#160;30, 2020 and December&#160;31, 2019 are presented below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following methods and assumptions were used to estimate the fair value of our notes payable: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes Payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;We use the income approach to value the aforementioned debt instrument. We use a present value calculation to discount principal and interest payments and the final maturity payment on these liabilities using a discounted cash flow model based on observable inputs. We discount these debt instruments based on what the current market rates would offer us as of the reporting date. Based on the assumptions used to value these liabilities at fair value, these debt instruments are categorized as Level 2 in the fair value hierarchy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The carrying amounts of certain of our financial instruments, including cash and cash equivalents, accounts payable, and accrued expenses approximate fair value due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We invest our excess cash in agency securities, debt instruments of financial institutions and corporations, commercial obligations, and U.S. Treasury securities, which we classify as available-for-sale investments. These investments are carried at fair value and are included in the tables above. The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of September&#160;30, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of our outstanding agency securities, $0.8 million have maturity dates of less than one year and $15.0 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDMyMA_168e5752-1e53-49ab-989a-a68d50119366"&gt;one&lt;/span&gt; to two years as of September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of our outstanding certificates of deposit, $3.0 million have maturity dates of less than one year and $0.7 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMzEzNQ_106d4e12-4b32-4f29-8d26-2b1735c0fda4"&gt;one&lt;/span&gt; to two years as of September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our outstanding commercial and corporate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;obligations have maturity dates of less than one year as of September&#160;30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of our outstanding U.S. Treasury securities, $86.7 million have maturity dates of less than one year and $20.4 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDY4MQ_e5da9ade-9ee6-43e3-9be3-70e98595210b"&gt;one&lt;/span&gt; to two years as of September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;September&#160;30, 2020&#160;and&#160;December&#160;31, 2019, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDk4OQ_f0cf36e8-8b54-47f0-a292-5c0fba9642bb">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at End of Period Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Market&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Prices for&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Identical&#160;Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&#160;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;At September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;At December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;(2)&#160;&#160;&#160;&#160;Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date.</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i486ee79f827548bc8e85e93940ce0440_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMy0xLTEtMS0w_cabad914-02c0-4610-adab-c1426aad207a"
      unitRef="usd">204678000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="ie988dd2210474da0a9388a1930bda1c6_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMy0zLTEtMS0w_fbea5c23-a00d-45fe-9b64-e4232f7cdc65"
      unitRef="usd">204678000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i2e9365f8894d443d987a0236bea2df0c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMy01LTEtMS0w_e21d1e39-5fe2-4cbf-82e0-9d1a0b693ceb"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="id29df9c5b8854830bcd8981e7835fc35_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMy03LTEtMS0w_97deda70-26fb-4699-bc9e-e5e46fdb60c6"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="ia56e6aad2b7c44aab9e288f7e9c76eef_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNC0xLTEtMS0w_a420e38f-fb3f-4a16-8b43-b14a7fd9c5e3"
      unitRef="usd">4833000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i164e1f96760745ea976bbb632c4983c3_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNC0zLTEtMS0w_2d15af87-2811-48a5-ba8d-70b7e9db444e"
      unitRef="usd">4833000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i7af76d44387a46c89ac52e0449f254f5_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNC01LTEtMS0w_e1f31a5e-bf95-4e18-b664-11a990b93b22"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="iadb2d6473570457a8faa9c1e6fb88863_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNC03LTEtMS0w_89e95589-932d-4be3-854c-2e712e4deffa"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63a8061e93f9480896f76c4620112a7c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNS0xLTEtMS0w_d0aa13b0-bbf4-49f7-89e5-645781084b95"
      unitRef="usd">107159000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie2f77996d88c440f99adbdd8f311cd20_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNS0zLTEtMS0w_f11b18a6-5109-491a-a9cb-9f8a867c5cdc"
      unitRef="usd">107159000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3a809753553044369236456513af1721_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNS01LTEtMS0w_b0eeba89-e522-4c58-ad7d-9e8fedc1856d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d91aeb2e9ae4d358e45e8c47c03c98b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNS03LTEtMS0w_63592b03-800a-4ed8-af54-7e5f3acbfeda"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5fc2261a1be6464d85beeb08fdb8bd77_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNi0xLTEtMS0w_1efa436a-2455-46db-a65a-d0e56a668835"
      unitRef="usd">3713000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4295dc2b4c0e4900bbb30c9191198893_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNi0zLTEtMS0w_1f896596-4b4b-4e23-b4c4-a66ce9fe8d02"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee0736e2d03d4071be6f21372a00b616_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNi01LTEtMS0w_0561c00a-7947-449a-90b0-2de3cbb790fc"
      unitRef="usd">3713000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i06badbd8e437492aab95efec2695045d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNi03LTEtMS0w_ab9316c8-97da-49e8-b13c-31530cdec26c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id77ca4847bba4305b096e411a0f88a98_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNy0xLTEtMS0w_807db64b-ed63-4edc-b74c-8aea35703fae"
      unitRef="usd">15805000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4baf9e14edba45e69f2f019ccd63867e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNy0zLTEtMS0w_50ba065d-a95d-4e53-9b1e-905874f2c21f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86cf9503128d472eaa3c206335a0a2fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNy01LTEtMS0w_1bb8136c-e9f5-47f0-a5f6-5705f6268fd1"
      unitRef="usd">15805000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i507cac2c7cca438e8dbb277c0fe458d2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfNy03LTEtMS0w_34c39243-4b0b-4796-8e2d-bb9144e84bb8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib8b77072d590434e92a3cb60e8a64f76_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfOC0xLTEtMS0w_297bfcf2-c008-407d-b845-fcd49fa09816"
      unitRef="usd">38692000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d965662c4e8442d9916e4cfd80ec8a7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfOC0zLTEtMS0w_2b6d534e-df20-4c36-b67e-3031540bc085"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i077e3faf20384ff0800aacc76bea84f4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfOC01LTEtMS0w_7cf9445c-dce3-4353-a0bd-d237b482fff9"
      unitRef="usd">38692000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iba71325b1ced4476b954c2bc33ca1f44_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfOC03LTEtMS0w_d0476ceb-c0e5-42f8-b43e-3b2e041a5fc4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="ieb57811cde1b45cdbd23bd6a14512d23_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTEtMS0xLTEtMA_4b40fd8b-819f-4927-aa24-137b8dfeca2a"
      unitRef="usd">162928000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="ia898b1250c31427581123c12f7daefee_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTEtMy0xLTEtMA_af110c63-11e6-4466-9a45-db8b590c3d0a"
      unitRef="usd">162928000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i8dd5a96a569344b783cdca534f4e6e9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTEtNS0xLTEtMA_95a92d0a-3247-4760-a8aa-88062e4ea8a5"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="ife860bdad5054daeaabbda9d6e52176d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTEtNy0xLTEtMA_e3dbe611-c592-4abe-91a4-7412dfcfaa5f"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i12ee59f67b6f424b910cc0844c794eb7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTItMS0xLTEtMA_caae1c5c-f0c4-4334-80ca-7559d583a694"
      unitRef="usd">7619000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i641d36b1119a4b48adad58e89443d069_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTItMy0xLTEtMA_8884b9f2-038d-4e4c-adeb-ac00205aea67"
      unitRef="usd">7619000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i8d6d9c78810d4e6ca294fa8649b67b58_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTItNS0xLTEtMA_730f4800-3aab-4665-95b8-1cb716dd4166"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i76c44023eb8043aeb3d411c59bc7cf4b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTItNy0xLTEtMA_61845aa8-ba3e-4c8b-8928-183d05a182f3"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3cabcd89e04549418fc44781cea4c283_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTMtMS0xLTEtMA_c7f1961e-0f33-4aaa-b9ad-da8ee43eb10f"
      unitRef="usd">96434000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3f51e0997cba47f6b82e8aa9efa6952b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTMtMy0xLTEtMA_17d27789-cd56-4bf0-b04f-82739c1196d4"
      unitRef="usd">96434000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id3f40c73d02a434eaaf57929475ddfc6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTMtNS0xLTEtMA_b3c79049-8127-47c0-849e-c904e7ec9171"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib3922432c0e84274970a003c02156320_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTMtNy0xLTEtMA_dd0d9865-c488-4ba8-b8a9-0e9f694366b5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b87f9f76e3a4b858f05b03e5189102d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTQtMS0xLTEtMA_4716205f-8556-4ea4-8d2c-b71d64b30072"
      unitRef="usd">5428000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i62c6c85777a546cc8922f55af953a635_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTQtMy0xLTEtMA_eeeba972-fdb4-471a-8af5-ebe57a898cbf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1bf3fb2ff20a4a8f8e90a71d67af78ea_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTQtNS0xLTEtMA_13a7f617-9b24-41fb-8850-2f00eef864e3"
      unitRef="usd">5428000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad0530eb18bc4ab29d6f3710ab1c6e67_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTQtNy0xLTEtMA_c02404d8-4040-4c72-b1ee-91db75ce3d79"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie8795b5aaad54f1a89041597a8c5f56f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTUtMS0xLTEtMA_2c967910-e9ca-400a-a625-644dbc46517c"
      unitRef="usd">33623000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i426b689f24654fc8a7cf7448cec90674_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTUtMy0xLTEtMA_aed85d61-9811-45ed-9b56-e1d82133a8bc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i75efafa8841f48729f56684090276568_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTUtNS0xLTEtMA_ef4dfbdc-f54a-4cf7-b214-67cef0f9157a"
      unitRef="usd">33623000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if3f1b9a2b98b41029f0b45d0b59ff7f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTUtNy0xLTEtMA_8a33191a-ccbe-4a6e-88da-582981c5fa9b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc9672695c6d4ab2811e97fcee8bcfe5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTYtMS0xLTEtMA_f7d58ce2-76c4-4a3f-a071-8bb78cc53df9"
      unitRef="usd">122030000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d92717b6f68494ba0890fed7d159f14_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTYtMy0xLTEtMA_ba5bcad0-fce7-4e8d-862b-76fd1cfe0c94"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c61b5956d7e46c6a38b815d302d5850_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTYtNS0xLTEtMA_7bd461c1-570d-40b4-93e8-18efc2c75396"
      unitRef="usd">122030000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b730ef0ddc64ea19f1632b5ab752783_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmQ0YjI5MmFjM2QxOTQwMWE4YTYxYjkyMjhkOGYzODc2L3RhYmxlcmFuZ2U6ZDRiMjkyYWMzZDE5NDAxYThhNjFiOTIyOGQ4ZjM4NzZfMTYtNy0xLTEtMA_4093fdfa-cf21-41c1-8906-54f2715081c5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDk4NA_3242cd5a-54a9-45df-a035-62f664113639">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our other financial instruments estimated as of September&#160;30, 2020 and December&#160;31, 2019 are presented below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i2ab47a7f50ba4fb2826b5e3dc7761fb5_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjcyZTUxNTcxYTRmYjRkMTc5YWViZTJkYmI3N2ZhMTVjL3RhYmxlcmFuZ2U6NzJlNTE1NzFhNGZiNGQxNzlhZWJlMmRiYjc3ZmExNWNfMi0xLTEtMS0w_0e590b50-be04-4d0c-bdbc-1f8d8b76c303"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i7825d3ea7a9349ca843c88225054e573_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjcyZTUxNTcxYTRmYjRkMTc5YWViZTJkYmI3N2ZhMTVjL3RhYmxlcmFuZ2U6NzJlNTE1NzFhNGZiNGQxNzlhZWJlMmRiYjc3ZmExNWNfMi0zLTEtMS0w_b7ec3c90-73e5-45b9-b4a0-1ec98565daf9"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i8635c548a31441e3992be83f1680e082_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjcyZTUxNTcxYTRmYjRkMTc5YWViZTJkYmI3N2ZhMTVjL3RhYmxlcmFuZ2U6NzJlNTE1NzFhNGZiNGQxNzlhZWJlMmRiYjc3ZmExNWNfMi01LTEtMS0w_0501dabf-30c0-4f1c-a0e1-657c31a30678"
      unitRef="usd">1375000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ia0a28d83f2ea4dbea79c3907f37a6431_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjcyZTUxNTcxYTRmYjRkMTc5YWViZTJkYmI3N2ZhMTVjL3RhYmxlcmFuZ2U6NzJlNTE1NzFhNGZiNGQxNzlhZWJlMmRiYjc3ZmExNWNfMi03LTEtMS0w_6b557946-d090-432b-9b48-f684a163a572"
      unitRef="usd">1365000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDk4NQ_23bc864e-23f6-45ea-9855-2d600d352825">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of September&#160;30, 2020 are as follows:&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of our outstanding agency securities, $0.8 million have maturity dates of less than one year and $15.0 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDMyMA_168e5752-1e53-49ab-989a-a68d50119366"&gt;one&lt;/span&gt; to two years as of September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of our outstanding certificates of deposit, $3.0 million have maturity dates of less than one year and $0.7 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMzEzNQ_106d4e12-4b32-4f29-8d26-2b1735c0fda4"&gt;one&lt;/span&gt; to two years as of September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our outstanding commercial and corporate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;obligations have maturity dates of less than one year as of September&#160;30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of our outstanding U.S. Treasury securities, $86.7 million have maturity dates of less than one year and $20.4 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDY4MQ_e5da9ade-9ee6-43e3-9be3-70e98595210b"&gt;one&lt;/span&gt; to two years as of September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8a898126f7a043ec824730e437299a7b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMS0xLTEtMS0w_adc6ea7d-0771-4a35-bd27-173c13f81cf5"
      unitRef="usd">15790000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8a898126f7a043ec824730e437299a7b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMS0zLTEtMS0w_25f91f2e-3a93-4c82-bbe5-44b8c93760db"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8a898126f7a043ec824730e437299a7b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMS01LTEtMS0w_0541e0e7-2df5-4504-a88b-84c10d5ff63a"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a898126f7a043ec824730e437299a7b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMS03LTEtMS0w_0e952a03-0515-49e9-9498-1f605401691b"
      unitRef="usd">15805000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0ef17d9b49d24d5c984eab8bedf09095_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMy0xLTEtMS0w_6b5cf696-9b29-405e-9858-9bc3e4f3ca72"
      unitRef="usd">3696000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0ef17d9b49d24d5c984eab8bedf09095_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMy0zLTEtMS0w_e0691bfa-4b53-422b-ae8d-0cd556437391"
      unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0ef17d9b49d24d5c984eab8bedf09095_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMy01LTEtMS0w_b3f395bd-b22b-456f-9da4-59fda627d20a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ef17d9b49d24d5c984eab8bedf09095_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfMy03LTEtMS0w_3da9b09a-4d07-4e75-b689-1fd378e08607"
      unitRef="usd">3713000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNC0xLTEtMS0w_e9ce1ed2-79d9-4d7e-a1bd-3fdacad18b98"
      unitRef="usd">38590000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNC0zLTEtMS0w_6e7d1313-16bd-4842-8cb0-87833a35c06c"
      unitRef="usd">105000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNC01LTEtMS0w_834b3a7d-40d9-4725-af13-bae7f92f320b"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNC03LTEtMS0w_3ad9b06e-2c8a-4833-837f-75540267349a"
      unitRef="usd">38692000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNS0xLTEtMS0w_97c8c66a-7385-4e29-86a1-6ee187b2cefa"
      unitRef="usd">106826000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNS0zLTEtMS0w_372902e7-3764-4eea-94d6-9ab145bfe6c7"
      unitRef="usd">343000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNS01LTEtMS0w_30be16c1-bc59-45dc-bfeb-00fc39eb9be2"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNS03LTEtMS0w_08611324-191a-4aa9-92a8-f10c568e8246"
      unitRef="usd">107159000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNi0xLTEtMS0w_6d63432a-cd28-437c-b048-3675d43fcaa1"
      unitRef="usd">164902000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNi0zLTEtMS0w_d35e6fc1-1710-43c2-92bb-e955ca897b52"
      unitRef="usd">481000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNi01LTEtMS0w_b3e05dfc-b627-42f9-a8f4-78334d4b728a"
      unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjBjZGMwMGUzMzIxYzRkZjY5YmIxYTkzMTY1MjAwOWIxL3RhYmxlcmFuZ2U6MGNkYzAwZTMzMjFjNGRmNjliYjFhOTMxNjUyMDA5YjFfNi03LTEtMS0w_eb9c10e9-849e-470c-8d0a-34d38ba357fd"
      unitRef="usd">165369000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8a898126f7a043ec824730e437299a7b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDIzNg_315cffe5-f319-47c1-916b-5facfb1f3af7"
      unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i856a405b5e294005b0da97db3dbe7ce2_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMzExOA_acc28fa8-ffa2-479a-a26d-58e2b3e7a9fd">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8a898126f7a043ec824730e437299a7b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDI4NQ_d28a2fe6-d809-4db4-babb-b473b7836e8f"
      unitRef="usd">15000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i421e55d1b84c466089165cde97803903_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDMyNg_55000c65-10c4-4b54-9b0e-b961141fc494">P2Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0ef17d9b49d24d5c984eab8bedf09095_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMjg0MQ_212b7f1b-4b4f-4bb2-85a2-3598a8eb5284"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i8f35c8d2bb134707949ab2d642ffe73b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMzExOQ_ff6c2946-8b30-4fea-9f34-fd19b3e5b6cf">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0ef17d9b49d24d5c984eab8bedf09095_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMjk0NQ_6919c3f3-aa52-430e-b4b0-fc440e627fb0"
      unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i658c9943823c428392acd64ea6860e66_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMzEzNA_a5a2f661-e239-486c-8725-87a545f19a85">P2Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i3a14f6c2f873440b8540983c27210b42_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDUzNA_1577f748-6b43-4305-a279-1fe7941a1479">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDU5Nw_9f24bc08-284f-4666-b925-4b31faaad7ba"
      unitRef="usd">86700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDY0Ng_bc1a5f5c-98db-4b38-a846-bfa2531a3f8d"
      unitRef="usd">20400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i1625cce2849647f3b4fdd28e3722f489_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDY4Nw_33fdc1d2-b91d-4f29-a122-55cbe78452f7">P2Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDk5Nw_58855008-c898-4377-8f14-c42294c4dffa">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;September&#160;30, 2020&#160;and&#160;December&#160;31, 2019, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i8a898126f7a043ec824730e437299a7b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfMy0xLTEtMS0w_3fbbaba7-b9e8-40f6-b10f-6b1d035f12e0"
      unitRef="usd">9998000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i8a898126f7a043ec824730e437299a7b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfMy0zLTEtMS0w_68f2f5bd-340d-479c-8751-3c3e5e222182"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i8a898126f7a043ec824730e437299a7b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfMy01LTEtMS0w_88a981d9-2733-401b-aac4-759584042d36"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i8a898126f7a043ec824730e437299a7b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfMy03LTEtMS0w_f3763275-f8ab-47ff-b091-84ffa1593bb2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i8a898126f7a043ec824730e437299a7b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfMy05LTEtMS0w_10fc7c0d-5ffa-4477-bcd9-e05d757177bb"
      unitRef="usd">9998000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i8a898126f7a043ec824730e437299a7b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfMy0xMS0xLTEtMA_1f3acf6e-b690-4353-a574-7412b4ad94fc"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNC0xLTEtMS0w_778b57ee-63e8-4dd8-97f4-99d7b6b7f7dd"
      unitRef="usd">4096000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNC0zLTEtMS0w_dc20618c-35be-4096-bae8-4e087a88a332"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNC01LTEtMS0w_9a02579a-8f55-4254-b81f-b3c1a4b51c08"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNC03LTEtMS0w_87eb545a-afd0-487b-9304-0d2184d5c727"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNC05LTEtMS0w_2affefe9-9c12-4372-967d-b6defe404733"
      unitRef="usd">4096000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i0aa15223feec45779fc8eb2c483d51ec_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNC0xMS0xLTEtMA_8b14bf73-868b-41a7-8de3-fe5e7fc2fec9"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS0xLTEtMS0zODA_7f3c381a-8ae5-4f1e-a8c9-d4f41a58153f"
      unitRef="usd">25223000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS0zLTEtMS0zODA_88759fb5-e213-4b46-a645-4c77fa154414"
      unitRef="usd">10000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS01LTEtMS0zODA_0a7aba0e-661e-4939-82cc-fb5400be0e7e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS03LTEtMS0zODA_58a1f557-9f70-4146-b1d7-9716c08e95e3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS05LTEtMS0zODQ_c4cd9be9-5672-43ca-8cae-474e4e3afbfd"
      unitRef="usd">25223000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ib1b346b9aee2453e943c261bcb153fa8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS0xMS0xLTEtMzg0_7468748b-e3a9-4b4f-ad49-cd14286e6174"
      unitRef="usd">10000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS0xLTEtMS0w_5227bef0-0c67-4d5c-ad9b-9144adebf7a6"
      unitRef="usd">39317000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS0zLTEtMS0w_de7b31f2-7474-48c9-b325-476c8d9806ac"
      unitRef="usd">14000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS01LTEtMS0w_0eb73453-df1a-454d-b0ee-ef4d486b6ee2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS03LTEtMS0w_07a11df6-ffce-495a-92a2-1c0609fe3036"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS05LTEtMS0w_dc860b96-8374-4fca-aeae-19494936bcb2"
      unitRef="usd">39317000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOjVlYTc3MDY5NjI0ODRmZDk4ZmRiMDQ2NDg3NjQ5YmQ3L3RhYmxlcmFuZ2U6NWVhNzcwNjk2MjQ4NGZkOThmZGIwNDY0ODc2NDliZDdfNS0xMS0xLTEtMA_4fee012a-ce25-4648-9f9f-13646e185dc1"
      unitRef="usd">14000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i04b8e21f36b048dfb63095af95035987_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfMy0xLTEtMS0w_da8ad655-7bee-43b4-9f86-02ae90b1f3f6"
      unitRef="usd">5986000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i04b8e21f36b048dfb63095af95035987_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfMy0zLTEtMS0w_730ce801-bfc1-437a-8acb-4b72b99bb5d1"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i04b8e21f36b048dfb63095af95035987_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfMy01LTEtMS0w_ede5da92-3ef8-4e8d-8df0-4658ea62c2e6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i04b8e21f36b048dfb63095af95035987_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfMy03LTEtMS0w_34388d1e-acab-49ff-ade2-ca05c8a99313"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i04b8e21f36b048dfb63095af95035987_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfMy05LTEtMS0w_ff5465e1-5d53-42c8-9019-19be6d2b9329"
      unitRef="usd">5986000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i04b8e21f36b048dfb63095af95035987_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfMy0xMS0xLTEtMA_591a5a25-6659-46b5-a484-506ea42698b4"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i8eed3626fb0548498facb46e0bee7d8c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNC0xLTEtMS0w_2fa40368-017e-4cd6-a193-ab7fbc5e46e8"
      unitRef="usd">17608000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i8eed3626fb0548498facb46e0bee7d8c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNC0zLTEtMS0w_a84bf833-32b9-4b93-afca-c118e67766f0"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i8eed3626fb0548498facb46e0bee7d8c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNC01LTEtMS0w_09c113ce-8235-4bc8-a559-9010bfb6edd2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i8eed3626fb0548498facb46e0bee7d8c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNC03LTEtMS0w_0f0389c6-2039-4aed-9c57-2d0fbbd0faf4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i8eed3626fb0548498facb46e0bee7d8c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNC05LTEtMS0w_0640b778-a9ba-4c4f-8c57-0abb88c02217"
      unitRef="usd">17608000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i8eed3626fb0548498facb46e0bee7d8c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNC0xMS0xLTEtMA_eb38e4f7-2b65-495a-a526-32652e725194"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNS0xLTEtMS0w_ded471a0-3c06-47f0-95b7-b2bd286d04da"
      unitRef="usd">23594000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNS0zLTEtMS0w_f6a61b5d-78c9-48a8-ba63-b64ff38749af"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNS01LTEtMS0w_9e1ca62b-0f01-4d62-9317-7a55cf222915"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNS03LTEtMS0w_a7892151-c932-486f-b7aa-d8b77736049a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNS05LTEtMS0w_704332db-5463-49c5-949e-9a2cc6a1bc7c"
      unitRef="usd">23594000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RhYmxlOmMxYzY2YjY4ZDFiYTQxODliN2VkOTY0MDIxZmI2YTBmL3RhYmxlcmFuZ2U6YzFjNjZiNjhkMWJhNDE4OWI3ZWQ5NjQwMjFmYjZhMGZfNS0xMS0xLTEtMA_62c91fdb-df25-42f1-b714-857788038e0d"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RleHRyZWdpb246MmZiMmRlMGQzNzdiNGE2Y2E0NWQwMjllZmUzYTMxYzFfMjg0_dcdffa3f-79f2-4ccc-a8c9-6b952e80dd1a">Stockholders&#x2019; Equity &lt;div style="margin-top:12pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the 500,000,000&#160;shares of common stock authorized, 27,346,228 shares were issued and outstanding as of September&#160;30, 2020. Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at September&#160;30, 2020 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued and Outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,876,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares Reserved For:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,040,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,913,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RleHRyZWdpb246MmZiMmRlMGQzNzdiNGE2Y2E0NWQwMjllZmUzYTMxYzFfNTE_4b0e6a53-4d22-41bc-ae01-a8a9dbe042fe"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RleHRyZWdpb246MmZiMmRlMGQzNzdiNGE2Y2E0NWQwMjllZmUzYTMxYzFfODk_7974b356-0ec7-4ea2-8431-75296e3fd8b0"
      unitRef="shares">27346228</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RleHRyZWdpb246MmZiMmRlMGQzNzdiNGE2Y2E0NWQwMjllZmUzYTMxYzFfODk_8dbc9e6d-51c8-498e-8f36-c13125f9bb71"
      unitRef="shares">27346228</us-gaap:CommonStockSharesOutstanding>
    <anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RleHRyZWdpb246MmZiMmRlMGQzNzdiNGE2Y2E0NWQwMjllZmUzYTMxYzFfMjg3_6bb7d230-bb9b-4fc0-a8ef-9b22612dea85">Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at September&#160;30, 2020 are as follows: &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued and Outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,876,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares Reserved For:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,040,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,913,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RhYmxlOmRjYWJjN2NjMDIyNzQ4NjNhZjVhMzk4NjRkMTI5Njg1L3RhYmxlcmFuZ2U6ZGNhYmM3Y2MwMjI3NDg2M2FmNWEzOTg2NGQxMjk2ODVfMS0xLTEtMS0w_fce7ad29-532f-4381-a683-3c23c7e1909e"
      unitRef="shares">2876063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ie5dc4745f8114a8fbed72cc75adbb0dc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RhYmxlOmRjYWJjN2NjMDIyNzQ4NjNhZjVhMzk4NjRkMTI5Njg1L3RhYmxlcmFuZ2U6ZGNhYmM3Y2MwMjI3NDg2M2FmNWEzOTg2NGQxMjk2ODVfNC0xLTEtMS0w_1b8fe2d9-d0e3-4578-a313-b715e42321ec"
      unitRef="shares">3040085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iede5636a43b44bc6be3c38a82fecb803_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RhYmxlOmRjYWJjN2NjMDIyNzQ4NjNhZjVhMzk4NjRkMTI5Njg1L3RhYmxlcmFuZ2U6ZGNhYmM3Y2MwMjI3NDg2M2FmNWEzOTg2NGQxMjk2ODVfNS0xLTEtMS0w_769331f5-4932-405c-b5b3-13f1181ee683"
      unitRef="shares">997682</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81Mi9mcmFnOjJmYjJkZTBkMzc3YjRhNmNhNDVkMDI5ZWZlM2EzMWMxL3RhYmxlOmRjYWJjN2NjMDIyNzQ4NjNhZjVhMzk4NjRkMTI5Njg1L3RhYmxlcmFuZ2U6ZGNhYmM3Y2MwMjI3NDg2M2FmNWEzOTg2NGQxMjk2ODVfNi0xLTEtMS0w_b24de20e-a586-4248-bb4c-a3bb307a3958"
      unitRef="shares">6913830</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMzYyOA_1c1e874c-39be-4a19-a582-8d0751534190">Equity Incentive Plans &lt;div style="margin-top:12pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;). The 2017 Plan became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017 and replaced our existing 2006 Equity Incentive Plan. Under the 2017 Plan, we may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then our employees, officers, directors or consultants. In addition, the number of shares of stock available for issuance under the 2017 Plan will be automatically increased each January 1, beginning on January 1, 2018, by 4% of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The 2017 Plan automatically increased by 1,090,203 shares as of January 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Employee Stock Purchase Plan or the ESPP. The ESPP became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017. In addition, the number shares of stock available for issuance under the ESPP will be automatically increased each January 1, beginning on January 1, 2018, by 1% of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The ESPP automatically increased by 272,550 shares as of January 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options granted to employees and non-employees generally vest over a four-year period while stock options granted to directors vest over a one year period. Each stock option award has a maximum term of 10 years from the date of grant, subject to earlier cancellation prior to vesting upon cessation of service to us. A summary of the activity related to stock option awards during the nine months ended September 30, 2020 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Subject to&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price per&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&#160;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,039,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures and cancellations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(534,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,876,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the appropriate risk-free interest rate, expected term for employee stock-based awards, contractual term for non-employee stock-based awards, and volatility assumptions. The weighted-average expected option term for employee and non-employee stock-based awards reflects the application of the simplified method, which defines the life as the average of the contractual term of the options and the weighted-average vesting period for all option tranches. Estimated volatility incorporates historical volatility of our stock price as well as similar entities whose share prices are publicly available. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected or contractual term of the stock-based payment awards. The assumed dividend yield is based on our expectation of not paying dividends in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020, there was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$24.8 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of unrecognized compensation cost related to unvested stock option awards, which is expected to be recognized over a remaining weighted-average vesting period o&lt;/span&gt;f 3.03 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding
      contextRef="i1689cf0ddbf847f1a5d41386bf8e581a_D20170126-20170126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfNzcw_18c72e6a-3fa1-43b9-b09d-a3eb9b280a9c"
      unitRef="number">0.04</anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding>
    <anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease
      contextRef="ib98c7394ae0241be92efa15ef59bb44f_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfOTg3_69816007-7d98-4101-adca-f389420481ef"
      unitRef="shares">1090203</anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease>
    <anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding
      contextRef="i86d89ac9401d465a9ffa094c58d86268_D20180101-20180101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMTQ4Mg_178166ce-af25-4496-839c-8a84d951457d"
      unitRef="number">0.01</anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding>
    <anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease
      contextRef="i4bdb7350e5c74ed089644cf190add40a_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMTY5NA_05db9ca5-ebd2-4b25-a7bb-5ef3f4e75249"
      unitRef="shares">272550</anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMzYyMQ_951734cd-c6b3-4cfc-b53f-149d5607a8b1">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifd8286d24eb44b9dada0fe300127f5bc_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMTg4NQ_08f56c22-170d-45ec-a462-c45d6e8879fc">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMTkyNA_bbaa4911-7448-41bd-895a-adc95a49bb89">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ifd8286d24eb44b9dada0fe300127f5bc_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMTkyNA_e4ea9f4b-d198-4b55-9f15-bcd8de7dbdf0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMzYzMA_42498d85-1ce4-4906-b79a-36ef3ed1107b">A summary of the activity related to stock option awards during the nine months ended September 30, 2020 is as follows: &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Subject to&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price per&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&#160;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,039,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures and cancellations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(534,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,876,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfMS0xLTEtMS0w_fb6595aa-2709-4116-9b5f-aec5558a051c"
      unitRef="shares">3039880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfMS0zLTEtMS0w_b5ba860e-3ed0-4466-b732-70421594b7d4"
      unitRef="usdPerShare">29.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfMi0xLTEtMS0w_ec27c9b5-f608-4c37-96ca-8bd49c1a093c"
      unitRef="shares">461425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfMi0zLTEtMS0w_38f56fe0-39ed-4259-b6b6-2c73ff0dfe65"
      unitRef="usdPerShare">18.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfMy0xLTEtMS0w_9021e4e9-6708-44ee-9bf4-56ed81b5b55b"
      unitRef="shares">91146</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfMy0zLTEtMS0w_2ab64a5d-f159-4495-8479-8ff5b7b2cce6"
      unitRef="usdPerShare">4.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNC0xLTEtMS0w_7a4f7e55-760d-4151-b764-b9af75ce0a5d"
      unitRef="shares">534096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNC0zLTEtMS0w_d493b715-41e8-4c5c-8455-6327502c3d32"
      unitRef="usdPerShare">37.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNS0xLTEtMS0w_86c791df-729d-498e-818b-042116a68430"
      unitRef="shares">2876063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNS0zLTEtMS0w_5bbf1fcb-d981-4d31-a805-e3cd83a52165"
      unitRef="usdPerShare">26.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNS01LTEtMS0w_86c914b5-ac3f-416a-af44-8b0a966bfc39">P7Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNS03LTEtMS0w_6d05fc20-0618-4444-bddd-aa8e176c3c4f"
      unitRef="usd">6747000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNi0xLTEtMS0w_e119edb9-4d51-492e-87fd-b8e2dcb84a3f"
      unitRef="shares">1355530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNi0zLTEtMS0w_9215b366-990f-45b8-9f96-2ea12252dd19"
      unitRef="usdPerShare">27.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNi01LTEtMS0w_f9a50d91-58b1-412d-895b-1b41fbf3fc27">P5Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjE3NTI4MzUwMWZlNjQ2MDQ5YzczODZiMzIxYzZlYWMwL3RhYmxlcmFuZ2U6MTc1MjgzNTAxZmU2NDYwNDljNzM4NmIzMjFjNmVhYzBfNi03LTEtMS0w_50633d97-4d8f-4a8f-81e1-0b629d7df68a"
      unitRef="usd">6365000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMzYzMQ_936a0ca0-ba6f-41e2-8b2d-06b907abab48">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfMy0yLTEtMS0w_692f2549-6b74-4a12-901a-07c93f13fc84"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7aa924de6d814250973b8ca6c02725b7_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfMy02LTEtMS0w_4bfb1f6b-35bc-47bd-8e13-fd4bf04e9e74"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNC0yLTEtMS0w_c8ccc886-d792-48a8-8555-cbb6b20294f5"
      unitRef="number">0.905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7aa924de6d814250973b8ca6c02725b7_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNC02LTEtMS0w_a8830779-ab5a-447b-b02d-34e3491eea72"
      unitRef="number">0.684</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNS0yLTEtMS0w_280d5443-4b5f-431f-bda1-0b01254b1b3b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7aa924de6d814250973b8ca6c02725b7_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNS02LTEtMS0w_f6c75d97-9638-4d9d-90f7-aa2519baa676"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNi0yLTEtMS0w_742be8cc-03fa-42f1-bb3c-784c237b447e">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7aa924de6d814250973b8ca6c02725b7_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNi02LTEtMS0w_4abc23bb-aa7f-42a2-8df0-35c3f5638990">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNy0yLTEtMS0w_75ea8fed-e683-45bf-a1b2-c3dbdd9ccaad"
      unitRef="usdPerShare">13.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7aa924de6d814250973b8ca6c02725b7_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOmJmOThiNjg4ZDk4YzRkM2I5ZDBlNGE1NWVjOGE0YmZlL3RhYmxlcmFuZ2U6YmY5OGI2ODhkOThjNGQzYjlkMGU0YTU1ZWM4YTRiZmVfNy02LTEtMS0w_e43f066c-f7af-4545-9d69-342fd73c8872"
      unitRef="usdPerShare">43.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMzYyNw_fae70a34-60d0-4bf9-a4cf-ff1462006b88">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.928%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i5ef232fdc16443ab824f750c8ecbc67b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMi0xLTEtMS0w_92a4e491-9a80-4925-a992-f4427246af4f"
      unitRef="usd">926000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i746c849226304957812801a396d96d98_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMi0zLTEtMS0w_9f6f566b-4edb-4e1c-a3cc-c4f886bc43a6"
      unitRef="usd">1580000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ifa8e6f18cae84e3abeb28a87d7e99b95_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMi01LTEtMS0w_f7eb2a70-5f56-4adc-8abb-75a41c2ba119"
      unitRef="usd">3030000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i619a360a42884bb8b5a3c0d6c4290323_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMi03LTEtMS0w_da1e4a2c-1ece-4d8e-b241-7b2625215ccc"
      unitRef="usd">4469000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i99c89f0f0b0f4523aa6c1cc41b1ca2dd_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMy0xLTEtMS0w_4370d8ae-ae6a-4f8e-9961-89fac0e22951"
      unitRef="usd">1879000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i2389b2e977c94f14aaafb743e9c2bf19_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMy0zLTEtMS0w_8072633a-0580-4c03-8f6c-3f731772e9fb"
      unitRef="usd">1564000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i13db0076e7d145118a79fd40a565430f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMy01LTEtMS0w_a1bac1a8-beea-4990-81c2-f12c6a52ebb9"
      unitRef="usd">5491000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i53442a555d5247dda9d21b2f725430ac_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfMy03LTEtMS0w_b1c659cc-3051-4756-a56b-5046d5aa10fb"
      unitRef="usd">5185000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i197dcc146a064825a722c622e39823b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfNC0xLTEtMS0w_ee09b55c-4aab-4184-bd7e-221485cc5c8a"
      unitRef="usd">2805000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i9bbe17c3b30d41fa83ff1aa18d1600bd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfNC0zLTEtMS0w_6f038b9b-122a-46f4-a102-e7229af01322"
      unitRef="usd">3144000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfNC01LTEtMS0w_646ada31-d1c1-4105-acbe-c9ee26aa2f62"
      unitRef="usd">8521000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RhYmxlOjJlNTZjOGRjMmZlZTRhNDA4N2VmZGU1M2Y4NTI2YWUzL3RhYmxlcmFuZ2U6MmU1NmM4ZGMyZmVlNGE0MDg3ZWZkZTUzZjg1MjZhZTNfNC03LTEtMS0w_12e3300e-4005-4bc1-9914-21e374b72a29"
      unitRef="usd">9654000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMzQ0NA_f502bb49-096f-40f1-a5db-f69bf3d0df92"
      unitRef="usd">24800000</anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions>
    <anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81NS9mcmFnOmUwZWZiN2RhMDhlMTQxMDk4ODRiYjAyMmUwNjVhMGNmL3RleHRyZWdpb246ZTBlZmI3ZGEwOGUxNDEwOTg4NGJiMDIyZTA2NWEwY2ZfMzYwOQ_0d4d445d-45fc-46f5-a6f7-7f3687115ce3">P3Y10D</anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMzU3NQ_33ed31cf-5877-4167-ac5b-9ab153fa03bd">Commitments and Contingencies&lt;div style="margin-top:6pt;text-indent:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have two non-cancellable office leases (the &#x201c;Office Leases&#x201d;), with remaining lease terms of approximately one year, each of which are classified as operating leases. Both leases expire in 2021. Only one of our leases has remaining renewal &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;options, which includes three options to renew for one additional year. The exercise of lease renewal options is at our sole discretion, which we currently do not anticipate exercising and as such were not recognized as part of our right-of-use (&#x201c;ROU&#x201d;)  asset and lease liabilities. Our lease payments are fixed, and we recognize lease expense for these leases on a straight-line basis over the lease term. Operating lease ROU assets and lease liabilities are recorded based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not provide an implicit rate, we used our incremental borrowing rate based on the information available at effective date of adoption in determining the present value of future payments. The weighted-average discount rate used was 8.59%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our balance sheet includes our ROU assets and lease liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following costs are included in our consolidated statements of cash flow (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification on the Cash Flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020, the future minimum annual obligations for the Office Leases in excess of one year are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments required&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 4, 2020, we entered into a lease agreement (the &#x201c;Lease Agreement&#x201d;) with Wateridge Property Owner, LP, with respect to facilities in the building at 10770 Wateridge Circle, San Diego, California 92121. Under the Lease Agreement, we agreed to lease approximately 45,000 square feet of space in the 10770 Wateridge Circle Building for a term of 124 months, beginning on March 1, 2021 (or on such later date as described in the Lease Agreement). The terms of the Lease Agreement provide us with an option to extend the term of the lease for an additional five years, as well as a one-time option to terminate the lease after seven years with the payment of a termination fee. The monthly base rent will be $4.20 per rentable square foot and will be increased by 3% annually. Under the Lease Agreement, we are also responsible for our pro rata share of real estate taxes, building insurance, maintenance, direct expenses, and utilities. As of September&#160;30, 2020, we have recorded $0.2&#160;million in prepaid rent and $0.3&#160;million as a security deposit in accordance with the terms of the Lease Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 25, 2020, a putative securities class action was filed in the United States District Court for the Southern District of California naming the Company and certain of its current or former officers as defendants. The complaint purports to assert claims under Section 10(b) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), Exchange Act  Rule 10b-5, and Section 20(a) of the Exchange Act, on behalf of persons and entities who acquired our common stock between October 10, 2017 and November 7, 2019 (the &#x201c;Class Period&#x201d;). An amended complaint was filed on September 30, 2020 alleging that, during the Class Period, the defendants made material misrepresentations or omissions regarding our etokimab product candidate that artificially inflated our stock price. The plaintiff seeks, among other things, damages in an unspecified amount, as well as costs and expenses. We believe that the plaintiff&#x2019;s allegations are without merit and intend to vigorously defend against the claims. On September 1, 2020, a related shareholder derivative complaint was filed based on allegations substantially similar to those in the class action, and asserting claims against current or former officers and directors for contribution under Sections 10(b) and 21D of the Exchange Act, breach of fiduciary duty, unjust enrichment and corporate waste. Because the Company is in the early stages of this litigation matter, we are unable to estimate a reasonably possible loss or range of loss, if any, that may result from these matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <anab:LesseeOperatingLeaseNumber
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfNjM_4340ee87-442e-410c-8a15-38dbfaeb4151"
      unitRef="lease">2</anab:LesseeOperatingLeaseNumber>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMTYz_4e30cff7-d0ce-4e23-adc5-e8d6089acf6e">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <anab:LesseeOperatingLeaseOneYearRenewalOptionsNumber
      contextRef="i8eacadeab29a42608e859587a94fccfe_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMzE0_61f7f8f5-d1b1-4cb1-90a2-2bd119b453e7"
      unitRef="renewal_option">3</anab:LesseeOperatingLeaseOneYearRenewalOptionsNumber>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMTExMA_c7967267-03d7-444b-b9f1-dff3224e22ed"
      unitRef="number">0.0859</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <anab:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMzU4OA_fb94d89d-7a36-45c7-81ed-b6b93501d98b">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our balance sheet includes our ROU assets and lease liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification on the Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</anab:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjdhM2UyOTc1NjU3MDQyMjk5OTMyN2FiNmI1OTNmNDM0L3RhYmxlcmFuZ2U6N2EzZTI5NzU2NTcwNDIyOTk5MzI3YWI2YjU5M2Y0MzRfMS00LTEtMS0w_c0cb7c54-c4ed-4903-8420-c749fb583992"
      unitRef="usd">824000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjdhM2UyOTc1NjU3MDQyMjk5OTMyN2FiNmI1OTNmNDM0L3RhYmxlcmFuZ2U6N2EzZTI5NzU2NTcwNDIyOTk5MzI3YWI2YjU5M2Y0MzRfMS02LTEtMS0w_79824138-af5a-425e-802b-f1f11216e8ce"
      unitRef="usd">1402000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjdhM2UyOTc1NjU3MDQyMjk5OTMyN2FiNmI1OTNmNDM0L3RhYmxlcmFuZ2U6N2EzZTI5NzU2NTcwNDIyOTk5MzI3YWI2YjU5M2Y0MzRfMi00LTEtMS0w_dd164169-822f-4ade-a339-0c7a9ede660b"
      unitRef="usd">851000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjdhM2UyOTc1NjU3MDQyMjk5OTMyN2FiNmI1OTNmNDM0L3RhYmxlcmFuZ2U6N2EzZTI5NzU2NTcwNDIyOTk5MzI3YWI2YjU5M2Y0MzRfMi02LTEtMS0w_262c4add-bd44-4b62-bf83-db4c8b6ae39b"
      unitRef="usd">871000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjdhM2UyOTc1NjU3MDQyMjk5OTMyN2FiNmI1OTNmNDM0L3RhYmxlcmFuZ2U6N2EzZTI5NzU2NTcwNDIyOTk5MzI3YWI2YjU5M2Y0MzRfMy00LTEtMS0w_dd63708b-9ba1-479c-bb5b-c0590ecd472b"
      unitRef="usd">33000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iaa7414d9fb2645cab8e4048e6169b41d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjdhM2UyOTc1NjU3MDQyMjk5OTMyN2FiNmI1OTNmNDM0L3RhYmxlcmFuZ2U6N2EzZTI5NzU2NTcwNDIyOTk5MzI3YWI2YjU5M2Y0MzRfMy02LTEtMS0w_6f17d770-03ed-4c64-be5c-4aa7fc053c26"
      unitRef="usd">654000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMzU4MA_04624a83-b741-492e-a68d-1a07c5f74556">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following costs are included in our consolidated statements of cash flow (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification on the Cash Flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgzMWY4YTFmZTRmMzRjZTZhMTkyYzEyYjJhYTlmYzFlL3RhYmxlcmFuZ2U6ODMxZjhhMWZlNGYzNGNlNmExOTJjMTJiMmFhOWZjMWVfMi00LTEtMS0w_b33ecb17-abd6-42f9-8b38-08b09c3a768d"
      unitRef="usd">660000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgzMWY4YTFmZTRmMzRjZTZhMTkyYzEyYjJhYTlmYzFlL3RhYmxlcmFuZ2U6ODMxZjhhMWZlNGYzNGNlNmExOTJjMTJiMmFhOWZjMWVfMi02LTEtMS0w_a85055b9-866a-4223-af50-ac6506db8263"
      unitRef="usd">660000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgzMWY4YTFmZTRmMzRjZTZhMTkyYzEyYjJhYTlmYzFlL3RhYmxlcmFuZ2U6ODMxZjhhMWZlNGYzNGNlNmExOTJjMTJiMmFhOWZjMWVfMy00LTEtMS0w_5490f72c-b5a7-40fd-8535-59f8880ec4d2"
      unitRef="usd">722000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i42197658cdbc42ad8b8560121bb61c24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgzMWY4YTFmZTRmMzRjZTZhMTkyYzEyYjJhYTlmYzFlL3RhYmxlcmFuZ2U6ODMxZjhhMWZlNGYzNGNlNmExOTJjMTJiMmFhOWZjMWVfMy02LTEtMS0w_9e4700b2-3bd6-4bd5-99a6-a38ea18e2ea8"
      unitRef="usd">698000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMzU3OA_1f0bc48c-4e5a-4304-80f5-07c746bc4ba8">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020, the future minimum annual obligations for the Office Leases in excess of one year are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments required&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfMS0xLTEtMS0w_256e9680-4741-4587-975e-c7fe9913588e"
      unitRef="usd">247000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfMi0xLTEtMS0w_d2b30cd9-7d24-49d4-bd3a-d65ee3f32124"
      unitRef="usd">676000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfMy0xLTEtMS0w_01a48501-5ce0-43f0-a010-d58a6a9e0a0a"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfNC0xLTEtMS0w_6534bb43-52b6-4ea9-a676-5acd909e5f12"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfNS0xLTEtMS0w_b6f5236b-a1f7-4dc9-b5a1-04b8a9997ca1"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <anab:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfNi0xLTEtMS0w_f3bdc473-a4f2-43e7-873f-6a77db2a06c8"
      unitRef="usd">0</anab:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfNy0xLTEtMS0w_a32fb713-2a79-48b3-af96-e46e1f187afb"
      unitRef="usd">923000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfOC0xLTEtMS0w_07f46127-4c84-4ec0-aae5-72aeb8ea7d6d"
      unitRef="usd">39000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RhYmxlOjgyZDMwMDk4ZWRmYzRiNzg5OThiNTM2YTZlMjNkMjUyL3RhYmxlcmFuZ2U6ODJkMzAwOThlZGZjNGI3ODk5OGI1MzZhNmUyM2QyNTJfOS0xLTEtMS0w_c3dd98a8-ffe5-4f62-bc19-3ddbf3fa222a"
      unitRef="usd">884000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i5d58efeb98774e8291e0a3b307d1a26b_I20200504"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMTY5Mw_b5ca71f7-b482-4b99-bd4f-571a4fa7ab9a"
      unitRef="sqft">45000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="i5d58efeb98774e8291e0a3b307d1a26b_I20200504"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMTc3MA_590ff0d1-e79a-4c5c-a331-11d740fa3e6e">P124M</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
      contextRef="i5d58efeb98774e8291e0a3b307d1a26b_I20200504"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMTk3MQ_e26a7b8d-4643-494f-b85f-f6afe4b5a84f">P5Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1>
    <anab:LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod
      contextRef="ie99b7535bd4a4aff813c79436f435dd6_D20200504-20200504"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMjA0MQ_3a2bb6bf-c733-4267-be11-614d948016dc">P7Y</anab:LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod>
    <anab:RentPerSquareFoot
      contextRef="ie99b7535bd4a4aff813c79436f435dd6_D20200504-20200504"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMjExMw_42b20e69-a4d0-43c0-bcbe-cba5889379a6"
      unitRef="usdPerSqft">4.20</anab:RentPerSquareFoot>
    <anab:AnnualRentIncreasePercent
      contextRef="ie99b7535bd4a4aff813c79436f435dd6_D20200504-20200504"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMjE2Nw_6f23b3a0-3a4f-480f-b205-36577b687c53"
      unitRef="number">0.03</anab:AnnualRentIncreasePercent>
    <us-gaap:PrepaidRent
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMjM2Nw_d4624a82-d925-4b3d-8e44-a65140e2b021"
      unitRef="usd">200000</us-gaap:PrepaidRent>
    <us-gaap:SecurityDeposit
      contextRef="i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF81OC9mcmFnOjFjZWNmMDZkNzBlNTQ0N2FhYzhhM2MxOWQ3NWJiOThiL3RleHRyZWdpb246MWNlY2YwNmQ3MGU1NDQ3YWFjOGEzYzE5ZDc1YmI5OGJfMjM5MA_79301ab1-68df-42aa-99a5-9d2a087fe2ed"
      unitRef="usd">300000</us-gaap:SecurityDeposit>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MTYvZnJhZzo1NjZiZjE1YjA0ZWQ0YjcxODM5YTU0ZmVmMTAyZGY4ZS90ZXh0cmVnaW9uOjU2NmJmMTViMDRlZDRiNzE4MzlhNTRmZWYxMDJkZjhlXzI3NDg3NzkwNzY3ODg_db60d00d-28f5-4ef2-8ebd-fcd391596511">Subsequent Event &lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 23, 2020, we entered into a confidential settlement agreement (the &#x201c;Settlement Agreement&#x201d;) with GSK and TESARO, Inc., and TESARO Development, Ltd. (together, &#x201c;Tesaro&#x201d;) to resolve the claims previously raised in the notice of breach (the &#x201c;Notice&#x201d;) we delivered to GSK and Tesaro on August 20, 2020.  Pursuant to the Settlement Agreement, we, GSK and Tesaro agreed to the terms of the Amendment described below and a mutual release of claims relating to the Notice, the Delaware Chancery Court action related to the Notice, the Collaboration Agreement and the obligations of the parties under the Collaboration Agreement.  Pursuant to the terms of the Settlement Agreement, we and Tesaro agreed to enter into the Amendment that provided GSK with freedom to conduct development and commercialization of Zejula in combination with third-party molecules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 23, 2020, we amended our GSK Agreement (the &#x201c;Amendment&#x201d;) with GSK and Tesaro.  Under the Amendment, we allowed for GSK to conduct development and commercialization of Zejula and we are entitled to increased royalties upon sales of dostarlimab, an anti-PD-1 antagonist antibody under development by GSK for multiple oncological disorders, including endometrial cancer, non-small cell lung cancer, ovarian cancer, colorectal cancer and mismatch repair deficient solid tumors, equal to 8% of Net Sales (as defined in the GSK Agreement) below $1.0&#160;billion and from 12% up to 25% of Net Sales above $1.0&#160;billion.   The Amendment also entitles us a one-time non-refundable cash payment of $60.0&#160;million payable to us within 30 days of the date of the Amendment.  Tesaro also agreed, starting January 1, 2021, to pay us a 1% royalty on all GSK and Tesaro Net Sales of Zejula &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which has received US approval for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, and is under development for additional cancer indications.  The $1.1&#160;billion in cash milestone payments due under the GSK Agreement remain unchanged.  Additionally, under the terms of the Amendment, Tesaro and GSK have agreed to certain diligence commitments with respect to the future development of dostarlimab, and the parties have agreed to review such commitments under regular joint review committee (JRC) meetings going forward.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent
      contextRef="id3e3599ed3624134a82b70d95e79fc4c_D20201023-20201023"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MTYvZnJhZzo1NjZiZjE1YjA0ZWQ0YjcxODM5YTU0ZmVmMTAyZGY4ZS90ZXh0cmVnaW9uOjU2NmJmMTViMDRlZDRiNzE4MzlhNTRmZWYxMDJkZjhlXzI3NDg3NzkwNzY3OTA_2752f4a7-ef1f-4901-9a12-fdfdb0c95781"
      unitRef="number">0.08</anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent>
    <anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent
      contextRef="i0d1574d508d24c7a9d2272819c456ea4_D20201023-20201023"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MTYvZnJhZzo1NjZiZjE1YjA0ZWQ0YjcxODM5YTU0ZmVmMTAyZGY4ZS90ZXh0cmVnaW9uOjU2NmJmMTViMDRlZDRiNzE4MzlhNTRmZWYxMDJkZjhlXzI3NDg3NzkwNzY4MDY_e8aa9257-ea07-43cf-91a2-2d7121aea8eb"
      unitRef="number">0.12</anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent>
    <anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent
      contextRef="i60cb8e6a37424af2bd4d11e7a7616ff7_D20201023-20201023"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MTYvZnJhZzo1NjZiZjE1YjA0ZWQ0YjcxODM5YTU0ZmVmMTAyZGY4ZS90ZXh0cmVnaW9uOjU2NmJmMTViMDRlZDRiNzE4MzlhNTRmZWYxMDJkZjhlXzI3NDg3NzkwNzY4MTE_daabdf38-0740-4c5a-81c8-d45669083b12"
      unitRef="number">0.25</anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent>
    <anab:RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable
      contextRef="ifa95208aff9f4c2086046f2657751ac3_I20201023"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MTYvZnJhZzo1NjZiZjE1YjA0ZWQ0YjcxODM5YTU0ZmVmMTAyZGY4ZS90ZXh0cmVnaW9uOjU2NmJmMTViMDRlZDRiNzE4MzlhNTRmZWYxMDJkZjhlXzI3NDg3NzkwNzY4Mjg_5b7613ed-bdd3-48cc-b224-bcf41871e187"
      unitRef="usd">60000000.0</anab:RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable>
    <anab:NetSalesRoyaltyPercent
      contextRef="i79eecb7fb35c40ad8dec2e63fb261996_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MTYvZnJhZzo1NjZiZjE1YjA0ZWQ0YjcxODM5YTU0ZmVmMTAyZGY4ZS90ZXh0cmVnaW9uOjU2NmJmMTViMDRlZDRiNzE4MzlhNTRmZWYxMDJkZjhlXzI3NDg3NzkwNzY4NTU_2e08111a-a20d-4855-bad8-d36993144afa"
      unitRef="number">0.01</anab:NetSalesRoyaltyPercent>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="iaa90cb92269c4595b23777618939cb79_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF85MTYvZnJhZzo1NjZiZjE1YjA0ZWQ0YjcxODM5YTU0ZmVmMTAyZGY4ZS90ZXh0cmVnaW9uOjU2NmJmMTViMDRlZDRiNzE4MzlhNTRmZWYxMDJkZjhlXzU0OTc1NTgxNTA1NjU_c60bfa4a-a4a7-4353-808e-777673f47dc3"
      unitRef="usd">1100000000</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237740411320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAPTYSBIO,&#160;INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-3828755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10421 Pacific Center Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">362-6295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANAB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,347,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001370053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237739916808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 209,154<span></span>
</td>
<td class="nump">$ 171,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">129,192<span></span>
</td>
<td class="nump">203,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,468<span></span>
</td>
<td class="nump">3,506<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">345,814<span></span>
</td>
<td class="nump">377,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,585<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">36,177<span></span>
</td>
<td class="nump">54,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">384,750<span></span>
</td>
<td class="nump">435,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,484<span></span>
</td>
<td class="nump">16,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">18,139<span></span>
</td>
<td class="nump">11,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,474<span></span>
</td>
<td class="nump">29,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at September 30, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 500,000 shares authorized, 27,346 shares and 27,255 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">657,560<span></span>
</td>
<td class="nump">648,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(297,603)<span></span>
</td>
<td class="num">(244,026)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">360,243<span></span>
</td>
<td class="nump">405,008<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 384,750<span></span>
</td>
<td class="nump">$ 435,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237817670616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">27,346,228<span></span>
</td>
<td class="nump">27,255,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">27,346,228<span></span>
</td>
<td class="nump">27,255,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237735369336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">19,542<span></span>
</td>
<td class="nump">29,931<span></span>
</td>
<td class="nump">58,458<span></span>
</td>
<td class="nump">77,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,794<span></span>
</td>
<td class="nump">3,814<span></span>
</td>
<td class="nump">13,766<span></span>
</td>
<td class="nump">12,262<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">24,336<span></span>
</td>
<td class="nump">33,745<span></span>
</td>
<td class="nump">72,224<span></span>
</td>
<td class="nump">90,174<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(24,336)<span></span>
</td>
<td class="num">(33,745)<span></span>
</td>
<td class="num">(57,224)<span></span>
</td>
<td class="num">(85,174)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(240)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(841)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">2,757<span></span>
</td>
<td class="nump">3,583<span></span>
</td>
<td class="nump">8,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(56)<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">2,661<span></span>
</td>
<td class="nump">3,647<span></span>
</td>
<td class="nump">7,971<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="num">(23,767)<span></span>
</td>
<td class="num">(31,084)<span></span>
</td>
<td class="num">(53,577)<span></span>
</td>
<td class="num">(77,203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,767)<span></span>
</td>
<td class="num">(31,033)<span></span>
</td>
<td class="num">(53,577)<span></span>
</td>
<td class="num">(77,073)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) income on available for sale securities, net of tax of $0, $(25), $0 and $189, respectively</a></td>
<td class="num">(494)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="nump">703<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (24,261)<span></span>
</td>
<td class="num">$ (31,127)<span></span>
</td>
<td class="num">$ (53,656)<span></span>
</td>
<td class="num">$ (76,370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.87)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
<td class="num">$ (1.96)<span></span>
</td>
<td class="num">$ (2.85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted-average number of shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">27,316<span></span>
</td>
<td class="nump">27,058<span></span>
</td>
<td class="nump">27,286<span></span>
</td>
<td class="nump">27,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237731074136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized income (loss) on available for sale securities, tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237815317384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 486,365<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 633,251<span></span>
</td>
<td class="num">$ (223)<span></span>
</td>
<td class="num">$ (146,690)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,922,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued under employee stock plans</a></td>
<td class="nump">574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued under employee stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">2,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss), net</a></td>
<td class="nump">427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,078)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Mar. 31, 2019</a></td>
<td class="nump">468,155<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">636,692<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="num">(168,768)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,006,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">486,365<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">633,251<span></span>
</td>
<td class="num">(223)<span></span>
</td>
<td class="num">(146,690)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,922,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(77,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">420,892<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">644,148<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="num">(223,763)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,098,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Beginning Balance at Mar. 31, 2019</a></td>
<td class="nump">468,155<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">636,692<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="num">(168,768)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Beginning Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,006,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued under employee stock plans</a></td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued under employee stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">3,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss), net</a></td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,962)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Jun. 30, 2019</a></td>
<td class="nump">448,421<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">640,550<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="num">(192,730)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,045,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued under employee stock plans</a></td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued under employee stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">3,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss), net</a></td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(31,033)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,033)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">420,892<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">644,148<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="num">(223,763)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,098,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">405,008<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">648,669<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="num">(244,026)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued under employee stock plans</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued under employee stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">2,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss), net</a></td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,262)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">400,564<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">651,680<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
<td class="num">(252,288)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 405,008<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">648,669<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="num">(244,026)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued under employee stock plans (in shares)</a></td>
<td class="nump">91,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (53,577)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">360,243<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">657,560<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="num">(297,603)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Beginning Balance at Mar. 31, 2020</a></td>
<td class="nump">400,564<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">651,680<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
<td class="num">(252,288)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Beginning Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued under employee stock plans</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued under employee stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">2,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss), net</a></td>
<td class="num">(392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,548)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,548)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Jun. 30, 2020</a></td>
<td class="nump">381,436<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">654,492<span></span>
</td>
<td class="nump">753<span></span>
</td>
<td class="num">(273,836)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,287,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued under employee stock plans</a></td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued under employee stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">2,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss), net</a></td>
<td class="num">(494)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(494)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,767)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 360,243<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 657,560<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
<td class="num">$ (297,603)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237740136872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (53,577)<span></span>
</td>
<td class="num">$ (77,073)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation</a></td>
<td class="nump">8,521<span></span>
</td>
<td class="nump">9,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Accretion/amortization of investments, net</a></td>
<td class="nump">239<span></span>
</td>
<td class="num">(2,449)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Non-cash interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(2,902)<span></span>
</td>
<td class="nump">2,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="num">(4,431)<span></span>
</td>
<td class="nump">13,180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(51,735)<span></span>
</td>
<td class="num">(53,712)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Acquisition of investments</a></td>
<td class="num">(156,572)<span></span>
</td>
<td class="num">(175,049)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">247,707<span></span>
</td>
<td class="nump">303,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(258)<span></span>
</td>
<td class="num">(701)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">90,877<span></span>
</td>
<td class="nump">127,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock, upon the exercise of stock options</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">1,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on notes payable</a></td>
<td class="num">(1,375)<span></span>
</td>
<td class="num">(5,625)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,005)<span></span>
</td>
<td class="num">(4,382)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">38,137<span></span>
</td>
<td class="nump">69,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">171,077<span></span>
</td>
<td class="nump">113,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">209,214<span></span>
</td>
<td class="nump">182,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for property and equipment</a></td>
<td class="nump">$ 165<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237733072136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of the Business</a></td>
<td class="text">Description of the Business <div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AnaptysBio, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in November 2005. We are a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We currently generate revenue from milestones achieved under our collaborative research and development arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Since our inception, we have devoted our primary effort to research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Our management believes our currently available resources will provide sufficient funds to enable us to meet our operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734388664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2019 financial information to conform to the current year presentation of prepaid expenses and other assets on the Consolidated Statements of Cash Flows. Operating results for the nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus (&#8220;COVID-19&#8221;) pandemic, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions, including the issuance of stay-at-home orders and social distancing guidelines, which have resulted in some businesses suspending operations or experiencing a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business, and delay our development programs and regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;the COVID-19 pandemic on the costs and timing associated with the conduct of our clinical trials and other related business activities. The financial statements should be read in conjunction with our audited financial statements for the year ended December&#160;31, 2019 included in our Annual Form 10-K. </span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in one reportable segment, and our functional and reporting currency is the U.S. dollar.  </span></div><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the weighted-average o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">utstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Recently Adopted</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intended to simplify the accounting for income taxes. The guidance removes the following exceptions: (1) exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, (2) exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, (3) exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary, and (4) exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. Additionally, the guidance simplifies the accounting for income taxes by: (1) requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, (2) requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, (3) specifying that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements (although the entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority), (4) requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, and (5) making minor improvements for income tax accounting related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method. The guidance will be effective for fiscal years and interim periods beginning after December 15, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption, and early adoption is permitted.&#160;We early adopted this standard on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses:&#160;Measurement of Credit Losses on Financial Instruments&#160;(Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;which changes the accounting treatment for recognizing the impairment of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also eliminates the other-than-temporary impairment model for available-for-sale (&#8220;AFS&#8221;) debt securities. Entities will begin to recognize credit losses on AFS debt securities as allowances rather than as reductions in the carrying value of the securities. Impairment that is not credit-related impairment will continue to be recognized in other comprehensive income and entities will no longer consider the length of time a security has been in an unrealized loss position when determining whether a credit loss exists. ASU 2016-13 becomes effective for annual and interim periods beginning after December 15, 2019.&#160;We adopted this standard prospectively on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements as credit losses are not expected to be significant based on historical trends, the financial condition of our investments and external market factors. We will continue to actively monitor the impact of the COVID-19 pandemic on expected credit losses.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237735009544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts and Supplemental Disclosures<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Accounts and Supplemental Disclosures</a></td>
<td class="text">Balance Sheet Accounts and Supplemental Disclosures <div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following: </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,218&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,911&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,662&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,297&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,077)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,679)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,585&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and related expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,782&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research, development and manufacturing expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,094&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,196&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,139&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,052&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734377896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and Development Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Research and Development Agreements</a></td>
<td class="text">Collaborative Research and Development Agreements<div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GlaxoSmithKline Collaboration </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, we entered into a Collaboration and Exclusive License Agreement (the &#8220;GSK Agreement&#8221;) with TESARO, Inc., an oncology-focused biopharmaceutical company now a part of GlaxoSmithKline (&#8220;GSK&#8221;). Under the terms of the GSK Agreement, we agreed to perform certain discovery and early preclinical development of therapeutic antibodies with the goal of generating immunotherapy antibodies for subsequent preclinical, clinical, regulatory, and commercial development to be performed by GSK. Under the terms of the GSK Agreement, GSK paid an upfront license fee of $17.0 million in March 2014 and agreed to provide funding to us for research and development services related to antibody discovery programs for three specific targets. In November 2014, we and TESARO, Inc. entered into Amendment No.&#160;1 to the GSK Agreement to add an antibody discovery program against an undisclosed fourth target for an upfront license fee of $2.0 million. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each development program, we are eligible to receive milestone payments of up to $18.0 million if certain preclinical and clinical trial events are achieved by GSK, up to an additional $90.0 million if certain U.S. and European regulatory submissions and approvals in multiple indications are achieved, and up to an additional $165.0 million upon the achievement of specified levels of annual worldwide net sales. We will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products developed under the collaboration. Unless earlier terminated by either party upon specified circumstances, the GSK Agreement will terminate, with respect to each specific developed product, upon the later of the 12th anniversary of the first commercial sale of the product or the expiration of the last to expire of any patent. Prior to the adoption of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we determined that the upfront license fees and research funding under the GSK Agreement, as amended, should be accounted for as a single unit of accounting and that the upfront license fees should be deferred and recognized as revenue over the same period that the research and development services are performed. In December 2015, we determined that the research and development services would be extended through December 31, 2016. As a result, the period over which the unrecognized license fees and discovery milestones were recognized was extended through December 31, 2016 and have since been recognized in full. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, GSK, is a customer.&#160;We identified the following material promises under the GSK Agreement: (1) the licenses under certain patent rights relating to six discovery programs (four targets) and transfer of certain development and regulatory information, (2) research and development (&#8220;R&amp;D&#8221;) services, and (3) joint steering committee meetings. We considered the research and discovery capabilities of GSK for these specific programs, GSK&#8217;s inability to sub-license, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the joint steering committee participation would not have been provided without the R&amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated and therefore concluded that the promises should be combined into a single performance obligation at the inception of the arrangement. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the transaction price for the GSK Agreement includes the upfront payment, research reimbursement revenue, and milestones earned to date, which are allocated in their entirety to the single performance obligation. We earned and recognized two clinical milestones for $15.0 million during the nine months ended September&#160;30, 2020. No other future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials, an outcome that is difficult to predict, and GSK&#8217;s efforts. Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the intellectual property license granted to GSK and therefore have also been excluded from the transaction price. We will re-evaluate the variable transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones recognized through September&#160;30, 2020 under the GSK Agreement are as follows:</span></div><div style="margin-bottom:5pt;margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.298%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-PD-1 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK4057190A/Dostarlimab)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-TIM-3 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK4069889A/Cobolimab)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-LAG-3 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK40974386)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestone Event</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Initiated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> toxicology studies using good laboratory practices (GLPs) </span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'15</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'15</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q3'16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IND clearance from the FDA</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$4.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$4.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$4.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'17</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2 clinical trial initiation</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'17</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'17</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'19</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3 clinical trial initiation - first indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$5.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q3'18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3 clinical trial initiation - second indication</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$5.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'19</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first NDA - first indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$10.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first MAA - first indication</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$5.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'20</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:18pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones achieved during the discovery period were recognized as revenue pro-rata through December 31, 2016. Milestones achieved during fiscal 2017 were recognized as revenue in the period earned, while milestones after December 31, 2017 are recognized upon determination that a significant reversal of revenue would not be probable. Cash is generally received within 30 days of milestone achievement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $0 and $15.0 million in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GSK Agreement </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three and nine months ended September 30, 2020, respectively, and $0 and $5.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three and nine months ended September 30, 2019, respectively.</span></div><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antibody Generation Agreement with Bristol-Myers Squibb </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2011, we entered into a license and collaboration agreement (the &#8220;BMS Agreement&#8221;) with Celgene, now a part of Bristol-Myers Squibb (&#8220;BMS&#8221;), to develop therapeutic antibodies against multiple targets. We granted BMS the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters pertaining to each target under the agreement. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BMS Agreement provided for an upfront payment of $6.0 million from BMS, which we received in 2011 and recognized through 2014, milestone payments of up to $53.0 million per target, low single-digit royalties on net sales of antibodies against each target, and reimbursement of specified research and development costs. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed this arrangement in accordance with ASC Topic 606 and concluded that the contract counterparty, BMS, is a customer.&#160;We identified the following material promises under the BMS Agreement: (1) the licenses under certain patent rights relating to four targets and transfer of certain development and regulatory information, (2) R&amp;D services, (3) a written report documenting findings, and (4) steering committee meetings. We considered the research and discovery capabilities of BMS, BMS&#8217;s inability to sub-license the four targets, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the report of findings and steering committee participation would not have been provided without the R&amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated, and therefore concluded that the promises should be combined into a single performance obligation at the inception the arrangement. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the transaction price of the BMS Agreement includes the upfront payment, success fees, expense reimbursement, and milestones earned to date, which are allocated in their entirety to the single performance obligation.&#160;None of the future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors, including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials and BMS&#8217;s efforts.&#160;Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the intellectual property license granted to BMS and therefore have also been excluded from the transaction price.&#160;We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones achieved through September&#160;30, 2020 under the BMS Agreement are as follows:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.258%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-PD-1 <br/>(CC-90006)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestone Event</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completion of first </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> toxicology studies using GLPs</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$0.5M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1 clinical trial initiation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'16</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from future contingent milestone payments will be recognized when it is more likely than not that the revenue will not be reversed in future periods. Cash is generally received within 30 days of milestone achievement. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  There was no revenue recognized under this agreement during the three and nine months ended September 30, 2020 and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734581256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text">Notes Payable <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;24, 2014, we entered into a Loan and Security Agreement, as amended from time to time (the &#8220;Loan Agreement&#8221;), with a bank and a financial institution whereby we may borrow up to $15.0 million in three separate draws of $5.0 million each. The Term A Loans, for an aggregate of $5.0 million, were drawn on December&#160;24, 2014 with a fixed interest rate of 6.97%. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, the Loan Agreement was amended to combine Term B Loans and Term C Loans for a total of $10.0 million available for draw through December 31, 2016 and delay the beginning of our Term A Loans&#8217; principal repayments from February&#160;1, 2016 until February&#160;1, 2017. The Term B Loans and Term C Loans became available for draw on July&#160;1, 2016. In December 2016, we further amended the Loan Agreement to (i)&#160;allow for the Term B Loans and Term C Loans to be drawn on December&#160;30, 2016, (ii)&#160;delay principal repayments of all Term Loans until February&#160;1, 2018, and (iii)&#160;amend the interest rate for each Term Loan. The Term B Loans and the Term C Loans were drawn on December&#160;30, 2016, and Term A, B and C Loans are now collectively referred to as the Term Loans. Principal repayments began in February 2018, and the Term Loans were paid in full, without penalty or premium, on January 1, 2020.</span></div>The costs incurred to issue the Term Loans were deferred and were included in the discount to the carrying value of the Term Loans in the accompanying balance sheet. The Term Loans also included a final payment fee of $0.8 million due at the earlier of prepayment or the maturity date of the Term Loans. The deferred costs and the final payment fee were amortized to interest expense over the expected term of the Term A Loans using the effective interest method.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734387544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Available for Sale Investments</a></td>
<td class="text">Fair Value Measurements and Available for Sale Investments<div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist principally of cash, cash equivalents, restricted cash, short-term and long-term investments, receivables, accounts payable, and notes payable. Certain of our financial assets and liabilities have been recorded at fair value in the consolidated balance sheet in accordance with the accounting standards for fair value measurements.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions. </span></div><div style="margin-top:12pt;padding-left:11.25pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at End of Period Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Market</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prices for</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identical&#160;Assets</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;Observable</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">At September 30, 2020</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,833&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,833&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,692&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,692&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">At December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,928&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,928&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,434&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,434&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,623&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,623&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.</span></div><div style="margin-top:2pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods and assumptions were used to estimate the fair value of our financial instruments for which it is practicable to estimate that value: </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For fair values determined by Level 1 inputs, which utilize quoted prices in active markets for identical assets, the level of judgment required to estimate fair value is relatively low. For fair values determined by Level 2 inputs, which utilize quoted prices in less active markets for similar assets, the level of judgment required to estimate fair value is also considered relatively low. </span></div><div style="margin-top:18pt;padding-left:13.5pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Other Financial Instruments </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our other financial instruments estimated as of September&#160;30, 2020 and December&#160;31, 2019 are presented below: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:46.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.366%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods and assumptions were used to estimate the fair value of our notes payable: </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes Payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We use the income approach to value the aforementioned debt instrument. We use a present value calculation to discount principal and interest payments and the final maturity payment on these liabilities using a discounted cash flow model based on observable inputs. We discount these debt instruments based on what the current market rates would offer us as of the reporting date. Based on the assumptions used to value these liabilities at fair value, these debt instruments are categorized as Level 2 in the fair value hierarchy. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The carrying amounts of certain of our financial instruments, including cash and cash equivalents, accounts payable, and accrued expenses approximate fair value due to their short-term nature. </span></div><div style="margin-top:18pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available for Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our excess cash in agency securities, debt instruments of financial institutions and corporations, commercial obligations, and U.S. Treasury securities, which we classify as available-for-sale investments. These investments are carried at fair value and are included in the tables above. The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of September&#160;30, 2020 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,902&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,369&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding agency securities, $0.8 million have maturity dates of less than one year and $15.0 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDMyMA_168e5752-1e53-49ab-989a-a68d50119366">one</span> to two years as of September&#160;30, 2020.</span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding certificates of deposit, $3.0 million have maturity dates of less than one year and $0.7 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMzEzNQ_106d4e12-4b32-4f29-8d26-2b1735c0fda4">one</span> to two years as of September&#160;30, 2020.</span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our outstanding commercial and corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations have maturity dates of less than one year as of September&#160;30, 2020. </span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding U.S. Treasury securities, $86.7 million have maturity dates of less than one year and $20.4 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDY4MQ_e5da9ade-9ee6-43e3-9be3-70e98595210b">one</span> to two years as of September&#160;30, 2020.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;September&#160;30, 2020&#160;and&#160;December&#160;31, 2019, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:26.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,317&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,317&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:26.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734856680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="margin-top:12pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the 500,000,000&#160;shares of common stock authorized, 27,346,228 shares were issued and outstanding as of September&#160;30, 2020. Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at September&#160;30, 2020 are as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued and Outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares Reserved For:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Equity Incentive Plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,040,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,913,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734522184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text">Equity Incentive Plans <div style="margin-top:12pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;). The 2017 Plan became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017 and replaced our existing 2006 Equity Incentive Plan. Under the 2017 Plan, we may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then our employees, officers, directors or consultants. In addition, the number of shares of stock available for issuance under the 2017 Plan will be automatically increased each January 1, beginning on January 1, 2018, by 4% of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The 2017 Plan automatically increased by 1,090,203 shares as of January 1, 2020.</span></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Employee Stock Purchase Plan or the ESPP. The ESPP became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017. In addition, the number shares of stock available for issuance under the ESPP will be automatically increased each January 1, beginning on January 1, 2018, by 1% of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The ESPP automatically increased by 272,550 shares as of January 1, 2020.</span></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted to employees and non-employees generally vest over a four-year period while stock options granted to directors vest over a one year period. Each stock option award has a maximum term of 10 years from the date of grant, subject to earlier cancellation prior to vesting upon cessation of service to us. A summary of the activity related to stock option awards during the nine months ended September 30, 2020 is as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subject to</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value&#160;(in</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,039,880&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.40&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,146)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.06&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures and cancellations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876,063&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.91&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.47</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,747&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,530&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.142%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.88&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.08&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the appropriate risk-free interest rate, expected term for employee stock-based awards, contractual term for non-employee stock-based awards, and volatility assumptions. The weighted-average expected option term for employee and non-employee stock-based awards reflects the application of the simplified method, which defines the life as the average of the contractual term of the options and the weighted-average vesting period for all option tranches. Estimated volatility incorporates historical volatility of our stock price as well as similar entities whose share prices are publicly available. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected or contractual term of the stock-based payment awards. The assumed dividend yield is based on our expectation of not paying dividends in the foreseeable future. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,469&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,491&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,805&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,521&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,654&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, there was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$24.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of unrecognized compensation cost related to unvested stock option awards, which is expected to be recognized over a remaining weighted-average vesting period o</span>f 3.03 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237832450120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two non-cancellable office leases (the &#8220;Office Leases&#8221;), with remaining lease terms of approximately one year, each of which are classified as operating leases. Both leases expire in 2021. Only one of our leases has remaining renewal </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options, which includes three options to renew for one additional year. The exercise of lease renewal options is at our sole discretion, which we currently do not anticipate exercising and as such were not recognized as part of our right-of-use (&#8220;ROU&#8221;)  asset and lease liabilities. Our lease payments are fixed, and we recognize lease expense for these leases on a straight-line basis over the lease term. Operating lease ROU assets and lease liabilities are recorded based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not provide an implicit rate, we used our incremental borrowing rate based on the information available at effective date of adoption in determining the present value of future payments. The weighted-average discount rate used was 8.59%.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our balance sheet includes our ROU assets and lease liabilities as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating ROU assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following costs are included in our consolidated statements of cash flow (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Cash Flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, the future minimum annual obligations for the Office Leases in excess of one year are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments required</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2020, we entered into a lease agreement (the &#8220;Lease Agreement&#8221;) with Wateridge Property Owner, LP, with respect to facilities in the building at 10770 Wateridge Circle, San Diego, California 92121. Under the Lease Agreement, we agreed to lease approximately 45,000 square feet of space in the 10770 Wateridge Circle Building for a term of 124 months, beginning on March 1, 2021 (or on such later date as described in the Lease Agreement). The terms of the Lease Agreement provide us with an option to extend the term of the lease for an additional five years, as well as a one-time option to terminate the lease after seven years with the payment of a termination fee. The monthly base rent will be $4.20 per rentable square foot and will be increased by 3% annually. Under the Lease Agreement, we are also responsible for our pro rata share of real estate taxes, building insurance, maintenance, direct expenses, and utilities. As of September&#160;30, 2020, we have recorded $0.2&#160;million in prepaid rent and $0.3&#160;million as a security deposit in accordance with the terms of the Lease Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lawsuit</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 25, 2020, a putative securities class action was filed in the United States District Court for the Southern District of California naming the Company and certain of its current or former officers as defendants. The complaint purports to assert claims under Section 10(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), Exchange Act  Rule 10b-5, and Section 20(a) of the Exchange Act, on behalf of persons and entities who acquired our common stock between October 10, 2017 and November 7, 2019 (the &#8220;Class Period&#8221;). An amended complaint was filed on September 30, 2020 alleging that, during the Class Period, the defendants made material misrepresentations or omissions regarding our etokimab product candidate that artificially inflated our stock price. The plaintiff seeks, among other things, damages in an unspecified amount, as well as costs and expenses. We believe that the plaintiff&#8217;s allegations are without merit and intend to vigorously defend against the claims. On September 1, 2020, a related shareholder derivative complaint was filed based on allegations substantially similar to those in the class action, and asserting claims against current or former officers and directors for contribution under Sections 10(b) and 21D of the Exchange Act, breach of fiduciary duty, unjust enrichment and corporate waste. Because the Company is in the early stages of this litigation matter, we are unable to estimate a reasonably possible loss or range of loss, if any, that may result from these matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237733022728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Event <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, we entered into a confidential settlement agreement (the &#8220;Settlement Agreement&#8221;) with GSK and TESARO, Inc., and TESARO Development, Ltd. (together, &#8220;Tesaro&#8221;) to resolve the claims previously raised in the notice of breach (the &#8220;Notice&#8221;) we delivered to GSK and Tesaro on August 20, 2020.  Pursuant to the Settlement Agreement, we, GSK and Tesaro agreed to the terms of the Amendment described below and a mutual release of claims relating to the Notice, the Delaware Chancery Court action related to the Notice, the Collaboration Agreement and the obligations of the parties under the Collaboration Agreement.  Pursuant to the terms of the Settlement Agreement, we and Tesaro agreed to enter into the Amendment that provided GSK with freedom to conduct development and commercialization of Zejula in combination with third-party molecules.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, we amended our GSK Agreement (the &#8220;Amendment&#8221;) with GSK and Tesaro.  Under the Amendment, we allowed for GSK to conduct development and commercialization of Zejula and we are entitled to increased royalties upon sales of dostarlimab, an anti-PD-1 antagonist antibody under development by GSK for multiple oncological disorders, including endometrial cancer, non-small cell lung cancer, ovarian cancer, colorectal cancer and mismatch repair deficient solid tumors, equal to 8% of Net Sales (as defined in the GSK Agreement) below $1.0&#160;billion and from 12% up to 25% of Net Sales above $1.0&#160;billion.   The Amendment also entitles us a one-time non-refundable cash payment of $60.0&#160;million payable to us within 30 days of the date of the Amendment.  Tesaro also agreed, starting January 1, 2021, to pay us a 1% royalty on all GSK and Tesaro Net Sales of Zejula </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which has received US approval for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, and is under development for additional cancer indications.  The $1.1&#160;billion in cash milestone payments due under the GSK Agreement remain unchanged.  Additionally, under the terms of the Amendment, Tesaro and GSK have agreed to certain diligence commitments with respect to the future development of dostarlimab, and the parties have agreed to review such commitments under regular joint review committee (JRC) meetings going forward.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237732724584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2019 financial information to conform to the current year presentation of prepaid expenses and other assets on the Consolidated Statements of Cash Flows. Operating results for the nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus (&#8220;COVID-19&#8221;) pandemic, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions, including the issuance of stay-at-home orders and social distancing guidelines, which have resulted in some businesses suspending operations or experiencing a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business, and delay our development programs and regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;the COVID-19 pandemic on the costs and timing associated with the conduct of our clinical trials and other related business activities. The financial statements should be read in conjunction with our audited financial statements for the year ended December&#160;31, 2019 included in our Annual Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text">Basis of ConsolidationThe accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in one reportable segment, and our functional and reporting currency is the U.S. dollar.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Recently Adopted</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Recently Adopted</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intended to simplify the accounting for income taxes. The guidance removes the following exceptions: (1) exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, (2) exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, (3) exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary, and (4) exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. Additionally, the guidance simplifies the accounting for income taxes by: (1) requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, (2) requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, (3) specifying that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements (although the entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority), (4) requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, and (5) making minor improvements for income tax accounting related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method. The guidance will be effective for fiscal years and interim periods beginning after December 15, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption, and early adoption is permitted.&#160;We early adopted this standard on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses:&#160;Measurement of Credit Losses on Financial Instruments&#160;(Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;which changes the accounting treatment for recognizing the impairment of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also eliminates the other-than-temporary impairment model for available-for-sale (&#8220;AFS&#8221;) debt securities. Entities will begin to recognize credit losses on AFS debt securities as allowances rather than as reductions in the carrying value of the securities. Impairment that is not credit-related impairment will continue to be recognized in other comprehensive income and entities will no longer consider the length of time a security has been in an unrealized loss position when determining whether a credit loss exists. ASU 2016-13 becomes effective for annual and interim periods beginning after December 15, 2019.&#160;We adopted this standard prospectively on January 1, 2020, and the adoption of the standard did not have a material impact to our consolidated financial statements as credit losses are not expected to be significant based on historical trends, the financial condition of our investments and external market factors. We will continue to actively monitor the impact of the COVID-19 pandemic on expected credit losses.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734455896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the weighted-average o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">utstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237732921752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts and Supplemental Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following: </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,218&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,911&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,662&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,297&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,077)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,679)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,585&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and related expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,782&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research, development and manufacturing expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,094&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,196&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,139&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,052&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734512952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and Development Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones recognized through September&#160;30, 2020 under the GSK Agreement are as follows:</span></div><div style="margin-bottom:5pt;margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.298%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-PD-1 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK4057190A/Dostarlimab)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-TIM-3 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK4069889A/Cobolimab)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-LAG-3 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK40974386)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestone Event</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Initiated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> toxicology studies using good laboratory practices (GLPs) </span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'15</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'15</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q3'16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IND clearance from the FDA</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$4.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$4.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$4.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'17</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2 clinical trial initiation</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'17</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'17</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'19</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3 clinical trial initiation - first indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$5.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q3'18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3 clinical trial initiation - second indication</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$5.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'19</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first NDA - first indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$10.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first MAA - first indication</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$5.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'20</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones achieved through September&#160;30, 2020 under the BMS Agreement are as follows:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.258%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-PD-1 <br/>(CC-90006)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestone Event</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completion of first </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> toxicology studies using GLPs</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$0.5M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1 clinical trial initiation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'16</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237732918648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at End of Period Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Market</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prices for</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identical&#160;Assets</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;Observable</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">At September 30, 2020</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,833&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,833&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,692&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,692&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">At December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,928&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,928&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,434&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,434&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,623&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,623&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.</span></div>(2)&#160;&#160;&#160;&#160;Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value of Other Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our other financial instruments estimated as of September&#160;30, 2020 and December&#160;31, 2019 are presented below: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:46.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.366%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Available-for-sale Investments</a></td>
<td class="text">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of September&#160;30, 2020 are as follows:<div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,902&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,369&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding agency securities, $0.8 million have maturity dates of less than one year and $15.0 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDMyMA_168e5752-1e53-49ab-989a-a68d50119366">one</span> to two years as of September&#160;30, 2020.</span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding certificates of deposit, $3.0 million have maturity dates of less than one year and $0.7 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfMTA5OTUxMTYzMzEzNQ_106d4e12-4b32-4f29-8d26-2b1735c0fda4">one</span> to two years as of September&#160;30, 2020.</span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our outstanding commercial and corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations have maturity dates of less than one year as of September&#160;30, 2020. </span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding U.S. Treasury securities, $86.7 million have maturity dates of less than one year and $20.4 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA4MzNkMzNmYTFiYzRjNTZhNTY5M2IxNjdmOTlmYzIwL3NlYzowODMzZDMzZmExYmM0YzU2YTU2OTNiMTY3Zjk5ZmMyMF80OS9mcmFnOjJlY2IyOTc5MmQyNDQyMmJiNTQzYzM2NzM3ZWE5M2VjL3RleHRyZWdpb246MmVjYjI5NzkyZDI0NDIyYmI1NDNjMzY3MzdlYTkzZWNfNDY4MQ_e5da9ade-9ee6-43e3-9be3-70e98595210b">one</span> to two years as of September&#160;30, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Schedule of Unrealized Loss and Fair Values in a Loss Position</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;September&#160;30, 2020&#160;and&#160;December&#160;31, 2019, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:26.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,317&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,317&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:26.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237732913464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text">Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at September&#160;30, 2020 are as follows: <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued and Outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares Reserved For:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Equity Incentive Plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,040,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,913,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734296392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity Related to Stock Option Awards</a></td>
<td class="text">A summary of the activity related to stock option awards during the nine months ended September 30, 2020 is as follows: <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subject to</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value&#160;(in</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,039,880&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.40&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,146)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.06&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures and cancellations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876,063&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.91&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.47</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,747&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,530&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Assumptions in Stock Option Valuations</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.142%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.88&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.08&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Non-cash Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,469&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,491&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,805&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,521&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,654&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237733001544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Classification on the Balance Sheet</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our balance sheet includes our ROU assets and lease liabilities as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating ROU assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Costs Included in Cash Flow Statement</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following costs are included in our consolidated statements of cash flow (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Cash Flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Annual Obligations</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, the future minimum annual obligations for the Office Leases in excess of one year are as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments required</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734368408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237733047704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">2,838<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
<td class="nump">2,899<span></span>
</td>
<td class="nump">2,451<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237832592056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,662<span></span>
</td>
<td class="nump">$ 6,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(5,077)<span></span>
</td>
<td class="num">(4,679)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">1,585<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=anab_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,218<span></span>
</td>
<td class="nump">4,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">827<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=anab_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=anab_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734589304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related expenses</a></td>
<td class="nump">$ 2,782<span></span>
</td>
<td class="nump">$ 2,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,039<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research, development and manufacturing expenses</a></td>
<td class="nump">14,094<span></span>
</td>
<td class="nump">8,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 18,139<span></span>
</td>
<td class="nump">$ 11,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237725032456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and Development Agreements (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="14">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>target</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Collaborative Research And Development Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived', window );">Upfront license fee received</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="nump">$ 17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets', window );">Number of outstanding research and development targets | target</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents', window );">Milestone payments, contingent upon preclinical and clinical trial events (up to)</a></td>
<td class="nump">$ 18,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals', window );">Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to)</a></td>
<td class="nump">90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales', window );">Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to)</a></td>
<td class="nump">$ 165,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent', window );">Agreement term following first commercial sale or expiration of the last to expire patent (in years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod', window );">Number of milestones achieved during period | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-PD-1 (GSK4057190A/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-TIM-3 (GSK4069889A/Cobolimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-LAG-3 (GSK40974386)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | IND clearance from the FDA | Anti-PD-1 (GSK4057190A/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | IND clearance from the FDA | Anti-TIM-3 (GSK4069889A/Cobolimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | IND clearance from the FDA | Anti-LAG-3 (GSK40974386)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Phase 2 clinical trial initiation | Anti-PD-1 (GSK4057190A/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Phase 2 clinical trial initiation | Anti-TIM-3 (GSK4069889A/Cobolimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Phase 2 clinical trial initiation | Anti-LAG-3 (GSK40974386)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Phase 3 clinical trial initiation | Anti-PD-1 (GSK4057190A/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Phase 3 clinical trial initiation - second indication [Domain] | Anti-PD-1 (GSK4057190A/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Filing of the first NDA - first indication | Anti-PD-1 (GSK4057190A/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Filing of the first MAA - first indication | Anti-PD-1 (GSK4057190A/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_CelgeneCorporationMember', window );">Celgene Corporation | Collaborative Research And Development Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived', window );">Upfront license fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone', window );">Maximum milestone payments per target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_CelgeneCorporationMember', window );">Celgene Corporation | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-PD-1 (CC-90006)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned', window );">Milestone Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_CelgeneCorporationMember', window );">Celgene Corporation | Phase 1 clinical trial initiation | Anti-PD-1 (CC-90006)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned', window );">Milestone Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognized, Milestone Method, Milestone Payment Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_InVivoToxicologyStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_InVivoToxicologyStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_ClearanceOfInvestigationalNewDrugFromFDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_ClearanceOfInvestigationalNewDrugFromFDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_Phase2ClinicalTrialInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_Phase2ClinicalTrialInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_Phase3clinicaltrialinitiationsecondindicationDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_Phase3clinicaltrialinitiationsecondindicationDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_FilingofNDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_FilingofNDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_FilingofMMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_FilingofMMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anab_CelgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anab_CelgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_Phase1ClinicalTrialInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_Phase1ClinicalTrialInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237815022920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable (Details) - Notes Payable to Banks<br></strong></div></th>
<th class="th">
<div>Dec. 24, 2014 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate borrowing capacity</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Loan and Security Agreement (LSA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_DebtInstrumentMaximumBorrowingCapacity', window );">Debt instrument, maximum borrowing capacity</a></td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_DebtInstrumentNumberOfLoanInstallments', window );">Number of loan installments (in installments) | installment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Final payment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Term A Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Aggregate draw on term loan</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed interest rate (as a percent)</a></td>
<td class="nump">6.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Term B and Term C Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_DebtInstrumentMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_DebtInstrumentMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_DebtInstrumentNumberOfLoanInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Loan Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_DebtInstrumentNumberOfLoanInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=anab_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=anab_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=anab_TermALoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=anab_TermALoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=anab_TermBLoansAndTermCLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=anab_TermBLoansAndTermCLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237817648968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">$ 165,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">107,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">3,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">15,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember', window );">Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">38,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">107,159<span></span>
</td>
<td class="nump">$ 96,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">3,713<span></span>
</td>
<td class="nump">5,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">15,805<span></span>
</td>
<td class="nump">33,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">38,692<span></span>
</td>
<td class="nump">122,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">204,678<span></span>
</td>
<td class="nump">162,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">4,833<span></span>
</td>
<td class="nump">7,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">107,159<span></span>
</td>
<td class="nump">96,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">204,678<span></span>
</td>
<td class="nump">162,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">4,833<span></span>
</td>
<td class="nump">7,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other&#160;Observable Inputs (Level 2) | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other&#160;Observable Inputs (Level 2) | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">3,713<span></span>
</td>
<td class="nump">5,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other&#160;Observable Inputs (Level 2) | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">15,805<span></span>
</td>
<td class="nump">33,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other&#160;Observable Inputs (Level 2) | Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">38,692<span></span>
</td>
<td class="nump">122,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other&#160;Observable Inputs (Level 2) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other&#160;Observable Inputs (Level 2) | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237731023768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Fair Value of Other Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237740719800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 164,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">165,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">129,192<span></span>
</td>
<td class="nump">$ 203,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">36,177<span></span>
</td>
<td class="nump">$ 54,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">15,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">15,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 3,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">3,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember', window );">Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 38,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">$ 38,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember', window );">Commercial and corporate obligations | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 106,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">107,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">86,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">$ 20,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale Debt Securities, Remaining Maturity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_AvailableforsaleDebtSecuritiesRemainingMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237739951496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">$ 39,317<span></span>
</td>
<td class="nump">$ 23,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">39,317<span></span>
</td>
<td class="nump">23,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">9,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">9,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember', window );">Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">4,096<span></span>
</td>
<td class="nump">5,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">4,096<span></span>
</td>
<td class="nump">5,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">25,223<span></span>
</td>
<td class="nump">17,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">25,223<span></span>
</td>
<td class="nump">17,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237731091384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">27,346,228<span></span>
</td>
<td class="nump">27,255,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">27,346,228<span></span>
</td>
<td class="nump">27,255,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237740004520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Issued and Outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options issued and outstanding (in shares)</a></td>
<td class="nump">2,876,063<span></span>
</td>
<td class="nump">3,039,880<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance (in shares)</a></td>
<td class="nump">6,913,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Issued and Outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares reserved for future award grants (in shares)</a></td>
<td class="nump">3,040,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member', window );">2017 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Issued and Outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares reserved for future award grants (in shares)</a></td>
<td class="nump">997,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237739313752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Jan. 26, 2017</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition', window );">Weighted average period remaining for amortization of unrecognized compensation cost (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock | Director Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding', window );">Annual increase in number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease', window );">Capital shares reserved for future issuance, increase (in shares)</a></td>
<td class="nump">1,090,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member', window );">2017 Employee Stock Purchase Plan | Employee stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding', window );">Annual increase in number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease', window );">Capital shares reserved for future issuance, increase (in shares)</a></td>
<td class="nump">272,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved For Future Issuance, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237739455464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding, beginning balance (in shares)</a></td>
<td class="nump">3,039,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">461,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises (in shares)</a></td>
<td class="num">(91,146)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeitures and cancellations (in shares)</a></td>
<td class="num">(534,096)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding, ending balance (in shares)</a></td>
<td class="nump">2,876,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable, ending balance (in shares)</a></td>
<td class="nump">1,355,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 29.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">18.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercises (in dollars per share)</a></td>
<td class="nump">4.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeitures and cancellations (in dollars per share)</a></td>
<td class="nump">37.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">26.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options exercisable, ending balance (in dollars per share)</a></td>
<td class="nump">$ 27.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, options outstanding (in years)</a></td>
<td class="text">7 years 5 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, options exercisable (in years)</a></td>
<td class="text">5 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding</a></td>
<td class="nump">$ 6,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, options exercisable</a></td>
<td class="nump">$ 6,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734509352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Option Fair Value Assumptions (Details) - Options to purchase common stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.50%<span></span>
</td>
<td class="nump">68.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 13.88<span></span>
</td>
<td class="nump">$ 43.08<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237815320328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation</a></td>
<td class="nump">$ 2,805<span></span>
</td>
<td class="nump">$ 3,144<span></span>
</td>
<td class="nump">$ 8,521<span></span>
</td>
<td class="nump">$ 9,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
<td class="nump">3,030<span></span>
</td>
<td class="nump">4,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,879<span></span>
</td>
<td class="nump">$ 1,564<span></span>
</td>
<td class="nump">$ 5,491<span></span>
</td>
<td class="nump">$ 5,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237740009992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> ft&#178; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 04, 2020 </div>
<div>ft&#178; </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>renewal_option </div>
<div>lease</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_LesseeOperatingLeaseNumber', window );">Non-cancellable office leases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_LeaseArrangementAxis=anab_OneOfficeLeaseMember', window );">One office lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber', window );">Number of one year renewal options | renewal_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_LeaseArrangementAxis=anab_A10770WateridgeCircleSanDiegoCalifornia92121Member', window );">10770 Wateridge Circle, San Diego, California 92121</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (sqft) | ft&#178;</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease term</a></td>
<td class="text">124 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1', window );">Lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod', window );">Lease termination term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RentPerSquareFoot', window );">Monthly base rate (usd per sqft) | $ / ft&#178;</a></td>
<td class="nump">4.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AnnualRentIncreasePercent', window );">Increase in annual rent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_AnnualRentIncreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Rent Increase, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_AnnualRentIncreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_LesseeOperatingLeaseNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_LesseeOperatingLeaseNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, One Year Renewal Options, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RentPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent Per Square Foot</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RentPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_LeaseArrangementAxis=anab_OneOfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_LeaseArrangementAxis=anab_OneOfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_LeaseArrangementAxis=anab_A10770WateridgeCircleSanDiegoCalifornia92121Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_LeaseArrangementAxis=anab_A10770WateridgeCircleSanDiegoCalifornia92121Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734511000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Classification on the Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating ROU assets, Other long-term assets</a></td>
<td class="nump">$ 824<span></span>
</td>
<td class="nump">$ 1,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, Other current liabilities</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, Other long-term liabilities</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherAssetsNoncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesCurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734482568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Costs Included in Cash Flow Statement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 660<span></span>
</td>
<td class="nump">$ 660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 722<span></span>
</td>
<td class="nump">$ 698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237734264344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum payments required</a></td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 884<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140237740628952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details) - Anti-PD-1 - TESARO - Amendment - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Oct. 23, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent', window );">Percent of net sales below $1 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable', window );">Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_NetSalesRoyaltyPercent', window );">Royalty percent on net sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent', window );">Percent of net sales above $1 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent', window );">Percent of net sales above $1 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_NetSalesRoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Sales Royalty, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_NetSalesRoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognized, Milestone Method, Milestone Payment Earned, Net Sales above $1 Billion, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognized, Milestone Method, Milestone Payment Earned, Net Sales below $1 Billion, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_CollaborationAndExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_CollaborationAndExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MR^;FM7??7 1_2JJGK)0HYQL]E'?%]%RKYFZU>5%B9RX/5T(I49C'+4]27M4
M_?^-$.KX4@_0W7#/_@502P,$%     @ <H!D4:W[6<:= @  V08  !@   !X
M;"]W;W)K<VAE971S+W-H965T-2YX;6RE55M/VS 4_BM'$0\@ 4G3P@"UD>AE
M&A)H%1W;P[0'-SEM+!P[L]V6[=?OV$E#@;9#VTM\.]]W+C[^TETI_6AR1 M/
MA9"F%^36EE=A:-(<"V9.58F23F9*%\S24L]#4VIDF0<5(HRCZ#PL&)=!TO5[
M8YUTU<(*+G&LP2R*@NE??11JU0M:P7KCGL]SZS;"I%NR.4[0/I1C3:NP8<EX
M@=)P)4'CK!=<MZY&'6?O#;YR7)F-.;A,IDH]NL5-U@LB%Q *3*UC8#0L<8!"
M."(*XV?-&30N'7!SOF;_Z'.G7*;,X$");SRS>2^X""##&5L(>Z]6G[#.Y\SQ
MI4H8_X55;1L%D"Z,544-I@@*+JN1/=5UV  0SW9 7 /BUX#.#D"[!K3?ZZ%3
M SKO]7!6 WSJ896[+]R0699TM5J!=M;$YB:^^AY-]>+2]<G$:CKEA+/)0$FC
M!,^8Q0PFE@9J FM S>!SB9JYVS3 9 8#55 GYJY%E@BWRA@X'#--UCE:GC)Q
M!"?P,!G"X<$1' "7\"57"T-0TPTMA>H<AFD=5K\**]X15AON%!$;&,D,LRWX
MX7[\Y1Y\2"5JZA2OZ]2/]Q).L#R%=G0,<11'6^(9O!O>NMR6SO]Y'_VS]Q?%
M:#=-T_9\[1U\-S)5!3ZW"WR_GAJKZ='_V,/>:=@[GKVS@_U!DN )_IL:DE>.
M#@5UVQ$X75DR+MA4()!$@F$T,9@N-+<<S3%8]K2MURI_Y]Z?$\YE0D5<;M[>
M6XN3^.RES?"O+*.W%JV+R\:F*D:X\58+U',OD@92M9"VNH%FM]'A:R\_K_;[
MK:M!:\O^D'2[DMEG^DKT[YB><WK- F?D*CK]0%*B*R&M%E:57BFFRI+N^&E.
M_Q[4SH#.9TK9]<(Y:/YFR1]02P,$%     @ <H!D42GO2-R;"   +CD  !@
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M\Q?=/VA#,D&K?5GEV[:QLF";9 ^O\;^M(XX:8-K3@+0-R- &M&U C08D[&G
MV@;,:,!$3P/>-N#F"$%/ ]$V$(WO'YS5>/HJKN*+LR*_1T6M5KW5;YIP-:V5
M@Y.LGEDW5:'^FZAVU<4BS\H\3=9Q)=?HIE(O:MI4*+]5'_+5^TV>KF51?O5%
M1'#X+;K^9Y]4']$4_7YSA5Y\^1)]B9(,_;;)]V6<K<NS6:5,JCN>K=KA+Q^&
M)SW#_Y97<0HT6[B;+?+M5DW+QD2@]96[]7?K=5)/ZSA%;^)D/567L(AW"6S)
MM:>OU6J_W:>-^WZM-K) RC9UCV_JF^^#1"]^RLOR)?HA6^5;"72_'-[]E;Q-
M5DG5[62FXGT(.CD$G32]LIY>CT/[=1O45^A2WB59EF1WZ#).XVPE45RI05>O
M$<6O$ EP!,7W8231C%2GL0\7+!)4\+/9A^-XVC(2=B57MD102CCNRJYMV900
MVA4M 1%F0LR#@Z[C.'IP'!W%<2_4E"HW<2%5Z <X<?$P*C_VCI@318<>>]G!
M7M:TI#WVJFFG<%,J@Y0)S;N7]0T+70;ZZVV>IDBEZ_NX6/_MF&7\,#AW.ZMQ
M $K*<J]F[SY3HR&YW:7Y1RE169N =LI=8-;@ED-XR(SYXM9T3!8'D\4H)A\'
M&(JGL$R+6&\PPX-QH7_R36N,KI'*)FIM4<9U&H/\%]H3*A+F#><1=8R,#D9&
M3B.[V2]ITAYZD=9)\!7*9 49&UEV,#,Y7+LU'5/G!U/G3E-_4>NVVC#(I+DU
MG$HR01@9:<8KZQB& PWEX(0\<YVMC>S\<UP<$LL<I&]@^TU$F)OIN=4Y\S/0
METKT*D\9H0)T)#!NWB4@FF(1A:+/=T<+&OSYOC,2M,^/BW;,SC6%:O'>>U-C
MS6+\=#!NA^(^&N,!. ;Z GD,Z  @0RH7D;%&,GX>)N/'0AEK*N-GP#+67,9N
M,+L2'[:I.@W#(*0]UZS)BCUH'9C2;N1.Q25PI#0;KHP$D9F&%JW./<?MO@1C
MF$7F' ?&C )SBMNB^D8(19_O-/CQ /(_,J7Y_+C  /[#8![USV^]!L#N1< C
M4IJ?8 #Y08)% \)M]P43S-8!!+-%;H+I=0EV+TQ.S&A^B-G+%3?$B%ZPD.#I
M,QK1S"<>YG]&J4$ M&-C=EUY1%VSC\IP#_I'*C>(#5<Z[X^J1BL9@-:!%0>Q
M<4D%HZ8?/:JNH1JHA(U>=;1==DP)C9Q^[1%US=4 )J<#F   )G0NC!RU].NZ
MQFE0DW% _>,^<X.: -!D$2/& G)!!H :Z$NP@',K7K;.VCA8 J(IGI.0]@56
M@YJ,#VJ?'Q<$!#7C_3>X!C6)GB%M:] 1#^@^)VW;,&/<W"+RB+I[@!IVU%.=
MCY2VJ5T#<]H;5:II2 =4P /3-K7!1C$S_>A3=0W5_*-N_IV2MBE02,X->Z\]
MHJZY1YN_;ARZTC:UP3:E.*!F'>S7=8W3"*1N!(Y67U$;>6!]U>J<:1OH"ZRO
MH#&M^@H0.>LKJGE,/3O5_T=]16U N^LKJA%-3T&T=\L(#C= Z4"Q)3+#/8#2
M0%^"1:K ,L-MZR@U]U8!T90P%A#1XSY-:7H*I1^U8P1'' (UX?V@IAK4]!E
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M-F\W,E;6UP+U_]L\KSY]J'^?=OB)Y,5_4$L#!!0    ( '* 9%$V.#V_W 4
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M4!C'T_$E^2Z/A(5/&##S8X.)GH-\@/W*H^=-+V)@_A_A_%]02P,$%     @
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M#30 [U?.Q?Q &XP_'GSV+U!+ P04    " !R@&11XYM8R$T#  "J!P  &0
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M3%$[!?I?*65/!P<PCN?UOU!+ P04    " !R@&11*Y-2Q64-  #Z+   &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6SM6EESXS82_BLHKRNQJR19DN^Y
MJC3V9#*5>-:Q)YN'K7V 2$A"0A(,2%I6?OU^W0!(R)8\DV2RV>O%U@'TW5\?
MU(NEL3]5"Z5J<9]G1?5R9U'7Y;.#@RI9J%Q6 U.J M_,C,UEC;=V?E"55LF4
M+^79P7@X/#G(I2YV7KW@SZ[MJQ>FJ3-=J&LKJB;/I5V]5IE9OMP9[80/;O1\
M4=,'!Z]>E'*N;E7]?7EM\>Z@I9+J7!65-H6P:O9R9S)Z]OJ(SO.!OVFUK*+7
M@C29&O,3O7F7OMP9DD J4TE-%"3^W:D+E65$"&+\[&GNM"SI8OPZ4/^*=8<N
M4UFI"Y/]H--Z\7+G;$>D:B:;K+XQRZ^5U^>8Z"4FJ_BO6+JSQ\,=D315;7)_
M&1+DNG#_Y;VW0W3A;-N%L;\P9KD=(Y;R4M;RU0MKEL+2:5"C%ZPJWX9PNB"G
MW-86WVK<JU]!FTQ.C95D''&C*B5MLA"R2,6ENH//2GB@%I.Y58I>52\.:K"E
MRP>)9_':L1AO87$NKDQ1+RKQIDA5NG[_ .*V,H^#S*_'3Q*\5>5 ' Y[8CP<
M#Y^@=]C:X)#I'6ZA=P-%BX:T3\R\T!PM?Y],J]HB9O[Q!(.CEL$1,SCZ(XW\
MF5F(MYF\-[>YKA??$#$148#^[PIQQ13&P]%13RR5P"5E52IT41LA'QPG/F_N
MDZRIB/VW.D':JHZ;V*L72GSQE[/Q>/C\[>TWW3?\V>CY/L*^7H@/;VXG-W_M
M@7LRZ(&H, 4"W,Q7_9E!,H#[5)MR(9&.B6IJG<A,)"8O9;$2!7PB12EM+<SL
MD79['?/ <B"^1T!:0:)!M;RB>_1F34#67=*[5$#Q4EE"0I$H6P/R1*JKQ-PI
MNV(3P.C92@ =$S!EZ=+(^(Z\E26+C@NUGII4J\HI3ZSG!G=P;JX*1:8MYD+G
M>5,8=W$57X(<P-)II7YNB'K$M2>Z5U;-FTS6QJYZ+"+,E2N;Z >R0;6I"MJ1
MG5=DAD\U$;TMI4[)94TYL\AWD?D@F"E%MW9'IX,A$"S+*%YT'%XL5V1B:^YT
MBHM-D9(!\%'CM+5Q6,?25\K>@5V%$]#5D?&66D4N N6YE;DC5B_ 4%2E2O0,
MWJBEG2O4-XK\]SB>3Z%W&_S$, [.]6R80(B4!7EO!F)$W!\9B45*V4+;)8,5
M$%15S78LZ.O,4-3/3&,I0EA&EOX)0X\[.P\$2A>B$B:+S>6Y.<TL4CO3<SW-
M%,F(*%*4PZ"@4'V0.J5<.<0 \::D,[NCL]B7LS8;XLCG8 MO:DL!1S@+.L02
M(FF\#8'6\Y3).FG*$(SSN^?#S7R^']P.'.8T%OV)+*(PIYS(=45=0^4BJZ2(
MDEE%49>C6NL2JFJ8-V'P6A?(9<E&:48GQY$X38D_Y&9_,Z2XCRBHEI')V6RR
M*!I00(.2I4N*[0)NK"0L/! _**1_!GME%>?@)F?4FH.M0CIDJI_B0"VL64GH
MLA[T&S@0?Q@@;1*8WD<!#C=M8B<QDE/&XU+%4*;I!-)>%TP?KE*:@(A1=N4L
MT*F;:)LT>57+ IG8VY !K&9+K^=0#SD-"IP>'*=M0G:B>NE[G<E)7QNP:#2N
M"1$*&,I6:"S#YS-MD4D1WI$YPI>>IC#.!NJ^U+Z4^0.9K)Q0](UR3D2>@G%1
M#\2UU733Y;E,31FN3FXOQ,GPI"="4X$<S5$L"VXF/-)?<%\':06G8*J<4<B%
M"UDSS0W)[:*YQ<  CYTC'X"RQ 4")HKI:F&:+*7PDDEBFJ)F4+%\QH<5"&D.
M8'^":!/#IT7J"*,55I:BU$G)K=0O])8"U-F"L(Y)51",BHTV$?V/HSOE:5NB
M&*DOD2 !J8^W&O/CE)=!"W5?L\FH/)AFON@X'(ZHX1R=#,2$C ::@!(7YEX3
M5F^YT(FKY4T16>&1'SOL;Y$68B#-8]LM8;R/2\3T%A(X 4\F"FJH(J8"V)LU
M6<90(ZL*V<W4-!G4RF+NLE,7['F;4OZZ./7![/N& NU=&ILU\5$M7$191H6>
M@W,B[N<799DS0 E!Q4C!V0G4,4L*LIR2F?(3.0G@AAFVA/0SL3?:=\GIK!E.
MMN6'LU-8FL0\+/H&HM+WF_J /2JLH?3ONW"'1:J90Y>VR8M"QD5W6VQTX09C
MI']/[(WWM\=:Z$!OOI!Y^?RR;7Q##+K"LW>X+WXTFF*S5C +Q"<$TS7>B1Q3
M'CYQ10/6KV!3Z^VYSK=5-9&EG.I,<Z&@OA@&==T/SG=@&RS"WB/11J?/J5ZZ
MNRLV83/M>[OW/## B^3^-B#6FV$"Q5S_$J-JI>(&%C$"OJ75JI;^3L)YB'87
M+!Q-T&#T;8.-0KQT]IZJT"QR<>(F60!J4F.I )DV:#L10QZF!@* C\\;%*VT
M+S-J=X"KB:OXI#@)!3F)LH+=%-^!GO!#@CHP:=N#;+45?K;ZDQ)&)[IT)EH&
MW9U,G,6M>I2/IG'T? 1%N%AT "-#M@S$:TF)[DIF%5*?6SD6-4I(B-]1<Z.
MIHP.G85WMS?!!BAH4[>K!U!SRG;P Z.O,AZ_&63,%+V.'R =G=:YH0Q'",7
MBX\Q_M<> /T.P*$P9ZYTRQX$5:)"H#]H0[23OEHK:K[)[75Y9)7.IXVMW"5?
MPESD1XB-LX5KO5+7TS#\<T,)?$O8>IH]H"T-#>@E7#IQ&7S*))SDGOR#DEHO
M3==:1\*0OKNCN$E-&PXY8E;0&)R[38PK*(\-.<  X]-HUM0-^3JPX?&KA;V(
M:1>L.H2%4_BQ0UQ/DD4RHT.AVN$K'R#F1]\+.DAS;0,A'6AI'P)AQ/<ER'^%
MX4)FC0?BY1H\%@UJD*$9$L( &KR@P3#K&,8M=\D,(B4! <@^(DA?4-%@/#)9
MJ(V$RQ0GKB=NDH1Z:"Z\ZV;D0:ARNXVF1HYX; *#5,\ Q6@JW!"L,)_4+MYB
M3%8S>)GFU G:T:"DRZ%H#N#.OS]E .C4Z$6:M^-#S_7ET_7&8Z$*;PY'TX\2
M2=)PTXBO5LYG,> 9?YRE-]3F%W761CLA2D;;V,;5>H0]4B'@%LI/X86G=%U'
M'(XQ/R!!,'7O XV;ZXVAULU55O5]:"@^>B?A IZO'N$%_,4SB%4E;$Q6\IT=
MCY'4;82.()ID 1@FHTD6&>)2)UD09+'[UV8B9[Z!N.KB*DYJW]X]SLIM_9"#
MF<JW4M4SA$2M^]>7_9'8P\&CX?'IZ'PX.;@T$ #37"ZG^^[,AW=7_4-_Z.3\
M[.Q\<G!AIB8^\NWD;7OD_/3H\.QDOQ-<O+GC;2(GK_BN049"P)M.F=_RS3M:
MO0; O--WB!ISK]W^#]6SX9ZA(<P4<P.G^*'5<$-'?B03[[W]]AJ=W.YH,+P2
MWXV_'!V'UT?1Z\,OT36_>W^)O 3",O"VH?35Y43L'O&Q$1WSK\?KKT_%]0+9
M)<8/=QS::4%!M7O8G?:OC]9?GWLJAT]0Z?M!MEM8B-WCH,49+U5'X^=;_W\*
M@PI.H#[G$8<QB?@Q#E^A181/UJ;N]S#B)L%'0V]81/5OH7LUV4SW^-/)1MG7
M+J&B,AE-"2[W'\YDT3P+$.LC N53P^(3[&9@!5?@W.E37'PU]>*XCH ;C4S%
M)4K.*)\>2G#J,:HES 4J@+:S'A<@:M!P!!5(^G;'5FX7'>3H^E/7=T\)10?B
M0E8+*E]N98T^.&RM7-,*Z0^':(Y6U5I)C;=FC-61B+M#!MSU3D87K2#;X##R
MHEON$I5/:7MZ80L%J3._)P]";.FF?@V#T?DZ@P$C+&^ W_H]/XC'>S+,WJ\M
MA@R3]:]6M">Z_;G1T^G#C<=HTX.9=A#@QF3M(<W&QS&OKVZW/8ZY4!EYM??@
MV<I&T?8Z<H$(CV!^!-[VY",LO-N];+N'_Z'K"4A$DMBOV4#53+D,=^O.:,WG
MQ__N$0#Q\0]4*+,\1Z[T'EP\TRBR9/3\AUMZSYLV,D#0^9Q-3D;UE_O35=_O
MY]%V(1]H($6SE*I,,YSP!K&5QX_R\>:\WZU286F94XY6E/9TP.\Q6&C/9H.P
M _$!;]<\VHV0#QX;^(F''QF<1$'.A1 D@N)+U24T!*6P>S2/>/ASCTN>?')P
M?!BQ*E58OO0$.IAM^VV<7-MF;PB?R"X]+UT\O:VMY;=N:!+T2=5OVY)],"7B
M^M?ORMC.GVE7MN;VW[$KBW=BGV4E]G!?T>,MEQ1+2VN0PK?;(C5HE95;/,\T
M+[?#4NQH_P]:A[']/60]N?+R?N@L\_\=V*_:@7D?0XG@6B;['[P4ZXD_82OV
MNU=BON"MEXBG-V)AFT&/+GKT/(Q-N@:P_]*UV'N*T# 5_/=NJ7I__IJ*;\7H
M^#^P?*+,^..63_\..Z=V#/VDC=,Z4FS?.'WZ;NC"Y&CT0T4,L_Q'-CZTUL%,
M-C@.JQBWUQ@]M7YI]SXGZT_C0[!WZ;"A9=T6EYIWM3D%1J9_4A1A,#U7J"@Y
M_<1,-/S [";J\#26!7".KC[/"/V!XI7'D\*T L1SO_<H-9N_?V+F@S39#C;]
M//(@^CTJ0&W.O[JM7.OK?IK:?MK^L'?B?L_:'7>_"KY"MX4.7V1JAJO#P>GQ
MCNM9PYO:E/SKUJFIT3_SRX62T)4.X/N9,75X0PS:GSN_^B=02P,$%     @
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M4+L!]'^M:-_N&BY!?X&:_PU02P,$%     @ <H!D4<#+=K&0"@  >2$  !D
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MEL44W4PU+,6%1U6E4#ZA]XKZXX<D&DP^=P? E:AK>ILM NYRT 7"* S]T/U
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M.TH#H/U<"'V8F /ZC\7R'U!+ P04    " !R@&11+1-(Y&P(  !.%@  &0
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MTO:C:G"R"]BZO*=GX9*=T-<X]*RYU.R.O#LJFX^1=#!O=P(!'E67T (>Y0,
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MJ(3?&M&8YCB3388RD&FEA"D*G2E1A9U'OE3BSW\Z3Y+%^[OP)LC@M>7[MU/
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M^HS;E3@].Z4?"3?69?*>'E;CA_7P  !@LBZ C_V2(<[H?1I8RZI?._3$7%Q
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MS3]+!3JPM 'O:8[H'TC!\+'\ZM]02P,$%     @ <H!D496FN9$\!@  ,PX
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MB0GO)A@MK752%E:H$NM4Z1#8'M>ZZ0U)TC&:),L:JQ>VX1 Z5A=-]#-5Y<#
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MT(XZ4!CFU/+1^ .TO]3TKLW$$[1_(N._4$L#!!0    ( '* 9%%A> O;:@,
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ML3,(!>;6(3!:GO C"N& R(P?/68P4#K%T_T1_3?O._FR8P8_*O&-%[9:!;,
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MVKL:4^/JZJ)03:PJ_.&\59:.>C_<T]T*M=M [S.E[''B'#2WM<6_4$L#!!0
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MBOIC@9N4:J> [[G"&=9<G(-V-T_^ E!+ P04    " !R@&11*L\6^B4#  "
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MTW/4\DZ1[_E>#7W43!_3".C8T''O)=T%JTJ__-(OW\9KO1)O6_DIFH!Q>L^
MGS< 1]>:QNI70[)6F:QED[7?2&:ST&V64[240M5:F8<+;3AS@-?#, S]OKNN
M&E8#\GN=$O1":;M4VFY4>D.5NH S&65QQHFF<SA*T%8B1O+#"OI)+*1FO^U"
MG?8\05"1=19XG<Z>^!I4.^STZM4'I?J@4?V=,%L\?<7MA.HZO<&!$AQT@SVY
M-: 0=^O5AJ7:L-EK,A.2:"&?=RH;-ENG#-OY^)W=+9-UWW=G=P^,#/R*D;G;
MAZ!V#^-ZMWNETEZCTF^+!8/^N,ADPC2TOY>*&ZS WJX%>Q_O/*YT?/R^WA?Q
MJKYV_?V#60=ZS7N\Z[;8?Z.OP"=Z)?@<L1C.Y]I^CE23#;O>BEO_P?5=@\3-
M'?+?76\?]FE\X/HA*.@$>ZZ[E>N!N9M])7+)$H4X70#+.^_ 2Y/Y=2>?:)':
M&\-,:+A_V.$*KHA4&@ \7PBAMQ-S"2DOG<,_4$L#!!0    ( '* 9%'W;SZV
MO (  %L'   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;(U5R6[;,!#]
M%4+H(0'2:/,:V (2NT5[*!K$27LH>J#ED46$(E62LM._[Y"252=2#%\D+O-F
MWCP.A[.]5,\Z!S#DI>!"S[W<F/+&]W6:0T'UM2Q!X$XF54$-3M76UZ4"NG&@
M@OM1$(S\@C+A)3.W=J^2F:P,9P+N%=%545#U]PZXW,^]T#LL/+!M;NR"G\Q*
MNH45F*?R7N',;[UL6 %",RF(@FSNW88WB[&U=P8_&.SUT9C83-92/MO)U\W<
M"RPAX) :ZX'B;P<+X-PZ0AI_&I]>&]("C\<'[Y]=[IC+FFI82/Z3;4P^]R8>
MV4!&*VX>Y/X+-/D,K;]4<NV^9-_8!AY)*VUDT8"10<%$_:<OC0Y'@'#P#B!J
M -&Y@+@!Q"[1FIE+:TD-369*[HFRUNC-#IPV#HW9,&%/<644[C+$F>2.<BI2
M("M7,K=I*BMA-*%B0U9567+ $S.4DR73*9>Z4J#)1VNG*MB03R]831J7+I9@
M*./Z$C>?5DMR\>&2?"!,D,=<5AJ]Z9EOD*X-ZJ<-M;N:6O0.M164UR0.KD@4
M1$$/?'$:OH04X:&%A]/7<!]%:I6*6J4BYR\^2ZD'X-2@ L>Z_+I=:Z.P,'^?
M"!>WX6(7;O!.N(/$J2RLQK0N>CP6U42&1OL^86O7(^?:WN-=$HTGT<S?'<O7
M8Q0._QN]8CUH60_.8ETJF8&V5QUK)X-^EK6KX1&!,(BG;UAVC0;QL)_DL"4Y
M/(LDGAE0E>97>.]WV,]*6^M.XX***L.#K!03VY-*#[LY#(+IX$T27:M).!WU
M9S%JLQB=S.*[R4'U41IU@D716T(]-J-I/Y]QRV=\DL^CM'V"-MJ>TFS<*;QP
M$G8.OL<J##KUZ1^U/OOL?*-JRX0F'#+$!==CS%'5K;R>&%FZ;KB6!GNK&^;X
M^H&R!KB?26D.$]M@V_<T^0=02P,$%     @ <H!D4>*%L&8["   _C   !D
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M$K.BI]UYA5H@4"$3?E#,+/2XFJ"YO\D,&H?-!F7Z6:<")S2,G#=QP ,Q7Q9
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M"5X0)AN([Y>4\O)&=E#]Y.'\?U!+ P04    " !R@&11X.JY8Q<#  #R"0
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M&ML _+"T+1J4*[#[*RG-?N*Z0-_TL[]02P,$%     @ <X!D47_A7P^] @
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MY8T6N3W>+(7&PY*]W.*)&:1Y 9^OA= O-^;$5)_!)_\ 4$L#!!0    ( '.
M9%%AHR0H'00  !L/   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;*V7
M2W/B.!" _XJ*FD-2E6#+3Y@"JO+:W3E,+14F,V=A-^"-;3&2'))_/RW9V.QB
M&YC:"\BVNOOKAUK29,?%J]P */*>I;F<#C9*;3];EHPVD#$YY%O(\<N*BXPI
M?!1K2VX%L-@(9:GEV'9@92S)![.)>3<7LPDO5)KD,!=$%EG&Q,<]I'PW'=#!
M_L5SLMXH_<*:3;9L#0M0+]NYP">KUA(G&>0RX3D1L)H.[NCG>\<(F!G?$]C)
M@S'1KBPY?]4/7^+IP-9$D$*DM J&?V_P &FJ-2''STKIH+:I!0_'>^U_&.?1
MF263\,#3'TFL-M/!:$!B6+$B5<]\]Q=4#OE:7\13:7[)KIIK#TA42,6S2A@)
MLB0O_]E[%8@# <?O$' J <=PEX8,Y2-3;#81?$>$GHW:],"X:J01+LEU5A9*
MX-<$Y=3LZ6>1J _R)8\@U_$A\Y3EDMR2O[<F:G<Z:GK&U2,HEJ3R&K^]+![)
MU:=K\HE81&Z8 $F2G+SDB9(W^!+'WS:\D"R/Y<122*EM65%%=%\2.1U$8_*5
MYVHCR5,>0_QO>0N]JUUT]B[>.[T*%[ =$M>^(8[MV#WZW#IDKM'G=NDK/5X4
MRW^PM(CB5:QDCVZOUNT9W5Z7;L6C5\)+?017D508Q21?WY EK),\QR%6(>8H
M G*%@2[#?]T6YM*2;RSIQ?DV<VUW/!IA#-Y:$/T:T>]%_%.P7$%\RKI_9-T+
MJ.?X[<:#VGC0:_SI'4242 S_"?/!D?G;,:5>T&X^K,V'O>:Q$:P@487./^:%
M1#H/:<K*=)U "H^1?->SQQU,HYII]+LE ^;_W'H9'?$YHS"P [>=;USSC2_@
M@S*!;)G"I7SC(S[J^K[O=M0SM9L6:/<NZ!^F=4-\>_<& K<BLJ\R,A<)<FU!
M$+/H>Q8X/6BX]/]=XC''"A/28)CPM$:GLCHZ3-]XZ'7$QFEHG;-7^YD@I4(=
M\R91HV%'%=&FZU+W@J5_)HM[S.(-[8X51YLN3?O;].D^<":?=\SGAD._*VU-
MCZ;]3?JRIG FK'\,ZP3#,>V ;7HZ[6_JEW6(,V&#X^40#KU1!VNS =#PLE[Q
M#/KLJR$?\-@B\)19L)1\ Y&9RKA;KP6LF0(\8BF1X&DV(M]96O3VDJ;UT_[>
MOZ<AK*(1-4UT0*.0YJ:M&DQ /P##V1[$?NMA*4I\DI4G-CHF,?OH.P?19M>@
M_=O&;[EV4#NG7.NW[E>NA7O7'/N4:TZSWSAVK_*F)I*Z)MYT3;3FJ(V^,A <
M5'<0>F%[<3O-UN3T;TUG@!U$N!6,'H.YP7\/?=;!?24#L3:W,HEY+7)57EWJ
MM_7-[ZZ\[S33RVOC5R9PSY0DA16*VL,0FY0H;V+E@^);<_M9<H5W*3/<X.T5
MA)Z WU><J_V#-E#?AV>_ %!+ P04    " !S@&11>GW&[AL#  #="   &0
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MZ&$B>TI@"B"_+R@5^XDR4'6I@[]02P,$%     @ <X!D40GL"^#? P  =PP
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M-1WX^!#PC>/:;HW!.UEH_>0GM\4X2KP@%)@[S\#H\XQ3%,(3D8Q?+6?4I?3
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MYP&!=/LAI_/==S8-RS"P^$[PG V'5+3G[7H=CGDE;]#)&QR4%RY7Q7@!U*"
M25W[\O"MZ^=*!$G2J3+AZNEEZT1PMN"".ZK>/D.#-V+/TW3'T-N8X>7%CJ%X
MZZU)-*O0@BS5D90V=[%;[;K<=7C<.^L3ZGY-L_I+T[3..V967%GRM23*Y/2<
M=)FF'343IZOPHA?:47\(PY(Z.!H?0/M+K=UFXA-T_PG9'U!+ P04    " !S
M@&11<MN_+J4"  "5!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R=
ME5U/VS 4AO^*%7$!TB ?;=,6I9&@%=JDH2$*V\6T"S<Y:2S\$6R'PK^?[82L
M6],6[2;QUWN>]SCQ<;(1\DF5 !J],LK5S"NUKBY]7V4E,*PN1 7<S!1",JQ-
M5ZY]54G N1,QZD=!$/L,$^ZEB1N[DVDB:DT)ASN)5,T8EF_70,5FYH7>^\ ]
M69?:#OAI4N$U+$$_5G?2]/PN2DX8<$4$1Q**F7<57EZ'3N!6?">P45MM9%-9
M"?%D.U_RF1=81T ATS8$-J\7F .E-I+Q\=P&]3JF%6ZWWZ/?N.1-,BNL8"[H
M#Y+K<N9-/)1#@6NJ[\7F,[0)C6R\3%#EGFC3K@T\E-5*"]:*C0-&>//&K^U&
M; FB<(\@:@61\]V G,L%UCA-I-@@:5>;:+;A4G5J8XYP^U666II98G0ZG0O&
MB#;;K!7"/$=SP37A:^ 9 87.T=+\!GE- 8D"W=2ZEH!N"2>L9NB*\QI3]&U%
MR1K;+5;H= $:$ZK.T DB'#V4HE8FJDI\;;Q:HI^UOJX;7]$>7TNH+M @^(2B
M( H>EPMT>G+V=Q3?9-JE&W7I1B[LX+_271"54:%LDC^O5DI+\\_\.D ==-2!
MHP[W4&T.?5O0J&*GLL?G)8V&X\1_Z4$-.]3P&"KL0S6JT18J'L?]J%&'&AU#
M17VHT0XJZ ?%'2@^!AKT@>*/@L8=:'P,-.P#C3\*FG2@R4'00PFFA!8:9!]N
M\E'<M,--#^.$-@>5M>>VPF_- 9#P7!,)>9^'Z8Z'J?T(?2["X$^M"0[Z^ I*
M(<*J6D-NZH-)'Y3NK0W!#OY\,-V#WRIUX?%MZ,6%.P=Q,AG^@_.WBJR]L&ZQ
M7!-3\R@41A5<C(U;V=P!34>+RM7=E="FBKMF:>Y-D':!F2^$T.\=6\J[FSC]
M#5!+ P04    " !S@&11A$2/YB0#  #W"@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6RU5EUOVC 4_2M6U$FM5$@</EL!$BVMUFFH"-;M8=J#DUS
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MF0XCHLF@)\4:2;O;L-E!)F:&-NE3;K_[3$OSEAJ<'LS20,%+"ERCNY5]GH]
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M-BX\L8%$,JF0-CMOI 0V4CV[=. \>RA:#J="JJ:VJ^!^EVWWO<36LP(I8YW
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MIS\(Z< LN(./1G>M4#>A&M^*2=2,/@[[XRZ(I^9?PJ@W&U'"0I== \KMXFA
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M)UG?M5[]]?^F=HUK539'?];]U)M_ E!+ 0(4 Q0    ( '* 9%$'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ <H!D4:TM)@KO    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ <H!D49E<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !R
M@&11VL26%DT%    %@  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ <H!D4; PM.<[!0  &!0  !@
M         ("!D0T  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( '* 9%$V?[(/U@(  +T)   8              " @0(3  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !R@&1131"0&;T%  #M%@
M&               @($.%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ <H!D4:W[6<:= @  V08  !@              ("! 1P  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( '* 9%$I[TC<FP@
M "XY   8              " @=0>  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " !R@&11-C@]O]P%  !P%0  &               @(&E
M)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ <H!D429@
M(,>*!0  +PP  !@              ("!MRT  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( '* 9%'*@NFT @\  $@H   8
M  " @7<S  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !R
M@&11XYM8R$T#  "J!P  &0              @(&O0@  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( '* 9%$KDU+%90T  /HL   9
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M970Q-2YX;6Q02P$"% ,4    " !R@&11,S9E.\P)   X%P  &0
M    @(%Z;@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M '* 9%&5IKF1/ 8  #,.   9              " @7UX  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ <H!D49"/C[+3#@  YR@  !D
M             ("!\'X  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " !R@&11)R(,*NP"  !0!@  &0              @('ZC0  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( '* 9%%A> O;:@,
M . '   9              " @1V1  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ <H!D49@'^\J> P  *@D  !D              ("!
MOI0  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !R@&11
MW)S30? &  "W%0  &0              @(&3F   >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( '* 9%%3?;H/O0(  +P%   9
M      " @;J?  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ <H!D48=!>NX6!0  C0L  !D              ("!KJ(  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !R@&1178M:BM\#  "Y"0
M&0              @('[IP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( '* 9%'SO+.;&P(  ( $   9              " @1&L  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ <H!D49/_J +9
M @  IP<  !D              ("!8ZX  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " !R@&11*L\6^B4#  " "@  &0
M@(%SL0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( '*
M9%'W;SZVO (  %L'   9              " @<^T  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ <H!D4>*%L&8["   _C   !D
M         ("!PK<  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    " !R@&11X.JY8Q<#  #R"0  &0              @($TP   >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( '* 9%$F_Z1_% <  %L[
M   9              " @8+#  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ <H!D4?E-H_"" @  HP8  !D              ("!S<H
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !S@&11H9J"
MS^H%  !I(@  &0              @(&&S0  >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( '. 9%'4?YD[:@0  /X5   9
M  " @:?3  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M<X!D4?0O@EA$ @    8  !D              ("!2-@  'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " !S@&11?^%?#[T"  #]!P  &0
M            @('#V@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( '. 9%%<_#[DYP,  (\/   9              " @;?=  !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ <X!D46&C)"@=!
M&P\  !D              ("!U>$  'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " !S@&11>GW&[AL#  #="   &0              @($I
MY@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( '. 9%%I
M3E/D*0,  +$*   9              " @7OI  !X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ <X!D40GL"^#? P  =PP  !D
M     ("!V^P  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '. 9%'&Z%5X0P(  'X+   -              "
M 27]  !X;"]S='EL97,N>&UL4$L! A0#%     @ <X!D49>*NQS     $P(
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9>&UL4$L%!@     V #8 L0X  $D( 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>213</ContextCount>
  <ElementCount>291</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statement of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity</Role>
      <ShortName>Consolidated Statement of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/DescriptionoftheBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures</Role>
      <ShortName>Balance Sheet Accounts and Supplemental Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Collaborative Research and Development Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements</Role>
      <ShortName>Collaborative Research and Development Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.anaptysbio.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - Fair Value Measurements and Available for Sale Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2138110 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables</Role>
      <ShortName>Balance Sheet Accounts and Supplemental Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Collaborative Research and Development Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables</Role>
      <ShortName>Collaborative Research and Development Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Fair Value Measurements and Available for Sale Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/StockholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/EquityIncentivePlans</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails</Role>
      <ShortName>Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Collaborative Research and Development Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails</Role>
      <ShortName>Collaborative Research and Development Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.anaptysbio.com/role/NotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/NotesPayable</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Fair Value Measurements and Available for Sale Investments - Fair Value of Other Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Fair Value of Other Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Equity Incentive Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails</Role>
      <ShortName>Equity Incentive Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Equity Incentive Plans - Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails</Role>
      <ShortName>Equity Incentive Plans - Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Equity Incentive Plans - Option Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails</Role>
      <ShortName>Equity Incentive Plans - Option Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Commitments and Contingencies - Classification on the Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails</Role>
      <ShortName>Commitments and Contingencies - Classification on the Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails</Role>
      <ShortName>Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="anab-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/SubsequentEvents</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="anab-20200930.htm">anab-20200930.htm</File>
    <File>anab-20200930.xsd</File>
    <File>anab-20200930_cal.xml</File>
    <File>anab-20200930_def.xml</File>
    <File>anab-20200930_lab.xml</File>
    <File>anab-20200930_pre.xml</File>
    <File>anab-93020x10qxexx311.htm</File>
    <File>anab-93020x10qxexx312.htm</File>
    <File>anab-93020x10qxexx321.htm</File>
    <File>anab-93020x10qxexx322.htm</File>
    <File>lizzulemploymentagreem.htm</File>
    <File>loumeauamendedandresta.htm</File>
    <File>mulroyemploymentagreem.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>anab-20200930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "anab-20200930.htm": {
   "axisCustom": 1,
   "axisStandard": 20,
   "contextCount": 213,
   "dts": {
    "calculationLink": {
     "local": [
      "anab-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "anab-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "anab-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "anab-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "anab-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "anab-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 381,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 3,
    "http://www.anaptysbio.com/20200930": 3,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 11
   },
   "keyCustom": 32,
   "keyStandard": 259,
   "memberCustom": 24,
   "memberStandard": 28,
   "nsprefix": "anab",
   "nsuri": "http://www.anaptysbio.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.anaptysbio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures",
     "role": "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures",
     "shortName": "Balance Sheet Accounts and Supplemental Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Collaborative Research and Development Agreements",
     "role": "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements",
     "shortName": "Collaborative Research and Development Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Notes Payable",
     "role": "http://www.anaptysbio.com/role/NotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - Fair Value Measurements and Available for Sale Investments",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments",
     "shortName": "Fair Value Measurements and Available for Sale Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Stockholders' Equity",
     "role": "http://www.anaptysbio.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Equity Incentive Plans",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlans",
     "shortName": "Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - Commitments and Contingencies",
     "role": "http://www.anaptysbio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138110 - Disclosure - Subsequent Events",
     "role": "http://www.anaptysbio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures (Tables)",
     "role": "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables",
     "shortName": "Balance Sheet Accounts and Supplemental Disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Collaborative Research and Development Agreements (Tables)",
     "role": "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables",
     "shortName": "Collaborative Research and Development Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Fair Value Measurements and Available for Sale Investments (Tables)",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables",
     "shortName": "Fair Value Measurements and Available for Sale Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.anaptysbio.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - Equity Incentive Plans (Tables)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansTables",
     "shortName": "Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anab:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.anaptysbio.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anab:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "if39316fb1c754dec9de54a11b19471c9_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)",
     "role": "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "if39316fb1c754dec9de54a11b19471c9_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment (Details)",
     "role": "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails",
     "shortName": "Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)",
     "role": "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails",
     "shortName": "Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i197dcc146a064825a722c622e39823b6_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Collaborative Research and Development Agreements (Details)",
     "role": "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails",
     "shortName": "Collaborative Research and Development Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ibaed7d0c461e4199ad5b9a83b5ed6c0b_D20141101-20141130",
      "decimals": "INF",
      "lang": "en-US",
      "name": "anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i77ef9b411b014186ae96e571e310a67c_I20141224",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Notes Payable (Details)",
     "role": "http://www.anaptysbio.com/role/NotesPayableDetails",
     "shortName": "Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i77ef9b411b014186ae96e571e310a67c_I20141224",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i63a8061e93f9480896f76c4620112a7c_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i2ab47a7f50ba4fb2826b5e3dc7761fb5_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Fair Value Measurements and Available for Sale Investments - Fair Value of Other Financial Instruments (Details)",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Fair Value of Other Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i2ab47a7f50ba4fb2826b5e3dc7761fb5_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)",
     "role": "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Equity Incentive Plans - Narrative (Details)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
     "shortName": "Equity Incentive Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "iaa7414d9fb2645cab8e4048e6169b41d_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Equity Incentive Plans - Option Activity (Details)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails",
     "shortName": "Equity Incentive Plans - Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i197dcc146a064825a722c622e39823b6_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i197dcc146a064825a722c622e39823b6_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Equity Incentive Plans - Option Fair Value Assumptions (Details)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails",
     "shortName": "Equity Incentive Plans - Option Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "if02daa3879aa4022bc89a201b218b9d3_D20200101-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i197dcc146a064825a722c622e39823b6_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails",
     "shortName": "Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i5ef232fdc16443ab824f750c8ecbc67b_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "anab:LesseeOperatingLeaseNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "anab:LesseeOperatingLeaseNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "anab:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Commitments and Contingencies - Classification on the Balance Sheet (Details)",
     "role": "http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails",
     "shortName": "Commitments and Contingencies - Classification on the Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "anab:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)",
     "role": "http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails",
     "shortName": "Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)",
     "role": "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i1c866d9da83e4dcc8770799fd0c1bd3c_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "iaa90cb92269c4595b23777618939cb79_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Subsequent Event (Details)",
     "role": "http://www.anaptysbio.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "iaa90cb92269c4595b23777618939cb79_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i197dcc146a064825a722c622e39823b6_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "role": "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "i197dcc146a064825a722c622e39823b6_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ia19642c61e8545afa9130417d92767d4_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statement of Stockholders\u2019 Equity",
     "role": "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity",
     "shortName": "Consolidated Statement of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ibe9518b119be40879fc2dbaacdfd8964_D20190101-20190331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of the Business",
     "role": "http://www.anaptysbio.com/role/DescriptionoftheBusiness",
     "shortName": "Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20200930.htm",
      "contextRef": "ie0113e4659b448a8adf05d8acc41f64b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 53,
   "tag": {
    "anab_A10770WateridgeCircleSanDiegoCalifornia92121Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "10770 Wateridge Circle, San Diego, California 92121",
        "label": "10770 Wateridge Circle, San Diego, California 92121 [Member]",
        "terseLabel": "10770 Wateridge Circle, San Diego, California 92121"
       }
      }
     },
     "localname": "A10770WateridgeCircleSanDiegoCalifornia92121Member",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Research And Development Expenses, Current",
        "label": "Accrued Research And Development Expenses, Current",
        "terseLabel": "Accrued research, development and manufacturing expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AnaptysBio Generated Anti-LAG3 Antagonist Antibody (TSR-033) [Member]",
        "label": "AnaptysBio Generated Anti-LAG3 Antagonist Antibody (TSR-033) [Member]",
        "terseLabel": "Anti-LAG-3 (GSK40974386)"
       }
      }
     },
     "localname": "AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member]",
        "label": "AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member]",
        "terseLabel": "Anti-PD-1 (CC-90006)"
       }
      }
     },
     "localname": "AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AnaptysBio Generated Anti-TIM3 Antagonist Antibody (TSR-022) [Member]",
        "label": "AnaptysBio Generated Anti-TIM3 Antagonist Antibody (TSR-022) [Member]",
        "terseLabel": "Anti-TIM-3 (GSK4069889A/Cobolimab)"
       }
      }
     },
     "localname": "AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) [Member]",
        "label": "AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) [Member]",
        "terseLabel": "Anti-PD-1 (GSK4057190A/Dostarlimab)",
        "verboseLabel": "Anti-PD-1"
       }
      }
     },
     "localname": "AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails",
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AnnualRentIncreasePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Annual Rent Increase, Percent",
        "label": "Annual Rent Increase, Percent",
        "terseLabel": "Increase in annual rent"
       }
      }
     },
     "localname": "AnnualRentIncreasePercent",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "anab_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Classification on the Balance Sheet"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "anab_AvailableforsaleDebtSecuritiesRemainingMaturity": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Available-for-sale Debt Securities, Remaining Maturity",
        "label": "Available-for-sale Debt Securities, Remaining Maturity",
        "terseLabel": "Investments outstanding, maturity date range (in years)"
       }
      }
     },
     "localname": "AvailableforsaleDebtSecuritiesRemainingMaturity",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure",
        "label": "Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure",
        "terseLabel": "Investments at fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_CelgeneCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Celgene Corporation [Member]",
        "label": "Celgene Corporation [Member]",
        "terseLabel": "Celgene Corporation"
       }
      }
     },
     "localname": "CelgeneCorporationMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_ClearanceOfInvestigationalNewDrugFromFDAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clearance Of Investigational New Drug From FDA [Member]",
        "label": "Clearance Of Investigational New Drug From FDA [Member]",
        "terseLabel": "IND clearance from the FDA"
       }
      }
     },
     "localname": "ClearanceOfInvestigationalNewDrugFromFDAMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_CollaborationAndExclusiveLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration and Exclusive License Agreement",
        "label": "Collaboration and Exclusive License Agreement [Member]",
        "terseLabel": "Amendment"
       }
      }
     },
     "localname": "CollaborationAndExclusiveLicenseAgreementMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_CommercialAndCorporateObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commercial And Corporate Obligations [Member]",
        "label": "Commercial And Corporate Obligations [Member]",
        "verboseLabel": "Commercial and corporate obligations"
       }
      }
     },
     "localname": "CommercialAndCorporateObligationsMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding",
        "label": "Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding",
        "terseLabel": "Annual increase in number of shares available for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved For Future Issuance, Increase",
        "label": "Common Stock, Capital Shares Reserved For Future Issuance, Increase",
        "terseLabel": "Capital shares reserved for future issuance, increase (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceIncrease",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "anab_DebtInstrumentMaximumBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Maximum Borrowing Capacity",
        "label": "Debt Instrument, Maximum Borrowing Capacity",
        "terseLabel": "Debt instrument, maximum borrowing capacity"
       }
      }
     },
     "localname": "DebtInstrumentMaximumBorrowingCapacity",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_DebtInstrumentNumberOfLoanInstallments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Number Of Loan Installments",
        "label": "Debt Instrument, Number Of Loan Installments",
        "terseLabel": "Number of loan installments (in installments)"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfLoanInstallments",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition",
        "label": "Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition",
        "terseLabel": "Weighted average period remaining for amortization of unrecognized compensation cost (in years)"
       }
      }
     },
     "localname": "EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options",
        "label": "Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_EmployeeStockPurchasePlan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, 2017 [Member]",
        "label": "Employee Stock Purchase Plan, 2017 [Member]",
        "terseLabel": "2017 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2017Member",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_EquityIncentivePlan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Incentive Plan, 2017 [Member]",
        "label": "Equity Incentive Plan, 2017 [Member]",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2017Member",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_FilingofMMAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Filing of MMA [Member]",
        "label": "Filing of MMA [Member]",
        "terseLabel": "Filing of the first MAA - first indication"
       }
      }
     },
     "localname": "FilingofMMAMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_FilingofNDAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Filing of NDA [Member]",
        "label": "Filing of NDA [Member]",
        "terseLabel": "Filing of the first NDA - first indication"
       }
      }
     },
     "localname": "FilingofNDAMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_InVivoToxicologyStudiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In Vivo Toxicology Studies [Member]",
        "label": "In Vivo Toxicology Studies [Member]",
        "terseLabel": "Initiated in vivo toxicology studies using good laboratory practices (GLPs)"
       }
      }
     },
     "localname": "InVivoToxicologyStudiesMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_LeaseArrangementAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Arrangement [Axis]",
        "label": "Lease Arrangement [Axis]",
        "terseLabel": "Lease Arrangement [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementAxis",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "anab_LeaseArrangementDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Lease Arrangement [Axis]",
        "label": "Lease Arrangement [Domain]",
        "terseLabel": "Lease Arrangement [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementDomain",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period",
        "terseLabel": "Lease termination term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_LesseeOperatingLeaseNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number",
        "label": "Lessee, Operating Lease, Number",
        "terseLabel": "Non-cancellable office leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumber",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, One Year Renewal Options, Number",
        "label": "Lessee, Operating Lease, One Year Renewal Options, Number",
        "terseLabel": "Number of one year renewal options"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOneYearRenewalOptionsNumber",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anab_LoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loan And Security Agreement [Member]",
        "label": "Loan And Security Agreement [Member]",
        "terseLabel": "Loan and Security Agreement (LSA)"
       }
      }
     },
     "localname": "LoanAndSecurityAgreementMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_NetSalesRoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net Sales Royalty, Percent",
        "label": "Net Sales Royalty, Percent",
        "terseLabel": "Royalty percent on net sales"
       }
      }
     },
     "localname": "NetSalesRoyaltyPercent",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "anab_OneOfficeLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "One Office Lease [Member]",
        "label": "One Office Lease [Member]",
        "terseLabel": "One office lease"
       }
      }
     },
     "localname": "OneOfficeLeaseMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_Phase1ClinicalTrialInitiationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phase 1 Clinical Trial Initiation [Member]",
        "label": "Phase 1 Clinical Trial Initiation [Member]",
        "verboseLabel": "Phase 1 clinical trial initiation"
       }
      }
     },
     "localname": "Phase1ClinicalTrialInitiationMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_Phase2ClinicalTrialInitiationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phase 2 Clinical Trial Initiation [Member]",
        "label": "Phase 2 Clinical Trial Initiation [Member]",
        "terseLabel": "Phase 2 clinical trial initiation"
       }
      }
     },
     "localname": "Phase2ClinicalTrialInitiationMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_Phase3ClinicalTrialInitiationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phase 3 Clinical Trial Initiation [Member]",
        "label": "Phase 3 Clinical Trial Initiation [Member]",
        "terseLabel": "Phase 3 clinical trial initiation"
       }
      }
     },
     "localname": "Phase3ClinicalTrialInitiationMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_Phase3clinicaltrialinitiationsecondindicationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phase 3 clinical trial initiation - second indication [Domain]",
        "label": "Phase 3 clinical trial initiation - second indication [Domain]",
        "terseLabel": "Phase 3 clinical trial initiation - second indication [Domain]"
       }
      }
     },
     "localname": "Phase3clinicaltrialinitiationsecondindicationDomain",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_RentPerSquareFoot": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rent Per Square Foot",
        "label": "Rent Per Square Foot",
        "terseLabel": "Monthly base rate (usd per sqft)"
       }
      }
     },
     "localname": "RentPerSquareFoot",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent",
        "label": "Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent",
        "terseLabel": "Agreement term following first commercial sale or expiration of the last to expire patent (in years)"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales",
        "label": "Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales",
        "terseLabel": "Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to)"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals",
        "label": "Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals",
        "terseLabel": "Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to)"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events",
        "label": "Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events",
        "terseLabel": "Milestone payments, contingent upon preclinical and clinical trial events (up to)"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone",
        "label": "Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone",
        "terseLabel": "Maximum milestone payments per target"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount",
        "label": "Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount",
        "terseLabel": "Milestones achieved, amount"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails",
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period",
        "label": "Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period",
        "terseLabel": "Number of milestones achieved during period"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets",
        "label": "Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets",
        "terseLabel": "Number of outstanding research and development targets"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Receivable",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Receivable",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Receivable"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsUpfrontFeeReceivable",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received",
        "terseLabel": "Upfront license fee received"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails",
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognized, Milestone Method, Milestone Payment Earned",
        "label": "Revenue Recognized, Milestone Method, Milestone Payment Earned",
        "terseLabel": "Milestone Event"
       }
      }
     },
     "localname": "RevenueRecognizedMilestoneMethodMilestonePaymentEarned",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognized, Milestone Method, Milestone Payment Earned, Net Sales above $1 Billion, Percent",
        "label": "Revenue Recognized, Milestone Method, Milestone Payment Earned, Net Sales above $1 Billion, Percent",
        "terseLabel": "Percent of net sales above $1 billion"
       }
      }
     },
     "localname": "RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesAbove1BillionPercent",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognized, Milestone Method, Milestone Payment Earned, Net Sales below $1 Billion, Percent",
        "label": "Revenue Recognized, Milestone Method, Milestone Payment Earned, Net Sales below $1 Billion, Percent",
        "terseLabel": "Percent of net sales below $1 billion"
       }
      }
     },
     "localname": "RevenueRecognizedMilestoneMethodMilestonePaymentEarnedNetSalesBelow1BillionPercent",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims",
        "label": "Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_TESAROInc.AndTESARODevelopmentInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TESARO, Inc. And TESARO Development, Inc. [Member]",
        "label": "TESARO, Inc. And TESARO Development, Inc. [Member]",
        "terseLabel": "TESARO"
       }
      }
     },
     "localname": "TESAROInc.AndTESARODevelopmentInc.Member",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails",
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_TermALoansMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term A Loans [Member]",
        "label": "Term A Loans [Member]",
        "terseLabel": "Term A Loans"
       }
      }
     },
     "localname": "TermALoansMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_TermBLoansAndTermCLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term B Loans And Term C Loans [Member]",
        "label": "Term B Loans And Term C Loans [Member]",
        "terseLabel": "Term B and Term C Loans"
       }
      }
     },
     "localname": "TermBLoansAndTermCLoansMember",
     "nsuri": "http://www.anaptysbio.com/20200930",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r45",
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails",
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director Stock options"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r214",
      "r216",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r338",
      "r363",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r214",
      "r216",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r338",
      "r363",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r143",
      "r203",
      "r204",
      "r339",
      "r362",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails",
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r143",
      "r203",
      "r204",
      "r339",
      "r362",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails",
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r205",
      "r214",
      "r216",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r338",
      "r363",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r205",
      "r214",
      "r216",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r338",
      "r363",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails",
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r186",
      "r215",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r146",
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails",
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r35"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r180"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r50",
      "r52",
      "r53",
      "r354",
      "r370",
      "r371"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r53",
      "r54",
      "r99",
      "r100",
      "r101",
      "r260",
      "r366",
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20",
      "r244"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r241",
      "r242",
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive securities excluded from computation of net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of leased property (sqft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails",
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r93",
      "r133",
      "r136",
      "r141",
      "r162",
      "r257",
      "r261",
      "r276",
      "r340",
      "r353"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r44",
      "r93",
      "r162",
      "r257",
      "r261",
      "r276"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r151",
      "r169"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r148",
      "r152",
      "r169",
      "r344"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Total Fair Value",
        "verboseLabel": "Available-for-sale securities, debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r150",
      "r169"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r150",
      "r169"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r218",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Amounts accrued for property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r28",
      "r84"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r78",
      "r84",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r277"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r253",
      "r254",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Research and Development Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Research And Development Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "totalLabel": "Common stock, shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r99",
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Issued and Outstanding:"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 500,000 shares authorized, 27,346 shares and 27,255 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r57",
      "r59",
      "r60",
      "r65",
      "r347",
      "r360"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r341",
      "r342",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r288",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate borrowing capacity"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Fixed interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "terseLabel": "Final payment fee"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r38",
      "r96",
      "r194",
      "r197",
      "r198",
      "r199",
      "r287",
      "r288",
      "r290",
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r160",
      "r173",
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Greater, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r160",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "12 Months or Greater, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r160",
      "r173",
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r160",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "Less than 12 Months, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r157",
      "r170",
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r158",
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueArrangementByTypeTable": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
        "label": "Deferred Revenue Arrangement, by Type [Table]",
        "terseLabel": "Deferred Revenue Arrangement, by Type [Table]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementByTypeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Revenue Arrangement [Line Items]",
        "terseLabel": "Deferred Revenue Arrangement [Line Items]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r82",
      "r131"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted-average number of shares outstanding:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r113",
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails",
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r103",
      "r108",
      "r110",
      "r115",
      "r163",
      "r193",
      "r200",
      "r241",
      "r242",
      "r243",
      "r249",
      "r250",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r263",
      "r274",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r263",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value of Other Financial Instruments"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r264",
      "r311",
      "r312",
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r263",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r263",
      "r264",
      "r266",
      "r267",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Available for Sale Investments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r206",
      "r207",
      "r212",
      "r213",
      "r264",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0Market Prices for Identical\u00a0Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r206",
      "r207",
      "r212",
      "r213",
      "r264",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other\u00a0Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r264",
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r311",
      "r312",
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r268",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r172",
      "r174",
      "r175",
      "r176",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r97",
      "r133",
      "r135",
      "r137",
      "r140",
      "r142"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r109",
      "r110",
      "r132",
      "r248",
      "r251",
      "r252",
      "r361"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r62",
      "r130",
      "r286",
      "r289",
      "r348"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r77",
      "r79",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Costs Included in Cash Flow Statement"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Annual Obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum payments required"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r93",
      "r162",
      "r276",
      "r343",
      "r356"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r36",
      "r93",
      "r162",
      "r258",
      "r261",
      "r262",
      "r276"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r38",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MutualFundMember": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.",
        "label": "Mutual Fund [Member]",
        "terseLabel": "Mutual funds"
       }
      }
     },
     "localname": "MutualFundMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r118",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of the Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/DescriptionoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r55",
      "r58",
      "r63",
      "r83",
      "r93",
      "r102",
      "r104",
      "r105",
      "r106",
      "r107",
      "r109",
      "r110",
      "r111",
      "r133",
      "r135",
      "r137",
      "r140",
      "r142",
      "r162",
      "r276",
      "r345",
      "r358"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity",
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Pronouncements Recently Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Notes payable, current portion"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableToBanksMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A written promise to pay a note to a bank.",
        "label": "Notes Payable to Banks [Member]",
        "terseLabel": "Notes Payable to Banks"
       }
      }
     },
     "localname": "NotesPayableToBanksMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office furniture and equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r133",
      "r135",
      "r137",
      "r140",
      "r142"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r297",
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, Other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, Other long-term liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r294",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating ROU assets, Other long-term assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesClassificationontheBalanceSheetDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r299",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r11",
      "r35"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r56",
      "r59",
      "r61",
      "r64",
      "r193",
      "r278",
      "r283",
      "r284",
      "r346",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Comprehensive income (loss), net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r47",
      "r50"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (loss) income on available for sale securities, net of tax of $0, $(25), $0 and $189, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r48",
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Unrealized income (loss) on available for sale securities, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r35"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r70",
      "r72",
      "r149"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Acquisition of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r218",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsFairValueofOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at September 30, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r26",
      "r27"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRent": {
     "auth_ref": [
      "r2",
      "r4",
      "r177",
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Rent",
        "terseLabel": "Prepaid rent"
       }
      }
     },
     "localname": "PrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Aggregate draw on term loan"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r70",
      "r71",
      "r149"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r74",
      "r240"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock, upon the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r179"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r181",
      "r357"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails",
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Payments on notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r247",
      "r373"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r6",
      "r14",
      "r84",
      "r89",
      "r372"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r200",
      "r244",
      "r355",
      "r369",
      "r371"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r103",
      "r108",
      "r110",
      "r163",
      "r241",
      "r242",
      "r243",
      "r249",
      "r250",
      "r366",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r128",
      "r129",
      "r134",
      "r138",
      "r139",
      "r143",
      "r144",
      "r145",
      "r202",
      "r203",
      "r339"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue",
        "verboseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails",
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue Recognition [Abstract]",
        "terseLabel": "Revenue Recognition [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Available-for-sale Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Non-cash Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r218",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r222",
      "r228",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Stock Option Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted Average Assumptions in Stock Option Valuations"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r40",
      "r91",
      "r116",
      "r117",
      "r190",
      "r191",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "Schedule of Unrealized Loss and Fair Values in a Loss Position"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares reserved for future award grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock options exercisable, ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Stock options exercisable, ending balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Forfeitures and cancellations (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeitures and cancellations (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r224",
      "r239"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Stock options outstanding, ending balance (in shares)",
        "periodStartLabel": "Stock options outstanding, beginning balance (in shares)",
        "terseLabel": "Stock options issued and outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares Subject to Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Stock options outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Stock options outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r217",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercises (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r233",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, options exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, options outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Stockholders' Equity, Ending Balance (in shares)",
        "periodStartLabel": "Stockholders' Equity, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r42",
      "r99",
      "r100",
      "r101",
      "r103",
      "r108",
      "r110",
      "r115",
      "r163",
      "r193",
      "r200",
      "r241",
      "r242",
      "r243",
      "r249",
      "r250",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r115",
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r193",
      "r200",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercises (in shares)",
        "terseLabel": "Shares issued under employee stock plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity",
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r193",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Shares issued under employee stock plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r23",
      "r24",
      "r93",
      "r147",
      "r162",
      "r276"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Stockholders' Equity, Ending Balance",
        "periodStartLabel": "Stockholders' Equity, Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets",
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r200",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r285",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r285",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r285",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r285",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r304",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Accounts and Supplemental Disclosures"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r155",
      "r156",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails",
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r206",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r206",
      "r213",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Accretion/amortization of investments, net"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922890-210455"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r374": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r375": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r376": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r377": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r378": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r379": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001370053-20-000065-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001370053-20-000065-xbrl.zip
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M>.>Z]0A8-L&C4FEQ)J->@P]$A H;#/$1N4*!=UGP,@M]FMEJHA4&KR?:1^V
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MCGNB%<\,\0$(B(J9DMQF5'HDK6)6<@RZ+N4+26E1='WULQ_=4VC*,,]ZI&E
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M[_>]$ /PG>1C0?(O*O_](Q+V/O3VCTPOS"1:VJF]N6-7V5%K<AB^-[W=WO[
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MWN>_B-.*:DN!4IT#!Y/I2Y- (7@7C=169Q?E;C+7=3)MW&1R(2AA<]@9>/2
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M_[;++A],W\5Q;S";^+U_+DHL_M7O#>/T9K(ERR27;B24<=TL<;W(3E_D6F6
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MT]E*2@O0%(LL(<D.6HH2=!(^*C3*"K*S*U'WI;S80*IR6^6V>\1M01!,U(C
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MM$S)?R+*>H(F2J[1F>AX4F6YER0&*B.YAA/XM?:_"F7>LK_FF^=\=.1!)8S
M70J 01O0I1!..Y[_9YTD5._L<M,1<9"*W,JO6V*E9?BUA2"[\NOZ^+49#T<:
MN)%2@7&) /J8N942#MY)'@6-0:'J$,'6C>Q;TB#>V%Q@S=A6*U4K52M5*U4K
M=<E*R_C/FGL40I* @:#/46[ '-A2I1AQ^2&_C/]<-4S7X$._/2=+H)(4TG!0
MU"3 Y#PX%11$HD64B85LLYU=1OL"6U EJ #N((#;#( K@-<"X'-!,+/1<C00
M?? Y",[@=481$.B\8Y0$B[);"%[WAO"MXN\'*L3_/AG&'B<KB!#?IX,HEXH
M>"-MTII:2Q-&DHQWR5G*)1<DT!07$BBK%+]4$>+5&.E#\]2_L#$(I!P(4Q(P
M4@N."PY4:%36:1J0SD6(]<JZI?78V0:C_1)7Y,90KY)&;0.Z(4+LG1>.$9"!
M!T"+ 5R2%((IXL2*!NY8&R+$%<Q;!6:TA =O7#">HXC&\2B2XB(QC2A9:F/=
MKCA?%>>- QQ&$YDXE\"CPK*=AF"=8> #%8'%Z+2-1808^WC)EEH%^WT&NXC*
M<A433\ZC=CJOVT%1ZVGV]F1(H:[<ZT-THP+),:9<QC%S(@(FR<'2C.WLH(ND
M\QQ.3N_L*L$KFK<?S4LU%F0A!,,-X4R@Q*25(8:9_)?61D=Y-9RKSO =0+Z1
MT(_"41TD :J9 .2&@I.D".\)DJ)D$BD69YWW-9>KU\54Q'<8\4MU(N0Q1B^,
M%22O$]9&DF%NN*)H*5'56>\$SIMY?X(J8B "*#6E^:#08+G+?KN@2MHD*!JR
ML\LU[>,E0._B^E[KX^Y(9W@QCO>"^B[=8M#)1BVMHMH+](YI1GA"H4U"&RF&
MQ1:H.MT"-55G^&ZY\/VCYHX#(990110P[ESV>53*88Y4P"65*<3L"<6TLRO,
M1JBMU]X*=U=@5BW;8<LNLX^DD8@4F#<V(7/<!B11<25IHDX[V1:?5_G"UNB\
MD8>F3"NM;2Q;31904I&C5ZLAJN214$1I; YAY<I9JXKZ[J.^\GFU;+7L9EEV
MB96:&A6\IR@MD:B9L(HQ+QF+W.CLS=>5NGLK=3,)9;TFTA,!#(W.2W7)-KND
M@"!GVFLO%7>;LU3_( $5!I/C0_NYW$;\/E/45V[F*UNJ3)Y-OD86L9&+O)A5
MO)NRY1N*2M\+]8"J\5"M5*VTB4F;JG:YT;[ELV86B$B>@DL,DO>E&E%ZT(9[
M2&B]X"$0EHIKV==DY2[IE10J=5<K52MMHI76FVNI"^R&+[#-Y(U*CBMO#%B"
M%- F"E:0!-80)GWBP3O;O16VI2JAC8W1?R0<?2_T#:J,3+52M5*UTOVQTC*G
M-PRBX\QPQKU"BLEP):S1R+&<^0G7*6>LDJ;K\LGVSAW8"EHGHK&HMRA DCA8
MEW^3F@4K3"BGK7=VT6 WE%PJ<BN_;HF5EN'7%@+IRJ_KX]=FS,L<>BZ( VZ%
M TSY-Y?-!LH2D:THF2.\0P1[WS>D+XA#WXN<7LV\5BM5*U4K52M5*W7)2DNI
MR@:I10I)1*E0:J6CS?ZRY\&+)()WR_C(555V#7[R\Z:*!!,J\, Y),4I("H"
MNAS&$8('(XG':-3.+N-])2_*OM7N5=L X#:#W K@M0"X&>AR)@USS %-97-7
M"0XN+[$@64S,A$S*(G4+P>N6?[A5_/U %OI%/)[&(Q?'JVE#GS\5,1_.ASR/
M?QB=N,/8.[VA*X]-;-GYHDO%'3)_:4XT"]0Z)#'_<(0&Y3553@1-%M(VJU2[
M5/WHU:CK55/-03'G/+H$1A$+:+D )P4!E6T7C4L<*9GI1W-<6=>F=0#=<8[^
MCIGB,KZ]2Z+XQ]U-A"4F0)<8]*(?>'/ZK/)?;9/DV48Q,TB-=@A*$I7=.Q;!
M)JG!"\*Y\X(A^C8TN2M!5H*L!/E=@I1&4*TQL60D*JTT8SHIXR.5@3A%V_ O
M*W>NRIV-DT6V5$,Q92"4:F?448.6F,#GM<TD)$XR5W3.55](4@FT$F@ET%LE
MT.Q$EI(,M$X33-89Y"DPQR,)A*1HJH>Y/I8\\S"%X$11:<"12  EHV!,4" Q
M>J_16R9*UY>V514K0U:&O!\,N<QF3.G0J92CSAJ.:)DFEI/ .;.1.L._XV-6
M/?X[H-'&3JJD(L<%+H(1)-,H"@G&&@TN^J I(K,^9!HUJB_)196DI8L.*XM6
M%KU7++K,CK;74@83K.810W9BE"+*F!2(IRYP7P/U+G!G<Q-;1BV(5@QHB#*3
M9\J\R9P$1B3C/O@8BK WEZ3/L&6)N3MDT-E&^$]3F[_T5,Z_T:K@R([?#H;S
MK]?G2<O'/-O';>.0DA\!D<VTPV+L65]4P^SP<QZ"WG TS9\^'65(VI,PF,XT
MQ8:SX;+E'VDPM$,_L(?Y2O,#,ZV !^>[&#1N>_%=6 K4CT>3V>G_A^-X:*>#
MO^//'P=A^NZ4$1KO6EB1G+W%NGP%)].KW]*5\>3?-'1H_"Q7.^,2HGFITDJ6
M.H]>2"NDX8Y*E3*M>4;^8F+G]$WOQJ=W<&S?1G#C:#^ 3?D&']K#C_;S9.>G
M\_,L3[+306</5!GWJX:L,27EUS89N__CQOD3+[F).QWL"X49L\%^-+3'T\^3
M7P:C?N_9T%\]#6_]@LT#::YUR8^;6'IQBJ#>*/6:B]"LL%;]W)LO1KW>W=W8
M-2WQS\&P-WTW.LF?$2;_ZO[E?B6WJZ]U 8\%%Q4@-0 S[RLS(_LSTIHM,/D6
M#NWQ)#X\_>7G4\G*P7!V(;,W?;N4Y,]<X-3H!U)C@>JBJ&KQ\0L4/YBA^)M5
M<?X<5P^0ZBN?)@_HE<]][V/E RK,C3[U^\\)O/H[[\.UF@>*8KW6^WZMC%WK
M4Q=EEM_X513G/'1I\/[#8FESX:67A-1SGEY/["BO58[Y>'1TE$/&V7IY9?WE
M$L.07SH>?;Q0MGDNH/AAR-#M(3N3\IJY=T7/"P;#V>\+5:\ZD-<;2.]/CDX.
M9][;[-1W[[RPTS]+!?R_>O-J^#JFRX[I;$8^B6G@!U=+8]71:X[>R]%T@>I+
M HC9X_,@XMQPWL9JPJ\]OLND8KH]^/,*\FO,U&O=<AW:)BL<C4Z&;9' ^E_:
MD@3$1AR+>1+]XE0,+:=BJ%Y%]^%>'WJ14GD:G(TR"93).BVBR'\%,2NQX66O
M@VK*.-W"0R_[+TZW.E[1O2>OR)N7C^CK+Z\_OWGR_/-KEK_C2]EN>,WVWC_[
MN,]^?5>^^^M6Q_M\3>S5YS<O7^'>;T_SW\_QX,\_!GM?#@<'3Q[A_I>WGP]^
M>UZ^[\NW6QU[[,W[-R__?;C_\NW'U^7O)V_%F]^>?3GX\QGN/7G+#YX\PS=/
MRKWMI[W!8HOX!?GX%T:M5#8($"82H%44K T$LOU",LKH$,HFL>P;QFZ[E7-;
MNQ@M'<B]791O[C;OTK>_F>1V2;GUC9EM8[9J-X2_OGSE+Z&,B41*0,4YH,<(
MED8$HE1^1F)PTK5Q&J5R5^6N3>8NZF2*:&44(:(35C-O78K6&2=%$J8-KZS2
MVHJT1K_2FK5>!X$"%+69UF@R18U5@-2>Z62$L+0<%.&\SP2MW%:Y;>NX;2G5
M:66-]D%K@1054TXJ*S633@G!++*KR>T*,=1*9:M2&3_ST/+(>^85A&!+3W6N
M0'-I,K.AB=9S2V:]/M@J)<B5P2J#;32#<18B(X0)%TW^-&:LL4ES8YAB229Z
M#0:K?MK:R$U\)3<2%)I$*"0M J F!#3&!"1;3QD,"87:V:4H^])</-!;":X2
MW 83W#)2+M1(9%[2F'TT89,UE!.D*F2"DRI@#3\[0&N?&E)8P0N)(000+.8
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M6D!F F@I$U NF0L8-(OE?&Q?7]*+MY)"ITFA4G>U4K72)N;;ZP*[X0MLLU.
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M6+*2(,<4N17:(D_$)2>L9V*FY+A:U4MM[[0:)3V?-@Z86BY,D(E#2"0"<N;
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MM'%"BJ2241:38\:AC2)0AOF?(:IK.'I?#VM5]>);]LE>-X]E4J4-(@JP0GE
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M,;N)) A"U<ZNH'W%+QX^7#J1U1F5[!:S7/>8%^Y* :/RPBWQ0B/OI8WGU%M
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M4TE99M8X:KUDF08IZ$!U/$;&&DY _&W#G\/JN&D!C[67_YR,X-!'2+USY[R
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M@WW"-\9$,SR7/N(2 /PQ%M,=A0Z!TU<>N'X-5AO)U_[@!$8<):,!+MDDAZ>
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M.A9^B(2TD'!QJ6K[Z HFT/3BB@DXW< 'J<@RFV5>46VXR0N5%S+3M$ K&?2
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M)5<FPR3*!Q$2MSO+J(I1'8QOU&D YU.K_A[ !!'*/S@#HF!\.@OVB-%?O2@
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M@!& L$(\ZH"TI XX.P4"D(R]F5]OE,+*"\S*7A(P>X0,*G+II67::2("PQ3
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MSG<./Y'69NN@>0&SN0B=G>T?%[O?6JFU^8.W-O88:" ^" NFD#6(BY#/'YA
MDB8I.2R^9&8%Z-S;8UA3V,!XZR'H LJW:S*J6Q'ES9)JR,Q9 N;K_X[')U5W
MWUJ+8CBW^*6XDI'#QK^#KP;=?QL6I.4QZ WPO(Q,$;C]?FE6FWSO,F^/K6:]
M<K4 &9J:W1[@238S._:X']\-?_EMV)BY?52M0W73#<?7OYVUP\G^.V/6%%99
M$QL<F@\>7W]+UBHE;<+*K;_C<HW*V[_&:^36[^YZ+"%K4L@'/?;N[P1C3S%8
MX(GE&>R2K>QT@[TGY.->EZ:Y=ND-/DN?N;CW/$Y+/44O\I7U2T1J#,%HBG[C
MKW4Q[NZ]/B6%O&CGKNGF^:_*D.V>PB-"_]]3;/A 3 SBDAJ5P=L8#O,1R5HW
MQSU=)Y*76:8_;*^7;?RI=.O%&?;&8??TZ.2>8*<9]W::9O=ODD:R*;!D]%%9
M+E.31Z& @A(%)0I*_)Q."YIOI?V7.,5O=7/EN6-[GDW>68//IR;O5]KA=?KY
MOYI0#FH=5U8E@9WER5%-I1.1!:^4),E54=-#-^+LH1P5-?Y5$^.K[75RX,]W
MM[_^:FW[7SO;7PYW#K[\:,+].]_^:>]N__ECY_ 3:]'=_>;VZ)YA!$?KXL].
M:_L]:5U\V&]]W&VW/G[^U;KH[.]^^[/3//S2WCGP+(^_]:V5FNU!],;?^&P/
M1V&P$QBYB#GB 7OD@O.()!VT4](S/+].)[-RQX*WJBXH]^903FDJ HM66<.X
M\59SYK6F-/>\CD*Q@G(+A'(7ERCG5/3,&XP4BP)QX0QRW&)$HC=:2!%LFE_A
MH()R!>66&^6T9,(+KBTCG)/(C*$N:I:(U#AB3><09E^@;JY01T8*G< D6)<0
MPQXCGHA'%D>"I%">$<NP5'IEG:PR)0K0%:![VT!GL:5@Y[!$H^7!@5YG/#-8
M)::LY(P4H%LTH&.70">=$,IPB0(&Q8XSZI!Q7*.<Y6F)9%;D<NL =')I@.Z&
MI(3I8KP)G8P04J\H_/5HW!7Y.F)8:^_J7U>]JR^Q6P.;YUNU&=7ZMX]\]S V
M[/%QKVO]?MZ?>C>JF&_ O9B#NF 38>]"="=CD5YKC<%S[#!6:W K$+P_[=1!
MZ?"\ /"7CUURY.B1;Q\/2FRTLYL?:"%O=1TXEC^M:*)]!-=<QHH/OA^$D\/[
M.FWKVITJ$!C>G^G.7KYDF&N1@"(;A]T0.XV<0Q#RW5T'R_:SB@2K(URK&5P.
MKW[XQ"3[H]O/<F1U'I\_[?7R@.J8UT:OZMIRUCWMP&4IQ1X,:A#Z5H>_'W<!
M!6"45=![X_?A\ZH5'F.2(7]<KO_$5.'M(VY9O6VX.70N]Y'YWNT!850Q>*.P
MWDF6VV_'GNWY_?/)6-KKF0YCG#<@*57EFEQ+YA@$(=7">>RN07@>'MUB'8#J
MZ<GMMSSYJ="4;$/HQ.J,_=SOC0Z-OT?D>M'^0#;!8-_9SID][Z_\YRIL 6:-
M+^!M<[\*;X.)K_^OZ_UG_:;!W)@,0CD8= )4%18#-\:Z0*2B-@G&C50N3F;'
M2)N<23XZ&R*GV!J0JUSBA&V2C#(Z?<CJRPFD6MAGL>0'9]0-6YWZ5@SI02!;
MX(.[4BU6,RAV3JL4EEOSNU:KA)CJL0-1M5I+/>][L)R-^.LX'O4SUV9D_74M
MNCV<5FD;P(_PT5@:SE%&O3A#:/L8CQR<@F1-YU=VH@YV7YC0]LLDW2I1(*?I
M/H\XO'DTC2=^^8R+\VF4=?4@K>?EF.Y;'*2,55P5?_F<&3+,>;23!<)7KTLM
MX,>KO-@^.:VEXG@UKOS!*OQU6:IKK#A7S7ZW=84?YK*< 2QT0.@"FV3):(?D
MB( <4=]VXGCJ&SRIDK'CV7"U>.WUVEFTC@ODFOM[<0 >=7Y=%K>5@@\WNN[/
MS-=/FZ3QM]^/X;03M]+MZ?!?(KS5@U91+=QVON9-)V]\WJ/,^=P7!%&69*ZE
M:Y'10B :),:!":KIM4Q2J@*)-"DKB.(!GA!4,EAS9V%_N&63R1Y9(MGOWWOQ
M>Y8$ ]5QH,KY+G .Z)GM 16#/0K\<WH$=-RIE+CO(+-J5NC -W6/P+MI-Z=S
M#<C_O'%R?IS?4A-^>RQS^8I &Y-"]9MNR@:])Z6CEU7:@4'8?W?-GIU,5[I!
M9;EO61<A\P.TM35<:VP/2?TP#\L6N"?F7V#]% D*E)?!+M5@R709)6\XL'^I
MTC,V#K/W (1 9?K] 9+B<3-<M-V[V3F[[+OV,4OP:L>^CJ3XQRS%R^XMZ>[]
MM]*\RO8M_O9M=\'BKK9OE$D_2U+;#4="/L;9*UV_?(>NU]";B]Q2POJ^S7J[
M!_RSSO_5'/#KW*Z74 GF(^8L>DUYKCC(F:+&6.6FB]><J6#HU=J"E\I:UM-^
MSP;]*SGQ__U@]V/SK/GQZT7SXM,O&-N/W8,=L7,(OV__N(!WD>;!QMG6MT^_
M)D_\FQ];/W8N-LYVMYL7S8,/!ZV/7PY;!YWVSL&'_:WM)LSKZWES<T/ W^FR
MGG<^\;?!RVA50%@IDBMZ"^0"58@HY@E+FO@D5M:)6%7FT55#9V69)X]MNFL\
M]]0;+;A8<'%NN#@3^'E_>IC/_6.H%.B1[IP-G]]C#B;8MK\*(LZ&B*.X=BJ2
M(8E&Q*QAB,,V(N=RA#MWVANF) X.$%$6-"QH^-;0\%]+!(?9DU#@\(%P.![[
MSDG$42$:4D[SP1Q9K1W2W!,<1$J268##:VAXS45<@+  X:L!PL4VEU]W4?[G
M0T$VEM)M!+68(2P(H*")!AEN-")) D!B(@UQE9FL\>,CXY\)#^_QSPX/ZV$F
M\6X(+5=>O?*96CR^O./[CSR@U/95:'8WY:+DV?N\A.[OTL'Q/C&&8R(J&,=-
MH#P(;S2/UFD70\(&FREKD12O[XN)L_,QKZ]TPB=I)#*.&L2QB#D43\.?GD6>
MF+<YSXNMPB4+U%^FM(I:&)XN'LL7Y^:1QS+BK'XFB[@3#'%*';*YGR/V00@)
MA@8S!)1355BYL/+#BN@4']P+,/C(!^=88D:X@%SF;2YD0B98CH1)P4JJ L5V
M$1O"%2Y?2"XOOJ07X.:1+XD%:QPV-E<&S)V7E4!.:H-("DSIB+7$*BO?BK %
MXN4W$\WWQRCQ;3PK+HZGP2VAAX,]QL-QPUZ^0G"UE@A*68K1<Z&425Y'1SW7
M+ @2??%P+#;(MOX8\W!$XR.)@2)E@@&D51%9 AH4 XW)VT"T,QI 5J^*N<6U
MO< 9Y:,TIL+4=S)U<7&\.#N/7!PRJD 888A(8&*N.47:.XRTTHQ9)CR6?F6=
MS.WPK?#R(H84O30S%W?&(YAYY,[0C#N68\XYSK)948%L MYV-JID:&(4.Y#-
MCP\I*ES\JB1R\6&\, N/^3!L, [+B*C7%N0Q8T@SE9 2@F,J%>/&5NJU-'2!
M1/*;B<RXK4+/$CHN> G-N =1'7&,2V=LC)0+%@UGGDKBO"."):N+XV+!D74\
M(<\HK[V4%BFF!>*1&J2E)4C&2+0".1E3CK?&<E73$IQ1N+IX+A:1GT>>BQSF
MC6E4B"G)@9]SU3,>)#+6$2Y<BM+GTQZ^2&<]A9?G[;EX:68NGHM',//(<\&P
MBT1Z@IP7!G$1/ (.=@CCY)F)SKB8Z^-?/U&8WG51V/@UBN3BNGAA'AY+Y=&2
M$$8Y(H98Q*TUR%"K42+8"ZFCIEQF'E:K1)@%$LH/#< 8Y!$-JG<R>'OHGN9J
MG</!397HN S9B/7>W/:SJE=U3SW7!^9HW;"V@\F6?,^Y+="KD2+$:RF#"5:S
MR(/W6BFLC$D!>^("*W$FBRY-QGO]RB#!=J,6^4 UXDR!1HBY1DPJ$3A+WMH<
M>R_Y*EB!\\T,G0-3/6\J_2-%T -S[0LX%W!^#G N7K<7A^61URTP$64"0YTH
MDAO9>0I*OG,H&B&\U48Y 88ZU]?KEA1(+I!<('FAG*<OC<G%>?H(3![/8HM8
MA 0*LJ0*<9H,LCIQE$,X>>!.49U/-OG<2DD5-"YH7-!X813DX@-_82@>^<"C
M,Y[@:)#F)B*NL$<Z8(L AYEVE@F50O9:B%4F'^T#7QA0OJ$5],T]_UANN5J_
M$&44&[8ZOM(($%'Z%$T?IPBFH_,H\S_708LU01\Q:KIFU%W#OLVE_Y)-GK?J
MWJ;=TY/^B3VJVIC>T(+Q_SQ]H4#Q!,CZ1]U[^1)@Y7("[",Z%GZZ:'W?8T3X
ME*) B9&<J. ),D0Z))+UR9'$;%(KZWA-7X/(!E!<)^_WOOT91TVVP[!26B>W
M[CS9![*]JU6E%M)R+)R(U  5"H>#-2HX%EQ4/M(;6U6.$0/0MG\73GMG@*S]
M>#2D!GMDW8@4X/K^-6/H2SRT[2,@ZN9@Z&^, )K;&V)K^^LO& =(Y?>_MC;V
MK/=4IWQ0G"P%8C 662H#$CI2,&V4-5EF=H]BXSS:WF13QBJ7?$G1H-4]\@40
M<@O3 "8J35&BH''.*G8<.>L<<K W#NQ8&77*94#7KD< 744$>Q43,B2X>'(6
M(P#"N#3+'(S:O]!^.X#2\>X-K3>\=V./2!V%$A21F"M;&>N0T9GQI X"$V*8
ME!7/#32!W.S[+D#E%!XD G&:>RXEU@#GPH=HE,;,8%8 ]2DW%"2J$*"5>2D0
MP9[G>F4<&8<C<D82PDGRW/"5]9.S;@6B_>LH>E=CW+5I^GF_7MV>_GM)]&1_
M<]G8V;3E!Y9"*MKR$RM+!]]Q\_,>)=2I1!RP.$_PPU&D!:A-3!A0;*(35 .?
MLWOEY(,UY\2$UX$Z1QC/#JHL.VB0G((^#[*Z /VS:<Z?]U*2'@P8B;1C&/&4
M4R 2XR@%8D!S%D[Z-$?->8&0H6C.$^#P X,6+0TQGB6&K 75CK,L_[G#"*0_
MQU%2E1S.9O7U@J5%B7X$*U[ TA,L X\$5MTQ^)%R=F&@$E%'5*ZBDH+ELRC4
M4FAO#&>:,L^I9H9:#R@;04&7L)6RX.RS;>[&G@4)FZ0D*%(&UJF6'NE<7$,K
M*[A(Q%@MBG+]T/)YBZA<;W0Z><NN*=BWE#!\GJ%>:Q==#;7QDNLT5KKQ<7HE
MLX1G;29IQ4!8.2TX-IIYJBC!CA>/[!,Z$+YFC"-"J:2X1M)QEG4'@2Q5N7AJ
M!"6?P/8H<Y<N>2?$-=XVQO%R./AT3H_;*K+,YO5X8 9B\7H\"2")UMF>290[
MCS6B.GLZI)3(&5"Z0,$FR5H;E+,KZUK>:\W<)9*&>#:S+;Q ]%)L82"9'=SZ
MON<\L2()CXP.V4/&-+*: ]TD2P4CEB4=5M9!'ET/A2P&\(SKS9N?]Z((UM@0
MD8E1@LX0&3(.?B@<C19&9-5M%J.72"J\C\#P1G*5F.,I!*HC4Y0FKDU1 I]R
M0P%S&4O!DT !:4FHO1B64(J$\"XJS07-<1GS,73SO7GWVT>GE0&Q?A=E1$P(
MBUP*XSC75MN0L C:>L])DOQFM_-5./W;[\=PVHE;Z6H ^M;1IU&>\G:FD&UX
M[>^=KO_QYHC@1Q:\0NM\FJB1UZ;*O%1()\*1YY0:[GE(R=;2$+8NAHW,>]@S
M%[F-A$K+3?2P/Y*QG!%$HC6<KS0BB*9CV(Z3WFE<N<T$('1"W:=J_KK^E*KF
M]GX$;.ETNF=9RZR"&_N-XUX$8#EI?,^)#* ?# FIT8&_X?NL1B3;[C5^VLXI
M_ U@ XI&MW\E&3ZK'B>-L]C+G\(MD\]I#!7VFI]J+KJ%J>J_X+7U+YO1CU]$
M\D7$K#;L]^^]^#VG8#3<^=A8&OFL\'L7%.<\\A.8<B<>?3_9SVQ\ JM9#Q4V
MH_VS'4YM9TR_KB6ERS(QSV)($-W3_M5)O+O/]AL$KF83:IP4U-6@=P^CC3V@
MA6HG+H-BZ]!6H(F./>['=\-??ANV#VT?53M;W31IZL!K?CMKAY/]=\:L46ER
MO/:@#L3@\?6W9*T*Y9Z(QZV_HW*-\]N_QFODUN_N>BS!:_2!C[W[.\'DFQ^L
M8'QY!HL-79[!+M7*BBEI]I[Z,/=6=V)C>4I70O7O#<:_CG_/D]RB[W,\5[DM
MEQ*I,11&5S(7'KML9G+5ILI?6.PE^^^EXX'01A,NW[]6&>>F[+9IYO^FUO%R
M]1J@7WT$Y0G&5Q;R 0M9U6YZ"-N^:%KB='/[%ZBEH'N?PB-"_UJJZT/)XP&5
MRF\R=&Y1;E]@F3YD<^6?;*[<4PY\7GSTUA>\2H*_U2A:D$&.?"2-_U:F[=3$
M4?:_,-QB+7AAN+>]_X7A"L,]C.&>J3<O;-\+U:?8F,RL?F#Q@;=>R>0M%2IY
M8 +M+(5*)@I(301"_'%YTG#U).^OP8E#]K)L[]LC0FLGP2LI9_)/9V?;L^;F
MCF@=?,);FU\.=S=_\-W#+^WFYF?:VOS.6@>?Q<[A9S99SJ3U[9_]UH4_:QW\
MH,V#S[SU<??'UO;^X>['3V<Y=&)KT\/]G?;N9L@=U4=%6%ERSCJKD#-1(XZ3
M1([@A*0C 3.1"(UX9=VL&G,]4_]1Q4P6IH#4(TM %5Q<<ER<I9S>PX'Q*=%O
MK/Q>OJR X6Q@.-8J62>:1&YUSG'(=2IR%H@@B'D61:24$IU[E,RMRE[!P,6"
M@C>+@<^N&U[$7C?8_OY\@7$(B%N]_W:/OH/969!P)B0<ZS.M+>QR,(@JQD M
M) Y9ZSE2P@C-,:>!R9P_H"FAOQ7%L(!B <5E <6B+3X*(T>50!-3DE$E4-+6
M@;:8$G+8$*1Y2I8(PYRC!2,+1A:,7 RGXLWP6/!O-OP3E_A'</+*@Z$L .\0
MYTHAYT%ES*7JE5!$*>>*Z["@W^M%O\5S'=Z,<47E>]QI"<!=?6*RL9<K%_LD
M(W+2Y.Y(@B$K%!C&G%#';3 \^>5P$<Y\\KV$;4W_N*6:2V.LJLFM8:-OOF<S
MMF#&4,I2C)X+I4SR.CKJN69!D#B/?A7E&/C%@*WUQ]@QL%+:"14CDBP? X>@
MD5&)(V."<M*II$)86>>KV,@%ZNM<NK3/6TMY.,N7 \Z%9?.QWHZ>8DFT1TRX
MB#AP,W(V,WS$6EFM+6-T99T]0GLIW/W:Y7DYNEM$'A\=W1F+J<@M-G02 G$J
M.'*:).28)Y8[03S6<W-+%W8O[%X.I5Z<^T>'4EI%)[BPR*: $=?*(=A@CG"@
M1.>2WHJJPOV%^Y_>>"_'+?/@[-%Q"[4IQ10-,CX7(6>*(B-50$X&^)ACKA@K
M)OIR\O7BF>CE(.$I_&UC!PG:$>Z28DA+[1 G5B$=(D,IBJB2IREZLS"F^#-E
MR;TH#W[]>U1C^.];L^6F J(;9K\D0/3T]7'+Z<!RH-7?EZ<#%UN;&WLJ,<\T
ML4C;*!!/)"*KO4&!)\ NH?.>KZQ3L0J2:4[1'@L4T/'*N7X6]>/A;%]."!:6
MU2_&65UK)4QR D5*6.Y")Y&5')C>*Y4#6SDG?&6=7.\_-W.,0^'P5RO7RRG!
M(O(Y&>=S;)5U%D<D)4AS;IA!FGJ/@/6!B%S$4<5YQZ\7CB\<7PX*7@X V#@
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MB@45EQL5D]51)J*]C9I'T >CH]IJ%50TQAEQ3T1B0<7%1L6Q[G$*=M8JC 2
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M*S!W#\Q9JSCA 7B&2BZ\=3IRS'641!K'2<@P1PRAC,R<)E,0\ D0D%XBH#*
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M?_^4(R'&G3Z0F6@/,<<_;8T#T6EUHF'0"8048.9C 5L#G57+NPNA03N<C.1
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MU< %.]%'S?'A' \5="H6PUC21U1A9;9Y@7^W7?H2$QF:7-<'N,^W%] 8?XF
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MK< .@FOHO<&23:XJU^WW]2<H(X)[[ACZX@HQ=58\IH1VC7\"1U[E=H'@IV?
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MC @F9>GBQMW+J\;;I89Z8K-:'=S^0KX3G#7>R]H6OP"+"U@;^8)HL:.D+>.
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M@*=%)Q[.4W(J0K(%XWEP5\/I8>AO.7Z$,3[A$ICS!R;D"H_\/W(V*"6U*J\
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MGBAPV;0]RC?.YY]]@MJPL*BX+/+*=W"2]",D++E.9M1F9V3\A+6"8N4ETKU
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M25Q63(2Q;-U-,7Z&T@SDG"C7-H2G42?1,5R7!5R"CZ4S/1B+4W0^HI9 %MU
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MYK9;42V8 4S<^!8R-V(2:NR'(Z!+5G,2^ZA'\?]LTLNV "C.C]"G4VE([0T
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M3S:4$E$C(#3]RI20.B_6NURLDD8@72$"4/CTWU+;NQ!<:3(8YVFYPU[5N!N
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MVUYMW%V$3,)S/,%8'/&(N)BQ_QVI7:'8XZ GS2PX1%X"\W;@FK#&Y[#GSCE
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MA?/V.^2Q@[3X( 4^)-HH5TB+:\E'T\SF83=M -1*%5%R*+9BXD9U=S$3#Y&
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MD<+L=[&,B<K2G)?!72V#M#[X!N GEJ]*&V(#LC()L91Y(E>$DF<E\;E;\[5
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M@PR@NQ61R/#L2>GZ]ZY:.:@IY_7[-\&B1%8YGY@+Z^85T2N4W"4((W*"":I
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MR5]GC>_I^=I:GM>.2^O"M3,N)C?%,@.BY[==@L=5UVK2D$5K"8V4L9S=HAB
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M#7Z#R^1N;*[AF[MBWW9(RP]$%)0BA^6^A0!-(QV6_I7@":1O5TR8"(M2CS]
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M1?)( 9DB-I42"GHC RZLUY.;LD#=C*H(5E)*BP8WCV/<<*H*(<$.N7S^:>1
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M>;VZ[4FW=&00X?3!>:\8,,!Q!^#GCA]Y-8H^B#-'FVK';2Z^"I%N!=48P73
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M7%6D!(O4K^? IP/E[3*H\_(>4Q8F^@7F]0^BN_EMCV^+D@-;RV)@:W@+BMH
M2(1N!V#,G>35# X!T^^%*G^D%.B/D"R*<)7@?^:&]V\L["*!=TA;H"W#'OJ
MQ$'1"G<39BR5"^D2P695"%WOSG)SIWD?IRE,GP@KM&@OS=5ITNO0Q1=,4]$1
M"C;@5=/@VTVKW=W;K6OW'8^NW#R-EVZH!7CXZO_SE1Z?[6CI\6&E,R)$=&HB
MI\_?_!Q[?9KO(YVYKI_EQ["W-$LZY)'C]U$:C<ZUUVJ/M)09AO44P4B&E+"F
M=BTDL> 8OF+YGF2(#BFZ&HRA0KC$D*6Z%7."L/:1WN>"F@KYRFM#:,O%.M0L
M_=PNYNE^I_(GH76(I(GSY2UF0*I J\9!$DULH.'<?*$([&=;@C92E5)0WF"7
MK>;IC1Q!("6&NG:D1= C/*#W2I?5F5+:[!>43A2',#\11 W,YP$930(ZD3M&
M=&S0Z<\M#?;L$E"@Q\OM=6T'(O$[#1=["LS>@^?C"4YCG)BU,Q,09JRY7) 8
M1H1>TCGMIT.!&?NG*Y:P8?[-'7)FYM6%O\OW;K\L8"61X8<\CZ;F](C)"_:8
MH4^6'IIB5T/P-Y7GW+#^4&QFVG'XD58"LPYI4J9PH".'78.OK4G3[ R<+.J^
MZ?N6]T$=T7,5T(5YZW=+=)2%,EU+6EX%&CG168Y(L45E)G6,+&<ASGJ;OW:
M_4#IG&][US*$5,>.&BY\C@$B@IRZG-!BAH;+[%II/TW2-*%DE>4+C/C>6H'+
MK<*IW;M^XOB/-ASXH2E4E,$]]?;WLKYBU)<4"+1\P?7*.XQ !L TV#V-83'R
M>F>"5DK1#*7.$)LQ49LF:Z3*2_E]W3]"RT> JD !W2,[]Y&-'&G[<(ZKBK7R
MT(2;4)K+3?ZN1)J,EH?$;!&U)/BQQH8S;#RE<%MK<0X!#>:$-LA9C>>9U+MR
MJMXR[4M$:NR/S#P0PC %55'F;J5K-'-,0,_U*OH!:)^$U 9@9%C>B!,(H0E[
M!P]&%+]/0K,L);S[/*]0Q5 6=!*YST6?C0J*?:Y5V"GBZ&5(0QZ  ]S7O XC
M$9;>R&%2N[Y6QQ5X2<IN+G8965F5'X1<#> G8=T'(-(%-%PP'F7&MR(ZWO"?
M5RXIR4%;%%KX"OYDF2VB"QKSP5I?(EP>5B0S;AY,YJN*G!^B?0;CO015ANQ:
M6,SEUPF3G;M+]'*->5A?N%@B(SF4:*'H5X7Y7?BC O?:]/U#KQ41F)$K?)3L
MIKO=E/F,0LL:Z!1-& )Q6EE*B#RSO'&WP'[]0;B/7C?V<NC(RU-('^B?0E]0
M"TC1ZSW0[)F[<&S88L<6\39F_"?A6AWT_@^CZ>Z0![<?!X>9AGY1^AYBQZ*E
M:=-F \'4>(&-Q+V%RW!%Q2AGRCR7SM"O0-^*Y11H;]=X8U8MJ0>^U!)A*2DB
MR+M)\_+T]0Z!CUB4I0@"#83G1<!6HJ%;>%[<'Q6C5X*VYT%P4*]LH"& F('8
MW2!N+G[YU92UPA.#S0A(^%^Q0C$':0;".IS#'9#-%7);R8TH*L$MW4QTZ :U
M$J.F14UD"49;8->(5U^%017^/KI4$3/&9D0V+]XWH2$A]<?R$C,*&.",6]%]
M5*=1476JO#&A0^=G1%X74X#]TD5KSS1XV7"D45Z+CS11+3.$7#D78JO.11/_
M."V3.+^=\/(,@!4+.,$\B#>BJ+M >16^Z.EV1)D4)7;2WDD^V+&MX?H OQFV
M8L)/:BBNO^M="IZ^ 9PAO @VHHF?+*UHYBZ):K&=!\3ZC_!YOX:\U[U/4% U
M,Z>T4NF@@HGWH5W'H"0I:Z>-N1P'YJ#)@6%R2$+()@IA,IA2=!4YVA!<Z]HW
M:(-;3?:@]S 7D09TQ_KT(9UVT -_GE7+IN:B-$#.G$E9]D^,F"$TWG2L(QBU
MF>CO-W5&EF"J\\N#N9OY"6F[)P=?Q/?KGR"D_GKRP_VUVL=S<_R(-DO4\2[T
MSHR8#(:I>^?$Z6<L*:(1.!#_E50I?]@OW!873E0\"[:(B,8SE7:BN (G"QT6
M04<-N1U\?<@-JQ<;&%ES6,-GHN,ZO-1_NC+RDZ,=+2/O3^*GFE#,NO"1"$V>
MAA; NA2D[6 !:G0:O(M\E2VQCLP*>2$&B>*-O5G=UF*B2Z9Q1V_L,G ;WF"
M">(DE!.K_/>JF:A1]#YSOXS;/)-$M.,/%,$55<$(%DO[G4+;MA;^_EEDT!8
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M:E$DTF%_+3><A3$KHM]LJWN-60ACOE+=@74$;0_CIGJ;5>\K;TRT<?FUK15
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M!>&*0$\:V[PQ">D?8;6EX4-R[L;<^\/M[S;2"KT'[#7ZYQ(\'*2"'Q]]C3^
M$#OO8!KH%.II=X9VX<KK#&\7N.(2_\G2N0/<1X0*1**Q"[>LL?#D'=#CQVRA
M(7&&)R^: S QIT]/N^.D^P$H-:[*HKF\\N[TE)YY>CR&YSZ*.^\":MF_W U,
M6MY]: 8N\=%W]%%8*UP<6E8@%C$,6I"<_R \/']Y?'CJ;^[Y7/*Y_A\>Z3\
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M_3^ QKG?_U#^(+XEU#9K2M#'0B9LJ6P_E9KUBP],BX_5ZM+(2\2LK,J/S>)
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MD)-CD!-P20X8+!:0=E8)299@.:1UHL*,V%;S-5:,%G&_200X&#PRR2K$!;:
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M,><CTII#@._@1704"T0DC !>.H=YE:QX%7"'Y"_K\J28B<JFSP\++:.3A+$
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MQ-$A(T- '#N&G 3?)*/FP1$?DW%_V6%WT<_G>&8;T'K[,;T!GVV'_QMM.Z!
MP&0U>&=&;#[0;\!C*_B?5%B9%#B555SCYI"_RP%X'0:N-0"7LVZQ47A5I7P
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M>MCJ&I:E+551Q)/+7G..Y+_R[I!??O@_4$L#!!0    ( '. 9%'C=:4\&#\
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M2TW.CM;#>0H:44'0&V_[_O.7%<&@,_UG_1#*YWYZ^FK4_54U\O7K0YN&/V[
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M3CAC:&;9>Y[Y;HO*OGCW<_FNG[^$<;(6QMOQ]:N7);TFMY!\O6JS6J%-"Y8
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M2>4H5YI$H)I(8X!XDPVA4O@D5!8R-3''U\,YO(UU.$J[ZGPT\-Q^F\_F?E0
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M(G!'39FK(&63V*.U:/9.[_TJS-_G94_'%YSZ26F[MHSW1.MCT<3P:QGUZ4E
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M#L)2@^R/DPGXM_D]^-'+:?&;WTTZ','L8J" .ZUM("SSTJ62*V)5D,2QA'-
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M71.;APK7]:&4A<T $@ 2(N)C1 2DQXB/D9&0D)]@H#[4&$]PT)\_Q<#'(23
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ME4[$[[PAJ^]I<#:./!7JH=$#PZTO9$9I^8*8WRQ8A3.P)$B$+7.^>_[ZV=
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MIG)G:]%!9=YSSFD)9]IJMQ8U0U$]\I))"8!3)7P8#IC(4Y&*/]LRH+/=&=B
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MZ+%F:XK2;;T<L]D]W7M]/PH^VE:=U>HDHFF <N6;TG3(?YEAA 81YUD1OU[
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MG9B(?%WUPI6Y@\8]??W/BF+=3K7QXF@/CTFK8F=0&JNP>T]QG7B+K92I#8
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M\^I0C_43JA6.8ZX=\$BSZ!_V)#R?T#,?=29*B!.Z2>JRBI8ZQLB*EM:X\;E
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M<ODUQBL*RRJ;:0S5E-C.1[1''MAX.WR\HJ2-!/'L;?DZ+$V;9J[.,5C$1D@
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MKHFGN=/8&TDM<--6&CN@]M/5F^:6L<FL"QD4$68^(@JIR'I+:2[?+;:6:$U
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MQX->$66[*8M\"P @^P'Y^?-MO8C)$8 (E7;<.5,.TXE(J[6[Q59?H4KX9"[
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ML#8)I[D7[?48K_X5>9-_W>IM,>^_(%[%ZVUP5(GI7]QY21\.Y-^:-N$IZ5G
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M]E,Q>*<"S"%=9>BFD>N9.H"GI$4F\:]R].HL!"  JX9'Z7>!V0C J'>J4]S
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M3#Y:O#2WZSFBFO(279FQ*GWF%ICI?VX?T)5-2$Z#)3PDJL22R:&4'*O6'O3
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MMYTT]/ZB]?(9+Z]@9YCL/RLA7?4O_=BJ@IU]<OL_R05!O0HR[B)=)+%U"W+
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MGP"+R(4\9=I+FW\_'TCH?SX?"'4C]$TDJ;DB!J@9G5G4@*3W0H@IQP>#FV^
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M*!AT!!%F3?WP=2'-K:Z>;4YVKN_ST$+CR6,(HT=(M#-1CNN=R*W,Z6I0*?4
MSZ66V[DN.6-"[OLP2F?;/^3?=^&A#,2[<"F\SJ\_)8JR\@)Q\D>A^R9KNV+4
M*D )=5PI\[<1_"UVA OIY")_YW3-8<*B!6M%EK(P\W>,62,XUG4W/KQET,W$
M34&DF_ 9>];J=^[)5>08[):.R,/?! X74,9)A(=LL5+Y?D+]]^'^I+#:RCJ1
MI1SVYL/VFDBOHS7N,#3=S5H+Q #G;#T_H,:RWCC'Y9N+.R.Y,=]YYS1(7I:^
M0E@)LS"EO(D^H%[6-3TN^L<XIV->AN)$?M5X?]3 30IC)."C@-)MMAF"+IX6
MEO %!'=-!1.F-=93590EU<9J=Y5_KDNXP)4VO+A=I&JKNCXSEEN_KT9U8[PW
MM+:SW^"&,[\ JXX3WU!"#&IS;:06&)/_20HA'W08FG[K9RT@F**(D_$;]OKM
MZ+6[<#O %6[6XZ/1 .L8NN)C+O4XU8[#-X9-'@C4U*A0N"P9*B6T&4T[O=TX
M>\NB=M=9)I0"QK<5J-6>FM9?RL*XMB]S)$AU+GE?ZE2 (&RJ)BTRCELD^_%Q
M:KP5)ED%KF;W7PY:MCI/'6P#)%4)[TCM+FC[74?H3W>A*%2/PC#EW ,YZ'VM
M S7X/*Q(>92^9.:YO0S,<--"Y5]\O:T!$EG6JDRYE<$'4G;P?7_# K<57@G"
M_D'RR^.1==RQ284JKG!1?ZDU22RIN;F_OM9VCG^FGS?H<^<TR?SXR.(,9@,K
MU7&7HA5$RD(BPY\V72O0\8HIGMZJUZ2YZ8\#F@X3Z9"S/B>)@?(OV4]N^S>'
M-O6^"NY$NO<15D9M/SM3*?( 2@"%E3,>*(J,K.OI3<<$^?(A.::,"E%*SP'Y
MS]3KD2"Y3=3?4NM'Y=H;GV$6"J<XDYR%%?7CG-6-O;EZ35&C5,8"]"\UR1LN
MD7 S8WF$":Z)>KK_)[_I\S^P_6^O+_JK[.<<O)@QA[[1P?AEW4<6)W4%#$\+
M"B)CWFS[21<JR5%WD-)4_WIG?&GJ:74-M$=6)5Z-5-[!2]1@X+/G[,B8Y^X#
M^+W]HDH4-:%M0U9HJJ^%#V/M9";<<I_\\3*HB@JUMTUN8[VHKH0;*. R"$*U
MTP#F)ZS%ZE()6$4'=(4"HHDHG3,W+'785X\Q3':S!>HQ/Y7O:$M\2K?#>X-U
M34ZFEOKKP"K>!Y>3<B^Y]0L5I4PG\5Q8V.O6[(%#;D7&&<I#Y7XJ89X#(4/N
M6T53@\"^7 ,C])+Z!=L_^2)+$5:_]$LCD ]>B0%I$((J@Q  "=E^]E^SV4?6
M&J;8\UO0!2)0LQ_$:G\S:WHYY @.# _DJ,)^>[&V<ZZ6E&&K87U+<8DA7)G,
ME]<8,[1^$=C+Y$WR%;%7O8T&AU6P^_'5-*=\%#\[41^U1D,\W!;"PCEWN%D=
M2?JA0I*#U!-SYC:/,L9 .6/ 9&CYQ ]=4=#:)S*^'W5'3I;=V[AJE=+\>(U>
MI%J$M[1\>:[)\ZIBIB=T4?J56)^N7T'.,722%FW%M9?'X,;F8\WD9^D_\B'?
MU?V 'OZ3$ .]ZG$5.BL+O&XZOOAL?\6O5"\-HYFS4R\?6RSEC>Y;RQ)VTFN*
ML&(*U,!NE6(? G3E$"P244CIIG*G8/O8V'/=$H7G(>EF&,J.(/;.QGB%#PDE
MW"M4BR5#?-C(>S5D3!$@=K>21E'?'4C+ ,C]BB0M7]N1NT8_),)KOJ^/!B,;
M0%D4?6'P .*SO>C;A@']5)A2MA:Z6PAP>]$1:*S$RDGF?"YR]?D=.6]>J^XN
M#Y\)\$'T!PS*#08%+-@8TK!VY@3D-$.UY1"2 Y$(:7"E)E;)5L9J^K8S+%P;
M$1U&VITSMX4EDKN $NB10[[8@IWG7JUJ[^J 4;X1-'94>]K:=S)L!71,"--T
MR#* DN@U9<>7>\0B'T7\JP\(=C"MV'LSA2.-5E,QO!F<4,TEP_C*IJ?/P+],
MO)X 9=W^86!9;Z3X0<A.-M7491:INV@,4 =?T13Z105-3_5G0 5JOW0J6M>;
M):D>%4F-$_>[G10)G2_I>VM+!L5LU?/AI=!2$)X>@D*A(H,&*L"TS=]83D]N
M7'OJMRC8Z'F*7O:_J7 XT_RMI3,GB"0,N//5+'[UR47B;Y..C3S_-CT'%O*(
M]MB0;05>XWJV(=^[_JMLR+^P)X4GR_?!ED\ :-$MVA;P;X^VN\ 8<W$]P%%9
MPJVL?RB%J]="/UXP)<;^:[?F=Q3_9F:YW!@> 2^M>N8+YZ1=_8\:]GN=4<Z>
M\MAVJT9R0_W]*H(R(WR^S0([AK*.-J+>@MXQ>6#N+ZCJ-;48A+>(_#YKP]V<
M)79S#7JV9X92R%UX^AFWZKB6MI$)3(G*.8L4]U'7 =NDXEH$?Q:49>);3OR&
M\LCDG7G@I%.Q/Y@27-E4Z<[Z5XVXVBM]<>'^$^E/@"^628K!*B-\@\)K,9:V
M4 [H5N3:F+7P>:*6CH>Y(M.6AF]%'[0C,EL+"#9@^(-U=/U8ZW@I5(*-9CSC
M-;6OG:$XZDXG5L%CGXJ7W/2%[14YR(2A(=DB8.7S9,4:Y>OS+F,\/PEU3-C$
M(+X"79U?<8VL-3J-ED.DDQ.6\UBM[2^?$JX]5Y<;D2'2B[*#FZ]P8+%?PRIT
MRWLCN2F-3IMC,^T;T7O+$^+8 &WQZ^#+UG(&R-<16.L<9X&OVP24[2MI$8_<
MYJK1,$PWF+0C44T,T6B3(+VABIKWL06\Y33B96(\OC$ZK210DZ@_-S>WN%1P
M'S84*]D4.IO+W FE=JD;7D*D&5XM0UFP;3@?=D=[]GD-Q8C#=.H]'O93Z Y^
MB^6OK"0[* P)KU?F9A\=#Y\R%<2:7W5V"1IS!^T9J AL*\+<!?JGQ^1.*TB\
M]<12L%:(T 0#$"Z%B=PAO)J/"Y53;K+5V6M+KT#Y-8W)N8IT+I#X/:A6,,TC
M'BI3@:.ZTA1I]YX_]2GF1NH9&QG?<*G=OHWGMC(-41WGM83,-H;BR*TW:[:@
MF;8:DM*92A*0V<]XZ(*OGFVTG4!!QLG_4Q[N?'8>8Z/(&\BS"P*A;&\L >OO
M.#G^V-<WB:B^=6LD9ZV5*O[=XMOD]#W=*TW^V\]Y$^18@<S5L&9EID"._!&L
MM*O>>$K"9\]%@*LO OUE+V)\5L,VX?RH4G^?QQ,@^-%B"SP-&7H]WC&755 J
M*'!%5&&/:__*Y700LFA4NE=1_7F S>IKP#T@WTEX.T*,?^4NAMC8-ZI.VRU6
M.2SH9.^:1_#8L(+:VFR3"06IQ$7.>9@RB^#/7VE'TCX&?QYAPI3*LJ<8M>F;
M+=D-+GI <JFFE-7[>>=-MD_O7HM#_37D#-U)?XF$!?-'9?DLKJ>_X;L##MA]
MMYF XL@0&/#BU*AO<O=7+'7E9'QO@WO+TI<>/]B5SS=4=!M[>78QCOD:R-7>
M25Y]334SG]BN]OVVP3%/IK"^2#1E)?D&-._=)@0I0]VI)2,.61DOBU;CZ6-M
M3:7K;16+OEEX O Z+23U01J8E?K;%A>'\, ("]VKS51C;;+;=K4:0R.R8/'T
M]Q1"3P CG*5\%,I8)WF9]&+(#;%>R]BX:OD9;94 ZPN#&IA',9!1M[ZC[(^"
M,.+UMYZES 3C&%DB]&\I<P#BN8U:^5?%35Z^WL9OI$N5OBW560ECR&&#?3I;
M3MSZUG;X18W(%:?85ZM"44UTFA**:MT2Y3F@HTJ*MW"&P/YI1UF)XC!EBJ\2
M..D,E33S\O0B@UL_V!(VN/6^[-4);;8E(PQ?^V2B175*D$Y>+,HK)FG$J<2R
M,ZDDJ<K#$A:WD7-IA]2?15PBR6& =,D_JRX]NOO@]B#5V-BZ;Y#9?1@6[M!D
M@3Q1DPX:2K+? R67Y<>LFW.=57JS4;:Q$3@"$/=<6/2\' UJ@>(",F8/R1;^
MUPD+I4,VWQQL=.=X,G0P[LM=XUO=;&+[([410]4PO:*T*Z?,3@GT/^GH)]?'
M.(+*Z#,&YEPI@/COODDEJ@TITO^):=27#:WB:.2 E,E;@6A@!K:0@R+O5/):
MWE1+F42G%^O1[L+K_I%XM9</GO@3SW;8]!^<7WKJTW/BN_7;"?=_W!OA=8AD
MAKJ:_C_LO75<7,V2-SX$0@C!DN#N@>#N$)+@P=T)#L/@;I.0X X!@@>'X('!
M);A#L $&=W>WF1^Y^CS/W;V[[^Z]>_=]?\\?S>%SIKJJN\\YU?7MKJK^1^6;
M^!>>HO?O%(Q=W==54.]TB'#!JNWT:A17BDNW:%SRSXC^NS\B>\W[D)_1_GF_
MG!AS7L;)J,HK=&'J1*E:=:X[_8;X#^'_\@A VKGA.0P!..1I4];U(FX>NB"Z
MU@%WNXD=?-QL/I[;AE\;PNDC+UXZSU_NNR  /J4(P%,]'MP_4#Z Y-T$_B?X
M2I47WB  [[Q^Y_O_*E_#'PC "M>#FSN0)<[#F:/!89?B4"!?[YBJ>4,E:'=S
M7H< -$W\*:L)']QK%CP/1 #:QSYI4E06WG0ITHFMTOQ&_,^$';D(P)!7Z?4N
M^"))ZUG UIS ;HY,1MRK+EH;(GU%2C]^FKET19@ZW&@E[R8;_'?:IZ(L]Y\C
MD[IK34N/XJ4T K#X<!2\WCAQ>];\AQPQ?ZV4G1EII7GY(2;]*!H!^%4;Q7Y9
M1T:"?*3T^,%_W+.8$)$<PS4L67"OU'_T1.APO62;^TD_(0"?(G\UD./7%-BP
MR9?& 3*)<K:7DQ;\5U[JLF.CX.6IYGFQ;K5!%^+Q.,+6*TKX0.#UT&7D0=8U
M+\6^V)I8:_&PUC&7@9K:O_&#%!?6[_?_7[N?(R]*ZV(T%"= 1'/S?!RW]K/V
M?5QEZ;?_.T/YC-RGU6I&&A@=8=Z.??GZ>)45$4\R8%98X],U[SOE'%^TI@%]
M0^0-);EW"Y:>;.X+"QI^P,PY\[,Y':\=U5B23K,TB9E;7;8W<5.M,HU%?N8/
M&#&P9@<FF9U<78Y4'B, #]\HS86;S\A9X1;D9?*;F;_H:U08K;%8Y=G#53=L
M/JV^M";8A<W[( #]A_)$-X)55^K-X>!OV0=C#_/I4CN6OD[JR9V]4U_"/F(X
MZD.;>(9.R/@V5GEK.X?/G_M#_LSFLB:D3 KR;:QX<DOS<3!A:WP,EQF=T;U5
M$]?!F87W!O,29,TE",":?+5PJ"Z(&*2K Y(5<CZ,/,M^(*WYZ&P8G_KH)GWI
MZ'C-=OH( 2B:O5'?T*R;K8I<+%95)]@MR$E^T\XDV<Y/ZX%LA$Q5]HXB641&
M&#J+)V8^/R'O(UG=_/-<=7=HJD_)A0YL6Q:_NH[LK)@N=43/T./I90*V P:?
MS=<8?MCKH$E:T@KG;1W!]HD>)US!H9"]XMT3N\?98C 5NB+Y\IVV@JC/#0T!
M45^HU'#:*%.(3V6?Q\*;K.?]RIR!$X<:"("?8Y+$8#Z)&KR[;'0/^ZR]D"^5
M;\H^677MDMJ. P&8ZP0WZC4'>+.)( "AK*>6W+NL/2"7[1[3<6JGL^DXC.T5
M]L?OR^+)]&N4CS[XB2B$?"JVH[/KNVG&\<RMKX>#U]S7/TZTY8JA\_DA '=O
MQB(UYIVJ%L_]A&%\--U/X,7USM#H?@O58<3IL#O\#"9VOT,LW'34N;ZC+KQX
M05\Y[1FUF@ )E'T%*4UMMU.JV!,3]TJ+O&1%H]KU'!JMKZV(-]#02\Z88;^Q
MY8G3YB?2(?>'G&?*T+OWV'!,;!MJ> L8Z]4K=]Q1T^22;E2SY1F@'[DL*H$(
M\;-"V82G>^Q#*2/YYRM3=H>(-I..^W85#:I';$U'( 7,E,,-;,#\+MOX8?XD
M/?FHU;'4CZ^1'GWX$4"Z"H.D;+-%V*Z,V9K)W,^_YLI^R=-+A8+S_F(%HWSA
M.'; BN&H=R[;\/7UG2D)+M@\T4P -G&,,S?1=IF9%&;;EV2!K.@379S0/%3D
MWV='(-F:,08B %KFR/;". #.+O 2Z)561;BPHL-/C]LM7E\]C?CUG<,6VF2B
M1U1"A^0CNO94D;U8Q'D[QV!#:):G$%AG_B;R369#VG&'*'W-CWG5*JAO[YD@
M7MSUR_CR2C<NX9C"_9E'*-0<1P6J0QA"4Q/"XH4;\01U/D-!J]I?QDVJ0]5K
M8Z #CXDG936LB.>DQTRCLJ5B9#%.:3W!!JYDD.I3R)!B9D."')3-12C]P;9.
M21/T6%@3VDO#'E1*JQVGS"?\(CZ*[>#C,UMUS6B%LL.(//IT9J@! W'CM.4$
MGZ=_@=_CVVC[(/22Q\CTI-]V/E>0-?IJ=)\T)]Q0_(R;T('8-D^<7I"72]@3
M-Y66NNMT*<3K:^@K;;GN XF2T!) Q[OL"]08S^8)!39J:5?&2\F[<B1R+CS%
M\ ?,1-.2/@%=6'-I<)HH$];LOU/V&9T@BS!X^IS=@$L;GZ2.WY1>@ T=8,,&
M)CDDTA_2L8.R#X[=_<:=AU>9HQB>"[?91;V0OVQ10+:%6=>[CZI6-QR2:GC^
MF'!YY*5;&"H'?+AKRT*I9H\K7=[Y+$()>]9XR]Z^_>;+)GC[=?J6:-7)C:YA
MQM:89C2X5;^P8Y&"UXY@,S81@A= IC*J!;'\0JYL+A?ZP6+U"ZWWEU<U\<II
M)WV1I%MR"[=/5<>\%3'35FL)'FOKP:0\O+[I1U<R.>#WN*M&H;Q>IW26=87.
M3]B+^(4<<Q\JU/.U%^RL0)T;!4>(6NF3P9[1\MSDTF >(W:/,$>9&7ITWBA-
M2FAD6^1C^2)Y,-"CI*K:Q8Y4GJ4#TE'<$<52'V0:P&WDOFI&1&IB?QFB$[(Z
M_Q\[!W+^5[= \<"O$("H?HH#MEN4<?3F# 2@VQS[@@#N9_W<&_M'OK?T=N&
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M.E^Q@W4Z-_LZ>/CB=#B%QG@.E(T%E%NIM4=\7^NHF*[]D&I2+0+-IU<!3T!
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M5Q^W/=S0M9DV*_:/7],1NP511>-@?ZJ:;<="0C&K T=_T;-TRQU5JQ]9'+6
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MS!2K==3KEC)1(X?!G\=&?+CUN5,UNIMR0U?PYN(P"9"LO%WKMVT56)\+C9[
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MKWYB;K<R$F^+^#:^U,V"-IHH:[2?!LA@\:X]S+%^--BIS9F?OW'1J=B@I.;
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M<)29&C1U$-JSC9OH+U-H.2<-%B/KX,,RUR_G7'RE<16H-6XR66P!VBNA2.'
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MLJ^,Q![XL+F)16<DH1Y/C_PE#?_S6NWYO9=.0*Q5_\TDR\2Y)L.W:8AL*)V
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M[4?NN:'O"U\_W-*[+#J!;@:LMKMU4Y0W&DM;2S@>JBO:M_2@R:NW;X_QH(^
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M%:^30J1&BT,I.-@;V2@+>HSLWWR_]>&/.">-7I%#[R %7:!5Y>UXR@LL5N@
M%W3MPF'27=:N-X32C=(9L&U0@4*)V;&ZY)O@@[1M>)FE?7KM%+BTMRD;@1OP
M4/EHDTR-9$M!(/*0H5.24Y(T_KEQ=*^QP+,8!0#:-Q5H?^.QD'?>-O@F_*$N
M%SHS;]!3GW3 $6(1%EXJ3T29ALJO>$P:F 5MM2O:Y?/PPQ/>H:JOEP+KLI^
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MN^,?JD@(WB4:6F\<9+[G5+ZY>.2[E3F%F7^MV"H@[8T<?G32_LV+&"_O(19
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MISF9ZTQJ(]&$/;\DI+>6_&5_I[E8,#U*8I^G?O:DMHE86WJIMY!?M"12S4W
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M98H"EA&8B#2 6" !:4(RJ$B:Q0F522"<#M[/]C8V JIE!!LAP6]&3,?XA/,
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MO[,U5_5O^_/TL-%!)N9)758S\?0#'5.QW,R?EHOR5C[+6=1\R3(E0L)I DE
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MT18J)]> RTAT< XXT_A@[@&7%=QV$+!XNG,2AU6*(:0XBZ1*8!Q1#+&D!-)
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MKR4%*U%;>]F> =CZ6M4#;/U?J;9!K,UUZ@4P/%^EGNIMZ&O4"UH?N4*]],;
MEF*3G^1NN2@7>ANB)3N7>OQ+/INIO# O3J@4(0YI %G (HB3.# [Y!0&"<$I
M2R*AZ6D0>[*U"F/CM[5G[O&:!E5MC J"@>S/]M^-GJW4049\_+;LND+&%A 7
M*V/T$T'Q:B,Y"NNXO19_#!NZ\RAYL[2[2](RN753P.J+?,J+A3G:N9</=5TU
MI4(NXTA G@D),>(F5%X&,"&1XB)D6"^*3DFL3W8UMO5J4R*P6,L*RD98QR35
MI_&U6TO\H-8SYV\ VX@)[B\!YIY3^B(67G-'G^YMV!S1%[4^R 5]^8VV677N
MO\G9S' ;G;\8)Y<HBR*L+653-PYQ;2D+DL PQ)3R$(586#FY'&]^;*Q02P@J
M$4$CHVOJG!WXSA- =U!ZGO1.>+3(CW-,[<YY<78:'3@?SC&%#O/@''VJ146L
M7-L-&]>-A*LT10@203*( T4@8TD(<<08E4RF"EOY%Q^T/+9)6@GG?'AV"-CE
MN=D:AIZGI34";M6LCFG;I8353GO#U:TZIL9.L:JC#_B(Z&ZL_7(2HT00'"50
MAB* 6* ($J3-;(63 )G",7KY;!^WO>IF=!/3U"2I NY,W2GZ:(X+3>%+/EN*
MJC8)6'R3X'%3KJJJT&TT:I^SZL0 V!G>W6'M>:(?1&2O9.PKY'H?@_X"J]<]
MO6+X]+ZVYX.D#Y[N=#U6ZN:,V;X*B N1WFPKO5X'0:@7;:4I@V7:T!9AR'F,
M62:44RK<X]V,C3)64FK:J,1L=1&V#Z73)5@'@(:Y "M!(V$_H81G,.CAWFN_
MI]>X\SJA[8G[KE-/NYOK[YLP)I/R:A*%# 64!3!-B0D>P1)2EJ10Q!P3'L0I
MXE8G;_L-CVV"KV2K<J[96^H[6%TVU-LBT/,,ME/>R4@_IFD'&WVGN<%,]&-*
M;%OH1__>;K7](DNI7_IV/1=;86--;H$FO#$)4TZ(RF"297KG3%,*&44,2L02
M&5*<T=AIZ;7H<VS3="5RY<XK-D*[K<<V8-LMSIXA['F>[Z"W)>\Z\8B_@-$6
M /E<QFVZ'71-=\!A?X%W>;5%8H"-G_6[_/&Q*:EC^BR>I?B8%Q^7"[T-OBG+
M)=6:[A6PDD1)EB095 0E$&>:N)F,"%0RB+'>*6 56CG*=99D;$2UTL4<'=3:
M- 7'5OI49P^U1F"EDD-,?*=1.\]M@XY%SXRW'H:[4\/P\7 87"J.>1X9APP&
M0XW00%D->A\IMUP'/M ]F_^@4P?#Y43P@<-.G@0O#;:SL=>5V=_2F6G\_IN4
MBY^+?/DTG3]\G,[U9U,Z6R=8?4=K1YC;=5TBG,I$A&;WBY')RLPXI#**M/$1
M(A6* ./ R2V\JT!C6_2,/J!2Z HT*H%*)[!2Z@JLU0*;1,0KQ3I4E.H\MG;V
M_I CUO/2.,Q@.6\8?"'L<S?16:9!MQJ^$-S?AWAKM^T)R8+JIL0'6LQUA^4U
MUW;)LBKG^UZJ*9\N)H+2($B2!(I($8CU%(!$!1+&69)RD6%*L%/XY>4NQ\;
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M4708%8N=XC!8]\S51L(JLK3Z84N/ZL.-)M7?30S(RJT;;-099D0<MG##C,Q
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M5T$0K+B0+A??\L+D-[@"87H5X63]%SUC]2=A'._=Q)H_;%$HH.;H[&E1';:
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MES4_+!)K\4Y+_RR33^"3%EVW6V<26'D59%RF* NI)I'0A,=&"!)DHF5%DK
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M+^6M39LI3^(DD$Q"A<-8FQU9#"D-M!^:QB$6<19DTK[1S'!RCXWFS*;'1D[
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M7J0C20A+XQ2R.,8FZ,\ATWZ;G@XE44I#IH33!O#)D<;&0[6@0%;Y\X[6SVE
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M0#("4<(XI*%(($M10 *,@E1(>S/!>?RQ&0BE F"K :A4F "M!"BU,.<V-WJ
M4A$7;G2?'YM%JE?4>UZ>.@#>:55R1]YE/>IU!@9:B7R^^H[K3F?XVE<<]\<.
MN-9TUGE_E>G^F [KR\,S+61\JW^=<SI[7.9T=F?J$Y9O9OW9)"'&@=(3PF(>
M:[\SIN8G M. \1AQ$A*EK!<4BP''MH*4(H,8\%IHL#)2@WPKM@-KV>!ML4!X
M1K'G%6$#X$9>4 H,=A)WX7\;)!T(WS.B S&\!V3=B-T!IE8FMWG.<-3MH-4>
M5[O<US%=P&P?WA7%>E,/MBH&6]9G.]XV-F!!&,<Q@BK,$$11RB%A&86)D!3A
M,*-(9DY)!*X2C(V^OS]3_;BRM:]VQ-=S#3Z0+Z^SQ9N4=0??5WV#XV:B^\38
M[47T"G?//%\E(%3";\I9;TI9EPI,^F_ZVQD_KZD+SD(,F]#0%:.#-(?.#^I8
M,.ZPQL17N;I7C_3G-(Z5T"\H-8>L)41*II"IA$"62:4$4IC$3H=>6L9R8K@!
MCKWLEZ:9+0I'+FN#U8ZU/('5,S_MXU37E:PJ^4R EM?D4VB))R<JTWBLSG4>
M+J^UMUJ&&[:RUGF]#^IF6=S2T;0R=L$';< ),X8>H+3:&MF>']YVESS0MS(!
M]$^Z%-L"N3>:^5XV#/<J3>&NC^8HI9R+;V6?NC!-51#%4)(@@XBI&-*01E"H
M" =(J3B33KV*>Y=X;*;;1D8@:B'!6RYGCG4,^Y]G2\MN3+/7MR5H%(',: *:
MVNXEN+,WT+RN5AF4.D^:!<8;>D_ ]IW8J Z^>>GW-_@T>34X>Q=Z6 -UJ#DX
M,&@'&[B/YF@W3TM92ODHER^?%[/9XD]MDW_.E\5*J_-B;' Z,U60[I=:MGQ9
M*J>7TF?-X\7J<5'^HWS08LY7TX!+O5AQ#%-,4HAX;$I!*@DQ#R,4",JP7;OE
MX44?VRJVU0V4Y8[41CN@C'J ;_4#95&QQ=*<+*U5-";IZED;]5I+8XF6OY'@
MM504_)+/P9NDR\(EQVG8U\@BF#W:EZ/G1=*R5]CN]3'J@ZW^H 0 [!  !@)P
MOP0[$,"]*AN*&1S XZ+ZC005%*-]9WRVDKO6NS.N?G/#OT.>>]/U,8V7-;#S
M*M&(NMSU@;1;*[Q>).@6(WA8U@?-RVCF UW>+\LF&%6(\T$N2VMP&FCS*$!$
M._I8>_LHC2/(" IAFH0I2@)&4^1T"LMNV+'9.5NIJUV5B;92EN!'Z<$90T68
M0\S+PO0B (61W])H<9P+.V?</\)][Z%OP?U>@:ME-J9B)77M*&NY*Y?:GSOL
M!I1/G]9RY$$=4S<TWGN7CG?WX2)^79M-Z7MUJMUHM8$SE8&*LBA@,"QK7)B3
MZ$1EPIP_BT+M$&::\/PY?W9"C8WN*JF-@_9RV$<;B&K[TZ7QBM<9].%W^9^7
M<7A4]<QIN[:E#_/#M6;.I_?C?P;'Y=?XF$G/GHH;Y)?Y()9CC<B[<$/'S6]P
M?':'Y;4LX_R^+I&4DL8<9S"0*M+&?YA!;!9,'/(X9B@+66"?'GMLA+$M?*6,
M>SLY+D6>3@-IL61="D_/ZT]?R#@L"9<B-!"_.R/EQM)M*+12[M$;A^//-KGW
MR+#UPHZ5*,P^EBEY5;YR<1H&B>(AS'""M >0$DAIED 2Q[&B,D%!X)1&NO?T
ML3%:*1PPTG6J5[>/G%T HC,>/5.8/13N)2:.J>RUM,3> ,.6E#BFVT$IB:,7
MN;=^^,[EG&I;YO=Y\2IYKG)MX50]!H*8*9$&^EO-4FV+A#2 C(08ID@JG$H1
M1:'5IFWK*&/[>C>"=NCA<!K)]J_8&SY]Y^%80^/4C.&LZI>V73@]P& -%L[J
MV&RE</[B#MZ&Z61U-R]6R](@^XW^S%_6+Q\6RV6Y'W)+]9SGJ[=IA AF(M+?
M?(B(]C]24S6*8*A,S7\>1"&FU-K_L!MS; Q0]FK+MV)/P$LE.& ;R0&O17<P
MQ2WQMW!;_*/:,V^4@-XU *UE!ENAP6UO@#IX._Z!'<C_\0&PFTOD!E6KDV3Y
MJ.'<)C?=]APIQUO=C;5O\E6_-.:@X'9?^W:QGFM:?*7+U=M7_9+4)D>BD,0J
MB2$.(@Y1@@1D.$LAYPD)*-6F&[(*)#F-.C8J;TH)C)@=K#I[R,];>;T V3-[
M=\#0R?QSQN12<]!^P,',0V<,FN:B^\T=TU>J#.7B<7'#_W-MDF*6BU>I1WC0
M[\OJ9BY,C_E7<XDFGR"2J2*0D#2N6I:2+-1_33(<$8DB%<8=&K_82V#U_5RA
MV4L]4879Z'VMA2]K]<N-Y(YI+/9S8A=)\@SQ0.DLM= FI[D6&VSDGH!2\DF)
M\J>S*+NGM#@#YC6MQ7[T85-;G%$Y2&]Q?X*[.55;:'6!#\:5RB*<0BI3#)&V
MF2 +%8(IQU&$%,&$6,>[]IX\-K.H%L[>!MK'Z;R=TUG[GHEBXQ?YJV-R4MM+
MK93]APYFB1S5I6EM'+_ [=,3,I_67=7?/OW4*^+\21HS91HE@J=($!@P&4)$
M> 1)*+#^ A$*0Z)B$5CU+#DUP-@^Q(V,8"-D:6#;?9<G06S_/'U TW><V0T5
MZV_UG.J[3[;8?+.%Y/_\M/CQ/_6M6O^0F!^@^:'QM9Y\[" ?[3FE-M_NV>NZ
MUGN+VJMF12HB-(@4E'%2?M(",E-V7$BB_Z?_CH1]\J?%@&/[Q*NB6I&_>F]G
M\+8(('M&L6_CO@;0?[VW,TBZUGOSA^B@]=XN0K9#O3<[F,[7>SOSG('KO=EI
M=5COS?(^'P>.JM)E-^O5\V*9_Y<I[H9XP% 40Z54 #4/<TW-20QCE:8Q(]KR
M2IVR<MJ'&QTQOS]@5%2EW>A6XO*@4?6O%YTN.@#>,A3C#<Z^&?K]::*Z2-Y.
MV+Y.$)T"I;^30P<C7O'$T"GMVT\*G;S+W8?[-%]I:_*1_KP3>K7*E>8QPUU5
MZO24I'%*94!AIO1_$(X%I$0P&$0)#[(P"K,8V3ISK2.-C5DJ84WQ+[ O;GW"
MP-Z_:P?XO*/G#;:>&:0S8DZ^GQ4:%SB![<\?S!NT4K/I%MK=T,$_-$>N;[XL
MZ+S81%C#-$I9FL*,(ZXMCBR#F*0(IC25L?[_,,HB:V?P_=/'1@-E<80;4$KH
MX)H<@&;AT5T"1<^?=A.%+I[: 1P.;MDEL SD@[G!X^9NG5*_U;<ZN&DX1^J4
MO'M>T\F+NKE(W^2*YG,I/M'E/)\_;5ZRE%*2I4I"DA(%49@*351"0B%%%%!)
MH@P[M<P\/LS8&.N&ZW=^/2MK 'R4>AW(';>C3Z!IY^]<CE'/5+81$&PD]/C!
MVH'@TZ\Y,=*@_DR[MN_]F#-7^XN1W*]7Q8K.A1YD&A)DJM-QF&'3KT0Q 0F.
M8QB%)(U"+%-I9[)8CC<V2C@5)5GL1/8;)FEBWSU.TA'1*P5*&M+V&RDY DO?
MH9+FD%>/E1S1WR98<NRV;FRSK>SYX>TW28OULJH#2HN\*(_[(9EQ(KDQ-# W
MI5(P)$(0: YBA4S$+ NL4E LQQL;VS1D!*60G4Y0G@/9CE8\0M<SK3BCYLPE
MEECXY))S0P[*)9;ZO^<2V]NZ<8DY;%#OZ.>RN/E!\YEI,?!YL33E['Z?+R6=
MF0"O:4GPL"C*(A<-"]_\\Y0*D412.X(T8=3P#:H\'I5@3%."LRS).B3J>A#-
MZOL:/H/W;TLM&]AI (RLTK%%AH^9LR.QH29BP(-D.W4F8*L05(LE- 6/)^_G
M!FS4TE<WW-LO;7U-G/G1(\P^.=2'6(/RK$<<WW.QST=W[C?TLIB79N4M?<U7
M=%99E]]D(9<_I-"B?%ZO]")A>B!1C=<T"V4:!$$&$Q4CB B-(,6)@"),:<1C
MA2F5CEV(W"1PL@^'Z4VD%7CGBBYKZ8'F@+(QFY&\NU/J/DUV5-PK^#T3;XU[
M[;76XF^\UV]-_"L5P$8'KUV.NL'GN?>1HQ!#=T3JAM&1/DD='W2A6WRCC:E5
M<3,77W+*\EG)U;7I+.[GWPQ_F^)K^H*O"TW9]5]+B_I+/I=W*_E23 -B3G&8
MX'W 4H@4#2"AB,*$1H1'YK>15<_Z7J0;F\N]ZXPS 95^Y4FIAH9@HR+0%+!5
MLKRJJ>;&]32:@E+5KFZ[EY? T<D?>FI[)NRKS&KWL()/]'L)0G@1\#HA"Y_8
MG@QP>!VD8P>^_&E>YJ[,5]IN-P>@397.Q2SG6I9'^7/U0</SCVD@F9(9YC +
M0A-A31-(@QA#I:04$:.IB)T6![MAQ\;ZW]<O+W3Y9HXA-Q0 .PW 1@7']GAV
MDV!'SOZA[9EUST )_C!"@U)JCRSJ!I/71G%V(P_;[<T)C8.6;6YW=V.JKW)U
M2XOGA^7"M'(3']Y^+Z2XF]_-?\C"C'?#5_F/DD*G(DZ3+%(*$I$0;<J&J39J
M903C@$=IS!16.'6) -@//3;7WW34Y5IT4S:AE-UT?,PW<@.Z%=R-L!SFPHZT
M^D&X9^(RX!JIP4,#W%^,Y!KB7\%6>'!S'F9G_G)'S">'.8P^*(^YH_*>RSH\
M8>#>QW5#]QLARG KG7W,"SY;&*NQN&'%:JF_ZBD.0T&S.("2L!BB($P@P4$*
M]3^J$"&:"65U)GP0:<=FY_U=YD_/*RG@S0^YI$^F!8*I!%16A%O,2Y'7YN"?
MR4(UKM_-T].RW$S3W_Q*F^A%SBLW<J NR59OA*7U.)9Y[MOHO+P[\OVF'?).
M9]!0&ORQ4=NGU3K$](RB*[*5P'^-CL@NV'OKANPTJ'L-H(_Y4G+]KM:YRBI.
M:2 5AS*4 4224<@DB6!( I4&4MOAR&JY.7STV-:&C735M@Y85##;%P5Z!UP[
M*U\&1]]Y!1LD_-8%.J[OI86!WCUUL,I Q[5IE@8Z<<4%1B4[3Q?L!%TT<C8W
M1E!M VU-H(8%9 R@:!H',B-4(JA(:KQMG$":R RF0DDDI8QYYG3JXPHZC(UD
M-G(#6AN@RZT!RAL&J.EE/ME0T$%RN4M7\FN^/PZ&Z7C?BK^0N=I 8@*V;]IY
M5\>S%7N=N?1NVPZLQO 6[W7FZ:@=?"51.B[%_%F*]4S>J[,V?''*B'\TR793
M*9.0<I5"BDAJZ@)'$%,50!7KM38-,8N453$P[Y*-;=G<*%9NT%DP9M%*F>"/
M4DG'? Q_TVZY+EYC,OM>[8:=1_?URS?F7E<E;\(-N];XQO1@!?$^0+=UX?Y5
M+SMF)Z'L'[C)_'B[72^7>IBR&;D9[UY]SN=TSG,ZVR16?_JYTL+F6H0O>;&:
MTB@-$D05%"1)($IB ;%*!%1ZN<A$QJ0(B,NRX$NPL:T*6[U J=ADF\_U-@&U
M<A.P5<]PSE;![3$(\,=.1V"4=%P5O$VZW:)PC:GL>4T8>!:=UP3?D/M<$KS)
M-NB*X!O1]PN"]^=WJ/7TZ>5UMGB3LDKQD_7?OLOECYS+XSZ/OLYL16O_Q:Q(
M1?-7MXMB]76Q^G>YJCMT_Y=>OLJ.VY\7RT;3[BF)$,:4AI!G"88("PDI4QR&
M:9HH'(=4)5;A^BOJ,+95YB!D]UH*W8C<F8,>]&6Q7.7_55FPFJ/6)JVSUA+P
MIGG+-0[.8;QKOE/M*]-?Y$WI>1';  !NJH3Q#02@QN"DMS,!6R JIZ:8['M#
M!@Q]S0IH., .CPFH$ $:$M# 9/RODT/!LO&_5@.511O_Z^56BNVZ$]M:\.U*
MH@U75NZZV.\5K[NR*!W#OW77B(_RU5B-4RP"K#A)8:*" **88$A3SJ!@'&&6
MD$PDW"F(N__\L9E#VVXDHI+/,8CZ#CS+4&AW2/H.:&[0^'@&#?=0Y'&=O084
MWPTQ;%CPN'X'P;T3E_64FGLR0%A%"?6HFJM,R[5&GU.:!DG,4 1I'"4027,H
M(0UB*&(5RD1&B2*IUXS<#D*.C46J^+T1U;$%;:\SZ9"P<,7YZ9G27*;&?YKK
M!=@-FMW:1<YQ);5>@+1S+NLE8W5C^KLY7[Q(4Z;FLX;&9 #D\W4^?ZIC@XMY
M\4&JQ5)6USW2G[+X+9\OS%)S9WH%:QM3B[3_%--B<_7VFUP]+T1U;*34;<HC
M)!*1$8BE:>\K4OU31A$,PR06$29!D#B=2AM0=J=U88!C;66)*E9J!_)2 ; R
M^KDM#D-.OMV:,=(I[7DIJ>0%OQB)?P6&H\!.=;#3?3/CE4:@4@DT=)J ^E$E
M,F50HTR77,QFYDD;B/RM4U>8+Y_+UY#B#[JJ76%>WB]VUQ#!O1?1XY*:E+CO
M;R]L,9LJE05$, E1DD80Q=BT-E,93(.(88IEJ+BP[3VT]^2Q^16U<*"2SKZS
MT#Y<[9Q^$0@],ZZE_DY]@H[J>D%?H/WG#=8'Z*@:S;X_QR_H9GY^D44AY?Y&
MM,D]O5>;9-1IBH,81X&"*0DRTUY=0H8U4BR+4Y1EIN2L53\P^R'']K'N,C]F
M5>:'.?9@-D\W1R'<K#X+S.V,-;](]OS%5\).P$$:S6,-YNTY,)V-(WM\?-HT
M%J,.:HK8H_#>@G"XTWWA_UCO2&HVFU=)+=_DZV*YFO)8!!3%&23<=)Y&(H98
M2 ZCD,5Q0H,HXU:=.]H&&1O#;.0$.T%!):F]:7 2T/-6@@^8>J:/#@@Y&0_G
M(+C CCCYZ,%,BG/*-:V+L]=>I]C(IY]RR?/"I#^_.SY3_T8^+',NIXHFDJ=1
M E,>*^U&< )QP#+(4H4#CC.9VIT#'UCNL1'2WMER('=*3("L#G@R.ML6;!:+
MV8PN"Y-Q5A5O[G+H<X"7P].^R?!3WO?NL,?#G9^:[\K!X<X- J"$8#QE21SG
M;$P%2FQ%']>NCM_Y\%VTQ'7XC@4%%RM9Z-'-,'72]S020K$@R6!(6011%*<0
M)T1!&458!30(PMAID_[(&&-;:TH1P6LEXP3P2DI@C [K1-$V2.U8_T*@>F;H
M"J.'#4:U@!Z+^9W6WFO5OB/##%N>[[2>!W7X6BZ]]$#V^W1 T\[D@(\:V](W
MLW(*]=6G#@^:IQ0?WLS>='E&<%>TEV$290&AD*N(:G]:^R>88 83@D+.-=G(
MP*TZRC6T&!MG-0HQ?UW,85GAM+29CUE1GWZ:GUUK\5WE9;&TD,?^"@QH+V_M
MX)V6DRI;71O,1HOZ]#?HIXCT-6>BGT/C0RIRI0/F5YBKTX?1KR%,Q\VJQ?S)
M;+V8GF F%ZO.AHP#DN$X2J'(L( HY3&D'&F[.>:1PIR%"7=:X(X/,[85R$@)
MRXTH(^?DDAS5$[A:;D)=C%;?&T^=@'+?;&K%P>L&T_&1AMU4:M7V8".I_>J+
M>S)_J&*1WY^E7/UMN5B_YO.GJH1-& 44$4T+/(H)1)(S2".50A)+(8B@L6/;
M$)M!Q\84S:9"VB:IY0:EX& C>;=:0U9S8,<COI'MF57\@'I)1^>S*/74UOGT
MN-?J[7P6B98&S^?OO3RVMQUN5P%YJG!, I5QF#"EO?((8XBS((6I=LHC)#+&
M,ZM,-\OQQL9)>S&_[B&^8\BZA_LNQ&O8T-^.>!JUWOL)!+;@TE=0\-B05PL0
MMNC?%BQLNZUCQ2ZE<BY-\NVK<<'JRMV4")0&%$.5I BB((X@PSR @@JNG:
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M:0$DARR)U-R5&=V6 /B<=12,9=X#_C;1NQTN7U7A[3$TUP! _P[#L_.R>'_
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M*4&\<-9+SY2ITP/Z(1G-M(+K"!5/&Z?N+?0&(IP[ZI<2*59Z,B[NT,G/X6P
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MP\[2:M F$48M2LIH26STFAAO@.,3A8C'=<\_M58HTX=WOI]^6D;<;]/);#8
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M[T!+39(J+?N$R<31\J-$'RU*H9S?<L[&<Z_IN_J_!B"ZD6ES/L?]D5<&)84
M1G1PZ+T+%%&PVA+@#DRVUM$Z WXWT-,2AKIV5?<3>M^6Y2$/-R?H;R;3Z:+(
M\ZV_]!&WS '2K*1/4"9!)G3/H%QG<;C*7(ZR=."1;KMM9KOWM>2![*G725TA
MMX6;VZK*8D'+IWXT6MQ/'5 C!20&Q F.OE4PAA0Y$?3D<[:05=ZRI'"[][7D
MM'2.FTZ$W-Q>]<%'N"EE="B/**(D3IK2<!B=,9^%1[<L*FLP!'3'V*SN"6II
MMSH,39V*O@$(?9E.(D":E4K$U23C(%*F*(N<,,[1<.:$'#FSF-27O3' 5:P"
MH4T$]7UIL'L(=2+Z!B#T4#8?R_@UF,V_^CDL;C2F+S"-15=GZ".&0'698918
M1A^1:\!U@8XB34H%!8KE[.K;I>=([/N67FU+U9EZF@/>LI9_&&\J!TL<.GN#
M._MD,K[]:/(&OOAA&EBMLH\N$NMDZ7@I4VESY(F@!J1D3!MUA/3Q]@3W?6>N
M-B@KJ:[=RJX/?CC]-S^Z@M_!EWJ6A??IQ^GDAQ^.RAZ0)]-R#W YTF;ID.]1
M^;7/:SJJ##N8PXXJQ^[HN"\>FMV7'F8!(2=/E%'HJR4:B*.)$T.UIIP!$[3*
M=O0<48<:Q77/OB^,5, \< ]$N]*^4BM%7,;HV 4&-&6FF%3'XKB1LM3.$/+8
MQG6GB3^5(5MD"X]ESFY>UI]16\?M,4R;HIIJ@WCB,E(BE2ZCJY,FD2E%0PXZ
MRBJ%HS5-V[=X#NEJ!*?Y[BWE?MRB=^:GH0_#T7"^F""X4$XZ'7\MYY3EJN<;
M/QLN57&_ #-W.5&MB D))230B?"*1?1AO,L*@ZZH<PT)=<I%PZ9S%P0^-IW]
M:;J!L.:.Y3?7Z 27V8;?S@'FOTTG5Y?EVO(=7V"TT,K<CGX1NK3P!V0S.Z$,
M^L*)QZIK_ 4"^\TA5P-G%?TT@+O[17>WGWU8[F<W]1ZXXLK%O7'$Y;=0XZ-U
M!BHJ$W@B45I'))2A,@$R$1@@<B., %UEFORAA/>;G3Z"$3V"/IO"[]_&4_"C
M<KWTTV0V.QT_]L?N64R64NVC(]G&3&01LM>&$PT.16NM5#'4A>S6M/:; #\"
M2NMH[4\5.RV=(+_6"?+SNP=.QOZA0W3 [<$>J.PO6NM4OL<(\P0-,@2*/H67
MFD@7&?&A3/_CO-PI\(K'*IGLHV2PMG3Y\0N?)V@[GD0 @S+8*J0H">-EVK=*
MB01C2[+801G[G4/@5:5S* <-AW>[(&^C!WU4#3?@HJR$#BM&Z<,4_N,*QO%Z
M4;H/#JS401-J)4?!^C*.+0 )E.L<@4;VN/E-YU'=)MH:@>-Q4;,Y^NM$A2VA
M<AU#-\7!,MF,$G-$"2A'P[:4]B-+$*U,.BD)O.Y1R6;:&D%E5WC8A+>.E-,H
MWF9WR_9V0FT.H)DT)'@KR@TF04+TDEBO<86:9$#736X]0UPCB.L*$5L@[B#U
MM 2Y-]=W?_V?0Y@B4>?7B\[3RU&H!E*.-!+IK2&2<8YK%!1)"FQ($E"&==WI
M9\EK))_:RO;;E2);@N?JDGO*W^U%'6UDT#$1KCW@=L(9RD\PPA(ZX"$EEBN'
M-=M0V8B-[! FVYC)3G36$B _CB^OYK.%Q-CMD$"OA4>/A2B.\9ZT16@^*&)M
MLMYF@Y]4Z2_S#$V-@*U[)&S"W(%J:11AMT-V(V/!,$4):(K^<AGG'%2F1*3
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MI:2&E7NS1/F(+IR3I>8R.I(%LT$REI*I<@FRR?KD8^+@N6KF7932$*!NBO*
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MQT^)J$U!BBQ0Y#H0-29PBC!6I-4\^> +:S^O[NC!8=.:6G<46#H/#CM&<R.
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M#LT$<7@)_4T(ICMWX[;_3*%(J3BGP<9JU+5RX*Q"*)$'&5S*,C;IRGH*L9T
M:A\Q0$_6W!A#CSL&/W_#X->!];?-7&9"1:]L08A.,I)JH4@KY>H%8V(N&]0A
MGQR#=*&@$^;<A#!W.7T,#3I:+==$]IM_W9"LGZ]6=7P'LZE.7G).6E Y._#U
MBPQ"A%HV+ERWB/8O']T))GYJ,#E/@D/K_VJYO F+RL//R[2NDKF+9%3P1FH3
MP 3OR'3&1"@V H+D)7MGD>?0"0<'']$MX<JF!HA^1#H"7^G5&C^&>=U0KV=1
M:)%=0$">B'1)<>UVRB!C.3D6):=XMX4+] T-W> RI03]N8(> 4;>8-K6EC[%
MCZO-_'J6 OE8FGE(/@F"N,,Z?I+VON*#$EYB9&T&&'Q/1S>L3#'??H[ )UG%
M^V01-IMYF>_ZU2VOW^-/85'OW[YYCWC=IIZWXT/;5_:>POT@-;Z8I4U:19!1
M<U#)!8@^1?""YWK%&4.;.0T7K?']?EV_KMG@E^6W#6X7^$PGDS&E H'+2,O:
MU9OFKH#4F2&JDI3B+43P(%53JNH]!D,/9^K/4<W)5O(3KN.JR5'1EZL<3V[6
M5>PS46=;>$S  [D*Y%=FB*4$\A(L*X7Y(-NT_'V8K"G=_>H/:V<I9P0NW %N
M?ETMTXZA$EW)JA;/1G(T%$F'Q$2A+>8D-&?"Z-+DUL(/*9O2]:X&@#M11:/#
MW)ZU_M)AZV5Y/E^2KS,/BU?5V=WV)2;?9C./"Y+"YGKF+4FSJ#H73FI0#@5X
M94C&=6:W,4*6W*3K8D_T#WMN/I+-N9&Z1X?R_7WB"+ZY<D;$2$&>":9.WU$0
MLV-0G P\!I>07Z"P]G0&ACV]']Q.MU7X>('^=7\Z@G638LD82/2VC@]GR9+3
M[CC)/^;H<HB)7<"DG\7#L$4"@\.]N=JGF<>J'>%_7J;%3<8\7SX)F_?/%ZL_
MOHBH42*KXU,OD,DZA?]!4EG%%*98\4#0(R\#48%//(*I9E=8IVV;CBH#IK*J
M<F9"Z))$#"!5$,1W]N"ES5"4TMI(&]-^'4$+RUM)F5+2ZABT/&Q CU;"Z';^
MNS$7LQP\5[)H0.[K"0=YZS&3M\ZM90I=U/$2#NL=.5/*2_4'IY.4,<FM]>Z.
MW:H\O[DF8?XR7\X_W'RX/8A_&1?S=]OG;]ILL<<^O?U6>Y8\!MERA4#T)1<H
MC+G:2C]!*$D"-\GZ3#%^"-/O$/-@DZ:[U?H:ZR5DLDC59=ZDL*B77V9,YJ -
ML5!4';];[X9ZXP5H&SR:K*SEZ6(5J)U(GM(6?@SZCNJ\U9]21[#5=^+TZ0W^
M2A;D[1^X^(2_U//JS<S7R2Z)MC3B+H JF8$S28,ECF7VS))\!P/O/01/R5UH
M#MUS%3HAX-9%^?:/U4Q%7XJ*&9@Q"127"H*5AIRF;(7.FG[7I)3A2#JG=/AU
M"9B>HKZIH9/@AK.D, C+&9A43T&"-^ I9H 4*600+ >1FHR#.IK2*1UO70RA
M1ZMP8AA]OKI9SY+CQ<0BP6JE0%'02M+4!K+/R&2Q.JHF%0/'$CJE@ZE+(?1H
M!0Y]A^%!YMZN?L)789ZO"CWM"WO<1Y;J\7&HI6"J8"9?)J2::C.80M28NS5#
M._[94SH<.@5REU#)A$SBC*LHO,P6$KIZ!=$@D)'/(+RGA<0DJMCD/+,K@<->
M&!V?"3Q*8:<#<74=%NV!^-LR[YI4U'N*B?[TZD-]-=/,92W1@)';9N."')"4
M! @7D04*X(J^/"H/43OL_=*10+0751Z/5W^+UR6^JV/-W[8N&9GQ&(1RA!T1
MLP"5BX?J# -#HQF]3.ZBM:;#WEF]'/3Z4,>_P]G1;.^:P*5/CV9\?.='^S+Y
M<H+T7Z=K[,U-W."_;HBZ9Y^V1[@G2/TOG]&3Y!ZFK:?SL_V'?%GEEJ.6H;8)
MM8G552XA6/HBF8K:)<:+:M*9Z1!!9]\@W?O<KP-*K"A,BWI-$E4")4J&@!2#
MLF2%B"XG]$U\E(,4#=SVO@]$_.4Z:2_2'Z_EW^/OC J  Y_4QJ:T/)D_B*.@
M!4_2DN<8R)M4 1,XD0.00E/A+!M;FAPR7\BRW+9:9DQ9Z3  UPI!10KQ''$-
M11<;#>,FMCE)OX^8D=J38W#P WMRO,Q'D-K9YX'^;3M2(BC-G:ZNM2BIEDH7
M\,Q*\,B-9T(IPR^Q\][1,RKTG*#H'R#G%*F/$SR[N0(B<B8-MR!%J@E.&R$6
M68#G4$Q!G7&_L5(S^ PYLJ57??\80R<(?WPHVDV+R"5S:6,$'T1M+$;.F?,E
M *TY%803LJ@F57+W4C,Z])RBZ8?Q<X+8!\3.9GT]>[5>Y9MT_7+]!M>?YNEV
M1<F@DRDA03#U:DWD$5QT$>BMS J+2; N]0+T^=] AE[MP^40 0,/X.AKH^I%
MON/ 1\TF[CC8[)8-5Y'BO4SAGA>T;#S]Y)@2H(7E5@FI?:?)A,> Y*]4#&-3
M^E'L7U%RII2'/E:_N@U3?YJOWN&R9H<Q7RVOYZ^><OH6WJV6\\UU?2.N\N>W
M;UX3&SM[Z:,Q)AA2N8N"=G"6(3IE@95L?&!:(U??0^E@Y\#3*!@<1N=J?G5I
M-0S:\Z8*[LGV8&M-$K[^_&OX<+O^"G-1\8#@@N"@.%KPCG.PS"?O<W1&=O&8
M.]FD^P@8ML*RUXWK;/D.O'&]QH\WZ_2^#FQ[M\;MA=%]EG8+K0@OHR+$ZZ2K
M_Z<"Q$#A1)0ADS%'@:Z+D]P)-)VI&LXBG:_X56LM#+W1O7WVYNKURY^7Z3_)
M;-^^>(J?<+'Z6!FL[^\L:DPQ:C*=8%T=9.1T *^=!Y88"R98[77JM+%U?>)P
ML&FDZ55KL8\@=J^QZ,NR/X_6(1GL%#EP)BP9[N# >U5[T?%:J*&8-TU&D]U+
MS;"%V;VG#L^7^ A@\PWYU7W\=;4,7]]Y2S]M0MJ>NM]E)9 )GDP"(3VQ5^_W
M.K+D8#%Z4[)FD34YR#B2SF'31#T@XR_S>MJI:>B-\,EJ06^M;H<9$'//_DR+
MF\W\$[Z@0&;YS5:PX\U*SBR/!FSV-3'&/'B&#HIGIG9M,=9VVP^/?/"PF&J*
M@-6%U#&T.U_EM5V+M3UF,!*)2ELOP1:*4BUW%+2B2,H*@Z7+H5HW=_WNJ<->
M^^@UL#M-DF-0_PZUB"[H6J\:;&UX(HN & VY>#%S+ZSB#DVO !C<M3Y-8_LZ
M/T%\ VM]5T9XY]4+GA&-H!@TYEI9:B$P)FA/]MQGAU[I+BUB.NG]NR</K/E3
M]+;J0XA#:S_\^0WAF?-"H6*&G 0Y7A(].%'W*O++M"[<\4YC_[II_]LG#W,8
MU9OV3Q;BP-K_TN;M#;DN83U?;0U@+A*C4IPB>TX>BV.LCK<L4()54FOIC.G2
M<:P3"NZE8-C+>+TZ N=+>&B([.C^;;GYB&E>YIAW*:; $RV6K$$HD>J8YPB.
M7&CP+J'V1=-&V=O9Y$$JAMLV>M#LJF\QCP0KSU=K3&'S)0+2V0HT'(1%":HD
M<JB4M!1ON9A0%!Y,EPD<1P'E>Q(&1$D_>KT'*6<(>01YM3TC^^++%*:2K2]U
M !/G6-OB:08.LP&)P7B3(Q>J28_"0P0->Q&W=3WG:7(?.B/V&HGV&WR-:?5N
M.?\_S+_,%[BY7BW)D;M^O_KZ<G>!^%E8+S'_BM=O OWB)URL_N _S1>+V^&@
MMT, +2K!:VF:38;L-E<0HF=@94 F0BQB?V3!P?F:?=,VJI*^$P&S&H_VI@W>
MJ[CZA/OL2T*@HU4/VEE792"!^,[ I3911Y;B?I_&)N"]C[9151D.#MZSM3<N
M\%8U_G*SN)Y_7&#&Q?P3KNL&]6TJ_K>/I)7E]7.L_X/T%WF6<K3>E (1;:Q]
MZA3X0BZ09RH+([@HIELA6@_$C*J6J'=XMM?/"/%X8#UNKD@9]-?YZ<UZOGSW
M]CW>S@7?M6N(NG;VCA2HN91N4W:1Y5J%H\E-E]SQD_;_TRD:53% &V2VU]30
M\+RS^Z]7G\/B^O.=Q0_%>LNDHEA-UA,&(\![<EPL^?7(9)!FOZ7_ ;#=__FC
M.D?K 3H]2'%H(!RVRT^[V>5MX.>U%#XP"3IH4Z=0DV56A228F9-HDY:,G[ES
M'D'.J+*T3??.5CIJ?T%_]XOZ)88-_O=__#]02P,$%     @ <X!D47+"N*/T
M!P  VB   !D   !A;F%B+3DS,#(P>#$P<7AE>'@S,3$N:'1MW5IM;]LX$OY^
MOX+KXKH)X'<[;>*D 1+'10WTDESJ17<_'6B1LHE(HI:D['A__3U#RB^)DXW;
MPUZS*5#7DH;#>7GFF:'5DY\NKOJCWZX';.K2A%W_<OYYV&>56J/QM=-O-"Y&
M%^S3Z%^?6;?>;+&1X9E53NF,)XW&X++"*E/G\EZC,9_/Z_-.79M)8W33(%7=
M1J*UE77A1.7TA.[@4W)Q^H^3GVHU=J&C(I698Y&1W$G!"JNR"?LJI+UEM5HI
MU=?YPJC)U+%VL]UD7[6Y53,>GCOE$GFZU'/2"-<G#;_)R5B+Q>F)4#.FQ(>*
M$OSH(#KH2M%IQ=T6/SP:'S0[G7?=PW:K%1U&\C\M&-F >%ACW2*1'RJIRFI3
M2?OWWK=S=SQ7PDU[K6;SGQ4O=WH2Z\QA,X/%X6O0L:6I9F54DW?.\,CU;)&F
MW"R.'6[4>*(F6<\[60GZEFLBG6C3>]/T?X[I22WFJ4H6O9]'*I667<HYN]$I
MSWZN6B0&>Q@5!T&K_I P%#;[RWGI!/0D*I-+IUIM\F3PZZ?A^7#$.JUZB]WW
M8S,6W$P0#J=S+(/>#>,CQ%^:'V1]?W S&GX<]L]&PZM+=O6170]NAE<7 /'-
MX/KJ9L1^N;P8W+ O@[X7Z#3;)/2DFR_%K=&G ?MR=G-^=CGX4KOZ]?/@-W;6
M'Y'I[29<V#5-?[GUW8?6O^_"^F&5?>+I'YQ]*8SB519)XU2\8&[*W=LW!X?'
MN]C_#EOE7 CP0BV1L>L=+6&G,H'<]&I'/\)!GYY6G0W9E,\D,W*FY!P$YJ;*
MLM\+;@":9('[N3:.Z8Q]U"9EK6;MWTS'["SCN5O8<Z6K;)A%=43CZ&\?C7:=
MG7.+&,#;=,%N,SU/I)C(:@A*&0JAL6.F0?E0R%7&>+9@1>9,(6$PFH#O!X@1
M9RFN )R$Q>!+I@W3J7+,Z2"W)9#)2%H+2B61E-]*[+NAT^*>@#'8,O'-!'N0
M0*0,F@?$,BR')4(:-I^J:,IL01_K]7-I9*F$'$B53=!EJ&'-E9O"09O+R!M(
M>G.8I@7<G&&98./%9AA>1<([?Y)PR6*5(:24G74(J\@VQ/'8;#Q768SBX#11
MX'N4% (ZD::->%618D4%E2/*!! "3I*L$5 &WS[8&B 3?E2IDD210 !IU\B-
MW\YZ>R)NIRQ.]-PN,6'D1%FT:6S$Z6:P&U96-U)KE\9L6?LJLMNML]&]4+Q]
M@SGI_;$M\U>R.<%?Q['"I0_2D'$C?3H07C5.)(6-26!@G"@[)7$22U'Z5/YT
M+92-$FT+K"-2,#H)><F-CJ3 ;<OVD 8AD=<0Z\%=-.791+(SU-M-D4"BU>&U
MUL&>W/=+6P<B7(5+13T\"W@@_8R*<@,F(6UDR[,;O7W3>M<\+G>+]\/EQI8Q
MMB2/'\(($M0IOK_OM=OU@Y>##K[/+J3%@(0X>9Y\/HE5HO"(%W;W)<2E8XF$
ME#L%=M:%@0(4X4Q97]J0DIG70Z/%FA0VB<7(A/L,E_2\SDVU)!UZJ$ 0L,7J
M!(<%YPT=6R44-XH<4*&)>*K+2%-AB=A]05C?!3P1X,0#@W 4\8MR# ,J*A).
M_ 6WO!'K!H$5H=UL=DE\&TL2!,5@O13?3RDO"S?CA[C9N32WX+-[4>^,(B!O
MI@2!@UL<;XF]N 6P:#8@Q' CEMD#GA0?JT2Y!76-Q[8E+/M$^QP&&-X3W9@M
M/$G>E0[EA<F!(>N[7!1I([P!?LJ8R S-*P&4\$3FA%$2P005X (LJ]SSU.L
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M'Z^"3S 8AEIAKFV[SYXH/YU ZY^%M);%FF!<)?:%Q"*]>A\?.6=V3ZNI":0
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MCB\O['<WE^=C#"GAE]T+XF/HC*GZEFV9.[6&JC-WR?H=NEO"29$E5;E^RV>
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MY&'\T)LT:XFXL@?PQT&454BRL/#Y1V5\1+C&&"L'.J@PFA2@B(9-,*XM<2+
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M*I@/JK ZBT&+TJ#'P:TH$%E21:">QF0,=[JD&>-@!V*#CT(7WK(Y?@Q,/Z>
MZ53D)-E3\)25"@GVX EF\54"'6GB:V'P_.6+@QA=[Z#*RST[<]H[#? S:[?@
M2K[+TFK;AO603W.1 3%Y5I6('@85&!=O9P@259DE*@:,E44A1N:#C?>U4$1=
MM,,^:G$X@QQ6A(CTQH.K%87%/)C@DN&3JB5>>W+X7TT'#PPT/0!+*"=@N<>W
M>LR4MDT'CAWA@I%AZ2\I;"7J-1X.YHYV"O8>@=@U=]LL0SQW/Q.MKKQQ?H_C
M[,.:BZ^H#?C3?MR:0" !_CB0B$H+]D2<6B!+[3CW]R#8 ?=B8SR4!DI18^WE
M*BR (TW(#DH+]-^T6)X.TX-6#AD3(DMC9="XPFCOYXI\'<@1P7X+%HIY\AJY
M6D$[ W)(B:ERN$]/@8%SH"U<H'_'^*6(L[#Q1E8(2NU0L\0FMP8QYCU-5\/Q
MMPS9#-)18Y/,A+(HSZ>#4-GUI'.6+J312!C)8^T,K@(%!?WQ65,8P/#P1R<4
MS*38LE^ Y,=@(7(AL937<'/&.\1Y=U%2Q08"$XO>"EK/0HQ'6A1Z@?BZ*&%%
MY_":-6'V8!\$+Q_NA%';?!WJ@)6H#D5-')/HM9!#7!^'@S,P5B>T"Z'^0/MQ
MJ]I5I\?J!H9[<)GV0J^JI=)R( )]$,:B@LV>P;<SV'H>.Z(/#[*4/U@MYS^/
M6BRJVC0;V;NUW^IGGG('5)!4BR60^8)Y6J% :<=CL+T(\O;JGK1OWO%CC6-O
M:;VBN<) "!MX*8S*6*0@( OX,:[09X>43_R6L\C7@2M/6^@7,U?"3\@Q!YY!
M+.:NF*IP@7*43E:R2N+6XP"/:R1".7L%8T,4Z)$14[I?$!R1IG5\\H=PDU=/
MCUX\!(JT?NS*;/GVX/G3UWC[G<(H9I@(,: &SS"E<KY-'FBD3WT+6/#A8B/%
MD)&X@$?-,;LB337&2RE]HRT5KA6&W2&$ZSE/#8T M9_3L.+(K$1LD7"RJ@1%
M*XN#:U+Q@CTX;W-TZ/OU#R3*N2_N:R&D0F%:R>?G,*C;O35D+9R020A'J:8[
MX+B 4S\_9!0MCX&T%$^+Y(A910%./&M9[AOQ]1UPB88QK8U1>KS'[8RFT)EQ
M<D.QU\ME#^#B0S@4&49R"^-U(PW1<:8V(FJPL7")<$W$"$PWZ.H#(71)4T'L
M'^'W@HS6@6BPRB,*(;%[Y0TK'R[XW6;@G'+(E)>TO[8EN3"WO^/6NJP#Z&NY
M).MK?'QX]"H8 :\H5\ #43U"6KA*PI0#CL#SXM;D@?[N!PZ^#QOA>[B9/!Q[
M]HZ9U0^(5Q(<P?O5ET(F 3?>;!2R9G%B=ES.6.-@KX^*1*?CX6R:?E;LD/:4
M\!M?E_/?]%(TL?^)U1F,P*[%&43_>[ P)V^P%?\DDO&BYR_YBX)SKTC<F62\
M3V *8PX-"-Z(#&,>OV5ZWK -D^,!F\HA24:5+D$_HGHD_)RPD#1,]GOBA1=A
M$8?_%([V@7$R\A.IL,VW@;(AW+2%F"R_K:4%\N'UTK8]CNQS!L]"$\ 1/Y6N
MQ: R30&?XO\:[ABD\7EWTM?H$_H[%:AL>C&!A:-I]\GXI_W/S>A(!),;#[YU
MKD0/K*%X0I)\E49PE^254&P0Z!815P)CQ3-"P*6!Y]IB*\D^&>5S13>.S*/7
MT7J#-7G4%$%5@4=)1N<F1-S-Y"TR.-VFH!D%'1@,IA2HPBDK</:(IJL)0NQ*
MS<Y0ZY:TBY!F 9@\9#"&HONG\9HGS/ 07V7B[]"'2_B,^F/O%4'$*$P4BPD
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M/OQI1XR\+@<-X;5LUR]$SN5@ZI3MJ7*,5A*X?Q+>.TQ=:7 [,'D@NQ2;#0D
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MF2GX%9=\S1%G\W.&1:$1;@?J%#;@D_(,S?HE->9B!8)?G.&QEK;KY H-AC#
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M:,87A+D*YBI7.@VG(!<#&%S"!P?.>:ZF*L]!A)19$!9!;RGT(LQ+K8I-+O9
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M]U@][S !Q 6//CD1"/71V-RH6E)?:(^3^K<](CW5WCL]M%<403A?]B#Q<U@
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MKP19JDK)'5HK2</83>V2"LL7K)?4>MPQ=9@"S9SX6S-R?1.8$Q]S<=B+D6R
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MD!P-\=,F)OI^UGH#-@26]%E6(IU:]%]1MKFS,M-?6BTFK"S+)F-C0#<1*<-
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M?_42UNJ=R5)>S= :U!.)I&ZQBM!Y#BLLAFW)T.J[*^>Q8R4_4[:OGK@ZB&Q
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MY X*\QPE,G\VK9J\!?#IB[ZF5WOD9V$G,35GXC5ZQ52"UXB9/&.P2Y5DMS4
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M*CVV$80V6.>U!L\][B(HAS$V_L4^'$5.+/ 3:TTZ+:PT%5UK"<)XH# #SM3
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M].F]L5!EF:BZMAZK"0Q^H]V83/,PRPI (4<-,G&55Y14J%/@7IC(62^<LN:
M4<-@2?VFW7C$J:B4N8(/7.:KCCB;W[+\PX!2#T&?PIZ] CG21%:I<1<K$7S
M$8-WN35<H<$0!MAH%VU$XLRF\HCX,.Z9*89E C8]I&73O"7C+4.-;V"J&X%<
M5]V@&#'  9CGWF0)2#>R\&J(N75W'G<8F)KN=>V/1=LV%G1$WEHN:@,JN F3
M2KGXQ1BFYO5O-3X]_"XU!_=&-<0^B;AIE3.F10=;)9PIPO&1?K"V;Y>X(,_1
M:1?\"N0)7-=T1<:6KJ40^A#-0WRD4VH\!N)[OF<H5Y$O4$-RQ[78YO98G-<Y
M&?9G@^!5GP@,]SH8O5G8*,$3M(7_W!9CS6$PV9-.*1T'Q9QJ37W@,R1X8R,[
M/Y\ONUK?X%GYH'""-"-^@?W9CO;)N"8J;Y>('A*3E8IR>@X/N.F'53=M!_6Z
MYVF]O\JEV@O*FX[7K-5.F&!?A-E<N%DTSS*XPO EV$JW(JKS*=+U9-=;F/A/
M7!AT8*6R-O5F\RNWM@R.@;NR#XI]<(R52\9.^_7,B-M_JP-NV4@Q=NWA"CL[
M5'JG\<X!U6<,L <J ?%#TXYB00*$W<SJ1H.9G=S)<#M'L3W"F# V<#5A.["N
M.$1XPM8PD0L$>=$A/R8$5JN2F)!?3&)B0N+YE9XUB?Z@F+(G7&M-ODBR?Q?B
M[M6N@>K -7$$XZXJI60GRVOMALWW;5@'?+90\<I0D7.0J.3!)$1\T<:H7E$T
M.A2=@MI*7XLE[PI&;Q&(P1>QC!!)V!LPV!WU:/9H8'%;BVJRS%0:.O>?T0[1
M%J\24S,#.B9ULP1JQ=@:Z9O!#&$64JZ)3]$(EZ#,]M"BI](PGP )4)$"M=*6
M '[_W"[TH#Y=-!PMG]W(?NQ;JVS4>[HK:7NDNY(=A:>*>E>S!SG)"K5:?<R(
M;'84M6+DU:;/\F2]6!#("D=VJ6,I,D5SI2WC)[>Y+:[=<18*7JT6DRS64HX[
M[1K%K@L/<KVNU).)APA4KD(5A813*+R0):2H>@M%_W=@/@L/_,(P;!L<87G%
MD6T!A*A%VA=W7IN 5F3*=G6$J6E&=7+8:ML1F)) N79MC;Z$NNYY"I_L]_H4
M7G>L((%H4B/P^W22<:1EB!C7*_=;S/AM5GP*7RAC(ILF48)M]#L:S.(S9!(D
M,A-O'>@K=\0I6,A@\:7FH^=W0<]6FA0306KCF3&^ DG,8+O&( .WK H5'B+B
M,,@PV]G"MK2@X*%M9$&!\X7@#08Q)K9Y%:<B7)L67]^3Z#F%FPS%?W;\KRNS
M6^I^NFYS_^M3TGU7%*!]BE^0C._-8L,)ZO<RE1_#.;^#_\S+1?+S_P=02P,$
M%     @ <X!D43/N;9[!.@  )U\! !H   !M=6QR;WEE;7!L;WEM96YT86=R
M965M+FAT;>U]:W/;1IKN]_,KL,Z96:F*DB59OB:3*EJB$\VQ)96D3$X^;36!
M)MDQ"'!PD<SY]?O>^@(0D.5,$E(<;]5F+)( &MWO_?*\W_W7Z<7)S2^7HVA6
MS=/H\J>W[\].HB=[3Y_^_.SDZ=/3F]/HQYL/[Z/C_8/#Z*9066DJDV<J??IT
M=/XD>C*KJL6;IT_O[N[V[Y[MY\7TZ<W54[S5\=,TSTN]GU3)D^^_PT_@OUHE
MW_^?[_YK;R\ZS>-ZKK,JB@NM*IU$=6FR:?1SHLN/T=Z>_.HD7RP+,YU5T='!
MT4'T<UY\-+>*OZ],E>KO[7V^>\I_?_>4'O+=.$^6WW^7F-O()'][8L:O)\ES
M]>+EJ^>O7AU/U/A5\O+%X8'2R?$DUL?J]?\<PB*?PL_YFK):IOIO3^8FVYMI
M?/Z;ET>+ZML[DU2S-X<'!W]Y0K_[_KM)GE7PL (NYG_R/5;N5.E/U9Y*S31[
M$\-J=?&$K[7?QWF:%V^^.:#_^Q:_V9NHN4F7;_[[QLQU&9WKN^@JGZOLOP<E
M',)>J0LSX1^6YE_ZS>$AK(_^O),%PWU2DVG[ H='N.KA^?#RYI?KMV<7@^CL
M_&2_N>SPU54QA;<?YU65S]\<[!_B^\N'5;ZPGVS*>XT^7+Z_^.7#Z/PF&OYP
M-1KAOU;>K?>X>M^[_8Z_UF5E)DO^R&0)O/*;9R\6U1_^UL>=;WTS,V5D7V53
MMOU/6E#WCNQ4N"5__>;5T='!MW_P0NB.;TP%I!$_A/6FA=8LJM:W/[0SA]_N
M1K!+<Y7H2$\F.J[,K8XF13Z/_EZGR^CP^8#E+>RFWLS-'+EEGX+VV(@='2\C
ME261FN>@Q];)E"T9O\[-V=]@$CK)YPN5+3>"=I!P3G66 5=^J-,B7T8[F[EG
M[RXV8;_VH^@&R$I.D'8/5A:I0D<S76B3J0F8(A$L*V4I 4*MT!-=%&!H5GFD
MRFACR?)2%971Y3JW>2#[3!L+5HZY-4FMTM5-5)N[A6OEZWV[@=%OM#/794L?
M/H?57XU.SFZ&[[?%1/9R GQ+4\"M@7CU?)&"E 6I,7#B X3OG4E3=$.1O.-8
M+V"Y=3R37Y.["EI>;C>(\HS$")S4O*2[E/7X5Q X>#E^$>? .^@MEU&IJVB2
M%]4,^"DB&]69@P_UP3:%1MC&Z'6R'B65G&5X6*5)=*'PP*)\0B<(1Z:G.5+$
ME8Y1_O YXU?SN@*9&"W :C:EYL_C_%9G*JM*44-XTTK!TQ*F,KA=E,/%133-
M\X0^NE5IK<:I;CY_0(\053  FJDTD!(3YEA'J9Z2.![G=8:W1E)">3P!A9??
ME7_]YOFK;Q_;P733V>'^^BSI;Q<JP4W?2_6D>G/T<O_E<]P'[_-^$><V;G:\
M__SSV_[BY?[S-6[\X5^_.7QQ\.WJ?V\PT+9>KR+R_A^0O3!KTR<<H$Q'/7SX
M\MLR6N0<MXS*&7 .\M#)S.A)] YLQ2PVP,@7DXF)@3/E9D[(MV2Z%_9_K'3O
M(@B,0:Z-'(YZR0%V9,W4<",'PX<7;K\[;]AJJZ^;=,**FWZ%TMIDM8YJ^-\T
M,A6:!'A?(!(,42_JHJQ!O",M7.,MX(;'5M1OKJ.[[@-R7MNVL,*S/E8XK=?M
MN@$SH"G+])SD1-P+78!PFD?X$=SV%L0<V!0J!C,%[!'@EVQ:1IF&3TM5+/$S
ME=R:DJP2H'18DYIJ)_)JE(5 ZF-,V, E+8$I]I&JR!O/X+EDJ:BRS$',(A?=
M&9"3>(63R7"'ATGCQML5>@$BU\IEOL'HDXYK8FVYP=;0W'$?S5WF( 6,&*"7
M!1PKGN\&".3 :2IT2F9M.3,+D,75G=99:.%ZK3P%"[H >QG]K)8DQ_>C3Y%R
M@G=>V'>.=%D!T9IRIMTO ZK\ZS?'+[\E@G<?._/@;:Z*!(GM%!S$N,J+<H/E
M.2UV$P3Z@&2%.-93UI%Q/I^;J@)_!/T<G4^ &L[XL/4M'B/)!F])K6KLQ(!^
M+C@=@?<',<*>U 2VI_+BHWV&CBC@(D\3/0<^(N*$5?X(E#'.\X^#;L,!38(B
M3[=&C#SO$R/O\YA8=,V"XZ<L19T2R@9RF._ QQ8_%XCAK@#%D4W9J=:?*% #
M?@#XXK?@0B?."K=&&KSW($KJ@CQHN#5:1($FL0H2O[(*TD:$"OW/VDC$T_XN
MM /;0JKJ)+><M%&)"[M6&4@9/<W!00$B@1MF1H''_OK;-29.F4 3'><<?WA3
M ZT6^*LGW]M=76M$>D/W9I;?@50KUKLU3J):93=72Q:?%3R(B!3_5RB9"!L_
M*]2M3D$*S\&,4@4L##_EZ%0JPJ 4R9L)'_7*7FL,?J7CQTG'D[K @U_OUM2+
M3@>=I3R[Y&JQ "5/G@E;BB1T3R[^<7:Z=_@Z^F>M"H4^/%)[614F9BH.+A-W
MP4EA$<UD9H T1A/&1GA7?@/FS$)GY:#!;)@R0-<JO[.<U:E."CW/*\Q#$F.&
MH:E9/M=;8E\<[?>:%Q>_#-_?_,+RX?SB_.3BP^7HYNSF[.+<?79]\?X,,T_X
MX=9L2&\4]7V^5.F:TY11=,I&44B/@=_6EO>#,+B@;X&@&U=.:G3B;%Q 9QI.
MRJ8OD!^!D\<F-97WW'(,)R"C.TV%WET!;%:P;8>,9W IPE0J S[$>$'PV(2B
M+A&)LP='7\.R3AN(>,-^ZJU>*?2T5]ER2'^)&I=Y6E>KEWRF-I3_.ROLG1=J
MJO?&A58?]ZAXX8U*[]2R?/('U:,^,B[J#3Y[RSO+R1XGKR$V"XSL@O'2-E3P
M;UT9]/ ?(>>1 U3:5U4Q&70##*[5P#[H]S;>'GP>"F>D%-3#0@[^:T!.NR5A
MY,];X$YZ+OV.N37ZF.5W&26\6:^--08&=5%J]OLK-<TS Y02NR"<7:RIO$TX
M8(<\+Q?P</AKXH)\-AN*SMV 'TTKB^UM@.E+7"!\!8LSU9)M75/VOQD9K'S&
M#8NU+UPI$0SX%-<\!'F38IBRC'; H4STQ% P2H-ZQZJCBSL0:AS%DN(!>!Z\
MVP3N3%7QZ5+BI0E(PRR!Q\&&17<S$\]H&Y-<SF\&UK>-+N B$E/&A:8UFRP\
M$3#8#-Z;]Y&*;A9PX"@T_:\&^ +B.8/54MV1%8(5 M'.T5]V[4OG=556BC/)
M(,6Q%@*^B=4"8T_  WG\$3_@,R@68BCR)N89'?L\!T,I3F$%?#'N6O,&*9 $
MO#Y<IZ),<;, V$%Q7;#D!W\=UCAE>JW'8)BAZU&HY*$7&;82<6?WX!][<5XC
MR<+&%Q^U#=S@'F-*'>B@QB1/A+(5#L'&FR0T &?ZCM8!;RMOU-0@ QL#=*3A
MJJ/F6N&IT.[ 5BXD2XB[AW\84%U"MLQP[%L%A-Q/Q=6LR.MI<].)+^<Z,>"L
MH585XD']6MH_4HY\XMVL0L2 7)XY4J/54E&+K!&NX"5MC<G5FYXYD?(,*T!9
M&:P[E?W;33!\#9U-,3O3)_8ZXM_=XDY$+[Q0AFF7 IE:Q4R[)2>$= $2&=:*
M^B7%JA-B#\\75 L#-B'^#/10AO]@SZFPE)[#O[2$7N'+._I-G.^Y?V5EG8*$
MJ@9V08N9*K657Z$0!_L3I/*"PH"PZGJBXHIW$@U'E@7X%_Q4[$P*!CN'C#2)
MXS_>/!TDI[JN:=<&2.@QN,C SS$Z66FN*"*=*E>-+AKY*U"GQ'@I!Q<Q/(-:
MM__J%4FS@,V&.X"DI//)B\8YVQV/\@4FRNJ,)>D";H"58_107 W6K:/0*Q(Z
M-G@MKZY \1G89R(/*EF:*%P#^;Q(?223)F N$,6T]S#/]KAXJD?Y_IX29XTU
M2L]ZO5[R<L^OR:.-+M[AEFZ)E'W6[]B^18:]5JDJUNW<AK6?$NE7;,V".8"K
M+&F5-F@/HJ^&S?X7L$:!!C00Z_^%>P]@G9N<#=R,[?8Y03)#8:/1' $I31X^
M!>&P.8;R]I)103DQRU.T1DM4&4L*T(&D*?2TAO=!$];D"5A1!NPXN!05(FNJ
M&,S3A&(!O2%I+CUP"W$90:&+8-N\/ :A7U 6<R)ZDOPIN,M2*ZI%"!2SQ"J!
MC@S)-14]>_%\+\'0.YCR<LW6<'NO W[J_!;<R;=Y5J_;L1XR-Y<Y$%/@58GJ
MX4R_#?'V5(VP*;- PX!+:E&)D?L !ZNS!(BA@R*:JAW.T4C &?2PIE+%8#VX
M6[$J9]$8MPSO5"_PM\<'?VG'MV"AV1YX0@75GP=R:X.%TKKIP(LCW#!R+,,M
MA:-$NR8H3KFEDX*SQWKM1K1QFF/9]V;V8UT&Z_P!U[D)>RZQHJYJG&YV:U?G
M2#6.K]S06<F1B!-77=)@Y\UE!+?@C3@87SI!6M1Z>X56)4BD,?E!68GQFP[/
MTQ?:H)=#SH3HTD3;(ED1M'<S3;$.E(C@OT5SS3)YA5R=HIT".60D5#G=9R8@
MP#G1IN88W[%Q*9(L[+R1%X):6QG6V!36(,&\8^C7P/Y.(-M%>FILDYE0%K4#
M]1 JAYY,P=J%+!J)_P>BG2N>P$#!=$3>5@:P//S2*P7[4NS9ST'S8[(0I9!X
MRBO%;#8ZQ.UY<5HGMK E$;L5K)ZY.(^T*?0 B7517XLIX#$KRNS!,0C>/CP)
M:[:%-M0>&U$]AIH$)C%J(4S<7(<O9^ *'.4V0O^!_N-:K:O>B-4U150O%AM0
MF34L@>@Q/EM:6YK.W=M'79G[5O.$6F 1!D;^)_=P(#."Y>XI9O0I*Q_EM \4
M^:B+F )#;#2]/AB\ "?-A[2[Q-8)!T)Y2S=78Y!CLOX3=SJC6>S6*-M<W>.C
M@\.7T0C\NVH),A#9'&GA,E49AQ%!G&"8?[4X:7// Q>_"0<1^JU,'E[F!FR&
M&2%*[Z#8YR1#\&THX&VW2W*_J#\DR^S8GKCP6(NQ5U>%ZPAZLUCA@+EA,(%(
M;09=35NDTE)^XJMJUGKH^I+YZX-QZB:*H\=:4K"F_7H8N:+)]4]LZ@4]4<W
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M[8U9#=!2ZE8;(M-8M2)A'!>E0A_GH^8Q=^91I'9@D_3BA1X^L[5^9D[('8P
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M2C?F;1/ZK[.#&-83YX>T6KHX?R*DU6K_(G25@GM4O6U5 "LE+B,)2I51GD#
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MB:T6LB4A.S*#%@P[$,P;>N2;P8KNL,.F#=!J G\9MV E>EKI6U,Q:G93&+(
M<450(F,^7*4T/4N*(5U*I]3H#7+)"]9=E>RQ6YK::5<K!*-S;@I"$5N"H+,4
MY(L8]G%W]PYW9KN[&YIVN_9O_@[?7&(5FT 1 WN,H2T0-,JU ?787*3(@$/;
M]9!\N>NE0DB/6&&IP]06 A)%L(WD8?-@,>1H,MN'_/+X!K;VQ+8JKJVN.,-&
MNZ@5UIP$$'PB+5=5A->!;I<GN40N&WH/YXE&PF).B,O%EL4FK?;S![#5T<YX
M=^=H=\?L!F5_G<&CCM?T8=[>UVMUOC1>"75..5D.FIBZ&(QM]M4)7,LG;.DE
MW>+*.ELUB0T%U3(C[MF+TLL8V(QCX)GP[^?<NQA^]!HWZT=;0[Y:-35H%O=(
MWU\=8W ;MEA<THHAOW=7>+!G*[]0AZ]RG(4^C2AAD'55IXC,'@12W<&VV'HI
MUY[9?&_;0MSSFH.5:K5 _H>KW%%$D&^1)D,K@[.! ^H+3-LMF#YQ@%X*DJ_4
M.H8UCBR:J(H9PULE"2B.@@4#GU;WC<^OPEZ.:2^I=Z"P)#I52YT$J%S@PZ=&
M%ZX$%.[6;)<A'\R6>9?F4XC5@JD'FIU-'ENHPWOTST"JJX-;=TZUVV&A[W-2
MC BXN8:V(\F1+>$[DZ)6ZYZ>PAMLAOIME_W=)PJX5,.=@S7G=H:[P9@D+'FO
MYPNXR=RF$AJY</S\\T3J4'HXA>L[G*63G@J@FEA4#]QV*P^M 1KJ/U=UU:LO
M9BJ1[AO,_.>.AU9*L2R#4K7&VUUO[\(S7"FF2E7 ^QV/ZTAW!'J%T'YL?D9@
M.^]5:5L2)_LWW'H/_&2+Z'IVWD,%^/$:+.6XZ1]O!/N]M/ABI0S3P"S2"@Q9
MX*\&1]= 'W,KK?K0QWR2%W^XW)MPTT$#A*Q7TG)BC1''<*$+U*M5V?C\2Y'(
MN@,LXE6WZ?(^LD34T>P^-K#I9\*N:P >R-1P2DD_%*(6UCWB9IBFDF[:C.)<
MK"K)A\J9_GQAD)7,0U#<-I0OH<RK9=3$_K_WW7JPZLD%ZM[;!TI:&^S2X01/
MPKOXF@NS<NGEUUS8%^V78UDR\(B:?4VCL%Y0KA,1[;"?WV"$$"?'\8%3EI_7
MLES\1<(%.[$*0Q5/V!5HL; 1$ 4S;1)XL&#T74SQ$-QO*LMBE!"'=?GH='.W
M\?M\OW=6Z\7YN[/3T?G-V?!]-#P_C2ZO+BZOSD8WPZM?HK/S=Q=7'X8W9Q?G
M^^LTC*,@BH@M>DZ_)VS\!CU;>>^LT?;4X(90=A<XJK"3?RZ+'#A"5VBYG&6$
MX>A,R+/LEI&U'D>NX?+L;","SI*JQN4@-A)-1@&!,JF!"6&#8T'P(4&R)0SX
MHI<!A]?79S^<?P .)/9[>W9^>G;^0S1Z]VYT<O/HWKXOA=X,X3D$)\,&*F-/
M4:DN=6$*V)JXG_FD<P2/3/EE29#C/UUXIM!@UI6<W;ZE4EL"%,%_)*#$30F.
M"/="8K&NGJY> B3Z5L>,/LT:JL[,/VMGIO-S,E75Q6I\A$%*NK%7,RF8;D4U
M,PF$4=*<*F##ANS.G&: -XLO1ZJ/,^#$7__FCC?JR_!W7-/ $0B_H_?NH!NB
M[D,7K3M;M2R8&=2^3L'*Q-D;]J=>JS,"ZFH3'351HVDMP6P7FV;P _S,->RZ
M%=FX)#?="L O88ASK5RS-U7<*->M*9$8+GX(IF\.W$@:.!%X=CPCZV>NBRD"
M]0:^TL#CL5 $W_VE8BJM*5VY=1\: YR$EJ+I;G3"QY<SZ9:A+WMEZ/G%S=G)
MZ'I+I.60D[$F9J2C!#1DEI06 NFCH8B&U%UA[H:"!I4KPN*Q2ZT22AEC=K\@
MX2NQ,[\P/.4*'N6^M5*/\G_6O]_A^ JU&3#34IG.!$SIQ$Y'R]!F2CUUSO*Z
MH#>;<U42+#761<7>.WXVL'6_<F-?XC/ ]$XE X!XHI!*$N 2PN&V,9??'?QX
MC42/Q;)M'-5[WFV!6=1LNI?JR5II^/#@^.@PNE08DXFC$_+_X0WJ E3@=6W
MISPZ.'C@"1WLTQFMO-KG3NU@?XT;<*VRZ-3H:3Z(3H;1ZZ/#H\-M?MUA)1C#
MG)GJP11;V8'>B,GC9E>R!A\#FY[J#*SAZ$.=%OERF^GS^-G+@^B#SD";(3:F
M+[-Y"+EMRFFMR)1G#Q6AFQ5A='Y!"Z0HR(&3.\#VB 7MDRRXV+;-NF.ZF]P%
MK?TN4X5< 6R4"2J8.:=$,6W;IO139M"2N:YH/A&:(U2#X-(+E'C"9 7[<9<*
M$: Q+1%+5P!6IK)-0AZ)M>3 RA%H* LDS6H]#V[3;#WTS[2Y&4E?;DE)\ZO^
MH.2/%V#/1Q?OHO?#G[?$JN_SR*E QXUYPE*I FS;JKNKCLM3I+X[57>^B*JR
MA1KP\D!V&4Z7D8H[GI5*Q79<$#1)#:/DTQT68*3'9I'J>X+=_W%)HU>/-6FT
M*<S]NI>YS\YO1C]<-9,*V\3:@P!PX,^)MO?!<LS,&/3:6D/^KLH?@_T\:IK"
M_5+K U('B\8FA&70A.WW(TA<QV]!<546.[ZNA,.!>+'+ I7WI('L@EHUC-V_
M9I"&LD:#0B>: X2"<BBU#?#77[\Y?ODMMW3A!)F\4)G.:PQQR%M9.R=<AGT]
MBH2HHD#C@?^V(U>"EWYTC-)-DH<'_6F0#Z/S4\R"/+I7?9"ZEWGS&*T74"4:
M2Y1(D2P7OHRQY]_2BJ=_#+3[[K96B]ZCVZX>RCCLI8R?AV?_&%T]NO?L*Y(C
MP3.@8?29]+ WLM>MX*SDA=#*B*4,#2NN6Y[2G<)R( <G[&Q%2TQ4J]P4I7Y,
MU=U,"N/OU"UZ6 A[F2IXZV3@6J[H 450KCUKO<<@?(O"KK<'&!W9P-U2H/5<
M'19W><::_Y(;V=&/B(XBBY NT,^O8DO<I<.C7A:Y'@&'#-^>O3^[^65+&.6&
MZN\X64ER,<;@,=*!'?Y51;_6A2D3$X>X('6F,ZHAD(E$:(W=PALFTL]O4LI6
M"LXK4UY^:\IN[O/T6VAI072EE/=<%BP"&SED!<'C$2>4\8[QI5KS7SQ,+/:"
MHXY8\L2+!0:NQ =T=VP\B]LD\G!U,A*:?T\FUGT_%R0L!ME5V&W J-<NN5N&
M9HE83'["7">\P+V+'30>ORVL^NQ>[^?J\FIT0PX0P]F?7)Q?WUS]=+)5+A$"
M02@:#WUO.Q=".T]8!X((-[;KIL F)?X#2[M](E)TB06M=O$2KL-ME-6O5$%@
M 1FU""0%^NL\ZY9J%Q"=H=1!#8.#^K"U8E@":8O0Z!ZP.&!>"]D@: Y$_P.'
M 2V?ZD0^#YV,_"YKX$?;)9!]ISYASY'!4HM.ENHI@;"%5>(IJ?ACEM^E.IGJ
MH,-0E+_4=-C',F0UZ/\[B43A'R6: #1A$3^+<D*/J#,13?SSX,>#E6H7:SX4
M6&M.LIN"7;'%=_(%H[Q <J_F8S.M>:B/*J0 'C<@3VE*<C!<D\Y1:K<;P^?&
M;DB%PUMWE++=H,J'Q[VBYVH$<N<:7"P2/==4;O;S\.IJ>'YSMC7%$\BC@;(B
M[YN\Z["HWLU$ F($\T'J*(J< B9(\W86:DTYA&:]#O614FS2(T-R41@6A^)G
MH<4:1B?81BUM%"0([+=8QB[41R0XDRHU6^$L\1XL<7P]GO"J W/<6R]!^*$]
MX34P<2B-$KF.LVUAD?NJH7\B_3R\NKG^8\)F1P]:XI8P8TO_2O..K=TFZK_+
M206A; 89CO6<PCR2V&LYNJB%I!-@8(O@[!P1@3SB2XB#S;BF+*$'&R$'TI 2
MVB:A?T]Y\=7;LYO/1=O_X]([K[<BO;-.SD:PQM*.S"G4PCJ7@EQ+]<!$#&)L
M):9<4$,FZ3:4!(I&)'T&:.;>_HU^+$QO3$JLWCY^P*&MDLS:F$=-8QP@MJ/%
M+3R;IHFJ UHESY7/Y^R%^^Q#7\X@]W7*C1D>:($'/_/PO6S:.D@+;(0($2U<
M@2?Z*S@&!_YWPB+0UG-+^F-BD#"PZ5$58,I(W7+8\PCD-9..;ZDGOI6B]B*/
M=5)CRL*YXRZ]_(XQKJ-A<-=A3#4385&*SSW+N&V/Y?GW.C&(EM>X!3[W TW6
M8F -:HLM*9TRRN3(!CC5=G]#,7S^/OSP!]D)7XH8D!<K)?I!Q3R"NS*H146^
M&!TL+IY\[X#)+)\T9U]&'LA03B\7/2M %&JW)WQ%P3J@Q@31!D 7X_QMG-FT
M=/7]33%!7AVO@5D;C.L[K%Z@D#,P']85@JO:;HOE^N0&F_ K4*?_&'&9RUJ'
MZ96 #!,=<ZRLB13OW]5S>5D*?TELTB4>*6UI(<P40Y2%V4MZ"^R)H(H.N#+M
M$6 8X1]+P-VWA#".XJ\(15/AD%CL3\E95J[<P6/SH]6><H""FNNYN80==IQH
M9\6Q]*2L@B?*/K?N1?*$N]!]6!9VO!."%!N=\2^F-I.2,)7Y6?X7/?L-/^1^
M]AG[6FU?IP$NA(#:W)3?_SXLQL?H?O$=?Z61NM133;1%^@A?*;B=*0KJX,>8
MY4P5\PAC-I9*_-G;@#(#HWCZZNC()REO\9&[Z8#L8,=4C@A$642,BXS'@"T"
MPC$FNX4O"7(YT 4#Y&/7PX@;4B!.:ZGC0J,(=SV-+$5@/PE!KV9- &Q5V;XD
MTCQ4Q2T:DTQIG)F(KQZ^\9;8U?TM)V!3GXZBZ]')U>CF&BO5+FY^'%UM2Q2%
MX<DXGP)*Q-$M'+,S(,+N,$8RD.B*#\/!Z]?I5+<Z&,*2"=99X]* $5 8*;!H
M&#(!?;9I%V,7:9Y-Q1PC;5"&Y3>-V=EP%VUU'?TNLTKLOL4-)RBSJ!:TU/HC
M/@<$18RS'E"4,.<*SP=+!9X_:4U?[>!YOU-NCN>].^47,U@U?/O7'22QJ(^&
M<50M G#)*>B%8:O ?RQA*A[!TGJ]+>'O_A+4X>D_1E<W9]?8B[M5%0BM$11D
M-#7=*M_B6OJ61YG+:7%:V<;[UPI6/_DP-89)%_4X->6,\12PXY:#,02E5K%/
MA?RGT!C%01BY8#^F!OPF[JM%U2KC/1FJ)4>?H@Q)7:#GVBV/S@>;@Q:%+2A8
M3*%3M^ ,;3")U>=*I;QBX*?3AA(DP]A1\.R%B7&9MM@,9P5Q^QR;!751KK0&
M-Y+&;NUMIE\LM$(\=\HW!>:@-=T(2T-$)7JSY)>2@4##<M6RC1=CG5BL!K:C
M<?TAQ4ZXNG/Z-UA\K7&=OW[S^O#;J]&'X=GYZ>@*U?+-CV?7T>7PAU&$F==S
MC(,-W[__)7H_>G<3O7T_//]_<,VS+VD6?')?T])#&IK^XZ)MAP?]X39<KDG^
M]L2,7T^2Y^K%RU?/7[TZGJCQJ^3EB\,#I9/C2:R/U>O_.7[R-43W1:UHY]'/
M9S?GH^OKZ&<P34<7[]89J1@T:GA)*KD\0!.J1SEASMA#8.+=/508'1VO8[L/
MGV-3T_GP\N:7Z[=G%P,0-2>K*U[/OK_EAN$^,V=]),%LDNA8T!7>D*>!OT(Q
M#AJ6XX#1CVK^+Q5=UX51&[*EYV '<-RK;U?O6W./+'FUOE ^QG7N)9)+,'+(
M'X,7?H;=O:.+3>+'GM96!"6[][7^CD"1A\\'T='!T4,;*=<C8*SA?G]3\8;T
M=SZ4L7]+[_&?PB;=VW\Z.C\'4_+#3^^O+G[9)&KY8\C_JY'[A?1!K@=">0UO
M?KH:L<MQ<Q&-/ER^O_B%X;U^N!J-\%\='L=O,XE?;KI)O-83&?W_'\_>GMWX
M!KC'M/BKT?O1\'HD17H8?T)O]N3]\,QG'!_3^P KO!U%R!^CT^CB/+JXBMY=
MO']_\3,&V&Y^Q%#ZY9#K5*+3X<T(?O/^H6)V8QRQWCFV6/=J,(4>YCD;@ZP$
M6*QG H865&-RD+RKY$&'&\*<@G!2%87Y,H*RQ%$@5:40.Q4<E$%3_0YLG&E2
M%QE&[8:96E3+\JW);?Y]8U$M)6RV&6GX(-)OT:&+ .!;>IXVLY@A1"+_F1:Z
M"7NZ)6%W$ +ZDT"$V-*'IE0(!R;Q#,1>OJ=4VUFDYI35\<'>,$DO&.' OI:W
M982OM%/8[FMJ[A&H^0[,1ULU@G]+"HTA"JG$)&=<)RS;%-1U^&=9Y?''69XF
M] 66=6;T+S!,,LPA@QC*BTPO\<M")]H5K(3%*W"9?:S+#R[Y!8VF)!]6G]%M
M6TDQBTS9F 2WP8-)A.T2&QS;!*;CY&980&?+YF"GJ;'.2#8B@"D=<&X8>TXR
M&0!'_QY(.1[5^TD*@GK>N82$NDN7(8PX55W@:<;X7RDEHY1./C>E%*9A;QI5
MX#N\<OP^\X%#81(DAG;9R*,CC1/:_4V@#*GQ::U,<NZ:^Z3P9%$PI69N^$A]
MF9BGI796B@>8=9##?'E_&>B#RBVY&@PKP8(5-!\2SL.BI@EKC+G)86X@N:LP
M*%4*<@DI/\-:T@%-E!$:'42W2G)K8.H-[ QF>*J9CS$[.&<R+QWV/?UL@E3M
ML'BM/)7_B?*%\%JC"QJX#&3AS"RXS4F7/*6F"1N)[Q\WWG_B6T.X.8N:7L"*
M*?)L.JG3<$]9N#;;L0W.@=>^M04_G^8Y: I%7:<9_0LA3!76?<D:$EX#*('*
MB16_H\'2)H6JP5A--%"TK$&[/#'E*D%;#&R&&91KP5.YN?%%Z(!3G-$BA_\N
M@YI S:N8<&7K@"OV^&9ICO7+^ $"2R_O7R0^N3!^EV 5H(&XPA>[S5(C7P!9
MP&5 &A/)N ::T#;23DB!NJ1[BU%\0:>L.CHQMR:-KKBN;\B@3H>O7QS3W$Q!
MFI!Q4O:2(:AP6$ FC86GIO0"W=WA]4'K(MC8T\:+XCZ'MHE[]LO&LS?8;QB>
MCC8"#5_F$/C:Z?=JC'"]-+W.5?GXK]\A1XV:@#8_YCQ4$X\AW/[/EQXV?14K
MN46<NQ*)MKC?W%,=?9*5;X[*#)1? ^$]$"+HG\PS)QG ;,$J#LJ2M@<6H9BK
M&(ICO PAX *H9QF7[(=:N7)H4H!=J\"RG2Q0LZ$R!)U4(P*UBF,"J@.B '5Y
M?'#XT0ZV=^KHEB>Q<_<$DI&F#H,R4#_^Z6(6,LFA:TQKI8$>(.\K!@=Q2\>Q
MA,FNKWHIF[T9N 6A=FKU13LOR#6'AKVAM)2!A13!:5[D>S5I:>!=+JSFUK;>
M5U9SQN>%N#Y4B\.5-]*M3 <S:?*2388WMN$SG+<MWC"/@UYI4#^S\ZU4(AZ$
MK3[U(VB?'Q\YDO=2D34A#1;GR!?>HVQC@O]),NM^O6,=<>=W)[GFAF1J^&$\
M :8I&\0#M@=/V6#;A?LQ;AV#Y3AH /T)C"*D'*1^[-O7",5^B[S)-7XTW X'
M=G,_L:B#PDUGHL>9B?APP"TSKB[#&\V!A/AX@#EU(7,(* ()Y!D\L=15E>JF
ML9[H,2Q^G=)XWTYZ<)( ['$T(%/?;$'%=28#X86%B\V."><-6"L,MC0<)XD<
M+B/I\9\A-DUH.>+;_)(7'P<=L^O;2 \-X>(40@B \%A!P'JE0DL@#'"X%[J(
M))AM$P*)83PSV_G&!&Q''<JA!5O&1X8&W\"V,@&YKL8[,4B."[#WO<U34&[D
MX+FV_-7 '<,43^RHD>[;HFLK \[E:+FG!:C@5J6U]B'[,WBU8-"5#>GA9YEE
MW%O=TOJDX29UP<W]/6*5<$L(5T0&9[DQ$A)LO,"87?0SD"=(73?^];+(*R'T
M(7J'>$MOTP0") QQ3U&MHER@N9E>:K'+'8BX8%H;G(^%'W+]H8S3?,_&VBHR
M;]^<1>6,VI9"4!;</.MN^9#1^M+7G\FP;G16=[WHX:'NZJ2*P,D'>Q.T&<D+
M'!IR?$"^-5%YMT8,D&&<5A3N.3J4N:[6VG2#/IN!I_O#5;ZT7%"#3'(/?>^H
M%#&<IS.19O$LS^$75BX9'FDN+-![%X%.WPTV)OD=-P;C5UE[YBTA^ZQ<VK$X
M!A+*/VH.P3%.H9W7W/%[%L3=WS4!@%QRU$^)=4NE9]K@' _[100D, E('EKH
M[#DI$(XRZUL#7G:ZE.7VKN+QC5OJU<;42X_;">>!/88X(;<[3>0304%V*,P)
M@=>J)2<4]E#8G)!$?@7Y/C4?-9/VF#LN*19)_N]<PKW&C[L:^-%"X-S5E?2H
MY$5C()S]O*NSF9D++:\<+3D/>T<1S#KEM> "J7]*3#K4G8+,1Q^+)^_;U>ZP
M[3K4L0PV1IWVL-@=O3_='SALOK(>+W*=*1_^L^8A^N)U:MM&P,BD&4NJI-P:
M&9S1%)NJ,^Z)S= )EZ3,%A%C8-2PI  =4),)M3(I#[[_TK&=8$!=MB(M7SSY
M\RST5]FK#ZQ7LO?(>B5/"MF*Q@MR"#G-2[W:_,BP5&X5C5[(U1E]<F<SGQ.F
M J=V:9 6BD7[2]?32W%SU^VWXWT4_+6>C_/$2'_@I&\5NSX_R V$TD$E(2(P
M@TI=EI)/H?Q"GI*I&FP4_;]'[9@''>]69+OL"&LL3FU+1W@CJSY?!KC)G5AY
MW48D4].4.L-P,J(G,"V9<N.',/PFZGH@&SX[V&@VO.G90L+UH\&-#X%V][1E
MJ1@WK @QWT,,])#$Y]IZR7:FA6"9T%1GB1HR#1*=2;P.3)8EB0I6,]AO:)CW
MPJF5^<K8/*)(8X,S-EQ J2+KVEB8R8Y=H4X\A*\$+>:POAW(-Z4/';0WI<ZY
MOQ"^3["<*VBR%/7:=OHVO12<RY#95]S43I--ZXOI7Y.T\CS2G7QX9^6F[/?#
M*OXW(U+P%"3J$OYG5LW3[_\74$L! A0#%     @ <X!D40N",& C;@( =_@5
M !$              ( !     &%N86(M,C R,# Y,S N:'1M4$L! A0#%
M  @ <X!D44N<^41.$   ^:   !$              ( !4FX" &%N86(M,C R
M,# Y,S N>'-D4$L! A0#%     @ <X!D4>:S6Z#(%P  5?,  !4
M     ( !SWX" &%N86(M,C R,# Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( '.
M9%'C=:4\&#\  (>9 @ 5              "  <J6 @!A;F%B+3(P,C P.3,P
M7V1E9BYX;6Q02P$"% ,4    " !S@&11F\64F5V* 0!T2@( %
M    @ $5U@( 86YA8BTR,#(P,#DS,%]G,2YJ<&=02P$"% ,4    " !S@&11
M/$>GPA.S  !3B0< %0              @ &D8 0 86YA8BTR,#(P,#DS,%]L
M86(N>&UL4$L! A0#%     @ <X!D4==!QQ %9@  ,)H$ !4
M ( !ZA,% &%N86(M,C R,# Y,S!?<')E+GAM;%!+ 0(4 Q0    ( '. 9%%R
MPKBC] <  -H@   9              "  2)Z!0!A;F%B+3DS,#(P>#$P<7AE
M>'@S,3$N:'1M4$L! A0#%     @ <X!D48M &&KI!P  4B   !D
M     ( !38(% &%N86(M.3,P,C!X,3!Q>&5X>#,Q,BYH=&U02P$"% ,4
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M=&$N:'1M4$L! A0#%     @ <X!D43/N;9[!.@  )U\! !H
M ( !K T& &UU;')O>65M<&QO>6UE;G1A9W)E96TN:'1M4$L%!@     .  X
*P ,  *5(!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
